| Description | Drug perturbation signatures created by profiling 4343 small molecules in the U2-OS cell line with the DRUG-seq platform |
| Measurement | gene expression by RNA-seq |
| Association | gene-drug perturbation associations by differential expression of gene following drug perturbation |
| Category | transcriptomics |
| Resource | Novartis Institutes for Biomedical Research |
| Citation(s) | |
| Last Updated | 2025 Apr 17 |
| Stats |
|
Gene Attribute
Gene Similarity
Attribute Similarity
UMAP
15960 sets of genes differentially expressed following drug perturbation from the NIBR DRUG-seq U2OS MoA Box dataset.
| Gene Set | Description |
|---|---|
| WE-48-PP43_10uM | Dose=10uM, (1S,2R)-2-[[9-ethyl-6-(4-piperidin-1-ylsulfonylanilino)purin-2-yl]amino]cyclohexane-1-carboxamide, Protein Kinase Inhibitors targeting SRC |
| RF-36-EI47_10uM | Dose=10uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2 |
| ND-39-PO34_10uM | Dose=10uM, n-(1-Methylbenzo[f]quinazolin-3-yl)guanidine targeting NPY1R, NPFFR1 |
| OE-31-YC41_1uM | Dose=1uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2 |
| GB-06-BA49_10uM | Dose=10uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1 |
| HC-92-HE59_10uM | Dose=10uM |
| GB-92-JY12_10uM | Dose=10uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3 |
| NF-21-HQ00_10uM | Dose=10uM, Cct251236 targeting PIR |
| ZB-16-BR73_10uM | Dose=10uM, N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide, p53 tumor suppressor protein inhibitor targeting TP53 |
| YA-85-VH07_10uM | Dose=10uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1 |
| BC-10-SB73_10uM | Dose=10uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14 |
| AE-19-BK71_10uM | Dose=10uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1 |
| NB-80-IM48_10uM | Dose=10uM, 1-(2-Fluorophenyl)-8-pyridin-4-ylimidazo[4,5-c]quinoline targeting RET |
| FA-63-WI26_1uM | Dose=1uM |
| HB-06-WU12_10uM | Dose=10uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| IC-76-JU42_10uM | Dose=10uM |
| BD-49-MD69_0.1uM | Dose=0.1uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| EA-18-FP00_0.1uM | Dose=0.1uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| ED-05-LQ40_10uM | Dose=10uM, N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine |
| BD-49-MD69_10uM | Dose=10uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| BC-54-ON71_10uM | Dose=10uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| QE-79-XO29_1uM | Dose=1uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3 |
| BC-14-CG34_1uM | Dose=1uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| DA-35-DU85_1uM | Dose=1uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| JC-06-ED36_10uM | Dose=10uM, CDDO-Im, PPARgamma Agonists;Apoptosis Inducers;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Nitric Oxide Production Inhibitors targeting NFE2L2, PPARG, KEAP1 |
| DD-75-HY40_10uM | Dose=10uM, Celastrol |
| DA-35-DU85_10uM | Dose=10uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| IC-07-VY79_10uM | Dose=10uM, Formoterol, ADRB2 agonist targeting ADRB2 |
| AA-22-UI44_1uM | Dose=1uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AB-18-YN11_0.1uM | Dose=0.1uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| AC-86-KF37_1uM | Dose=1uM, Capzimin, Proteasome inhibitor targeting PSMD14 |
| AE-39-DG66_1uM | Dose=1uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| YD-49-HM53_0.1uM | Dose=0.1uM, MELK inhibitor targeting MELK |
| AC-30-XU83_0.1uM | Dose=0.1uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| YA-92-YO01_10uM | Dose=10uM, LL-Z 1271alpha |
| IB-33-TE51_10uM | Dose=10uM, 5-methyl-10H-indolo[3,2-b]quinolin-5-ium |
| FB-66-UU47_10uM | Dose=10uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| UF-27-HS98_1uM | Dose=1uM, Toyocamycin targeting ADK |
| AF-41-QY60_10uM | Dose=10uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| FB-66-UU47_0.1uM | Dose=0.1uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| PD-70-VS77_0.1uM | Dose=0.1uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide |
| BC-01-JL64_10uM | Dose=10uM, Calcimycin |
| QE-79-XO29_0.1uM | Dose=0.1uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3 |
| S0-EE-WJKI_10uM | Dose=10uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL |
| KA-75-LP02_10uM | Dose=10uM |
| KA-29-AB08_10uM | Dose=10uM, 4-(2-aminopyridin-4-yl)-N-(3-chlorophenyl)pyrimidin-2-amine, CDK1 Inhibitors targeting CDK1 |
| DF-84-RT50_10uM | Dose=10uM |
| YD-49-HM53_10uM | Dose=10uM, MELK inhibitor targeting MELK |
| PD-70-VS77_0.01uM | Dose=0.01uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide |
| GE-54-IF41_10uM | Dose=10uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3 |
| FF-86-NH56_0.1uM | Dose=0.1uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| AC-84-QG99_1uM | Dose=1uM |
| BC-25-VR48_10uM | Dose=10uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB |
| AB-18-YN11_1uM | Dose=1uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| GA-88-CF36_0.1uM | Dose=0.1uM, Brusatol |
| QA-50-YO37_10uM | Dose=10uM, Semapimod, inhibits TNF-alpha - proposed NO inhibitor and/or p38 MAPK pathway; proposed to act via vagus nerve targeting DHPS |
| DD-36-YH76_10uM | Dose=10uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| LC-12-VN85_10uM | Dose=10uM, (E)-N-hydroxy-3-[4-[(3-phenylpropylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| TB-06-VB30_10uM | Dose=10uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2 |
| FA-80-DR66_1uM | Dose=1uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| MD-86-UW46_10uM | Dose=10uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide |
| BC-54-ON71_0.1uM | Dose=0.1uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| AD-16-HL96_0.1uM | Dose=0.1uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| JD-81-YX02_10uM | Dose=10uM, Jnj-7706621, Aurora Kinase Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting CDK1, CDK2, AURKA, CCNA1 |
| DB-21-FY75_10uM | Dose=10uM, CID 67042933, CDK9 inhibitor targeting CDK9 |
| TA-34-CK62_10uM | Dose=10uM, 3-[[4-[2-(3-Chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propanamide, CDK1 Inhibitors targeting CDK1 |
| FA-63-WI26_0.1uM | Dose=0.1uM |
| FB-29-KC76_10uM | Dose=10uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5 |
| EE-03-SG02_0.1uM | Dose=0.1uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| TA-34-CK62_1uM | Dose=1uM, 3-[[4-[2-(3-Chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propanamide, CDK1 Inhibitors targeting CDK1 |
| ME-31-RM40_1uM | Dose=1uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AD-16-HL96_10uM | Dose=10uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| PD-70-VS77_1uM | Dose=1uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide |
| JC-06-ED36_1uM | Dose=1uM, CDDO-Im, PPARgamma Agonists;Apoptosis Inducers;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Nitric Oxide Production Inhibitors targeting NFE2L2, PPARG, KEAP1 |
| DA-27-BW40_10uM | Dose=10uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| HF-91-IU60_10uM | Dose=10uM, PD-166326, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, BCR, SRC, ABL2 |
| GA-88-CF36_10uM | Dose=10uM, Brusatol |
| FF-86-NH56_0.01uM | Dose=0.01uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| AC-30-XU83_1uM | Dose=1uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| YD-49-HM53_1uM | Dose=1uM, MELK inhibitor targeting MELK |
| WB-48-EF24_10uM | Dose=10uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1 |
| AB-18-YN11_10uM | Dose=10uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| BD-04-NG34_10uM | Dose=10uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2 |
| RD-90-OY66_10uM | Dose=10uM, Benzeneacetamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-(((2-hydroxy-1-(hydroxymethyl)ethyl)amino)methyl)-, CDK4 Inhibitors;CDK1 Inhibitors;CDK2/Cyclin E Inhibitors targeting CCNE1, CDK1, CDK2, CDK4, CCNE2 |
| CC-17-JL38_10uM | Dose=10uM, Ilk-IN-1 targeting ILK |
| GE-53-SM76_10uM | Dose=10uM |
| AB-33-EM56_10uM | Dose=10uM |
| BC-54-ON71_0.01uM | Dose=0.01uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| DB-54-GQ68_10uM | Dose=10uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| DB-54-GQ68_1uM | Dose=1uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| CD-05-PU90_10uM | Dose=10uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3 |
| DE-73-EF24_10uM | Dose=10uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| LF-94-HB11_10uM | Dose=10uM, Apicidin, HDAC inhibitor targeting HDAC3, HDAC4 |
| CE-96-GH46_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AD-00-WA10_10uM | Dose=10uM, 1-{4-[N-(2-isopropyloxyethyl)-N-chloroacetylamino]benzoyl}-4-[2-(4-chlorophenyl)ethyl]piperazine |
| FD-91-OK66_10uM | Dose=10uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| AA-23-FM46_0.1uM | Dose=0.1uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| UF-27-HS98_10uM | Dose=10uM, Toyocamycin targeting ADK |
| LC-12-VN85_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[(3-phenylpropylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| FF-86-NH56_1uM | Dose=1uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| AF-99-HA02_10uM | Dose=10uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| ME-31-RM40_0.1uM | Dose=0.1uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| WC-16-IR43_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AC-30-XU83_10uM | Dose=10uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| EE-03-SG02_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| KF-18-RY71_10uM | Dose=10uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4 |
| CE-96-GH46_10uM | Dose=10uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EC-62-OE64_1uM | Dose=1uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BE-79-QU25_0.1uM | Dose=0.1uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| IA-76-ZU47_10uM | Dose=10uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1 |
| BD-49-MD69_1uM | Dose=1uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| EE-03-SG02_0.01uM | Dose=0.01uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| FC-20-EQ58_1uM | Dose=1uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| BB-86-BE19_10uM | Dose=10uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| CA-75-HA22_10uM | Dose=10uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2 |
| GA-59-RW04_10uM | Dose=10uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| YA-78-MS95_1uM | Dose=1uM, 2164U90, Ileal Bile Acid Transporter (IBAT) Inhibitors targeting SLC10A2 |
| FA-36-VA24_10uM | Dose=10uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea |
| BB-11-JI42_10uM | Dose=10uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| DC-51-WE27_0.1uM | Dose=0.1uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| EC-62-OE64_0.1uM | Dose=0.1uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EE-03-SG02_10uM | Dose=10uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| BD-18-MM33_10uM | Dose=10uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CB-16-SY72_0.1uM | Dose=0.1uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| JF-30-FW92_10uM | Dose=10uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R |
| QF-71-QI30_10uM | Dose=10uM, 4-Dimethylamino-N-(7-hydroxycarbamoyl-heptyl)-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| XE-69-AT35_1uM | Dose=1uM, Nocardimicin A |
| VA-48-RJ44_10uM | Dose=10uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5 |
| BC-54-ON71_1uM | Dose=1uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| EA-18-FP00_1uM | Dose=1uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| LE-40-JW92_10uM | Dose=10uM |
| AA-23-FM46_1uM | Dose=1uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| HD-51-KD29_10uM | Dose=10uM, 5-bromo-2-N-[4-[3-(propan-2-ylamino)propylamino]phenyl]-4-N-pyridin-2-ylpyrimidine-2,4-diamine, Cyclin-Dependent Kinase Inhibitors targeting CDK4, CDKL5, CDK6 |
| FD-91-OK66_1uM | Dose=1uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| EF-74-KW12_10uM | Dose=10uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3 |
| FC-20-EQ58_10uM | Dose=10uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| AA-22-UI44_0.1uM | Dose=0.1uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| LF-94-HB11_1uM | Dose=1uM, Apicidin, HDAC inhibitor targeting HDAC3, HDAC4 |
| DE-69-QQ25_10uM | Dose=10uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| FF-86-NH56_10uM | Dose=10uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| WC-09-GD62_0.1uM | Dose=0.1uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1 |
| KA-81-AG66_10uM | Dose=10uM, Alvocidib, CDK9 inhibitor targeting CDK9, CCNB2 |
| GB-57-XV52_10uM | Dose=10uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1 |
| PD-05-HV36_10uM | Dose=10uM, N-[1-[[(1S,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl]piperidin-4-yl]-4-[(5-chloro-1-benzofuran-3-yl)methoxy]-1H-indole-2-carboxamide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2 |
| DA-20-VR86_1uM | Dose=1uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN |
| AA-99-PN83_10uM | Dose=10uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide |
| FB-66-UU47_1uM | Dose=1uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| EE-01-FB85_1uM | Dose=1uM, Indolactam V, PKC agonist targeting PRKCA |
| CF-87-AS90_10uM | Dose=10uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| ZE-45-CG69_10uM | Dose=10uM |
| AC-76-JB92_10uM | Dose=10uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2 |
| GD-66-XE49_10uM | Dose=10uM |
| AC-50-FR41_10uM | Dose=10uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| GA-88-CF36_1uM | Dose=1uM, Brusatol |
| AA-22-UI44_10uM | Dose=10uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CB-16-SY72_10uM | Dose=10uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| AA-11-RO46_10uM | Dose=10uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6 |
| DA-35-DU85_0.1uM | Dose=0.1uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| JB-74-LF71_10uM | Dose=10uM, 6-(6-(Diethylamino)pyridin-3-yl)-N-(4-morpholinophenyl)-9H-purin-2-amine, Jak3 Inhibitors targeting JAK3 |
| EC-82-LV30_10uM | Dose=10uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| GA-87-BR97_10uM | Dose=10uM |
| DC-51-WE27_1uM | Dose=1uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| LA-42-ER00_10uM | Dose=10uM, Arenobufagin, Arenobufagin, SMUT targeting PSMB1, PSMB2, PSMB5, ATP1B4 |
| CB-24-FA25_10uM | Dose=10uM, Spiperone |
| FF-06-MO73_10uM | Dose=10uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3 |
| QA-50-YO37_1uM | Dose=1uM, Semapimod, inhibits TNF-alpha - proposed NO inhibitor and/or p38 MAPK pathway; proposed to act via vagus nerve targeting DHPS |
| PD-70-VS77_10uM | Dose=10uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide |
| AB-09-EA37_10uM | Dose=10uM |
| FE-82-WB22_10uM | Dose=10uM, MRT67307 HCl targeting ULK1 |
| BF-02-AC35_10uM | Dose=10uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| DF-00-DK69_10uM | Dose=10uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1 |
| CC-68-YZ44_10uM | Dose=10uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| GB-46-CK08_10uM | Dose=10uM |
| AA-99-HO76_1uM | Dose=1uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1 |
| DE-97-IV02_10uM | Dose=10uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1 |
| AC-86-KF37_10uM | Dose=10uM, Capzimin, Proteasome inhibitor targeting PSMD14 |
| PB-18-HD85_10uM | Dose=10uM |
| VA-06-DB75_10uM | Dose=10uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA |
| BF-97-LS55_1uM | Dose=1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| CB-55-AK76_10uM | Dose=10uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| KA-29-AB08_0.1uM | Dose=0.1uM, 4-(2-aminopyridin-4-yl)-N-(3-chlorophenyl)pyrimidin-2-amine, CDK1 Inhibitors targeting CDK1 |
| WC-16-IR43_10uM | Dose=10uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| ZB-16-BR73_1uM | Dose=1uM, N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide, p53 tumor suppressor protein inhibitor targeting TP53 |
| JD-44-KF86_1uM | Dose=1uM, Cinobufagin, Na+/K+-ATPase Inhibitors;Cinobufagin, SMUT;Chloride Channel Activators targeting ATAD5 |
| BD-69-GX17_10uM | Dose=10uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| GB-57-XV52_1uM | Dose=1uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1 |
| NA-30-HS87_1uM | Dose=1uM, Gsk-J4, KDM6A gene inhibitor, KDM6B gene inhibitor;pan-KDM6 family (KDM6A / KDM6B / UTY);Histone demethylation inhibitors targeting KDM6A, KDM6B |
| OF-05-CB18_1uM | Dose=1uM |
| CE-18-AP15_10uM | Dose=10uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BB-23-PM31_10uM | Dose=10uM, 4-(1-Methylpiperidin-4-yl)oxy-5-propan-2-yl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| FE-10-KQ78_10uM | Dose=10uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| BC-62-RZ55_10uM | Dose=10uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4 |
| AE-39-DG66_10uM | Dose=10uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BC-40-TU13_10uM | Dose=10uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C |
| AE-39-DG66_0.1uM | Dose=0.1uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| SE-15-AV21_10uM | Dose=10uM, 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea, Eukaryotic Translation Initiation Factor 2-alpha Kinase 1 (HRI) Activators targeting EIF2AK1 |
| KA-81-AG66_1uM | Dose=1uM, Alvocidib, CDK9 inhibitor targeting CDK9, CCNB2 |
| LA-42-ER00_1uM | Dose=1uM, Arenobufagin, Arenobufagin, SMUT targeting PSMB1, PSMB2, PSMB5, ATP1B4 |
| AE-85-LR48_10uM | Dose=10uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7 |
| BA-88-HT15_10uM | Dose=10uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| HF-91-IU60_1uM | Dose=1uM, PD-166326, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, BCR, SRC, ABL2 |
| FE-10-KQ78_1uM | Dose=1uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| AC-05-MR83_10uM | Dose=10uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| CF-65-GU65_10uM | Dose=10uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| PF-59-CY33_10uM | Dose=10uM, 8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-1-(3-methyl-1-propan-2-ylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one, dual mTOR PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| YA-78-MS95_10uM | Dose=10uM, 2164U90, Ileal Bile Acid Transporter (IBAT) Inhibitors targeting SLC10A2 |
| CC-61-HH09_10uM | Dose=10uM, 6-Chrysenamine targeting HPRT1 |
| AA-94-TU18_10uM | Dose=10uM |
| AE-95-UU45_1uM | Dose=1uM, Terguride, Prolactin Secretion Inhibitors;5-HT2A Antagonists;5-HT2B Antagonists targeting DRD2, HTR2A, HTR2B, PRL |
| GC-04-UF36_0.1uM | Dose=0.1uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| EC-62-OE64_10uM | Dose=10uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| GB-46-CK08_1uM | Dose=1uM |
| HC-74-HM63_10uM | Dose=10uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| AF-72-PP21_10uM | Dose=10uM, Donepezil, Acetylcholinesterase Inhibitors targeting ACHE |
| KB-46-EJ60_10uM | Dose=10uM |
| FF-28-ES17_1uM | Dose=1uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| FC-85-OX77_10uM | Dose=10uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| BD-18-MM33_1uM | Dose=1uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BD-11-DV28_10uM | Dose=10uM |
| QA-14-AU91_10uM | Dose=10uM, Cephalochromin, Phosphodiesterase Inhibitors;NOS2 Expression Inhibitors targeting NOS2 |
| ZD-18-MI26_10uM | Dose=10uM, N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide, Calcitonin Gene-Related Peptides (CGRP) Antagonists targeting CALCRL |
| VD-88-MW70_10uM | Dose=10uM, [4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine, CDK Inhibitor;Pan Kinase Inhibitor targeting CDK2, CCNE2 |
| BE-28-WW67_10uM | Dose=10uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BD-69-XG81_0.1uM | Dose=0.1uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| BB-77-QQ71_10uM | Dose=10uM, Ricolinostat, HDAC6 targeting HDAC6 |
| CC-68-YZ44_1uM | Dose=1uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BA-56-QV45_10uM | Dose=10uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1 |
| AC-74-ZA35_10uM | Dose=10uM, Golgicide A, Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors targeting GBF1 |
| JF-62-LU77_10uM | Dose=10uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN |
| JD-44-KF86_10uM | Dose=10uM, Cinobufagin, Na+/K+-ATPase Inhibitors;Cinobufagin, SMUT;Chloride Channel Activators targeting ATAD5 |
| AC-50-FR41_0.1uM | Dose=0.1uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| GF-35-IT27_1uM | Dose=1uM |
| LB-67-JK40_10uM | Dose=10uM |
| GC-04-UF36_10uM | Dose=10uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| PB-09-OE00_10uM | Dose=10uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DA-33-BM26_10uM | Dose=10uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| KE-73-XV62_10uM | Dose=10uM, Tubercidin |
| AA-58-FJ71_0.01uM | Dose=0.01uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| HB-06-WU12_0.1uM | Dose=0.1uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| EA-18-FP00_10uM | Dose=10uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| UD-07-US73_10uM | Dose=10uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB |
| BB-87-SF89_1uM | Dose=1uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| AC-50-FR41_1uM | Dose=1uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AA-23-FM46_10uM | Dose=10uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| ME-31-RM40_10uM | Dose=10uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| WE-43-PZ45_10uM | Dose=10uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone |
| S0-EE-Y4UM_10uM | Dose=10uM, (1R)-1-(3,4-dichlorophenyl)-2-[2-imino-3-[(2-methylphenyl)methyl]benzimidazol-1-yl]ethanol, small-molecule antogonist of CBX7ChD binding to H3K27me3 when the protein is bound to RNA targeting CBX7 |
| CD-13-QZ32_10uM | Dose=10uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| GD-79-TW34_10uM | Dose=10uM, N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide, SIRT1;Histone Deacetylase SIRT1 Activators targeting SIRT1 |
| KB-78-BE93_0.1uM | Dose=0.1uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4 |
| QA-07-KC40_10uM | Dose=10uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| QA-07-KC40_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AC-43-ZC52_1uM | Dose=1uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3 |
| BE-17-CS60_1uM | Dose=1uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| RB-34-TO07_10uM | Dose=10uM, N'-[4-[[4-[Hydroxybis[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-urea, EHMT2 inhibitor targeting EHMT2 |
| WC-09-GD62_1uM | Dose=1uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1 |
| DD-42-PC65_10uM | Dose=10uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| AA-58-FJ71_0.1uM | Dose=0.1uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| AB-30-CR11_10uM | Dose=10uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| QB-42-MC63_1uM | Dose=1uM, [4-[4-[[Methyl(prop-2-enyl)amino]methyl]phenyl]phenyl]-phenylmethanone, Lanosterol Synthase Inhibitors targeting LSS |
| KB-78-BE93_10uM | Dose=10uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4 |
| AC-35-CK01_10uM | Dose=10uM, Mitonafide |
| CB-16-SY72_1uM | Dose=1uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| HA-22-CY42_10uM | Dose=10uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| GA-59-RW04_1uM | Dose=1uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| AB-71-CI37_0.1uM | Dose=0.1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| LA-42-ER00_0.1uM | Dose=0.1uM, Arenobufagin, Arenobufagin, SMUT targeting PSMB1, PSMB2, PSMB5, ATP1B4 |
| GC-69-JF03_10uM | Dose=10uM |
| KE-37-MN32_10uM | Dose=10uM, Psammaplin D, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-32-DP01_10uM | Dose=10uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1 |
| HC-74-HM63_0.1uM | Dose=0.1uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| PF-59-CY33_1uM | Dose=1uM, 8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-1-(3-methyl-1-propan-2-ylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one, dual mTOR PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| BE-17-CS60_10uM | Dose=10uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| YE-80-LN04_10uM | Dose=10uM |
| AD-06-OB47_1uM | Dose=1uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| FA-88-II68_10uM | Dose=10uM |
| AD-16-HL96_1uM | Dose=1uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| SA-53-XG95_10uM | Dose=10uM, N-(1S-[2-{4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]-1-piperazinyl}-5-chlorophenyl]-3-methylbutyl)-3-(dimethylamino)propionamide, Melanocortin MC4 Receptor Antagonists targeting MC4R |
| RA-27-ST16_10uM | Dose=10uM, Istaroxime, Na+/K+-ATPase Inhibitors;SERCA2a Activator targeting ATP2A2, ATP1B1, ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B2, ATP1B3, FXYD2, ATP1B4 |
| GE-29-ZM45_10uM | Dose=10uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| S0-EE-Y7IR_10uM | Dose=10uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1 |
| NB-12-ZK38_10uM | Dose=10uM, 4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid, BET bromodomain inhibitor targeting BRDT, BRD2, BRD3, BRD4 |
| KB-78-BE93_1uM | Dose=1uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4 |
| WC-16-IR43_0.1uM | Dose=0.1uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| FB-49-NW04_10uM | Dose=10uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3 |
| WB-54-WD35_1uM | Dose=1uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B |
| WC-09-GD62_10uM | Dose=10uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1 |
| FC-22-VC55_10uM | Dose=10uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR |
| AB-33-EM56_1uM | Dose=1uM |
| IC-28-HS37_10uM | Dose=10uM, Nvs-cecr2-1, CECR2 inhibitor;CECR2 inhbitor targeting CECR2 |
| OA-54-FL10_10uM | Dose=10uM |
| CB-55-AK76_1uM | Dose=1uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| DC-93-NP78_10uM | Dose=10uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN |
| BE-04-AN21_10uM | Dose=10uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| BD-38-QC39_10uM | Dose=10uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| BE-79-QU25_10uM | Dose=10uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| AF-30-GH67_10uM | Dose=10uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| EC-37-MB09_10uM | Dose=10uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| AC-49-NG46_10uM | Dose=10uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| JB-14-ZM03_10uM | Dose=10uM, Idronoxil, Apoptosis Inducers;BIRC4 Expression Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Inhibitors of Signal Transduction Pathways;Sphingosine Kinase Inhibitors targeting ENOX2, SPHK2 |
| BA-84-WN26_0.1uM | Dose=0.1uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| AF-83-BX08_10uM | Dose=10uM |
| AE-85-KE62_10uM | Dose=10uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| DF-00-BU08_10uM | Dose=10uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4 |
| QE-79-XO29_10uM | Dose=10uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3 |
| NF-21-HQ00_1uM | Dose=1uM, Cct251236 targeting PIR |
| DF-75-OU25_10uM | Dose=10uM, Dot1L-IN-4 |
| JE-72-KV75_10uM | Dose=10uM, 6-Chloro-2-(2-Fluoro-4,5-Dimethoxyphenyl)-N-(Piperidin-4-Ylmethyl)-3h-Imidazo[4,5-B]pyridin-7-Amine, JAK1 selective inhibitors targeting CDK2, JAK1, AURKB |
| UD-07-US73_1uM | Dose=1uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB |
| AB-97-BI36_10uM | Dose=10uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| GA-94-MC54_1uM | Dose=1uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4 |
| BC-61-ZY95_10uM | Dose=10uM |
| AB-71-CI37_10uM | Dose=10uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| NE-00-JZ19_10uM | Dose=10uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ |
| BB-87-SF89_0.1uM | Dose=0.1uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| VD-76-SO91_1uM | Dose=1uM, N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide, NF-kappaB (NFKB) Activation Inhibitors;Antiinflammatory Drugs targeting NFKB1 |
| AA-88-PJ86_1uM | Dose=1uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5 |
| GA-28-SS67_1uM | Dose=1uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| ZB-29-GC39_10uM | Dose=10uM |
| JD-62-HR05_10uM | Dose=10uM, (1S,3R)-Rsl3, GPX4 covalent inhibitor targeting GPX4 |
| DA-35-DU85_0.01uM | Dose=0.01uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| BB-20-UU03_10uM | Dose=10uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| HE-16-PO98_10uM | Dose=10uM, Azd-5153, inhibitor of BRD4 targeting BRD4 |
| GA-01-EO66_10uM | Dose=10uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1 |
| HA-99-PM50_10uM | Dose=10uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| BD-93-AM31_10uM | Dose=10uM, Veliparib targeting PARP1, PARP2 |
| LD-69-ZV56_10uM | Dose=10uM, 11-Desethyl Irinotecan |
| AC-84-QG99_0.1uM | Dose=0.1uM |
| YF-00-IN39_10uM | Dose=10uM |
| BB-44-SX65_10uM | Dose=10uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| VD-88-MW70_1uM | Dose=1uM, [4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine, CDK Inhibitor;Pan Kinase Inhibitor targeting CDK2, CCNE2 |
| AD-54-FG24_10uM | Dose=10uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB |
| DB-56-XL71_1uM | Dose=1uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| FF-28-ES17_10uM | Dose=10uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| CB-02-XL81_0.1uM | Dose=0.1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| MA-43-MR37_10uM | Dose=10uM |
| HD-19-IW09_10uM | Dose=10uM |
| UF-06-JB00_10uM | Dose=10uM, ethyl N-[4-[(E)-3-(4-morpholin-4-ylquinolin-2-yl)prop-2-enoyl]phenyl]carbamate, TNF-alpha Production Inhibitors;Heat Shock Protein 70 (hsp70) Inducers targeting HSPA1A |
| TB-06-VB30_1uM | Dose=1uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2 |
| KA-29-AB08_1uM | Dose=1uM, 4-(2-aminopyridin-4-yl)-N-(3-chlorophenyl)pyrimidin-2-amine, CDK1 Inhibitors targeting CDK1 |
| CA-75-HA22_1uM | Dose=1uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2 |
| AE-13-CX28_10uM | Dose=10uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3 |
| AA-18-GQ83_0.1uM | Dose=0.1uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| AC-47-YZ27_10uM | Dose=10uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2 |
| BC-00-YH62_1uM | Dose=1uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| GA-16-IU17_10uM | Dose=10uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| AB-85-JR73_0.1uM | Dose=0.1uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| CB-55-AK76_0.1uM | Dose=0.1uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| BA-68-FJ41_10uM | Dose=10uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BB-87-SF89_10uM | Dose=10uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| PD-60-FM93_1uM | Dose=1uM, Cathepsin G Inhibitor I, Dual mast cell chymase, Cathepsin G inhibitor targeting CMA1, CTSG |
| CA-68-KG29_1uM | Dose=1uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| AE-32-DP61_10uM | Dose=10uM, Cpi-203, BRD4 gene inhibitor targeting BRD4 |
| TA-19-YA45_10uM | Dose=10uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1 |
| SB-94-ZA83_10uM | Dose=10uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| CB-49-OG36_10uM | Dose=10uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1 |
| YA-44-LW45_10uM | Dose=10uM, 4-(4-Chlorophenyl)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propyl]piperidin-4-ol, Chemokine CC Antagonists;Antiinflammatory Drugs targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| RD-90-OY66_1uM | Dose=1uM, Benzeneacetamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-(((2-hydroxy-1-(hydroxymethyl)ethyl)amino)methyl)-, CDK4 Inhibitors;CDK1 Inhibitors;CDK2/Cyclin E Inhibitors targeting CCNE1, CDK1, CDK2, CDK4, CCNE2 |
| DA-10-GX45_0.1uM | Dose=0.1uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| VA-92-QP54_10uM | Dose=10uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R |
| NF-21-HQ00_0.1uM | Dose=0.1uM, Cct251236 targeting PIR |
| GA-77-MH38_10uM | Dose=10uM |
| ED-91-LY45_10uM | Dose=10uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B |
| AA-18-GQ83_10uM | Dose=10uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| AA-52-JS03_10uM | Dose=10uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| HE-16-PO98_1uM | Dose=1uM, Azd-5153, inhibitor of BRD4 targeting BRD4 |
| AB-80-CK34_10uM | Dose=10uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| FF-34-KW62_10uM | Dose=10uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| GC-04-UF36_1uM | Dose=1uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| BC-33-BM51_10uM | Dose=10uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| BF-49-QA17_1uM | Dose=1uM, Vaf347 |
| DB-88-VW47_10uM | Dose=10uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3 |
| DB-21-FY75_1uM | Dose=1uM, CID 67042933, CDK9 inhibitor targeting CDK9 |
| BE-81-QL64_10uM | Dose=10uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| BD-61-OO16_10uM | Dose=10uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| NA-16-OJ70_1uM | Dose=1uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| ND-15-RC31_10uM | Dose=10uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1 |
| PC-80-LV29_10uM | Dose=10uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide |
| QB-35-FO29_0.1uM | Dose=0.1uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12 |
| CA-68-KG29_10uM | Dose=10uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| EA-62-MI89_10uM | Dose=10uM, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, Apoptosis Inducers;Wnt Signaling Inhibitors;CREBBP - beta-catenin interaction inhibitor targeting CREBBP, CTNNB1 |
| AA-68-OJ16_10uM | Dose=10uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| BA-84-WN26_10uM | Dose=10uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| OB-17-DQ74_10uM | Dose=10uM, Selinexor, Exportin 1 inhibitor targeting XPO1 |
| BB-87-SF89_0.01uM | Dose=0.01uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| DC-22-OP01_10uM | Dose=10uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4 |
| BB-86-BE19_1uM | Dose=1uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| AA-58-FJ71_10uM | Dose=10uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| AE-56-SL06_10uM | Dose=10uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1 |
| MA-58-RR04_1uM | Dose=1uM, VU-0238429, M5 positive allosteric modulator targeting CHRM5 |
| CB-87-RB49_10uM | Dose=10uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| AB-12-IS33_1uM | Dose=1uM, Melphalan |
| GA-88-PV69_10uM | Dose=10uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| BE-61-OB65_0.01uM | Dose=0.01uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| FF-28-ES17_0.1uM | Dose=0.1uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| EF-73-IP33_10uM | Dose=10uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| MA-58-RR04_10uM | Dose=10uM, VU-0238429, M5 positive allosteric modulator targeting CHRM5 |
| EF-80-OD07_10uM | Dose=10uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-33-EM56_0.1uM | Dose=0.1uM |
| DB-56-XL71_0.1uM | Dose=0.1uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| AC-30-XU83_0.01uM | Dose=0.01uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| BE-31-XV38_10uM | Dose=10uM, Camptothecin, topoisomerase I targeting TOP1 |
| HC-74-HM63_1uM | Dose=1uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| AD-86-OB87_10uM | Dose=10uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2 |
| BA-29-OX17_10uM | Dose=10uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| AA-62-JP26_10uM | Dose=10uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| KC-48-OO62_10uM | Dose=10uM, PKC theta inhibitor targeting PRKCQ |
| PD-71-MW24_10uM | Dose=10uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA |
| AC-36-TL21_10uM | Dose=10uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1 |
| XA-12-UL84_10uM | Dose=10uM |
| JE-04-LS32_10uM | Dose=10uM |
| CF-24-KQ98_10uM | Dose=10uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| BA-59-EN38_10uM | Dose=10uM |
| TD-17-NF32_10uM | Dose=10uM |
| KB-17-PN92_10uM | Dose=10uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate |
| CB-99-OG76_10uM | Dose=10uM |
| CE-20-VA70_10uM | Dose=10uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| KA-63-FH23_10uM | Dose=10uM, Cgp 77675, Src Kinase Inhibitors targeting SRC |
| BB-42-FF52_10uM | Dose=10uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ |
| BB-79-AG41_10uM | Dose=10uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| GD-82-CS38_10uM | Dose=10uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| BD-93-AM31_0.1uM | Dose=0.1uM, Veliparib targeting PARP1, PARP2 |
| AD-51-SS86_10uM | Dose=10uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2 |
| GA-10-WX15_0.01uM | Dose=0.01uM |
| KA-62-FE69_10uM | Dose=10uM, 2-Methoxy-N-(3-Methyl-2-Oxo-1,2,3,4-Tetrahydroquinazolin-6-Yl)benzenesulfonamide, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| BD-96-HO33_1uM | Dose=1uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1 |
| TD-48-XJ84_10uM | Dose=10uM, 4-[2-Methoxy-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]benzonitrile |
| NB-12-ZK38_1uM | Dose=1uM, 4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid, BET bromodomain inhibitor targeting BRDT, BRD2, BRD3, BRD4 |
| TF-29-QU48_10uM | Dose=10uM |
| BB-79-AG41_1uM | Dose=1uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| DF-26-EY87_10uM | Dose=10uM |
| JF-96-HH81_0.1uM | Dose=0.1uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5 |
| CB-02-XL81_1uM | Dose=1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| AA-52-JS03_1uM | Dose=1uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| PC-62-AQ92_1uM | Dose=1uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD |
| ZD-85-ND87_10uM | Dose=10uM |
| HD-62-KE69_1uM | Dose=1uM, Roflumilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4, PDE2A |
| ID-90-NM43_10uM | Dose=10uM, Rx-5902, phosphorylated-p68 RNA helicase inhibitor targeting DDX5 |
| JE-22-JR20_0.1uM | Dose=0.1uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1 |
| EC-89-AJ93_10uM | Dose=10uM, Valinomycin |
| BA-84-WN26_1uM | Dose=1uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| IB-56-JN40_10uM | Dose=10uM, Y-33075, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| BE-79-QU25_1uM | Dose=1uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| BA-84-TD72_10uM | Dose=10uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| GA-28-SS67_0.1uM | Dose=0.1uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| AC-55-XA97_10uM | Dose=10uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| KE-58-BO47_10uM | Dose=10uM, Bms 433771 |
| FA-80-DR66_10uM | Dose=10uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| HD-89-HC56_10uM | Dose=10uM, eIF4A3-IN-2 targeting EIF4A3 |
| XB-53-OZ95_10uM | Dose=10uM |
| QC-76-GI57_10uM | Dose=10uM |
| HA-22-CY42_1uM | Dose=1uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DA-58-LZ09_10uM | Dose=10uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13 |
| AB-30-CR11_1uM | Dose=1uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| BB-04-KA05_1uM | Dose=1uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| FA-63-WI26_10uM | Dose=10uM |
| DB-34-KT45_1uM | Dose=1uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| YB-58-IZ37_10uM | Dose=10uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4 |
| BA-50-HH67_10uM | Dose=10uM, Tomatidine |
| EC-89-AJ93_0.1uM | Dose=0.1uM, Valinomycin |
| EE-02-BO83_10uM | Dose=10uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| KA-75-LP02_1uM | Dose=1uM |
| CE-18-AP85_10uM | Dose=10uM |
| KB-65-GP42_10uM | Dose=10uM, 4-[(4-Amino-5-cyanopyrimidin-2-yl)amino]benzenesulfonamide, CDK2 Inhibitors targeting CDK2 |
| AA-68-OJ16_1uM | Dose=1uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| OE-75-WF43_10uM | Dose=10uM, 8-(2-(3,5-Dimethylpiperazin-1-yl)-4- targeting EED |
| FC-35-BX82_10uM | Dose=10uM, Cyclosporin V |
| HE-16-PO98_0.1uM | Dose=0.1uM, Azd-5153, inhibitor of BRD4 targeting BRD4 |
| HB-77-UY14_0.1uM | Dose=0.1uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B |
| BA-53-FM66_1uM | Dose=1uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN |
| S0-EE-YMWJ_10uM | Dose=10uM, TX1-85-1, ERBB3 covalent inhibitor targeting ERBB3 |
| KB-92-MK13_1uM | Dose=1uM, 4-Cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonitrile, TNF-alpha Production Inhibitors;Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8 |
| DC-45-WU45_10uM | Dose=10uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2 |
| BD-96-HO33_10uM | Dose=10uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1 |
| AD-52-UZ45_10uM | Dose=10uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| AE-52-NW93_10uM | Dose=10uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| BB-86-UL91_10uM | Dose=10uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| AC-75-LR63_10uM | Dose=10uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10 |
| DE-62-FI29_1uM | Dose=1uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| XD-08-ZW85_10uM | Dose=10uM |
| WC-09-GD62_0.01uM | Dose=0.01uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1 |
| DC-47-KV62_10uM | Dose=10uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| CB-44-RT90_10uM | Dose=10uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| YF-77-FV50_10uM | Dose=10uM |
| YB-58-IZ37_0.1uM | Dose=0.1uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4 |
| CD-35-BD44_10uM | Dose=10uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| BC-09-XQ45_10uM | Dose=10uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2 |
| HC-76-PX74_0.1uM | Dose=0.1uM |
| RD-92-QT24_10uM | Dose=10uM, Autophinib targeting PIK3C3 |
| AE-32-DP61_1uM | Dose=1uM, Cpi-203, BRD4 gene inhibitor targeting BRD4 |
| JE-22-JR20_10uM | Dose=10uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1 |
| EF-85-DA07_10uM | Dose=10uM |
| RA-86-LI22_10uM | Dose=10uM, Bromosporine |
| DB-24-CQ08_10uM | Dose=10uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol |
| AB-21-VE32_10uM | Dose=10uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AA-86-YY62_10uM | Dose=10uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12 |
| GF-90-DG49_10uM | Dose=10uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| AD-86-OB87_1uM | Dose=1uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2 |
| VA-06-DB75_1uM | Dose=1uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA |
| MA-06-DJ95_10uM | Dose=10uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7 |
| EC-82-LV30_1uM | Dose=1uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| XC-81-LR46_10uM | Dose=10uM |
| BE-42-IC00_10uM | Dose=10uM, Zygosporin A, actin polymerization targeting ACTA1 |
| EC-41-PH99_10uM | Dose=10uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide |
| DC-23-UM36_10uM | Dose=10uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DC-70-EK34_10uM | Dose=10uM, BF-844, CLRN stabilizer targeting CLRN1 |
| ED-02-CL76_10uM | Dose=10uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT |
| BE-92-TW08_10uM | Dose=10uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1 |
| EB-09-LQ45_0.1uM | Dose=0.1uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| AD-06-OB47_10uM | Dose=10uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| FD-59-TC81_10uM | Dose=10uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4 |
| DA-10-GX45_10uM | Dose=10uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| RB-55-KL42_1uM | Dose=1uM |
| BA-95-YU85_10uM | Dose=10uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| FD-20-OG99_10uM | Dose=10uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| EC-89-AJ93_1uM | Dose=1uM, Valinomycin |
| FD-25-KX07_10uM | Dose=10uM |
| SC-25-HE80_10uM | Dose=10uM, 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-methylphenyl]-3-(trifluoromethyl)benzamide, DDR tyrosine kinase receptor inhibitor targeting DDR1, DDR2 |
| AE-51-ZO26_10uM | Dose=10uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9 |
| HB-54-ZC59_10uM | Dose=10uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2 |
| AF-67-LZ82_10uM | Dose=10uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| UC-58-DM11_10uM | Dose=10uM, Pozanicline, Nicotinic Receptor Partial Agonists targeting CHRNA4, CHRNB2 |
| IC-18-TY61_10uM | Dose=10uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD |
| CE-04-HT15_10uM | Dose=10uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1 |
| BE-27-XF09_10uM | Dose=10uM, (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione, bacterial DNA Primase Inhibitors;tat Inhibitors targeting PRIM1 |
| QA-34-PH05_0.1uM | Dose=0.1uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2 |
| DA-27-BW40_1uM | Dose=1uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| DC-84-GJ21_10uM | Dose=10uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK |
| KD-68-JH25_10uM | Dose=10uM, Devazepide, CCK1 (CCKA) Antagonists targeting CCKAR |
| MA-31-VM30_10uM | Dose=10uM, Sabeluzole |
| QA-58-CX23_10uM | Dose=10uM, N-hydroxy-2-[(1-naphthalen-2-ylsulfonylpiperidin-3-yl)methylamino]pyrimidine-5-carboxamide |
| AF-00-QK19_10uM | Dose=10uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA |
| HA-42-TE64_0.1uM | Dose=0.1uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| FA-10-SN61_10uM | Dose=10uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN |
| HC-11-RK51_10uM | Dose=10uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| DA-81-VY50_10uM | Dose=10uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG |
| FA-47-IB34_10uM | Dose=10uM |
| FE-29-XM40_10uM | Dose=10uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2 |
| NE-20-WM78_10uM | Dose=10uM, Cct-241533, Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2 |
| AA-39-BD24_1uM | Dose=1uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1 |
| EF-73-IP33_1uM | Dose=1uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| UF-27-HS98_0.1uM | Dose=0.1uM, Toyocamycin targeting ADK |
| PF-84-RH50_10uM | Dose=10uM |
| BE-49-XN43_1uM | Dose=1uM |
| ZB-29-GC39_1uM | Dose=1uM |
| JA-63-WB39_10uM | Dose=10uM |
| BC-13-OQ01_0.1uM | Dose=0.1uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| PD-26-DC63_10uM | Dose=10uM, Diazepinomicin, 5-Lipoxygenase Inhibitors;Apoptosis Inducers;MAPK-Activated Protein Kinase Inhibitors;Peripheral Benzodiazepine Receptor (PBR) Ligands targeting ALOX5, TSPO |
| KB-78-BE93_0.01uM | Dose=0.01uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4 |
| FD-49-XC21_10uM | Dose=10uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| IA-76-ZU47_1uM | Dose=1uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1 |
| WB-17-DI74_10uM | Dose=10uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2 |
| WD-26-EB85_0.01uM | Dose=0.01uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1 |
| HE-80-BQ08_10uM | Dose=10uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1 |
| AC-97-KP88_10uM | Dose=10uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| CB-31-UO16_10uM | Dose=10uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1 |
| MF-37-KQ09_10uM | Dose=10uM, 7alpha-Hydroxydehydroepiandrosterone, Estrogen Receptor (ER) beta Ligands targeting ESR2 |
| CE-18-ZM38_10uM | Dose=10uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ |
| CC-18-YW57_1uM | Dose=1uM |
| LD-69-ZV56_1uM | Dose=1uM, 11-Desethyl Irinotecan |
| FE-56-PV35_10uM | Dose=10uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B |
| AF-00-QK19_1uM | Dose=1uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA |
| FE-82-WB22_1uM | Dose=1uM, MRT67307 HCl targeting ULK1 |
| AD-30-VB23_10uM | Dose=10uM, Rotenone, Apoptosis Inducers;NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitors;Non-Steroidal Antiinflammatory Drugs;Electron Transport Chain Inhibitors;Electron transport chain inhibitor targeting NDUFS1, NOX4, NOX5 |
| DE-98-FC24_1uM | Dose=1uM |
| AC-83-LN99_10uM | Dose=10uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3 |
| LD-47-RN92_10uM | Dose=10uM, 1-(3,3-Dimethylbutyl)-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| AD-58-PW17_10uM | Dose=10uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| AB-97-BI36_1uM | Dose=1uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| SC-72-YW56_10uM | Dose=10uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5 |
| BA-39-HG26_10uM | Dose=10uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2 |
| QB-88-PG52_10uM | Dose=10uM, 2-Benzyloxy-4H-3,1-benzoxazin-4-one, Cathepsin G inhibitor targeting CTSG |
| PC-68-DU31_10uM | Dose=10uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1 |
| AC-36-FB52_10uM | Dose=10uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| LC-12-VN85_0.1uM | Dose=0.1uM, (E)-N-hydroxy-3-[4-[(3-phenylpropylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| JF-96-HH81_10uM | Dose=10uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5 |
| YC-45-JD42_10uM | Dose=10uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate |
| ND-68-CU31_10uM | Dose=10uM, MR 16728, Acetylcholine Release Enhancers targeting KCNN4 |
| EA-02-ZO63_10uM | Dose=10uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3 |
| GA-81-DL34_10uM | Dose=10uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7 |
| KC-32-GO33_1uM | Dose=1uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7 |
| CA-25-LR28_10uM | Dose=10uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| JF-96-HH81_0.01uM | Dose=0.01uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5 |
| QE-18-WG07_10uM | Dose=10uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2 |
| LE-60-VC29_10uM | Dose=10uM, N-(2,4-dichlorobenzyl)-1-benzyl-5-oxopyrrolidine-3-carboxamide, P2X7 Receptor Antagonists targeting P2RX7 |
| AF-30-GH67_1uM | Dose=1uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| RD-92-QT24_1uM | Dose=1uM, Autophinib targeting PIK3C3 |
| PB-09-OE00_1uM | Dose=1uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DA-27-BW20_10uM | Dose=10uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| BA-95-YU85_1uM | Dose=1uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| CF-24-KQ98_1uM | Dose=1uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| FF-22-NB12_1uM | Dose=1uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| DE-20-VX20_10uM | Dose=10uM |
| AC-28-RT00_10uM | Dose=10uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| AE-88-WQ63_10uM | Dose=10uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB |
| GE-40-GQ38_10uM | Dose=10uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| HB-77-UY14_10uM | Dose=10uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B |
| CA-64-LT35_0.1uM | Dose=0.1uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| S0-EE-Y7IR_1uM | Dose=1uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1 |
| LD-39-FL02_10uM | Dose=10uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside |
| DE-80-BU08_10uM | Dose=10uM, DC_AC50, ATOX1 inhibitor targeting ATOX1 |
| KC-32-GO33_10uM | Dose=10uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7 |
| EA-84-SC49_10uM | Dose=10uM, (3-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone, CDK inhibitor targeting CDK2, CDK4, CCNA1 |
| CD-59-MG26_10uM | Dose=10uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| JD-44-KF86_0.1uM | Dose=0.1uM, Cinobufagin, Na+/K+-ATPase Inhibitors;Cinobufagin, SMUT;Chloride Channel Activators targeting ATAD5 |
| FD-59-TC81_0.1uM | Dose=0.1uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4 |
| AC-51-WE57_10uM | Dose=10uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| S0-EE-Y6WJ_1uM | Dose=1uM, 4-(2-Amino-1,3-benzothiazol-6-yl)-1-(cyclopropylmethyl)pyridin-2-one, PI4KA gene inhibitor targeting PI4KA |
| CA-66-YB17_10uM | Dose=10uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A |
| CC-31-VS31_10uM | Dose=10uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1 |
| TD-40-ZR64_10uM | Dose=10uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-cyclopropylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide |
| S0-EE-YEKU_10uM | Dose=10uM, (E)-6-Chloro-3-(3-(5-fluoropyridin-3-yl)acryloyl)-4-phenylquinolin-2(1H)-one, EIF4G gene inhibitor targeting EIF4G1 |
| TE-15-RO34_1uM | Dose=1uM, N-[1-[[5-chloro-2-(cyclopropylmethoxy)phenyl]methyl]-5-methylpyrazol-3-yl]-1,2,3,4-tetrahydroisoquinoline-6-carboxamide, SCD gene inhibitor targeting SCD |
| FB-66-UU47_0.01uM | Dose=0.01uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| AC-28-RT00_0.01uM | Dose=0.01uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| FA-88-II68_1uM | Dose=1uM |
| NF-24-NB76_10uM | Dose=10uM, N-(3-(5-Amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-chloropicolinamide, beta-Secretase 1 (BACE1) Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting BACE1, BACE2 |
| VA-48-RJ44_1uM | Dose=1uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5 |
| RD-50-EO07_10uM | Dose=10uM, Efipladib, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| BB-62-SZ35_10uM | Dose=10uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| ND-54-NO97_10uM | Dose=10uM, 3-Epioleanolic acid |
| AB-21-VE32_1uM | Dose=1uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AC-75-CE67_10uM | Dose=10uM |
| DC-23-UM36_1uM | Dose=1uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| OB-17-DQ74_1uM | Dose=1uM, Selinexor, Exportin 1 inhibitor targeting XPO1 |
| JA-85-SW39_1uM | Dose=1uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2 |
| AC-28-RT00_0.1uM | Dose=0.1uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| CB-73-HZ47_10uM | Dose=10uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| LB-65-SM65_10uM | Dose=10uM, Imd-0354, NF-kappaB (NFKB) Activation Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting IKBKB |
| DD-38-MZ39_0.01uM | Dose=0.01uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| BC-43-PD20_10uM | Dose=10uM, GPR52 agonist-1, GPR52 agonist targeting GPR52 |
| DA-28-TM43_10uM | Dose=10uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2 |
| AC-92-HS43_1uM | Dose=1uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4 |
| ED-15-OX47_0.01uM | Dose=0.01uM, Dimaprit, HRH2 agonist targeting HRH2 |
| AA-62-HP31_10uM | Dose=10uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| DC-08-KP05_10uM | Dose=10uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| CB-82-PL01_10uM | Dose=10uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK |
| AC-51-WE57_0.1uM | Dose=0.1uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AE-06-FY47_10uM | Dose=10uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| AC-36-TL21_0.1uM | Dose=0.1uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1 |
| FD-79-TC61_10uM | Dose=10uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| AC-28-RT00_1uM | Dose=1uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| EB-82-HZ30_10uM | Dose=10uM |
| GA-79-DW49_0.1uM | Dose=0.1uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| GF-37-MB64_10uM | Dose=10uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| GD-46-BU97_10uM | Dose=10uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| QD-32-CW16_10uM | Dose=10uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R |
| ID-90-NM43_1uM | Dose=1uM, Rx-5902, phosphorylated-p68 RNA helicase inhibitor targeting DDX5 |
| GE-47-OO30_10uM | Dose=10uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3 |
| PC-80-LV29_1uM | Dose=1uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide |
| RB-55-KL42_0.1uM | Dose=0.1uM |
| MA-43-MR37_1uM | Dose=1uM |
| DF-92-CF17_10uM | Dose=10uM, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone |
| BC-00-YH62_10uM | Dose=10uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AC-93-OJ74_0.1uM | Dose=0.1uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| DA-40-HO94_10uM | Dose=10uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR |
| FB-39-CW59_1uM | Dose=1uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| EA-95-OQ30_10uM | Dose=10uM, Azinphos-methyl |
| AB-18-YN11_0.01uM | Dose=0.01uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| EF-01-LB20_1uM | Dose=1uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| DA-07-LL18_10uM | Dose=10uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| DA-10-GX45_1uM | Dose=1uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AA-62-JP26_1uM | Dose=1uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| GB-64-HC34_10uM | Dose=10uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| QA-34-PH05_10uM | Dose=10uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2 |
| BC-15-EL49_10uM | Dose=10uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| HE-10-QN66_10uM | Dose=10uM, Cytoxazone |
| BA-69-TQ80_1uM | Dose=1uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| BA-68-FJ41_1uM | Dose=1uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BD-73-TX58_10uM | Dose=10uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8 |
| UF-14-LK87_10uM | Dose=10uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1 |
| JE-55-OJ53_10uM | Dose=10uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile |
| QA-98-TQ46_10uM | Dose=10uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one |
| S0-EE-Y97N_10uM | Dose=10uM, 4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, ALK2 inhibitor targeting TGFBR2 |
| DD-73-IP88_10uM | Dose=10uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| S0-EE-XMXE_10uM | Dose=10uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2 |
| SA-31-VB03_10uM | Dose=10uM, Ascochlorin, Electron Transport Chain Inhibitors;AP-1 Inhibitors targeting JUN, UQCRC1 |
| XB-35-TO54_10uM | Dose=10uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4 |
| GD-82-CS38_1uM | Dose=1uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| LB-65-SM65_1uM | Dose=1uM, Imd-0354, NF-kappaB (NFKB) Activation Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting IKBKB |
| AF-48-FX20_10uM | Dose=10uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| CA-65-MK91_10uM | Dose=10uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H |
| BC-76-HY47_10uM | Dose=10uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1 |
| FB-33-LI31_10uM | Dose=10uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile |
| BF-54-GX35_10uM | Dose=10uM |
| AD-40-WB93_10uM | Dose=10uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1 |
| BF-10-IO69_10uM | Dose=10uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| NA-16-OJ70_0.1uM | Dose=0.1uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| RB-55-KL42_0.01uM | Dose=0.01uM |
| YE-55-YX75_1uM | Dose=1uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4 |
| DE-30-UR76_10uM | Dose=10uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| HB-87-YY34_10uM | Dose=10uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9 |
| GC-04-UF36_0.01uM | Dose=0.01uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| JD-62-TK68_10uM | Dose=10uM |
| FA-12-QB17_10uM | Dose=10uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2 |
| BC-74-QN56_10uM | Dose=10uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| DE-80-BU08_0.1uM | Dose=0.1uM, DC_AC50, ATOX1 inhibitor targeting ATOX1 |
| BF-26-MB27_10uM | Dose=10uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG |
| AA-69-TD29_10uM | Dose=10uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1 |
| NB-12-ZK38_0.1uM | Dose=0.1uM, 4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid, BET bromodomain inhibitor targeting BRDT, BRD2, BRD3, BRD4 |
| EB-09-LQ45_10uM | Dose=10uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| CD-20-GE75_10uM | Dose=10uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| XB-53-OZ95_1uM | Dose=1uM |
| CF-97-AV07_10uM | Dose=10uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4 |
| EC-01-PH79_10uM | Dose=10uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| DB-98-LQ88_10uM | Dose=10uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| TA-19-YA45_0.1uM | Dose=0.1uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1 |
| BA-86-AL61_10uM | Dose=10uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1 |
| ED-32-VE54_0.1uM | Dose=0.1uM, Thiosalicylic Acid |
| CB-32-EI69_10uM | Dose=10uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| ND-54-NO97_1uM | Dose=1uM, 3-Epioleanolic acid |
| ZB-33-MZ40_10uM | Dose=10uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1 |
| GB-57-XV52_0.1uM | Dose=0.1uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1 |
| ZB-72-PE17_10uM | Dose=10uM |
| JF-84-QZ64_0.1uM | Dose=0.1uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2 |
| EE-32-EY37_10uM | Dose=10uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2 |
| EF-92-OO68_10uM | Dose=10uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| SC-50-ME48_0.01uM | Dose=0.01uM |
| AF-83-BX08_1uM | Dose=1uM |
| BE-59-WG31_10uM | Dose=10uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| HA-32-YH61_10uM | Dose=10uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP |
| DB-18-UF01_10uM | Dose=10uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| CE-15-DU45_10uM | Dose=10uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3 |
| FC-85-OX77_1uM | Dose=1uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| BC-13-OQ01_1uM | Dose=1uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| AA-18-GQ83_0.01uM | Dose=0.01uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| CE-95-YX02_1uM | Dose=1uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3 |
| FB-94-TJ61_10uM | Dose=10uM |
| BE-31-XV38_1uM | Dose=1uM, Camptothecin, topoisomerase I targeting TOP1 |
| UF-14-LK87_1uM | Dose=1uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1 |
| LA-27-FR67_0.1uM | Dose=0.1uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1 |
| BD-62-ZF67_10uM | Dose=10uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| AD-29-MQ00_0.1uM | Dose=0.1uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| BD-61-OO16_1uM | Dose=1uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| TF-04-RX73_1uM | Dose=1uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile |
| CC-18-YW57_10uM | Dose=10uM |
| QB-00-CS87_10uM | Dose=10uM |
| BD-04-NG34_1uM | Dose=1uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2 |
| AD-18-XC14_1uM | Dose=1uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1 |
| EE-08-SZ54_10uM | Dose=10uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| RC-65-VL12_0.1uM | Dose=0.1uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT |
| AB-64-ZX70_10uM | Dose=10uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| CE-35-LA42_10uM | Dose=10uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide |
| DE-30-UR76_0.01uM | Dose=0.01uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| LD-69-TV81_0.1uM | Dose=0.1uM, 7-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| DE-81-OY65_10uM | Dose=10uM, Erlotinib, EGFR (HER1 or erbB1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting EGFR |
| CB-06-FE89_10uM | Dose=10uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| JC-63-DO70_1uM | Dose=1uM, Tachykinin NK1 Antagonists targeting TACR1 |
| DC-08-KP05_0.1uM | Dose=0.1uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| WC-89-JT40_0.1uM | Dose=0.1uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10 |
| AD-90-PA45_0.1uM | Dose=0.1uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| EA-17-BY69_10uM | Dose=10uM |
| BB-05-NK66_0.1uM | Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| BA-84-TD72_1uM | Dose=1uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| RD-79-FH72_10uM | Dose=10uM, 4-(4-Chlorophenyl)-2-[(5-nitrofuran-2-carbonyl)amino]thiophene-3-carboxylic acid |
| GA-04-JM33_10uM | Dose=10uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4 |
| CA-68-TC79_1uM | Dose=1uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| CE-03-YQ91_10uM | Dose=10uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine |
| FD-86-NE74_10uM | Dose=10uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300 |
| YF-47-HO48_1uM | Dose=1uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC |
| LE-80-BM08_0.1uM | Dose=0.1uM, CID 10481388 targeting ACAT2 |
| S0-EE-Y9JI_10uM | Dose=10uM, Spt-IN-1, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| BE-50-RK99_1uM | Dose=1uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| AF-99-HA02_1uM | Dose=1uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| MF-81-RJ18_10uM | Dose=10uM |
| CC-49-CQ25_0.1uM | Dose=0.1uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| AE-04-DX45_0.1uM | Dose=0.1uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5 |
| S0-EE-Y96T_0.1uM | Dose=0.1uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A |
| AB-12-PP61_10uM | Dose=10uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2 |
| TC-95-IR96_10uM | Dose=10uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2 |
| LA-44-KW22_1uM | Dose=1uM, targeting GSK3B |
| PB-09-OE00_0.1uM | Dose=0.1uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| FD-48-HZ39_10uM | Dose=10uM |
| CE-15-YU05_0.1uM | Dose=0.1uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| AE-14-NN26_10uM | Dose=10uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| ED-71-GA72_10uM | Dose=10uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1 |
| CB-02-XL81_0.01uM | Dose=0.01uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| EE-02-BO83_1uM | Dose=1uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| LA-86-XT29_10uM | Dose=10uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2 |
| AC-96-OO08_10uM | Dose=10uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| ID-55-OJ03_0.01uM | Dose=0.01uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10 |
| KA-00-HF91_10uM | Dose=10uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate |
| CC-03-PW00_1uM | Dose=1uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH |
| S0-EE-XKW4_10uM | Dose=10uM, NFATc1-IN-1, RANKL inhibitor targeting TNFSF11 |
| YA-85-VH07_1uM | Dose=1uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1 |
| LD-69-TV81_1uM | Dose=1uM, 7-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| BD-69-XG81_10uM | Dose=10uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| YC-57-OY42_10uM | Dose=10uM, SB-267268, Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha-V/beta-3 antagonist, integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3 |
| DD-26-VR55_10uM | Dose=10uM, 6-[[2-(3-Methoxyanilino)pyrimidin-4-yl]amino]-2,3-dihydro-1,4-benzodioxine-5-sulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ALK, ZAP70 |
| CF-61-EH59_10uM | Dose=10uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| BD-69-XG81_1uM | Dose=1uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| DD-41-AE67_10uM | Dose=10uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| CD-97-ZV62_10uM | Dose=10uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B |
| HC-92-HE59_1uM | Dose=1uM |
| CB-24-AT90_10uM | Dose=10uM, Monensin |
| AE-34-SK19_0.1uM | Dose=0.1uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4 |
| AA-79-SX47_10uM | Dose=10uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2 |
| DE-98-FC24_10uM | Dose=10uM |
| AC-36-TL21_1uM | Dose=1uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1 |
| AA-45-AA67_10uM | Dose=10uM, Fluorouracil, thymidylate synthase targeting TYMS |
| SD-69-QA40_10uM | Dose=10uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| HF-79-EC41_10uM | Dose=10uM, Blu-9931, FGFR4 inhibior targeting FGFR4 |
| AD-58-PW17_1uM | Dose=1uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| FF-46-OR35_10uM | Dose=10uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| PC-80-LV29_0.01uM | Dose=0.01uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide |
| BA-39-HG26_1uM | Dose=1uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2 |
| EA-95-YN88_10uM | Dose=10uM, rel-(3R,4S)-3-((4-Chlorophenyl)sulfonyl)-4-(isobutylamino)tetrahydrothiophene 1,1-dioxide targeting PGK1 |
| NA-29-UI75_10uM | Dose=10uM, Casp8-IN-1, covalent modifier of catalytic cysteine of pro-CASP8 targeting CASP8 |
| DE-62-FI29_10uM | Dose=10uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| GB-92-JY12_1uM | Dose=1uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3 |
| CE-18-AP85_0.01uM | Dose=0.01uM |
| BB-84-DG64_10uM | Dose=10uM |
| BB-86-UL91_0.1uM | Dose=0.1uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| QF-00-NO42_10uM | Dose=10uM |
| EC-89-AJ93_0.01uM | Dose=0.01uM, Valinomycin |
| BB-83-ZM06_10uM | Dose=10uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3 |
| KC-17-YN77_10uM | Dose=10uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5 |
| DD-42-DB72_10uM | Dose=10uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1 |
| AE-22-QI24_10uM | Dose=10uM, Mozavaptan, Vasopressin (AVP) V2 Antagonists targeting AVPR2 |
| FD-62-ZB67_10uM | Dose=10uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| AF-06-AY37_1uM | Dose=1uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| FB-32-TL51_0.01uM | Dose=0.01uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| DB-42-FS68_10uM | Dose=10uM, Valspodar |
| FE-06-GR60_1uM | Dose=1uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| AE-43-UJ94_10uM | Dose=10uM |
| DC-51-WE27_10uM | Dose=10uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| VD-20-SR39_10uM | Dose=10uM, 4-{[4-(2,4-Difluorophenyl)-1,3-thiazol-2-yl]amino}phenol |
| QE-00-EB96_10uM | Dose=10uM, MERTK gene inhibitor targeting MERTK |
| EF-01-LB20_10uM | Dose=10uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| QA-81-IM40_10uM | Dose=10uM, 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine targeting KMT5A |
| HA-22-CY42_0.1uM | Dose=0.1uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| QF-00-NO42_1uM | Dose=1uM |
| CF-48-QD87_10uM | Dose=10uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| LA-10-VZ79_10uM | Dose=10uM, AZ-628, Raf kinase B Inhibitors;Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| CF-24-KQ98_0.1uM | Dose=0.1uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| GA-43-FL03_0.1uM | Dose=0.1uM, Aliskiren, Renin Inhibitors targeting REN |
| KE-24-RZ94_10uM | Dose=10uM, Yoda-1, Piezo1 channel activator;GlyT-2 Inhibitors targeting SLC6A5, PIEZO1 |
| KB-00-DM33_10uM | Dose=10uM |
| NA-30-HS87_10uM | Dose=10uM, Gsk-J4, KDM6A gene inhibitor, KDM6B gene inhibitor;pan-KDM6 family (KDM6A / KDM6B / UTY);Histone demethylation inhibitors targeting KDM6A, KDM6B |
| FF-46-OR35_0.1uM | Dose=0.1uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| ED-91-LY45_1uM | Dose=1uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B |
| DB-56-XL71_10uM | Dose=10uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| BF-19-KU00_10uM | Dose=10uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS |
| MA-96-GW26_10uM | Dose=10uM |
| DF-93-BT88_10uM | Dose=10uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C |
| DC-17-ZB19_10uM | Dose=10uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13 |
| HB-92-XE24_10uM | Dose=10uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| LD-69-ZV56_0.1uM | Dose=0.1uM, 11-Desethyl Irinotecan |
| BE-37-IC77_0.01uM | Dose=0.01uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1 |
| RD-92-QT24_0.1uM | Dose=0.1uM, Autophinib targeting PIK3C3 |
| EF-80-OD07_0.1uM | Dose=0.1uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| XC-88-ZM66_0.01uM | Dose=0.01uM |
| BB-20-UU03_0.1uM | Dose=0.1uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| ID-00-IC14_10uM | Dose=10uM |
| JD-87-KA71_10uM | Dose=10uM, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethyl-quinazoline, Antimitotic Drugs targeting TUBB |
| NA-16-OJ70_10uM | Dose=10uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| FA-16-HR75_10uM | Dose=10uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2 |
| FD-62-ZB67_1uM | Dose=1uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| FB-94-TJ61_1uM | Dose=1uM |
| FB-33-LI31_1uM | Dose=1uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile |
| ID-69-QF93_10uM | Dose=10uM |
| BF-94-CQ58_0.1uM | Dose=0.1uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| OF-05-CB18_10uM | Dose=10uM |
| BE-73-KD75_10uM | Dose=10uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1 |
| KC-87-DN47_0.1uM | Dose=0.1uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR |
| AC-21-IE62_10uM | Dose=10uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| BB-79-AG41_0.01uM | Dose=0.01uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| BB-86-BE39_10uM | Dose=10uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| HB-06-WU12_1uM | Dose=1uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| DD-54-MA35_1uM | Dose=1uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB |
| WC-33-YP46_1uM | Dose=1uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2 |
| AA-85-LB25_10uM | Dose=10uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| LD-30-MF71_0.01uM | Dose=0.01uM |
| TE-32-AC63_10uM | Dose=10uM, Bay-299, Bromodomain inhibitor targeting TAF1, BRD1, TAF1L |
| WB-17-DI74_1uM | Dose=1uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2 |
| HD-29-LW24_10uM | Dose=10uM, Mocetinostat, Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;HDAC1/2 targeting HDAC1, HDAC2, HDAC3 |
| NF-21-HQ00_0.01uM | Dose=0.01uM, Cct251236 targeting PIR |
| HE-11-PK61_10uM | Dose=10uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8 |
| AE-05-CB45_10uM | Dose=10uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| BE-90-YK54_10uM | Dose=10uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| AA-46-GL76_10uM | Dose=10uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| SC-50-ME48_1uM | Dose=1uM |
| RE-97-MC55_10uM | Dose=10uM, 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCG |
| BE-81-QL64_1uM | Dose=1uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| BD-81-LB65_10uM | Dose=10uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1 |
| HD-08-BP45_0.1uM | Dose=0.1uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12 |
| CA-43-YM01_10uM | Dose=10uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R |
| AE-07-IZ32_10uM | Dose=10uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2 |
| S0-EE-YEL3_10uM | Dose=10uM, N-(4-{5-[3-(Acetylamino)phenyl]-2-(2-Aminopyridin-3-Yl)-3h-Imidazo[4,5-B]pyridin-3-Yl}benzyl)-3-Fluorobenzamide, allosteric AKT inhbitor targeting AKT1 |
| KB-71-QJ23_10uM | Dose=10uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine |
| HA-32-YH61_1uM | Dose=1uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP |
| GD-96-AK08_0.1uM | Dose=0.1uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DE-65-KO26_10uM | Dose=10uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG |
| CD-70-GD72_0.1uM | Dose=0.1uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| DE-81-PO11_10uM | Dose=10uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300 |
| YA-34-DT48_0.01uM | Dose=0.01uM |
| FA-36-VA24_1uM | Dose=1uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea |
| AF-80-GK24_10uM | Dose=10uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| WC-67-DI84_0.01uM | Dose=0.01uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide |
| CC-05-MK46_0.1uM | Dose=0.1uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| DE-00-JU18_0.1uM | Dose=0.1uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| KB-17-PN92_0.1uM | Dose=0.1uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate |
| AE-67-FF84_0.1uM | Dose=0.1uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| WB-82-EL69_0.1uM | Dose=0.1uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone |
| RC-21-IF98_10uM | Dose=10uM |
| JD-00-YJ41_0.1uM | Dose=0.1uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK |
| CD-20-MH57_10uM | Dose=10uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3 |
| BD-01-RI07_10uM | Dose=10uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC |
| GC-72-GY67_10uM | Dose=10uM |
| GA-43-FL03_10uM | Dose=10uM, Aliskiren, Renin Inhibitors targeting REN |
| DA-10-HD17_1uM | Dose=1uM, N-Phthalylglycine |
| AE-78-XJ76_10uM | Dose=10uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| KC-26-JQ92_0.1uM | Dose=0.1uM, Gsk-923295a, Centromere protein E inhibitor targeting CENPE |
| HD-08-BP45_1uM | Dose=1uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12 |
| AD-29-IG16_10uM | Dose=10uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1 |
| HA-17-MS45_10uM | Dose=10uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| AA-86-YV75_10uM | Dose=10uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| DA-07-LL18_1uM | Dose=1uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| GD-51-SU60_0.1uM | Dose=0.1uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| AC-36-SY22_1uM | Dose=1uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| AF-06-AY37_0.01uM | Dose=0.01uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| CC-03-PW00_0.1uM | Dose=0.1uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH |
| FF-34-KW62_0.01uM | Dose=0.01uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| AD-86-OB87_0.1uM | Dose=0.1uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2 |
| S0-EE-XMXE_1uM | Dose=1uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2 |
| AD-18-XC14_10uM | Dose=10uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1 |
| QF-55-QV81_1uM | Dose=1uM |
| AA-62-HP31_0.1uM | Dose=0.1uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| EE-18-HW72_10uM | Dose=10uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2 |
| DA-17-YW85_0.01uM | Dose=0.01uM, Tgba01AD |
| FD-62-ZB67_0.1uM | Dose=0.1uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| BB-41-XE67_1uM | Dose=1uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| OC-40-XI13_1uM | Dose=1uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12 |
| DF-00-BX35_0.1uM | Dose=0.1uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| BA-77-US35_1uM | Dose=1uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139 |
| S0-EE-Y96T_10uM | Dose=10uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A |
| JA-79-II25_1uM | Dose=1uM, Jnj-10329670, Cathepsin S Inhibitors targeting CTSS |
| AC-31-PL89_10uM | Dose=10uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| JD-94-BC04_0.1uM | Dose=0.1uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1 |
| S0-EE-YEKU_1uM | Dose=1uM, (E)-6-Chloro-3-(3-(5-fluoropyridin-3-yl)acryloyl)-4-phenylquinolin-2(1H)-one, EIF4G gene inhibitor targeting EIF4G1 |
| ZA-63-AC60_10uM | Dose=10uM, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone targeting GPX4 |
| BA-28-XM73_10uM | Dose=10uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide |
| PC-87-OG75_1uM | Dose=1uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile |
| GD-07-HO70_10uM | Dose=10uM |
| HD-29-PZ41_1uM | Dose=1uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one |
| AB-82-EP26_1uM | Dose=1uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| CE-38-KX20_10uM | Dose=10uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| BB-41-XE67_0.1uM | Dose=0.1uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| BF-10-IO69_0.1uM | Dose=0.1uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| CD-97-ZV62_1uM | Dose=1uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B |
| BF-24-JN36_1uM | Dose=1uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| EE-08-SZ54_1uM | Dose=1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| UB-21-MV06_10uM | Dose=10uM, 7-amino-6-(1H-benzo[d]imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-5(4H)-one, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| AB-66-IL06_10uM | Dose=10uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AC-55-XA97_1uM | Dose=1uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| DC-47-KV62_1uM | Dose=1uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| MD-17-VD78_10uM | Dose=10uM |
| DD-38-BM78_10uM | Dose=10uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2 |
| FF-54-JC89_0.01uM | Dose=0.01uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| RC-52-AC88_10uM | Dose=10uM, (Z)-N-(4-bromophenyl)-N'-(3-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1 |
| EE-01-FB85_10uM | Dose=10uM, Indolactam V, PKC agonist targeting PRKCA |
| BB-79-AG41_0.1uM | Dose=0.1uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| BD-85-GY20_10uM | Dose=10uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| AC-55-CK61_10uM | Dose=10uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2 |
| FF-46-OR35_1uM | Dose=1uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| BC-09-JG96_10uM | Dose=10uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| AB-25-XU75_10uM | Dose=10uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| PC-87-OG75_10uM | Dose=10uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile |
| HC-76-HU27_10uM | Dose=10uM |
| HC-11-RK51_0.1uM | Dose=0.1uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| BE-42-IC00_1uM | Dose=1uM, Zygosporin A, actin polymerization targeting ACTA1 |
| AC-60-EU98_0.1uM | Dose=0.1uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| EA-43-FS10_0.1uM | Dose=0.1uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| VC-19-YG34_10uM | Dose=10uM, 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, Flt3 (FLK2/STK1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting CHUK, FLT3, IKBKB, IKBKG |
| ME-93-CO85_10uM | Dose=10uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine |
| AA-62-HP31_1uM | Dose=1uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| KB-00-DM33_0.01uM | Dose=0.01uM |
| WA-15-KX40_10uM | Dose=10uM |
| QF-00-NO42_0.01uM | Dose=0.01uM |
| PA-40-NS72_10uM | Dose=10uM, Oseltamivir Acid |
| AE-32-DP61_0.1uM | Dose=0.1uM, Cpi-203, BRD4 gene inhibitor targeting BRD4 |
| QB-42-MC63_10uM | Dose=10uM, [4-[4-[[Methyl(prop-2-enyl)amino]methyl]phenyl]phenyl]-phenylmethanone, Lanosterol Synthase Inhibitors targeting LSS |
| CA-00-AR16_10uM | Dose=10uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10 |
| CE-69-HJ13_1uM | Dose=1uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| UD-20-ER54_0.1uM | Dose=0.1uM, Paprazine, uncompetitive inhibitor targeting GAA |
| OB-22-TT14_0.01uM | Dose=0.01uM, 3,4-Dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone, Influenza A virus RNA Promoter Binder;PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| CA-68-TC79_0.1uM | Dose=0.1uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| AD-99-SN88_10uM | Dose=10uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| BC-14-CG34_0.1uM | Dose=0.1uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| CA-66-FY97_10uM | Dose=10uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| KB-71-QJ23_0.1uM | Dose=0.1uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine |
| HA-21-ND29_0.1uM | Dose=0.1uM |
| GD-72-XO18_10uM | Dose=10uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| AF-73-HJ84_1uM | Dose=1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| LC-78-EV09_1uM | Dose=1uM |
| HA-27-FV67_10uM | Dose=10uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4 |
| GD-51-SU60_1uM | Dose=1uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| BF-02-AC35_0.01uM | Dose=0.01uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| CC-50-FK24_10uM | Dose=10uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| GF-35-IT27_0.1uM | Dose=0.1uM |
| GB-46-CK08_0.1uM | Dose=0.1uM |
| AC-71-YF45_10uM | Dose=10uM |
| WA-15-KX40_1uM | Dose=1uM |
| FE-69-HJ93_10uM | Dose=10uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| WC-33-YP46_10uM | Dose=10uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2 |
| GE-25-DQ65_0.01uM | Dose=0.01uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| RB-55-KL42_10uM | Dose=10uM |
| AD-59-IN33_10uM | Dose=10uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| XD-44-FJ34_0.1uM | Dose=0.1uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| S0-EE-YFM9_10uM | Dose=10uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K |
| HC-74-FM38_10uM | Dose=10uM |
| CD-30-AD57_0.1uM | Dose=0.1uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| DA-10-HD17_0.01uM | Dose=0.01uM, N-Phthalylglycine |
| BC-09-XN48_10uM | Dose=10uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A |
| AA-43-TW35_10uM | Dose=10uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B |
| AD-26-RY42_1uM | Dose=1uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| DC-43-KF54_1uM | Dose=1uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| BE-37-IC77_0.1uM | Dose=0.1uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1 |
| BC-32-DI69_10uM | Dose=10uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1 |
| CE-66-GR30_10uM | Dose=10uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2 |
| VE-46-XV53_10uM | Dose=10uM, LY466195 Diethyl ester prodrug |
| CC-47-VS90_10uM | Dose=10uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| OB-15-UL37_1uM | Dose=1uM, [(1S)-1-[ethyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]ethyl]phosphonic acid targeting GRIA4 |
| GE-98-ZI68_10uM | Dose=10uM |
| BC-82-PP66_10uM | Dose=10uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| JC-02-ZR15_10uM | Dose=10uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2 |
| BF-22-EP86_10uM | Dose=10uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| EB-67-WB79_10uM | Dose=10uM |
| TA-20-FO62_10uM | Dose=10uM |
| DC-23-UM36_0.1uM | Dose=0.1uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| SD-69-QA40_0.1uM | Dose=0.1uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| ZD-43-CS43_1uM | Dose=1uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B |
| UE-58-EW15_10uM | Dose=10uM, (E)-1-(4-Hydroxy-3,5-dimethoxyphenyl)-7-phenylhept-1-en-3-one, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| JA-85-SW39_10uM | Dose=10uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2 |
| PB-63-WH18_10uM | Dose=10uM |
| VE-11-PV61_0.01uM | Dose=0.01uM, Tak-259, Orally Active α1D Adrenoceptor targeting ADRA1D |
| UD-20-ER54_10uM | Dose=10uM, Paprazine, uncompetitive inhibitor targeting GAA |
| AA-48-XT80_1uM | Dose=1uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine |
| DC-84-GJ21_1uM | Dose=1uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK |
| DD-71-LY65_10uM | Dose=10uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| AA-70-DH87_10uM | Dose=10uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B |
| ND-36-VC68_0.01uM | Dose=0.01uM |
| CC-03-PW00_10uM | Dose=10uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH |
| DE-30-UR76_1uM | Dose=1uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| KC-26-JQ92_1uM | Dose=1uM, Gsk-923295a, Centromere protein E inhibitor targeting CENPE |
| KB-49-NF63_10uM | Dose=10uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-phenylpropanamide, VPAC1 (VIP1) Antagonists targeting VIPR1 |
| DB-42-PI54_0.01uM | Dose=0.01uM |
| DA-23-TZ42_10uM | Dose=10uM |
| OA-80-YT10_10uM | Dose=10uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3 |
| DE-99-OT37_0.1uM | Dose=0.1uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| AA-80-XK94_0.1uM | Dose=0.1uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| TA-19-YA45_1uM | Dose=1uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1 |
| BE-07-XF09_10uM | Dose=10uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2 |
| BB-28-MC54_10uM | Dose=10uM, GPBAR1 agonist targeting GPBAR1 |
| AF-12-IW93_10uM | Dose=10uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| DE-48-HZ49_10uM | Dose=10uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2 |
| BA-84-TD72_0.1uM | Dose=0.1uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| ZB-16-BR73_0.1uM | Dose=0.1uM, N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide, p53 tumor suppressor protein inhibitor targeting TP53 |
| GD-82-CS38_0.1uM | Dose=0.1uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| DF-11-IL69_0.1uM | Dose=0.1uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS |
| GC-42-LL86_10uM | Dose=10uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| XE-29-LT20_0.1uM | Dose=0.1uM, 6-Chloro-3-hydroxy-1,2-benzisoxazole, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO |
| AA-35-QK71_0.1uM | Dose=0.1uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH |
| WF-96-ME07_1uM | Dose=1uM, Cur 61414, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| CE-03-YQ91_1uM | Dose=1uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine |
| DC-61-QV78_1uM | Dose=1uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2 |
| DC-70-EK34_0.1uM | Dose=0.1uM, BF-844, CLRN stabilizer targeting CLRN1 |
| QB-35-FO29_1uM | Dose=1uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12 |
| MA-32-UX14_10uM | Dose=10uM, (S)-2-Amino-N-(1-((5-chloro-1H-indol-3-yl)methyl)piperidin-4-yl)-3-(1H-indol-3-yl)propanamide, RAS-SOS molecular glue targeting SOS1 |
| VA-27-OT56_0.01uM | Dose=0.01uM |
| DE-00-JU18_10uM | Dose=10uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| XE-69-AT35_0.01uM | Dose=0.01uM, Nocardimicin A |
| BF-52-HF07_10uM | Dose=10uM, APOA1 Expression Enhancers;BRD2/3/4/T BET familiy inhibitor;BRD4 inhibitor targeting BRD4 |
| WA-45-ZD47_10uM | Dose=10uM, (R)-2-(N-Benzyl-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide, Leukocyte Elastase Inhibitors targeting ELANE |
| PF-59-CY33_0.1uM | Dose=0.1uM, 8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-1-(3-methyl-1-propan-2-ylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one, dual mTOR PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| IB-56-BR35_0.1uM | Dose=0.1uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3 |
| AD-33-YW85_0.01uM | Dose=0.01uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| CA-84-IJ41_1uM | Dose=1uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| GE-29-ZM45_1uM | Dose=1uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| QA-07-KC40_0.1uM | Dose=0.1uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EE-64-WM03_0.1uM | Dose=0.1uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| LB-54-MZ19_10uM | Dose=10uM, Cetilistat, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Pancreatic Triacylglycerol Lipase Inhibitors targeting LIPC, LIPE, PNLIP, LIPG, LIPF |
| AD-11-RL84_1uM | Dose=1uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| ID-00-IC14_1uM | Dose=1uM |
| BA-88-HT15_1uM | Dose=1uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| AC-91-ME22_10uM | Dose=10uM, (R)-Aminoglutethimide |
| DC-61-QV78_10uM | Dose=10uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2 |
| BB-86-BE39_0.1uM | Dose=0.1uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| NC-52-AG88_10uM | Dose=10uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1 |
| BE-37-ZF44_0.01uM | Dose=0.01uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| TB-06-VB30_0.01uM | Dose=0.01uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2 |
| AE-04-SN76_10uM | Dose=10uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6 |
| DD-55-SD64_0.01uM | Dose=0.01uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C |
| BE-03-XC62_10uM | Dose=10uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| BB-41-XE67_10uM | Dose=10uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| KA-00-HF91_0.01uM | Dose=0.01uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate |
| AC-37-OZ52_10uM | Dose=10uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| AA-27-TF89_10uM | Dose=10uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| OC-71-BZ81_1uM | Dose=1uM |
| BB-62-MS83_0.1uM | Dose=0.1uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| BE-17-CS60_0.1uM | Dose=0.1uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| YD-38-CI01_0.01uM | Dose=0.01uM, 4-Amino-5-chloro-2-methoxy-benzoic acid 2-pyrrolidin-1-yl-ethyl ester, HTR4 agonist targeting HTR4 |
| KC-87-DN47_10uM | Dose=10uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR |
| EB-90-BR21_10uM | Dose=10uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| BB-16-BE49_10uM | Dose=10uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| UB-62-DF90_10uM | Dose=10uM |
| DE-79-FD94_10uM | Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| CC-93-RP38_0.1uM | Dose=0.1uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| BB-10-PR06_10uM | Dose=10uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| BA-60-DR11_10uM | Dose=10uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| XD-44-FJ34_10uM | Dose=10uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| SD-82-GT69_10uM | Dose=10uM, N~4~-Cyclopropyl-6-(2,3-Dichlorophenyl)pyrimidine-2,4-Diamine, NUDT1 gene inhibitor targeting NUDT1 |
| HA-42-TE64_10uM | Dose=10uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| BC-20-WA90_10uM | Dose=10uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| JD-00-YJ41_10uM | Dose=10uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK |
| HA-21-ND29_1uM | Dose=1uM |
| CC-55-CD84_10uM | Dose=10uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| BC-13-OQ01_0.01uM | Dose=0.01uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| BC-00-YH62_0.1uM | Dose=0.1uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| FD-29-MM50_0.1uM | Dose=0.1uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| BB-11-JI42_1uM | Dose=1uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BE-31-XV38_0.1uM | Dose=0.1uM, Camptothecin, topoisomerase I targeting TOP1 |
| AB-87-II61_0.1uM | Dose=0.1uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| TC-95-IR96_1uM | Dose=1uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2 |
| AA-19-EX72_0.1uM | Dose=0.1uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A |
| GC-40-VJ01_10uM | Dose=10uM, Pterocarpanquinone |
| YB-54-ET23_10uM | Dose=10uM, 5-Chloro-2-{2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl}pyridine, JMJD2 Histone Demethylase Inhibitor targeting KDM4C, KDM4E, KDM4B |
| FD-79-TC61_1uM | Dose=1uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| HC-01-CN33_10uM | Dose=10uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile |
| AA-12-SS68_10uM | Dose=10uM |
| NC-01-ET52_0.1uM | Dose=0.1uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD |
| BA-60-DR11_0.1uM | Dose=0.1uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| UC-80-UO92_10uM | Dose=10uM, Momipp, Methuosis inducer targeting PIKFYVE, PIP5K1C |
| AA-58-FJ71_1uM | Dose=1uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| GB-06-BA49_1uM | Dose=1uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1 |
| GA-47-MH68_10uM | Dose=10uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| FA-70-ZG69_1uM | Dose=1uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| YB-58-IZ37_1uM | Dose=1uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4 |
| DA-27-BW40_0.1uM | Dose=0.1uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| AD-31-GO06_10uM | Dose=10uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| GE-22-ME44_10uM | Dose=10uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2 |
| AD-72-MJ27_1uM | Dose=1uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| VE-46-XV53_0.1uM | Dose=0.1uM, LY466195 Diethyl ester prodrug |
| OB-65-AI50_10uM | Dose=10uM, Rgfp966, HDAC3 active-site competitive inhibitor;HDAC3 targeting HDAC3 |
| AE-67-DS75_10uM | Dose=10uM, (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide, SMYD2 gene inhibitor;SMYD2 inhibitor targeting SMYD2 |
| PC-85-EL52_10uM | Dose=10uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139 |
| OE-34-NH10_10uM | Dose=10uM, 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one, TIC10 inactivates Akt and ERK and induces TRAIL expression targeting TNFSF10 |
| LD-39-FL02_1uM | Dose=1uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside |
| GB-11-TA37_10uM | Dose=10uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| GE-77-FY84_10uM | Dose=10uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| ED-35-EX82_10uM | Dose=10uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO |
| HA-21-ND29_0.01uM | Dose=0.01uM |
| KB-05-VJ83_0.1uM | Dose=0.1uM, 2-Chloro-N-[(9H-fluoren-9-ylamino)carbonyl]-6-fluorobenzamide, PPIA gene inhibitor targeting PPIA |
| GD-63-XB79_10uM | Dose=10uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| CA-68-KG29_0.1uM | Dose=0.1uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| GC-86-TD91_10uM | Dose=10uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| XE-29-LT20_10uM | Dose=10uM, 6-Chloro-3-hydroxy-1,2-benzisoxazole, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO |
| DC-78-CM38_1uM | Dose=1uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| KB-49-NF63_1uM | Dose=1uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-phenylpropanamide, VPAC1 (VIP1) Antagonists targeting VIPR1 |
| BE-50-RK99_0.1uM | Dose=0.1uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| ID-13-PY29_1uM | Dose=1uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B |
| KB-71-QJ23_1uM | Dose=1uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine |
| CD-26-MB82_0.1uM | Dose=0.1uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| CA-48-JF51_1uM | Dose=1uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| VC-19-YG34_1uM | Dose=1uM, 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, Flt3 (FLK2/STK1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting CHUK, FLT3, IKBKB, IKBKG |
| BE-04-AN21_1uM | Dose=1uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| WB-82-EL69_0.01uM | Dose=0.01uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone |
| IE-49-AI35_0.1uM | Dose=0.1uM, Sovateltide, EDNRB agonist targeting EDNRB |
| PC-87-OG75_0.01uM | Dose=0.01uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile |
| FA-57-CO50_0.1uM | Dose=0.1uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| HA-50-AT10_0.1uM | Dose=0.1uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2 |
| GD-07-HO70_0.01uM | Dose=0.01uM |
| S0-EE-Y737_1uM | Dose=1uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6 |
| AC-60-EU98_1uM | Dose=1uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| TD-33-TT56_10uM | Dose=10uM |
| AB-73-ZX03_10uM | Dose=10uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5 |
| VE-46-XV53_0.01uM | Dose=0.01uM, LY466195 Diethyl ester prodrug |
| RF-36-EI47_0.1uM | Dose=0.1uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2 |
| AE-34-SK19_10uM | Dose=10uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4 |
| CC-86-IO63_10uM | Dose=10uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6 |
| BA-92-YC70_10uM | Dose=10uM, Temozolomide |
| JE-13-EV67_10uM | Dose=10uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| AC-83-LN99_1uM | Dose=1uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3 |
| RA-49-ZB08_10uM | Dose=10uM |
| AA-03-QM41_10uM | Dose=10uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R |
| AA-68-OJ16_0.1uM | Dose=0.1uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| AC-38-WM38_10uM | Dose=10uM |
| EC-01-PH79_0.1uM | Dose=0.1uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| PD-60-FM93_10uM | Dose=10uM, Cathepsin G Inhibitor I, Dual mast cell chymase, Cathepsin G inhibitor targeting CMA1, CTSG |
| DB-93-SW55_10uM | Dose=10uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| BD-90-DK64_10uM | Dose=10uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1 |
| CE-24-LQ98_10uM | Dose=10uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide |
| FE-25-GD89_10uM | Dose=10uM |
| EB-09-GW59_10uM | Dose=10uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| EA-18-FP00_0.01uM | Dose=0.01uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| GC-40-VJ01_0.1uM | Dose=0.1uM, Pterocarpanquinone |
| AF-73-ON54_10uM | Dose=10uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| BC-61-ZY95_1uM | Dose=1uM |
| BA-71-BE32_0.1uM | Dose=0.1uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| AB-30-CR11_0.1uM | Dose=0.1uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| S0-EE-YLU9_10uM | Dose=10uM, PAK1 inhibitor targeting PAK1 |
| QB-35-FO29_0.01uM | Dose=0.01uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12 |
| PD-94-WO47_10uM | Dose=10uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1 |
| IE-49-AI35_10uM | Dose=10uM, Sovateltide, EDNRB agonist targeting EDNRB |
| AB-30-DA10_10uM | Dose=10uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2 |
| JC-64-QI43_10uM | Dose=10uM, 4-Bromo-2,6-diisopropylphenol, Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.4 (SkM1) Sodium Channel Blockers targeting SCN2A, SCN4A |
| AD-90-PA45_0.01uM | Dose=0.01uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| GC-73-YI26_10uM | Dose=10uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2 |
| BB-05-NK66_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| BC-40-TU13_1uM | Dose=1uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C |
| HD-18-YL30_10uM | Dose=10uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1 |
| BE-89-DG86_10uM | Dose=10uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| BE-24-LQ28_0.1uM | Dose=0.1uM |
| CB-55-AK76_0.01uM | Dose=0.01uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| DA-46-KH36_0.01uM | Dose=0.01uM, 1,2,3,4-Tetrahydroisoquinoline |
| BD-93-AM31_0.01uM | Dose=0.01uM, Veliparib targeting PARP1, PARP2 |
| AA-38-TT50_0.01uM | Dose=0.01uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| MA-96-GW26_0.01uM | Dose=0.01uM |
| FD-59-TC81_1uM | Dose=1uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4 |
| HE-80-BQ08_1uM | Dose=1uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1 |
| UF-14-LK87_0.1uM | Dose=0.1uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1 |
| GD-46-BU97_1uM | Dose=1uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| WA-15-KX40_0.01uM | Dose=0.01uM |
| LB-54-MZ19_0.01uM | Dose=0.01uM, Cetilistat, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Pancreatic Triacylglycerol Lipase Inhibitors targeting LIPC, LIPE, PNLIP, LIPG, LIPF |
| MD-06-ZJ05_0.1uM | Dose=0.1uM, Deoxycytidine |
| GE-25-DQ65_0.1uM | Dose=0.1uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| HB-24-AP80_0.01uM | Dose=0.01uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| AE-38-LX10_10uM | Dose=10uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| AW-10-0667_0.1uM | Dose=0.1uM, Clofibrate |
| S0-EE-XMXE_0.1uM | Dose=0.1uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2 |
| JC-24-MC69_0.01uM | Dose=0.01uM, [4-(4-Phenylphenyl)-1-triazolyl]-(1-pyrrolidinyl)methanone, Acylaminoacyl peptidase inhibitor targeting APEH |
| QA-34-PH05_1uM | Dose=1uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2 |
| FF-54-JC89_10uM | Dose=10uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| GE-25-DQ65_1uM | Dose=1uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| S0-EE-WJKI_0.1uM | Dose=0.1uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL |
| EA-39-YN88_10uM | Dose=10uM |
| CF-42-OS28_10uM | Dose=10uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| AE-06-FY47_0.1uM | Dose=0.1uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| QA-25-HL62_0.1uM | Dose=0.1uM, 4-({3-chloro-4-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinoline-3-carbonitrile, Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors targeting MAP2K1 |
| VA-19-EX85_10uM | Dose=10uM, CID 71716944, Bcl-2 Inhibitors;Apoptosis Inducers targeting BCL2 |
| KB-71-QJ23_0.01uM | Dose=0.01uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine |
| XF-76-GE52_0.1uM | Dose=0.1uM |
| ID-70-SM63_10uM | Dose=10uM, Masoprocol, IGF-1R Phosphorylation Inhibitors;ER stress inducer;Lipoxygenase Inhibitors targeting ALOX5, ALOX15 |
| RB-56-FZ63_0.01uM | Dose=0.01uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1 |
| HD-51-KD29_0.1uM | Dose=0.1uM, 5-bromo-2-N-[4-[3-(propan-2-ylamino)propylamino]phenyl]-4-N-pyridin-2-ylpyrimidine-2,4-diamine, Cyclin-Dependent Kinase Inhibitors targeting CDK4, CDKL5, CDK6 |
| CF-91-JY05_0.1uM | Dose=0.1uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| GA-28-SS67_10uM | Dose=10uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| JD-87-KA71_1uM | Dose=1uM, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethyl-quinazoline, Antimitotic Drugs targeting TUBB |
| EA-73-UC67_10uM | Dose=10uM |
| BC-33-BM51_1uM | Dose=1uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| AD-26-RY42_0.01uM | Dose=0.01uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| S0-EE-XMWH_10uM | Dose=10uM, 4-[4-(1-Benzofuran-5-Yl)phenyl]-5-{[(3s)-1-(Cyclopropylcarbonyl)pyrrolidin-3-Yl]methyl}-2,4-Dihydro-3h-1,2,4-Triazol-3-One, FAS inhibitor targeting FASN |
| CB-44-FA25_10uM | Dose=10uM, N-Tosyl-L-phenylalanyl chloromethyl ketone |
| FB-94-TJ61_0.1uM | Dose=0.1uM |
| BD-84-ZR31_10uM | Dose=10uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3 |
| DE-42-QB97_0.01uM | Dose=0.01uM, N-Acetylserotonin |
| CC-50-FK24_1uM | Dose=1uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| EB-66-IH06_1uM | Dose=1uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2 |
| HB-75-KT12_10uM | Dose=10uM |
| GF-03-HI41_0.1uM | Dose=0.1uM, RS 39604, HTR4 antagonist targeting HTR4 |
| CC-29-RG66_1uM | Dose=1uM |
| AD-31-GO06_0.01uM | Dose=0.01uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| GD-08-JL45_10uM | Dose=10uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid |
| AD-51-LE62_1uM | Dose=1uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| ZD-43-CS43_0.1uM | Dose=0.1uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B |
| AB-74-VK99_10uM | Dose=10uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| S0-EE-Y6WJ_10uM | Dose=10uM, 4-(2-Amino-1,3-benzothiazol-6-yl)-1-(cyclopropylmethyl)pyridin-2-one, PI4KA gene inhibitor targeting PI4KA |
| BE-66-UB12_1uM | Dose=1uM |
| YA-92-YO01_1uM | Dose=1uM, LL-Z 1271alpha |
| AA-56-QO38_10uM | Dose=10uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| GA-04-SF76_10uM | Dose=10uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| AB-71-VZ28_0.1uM | Dose=0.1uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| ID-12-GA19_10uM | Dose=10uM, Apoptosis Inducers;Polyamine Oxidase Inhibitors targeting SMOX |
| KC-26-JQ92_10uM | Dose=10uM, Gsk-923295a, Centromere protein E inhibitor targeting CENPE |
| EB-09-LQ45_1uM | Dose=1uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| DB-86-XL71_10uM | Dose=10uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2 |
| JB-60-JM38_1uM | Dose=1uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4 |
| FD-48-HZ39_0.01uM | Dose=0.01uM |
| EB-19-SM10_10uM | Dose=10uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| VB-48-KG22_0.1uM | Dose=0.1uM, 6,8-Dimercapto-2-hydroxypurine |
| GA-13-WB79_10uM | Dose=10uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| HC-04-ZM18_10uM | Dose=10uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| SB-74-OD45_1uM | Dose=1uM, N-1-(Fur-3-ylethyl)-N-hydroxyurea, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| AB-26-BE29_0.1uM | Dose=0.1uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2 |
| EB-33-ZP53_10uM | Dose=10uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA |
| FF-96-HL81_10uM | Dose=10uM |
| SD-69-QA40_1uM | Dose=1uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| S0-EE-Y79N_10uM | Dose=10uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4 |
| LA-42-CN75_0.01uM | Dose=0.01uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| LD-69-ZV56_0.01uM | Dose=0.01uM, 11-Desethyl Irinotecan |
| BA-19-VU85_10uM | Dose=10uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| BC-84-BQ58_0.1uM | Dose=0.1uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1 |
| DD-89-HG56_10uM | Dose=10uM, eIF4A3-IN-1 targeting EIF4A3 |
| QA-73-SR92_0.01uM | Dose=0.01uM |
| NE-00-JZ19_0.1uM | Dose=0.1uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ |
| QB-42-ET79_10uM | Dose=10uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1 |
| CB-83-ZW70_0.1uM | Dose=0.1uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| AC-10-JK64_0.1uM | Dose=0.1uM |
| JB-99-UC61_10uM | Dose=10uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid |
| OB-61-XZ91_1uM | Dose=1uM, Neurotrophic Agents targeting ADA, PNP |
| BD-63-KJ69_10uM | Dose=10uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| NE-95-RP07_10uM | Dose=10uM, N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea, ACAT Inhibitors;Lipid Lowering Agents targeting ACAT1, ACAT2, SOAT1 |
| FD-19-TD14_10uM | Dose=10uM |
| NE-34-OZ69_10uM | Dose=10uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1 |
| GC-74-QF56_1uM | Dose=1uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| DE-30-UR76_0.1uM | Dose=0.1uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| CA-42-YI34_0.1uM | Dose=0.1uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| QB-00-CS87_1uM | Dose=1uM |
| JD-62-TK68_0.01uM | Dose=0.01uM |
| RA-42-CM42_1uM | Dose=1uM, Lestaurtinib |
| JF-96-HH81_1uM | Dose=1uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5 |
| SA-03-IQ14_10uM | Dose=10uM |
| ED-15-OX47_0.1uM | Dose=0.1uM, Dimaprit, HRH2 agonist targeting HRH2 |
| AD-21-WS76_10uM | Dose=10uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| AA-49-BD04_10uM | Dose=10uM, Purvalanol A, CDK1/Cyclin B Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors;CDK2/Cyclin A Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK2/Cyclin E Inhibitors;CDK5 Inhibitors targeting CHUK, CCNA1, CCNB2, CCNE2, CCNB3 |
| YF-47-HO48_0.1uM | Dose=0.1uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC |
| CF-81-DS26_10uM | Dose=10uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C |
| AD-18-XC14_0.1uM | Dose=0.1uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1 |
| BA-41-VY30_0.1uM | Dose=0.1uM, 2-methyl-5-HT targeting HTR1F |
| BD-07-IW65_1uM | Dose=1uM |
| BC-14-CG34_10uM | Dose=10uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| KB-17-PN92_1uM | Dose=1uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate |
| CB-13-ZM96_10uM | Dose=10uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine |
| CF-42-OS28_1uM | Dose=1uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| AF-73-ON54_0.1uM | Dose=0.1uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| AB-07-KC02_10uM | Dose=10uM, PT2399, HIF2A/EPAS1 inhibitor targeting EPAS1 |
| EA-40-KQ08_1uM | Dose=1uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| FB-24-UT80_10uM | Dose=10uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2 |
| FD-72-CE19_10uM | Dose=10uM, Zaldaride, Calmodulin Antagonists targeting CALM1 |
| IE-38-FB31_10uM | Dose=10uM |
| CF-87-AS90_0.1uM | Dose=0.1uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| PF-39-DY68_1uM | Dose=1uM, 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione |
| DB-18-UF01_1uM | Dose=1uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| AE-38-EW82_10uM | Dose=10uM |
| EA-22-SB72_10uM | Dose=10uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R |
| TE-26-XS06_1uM | Dose=1uM, Brivudine, Heat Shock Protein 27 (hsp27) Inhibitors;Reverse Transcriptase Inhibitors targeting HSPB1 |
| AA-87-EI21_0.1uM | Dose=0.1uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| BB-86-UL91_0.01uM | Dose=0.01uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| IB-33-TE51_1uM | Dose=1uM, 5-methyl-10H-indolo[3,2-b]quinolin-5-ium |
| JE-61-EQ70_1uM | Dose=1uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine |
| CE-15-YU05_10uM | Dose=10uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| CB-30-KN11_10uM | Dose=10uM, Sardomozide, SAMDC inhibitor targeting AMD1 |
| PC-68-DU31_1uM | Dose=1uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1 |
| AA-24-UO04_1uM | Dose=1uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F |
| GC-57-HV87_10uM | Dose=10uM |
| OD-07-NJ52_1uM | Dose=1uM, 5-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-2,2-diphenyl-pentanenitrile, CCR1 antagonist;Chemokine US28 Receptor Inverse Agonists targeting CCR1 |
| TA-10-KH35_10uM | Dose=10uM, 3-Chloro-1-(3,4-dichlorophenyl)-4-(4-methylpiperazin-1-yl)pyrrole-2,5-dione targeting BCL2A1 |
| AB-08-HT45_10uM | Dose=10uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1 |
| BE-71-AV63_10uM | Dose=10uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3 |
| FC-96-WR45_0.1uM | Dose=0.1uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| AC-49-NG46_0.1uM | Dose=0.1uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| BE-57-VZ17_10uM | Dose=10uM |
| WC-67-DI84_10uM | Dose=10uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide |
| CC-17-JL38_0.01uM | Dose=0.01uM, Ilk-IN-1 targeting ILK |
| IC-91-IX22_10uM | Dose=10uM, 1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Angiogenesis Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;EphB4 Inhibitors targeting CAMK2B, EPHB4, FYN, MAPK13, CAMK2G |
| JF-55-EN33_10uM | Dose=10uM, 3-[6-Amino-5-(3,4,5-Trimethoxyphenyl)pyridin-3-Yl]phenol, ACVRL1 gene inhibitor targeting ACVRL1 |
| FC-19-RM40_10uM | Dose=10uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR |
| EA-93-KT88_10uM | Dose=10uM |
| BB-79-GA42_10uM | Dose=10uM, Pratol |
| NB-58-SA13_10uM | Dose=10uM |
| OF-28-PH15_0.1uM | Dose=0.1uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3 |
| BD-63-KJ69_0.1uM | Dose=0.1uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| CF-42-OS28_0.1uM | Dose=0.1uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| AA-89-HG56_0.1uM | Dose=0.1uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A |
| EA-92-CV45_0.1uM | Dose=0.1uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| BC-02-WF67_10uM | Dose=10uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2 |
| BF-24-JN36_10uM | Dose=10uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| BE-07-XI66_0.01uM | Dose=0.01uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| FC-85-OX77_0.01uM | Dose=0.01uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| AA-80-XK94_0.01uM | Dose=0.01uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| UA-17-QS18_0.01uM | Dose=0.01uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2 |
| ZD-78-BS65_0.01uM | Dose=0.01uM |
| IF-03-OL58_10uM | Dose=10uM, Tazarotenic acid, Drugs Acting on Retinoid Receptors targeting RARB |
| AE-43-UJ94_0.01uM | Dose=0.01uM |
| LD-98-CY91_10uM | Dose=10uM, 2-(4-Chlorophenoxy)-N-(2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl)acetamide, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Ligands targeting MCHR1 |
| JB-23-ZE86_10uM | Dose=10uM, N-benzyl-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine, Lck Kinase Inhibitors targeting LCK |
| FC-96-WR45_1uM | Dose=1uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| VA-92-QP54_1uM | Dose=1uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R |
| AB-85-JR73_10uM | Dose=10uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| BC-10-OR76_10uM | Dose=10uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| WD-62-UB45_0.1uM | Dose=0.1uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3 |
| IB-78-AY41_1uM | Dose=1uM, 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Cyclooxygenase-2 Inhibitors targeting SC5D |
| IF-03-OL58_1uM | Dose=1uM, Tazarotenic acid, Drugs Acting on Retinoid Receptors targeting RARB |
| HC-14-FM48_1uM | Dose=1uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| ZD-23-ZF57_0.1uM | Dose=0.1uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2 |
| AC-40-KV26_10uM | Dose=10uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1 |
| EB-19-SM10_0.1uM | Dose=0.1uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| BF-94-GX05_10uM | Dose=10uM |
| IC-05-WD74_10uM | Dose=10uM, N-[(2,6-dimethylphenyl)methyl]-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine, HRI Kinase inhibitor targeting EIF2AK1 |
| CB-46-FO63_1uM | Dose=1uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| FF-07-FL63_10uM | Dose=10uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| BB-86-BE39_1uM | Dose=1uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| FB-94-TJ61_0.01uM | Dose=0.01uM |
| BA-28-XM73_1uM | Dose=1uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide |
| DA-66-OE69_10uM | Dose=10uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| KA-72-WY22_10uM | Dose=10uM, (S)-benzyl [1-benzyl-3-chloro-2-oxopropyl]carbamate, ATG4B gene Inhibitor targeting ATG4B |
| AD-26-RY42_10uM | Dose=10uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| QF-55-QV81_0.1uM | Dose=0.1uM |
| RC-65-VL12_0.01uM | Dose=0.01uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT |
| QE-18-WG07_1uM | Dose=1uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2 |
| DD-49-YG96_10uM | Dose=10uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| FA-88-PW92_10uM | Dose=10uM |
| AA-52-JS03_0.1uM | Dose=0.1uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| NC-35-BF58_10uM | Dose=10uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
| EE-32-EY37_0.1uM | Dose=0.1uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2 |
| AE-67-FF84_0.01uM | Dose=0.01uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| PC-05-MI00_10uM | Dose=10uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2 |
| KB-05-VJ83_10uM | Dose=10uM, 2-Chloro-N-[(9H-fluoren-9-ylamino)carbonyl]-6-fluorobenzamide, PPIA gene inhibitor targeting PPIA |
| BD-98-TG79_10uM | Dose=10uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| AA-46-GL76_1uM | Dose=1uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| JA-32-HE94_0.01uM | Dose=0.01uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT |
| S0-EE-XGEL_10uM | Dose=10uM, L-Moses, KAT2B, KAT2A inhibitor targeting KAT2B |
| CE-37-XI06_10uM | Dose=10uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| EA-17-BY69_1uM | Dose=1uM |
| WB-54-WD35_0.1uM | Dose=0.1uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B |
| DA-54-NN76_0.1uM | Dose=0.1uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| BA-46-RB17_0.1uM | Dose=0.1uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| GA-10-WX15_10uM | Dose=10uM |
| QB-72-LM87_10uM | Dose=10uM, NMDA Glycine B Receptor Antagonists targeting GRIN1 |
| CC-17-HI11_0.01uM | Dose=0.01uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| FB-86-IO73_0.1uM | Dose=0.1uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| S0-EE-WNJ9_10uM | Dose=10uM, 2-N-methyl-6-[(1S)-1-phenylethyl]-4-N-(1H-pyrazol-4-yl)pyridine-2,4-dicarboxamide targeting BRD4 |
| XC-88-ZM66_1uM | Dose=1uM |
| DA-81-VY50_1uM | Dose=1uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG |
| GA-88-PV69_1uM | Dose=1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| BE-25-UR78_10uM | Dose=10uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB |
| BC-51-ME52_1uM | Dose=1uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1 |
| JF-84-QZ64_1uM | Dose=1uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2 |
| WB-54-WD35_10uM | Dose=10uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B |
| IC-72-HR20_10uM | Dose=10uM, 3-Hydroxykynurenine |
| KE-73-XV62_1uM | Dose=1uM, Tubercidin |
| ED-31-AA47_0.1uM | Dose=0.1uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2 |
| BB-28-MC54_1uM | Dose=1uM, GPBAR1 agonist targeting GPBAR1 |
| AW-15-2439_10uM | Dose=10uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| ID-13-PY29_0.1uM | Dose=0.1uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B |
| VA-27-OT56_1uM | Dose=1uM |
| AA-38-TT50_1uM | Dose=1uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| HC-74-HM63_0.01uM | Dose=0.01uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| EF-61-NY75_10uM | Dose=10uM, US9580437, Example 229, PRC2/EED targeting EED |
| MB-86-VG83_0.01uM | Dose=0.01uM, N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, BRD7/9 inhbitor;BRD9 inhibitor;BRD7/9 Bromodomain Inhibitor targeting BRD7, BRD9 |
| AB-85-JR73_1uM | Dose=1uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| CB-25-VR83_10uM | Dose=10uM |
| JD-58-MV19_10uM | Dose=10uM, mTOR Complex 2 (mTORC2) Inhibitors;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| GC-28-YS77_0.1uM | Dose=0.1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| PC-68-HN64_10uM | Dose=10uM, 3-(6-fluoro-1H-1,3-benzodiazol-2-yl)-5-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrazin-2-amine, c-Met) Inhibitors;AXL Kinase Inhibitors;HGFR (MET targeting AXL, MET |
| HF-67-IR57_10uM | Dose=10uM |
| HC-11-RK51_1uM | Dose=1uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| RB-80-RO52_10uM | Dose=10uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1 |
| BE-05-KR03_10uM | Dose=10uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK |
| EB-44-GM58_10uM | Dose=10uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| EA-69-VJ68_1uM | Dose=1uM |
| JE-61-EQ70_0.1uM | Dose=0.1uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine |
| EB-30-VD02_10uM | Dose=10uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2 |
| TC-66-CI47_10uM | Dose=10uM |
| DA-69-UN88_10uM | Dose=10uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1 |
| WB-82-EL69_1uM | Dose=1uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone |
| AW-10-0667_1uM | Dose=1uM, Clofibrate |
| NF-19-JL47_0.1uM | Dose=0.1uM, 2-Amino-5-[(1-Methoxy-2-Methylindolizin-3-Yl)carbonyl]benzoic Acid, Allosteric inhibitor binding extracellular domain targeting FGFR3, FGFR2, FGFR4 |
| AB-87-II61_10uM | Dose=10uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| EE-66-CK83_10uM | Dose=10uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| EC-98-KI28_1uM | Dose=1uM, CID 196804 |
| ZE-14-BN99_1uM | Dose=1uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19 |
| HA-99-PM50_1uM | Dose=1uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| BB-10-PR06_0.1uM | Dose=0.1uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| FA-92-JL46_10uM | Dose=10uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2 |
| SC-50-ME48_0.1uM | Dose=0.1uM |
| IF-75-AJ33_0.01uM | Dose=0.01uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1 |
| JA-32-HE94_10uM | Dose=10uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT |
| XD-50-BD50_10uM | Dose=10uM, 2-(4-Amylcinnamoyl)amino-4-chlorobenzoic acid, Phospholipase A2 (PLA2) Inhibitors targeting PLA2G10 |
| AB-70-GR31_10uM | Dose=10uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| ED-15-OX47_1uM | Dose=1uM, Dimaprit, HRH2 agonist targeting HRH2 |
| TA-20-FO62_1uM | Dose=1uM |
| GD-43-TP28_10uM | Dose=10uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2 |
| BD-10-ZH17_10uM | Dose=10uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR |
| LA-86-XT29_1uM | Dose=1uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2 |
| CA-60-LK14_10uM | Dose=10uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| BF-29-LU75_10uM | Dose=10uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| HD-22-GO73_0.01uM | Dose=0.01uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2 |
| CC-62-XM29_10uM | Dose=10uM, Skf-81297, DRD1 agonist targeting DRD1 |
| PC-62-AQ92_10uM | Dose=10uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD |
| DA-17-YW85_1uM | Dose=1uM, Tgba01AD |
| PA-70-ZC89_0.01uM | Dose=0.01uM |
| PC-18-VX23_10uM | Dose=10uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1 |
| AA-46-GL76_0.1uM | Dose=0.1uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| BC-34-IH52_10uM | Dose=10uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| OC-71-BZ81_0.1uM | Dose=0.1uM |
| BC-20-WA90_1uM | Dose=1uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| GE-77-FY84_0.1uM | Dose=0.1uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| VA-71-JY23_0.1uM | Dose=0.1uM |
| GD-51-SU60_10uM | Dose=10uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| GE-29-ZM45_0.1uM | Dose=0.1uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| AD-30-OK99_10uM | Dose=10uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| ED-27-OE11_10uM | Dose=10uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| DC-91-ME12_0.1uM | Dose=0.1uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| EA-09-HM95_10uM | Dose=10uM |
| BB-09-GD09_10uM | Dose=10uM, Sunitinib targeting PTK2B, RET, FGFR3P1 |
| TE-87-FM14_0.01uM | Dose=0.01uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid |
| AA-87-EI21_10uM | Dose=10uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| BA-92-CZ75_10uM | Dose=10uM |
| CB-32-EI69_1uM | Dose=1uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| BE-38-UW72_10uM | Dose=10uM |
| BE-42-WI29_0.1uM | Dose=0.1uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| MF-81-RJ18_1uM | Dose=1uM |
| GB-64-HC34_0.1uM | Dose=0.1uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| RA-49-ZB08_0.01uM | Dose=0.01uM |
| BE-66-UB12_0.01uM | Dose=0.01uM |
| BF-24-JN36_0.1uM | Dose=0.1uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| CD-96-HO43_10uM | Dose=10uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ |
| RB-56-FZ63_0.1uM | Dose=0.1uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1 |
| IA-76-ZU47_0.1uM | Dose=0.1uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1 |
| AA-30-BE85_10uM | Dose=10uM, 4,7-Dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one, EWS-FLI1 Inhibitors targeting EWSR1, FLI1 |
| DA-83-VJ09_1uM | Dose=1uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| QE-93-PG25_10uM | Dose=10uM, 3-(8-(Hydroxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| JB-60-JM38_0.01uM | Dose=0.01uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4 |
| FA-92-JL46_0.01uM | Dose=0.01uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2 |
| HA-42-TE64_0.01uM | Dose=0.01uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| HE-15-UQ55_10uM | Dose=10uM |
| S0-EE-X7LX_10uM | Dose=10uM, (R)-2-(6-(4-(1-Hydroxypropan-2-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-isopropoxyisoindolin-1-one, ASK1 targeting MAP3K5 |
| DB-18-UF01_0.1uM | Dose=0.1uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| HE-68-XL70_0.1uM | Dose=0.1uM, 1,2,5-Thiadiazolidin-3-one, 5-[4-(cyclohexylmethyl)-2-fluoro-6-hydroxyphenyl]-, 1,1-dioxide, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1 |
| EC-82-LV30_0.1uM | Dose=0.1uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| AD-90-PA45_1uM | Dose=1uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| RE-62-FC93_0.01uM | Dose=0.01uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| BA-26-GI09_1uM | Dose=1uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR |
| MB-15-ZF03_10uM | Dose=10uM |
| CA-48-CT20_1uM | Dose=1uM |
| IB-06-YD91_10uM | Dose=10uM, dual thymidylate synthase and dihydrofolate reductase inhibitors targeting DHFR, FOLR1, GART, SLC19A1, TYMS |
| AB-11-QV43_0.01uM | Dose=0.01uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| UD-78-YQ06_10uM | Dose=10uM, CID 91826512, Tip60 (KAT5) inhibitor targeting KAT5 |
| HD-08-BP45_10uM | Dose=10uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12 |
| IC-27-TE11_10uM | Dose=10uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4 |
| FA-92-JL46_0.1uM | Dose=0.1uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2 |
| TC-95-IR96_0.1uM | Dose=0.1uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2 |
| FD-77-ZV22_10uM | Dose=10uM, n-(2-(1h-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9h-purin-6-amine, Aryl hydrocarbon receptor antagonist targeting AHR |
| BC-13-OQ01_10uM | Dose=10uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| EA-43-FS10_0.01uM | Dose=0.01uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| FB-91-BU05_10uM | Dose=10uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| BA-29-GH49_10uM | Dose=10uM, Orforglipron targeting GLP1R |
| AA-24-UO04_10uM | Dose=10uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F |
| AA-81-IB40_10uM | Dose=10uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE |
| QB-29-GK19_10uM | Dose=10uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL |
| AC-14-JQ68_0.1uM | Dose=0.1uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| CF-97-KZ12_0.1uM | Dose=0.1uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| EA-93-KT88_0.01uM | Dose=0.01uM |
| GB-10-QG19_10uM | Dose=10uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DB-29-HQ45_10uM | Dose=10uM |
| FC-35-BX82_0.01uM | Dose=0.01uM, Cyclosporin V |
| HA-21-ND29_10uM | Dose=10uM |
| BA-46-QO78_0.01uM | Dose=0.01uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| IF-31-RN78_10uM | Dose=10uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1 |
| NC-14-ES72_0.1uM | Dose=0.1uM |
| IF-31-BQ95_0.1uM | Dose=0.1uM, Calcium-Sensing Receptor Antagonists I, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| CC-17-HI11_10uM | Dose=10uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| GF-92-IR00_10uM | Dose=10uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| CB-24-AT90_1uM | Dose=1uM, Monensin |
| AC-38-WM38_0.01uM | Dose=0.01uM |
| CA-64-LT35_1uM | Dose=1uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| GC-72-GY67_0.1uM | Dose=0.1uM |
| QA-73-SR92_10uM | Dose=10uM |
| DA-17-YW85_0.1uM | Dose=0.1uM, Tgba01AD |
| AC-35-CK01_1uM | Dose=1uM, Mitonafide |
| NC-27-AD53_10uM | Dose=10uM, Azd-1480, Jak2 Inhibitors targeting JAK1, JAK2 |
| FA-14-WC79_0.01uM | Dose=0.01uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| AB-02-TI14_0.1uM | Dose=0.1uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| PF-39-DY68_0.1uM | Dose=0.1uM, 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione |
| AD-30-VB23_1uM | Dose=1uM, Rotenone, Apoptosis Inducers;NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitors;Non-Steroidal Antiinflammatory Drugs;Electron Transport Chain Inhibitors;Electron transport chain inhibitor targeting NDUFS1, NOX4, NOX5 |
| ND-36-VC68_0.1uM | Dose=0.1uM |
| ED-32-VE54_0.01uM | Dose=0.01uM, Thiosalicylic Acid |
| GC-49-HD44_10uM | Dose=10uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1 |
| KC-17-YN77_0.1uM | Dose=0.1uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5 |
| OC-71-BZ81_10uM | Dose=10uM |
| AA-52-JS03_0.01uM | Dose=0.01uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AC-33-YJ09_1uM | Dose=1uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| YC-45-JD42_1uM | Dose=1uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate |
| BE-13-XC52_0.1uM | Dose=0.1uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| BC-85-QR33_10uM | Dose=10uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF |
| RA-86-LI22_1uM | Dose=1uM, Bromosporine |
| ZD-23-ZF57_10uM | Dose=10uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2 |
| BD-18-FM58_0.01uM | Dose=0.01uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| NB-05-VI80_10uM | Dose=10uM |
| EC-01-PH79_1uM | Dose=1uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| S0-EE-Y9JI_0.1uM | Dose=0.1uM, Spt-IN-1, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| AF-81-IV73_10uM | Dose=10uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13 |
| CE-20-VA70_1uM | Dose=1uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| AD-51-SS86_1uM | Dose=1uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2 |
| RB-22-TT44_10uM | Dose=10uM, (2E)-3-{4-[bicyclo[3.3.1]non-9-ylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;Selective Estrogen Receptor Destabilizers (SERD) targeting ESR1, ESR2 |
| DC-08-CM08_0.1uM | Dose=0.1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| GA-18-KF56_10uM | Dose=10uM |
| BE-38-UW72_1uM | Dose=1uM |
| BE-89-DG86_1uM | Dose=1uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| VA-71-JY23_0.01uM | Dose=0.01uM |
| BB-44-SX65_1uM | Dose=1uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| TA-57-FF07_0.01uM | Dose=0.01uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl |
| IA-14-WP20_1uM | Dose=1uM, Tazarotene, Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists targeting ODC1, RARB, RARG |
| YA-34-DT48_0.1uM | Dose=0.1uM |
| AD-56-VO78_10uM | Dose=10uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E |
| AB-00-IL62_1uM | Dose=1uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| EB-09-LQ45_0.01uM | Dose=0.01uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| JD-94-BC04_1uM | Dose=1uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1 |
| CC-55-CD84_0.1uM | Dose=0.1uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| HA-17-MS45_1uM | Dose=1uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| IE-19-LI00_10uM | Dose=10uM, Bis-indolylmaleimide deriv. 8d, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| PA-09-IB98_0.01uM | Dose=0.01uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one |
| DA-33-BM26_0.1uM | Dose=0.1uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| CB-20-ND22_0.1uM | Dose=0.1uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| RB-18-SX73_0.01uM | Dose=0.01uM |
| CA-63-LW25_10uM | Dose=10uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| RB-80-RO52_0.1uM | Dose=0.1uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1 |
| KC-17-YN77_1uM | Dose=1uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5 |
| NC-73-QU79_0.01uM | Dose=0.01uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| CB-13-ZM26_1uM | Dose=1uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA |
| OC-40-XI13_0.1uM | Dose=0.1uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12 |
| AA-38-TT50_0.1uM | Dose=0.1uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| HB-06-WU12_0.01uM | Dose=0.01uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| BB-42-FF52_1uM | Dose=1uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ |
| VB-48-KG22_10uM | Dose=10uM, 6,8-Dimercapto-2-hydroxypurine |
| GF-03-HI41_10uM | Dose=10uM, RS 39604, HTR4 antagonist targeting HTR4 |
| AF-73-HJ84_0.1uM | Dose=0.1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| XC-50-TN39_1uM | Dose=1uM |
| CB-32-EI69_0.1uM | Dose=0.1uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| BE-50-RK99_10uM | Dose=10uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| BB-28-MC54_0.1uM | Dose=0.1uM, GPBAR1 agonist targeting GPBAR1 |
| CB-36-QH71_0.01uM | Dose=0.01uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| VA-27-OT56_10uM | Dose=10uM |
| HB-24-AP80_0.1uM | Dose=0.1uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| BE-87-TM66_10uM | Dose=10uM, [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone, Known Tryptase inhibitor targeting TPSB2 |
| BE-66-UB12_10uM | Dose=10uM |
| IB-80-NT15_0.1uM | Dose=0.1uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| ED-92-AL11_1uM | Dose=1uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1 |
| NC-52-HX69_0.01uM | Dose=0.01uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1 |
| BE-03-XC62_0.01uM | Dose=0.01uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| DA-10-VU83_1uM | Dose=1uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2 |
| UE-41-CL72_0.1uM | Dose=0.1uM, N-(7-hydroxy-1-naphthyl)-N'-[3-(methylthio)phenyl]urea, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting P2RX1, TRPV1 |
| BD-17-LT43_10uM | Dose=10uM, 3-((6-((5-Chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide, Tnni3 kinase inhibitor targeting TNNI3K |
| LE-43-AR77_0.01uM | Dose=0.01uM, N-hydroxy-4-phenylbutanamide |
| DB-34-QA60_10uM | Dose=10uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| HB-79-CZ36_10uM | Dose=10uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2 |
| DC-47-KV62_0.1uM | Dose=0.1uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| WC-59-RG09_1uM | Dose=1uM, Osi-930, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors targeting ABL1, KDR, KIT, PDGFRB |
| OB-46-IM27_0.01uM | Dose=0.01uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide |
| DC-98-CP35_10uM | Dose=10uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1 |
| GF-90-DG49_1uM | Dose=1uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| BB-21-XL84_10uM | Dose=10uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA |
| BC-03-OQ01_1uM | Dose=1uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM |
| BB-86-UL91_1uM | Dose=1uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| SC-50-ME48_10uM | Dose=10uM |
| ZE-46-XH09_10uM | Dose=10uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide |
| FA-77-YL98_0.1uM | Dose=0.1uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| GB-73-QS80_10uM | Dose=10uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| DB-07-WB29_10uM | Dose=10uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| WC-38-CZ02_10uM | Dose=10uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol |
| DD-67-EC82_10uM | Dose=10uM, Quetiapine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| AD-43-XJ59_0.1uM | Dose=0.1uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| XB-22-LI07_0.1uM | Dose=0.1uM |
| BC-09-XQ45_0.01uM | Dose=0.01uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2 |
| AD-58-PW17_0.1uM | Dose=0.1uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| ZD-18-MI26_1uM | Dose=1uM, N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide, Calcitonin Gene-Related Peptides (CGRP) Antagonists targeting CALCRL |
| FC-68-LJ11_10uM | Dose=10uM |
| DB-42-PI54_0.1uM | Dose=0.1uM |
| DB-80-CD47_10uM | Dose=10uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT |
| GA-81-DL34_1uM | Dose=1uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7 |
| AA-22-PQ14_10uM | Dose=10uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A |
| GE-26-BO33_10uM | Dose=10uM, USP7/USP47 inhibitor targeting USP7 |
| AD-29-MQ00_0.01uM | Dose=0.01uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| FC-96-WR45_10uM | Dose=10uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| YE-80-LN04_1uM | Dose=1uM |
| HB-36-FN80_1uM | Dose=1uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| DB-62-ES23_1uM | Dose=1uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| FC-68-LJ11_0.01uM | Dose=0.01uM |
| AD-33-YW85_0.1uM | Dose=0.1uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| TC-22-OM27_10uM | Dose=10uM |
| S0-EE-Y79N_0.01uM | Dose=0.01uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4 |
| XF-76-GE52_1uM | Dose=1uM |
| OB-06-WW76_10uM | Dose=10uM, Roxatidine acetate, HRH2 antagonist targeting HRH2 |
| JA-62-XU82_0.1uM | Dose=0.1uM, benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-phenylethyl]carbamate, Cathepsin K Inhibitors;Cathepsin S Inhibitors;Cathepsin L Inhibitors targeting CTSK, CTSL, CTSS |
| BE-37-ZF44_0.1uM | Dose=0.1uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| IF-08-GY16_0.1uM | Dose=0.1uM, (1E)-1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-1-hepten-3-one, IL-1 Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Tyrosinase Inhibitors;TNF-alpha Production Inhibitors;Antioxidants targeting NOS2, TYR |
| HB-09-OC16_0.1uM | Dose=0.1uM |
| WB-48-EF24_0.1uM | Dose=0.1uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1 |
| DB-42-PI54_1uM | Dose=1uM |
| JD-10-HW02_0.1uM | Dose=0.1uM |
| BC-14-CG34_0.01uM | Dose=0.01uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| DD-99-WQ55_10uM | Dose=10uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)- |
| PB-40-CS17_10uM | Dose=10uM |
| ND-36-VC68_1uM | Dose=1uM |
| BC-01-JL64_1uM | Dose=1uM, Calcimycin |
| KA-00-HF91_0.1uM | Dose=0.1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate |
| AE-37-MC27_1uM | Dose=1uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| SB-75-TY18_10uM | Dose=10uM |
| XC-13-LW13_10uM | Dose=10uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile |
| AA-24-UO04_0.1uM | Dose=0.1uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F |
| FD-25-KX07_0.1uM | Dose=0.1uM |
| BE-81-QL64_0.1uM | Dose=0.1uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| AD-43-XJ59_0.01uM | Dose=0.01uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| KA-27-KH73_10uM | Dose=10uM, 3-(6-Ethoxynaphthalen-2-Yl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine, camk1 gene inhibitor targeting CAMK1, CAMK1D, CAMK1G |
| GA-88-PV69_0.1uM | Dose=0.1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| DD-43-WW40_10uM | Dose=10uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| CB-68-GZ09_0.01uM | Dose=0.01uM, SB-204741, HTR2B antagonist targeting HTR2B |
| AA-17-RC87_0.01uM | Dose=0.01uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| AA-84-BX70_10uM | Dose=10uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AB-25-XU75_1uM | Dose=1uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| DD-43-WW40_0.1uM | Dose=0.1uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| BF-10-IO69_1uM | Dose=1uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| AC-37-OZ52_1uM | Dose=1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| CB-87-RB49_0.1uM | Dose=0.1uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| MD-86-UW46_0.01uM | Dose=0.01uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide |
| S0-EE-XXLY_0.1uM | Dose=0.1uM, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(3S)-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]urea, CDK8 inhibitor targeting CDK8 |
| CF-03-QN99_1uM | Dose=1uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8 |
| AA-70-VU13_10uM | Dose=10uM |
| AA-56-QO38_0.1uM | Dose=0.1uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| MF-41-QM60_0.1uM | Dose=0.1uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9 |
| CB-47-SB29_10uM | Dose=10uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| BB-21-XL84_0.1uM | Dose=0.1uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA |
| RB-06-YP44_1uM | Dose=1uM, m-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| FE-10-KQ78_0.1uM | Dose=0.1uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| FC-40-QD52_0.01uM | Dose=0.01uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| PC-80-LV29_0.1uM | Dose=0.1uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide |
| GD-59-QF63_10uM | Dose=10uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| AB-26-BE29_10uM | Dose=10uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2 |
| BD-22-KS33_10uM | Dose=10uM, Aptazapine, ADRA2A antagonist targeting ADRA2A |
| KD-00-UJ81_10uM | Dose=10uM, 3-anilinoisoquinolin-1(2H)-one |
| DE-00-JU18_1uM | Dose=1uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| OE-68-FR64_0.1uM | Dose=0.1uM, n-(2,6-Diethylphenyl)-homophthalimide, Puromycin-Sensitive Aminopeptidase Inhibitors targeting ANPEP, NPEPPS |
| NB-62-DN30_0.1uM | Dose=0.1uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB |
| DE-28-BW67_0.1uM | Dose=0.1uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| YB-58-IZ37_0.01uM | Dose=0.01uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4 |
| CB-92-VC05_10uM | Dose=10uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R |
| FA-77-LS25_0.01uM | Dose=0.01uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| ID-55-OJ03_10uM | Dose=10uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10 |
| AF-73-HJ84_10uM | Dose=10uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| BB-51-DP49_0.1uM | Dose=0.1uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| AA-76-VE74_0.1uM | Dose=0.1uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| CE-20-VA70_0.01uM | Dose=0.01uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| JD-62-TK68_0.1uM | Dose=0.1uM |
| S0-EE-X3ZZ_10uM | Dose=10uM, Pesampator targeting GRIA1 |
| SB-87-LQ34_0.01uM | Dose=0.01uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10 |
| FF-34-KW62_0.1uM | Dose=0.1uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| OB-78-PA58_10uM | Dose=10uM, Teglarinad, Glycerol-3-Phosphate Dehydrogenase (NAD+) Inhibitors;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Signal Transduction Modulators;Inhibitory kappaB Kinase (IKK) Inhibitors targeting GPD1, NAMPT, CHUK |
| HA-17-MS45_0.1uM | Dose=0.1uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| HB-51-FH64_1uM | Dose=1uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3 |
| CB-06-FE89_0.01uM | Dose=0.01uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| JD-12-CE09_10uM | Dose=10uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| CD-30-AD57_0.01uM | Dose=0.01uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| DA-54-NN76_1uM | Dose=1uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| RC-65-VL12_1uM | Dose=1uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT |
| GA-79-DW49_10uM | Dose=10uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| DD-30-NA60_0.1uM | Dose=0.1uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| BE-24-LQ28_0.01uM | Dose=0.01uM |
| HC-76-PX74_0.01uM | Dose=0.01uM |
| MF-41-QM60_0.01uM | Dose=0.01uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9 |
| CB-12-HC20_0.1uM | Dose=0.1uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55 |
| CA-10-RU23_0.1uM | Dose=0.1uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2 |
| CB-31-UO16_1uM | Dose=1uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1 |
| CB-15-RU50_0.01uM | Dose=0.01uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| FB-98-HM88_10uM | Dose=10uM, N-(1-morpholin-4-ylpropan-2-yl)-6-(8-pyridin-4-ylimidazo[4,5-c][1,7]naphthyridin-1-yl)quinolin-2-amine, Cot kinase inhibitor targeting MAP3K8, FLT3 |
| CB-80-CK24_10uM | Dose=10uM, F1174-1718 |
| DA-29-ZD04_10uM | Dose=10uM, Losartan, AGTR1 gene inhibitor targeting AGTR1 |
| BE-92-TW08_1uM | Dose=1uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1 |
| IA-14-WP20_10uM | Dose=10uM, Tazarotene, Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists targeting ODC1, RARB, RARG |
| AC-71-VV28_0.1uM | Dose=0.1uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119 |
| FD-29-MM50_10uM | Dose=10uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| ZB-29-GC39_0.1uM | Dose=0.1uM |
| AE-04-DX45_10uM | Dose=10uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5 |
| S0-EE-Y79N_0.1uM | Dose=0.1uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4 |
| KC-87-DN47_1uM | Dose=1uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR |
| GB-11-TA37_1uM | Dose=1uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| LE-80-BM08_10uM | Dose=10uM, CID 10481388 targeting ACAT2 |
| JB-09-SI50_10uM | Dose=10uM, 3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCG |
| AB-30-CR11_0.01uM | Dose=0.01uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| TB-06-VB30_0.1uM | Dose=0.1uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2 |
| DE-85-DO61_10uM | Dose=10uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2 |
| AB-71-CI37_1uM | Dose=1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| BF-22-EP86_1uM | Dose=1uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| CE-96-GH46_0.1uM | Dose=0.1uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AD-90-PA45_10uM | Dose=10uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| JE-22-JR20_1uM | Dose=1uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1 |
| IA-48-KI53_10uM | Dose=10uM, Vinaxanthone, semaphorin inhibitor targeting SEMA3A |
| HB-92-PE54_10uM | Dose=10uM |
| JB-82-MH86_0.01uM | Dose=0.01uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| BD-69-GX17_1uM | Dose=1uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| DE-85-FR73_0.01uM | Dose=0.01uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| TD-29-IN36_0.01uM | Dose=0.01uM |
| CC-91-VE57_1uM | Dose=1uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| CC-17-JL38_1uM | Dose=1uM, Ilk-IN-1 targeting ILK |
| CB-88-LG34_10uM | Dose=10uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| DE-03-NP53_0.01uM | Dose=0.01uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| EC-67-PV87_10uM | Dose=10uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| GB-56-TN25_0.1uM | Dose=0.1uM |
| CB-11-GB40_10uM | Dose=10uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| CB-06-FE89_1uM | Dose=1uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| RB-56-FZ63_1uM | Dose=1uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1 |
| GC-09-XF08_0.1uM | Dose=0.1uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| JA-46-LK88_0.1uM | Dose=0.1uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3 |
| AF-06-AY37_0.1uM | Dose=0.1uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| IC-23-YE16_10uM | Dose=10uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide |
| ID-13-PY29_0.01uM | Dose=0.01uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B |
| WB-17-DI74_0.01uM | Dose=0.01uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2 |
| KE-89-DV96_10uM | Dose=10uM, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| DA-54-NN76_10uM | Dose=10uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| RA-42-CM42_0.01uM | Dose=0.01uM, Lestaurtinib |
| MD-06-ZJ05_0.01uM | Dose=0.01uM, Deoxycytidine |
| FA-23-LP18_10uM | Dose=10uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| EC-71-PH39_10uM | Dose=10uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1 |
| TE-87-FM14_0.1uM | Dose=0.1uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid |
| GA-10-WX15_0.1uM | Dose=0.1uM |
| HD-22-GO73_0.1uM | Dose=0.1uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2 |
| MF-81-RJ18_0.01uM | Dose=0.01uM |
| IC-72-HR20_0.01uM | Dose=0.01uM, 3-Hydroxykynurenine |
| MB-46-BT89_0.1uM | Dose=0.1uM, 4-Hydroxy-3,5-dimethoxycinnamic acid, GABA(A) Receptor Agonists;Alleviation of Cartilage Destruction;Antioxidants targeting KEAP1 |
| DC-43-KF54_10uM | Dose=10uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| NB-17-SQ59_1uM | Dose=1uM, SDZ-62-434 free, Platelet-Activating Factor Receptor (PAFR) Antagonists targeting PTAFR |
| BE-04-AN21_0.1uM | Dose=0.1uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| EB-67-WB79_0.01uM | Dose=0.01uM |
| DF-75-MR73_0.1uM | Dose=0.1uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4 |
| JA-46-LK88_0.01uM | Dose=0.01uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3 |
| TA-57-FF07_10uM | Dose=10uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl |
| MF-11-EW49_0.1uM | Dose=0.1uM, Biochanin A, PPARgamma Agonists;Androgen Receptor Antagonists;Steroid 5alpha-Reductase Inhibitors;PPARalpha Agonists targeting AR, PPARA, PPARG, SRD5A1, SRD5A2 |
| BD-69-XG81_0.01uM | Dose=0.01uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| KE-18-XY06_1uM | Dose=1uM, Ibopamine, Dopamine D1 Agonists targeting DRD1 |
| AC-31-PL89_0.01uM | Dose=0.01uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| BB-94-HN41_0.1uM | Dose=0.1uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1 |
| EC-81-BA87_1uM | Dose=1uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| DB-93-SW55_0.1uM | Dose=0.1uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| EA-17-BY69_0.01uM | Dose=0.01uM |
| DD-38-MZ39_0.1uM | Dose=0.1uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| DA-08-XJ96_1uM | Dose=1uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| DE-28-BW67_1uM | Dose=1uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| BB-75-JK26_0.1uM | Dose=0.1uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| DA-33-CW45_0.1uM | Dose=0.1uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2 |
| IF-03-OL58_0.1uM | Dose=0.1uM, Tazarotenic acid, Drugs Acting on Retinoid Receptors targeting RARB |
| BC-07-FZ32_10uM | Dose=10uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2 |
| FE-25-GD89_0.01uM | Dose=0.01uM |
| CD-16-KY17_0.1uM | Dose=0.1uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| GB-19-AP57_10uM | Dose=10uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| AF-81-JB15_10uM | Dose=10uM, Ketoconazole |
| QC-12-DW06_10uM | Dose=10uM, 4-Phenyl-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]piperidine-4-carboxamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| BF-59-OR93_1uM | Dose=1uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| DF-00-NA25_10uM | Dose=10uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES |
| GA-13-WB79_0.01uM | Dose=0.01uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| XF-76-GE52_0.01uM | Dose=0.01uM |
| NE-93-AH13_1uM | Dose=1uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one |
| GC-74-QF56_0.1uM | Dose=0.1uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| ID-96-UX79_10uM | Dose=10uM, Vaniprevir |
| S0-EE-YFM9_0.1uM | Dose=0.1uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K |
| QE-00-EB96_1uM | Dose=1uM, MERTK gene inhibitor targeting MERTK |
| QE-11-DP47_10uM | Dose=10uM, 9-Hydroxycalabaxanthone |
| DA-88-JF21_1uM | Dose=1uM, FG-9041 targeting GRIA4 |
| HB-09-RP77_10uM | Dose=10uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| BB-05-NK66_1uM | Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| BA-87-NF64_0.1uM | Dose=0.1uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| OA-62-NJ00_10uM | Dose=10uM |
| NB-61-FT12_0.1uM | Dose=0.1uM, N-Salicyloyltryptamine, Potassium Channel Modulators;Sodium Channel Blockers;L-Type Calcium Channel Blockers targeting KCND3 |
| DF-40-CD57_10uM | Dose=10uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1 |
| SB-87-LQ34_0.1uM | Dose=0.1uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10 |
| MA-25-RP17_10uM | Dose=10uM, 4-{3-[2-(7-Methyl-1H-indol-3-yl)-ethylsulfanyl]-5-quinolin-2-yl-[1,2,4]triazol-4-yl}-butylamine, Somatostatin SRIF1B (sst5) Agonists;Somatostatin SRIF1A (sst2) Agonists targeting SSTR2, SSTR5 |
| UD-20-ER54_0.01uM | Dose=0.01uM, Paprazine, uncompetitive inhibitor targeting GAA |
| BA-09-PG96_0.01uM | Dose=0.01uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3 |
| S0-EE-Y6Y9_0.1uM | Dose=0.1uM, 6-chloro-N-(1-ethylpiperidin-4-yl)-1,2,3,4-tetrahydroacridin-9-amine |
| CC-90-EX35_1uM | Dose=1uM |
| CB-44-FA25_1uM | Dose=1uM, N-Tosyl-L-phenylalanyl chloromethyl ketone |
| AA-87-EI21_1uM | Dose=1uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| CE-88-RJ81_10uM | Dose=10uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| NC-73-QU79_10uM | Dose=10uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| AA-87-EI21_0.01uM | Dose=0.01uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| DC-31-WP64_0.01uM | Dose=0.01uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| AD-51-SS86_0.1uM | Dose=0.1uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2 |
| BB-79-GA42_1uM | Dose=1uM, Pratol |
| TD-29-IN36_10uM | Dose=10uM |
| CC-44-MG29_10uM | Dose=10uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| HF-76-AK33_10uM | Dose=10uM, VU0409551, GRM5 positive allosteric modulator targeting GRM5 |
| JE-13-EV67_0.1uM | Dose=0.1uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| AB-71-CI37_0.01uM | Dose=0.01uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| PC-62-AQ92_0.1uM | Dose=0.1uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD |
| BC-82-PP66_1uM | Dose=1uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| GC-21-AN18_10uM | Dose=10uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1 |
| FA-89-PW29_1uM | Dose=1uM, P505-15 targeting SYK |
| AA-62-OC45_10uM | Dose=10uM |
| DE-85-DO61_0.1uM | Dose=0.1uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2 |
| DD-49-YG96_0.1uM | Dose=0.1uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| ZB-09-RC84_1uM | Dose=1uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| OA-12-SU22_0.01uM | Dose=0.01uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| VE-46-XV53_1uM | Dose=1uM, LY466195 Diethyl ester prodrug |
| GC-46-CA74_10uM | Dose=10uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R |
| BB-10-PR06_1uM | Dose=1uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| GD-69-KC91_10uM | Dose=10uM, Bleomycin |
| FA-89-PW29_10uM | Dose=10uM, P505-15 targeting SYK |
| EA-98-NW07_10uM | Dose=10uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3 |
| NC-52-HX69_0.1uM | Dose=0.1uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1 |
| BB-77-IG67_10uM | Dose=10uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| LE-43-AR77_10uM | Dose=10uM, N-hydroxy-4-phenylbutanamide |
| LD-30-MF71_0.1uM | Dose=0.1uM |
| BB-77-IG67_1uM | Dose=1uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| AD-43-XJ59_1uM | Dose=1uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| DB-40-HA40_10uM | Dose=10uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| CA-10-RU23_1uM | Dose=1uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2 |
| EF-30-GD67_10uM | Dose=10uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2 |
| HF-51-NR28_10uM | Dose=10uM, 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide, ARP2/3 Complex inhibitor targeting ACTR3, ACTR2 |
| EC-17-MF19_0.1uM | Dose=0.1uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| JA-88-IO52_1uM | Dose=1uM |
| LB-17-PD08_0.1uM | Dose=0.1uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1 |
| BB-99-UN48_0.01uM | Dose=0.01uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| FB-39-VW14_10uM | Dose=10uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1 |
| AE-21-BF25_10uM | Dose=10uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| JD-38-MY26_10uM | Dose=10uM, FTY720 (R)-Phosphate, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR1, S1PR3, S1PR4 |
| LC-11-GG16_1uM | Dose=1uM |
| KB-58-XI48_0.1uM | Dose=0.1uM, Diosmin, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| GB-19-AP57_1uM | Dose=1uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| DF-03-OP38_10uM | Dose=10uM |
| AA-72-QI84_1uM | Dose=1uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| DB-69-JG66_10uM | Dose=10uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide |
| RA-49-ZB08_1uM | Dose=1uM |
| FB-39-CW59_0.01uM | Dose=0.01uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| AA-32-DP01_1uM | Dose=1uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1 |
| QA-73-SR92_1uM | Dose=1uM |
| AB-97-BI36_0.01uM | Dose=0.01uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| DD-12-RF07_0.1uM | Dose=0.1uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| OA-12-SU22_0.1uM | Dose=0.1uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| DB-73-BC12_1uM | Dose=1uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4 |
| JB-82-MH86_1uM | Dose=1uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| EC-71-PH39_1uM | Dose=1uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1 |
| HC-14-FM48_0.01uM | Dose=0.01uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| FD-20-OG99_1uM | Dose=1uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| AD-40-WB93_1uM | Dose=1uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1 |
| DD-36-YH76_0.1uM | Dose=0.1uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| HE-14-AT80_1uM | Dose=1uM, Filgotinib targeting JAK1, JAK2, JAK3, TYK2 |
| BA-02-FS63_0.1uM | Dose=0.1uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| GC-72-GY67_0.01uM | Dose=0.01uM |
| ME-11-OJ38_10uM | Dose=10uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4 |
| BA-52-FW03_0.01uM | Dose=0.01uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| TD-31-KS49_10uM | Dose=10uM, Sertindole, Dopamine D2 Antagonists;5-HT2A Antagonists targeting ADRA1B, HTR1E, HTR1F |
| DE-81-PO11_1uM | Dose=1uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300 |
| WC-38-CZ02_0.01uM | Dose=0.01uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol |
| BB-84-DG64_1uM | Dose=1uM |
| AW-15-2439_0.01uM | Dose=0.01uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| AB-96-XV75_1uM | Dose=1uM, Dapsone |
| LA-27-FR67_10uM | Dose=10uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1 |
| CC-91-VE57_0.1uM | Dose=0.1uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| BB-74-RX30_0.01uM | Dose=0.01uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| CC-48-OM48_10uM | Dose=10uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| DF-37-AV77_0.01uM | Dose=0.01uM, Chlorthalidone, Carbonic Anhydrase Type VII Inhibitors targeting CA1, CA4, CA5A, CA7, CA12, CA5B |
| JF-45-JM50_0.1uM | Dose=0.1uM, Rauwolscine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| OF-97-MQ74_10uM | Dose=10uM |
| BA-59-QN98_0.01uM | Dose=0.01uM, AX-024 targeting NCK1, NCK2 |
| BD-58-PW57_10uM | Dose=10uM, Carbonyl Cyanide m-Chlorophenyl Hydrazone |
| BA-59-QN98_1uM | Dose=1uM, AX-024 targeting NCK1, NCK2 |
| BC-48-WT15_0.1uM | Dose=0.1uM, Thymidine Phosphorylase Inhibitors targeting TYMP |
| AB-00-IL62_10uM | Dose=10uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| BB-01-IO76_0.1uM | Dose=0.1uM, Aspartic Acid |
| BE-07-XI66_0.1uM | Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| CB-06-FE89_0.1uM | Dose=0.1uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| TF-43-DT71_10uM | Dose=10uM |
| DD-41-AE67_0.1uM | Dose=0.1uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| AE-78-XJ76_0.01uM | Dose=0.01uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| MA-96-GW26_0.1uM | Dose=0.1uM |
| BD-46-RY02_10uM | Dose=10uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1 |
| NC-27-AD53_0.1uM | Dose=0.1uM, Azd-1480, Jak2 Inhibitors targeting JAK1, JAK2 |
| AA-67-TF79_0.01uM | Dose=0.01uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1 |
| CF-87-AS90_0.01uM | Dose=0.01uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| TE-15-RO34_10uM | Dose=10uM, N-[1-[[5-chloro-2-(cyclopropylmethoxy)phenyl]methyl]-5-methylpyrazol-3-yl]-1,2,3,4-tetrahydroisoquinoline-6-carboxamide, SCD gene inhibitor targeting SCD |
| BA-64-PX65_10uM | Dose=10uM, Carnosine |
| DA-15-PU65_10uM | Dose=10uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| JF-45-JM50_10uM | Dose=10uM, Rauwolscine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| XC-88-ZM66_0.1uM | Dose=0.1uM |
| AE-67-FF84_10uM | Dose=10uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| KE-04-OV29_1uM | Dose=1uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)- |
| CF-65-GU65_1uM | Dose=1uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| JA-79-II25_10uM | Dose=10uM, Jnj-10329670, Cathepsin S Inhibitors targeting CTSS |
| CB-87-GT98_1uM | Dose=1uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL |
| PC-05-MI00_0.1uM | Dose=0.1uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2 |
| CD-80-ZD47_0.1uM | Dose=0.1uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT |
| BC-94-GN01_10uM | Dose=10uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1 |
| OD-03-CA36_10uM | Dose=10uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide |
| NC-52-HX69_1uM | Dose=1uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1 |
| ZE-53-LS38_10uM | Dose=10uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine |
| AB-96-JV50_0.1uM | Dose=0.1uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2 |
| QE-98-XD90_1uM | Dose=1uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine |
| AB-50-OH27_1uM | Dose=1uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB |
| VC-30-QH05_0.1uM | Dose=0.1uM, Zucapsaicin, TRPV1 (Vanilloid VR1 Receptor) Agonists targeting TRPV1 |
| AC-91-ME22_0.01uM | Dose=0.01uM, (R)-Aminoglutethimide |
| AD-42-US78_0.1uM | Dose=0.1uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3 |
| BB-77-QQ71_1uM | Dose=1uM, Ricolinostat, HDAC6 targeting HDAC6 |
| EC-60-CX20_10uM | Dose=10uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A |
| FE-72-KZ75_0.01uM | Dose=0.01uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3 |
| DA-40-HO94_0.1uM | Dose=0.1uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR |
| AB-90-YR46_1uM | Dose=1uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| AA-84-BX70_0.1uM | Dose=0.1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| MF-20-QI53_0.1uM | Dose=0.1uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2 |
| VA-06-DB75_0.1uM | Dose=0.1uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA |
| FA-95-HA77_10uM | Dose=10uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2 |
| HA-83-MI31_10uM | Dose=10uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| WC-16-IR43_0.01uM | Dose=0.01uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| NC-14-ES72_1uM | Dose=1uM |
| AA-70-VU13_0.01uM | Dose=0.01uM |
| SB-29-ZH97_10uM | Dose=10uM, Tetrahydrouridine, CDA gene inhibitor targeting CDA |
| WF-85-JN16_0.01uM | Dose=0.01uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| BE-70-YH17_10uM | Dose=10uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| AD-16-OE34_1uM | Dose=1uM, Octopamine |
| CE-00-EK89_0.01uM | Dose=0.01uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| DB-28-SP20_10uM | Dose=10uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4 |
| FE-94-WT30_0.1uM | Dose=0.1uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2 |
| DD-61-DY35_0.01uM | Dose=0.01uM |
| DA-49-ZD74_0.1uM | Dose=0.1uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| AB-85-YK41_1uM | Dose=1uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME |
| GC-28-YS77_10uM | Dose=10uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| BA-40-IU73_10uM | Dose=10uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR |
| FA-56-WH26_10uM | Dose=10uM, Venglustat targeting UGCG |
| OB-22-TT14_0.1uM | Dose=0.1uM, 3,4-Dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone, Influenza A virus RNA Promoter Binder;PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| WD-62-UB45_1uM | Dose=1uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3 |
| AC-94-YX80_0.1uM | Dose=0.1uM, Loratadine |
| LE-48-SO37_1uM | Dose=1uM, 4-[(3-chlorophenyl)methoxy]-1-methyl-5-pyridin-3-yl-3H-indol-2-one |
| BB-78-LT85_10uM | Dose=10uM |
| TA-20-FO62_0.01uM | Dose=0.01uM |
| KB-05-VJ83_1uM | Dose=1uM, 2-Chloro-N-[(9H-fluoren-9-ylamino)carbonyl]-6-fluorobenzamide, PPIA gene inhibitor targeting PPIA |
| ED-11-KK36_0.01uM | Dose=0.01uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1 |
| CA-10-RU23_10uM | Dose=10uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2 |
| CC-48-OM48_0.1uM | Dose=0.1uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| XC-13-LW13_0.01uM | Dose=0.01uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile |
| TA-20-FO62_0.1uM | Dose=0.1uM |
| LD-22-SA99_10uM | Dose=10uM, (S)-Crizotinib, ALK gene inhibitor,ROS1 gene inhibitor, MET gene inhibitor, NUDT1 gene inhibitor;NUDT1 gene inhibitor targeting NUDT1 |
| DA-35-ZK21_1uM | Dose=1uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| BC-80-FK74_10uM | Dose=10uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| QB-35-FO29_10uM | Dose=10uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12 |
| EC-09-DC91_0.1uM | Dose=0.1uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| RE-62-FC93_10uM | Dose=10uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| S0-EE-YFM9_1uM | Dose=1uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K |
| RB-06-YP44_10uM | Dose=10uM, m-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| GB-94-XG34_10uM | Dose=10uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN |
| AE-14-NN26_1uM | Dose=1uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| BB-19-ZK81_0.01uM | Dose=0.01uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH |
| FB-67-PL18_0.01uM | Dose=0.01uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| CC-04-FJ21_10uM | Dose=10uM, ML315, CLK4 inhibitor targeting CLK4 |
| EC-67-PV87_1uM | Dose=1uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| IF-31-RN78_0.01uM | Dose=0.01uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1 |
| AE-00-NY23_10uM | Dose=10uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| UF-85-NE30_10uM | Dose=10uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile |
| BD-62-ZF67_0.01uM | Dose=0.01uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| FB-39-CW59_10uM | Dose=10uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| JD-02-GA59_10uM | Dose=10uM |
| DE-81-UE07_1uM | Dose=1uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| BB-31-EB45_10uM | Dose=10uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1 |
| ZD-23-ZF57_0.01uM | Dose=0.01uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2 |
| QC-49-CA55_0.01uM | Dose=0.01uM |
| AB-92-GP61_10uM | Dose=10uM, JTE-607 free base |
| LE-80-BM08_1uM | Dose=1uM, CID 10481388 targeting ACAT2 |
| HB-51-FH64_0.1uM | Dose=0.1uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3 |
| KD-50-WP70_10uM | Dose=10uM, N-(3,4-dichlorophenyl)guanidine, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| IC-23-YE16_0.01uM | Dose=0.01uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide |
| AD-58-PW17_0.01uM | Dose=0.01uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| AD-51-ZE47_1uM | Dose=1uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| AF-60-GR11_10uM | Dose=10uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8 |
| CE-23-HP88_0.1uM | Dose=0.1uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| LB-17-PD08_1uM | Dose=1uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1 |
| IB-56-BR35_1uM | Dose=1uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3 |
| BC-57-KZ72_0.1uM | Dose=0.1uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| CF-61-EH59_1uM | Dose=1uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| CC-09-YG11_10uM | Dose=10uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2 |
| AC-95-NR38_10uM | Dose=10uM |
| PC-85-EL52_0.1uM | Dose=0.1uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139 |
| ID-69-QF93_1uM | Dose=1uM |
| XB-22-LI07_0.01uM | Dose=0.01uM |
| WB-48-EF24_0.01uM | Dose=0.01uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1 |
| BD-47-NP88_0.01uM | Dose=0.01uM, A-967079, TRPA1 Antagonists targeting TRPA1 |
| XB-53-OZ95_0.01uM | Dose=0.01uM |
| AC-42-SI74_0.01uM | Dose=0.01uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| AD-59-IN33_0.1uM | Dose=0.1uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| LC-03-KY64_1uM | Dose=1uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2 |
| PC-18-VX23_1uM | Dose=1uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1 |
| IF-43-EO10_0.1uM | Dose=0.1uM |
| S0-EE-U3YG_0.1uM | Dose=0.1uM, ACMSD inhibitor targeting ACMSD |
| CD-30-AD57_10uM | Dose=10uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| RA-42-CM42_0.1uM | Dose=0.1uM, Lestaurtinib |
| SD-15-WR01_10uM | Dose=10uM, 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoic acid, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| OA-51-KF88_0.01uM | Dose=0.01uM, Lodoxamide targeting ARRB2, GPR35 |
| ND-15-RC31_1uM | Dose=1uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1 |
| CA-90-RU33_10uM | Dose=10uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| DF-85-QA87_0.1uM | Dose=0.1uM, Htfmt, HRH1 agonist targeting HRH1 |
| MA-45-US84_10uM | Dose=10uM, 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, SUV420H1/H2 inhibitor;kmt5b and kmt5c inhibitor targeting KMT5B, KMT5C |
| TE-16-VT54_10uM | Dose=10uM, Atglistatin, Patatin like phospholipase protein inhibitor targeting PNPLA2 |
| AF-11-IL39_10uM | Dose=10uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2 |
| NC-85-PZ41_10uM | Dose=10uM, Mln-4760, Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors targeting ACE2 |
| KB-00-DM33_1uM | Dose=1uM |
| CC-47-VS90_1uM | Dose=1uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| AE-85-KE62_1uM | Dose=1uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-97-TS20_0.1uM | Dose=0.1uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| FC-35-BX82_1uM | Dose=1uM, Cyclosporin V |
| CB-12-BV05_0.01uM | Dose=0.01uM |
| FC-55-IG96_0.1uM | Dose=0.1uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6 |
| CC-15-MK46_0.1uM | Dose=0.1uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2 |
| LD-30-MF71_1uM | Dose=1uM |
| KB-88-OR49_0.1uM | Dose=0.1uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| JA-88-IO52_0.01uM | Dose=0.01uM |
| DB-77-AV67_0.1uM | Dose=0.1uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate |
| DD-85-WO51_10uM | Dose=10uM |
| LA-42-CN75_10uM | Dose=10uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| AB-14-GQ48_10uM | Dose=10uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| BC-81-LO06_10uM | Dose=10uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde |
| HB-69-CT62_0.01uM | Dose=0.01uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| YA-34-DT48_10uM | Dose=10uM |
| MB-35-NZ76_0.01uM | Dose=0.01uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone) |
| BE-45-XA42_10uM | Dose=10uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1 |
| IF-31-BQ95_10uM | Dose=10uM, Calcium-Sensing Receptor Antagonists I, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| LD-14-PB06_10uM | Dose=10uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET |
| BB-04-KA05_0.01uM | Dose=0.01uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| EC-14-UM93_0.1uM | Dose=0.1uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CA-23-BW20_0.1uM | Dose=0.1uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2 |
| DA-46-KH36_1uM | Dose=1uM, 1,2,3,4-Tetrahydroisoquinoline |
| JB-99-UC61_1uM | Dose=1uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid |
| UA-56-RO11_1uM | Dose=1uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3 |
| BA-85-ZA57_0.01uM | Dose=0.01uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| NC-11-BC71_10uM | Dose=10uM, Lck Kinase Inhibitors;IL-2 Production Inhibitors;Inhibitors of Signal Transduction Pathways targeting IL2, LCK |
| TD-09-SX65_0.1uM | Dose=0.1uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2 |
| TC-80-LY86_1uM | Dose=1uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid |
| CA-42-YI34_1uM | Dose=1uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| TD-57-NZ75_10uM | Dose=10uM |
| IE-13-CP28_10uM | Dose=10uM, CLK1 protein kinase inhibitor targeting CLK1, DYRK1A, DYRK2 |
| FB-75-YG01_1uM | Dose=1uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| JC-52-RH51_10uM | Dose=10uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1 |
| JF-16-BD66_10uM | Dose=10uM, Gsk-690693, PKB gamma/Akt3 Inhibitors;Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors targeting AKT1, AKT2, DAPK3, PRKG1, PRKX, AKT3, PAK6 |
| DB-73-KP48_0.1uM | Dose=0.1uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN |
| DC-45-WU45_1uM | Dose=1uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2 |
| PC-05-MI00_1uM | Dose=1uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2 |
| IF-87-AU84_1uM | Dose=1uM |
| GB-11-TA37_0.1uM | Dose=0.1uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| EF-80-OD07_0.01uM | Dose=0.01uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| GC-28-YS77_1uM | Dose=1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| TD-09-SX65_10uM | Dose=10uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2 |
| BE-03-XC62_0.1uM | Dose=0.1uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| BF-89-QD24_10uM | Dose=10uM |
| DC-31-WP64_0.1uM | Dose=0.1uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| DA-33-NF79_0.01uM | Dose=0.01uM, Brofaromine, MAO-A Inhibitors targeting MAOA |
| DA-08-XJ96_0.1uM | Dose=0.1uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| HB-75-KT12_0.1uM | Dose=0.1uM |
| FB-39-CW59_0.1uM | Dose=0.1uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| PE-69-DO79_10uM | Dose=10uM, N-phenylaminosulfonamide, carbonic anhydrase inhibitor targeting CA1 |
| BA-75-VA57_10uM | Dose=10uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2 |
| CF-97-AV07_0.1uM | Dose=0.1uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4 |
| UE-01-HV71_0.01uM | Dose=0.01uM |
| DA-60-KU38_10uM | Dose=10uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| JC-96-ID26_10uM | Dose=10uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A |
| XE-69-AT35_0.1uM | Dose=0.1uM, Nocardimicin A |
| VE-11-PV61_0.1uM | Dose=0.1uM, Tak-259, Orally Active α1D Adrenoceptor targeting ADRA1D |
| ED-84-WW97_0.01uM | Dose=0.01uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5 |
| TC-22-OM27_0.1uM | Dose=0.1uM |
| ZB-33-MZ40_1uM | Dose=1uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1 |
| QA-73-SR92_0.1uM | Dose=0.1uM |
| MC-51-BT07_1uM | Dose=1uM, Cx516, AMPA Receptor Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| EA-92-CV45_1uM | Dose=1uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| BC-43-JW95_1uM | Dose=1uM, Phenylalanine |
| DE-99-OT37_0.01uM | Dose=0.01uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| YA-34-DT48_1uM | Dose=1uM |
| QE-35-YE15_0.1uM | Dose=0.1uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine |
| FA-77-YL98_1uM | Dose=1uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| LE-50-AP60_0.1uM | Dose=0.1uM |
| BD-48-JW52_10uM | Dose=10uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR |
| DD-10-NA60_10uM | Dose=10uM |
| GC-86-TD91_0.1uM | Dose=0.1uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| CA-44-LT45_0.01uM | Dose=0.01uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| DE-15-GD59_0.01uM | Dose=0.01uM |
| PC-44-DH10_10uM | Dose=10uM, (1R,3S,6S,10S,11R)-7-[(dimethylamino)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA |
| LA-42-CN75_0.1uM | Dose=0.1uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| AB-84-PK04_10uM | Dose=10uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| FB-67-PL18_1uM | Dose=1uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| WC-82-YS26_10uM | Dose=10uM, 4-[5-(2-methylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine |
| CB-73-HZ47_1uM | Dose=1uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| EB-85-DG91_10uM | Dose=10uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| BB-55-JH29_0.01uM | Dose=0.01uM |
| DA-08-XJ96_10uM | Dose=10uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| AE-39-DG66_0.01uM | Dose=0.01uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| HC-76-HU27_0.1uM | Dose=0.1uM |
| FA-89-PW29_0.1uM | Dose=0.1uM, P505-15 targeting SYK |
| GC-28-YS77_0.01uM | Dose=0.01uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| FF-06-MO73_1uM | Dose=1uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3 |
| S0-EE-XXLY_10uM | Dose=10uM, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(3S)-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]urea, CDK8 inhibitor targeting CDK8 |
| AD-92-QZ55_10uM | Dose=10uM, Tmc-353121 |
| JB-82-MH86_0.1uM | Dose=0.1uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| EC-14-UM93_10uM | Dose=10uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| MB-32-LQ97_0.1uM | Dose=0.1uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1 |
| CA-73-BW50_10uM | Dose=10uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2 |
| DC-08-KP05_1uM | Dose=1uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| BC-34-IH52_0.1uM | Dose=0.1uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| OC-23-QX66_0.1uM | Dose=0.1uM, 3,5-Dihydroxy-4-methoxybenzoic acid, NF-kappaB (NFKB) Activation Inhibitors;Free Radical Scavengers targeting RELA |
| DC-81-PH69_10uM | Dose=10uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1 |
| VA-39-AQ18_0.01uM | Dose=0.01uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R |
| EA-00-RN06_0.1uM | Dose=0.1uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| JA-77-UH38_10uM | Dose=10uM |
| LC-19-SF48_0.01uM | Dose=0.01uM, N-[5-(Adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin, Glucosylceramidase inhibitor targeting GBA2 |
| SB-28-EJ14_1uM | Dose=1uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2 |
| AA-54-WG39_1uM | Dose=1uM, 4-Aminobenzamide |
| GB-45-YG91_0.1uM | Dose=0.1uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AW-10-0667_0.01uM | Dose=0.01uM, Clofibrate |
| IB-56-BR35_10uM | Dose=10uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3 |
| MA-20-ZI33_10uM | Dose=10uM |
| ZD-18-MI26_0.1uM | Dose=0.1uM, N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide, Calcitonin Gene-Related Peptides (CGRP) Antagonists targeting CALCRL |
| AD-37-UF49_10uM | Dose=10uM, (S)-N1-(4-Methyl-5-(2-(1-methylcyclopropyl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| EC-81-BA87_0.1uM | Dose=0.1uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| BB-20-UU03_1uM | Dose=1uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| VD-88-MW70_0.1uM | Dose=0.1uM, [4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine, CDK Inhibitor;Pan Kinase Inhibitor targeting CDK2, CCNE2 |
| BF-44-HD37_10uM | Dose=10uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB |
| JC-53-YE56_10uM | Dose=10uM, Quiflapon |
| KB-88-OR49_0.01uM | Dose=0.01uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| LD-30-MF71_10uM | Dose=10uM |
| VB-48-KG22_0.01uM | Dose=0.01uM, 6,8-Dimercapto-2-hydroxypurine |
| CC-70-BD07_0.01uM | Dose=0.01uM, Voriconazole Impurity 7 |
| JD-00-YJ41_1uM | Dose=1uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK |
| HB-09-OC16_0.01uM | Dose=0.01uM |
| AA-76-VE74_0.01uM | Dose=0.01uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| IC-80-CT90_10uM | Dose=10uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea |
| CA-43-WF29_0.1uM | Dose=0.1uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| S0-EE-Y96U_0.1uM | Dose=0.1uM, Jnj-42165279, FAAH inhibitor targeting FAAH |
| SB-74-OD45_0.1uM | Dose=0.1uM, N-1-(Fur-3-ylethyl)-N-hydroxyurea, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| XC-88-ZM66_10uM | Dose=10uM |
| ZA-28-BF44_10uM | Dose=10uM, Amg-458, HGFR (MET;c-Met) Inhibitors targeting MET |
| AD-84-LG49_0.01uM | Dose=0.01uM |
| DB-41-SH04_10uM | Dose=10uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3 |
| HC-83-TS50_10uM | Dose=10uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC |
| BC-75-FA82_10uM | Dose=10uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| IA-03-BO30_10uM | Dose=10uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2 |
| PB-18-HD85_0.01uM | Dose=0.01uM |
| QE-35-YE15_1uM | Dose=1uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine |
| JE-47-FU54_0.1uM | Dose=0.1uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4 |
| UF-98-OM26_0.1uM | Dose=0.1uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| ZD-78-BS65_10uM | Dose=10uM |
| GE-68-FZ64_10uM | Dose=10uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA |
| CA-42-YI34_0.01uM | Dose=0.01uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| DE-97-IV02_1uM | Dose=1uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1 |
| BD-36-VB52_10uM | Dose=10uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| BB-04-KA05_0.1uM | Dose=0.1uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| BB-31-EB45_0.1uM | Dose=0.1uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1 |
| EC-07-AO30_0.1uM | Dose=0.1uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| AE-00-NY23_0.1uM | Dose=0.1uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| OE-91-GF88_0.1uM | Dose=0.1uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG |
| AA-85-LB25_0.1uM | Dose=0.1uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| DD-61-DY35_0.1uM | Dose=0.1uM |
| AE-06-JY57_0.1uM | Dose=0.1uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| ZA-63-AC60_1uM | Dose=1uM, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone targeting GPX4 |
| TC-80-LY86_0.01uM | Dose=0.01uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid |
| FC-96-WR45_0.01uM | Dose=0.01uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| OC-71-BZ81_0.01uM | Dose=0.01uM |
| AA-17-RC87_0.1uM | Dose=0.1uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| DC-98-HC94_0.01uM | Dose=0.01uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| AA-24-EN31_10uM | Dose=10uM, (5R,8S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-7-[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]amino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| NC-73-QU79_1uM | Dose=1uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| BD-98-TG79_0.1uM | Dose=0.1uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| PA-93-BD53_0.1uM | Dose=0.1uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC |
| EB-85-DG91_0.1uM | Dose=0.1uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| BC-39-JG96_0.1uM | Dose=0.1uM, Gemfibrozil, PPARalpha Agonists targeting PPARA |
| KA-58-YE68_10uM | Dose=10uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B |
| NC-14-ES72_0.01uM | Dose=0.01uM |
| BD-70-PH02_0.01uM | Dose=0.01uM |
| FC-22-ZV65_10uM | Dose=10uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2 |
| KF-00-NW62_1uM | Dose=1uM, 6-[(2-Aminopyridin-3-yl)methylamino]-1,3-bis[(4-methoxyphenyl)methyl]-1,3,5-triazine-2,4-dione, Prokineticin 1 Receptor (PKR1) Antagonist targeting PROKR1 |
| CB-99-NG16_10uM | Dose=10uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD |
| HE-34-NJ16_0.1uM | Dose=0.1uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9 |
| AD-94-EX35_0.1uM | Dose=0.1uM, Pretomanid |
| KE-18-XY06_10uM | Dose=10uM, Ibopamine, Dopamine D1 Agonists targeting DRD1 |
| FE-37-OL13_10uM | Dose=10uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| GD-43-TP28_0.01uM | Dose=0.01uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2 |
| JE-04-LS32_0.01uM | Dose=0.01uM |
| CB-82-PL01_1uM | Dose=1uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK |
| BD-83-QC82_0.1uM | Dose=0.1uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| CA-43-WF29_0.01uM | Dose=0.01uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| S0-EE-YC7H_10uM | Dose=10uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6 |
| EB-89-KM10_10uM | Dose=10uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| NC-76-YX69_1uM | Dose=1uM, 2-Amino-4-methylbenzothiazole |
| BA-46-YF32_1uM | Dose=1uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| MD-06-ZJ05_1uM | Dose=1uM, Deoxycytidine |
| ID-55-OJ03_1uM | Dose=1uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10 |
| DA-69-UN88_0.1uM | Dose=0.1uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1 |
| EF-62-IO23_10uM | Dose=10uM |
| AC-93-OJ74_1uM | Dose=1uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| VB-89-RG34_1uM | Dose=1uM, [(2R)-2-amino-2-methyl-4-[4-[3-(4-phenylphenyl)propanoyl]phenyl]butyl] dihydrogen phosphate, Lysophospholipid Receptor Agonists targeting S1PR1, S1PR5 |
| GA-88-PV69_0.01uM | Dose=0.01uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| GC-72-GY67_1uM | Dose=1uM |
| AC-95-TK81_0.1uM | Dose=0.1uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| ID-00-IC14_0.01uM | Dose=0.01uM |
| DC-31-WP64_1uM | Dose=1uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| BE-49-AQ65_1uM | Dose=1uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
| IE-46-VU57_0.1uM | Dose=0.1uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1 |
| ED-03-IP48_10uM | Dose=10uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1 |
| BE-07-BZ97_1uM | Dose=1uM, 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide targeting GHSR |
| EC-55-XG31_10uM | Dose=10uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2 |
| ED-05-KX67_0.1uM | Dose=0.1uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| FD-48-HZ39_0.1uM | Dose=0.1uM |
| AB-84-PK04_0.1uM | Dose=0.1uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| WB-82-EL69_10uM | Dose=10uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone |
| BB-83-OX58_0.01uM | Dose=0.01uM |
| BF-03-RM76_10uM | Dose=10uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2 |
| QF-00-NO42_0.1uM | Dose=0.1uM |
| AE-04-DX45_0.01uM | Dose=0.01uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5 |
| AF-25-BS76_10uM | Dose=10uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4 |
| CB-93-YZ07_0.1uM | Dose=0.1uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| AF-87-II41_0.01uM | Dose=0.01uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10 |
| BB-45-NH69_10uM | Dose=10uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| AC-84-QG99_0.01uM | Dose=0.01uM |
| DA-83-VJ09_0.01uM | Dose=0.01uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| FB-75-YG01_10uM | Dose=10uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| CD-26-MB82_10uM | Dose=10uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| NE-37-JX51_0.01uM | Dose=0.01uM |
| ED-26-RU42_0.01uM | Dose=0.01uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| DE-81-UE07_0.1uM | Dose=0.1uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| DF-85-QA87_10uM | Dose=10uM, Htfmt, HRH1 agonist targeting HRH1 |
| HE-55-AG11_0.01uM | Dose=0.01uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3 |
| IB-80-NT65_10uM | Dose=10uM |
| ND-36-VC68_10uM | Dose=10uM |
| ED-39-VX22_0.1uM | Dose=0.1uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| FA-14-WC79_1uM | Dose=1uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| PE-86-SC73_0.1uM | Dose=0.1uM, PF-543, SPHK1 inhibitor targeting SPHK1 |
| CA-56-GE89_10uM | Dose=10uM, 7-Deaza-2'-C-ethynyladenosine |
| GC-07-UO80_0.1uM | Dose=0.1uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68 |
| BE-36-XE09_10uM | Dose=10uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| AA-69-TD29_1uM | Dose=1uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1 |
| RC-18-AD40_10uM | Dose=10uM, N-(3,5-dimethylphenyl)-4-(thiazol-2-yl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors;Syk Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting SYK, AURKB, GSK3A |
| FB-75-YG01_0.1uM | Dose=0.1uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| CA-64-LT35_0.01uM | Dose=0.01uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| JE-61-EQ70_10uM | Dose=10uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine |
| WC-54-BJ14_0.01uM | Dose=0.01uM, Integrin-antagonist-1, ITGB6 antagonist targeting ITGA6, ITGB6 |
| GA-47-MH68_0.1uM | Dose=0.1uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| EC-41-PH99_0.1uM | Dose=0.1uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide |
| BF-94-CQ58_1uM | Dose=1uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| WB-17-DI74_0.1uM | Dose=0.1uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2 |
| BD-85-GY20_0.01uM | Dose=0.01uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| BA-59-QN98_0.1uM | Dose=0.1uM, AX-024 targeting NCK1, NCK2 |
| PA-93-BD53_10uM | Dose=10uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC |
| PA-40-NS72_1uM | Dose=1uM, Oseltamivir Acid |
| DA-10-HD17_0.1uM | Dose=0.1uM, N-Phthalylglycine |
| KD-42-UK08_0.01uM | Dose=0.01uM, AZ11657312 (salt free), P2X7 Receptor Antagonists targeting P2RX7 |
| CD-41-RE87_10uM | Dose=10uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R |
| FE-25-GD89_1uM | Dose=1uM |
| BD-25-SA37_10uM | Dose=10uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| IB-80-NT15_10uM | Dose=10uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| TC-59-QN21_1uM | Dose=1uM, SB-332235, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| UC-19-KX65_1uM | Dose=1uM |
| AA-43-TW35_0.01uM | Dose=0.01uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B |
| SD-51-LL22_10uM | Dose=10uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1 |
| AC-57-ZF49_10uM | Dose=10uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| AA-14-VK39_10uM | Dose=10uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide |
| TD-57-NZ75_1uM | Dose=1uM |
| JD-51-GD99_0.1uM | Dose=0.1uM, 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one, MAP3K11 gene inhibitor targeting MAP3K9, MAP3K11 |
| ED-10-ED67_0.1uM | Dose=0.1uM, Dcebio |
| FE-94-NQ13_0.1uM | Dose=0.1uM, Tirasemtiv targeting TNNI2, TNNT3 |
| DC-70-EK34_1uM | Dose=1uM, BF-844, CLRN stabilizer targeting CLRN1 |
| FE-37-OL13_0.1uM | Dose=0.1uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| BF-61-IO76_10uM | Dose=10uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| AB-11-QV43_0.1uM | Dose=0.1uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| RB-80-II48_10uM | Dose=10uM, 8-(2,5-Dimethoxyphenyl)-1-(2-fluorophenyl)imidazo[4,5-c]quinoline, RET inhibitor targeting RET |
| AB-17-DF74_10uM | Dose=10uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL |
| NC-29-PY58_10uM | Dose=10uM, N-[5-[[6-(3-aminophenyl)pyrimidin-4-yl]amino]-2-methylphenyl]-1-methylimidazole-4-sulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| BD-18-FM58_0.1uM | Dose=0.1uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| TF-29-QU48_1uM | Dose=1uM |
| DE-37-JV37_0.01uM | Dose=0.01uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| BA-96-YB32_10uM | Dose=10uM |
| DC-51-WE27_0.01uM | Dose=0.01uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| JD-94-BC04_10uM | Dose=10uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1 |
| KE-58-BO47_1uM | Dose=1uM, Bms 433771 |
| FB-91-BU05_1uM | Dose=1uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| JD-51-GD99_10uM | Dose=10uM, 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one, MAP3K11 gene inhibitor targeting MAP3K9, MAP3K11 |
| BE-24-LQ28_1uM | Dose=1uM |
| AC-60-EU98_10uM | Dose=10uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| BA-87-NF64_0.01uM | Dose=0.01uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| GA-47-MH68_1uM | Dose=1uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| DE-91-FH69_0.1uM | Dose=0.1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| AE-42-HT01_10uM | Dose=10uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| AB-06-KB32_1uM | Dose=1uM |
| CA-16-ZL71_1uM | Dose=1uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b |
| FD-62-ZB67_0.01uM | Dose=0.01uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| TD-49-MO89_0.01uM | Dose=0.01uM |
| HC-95-WQ65_0.01uM | Dose=0.01uM, Monomethyl Fumarate |
| FD-05-QX72_10uM | Dose=10uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11 |
| CB-36-QH71_1uM | Dose=1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| AE-89-KX47_0.01uM | Dose=0.01uM |
| ZE-53-LS38_0.01uM | Dose=0.01uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine |
| HC-89-WQ85_10uM | Dose=10uM, Siramesine targeting TMEM97 |
| FF-28-ES17_0.01uM | Dose=0.01uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| WB-54-WD35_0.01uM | Dose=0.01uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B |
| JC-14-YI23_0.01uM | Dose=0.01uM, Sdccgsbi-0050877.P002 |
| LC-03-KY64_0.1uM | Dose=0.1uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2 |
| EC-37-MB09_0.1uM | Dose=0.1uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| GC-54-IZ89_1uM | Dose=1uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| VE-28-FM71_1uM | Dose=1uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3 |
| XB-70-NK42_0.1uM | Dose=0.1uM, SR1001, Retinoid RORalpha Inverse Agonists;Retinoid RORgamma Inverse Agonists targeting RORA |
| OA-80-YT10_0.1uM | Dose=0.1uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3 |
| IC-80-CT90_0.01uM | Dose=0.01uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea |
| DA-48-IP75_1uM | Dose=1uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG |
| GD-46-OD81_0.1uM | Dose=0.1uM, U 41792 |
| AB-21-VE32_0.1uM | Dose=0.1uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EE-13-PS05_10uM | Dose=10uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| JB-75-NC66_1uM | Dose=1uM, 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, HSP70 co-inducer or chaperone targeting HSPA1A |
| CF-50-MN16_10uM | Dose=10uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1 |
| ID-30-NC19_0.1uM | Dose=0.1uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R |
| TD-29-IN36_0.1uM | Dose=0.1uM |
| UA-17-QS18_0.1uM | Dose=0.1uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2 |
| AB-53-AW00_10uM | Dose=10uM, Deferasirox |
| HA-53-FL63_10uM | Dose=10uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| CB-44-RT90_0.1uM | Dose=0.1uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| CE-04-OJ56_0.01uM | Dose=0.01uM, 2-(2-Aminoethyl)pyridine |
| NC-54-XY91_1uM | Dose=1uM, 1-(4-Chlorophenyl)-5-cyclohexylpyrazolo[3,4-d]pyrimidin-4-one |
| BB-25-NU80_1uM | Dose=1uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| FB-19-ZG81_10uM | Dose=10uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY |
| VB-89-RG34_0.1uM | Dose=0.1uM, [(2R)-2-amino-2-methyl-4-[4-[3-(4-phenylphenyl)propanoyl]phenyl]butyl] dihydrogen phosphate, Lysophospholipid Receptor Agonists targeting S1PR1, S1PR5 |
| AE-04-SN76_1uM | Dose=1uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6 |
| AE-15-KH69_0.1uM | Dose=0.1uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3 |
| GC-54-IZ89_0.1uM | Dose=0.1uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| BE-38-UW72_0.01uM | Dose=0.01uM |
| AC-84-QG99_10uM | Dose=10uM |
| DE-99-OT37_1uM | Dose=1uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| GF-32-FY02_0.1uM | Dose=0.1uM |
| AA-76-VE74_10uM | Dose=10uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| AW-15-2439_1uM | Dose=1uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| CC-08-JZ09_10uM | Dose=10uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4 |
| ZB-33-MZ40_0.1uM | Dose=0.1uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1 |
| AC-24-NX95_0.01uM | Dose=0.01uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| AF-10-QK79_0.01uM | Dose=0.01uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| CD-13-QZ32_0.1uM | Dose=0.1uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AD-66-NV75_1uM | Dose=1uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| HE-11-PK61_0.1uM | Dose=0.1uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8 |
| LF-85-QP07_0.1uM | Dose=0.1uM, (5,6-Dimethyl-thieno[2,3-d]pyrimidin-4-ylsulfanyl)-acetic acid, Palmitoleoyl-Protein Carboxylesterase NOTUM Inhibitors targeting NOTUM |
| CC-70-BD07_1uM | Dose=1uM, Voriconazole Impurity 7 |
| DA-66-OE69_0.1uM | Dose=0.1uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| DD-85-WO51_0.01uM | Dose=0.01uM |
| OD-77-AG95_10uM | Dose=10uM, VE-821, ATR gene inhibitor targeting ATR, ATRIP |
| VA-92-QP54_0.01uM | Dose=0.01uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R |
| BB-74-RX30_1uM | Dose=1uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| AE-13-CX28_0.1uM | Dose=0.1uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3 |
| FA-77-YL98_10uM | Dose=10uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| AF-40-QU33_0.1uM | Dose=0.1uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| AA-98-HX85_0.01uM | Dose=0.01uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| GA-94-MC54_10uM | Dose=10uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4 |
| HA-10-LJ21_10uM | Dose=10uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88 |
| SE-81-RI20_1uM | Dose=1uM |
| CB-87-RB49_1uM | Dose=1uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| ED-83-GF49_10uM | Dose=10uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide |
| HA-22-YE24_10uM | Dose=10uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR |
| AB-71-VZ28_0.01uM | Dose=0.01uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| BB-27-MC77_10uM | Dose=10uM |
| KD-30-SM33_0.01uM | Dose=0.01uM, Pyridoxamine |
| DB-62-ES23_0.1uM | Dose=0.1uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| MD-86-UW46_1uM | Dose=1uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide |
| EE-60-CG74_0.1uM | Dose=0.1uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| CA-56-GE89_0.1uM | Dose=0.1uM, 7-Deaza-2'-C-ethynyladenosine |
| AB-06-KB32_10uM | Dose=10uM |
| AC-60-EU98_0.01uM | Dose=0.01uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| EF-85-DA07_0.1uM | Dose=0.1uM |
| BB-20-UU03_0.01uM | Dose=0.01uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| SC-64-CU21_1uM | Dose=1uM, 3-cyano-N-(6-methoxy-1,3-dimethyl-2-oxobenzimidazol-5-yl)benzenesulfonamide |
| DE-03-NP53_10uM | Dose=10uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| DA-10-HD17_10uM | Dose=10uM, N-Phthalylglycine |
| GA-79-DW49_1uM | Dose=1uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| OE-78-TD20_10uM | Dose=10uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1 |
| DA-46-KH36_10uM | Dose=10uM, 1,2,3,4-Tetrahydroisoquinoline |
| UE-01-HV71_10uM | Dose=10uM |
| AF-33-HJ54_10uM | Dose=10uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2 |
| TD-29-IN36_1uM | Dose=1uM |
| RC-52-AC88_1uM | Dose=1uM, (Z)-N-(4-bromophenyl)-N'-(3-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1 |
| AA-81-CY65_1uM | Dose=1uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3 |
| GE-14-EF51_0.1uM | Dose=0.1uM, LL-Z1272.Episilon. targeting FNTB |
| QE-35-YE15_0.01uM | Dose=0.01uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine |
| PA-75-VL17_10uM | Dose=10uM |
| DB-87-WL13_0.01uM | Dose=0.01uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| TD-69-UA90_1uM | Dose=1uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| CB-75-PH34_0.1uM | Dose=0.1uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A |
| BE-07-XI66_10uM | Dose=10uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| MA-42-UX14_1uM | Dose=1uM |
| JD-62-HR05_1uM | Dose=1uM, (1S,3R)-Rsl3, GPX4 covalent inhibitor targeting GPX4 |
| JC-63-BE61_10uM | Dose=10uM |
| ID-12-NA84_10uM | Dose=10uM, 1-(2-Methoxyphenyl)-4-(3-phenylpropyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| UA-39-TN76_0.1uM | Dose=0.1uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2 |
| SD-69-QA40_0.01uM | Dose=0.01uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| RA-42-CM42_10uM | Dose=10uM, Lestaurtinib |
| NE-34-OZ69_0.1uM | Dose=0.1uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1 |
| BC-03-OQ01_0.1uM | Dose=0.1uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM |
| DB-51-UO66_0.1uM | Dose=0.1uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2 |
| LE-50-AP60_0.01uM | Dose=0.01uM |
| DB-06-HE04_10uM | Dose=10uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF |
| ED-33-YZ72_10uM | Dose=10uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300 |
| ND-27-UQ99_10uM | Dose=10uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2 |
| LA-42-CN75_1uM | Dose=1uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| CC-04-WK34_0.1uM | Dose=0.1uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1 |
| CF-32-LB77_10uM | Dose=10uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2 |
| AA-70-VU13_1uM | Dose=1uM |
| AD-94-EX35_10uM | Dose=10uM, Pretomanid |
| BA-96-YB32_1uM | Dose=1uM |
| LE-50-AP60_1uM | Dose=1uM |
| SB-28-EJ14_10uM | Dose=10uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2 |
| HC-76-HU27_1uM | Dose=1uM |
| KB-72-ID36_0.1uM | Dose=0.1uM, Tolimidone, Lyn kinase activator;Lyn Kinase Activators targeting LYN |
| BE-58-FC64_10uM | Dose=10uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D |
| FA-14-WC79_0.1uM | Dose=0.1uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| BA-02-FS63_0.01uM | Dose=0.01uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| AD-89-LX67_0.1uM | Dose=0.1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| UF-98-OM26_1uM | Dose=1uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| BD-15-VR68_1uM | Dose=1uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1 |
| BE-33-IM71_10uM | Dose=10uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| YF-00-IN39_1uM | Dose=1uM |
| GB-84-KP45_0.1uM | Dose=0.1uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| ED-83-GF49_0.1uM | Dose=0.1uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide |
| BD-85-VR28_10uM | Dose=10uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol |
| CA-37-NI01_10uM | Dose=10uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2 |
| NB-21-MW29_1uM | Dose=1uM |
| EA-73-WI86_0.1uM | Dose=0.1uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1 |
| DA-46-KH36_0.1uM | Dose=0.1uM, 1,2,3,4-Tetrahydroisoquinoline |
| JB-60-JM38_10uM | Dose=10uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4 |
| AD-66-NV75_0.1uM | Dose=0.1uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| AC-45-EE32_10uM | Dose=10uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| BF-29-LU75_1uM | Dose=1uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| OA-10-PB21_10uM | Dose=10uM, Tiospirone, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| BC-95-MO06_0.1uM | Dose=0.1uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D |
| TC-80-LY86_0.1uM | Dose=0.1uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid |
| QE-03-UA61_1uM | Dose=1uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1 |
| WC-89-JT40_1uM | Dose=1uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10 |
| HB-19-DP22_10uM | Dose=10uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| ID-43-YL08_10uM | Dose=10uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3 |
| CA-65-MK91_1uM | Dose=1uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H |
| DC-91-ME12_10uM | Dose=10uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| AC-14-JQ68_0.01uM | Dose=0.01uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| FF-90-JK74_0.1uM | Dose=0.1uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A |
| DE-29-MT22_0.01uM | Dose=0.01uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| CE-19-PD79_10uM | Dose=10uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| XE-45-YU38_0.01uM | Dose=0.01uM |
| CE-38-KX20_1uM | Dose=1uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| AC-10-JK64_1uM | Dose=1uM |
| IF-06-KQ42_0.1uM | Dose=0.1uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4 |
| DB-41-IH69_0.01uM | Dose=0.01uM |
| RB-22-TT44_1uM | Dose=1uM, (2E)-3-{4-[bicyclo[3.3.1]non-9-ylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;Selective Estrogen Receptor Destabilizers (SERD) targeting ESR1, ESR2 |
| SB-75-UH17_10uM | Dose=10uM, Osanetant, Tachykinin NK3 Antagonists targeting TACR3 |
| CC-49-CQ25_0.01uM | Dose=0.01uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| IB-30-KN41_10uM | Dose=10uM, ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, Known Thrombin inhibitor targeting F2 |
| XC-61-SE50_1uM | Dose=1uM, A-971432, selective agonist of sphingosine-1-phosphate receptor 5 (S1PR5) targeting S1PR5 |
| WC-33-YP46_0.01uM | Dose=0.01uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2 |
| OE-18-ZX28_0.1uM | Dose=0.1uM |
| CF-65-GU65_0.1uM | Dose=0.1uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| AA-12-SS68_1uM | Dose=1uM |
| S0-EE-YAXR_0.1uM | Dose=0.1uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84 |
| BE-16-VM54_0.1uM | Dose=0.1uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC |
| DA-66-OE69_1uM | Dose=1uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| SB-75-TY18_0.01uM | Dose=0.01uM |
| AB-26-BE29_1uM | Dose=1uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2 |
| CC-37-QW80_0.01uM | Dose=0.01uM |
| GB-84-KP45_1uM | Dose=1uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| GF-35-IT27_10uM | Dose=10uM |
| LA-27-FR67_0.01uM | Dose=0.01uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1 |
| MB-53-WO35_1uM | Dose=1uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5 |
| OE-18-ZX28_1uM | Dose=1uM |
| BB-14-KA05_10uM | Dose=10uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
| BF-49-IA57_10uM | Dose=10uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2 |
| XC-68-NP33_10uM | Dose=10uM, 1-(3-Phenylpropyl)-4-[[(4R)-2-(3-pyridyl)thiazolidin-4-yl]carbonyl]piperazine, PTAFR antagonist targeting PTAFR |
| CD-62-GL56_1uM | Dose=1uM, Fenesin |
| HF-91-IU60_0.1uM | Dose=0.1uM, PD-166326, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, BCR, SRC, ABL2 |
| RB-80-RO52_1uM | Dose=1uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1 |
| ED-39-VX22_0.01uM | Dose=0.01uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| ND-54-NO97_0.01uM | Dose=0.01uM, 3-Epioleanolic acid |
| CE-15-YU05_1uM | Dose=1uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| OA-45-SS39_0.01uM | Dose=0.01uM, (4-((5S,7R)-5-(3,4-Dimethoxyphenyl)-7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-2-yl)phenyl)(piperazin-1-yl)methanone, Toll-like receptor 7, toll-like receptor 8 targeting TLR7, TLR8 |
| WC-59-RG09_0.1uM | Dose=0.1uM, Osi-930, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors targeting ABL1, KDR, KIT, PDGFRB |
| AA-56-AB37_10uM | Dose=10uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1 |
| TD-69-UA90_0.1uM | Dose=0.1uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| CC-67-LI41_10uM | Dose=10uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| CD-26-MB82_0.01uM | Dose=0.01uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| AB-43-XJ34_10uM | Dose=10uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| FC-05-LX47_10uM | Dose=10uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| LF-37-AX51_10uM | Dose=10uM, 2'-Hydroxy-4'-Methoxychalcone |
| VD-41-XP62_1uM | Dose=1uM, 3-fluoro-N'-(2-fluorobenzenesulfonyl)-5-(pyridin-2-yl)benzohydrazide targeting KAT6A, KAT6B |
| EC-07-AO30_10uM | Dose=10uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| DE-48-PP80_0.01uM | Dose=0.01uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| GB-64-HC34_0.01uM | Dose=0.01uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| ID-43-YL08_0.1uM | Dose=0.1uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3 |
| JA-42-MU37_0.1uM | Dose=0.1uM |
| XC-86-SR58_0.01uM | Dose=0.01uM |
| DC-59-NQ20_0.1uM | Dose=0.1uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| JA-32-HE94_0.1uM | Dose=0.1uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT |
| FD-79-TC61_0.01uM | Dose=0.01uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| IC-72-HR20_0.1uM | Dose=0.1uM, 3-Hydroxykynurenine |
| FD-48-HZ39_1uM | Dose=1uM |
| DB-56-XL71_0.01uM | Dose=0.01uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| ME-11-OJ38_0.1uM | Dose=0.1uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4 |
| HC-76-PX74_1uM | Dose=1uM |
| GD-71-OU80_10uM | Dose=10uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| BE-45-VH04_10uM | Dose=10uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate |
| SA-03-IQ14_1uM | Dose=1uM |
| JD-54-BS97_1uM | Dose=1uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO |
| EB-97-AV17_0.1uM | Dose=0.1uM, Diphenylamine-2,2'-dicarboxylic acid |
| AC-51-WE57_0.01uM | Dose=0.01uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| KA-14-VZ39_0.01uM | Dose=0.01uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3 |
| NE-94-VE83_0.01uM | Dose=0.01uM |
| AA-70-VU13_0.1uM | Dose=0.1uM |
| CB-16-JO93_0.01uM | Dose=0.01uM |
| OB-78-PA58_1uM | Dose=1uM, Teglarinad, Glycerol-3-Phosphate Dehydrogenase (NAD+) Inhibitors;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Signal Transduction Modulators;Inhibitory kappaB Kinase (IKK) Inhibitors targeting GPD1, NAMPT, CHUK |
| DA-40-HO94_1uM | Dose=1uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR |
| FC-22-ZV65_0.1uM | Dose=0.1uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2 |
| EA-43-FS10_1uM | Dose=1uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| ED-00-OH22_10uM | Dose=10uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT |
| BD-62-ZF67_1uM | Dose=1uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| CE-48-TP40_10uM | Dose=10uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| RF-36-EI47_1uM | Dose=1uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2 |
| BA-09-PG96_0.1uM | Dose=0.1uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3 |
| AC-71-VV28_10uM | Dose=10uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119 |
| VF-06-RV33_10uM | Dose=10uM, 3-[(4-chlorophenyl)methyl]-4-methyl-5,7-bis(2H-tetrazol-5-ylmethoxy)chromen-2-one targeting PLN |
| QB-29-GK19_0.1uM | Dose=0.1uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL |
| CA-68-TC79_10uM | Dose=10uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| IB-78-AY41_0.1uM | Dose=0.1uM, 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Cyclooxygenase-2 Inhibitors targeting SC5D |
| UE-02-UW61_10uM | Dose=10uM, 4-Methyl-1-(1h-Pyrazol-4-Ylmethyl)-5-[(4-{[6-(2,2,2-Trifluoroethyl)thieno[2,3-D]pyrimidin-4-Yl]amino}piperidin-1-Yl)methyl]-1h-Indole-2-Carbonitrile, Menin inhibitor targeting MEN1 |
| HE-01-ND39_0.01uM | Dose=0.01uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| DE-62-FI29_0.1uM | Dose=0.1uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| AB-04-MQ83_1uM | Dose=1uM |
| AD-70-LA75_0.01uM | Dose=0.01uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6 |
| OB-46-IM27_10uM | Dose=10uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide |
| AA-56-QO38_0.01uM | Dose=0.01uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| RC-62-LC43_0.01uM | Dose=0.01uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One |
| JC-52-RH51_0.1uM | Dose=0.1uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1 |
| DF-00-BX35_10uM | Dose=10uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| GB-14-AJ76_10uM | Dose=10uM |
| DB-51-UO66_0.01uM | Dose=0.01uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2 |
| AC-55-GO91_10uM | Dose=10uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| MD-92-KD16_10uM | Dose=10uM, 1-Methyl-2-[(2-methyl-6-propan-2-ylphenyl)methylcarbamoyl]-3-oxoindazole-7-carboxylic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| FB-62-KB87_10uM | Dose=10uM |
| LC-11-GG16_10uM | Dose=10uM |
| GF-58-OL90_1uM | Dose=1uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| IA-03-BO30_0.01uM | Dose=0.01uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2 |
| ID-96-UX79_0.1uM | Dose=0.1uM, Vaniprevir |
| MA-88-CA03_1uM | Dose=1uM, 6,7,4'-Trihydroxyisoflavan |
| HD-99-BT62_10uM | Dose=10uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1 |
| FF-35-JG06_0.1uM | Dose=0.1uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| QB-88-PG52_1uM | Dose=1uM, 2-Benzyloxy-4H-3,1-benzoxazin-4-one, Cathepsin G inhibitor targeting CTSG |
| EF-99-HJ48_10uM | Dose=10uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| BC-56-CP81_10uM | Dose=10uM, Adefovir Dipivoxil |
| EB-19-SM10_1uM | Dose=1uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| WD-73-QC55_10uM | Dose=10uM, Pirenoxine |
| S0-EE-Y96T_0.01uM | Dose=0.01uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A |
| GB-84-KP45_10uM | Dose=10uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| CC-90-NK44_10uM | Dose=10uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| DB-62-ES23_0.01uM | Dose=0.01uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| WC-38-CZ02_0.1uM | Dose=0.1uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol |
| GD-59-OG21_1uM | Dose=1uM, Stavudine |
| RC-47-HT31_1uM | Dose=1uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| BA-46-YF32_0.1uM | Dose=0.1uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| GB-56-TN25_0.01uM | Dose=0.01uM |
| JD-10-HW02_0.01uM | Dose=0.01uM |
| CC-17-HI11_0.1uM | Dose=0.1uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| UB-41-DY23_0.01uM | Dose=0.01uM |
| AC-91-ME22_1uM | Dose=1uM, (R)-Aminoglutethimide |
| DF-41-HL79_0.1uM | Dose=0.1uM, D-Methionine |
| GF-37-MB64_0.1uM | Dose=0.1uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| GD-07-HO70_0.1uM | Dose=0.1uM |
| AF-10-QK79_0.1uM | Dose=0.1uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AA-14-DQ28_10uM | Dose=10uM, Estradiol |
| GF-72-OO48_0.01uM | Dose=0.01uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| WA-62-RP29_10uM | Dose=10uM, N4-methyl-N2-{2-methyl-1-[2-({3-methyl-3H-imidazo[4,5-b]pyridin-6-yl}oxy)phenyl]-1H-indol-6-yl}pyrimidine-2,4-diamine, Dot1L inhibitors targeting DOT1L |
| BB-09-GD09_1uM | Dose=1uM, Sunitinib targeting PTK2B, RET, FGFR3P1 |
| EC-62-HO43_1uM | Dose=1uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1 |
| AA-31-OE22_0.01uM | Dose=0.01uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione |
| XB-75-YN01_0.1uM | Dose=0.1uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV |
| YD-21-ZR41_0.01uM | Dose=0.01uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2 |
| ZA-63-AC60_0.1uM | Dose=0.1uM, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone targeting GPX4 |
| AD-16-OE34_0.01uM | Dose=0.01uM, Octopamine |
| SC-72-YW56_1uM | Dose=1uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5 |
| AC-38-WM38_1uM | Dose=1uM |
| BB-75-JK26_1uM | Dose=1uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| IC-61-PQ10_1uM | Dose=1uM, Coumate, Steryl Sulfatase Inhibitors targeting STS |
| AC-93-LT43_10uM | Dose=10uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2 |
| FE-82-MY37_10uM | Dose=10uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| HD-85-AJ28_0.1uM | Dose=0.1uM, Nelivaptan, DNA-Directed RNA Polymerase Inhibitors targeting AVPR1B |
| VA-71-JY23_1uM | Dose=1uM |
| BD-70-PH02_0.1uM | Dose=0.1uM |
| BC-06-OP01_0.1uM | Dose=0.1uM, Ubo-Qic |
| YB-18-SI56_0.01uM | Dose=0.01uM |
| GA-10-WX15_1uM | Dose=1uM |
| S0-EE-XPGU_0.01uM | Dose=0.01uM, 2-Hydroxy-6-(2-naphthalen-2-yl-ethyl)-benzoic acid targeting SOX18 |
| DC-11-AR68_1uM | Dose=1uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB |
| IF-86-JG83_0.1uM | Dose=0.1uM, (S)-2-benzylamino-3-phenyl-1-propanol |
| BB-57-NT83_10uM | Dose=10uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2 |
| GB-92-MH66_0.01uM | Dose=0.01uM, Ureidosuccinic acid |
| LB-17-PD08_10uM | Dose=10uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1 |
| CE-69-HJ13_0.1uM | Dose=0.1uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| QF-00-CY91_10uM | Dose=10uM, 3-Phenylacetylamino-2,6-piperidinedione |
| XC-86-SR58_0.1uM | Dose=0.1uM |
| QC-49-CA55_10uM | Dose=10uM |
| DB-87-WL13_0.1uM | Dose=0.1uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| HE-22-JR80_10uM | Dose=10uM, Telbivudine |
| EC-37-MB09_1uM | Dose=1uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| LB-72-WN85_0.01uM | Dose=0.01uM |
| BE-37-IC77_10uM | Dose=10uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1 |
| HA-83-MI31_0.1uM | Dose=0.1uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| FA-63-WI26_0.01uM | Dose=0.01uM |
| QB-42-ET79_0.1uM | Dose=0.1uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1 |
| DE-81-UE07_0.01uM | Dose=0.01uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| DA-48-IP75_0.01uM | Dose=0.01uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG |
| WA-62-RP29_0.1uM | Dose=0.1uM, N4-methyl-N2-{2-methyl-1-[2-({3-methyl-3H-imidazo[4,5-b]pyridin-6-yl}oxy)phenyl]-1H-indol-6-yl}pyrimidine-2,4-diamine, Dot1L inhibitors targeting DOT1L |
| HD-29-LW24_1uM | Dose=1uM, Mocetinostat, Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;HDAC1/2 targeting HDAC1, HDAC2, HDAC3 |
| DB-82-PI34_1uM | Dose=1uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4 |
| HA-99-UT82_1uM | Dose=1uM |
| CC-08-JZ09_0.1uM | Dose=0.1uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4 |
| ZA-84-ZC97_1uM | Dose=1uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA |
| OE-18-ZX28_0.01uM | Dose=0.01uM |
| JD-70-IC84_10uM | Dose=10uM, Genipin, Free Radical Scavengers;Apoptosis Inhibitors;UCP2 inhibitor;Non-Steroidal Antiinflammatory Drugs targeting UCP2 |
| FE-95-PU35_0.1uM | Dose=0.1uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| DA-11-GV88_0.1uM | Dose=0.1uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| GA-79-DW49_0.01uM | Dose=0.01uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| SD-69-IX30_10uM | Dose=10uM, Etomoxir |
| DF-11-IL69_10uM | Dose=10uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS |
| FA-79-WC91_10uM | Dose=10uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ |
| KD-00-UJ81_1uM | Dose=1uM, 3-anilinoisoquinolin-1(2H)-one |
| FC-13-VS25_0.1uM | Dose=0.1uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| HC-19-UZ81_10uM | Dose=10uM, Galgravin |
| BA-85-ZA57_1uM | Dose=1uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| CA-00-AR16_1uM | Dose=1uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10 |
| WE-43-PZ45_1uM | Dose=1uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone |
| PE-82-OK78_10uM | Dose=10uM, 1-Cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine targeting SIGMAR1, TMEM97 |
| CC-90-EX35_0.1uM | Dose=0.1uM |
| CD-05-PU90_1uM | Dose=1uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3 |
| HE-17-FY34_0.01uM | Dose=0.01uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| FE-69-HJ93_1uM | Dose=1uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| BA-71-BE32_0.01uM | Dose=0.01uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| RB-06-YP44_0.1uM | Dose=0.1uM, m-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AD-66-NO48_10uM | Dose=10uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| CF-91-JY05_10uM | Dose=10uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| KA-54-QW27_1uM | Dose=1uM, Phosphodiesterase V (PDE5A) Inhibitors;GPR35 agonist targeting GPR35, PDE6A, PDE5A, ENPP6 |
| AB-09-YX02_0.1uM | Dose=0.1uM, p-Coumaric acid |
| AA-80-XK94_1uM | Dose=1uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| CD-59-MG26_1uM | Dose=1uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| GD-59-QF63_0.1uM | Dose=0.1uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| MB-48-VA23_0.1uM | Dose=0.1uM, 9-Benzyl-2-methyl-4-phenyl-5-oxa-1,2,9-triazaspiro[5.5]undecane, Vascular adhesion molecule antagonists targeting AOC3 |
| PF-72-IT39_10uM | Dose=10uM |
| JA-88-IO52_10uM | Dose=10uM |
| AA-90-YI00_1uM | Dose=1uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| AF-67-LZ82_0.01uM | Dose=0.01uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| UB-90-TA33_1uM | Dose=1uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile |
| LE-43-AR77_1uM | Dose=1uM, N-hydroxy-4-phenylbutanamide |
| AA-44-BX20_0.1uM | Dose=0.1uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| DB-41-IH69_10uM | Dose=10uM |
| FE-49-VJ28_10uM | Dose=10uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A |
| CA-60-LK14_1uM | Dose=1uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| BA-34-BQ43_0.1uM | Dose=0.1uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB |
| S0-EE-Y7IR_0.1uM | Dose=0.1uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1 |
| AD-30-TH82_10uM | Dose=10uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1 |
| DA-32-QL71_10uM | Dose=10uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3 |
| CC-93-RP38_10uM | Dose=10uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| BD-07-IW65_0.01uM | Dose=0.01uM |
| CC-14-WK34_10uM | Dose=10uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| EC-62-OE64_0.01uM | Dose=0.01uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AB-80-CK34_0.1uM | Dose=0.1uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| PA-25-OV46_10uM | Dose=10uM, Bjb-432 |
| QA-98-TQ46_1uM | Dose=1uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one |
| BC-76-HY47_0.1uM | Dose=0.1uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1 |
| DD-85-WO51_1uM | Dose=1uM |
| GF-32-FY02_1uM | Dose=1uM |
| KA-54-QW27_0.1uM | Dose=0.1uM, Phosphodiesterase V (PDE5A) Inhibitors;GPR35 agonist targeting GPR35, PDE6A, PDE5A, ENPP6 |
| DA-33-BM26_0.01uM | Dose=0.01uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| AD-52-UZ45_0.1uM | Dose=0.1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| WC-67-DI84_1uM | Dose=1uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide |
| GD-33-XB49_0.1uM | Dose=0.1uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| BA-09-PG96_1uM | Dose=1uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3 |
| HB-19-DP22_0.01uM | Dose=0.01uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| FA-66-LB92_10uM | Dose=10uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR |
| JF-25-NM40_0.1uM | Dose=0.1uM |
| BD-85-AU55_10uM | Dose=10uM, N-[1-[4-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]phenyl]cyclopropyl]acetamide |
| VA-27-OT56_0.1uM | Dose=0.1uM |
| GD-66-LN30_0.1uM | Dose=0.1uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A |
| RC-65-VL12_10uM | Dose=10uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT |
| ZB-62-QB90_10uM | Dose=10uM, Vidofludimus, Anti-IL-17;Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| EA-81-CR68_0.1uM | Dose=0.1uM |
| OA-15-DB28_0.1uM | Dose=0.1uM |
| GC-74-QF56_10uM | Dose=10uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| OA-12-SU22_10uM | Dose=10uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| PC-68-DU31_0.01uM | Dose=0.01uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1 |
| DA-83-IZ87_0.1uM | Dose=0.1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| RA-23-IX31_0.01uM | Dose=0.01uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1 |
| ED-91-LA02_0.1uM | Dose=0.1uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B |
| AA-56-JY17_1uM | Dose=1uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1 |
| ED-32-VE54_10uM | Dose=10uM, Thiosalicylic Acid |
| BE-03-XC62_1uM | Dose=1uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| YE-80-LN04_0.01uM | Dose=0.01uM |
| FB-99-SM50_0.01uM | Dose=0.01uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| NE-00-JZ19_1uM | Dose=1uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ |
| S0-EE-YC7H_0.1uM | Dose=0.1uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6 |
| DA-33-NF79_0.1uM | Dose=0.1uM, Brofaromine, MAO-A Inhibitors targeting MAOA |
| BB-53-SW55_1uM | Dose=1uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| MC-40-IP75_1uM | Dose=1uM, Milnacipran, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| AB-90-YR46_0.1uM | Dose=0.1uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| MA-31-VM30_0.1uM | Dose=0.1uM, Sabeluzole |
| EC-14-UM93_0.01uM | Dose=0.01uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| BA-19-VU85_0.1uM | Dose=0.1uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| MB-72-YK93_0.01uM | Dose=0.01uM |
| EA-86-QK08_10uM | Dose=10uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10 |
| AE-88-WQ63_1uM | Dose=1uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB |
| CF-26-ME34_10uM | Dose=10uM, N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide, 15-Lipoxygenase Inhibitors targeting ALOX15, ALOX15B |
| DB-87-WL13_1uM | Dose=1uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| VB-76-UE47_1uM | Dose=1uM |
| SB-87-LQ34_1uM | Dose=1uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10 |
| GF-58-OL90_0.01uM | Dose=0.01uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| NB-79-SE70_10uM | Dose=10uM, N-(4-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| NB-80-IM48_1uM | Dose=1uM, 1-(2-Fluorophenyl)-8-pyridin-4-ylimidazo[4,5-c]quinoline targeting RET |
| KF-18-RY71_1uM | Dose=1uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4 |
| IE-46-OA29_0.1uM | Dose=0.1uM, 6-Fluoro-3-((1E)-2-(3-pyridinyl)ethenyl)-1H-indole, Tryptophan 2,3 dioxygenase inhibitor targeting TDO2 |
| JA-38-XE73_0.01uM | Dose=0.01uM |
| HB-24-AP80_10uM | Dose=10uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| LB-67-FA06_10uM | Dose=10uM |
| BE-68-PM13_10uM | Dose=10uM, (2R)-3-cyclopentyl-N-(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)-2-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}propanamide, Glucokinase Activators targeting GCK |
| BC-48-WT15_1uM | Dose=1uM, Thymidine Phosphorylase Inhibitors targeting TYMP |
| JE-63-IE01_10uM | Dose=10uM, Vercirnon, CCR9 chemokine antagonist targeting CCR9 |
| AD-11-RL84_10uM | Dose=10uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| EA-98-NW07_1uM | Dose=1uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3 |
| FD-35-PQ00_10uM | Dose=10uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2 |
| TC-95-IR96_0.01uM | Dose=0.01uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2 |
| BE-36-XE09_0.01uM | Dose=0.01uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| BC-22-RZ85_10uM | Dose=10uM, n,n-Bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1h-imidazole-5-methanamine, C5a Antagonists targeting C5AR1 |
| RC-62-LC43_1uM | Dose=1uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One |
| AD-09-MD49_0.1uM | Dose=0.1uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR |
| CA-96-UO48_0.1uM | Dose=0.1uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| GA-04-JM33_0.1uM | Dose=0.1uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4 |
| AF-67-LZ82_1uM | Dose=1uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| HA-64-OZ89_0.1uM | Dose=0.1uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| DD-68-ZP95_10uM | Dose=10uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A |
| AD-14-QD12_0.1uM | Dose=0.1uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2 |
| JF-74-GS02_10uM | Dose=10uM, alpha-Trifluoromethyl-alpha-hydroxybenzeneacetamide, T-Type Calcium Channel Blockers targeting KCNK3, KCNK9 |
| BC-06-OP01_10uM | Dose=10uM, Ubo-Qic |
| EB-09-OC36_10uM | Dose=10uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| VE-22-XI52_0.01uM | Dose=0.01uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| HB-45-XQ45_1uM | Dose=1uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| BE-41-AV63_10uM | Dose=10uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| CE-00-EK89_10uM | Dose=10uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| FC-05-LX47_0.1uM | Dose=0.1uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| BA-39-OX47_0.1uM | Dose=0.1uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| FA-95-HA77_0.1uM | Dose=0.1uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2 |
| AD-33-YW85_1uM | Dose=1uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| TA-57-FF07_0.1uM | Dose=0.1uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl |
| GB-69-YC71_10uM | Dose=10uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3 |
| TA-82-BQ12_10uM | Dose=10uM, CU-Cpt22, TLR1/2 complex inhibitor targeting TLR1, TLR2 |
| BF-72-LI04_0.1uM | Dose=0.1uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| DE-28-BW67_10uM | Dose=10uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| BB-01-IO76_0.01uM | Dose=0.01uM, Aspartic Acid |
| DA-63-NP63_0.1uM | Dose=0.1uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID |
| VF-06-RV33_0.1uM | Dose=0.1uM, 3-[(4-chlorophenyl)methyl]-4-methyl-5,7-bis(2H-tetrazol-5-ylmethoxy)chromen-2-one targeting PLN |
| DF-00-BU08_1uM | Dose=1uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4 |
| CF-31-GE67_0.1uM | Dose=0.1uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| BC-10-OR76_1uM | Dose=1uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| EC-09-DC91_1uM | Dose=1uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| BE-82-TS38_0.1uM | Dose=0.1uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| PA-84-RB96_0.01uM | Dose=0.01uM, 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one |
| FD-09-BQ45_0.1uM | Dose=0.1uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2 |
| BC-75-CK91_10uM | Dose=10uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| ID-12-GA19_0.01uM | Dose=0.01uM, Apoptosis Inducers;Polyamine Oxidase Inhibitors targeting SMOX |
| AA-68-MW92_0.1uM | Dose=0.1uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| HA-99-UT82_10uM | Dose=10uM |
| CF-97-KZ12_10uM | Dose=10uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| EC-31-MR88_10uM | Dose=10uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14 |
| BD-69-GX17_0.01uM | Dose=0.01uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| VA-92-QP54_0.1uM | Dose=0.1uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R |
| AC-18-DC84_0.01uM | Dose=0.01uM, 7-Nitroindazole |
| ID-30-ST90_1uM | Dose=1uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide |
| AD-23-AN14_0.1uM | Dose=0.1uM, Tranilast, Urate Transporter 1 (URAT1) Inhibitors;Indoleamine 2,3-dioxygenase Activators;IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;TNF-alpha Production Inhibitors;IL-10 Production Enhancers;IL-4 Modulators;Signal Transduction Modulators targeting HEXB, IDO1, TRPV2, SLC22A12 |
| CE-04-HT15_0.1uM | Dose=0.1uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1 |
| VD-41-XP62_10uM | Dose=10uM, 3-fluoro-N'-(2-fluorobenzenesulfonyl)-5-(pyridin-2-yl)benzohydrazide targeting KAT6A, KAT6B |
| CF-68-DM58_0.1uM | Dose=0.1uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| SD-69-IX30_0.01uM | Dose=0.01uM, Etomoxir |
| CF-97-KZ12_1uM | Dose=1uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| KA-54-MB31_0.1uM | Dose=0.1uM, 3-Amino-3,4-dihydro-1-hydroxy-2(1H)-quinolinone, Kynurenine Aminotransferase II (KAT II) Inhibitors targeting AADAT |
| YB-83-AS93_1uM | Dose=1uM, 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4, PRKCH, PRKCZ |
| ND-68-CU31_1uM | Dose=1uM, MR 16728, Acetylcholine Release Enhancers targeting KCNN4 |
| HE-95-KK46_0.1uM | Dose=0.1uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A |
| DD-71-LY65_0.1uM | Dose=0.1uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| AE-06-JY57_10uM | Dose=10uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| DD-38-BM78_1uM | Dose=1uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2 |
| BE-82-TS38_10uM | Dose=10uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| DA-79-ZD74_0.1uM | Dose=0.1uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DE-09-HJ53_0.1uM | Dose=0.1uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| JD-70-IC84_0.1uM | Dose=0.1uM, Genipin, Free Radical Scavengers;Apoptosis Inhibitors;UCP2 inhibitor;Non-Steroidal Antiinflammatory Drugs targeting UCP2 |
| JE-13-EV67_1uM | Dose=1uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| CE-69-FD64_10uM | Dose=10uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1 |
| FD-69-CC31_10uM | Dose=10uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| EE-85-SK26_1uM | Dose=1uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| UB-90-TA33_0.01uM | Dose=0.01uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile |
| CE-18-CG29_1uM | Dose=1uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1 |
| LE-43-AR77_0.1uM | Dose=0.1uM, N-hydroxy-4-phenylbutanamide |
| CD-80-ZD47_10uM | Dose=10uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT |
| LE-08-BO67_0.1uM | Dose=0.1uM, 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide, Muscarinic M5 receptor antagonist targeting CHRM5 |
| FA-02-RV60_0.01uM | Dose=0.01uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| CF-91-JY05_0.01uM | Dose=0.01uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| DC-59-NQ20_10uM | Dose=10uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| BC-48-WT15_10uM | Dose=10uM, Thymidine Phosphorylase Inhibitors targeting TYMP |
| AA-58-BW57_10uM | Dose=10uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G |
| FE-06-GR60_10uM | Dose=10uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| CB-83-ZW70_0.01uM | Dose=0.01uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| KD-00-UJ81_0.01uM | Dose=0.01uM, 3-anilinoisoquinolin-1(2H)-one |
| JE-55-OJ53_0.01uM | Dose=0.01uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile |
| BE-28-QT65_10uM | Dose=10uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| WC-33-YP46_0.1uM | Dose=0.1uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2 |
| DA-59-ZD74_0.1uM | Dose=0.1uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| DD-38-MZ39_10uM | Dose=10uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| AF-20-MK39_0.1uM | Dose=0.1uM, Gabapentin, Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands targeting CACNA1D, CACNA2D1, CACNA2D2, CACNA2D3 |
| AA-59-HG56_0.1uM | Dose=0.1uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B |
| DD-30-NA60_1uM | Dose=1uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| BD-18-FM58_10uM | Dose=10uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| DE-86-XV75_10uM | Dose=10uM, Griseofulvin, Keratin 12 modulator targeting KRT12 |
| DD-38-MZ39_1uM | Dose=1uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| AF-80-GK24_0.1uM | Dose=0.1uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| TE-87-FM14_1uM | Dose=1uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid |
| QE-03-UA61_0.1uM | Dose=0.1uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1 |
| EA-93-KT88_1uM | Dose=1uM |
| ID-31-PA82_10uM | Dose=10uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1 |
| CA-44-LT45_0.1uM | Dose=0.1uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| RD-66-DP49_10uM | Dose=10uM, 2-[(1-Methyl-2-Oxidanyl-4-Oxidanylidene-Quinolin-3-Yl)carbonylamino]ethanoic Acid, Prolyl 4-Hydroxylase Inhibitors;Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| DA-83-IZ87_1uM | Dose=1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| ZD-78-BS65_1uM | Dose=1uM |
| GE-28-EL65_10uM | Dose=10uM, 3-O-Methyldopa, DL- |
| AE-19-BK71_1uM | Dose=1uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1 |
| AD-31-GO06_0.1uM | Dose=0.1uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| JD-12-CE09_0.1uM | Dose=0.1uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| FF-07-FL63_0.1uM | Dose=0.1uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| PA-80-RV09_0.1uM | Dose=0.1uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1 |
| OB-65-AI50_0.1uM | Dose=0.1uM, Rgfp966, HDAC3 active-site competitive inhibitor;HDAC3 targeting HDAC3 |
| DE-58-OW37_10uM | Dose=10uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L |
| HD-26-KX74_1uM | Dose=1uM |
| EC-31-MR88_1uM | Dose=1uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14 |
| AC-50-JK54_10uM | Dose=10uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4 |
| AF-67-LZ82_0.1uM | Dose=0.1uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| CE-24-LQ98_0.01uM | Dose=0.01uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide |
| AC-93-OJ74_0.01uM | Dose=0.01uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| BA-88-HT15_0.1uM | Dose=0.1uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| HE-34-NJ16_1uM | Dose=1uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9 |
| SB-75-TY18_1uM | Dose=1uM |
| AE-78-XJ76_0.1uM | Dose=0.1uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| XB-22-LI07_1uM | Dose=1uM |
| JA-95-PQ25_10uM | Dose=10uM, Tocopherol Nicotinate |
| GD-72-XO18_0.1uM | Dose=0.1uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| FE-99-RJ28_0.1uM | Dose=0.1uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1 |
| DC-91-ME12_1uM | Dose=1uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| WA-00-QY36_10uM | Dose=10uM, US10189788, Example 7, Prostaglandin F2a receptor (PGF2a-DP aka PTGFR) antagnoist targeting PTGFR |
| XD-37-GI34_1uM | Dose=1uM |
| YA-21-RR66_0.1uM | Dose=0.1uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4 |
| GD-98-WZ24_10uM | Dose=10uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| EB-09-GW59_1uM | Dose=1uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| XC-61-SE50_0.01uM | Dose=0.01uM, A-971432, selective agonist of sphingosine-1-phosphate receptor 5 (S1PR5) targeting S1PR5 |
| DA-48-IP75_0.1uM | Dose=0.1uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG |
| FB-12-UL66_1uM | Dose=1uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| GE-53-SM76_1uM | Dose=1uM |
| XA-36-WV33_10uM | Dose=10uM, Ethyl 4-(3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| JC-63-BE61_1uM | Dose=1uM |
| UA-39-TN76_0.01uM | Dose=0.01uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2 |
| KC-96-UA29_10uM | Dose=10uM, 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol, ADRB3 agonist targeting ADRB3 |
| ME-54-JY76_10uM | Dose=10uM |
| DD-96-DE39_0.01uM | Dose=0.01uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| KA-60-LC14_0.1uM | Dose=0.1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-3,3-dimethyl-2-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]amino]butanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AA-12-SS68_0.01uM | Dose=0.01uM |
| SE-89-DO49_0.01uM | Dose=0.01uM, [4-[[(3R)-7-(5-cyanofuran-2-yl)-4-(4-methoxyphenyl)sulfonyl-1-[(3-methylimidazol-4-yl)methyl]-3,5-dihydro-2H-1,4-benzodiazepin-3-yl]methyl]phenyl] N-benzylcarbamate, Rab GGTase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting RABGGTA, RABGGTB |
| AB-79-ZD24_10uM | Dose=10uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4 |
| CA-57-TC62_0.1uM | Dose=0.1uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1 |
| DE-48-FF01_10uM | Dose=10uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK |
| UE-13-LK75_10uM | Dose=10uM, RN486, reversible BTK inhibitor targeting BTK |
| AA-80-XK94_10uM | Dose=10uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| QC-32-ZC28_10uM | Dose=10uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid |
| BF-76-AO03_10uM | Dose=10uM, ML SA1 |
| OA-51-KF88_0.1uM | Dose=0.1uM, Lodoxamide targeting ARRB2, GPR35 |
| FE-69-HJ93_0.01uM | Dose=0.01uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| AE-80-WH32_10uM | Dose=10uM |
| BA-10-WH12_1uM | Dose=1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| NC-52-AG88_0.1uM | Dose=0.1uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1 |
| AA-20-DK54_10uM | Dose=10uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| HE-55-AG11_0.1uM | Dose=0.1uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3 |
| AB-71-VZ28_10uM | Dose=10uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| YE-45-AD07_0.1uM | Dose=0.1uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS |
| KA-60-LC14_10uM | Dose=10uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-3,3-dimethyl-2-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]amino]butanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| RF-04-GI28_10uM | Dose=10uM |
| KD-36-KT24_10uM | Dose=10uM, (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide |
| CC-90-EX35_0.01uM | Dose=0.01uM |
| AB-00-IL62_0.1uM | Dose=0.1uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| AE-11-VB80_10uM | Dose=10uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide |
| EF-99-HJ48_0.01uM | Dose=0.01uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| CA-90-RU33_0.1uM | Dose=0.1uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| DB-42-PI54_10uM | Dose=10uM |
| ZB-72-PE17_1uM | Dose=1uM |
| ZC-12-OO11_10uM | Dose=10uM, 5-(Pyridin-4-YL)-1H-imidazole-2-thiol, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| AA-22-SF72_1uM | Dose=1uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET |
| AA-33-DN24_0.01uM | Dose=0.01uM, Olprinone |
| BA-46-QO78_10uM | Dose=10uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| AE-34-SK19_1uM | Dose=1uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4 |
| CF-24-KQ98_0.01uM | Dose=0.01uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| AC-42-SI74_0.1uM | Dose=0.1uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| BF-59-OR93_10uM | Dose=10uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| AD-91-LE02_0.1uM | Dose=0.1uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| BA-85-ZA57_0.1uM | Dose=0.1uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| DC-13-RZ62_0.1uM | Dose=0.1uM, Ubidecarenone |
| KA-50-OP35_0.01uM | Dose=0.01uM |
| YC-45-JD42_0.01uM | Dose=0.01uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate |
| ED-62-DB62_0.1uM | Dose=0.1uM |
| IB-80-NT65_0.01uM | Dose=0.01uM |
| AA-62-XS38_10uM | Dose=10uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2 |
| BA-19-VU85_1uM | Dose=1uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| EF-22-PB37_0.1uM | Dose=0.1uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| QA-24-ZK07_10uM | Dose=10uM, Docarpamine, Dopamine Receptor Agonists;Dopamine Precursors targeting DRD2, DRD3 |
| CB-88-LG34_0.1uM | Dose=0.1uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| UE-99-BK94_0.1uM | Dose=0.1uM, 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, KCNK3 gene inhibitor targeting KCNK3 |
| SE-91-VW19_10uM | Dose=10uM, Pimavanserin, SELECTIVE inverse agonist on the serotonin receptor subtype 5-HT2A;HTR2A (5HT2A) inverse agonist targeting HTR2A, HTR5A |
| WA-15-KX40_0.1uM | Dose=0.1uM |
| EA-90-PK44_0.01uM | Dose=0.01uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| HE-11-PK61_0.01uM | Dose=0.01uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8 |
| AC-14-JQ68_10uM | Dose=10uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| FD-20-OG99_0.1uM | Dose=0.1uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| JF-30-FW92_0.01uM | Dose=0.01uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R |
| HC-04-ZM18_0.01uM | Dose=0.01uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| CF-53-HM41_10uM | Dose=10uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8 |
| HE-80-BQ08_0.1uM | Dose=0.1uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1 |
| EC-07-AO30_1uM | Dose=1uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| ZB-67-SE99_1uM | Dose=1uM |
| AA-59-HG56_10uM | Dose=10uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B |
| DB-73-BC12_10uM | Dose=10uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4 |
| DD-44-OX00_10uM | Dose=10uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| CC-91-VE57_10uM | Dose=10uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| KA-35-YF58_0.1uM | Dose=0.1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| ND-06-AJ85_0.01uM | Dose=0.01uM, N-[7-[1-[[2-(4-chlorophenyl)-6-fluorophenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2 |
| JE-47-FU54_0.01uM | Dose=0.01uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4 |
| AC-47-YZ27_1uM | Dose=1uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2 |
| MA-20-ZI33_1uM | Dose=1uM |
| WB-92-FB15_10uM | Dose=10uM, (2S)-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| AD-41-WB70_10uM | Dose=10uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AD-30-TH82_0.1uM | Dose=0.1uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1 |
| S0-EE-YAXR_10uM | Dose=10uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84 |
| FF-54-JC89_0.1uM | Dose=0.1uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| AA-99-HG56_0.01uM | Dose=0.01uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3 |
| ME-11-OJ38_1uM | Dose=1uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4 |
| ED-27-OE11_0.1uM | Dose=0.1uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| MB-49-LL22_10uM | Dose=10uM, Pinometostat, Dot1L / KMT4;Dot1L inhibitor targeting DOT1L |
| BC-15-EL49_1uM | Dose=1uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| GA-04-SF76_0.1uM | Dose=0.1uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| ZD-43-CS43_10uM | Dose=10uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B |
| GD-33-XB49_0.01uM | Dose=0.01uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| BA-10-WH12_0.1uM | Dose=0.1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BB-10-PR06_0.01uM | Dose=0.01uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| LD-47-RN92_1uM | Dose=1uM, 1-(3,3-Dimethylbutyl)-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DC-22-OP01_0.1uM | Dose=0.1uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4 |
| HC-95-WQ65_1uM | Dose=1uM, Monomethyl Fumarate |
| UB-90-TA33_10uM | Dose=10uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile |
| BC-62-RZ55_1uM | Dose=1uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4 |
| UC-80-UO92_1uM | Dose=1uM, Momipp, Methuosis inducer targeting PIKFYVE, PIP5K1C |
| PA-40-NS72_0.01uM | Dose=0.01uM, Oseltamivir Acid |
| GA-66-XX49_0.01uM | Dose=0.01uM |
| BD-99-DU20_10uM | Dose=10uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| HE-55-AG11_10uM | Dose=10uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3 |
| AA-71-XO01_10uM | Dose=10uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38 |
| HD-99-BT62_0.1uM | Dose=0.1uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1 |
| LA-25-VT07_0.1uM | Dose=0.1uM, Dmxb-A, Nicotinic alpha7 Partial Agonists targeting CHRNA7 |
| FF-46-CU92_1uM | Dose=1uM |
| AA-90-YI00_10uM | Dose=10uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| AC-49-ZR23_1uM | Dose=1uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| AD-94-EX35_1uM | Dose=1uM, Pretomanid |
| PD-58-VA68_10uM | Dose=10uM |
| AD-89-ID99_10uM | Dose=10uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B |
| XE-29-LT20_1uM | Dose=1uM, 6-Chloro-3-hydroxy-1,2-benzisoxazole, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO |
| AD-99-SN88_1uM | Dose=1uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| ME-77-JX81_0.01uM | Dose=0.01uM, PF-514273, Cannabinoid CB1 Antagonists targeting CNR1 |
| AA-77-MP68_0.1uM | Dose=0.1uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| QC-49-CA55_1uM | Dose=1uM |
| MA-45-US84_1uM | Dose=1uM, 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, SUV420H1/H2 inhibitor;kmt5b and kmt5c inhibitor targeting KMT5B, KMT5C |
| AA-15-VA57_0.1uM | Dose=0.1uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| HE-09-WC21_10uM | Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| EA-12-SS08_10uM | Dose=10uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8 |
| ME-49-AE45_0.1uM | Dose=0.1uM, (2S)-1-[2-(tert-butylamino)acetyl]pyrrolidine-2-carbonitrile |
| BC-09-JG96_0.1uM | Dose=0.1uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| CE-85-KN13_0.1uM | Dose=0.1uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| CC-15-MK46_10uM | Dose=10uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2 |
| ED-93-KF69_0.01uM | Dose=0.01uM, 3-(2-Aminoethyl)adamantan-1-ol |
| EB-66-IH06_0.1uM | Dose=0.1uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2 |
| PD-71-MW24_1uM | Dose=1uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA |
| BE-36-XE09_1uM | Dose=1uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| FA-02-RV60_0.1uM | Dose=0.1uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| UF-06-JB00_1uM | Dose=1uM, ethyl N-[4-[(E)-3-(4-morpholin-4-ylquinolin-2-yl)prop-2-enoyl]phenyl]carbamate, TNF-alpha Production Inhibitors;Heat Shock Protein 70 (hsp70) Inducers targeting HSPA1A |
| CC-01-PR23_10uM | Dose=10uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2 |
| AB-62-TF27_0.1uM | Dose=0.1uM, (2S,4R)-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-4-[(4-chlorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide |
| JF-76-BD96_10uM | Dose=10uM, 1-(4-Chlorophenyl)-N-[3-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1H-pyrazole-4-carboxamide |
| PA-57-FX61_10uM | Dose=10uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide |
| DB-11-SS01_10uM | Dose=10uM, Thal-sns-032 targeting CDK9 |
| CB-36-QH71_10uM | Dose=10uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| HB-09-OC16_10uM | Dose=10uM |
| OF-19-JH77_0.1uM | Dose=0.1uM, 2-[1-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-2,2-diphenyl-ethylamino]-acetamide, TACR1 antagonist targeting TACR1 |
| FA-80-DR66_0.1uM | Dose=0.1uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| OC-55-QZ56_0.1uM | Dose=0.1uM, Icrf 193 |
| AC-96-OO08_0.1uM | Dose=0.1uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| DE-29-MT22_0.1uM | Dose=0.1uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| SA-03-IQ14_0.01uM | Dose=0.01uM |
| QE-48-NG07_0.1uM | Dose=0.1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-[4-[[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-(diaminomethylideneamino)-1,3,5-triazin-2-yl]amino]anilino]-1,3,5-triazin-2-yl]guanidine, NPR1 agonist of the extracellular domain targeting NPR1 |
| BD-66-QO48_10uM | Dose=10uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12 |
| VC-79-JG59_10uM | Dose=10uM, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-(dimethylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, PYK2 inhibitor targeting PTK2B |
| DD-44-OX00_0.01uM | Dose=0.01uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| EA-32-CY22_1uM | Dose=1uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| CF-35-NN63_10uM | Dose=10uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| PC-18-VX23_0.1uM | Dose=0.1uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1 |
| WD-26-EB85_10uM | Dose=10uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1 |
| AD-72-MJ27_10uM | Dose=10uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| GF-57-LR72_10uM | Dose=10uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| AE-05-CB45_0.01uM | Dose=0.01uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| HE-17-FY34_1uM | Dose=1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| XD-40-HA98_0.1uM | Dose=0.1uM, ;Mammalian Target of Rapamycin (mTOR;FRAP1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting MTOR, IKBKB |
| BF-31-BY55_0.1uM | Dose=0.1uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| GC-42-LL86_1uM | Dose=1uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| BD-65-VV48_10uM | Dose=10uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG |
| S0-EE-YRH3_0.01uM | Dose=0.01uM, [3-[[4-(aminomethyl)-1-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate, LIMK2 gene inhibitor;LIMK1 gene inhibitor targeting LIMK1, LIMK2 |
| JA-23-QE71_1uM | Dose=1uM, [4-(8-chloro-5-methyl-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)piperidin-1-yl]-(1H-indol-6-yl)methanone, AVPR1A antagonist targeting AVPR1A |
| BC-36-PL31_10uM | Dose=10uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| CC-04-WK34_0.01uM | Dose=0.01uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1 |
| MA-96-GW26_1uM | Dose=1uM |
| AA-87-MP18_10uM | Dose=10uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5 |
| BC-57-KZ72_10uM | Dose=10uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| DE-85-FR73_10uM | Dose=10uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| DB-29-HQ45_0.01uM | Dose=0.01uM |
| GC-54-IZ89_10uM | Dose=10uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| HC-76-SY22_1uM | Dose=1uM, Sulprostone |
| OD-96-TZ83_10uM | Dose=10uM, BAY 598-Bio-X, SMYD2 inhibitor targeting SMYD2 |
| DA-05-NN93_0.1uM | Dose=0.1uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| CF-82-FS38_10uM | Dose=10uM |
| CB-29-AX17_10uM | Dose=10uM, (2R,3S,5R)-5-[[4,6-difluoro-5-(4-phenylphenyl)-1H-benzimidazol-2-yl]oxy]-2-(hydroxymethyl)oxan-3-ol |
| CF-48-QD87_1uM | Dose=1uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| VA-84-EQ91_10uM | Dose=10uM, [(2R,3R,5R,10S,11R,12R,13R,14S,17R)-2,3,11-trihydroxy-4,4,10,13-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-12-yl] acetate, Elastase Inhibitors targeting PI3 |
| LB-72-WN85_1uM | Dose=1uM |
| EE-66-CK83_0.1uM | Dose=0.1uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| IC-43-CV07_0.01uM | Dose=0.01uM |
| EC-86-EK93_10uM | Dose=10uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4 |
| BB-93-VT73_1uM | Dose=1uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1 |
| QE-48-NG07_1uM | Dose=1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-[4-[[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-(diaminomethylideneamino)-1,3,5-triazin-2-yl]amino]anilino]-1,3,5-triazin-2-yl]guanidine, NPR1 agonist of the extracellular domain targeting NPR1 |
| BF-02-AC35_1uM | Dose=1uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| AE-64-IK64_10uM | Dose=10uM |
| BA-60-RH02_10uM | Dose=10uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1 |
| HB-19-DP22_0.1uM | Dose=0.1uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| BB-36-LB57_10uM | Dose=10uM |
| FB-20-YQ23_1uM | Dose=1uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R |
| SE-29-ZA15_0.1uM | Dose=0.1uM, UT-B-IN-1, Urea transporter inhibitor targeting SLC14A1, SLC14A2 |
| QA-98-TQ46_0.01uM | Dose=0.01uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one |
| AC-44-UR36_10uM | Dose=10uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT |
| DE-42-QB97_10uM | Dose=10uM, N-Acetylserotonin |
| AA-90-YI00_0.1uM | Dose=0.1uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| FD-91-OK66_0.01uM | Dose=0.01uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| OC-23-QX66_0.01uM | Dose=0.01uM, 3,5-Dihydroxy-4-methoxybenzoic acid, NF-kappaB (NFKB) Activation Inhibitors;Free Radical Scavengers targeting RELA |
| CB-44-RT90_0.01uM | Dose=0.01uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| AB-17-DF74_1uM | Dose=1uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL |
| AB-63-UX23_0.1uM | Dose=0.1uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| LF-94-HB11_0.1uM | Dose=0.1uM, Apicidin, HDAC inhibitor targeting HDAC3, HDAC4 |
| AD-92-QZ55_0.01uM | Dose=0.01uM, Tmc-353121 |
| UA-44-EN14_0.1uM | Dose=0.1uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone |
| UE-90-KK72_0.01uM | Dose=0.01uM |
| LB-90-DC89_0.01uM | Dose=0.01uM, (S)-Albuterol |
| GA-28-SS67_0.01uM | Dose=0.01uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| DB-42-FS68_0.01uM | Dose=0.01uM, Valspodar |
| GD-96-AK08_1uM | Dose=1uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| BD-68-ZT55_0.1uM | Dose=0.1uM, Triclosan |
| BE-58-FC64_0.01uM | Dose=0.01uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D |
| DE-03-NP53_0.1uM | Dose=0.1uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| HA-42-TE64_1uM | Dose=1uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| AE-09-IN08_0.1uM | Dose=0.1uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3 |
| XC-50-TN39_0.01uM | Dose=0.01uM |
| PA-15-CP52_0.1uM | Dose=0.1uM, (3aS,9bS)-2-(1-benzofuran-5-sulfonyl)-5-methyl-1H,2H,3H,3aH,4H,5H,9bH-pyrrolo[3,4-c]1,6-naphthyridin-4-one targeting GLRA1, GLRA2, GLRA3, GLRA4 |
| UA-39-TN76_1uM | Dose=1uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2 |
| FF-46-CU92_10uM | Dose=10uM |
| FA-43-TP28_0.1uM | Dose=0.1uM, Doxapram targeting KCNK3, KCNK9 |
| CC-05-MK46_1uM | Dose=1uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| GB-51-MD79_0.1uM | Dose=0.1uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG |
| LA-27-FR67_1uM | Dose=1uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1 |
| AE-36-GL26_10uM | Dose=10uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide |
| BB-65-SY95_10uM | Dose=10uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| FC-71-PK06_10uM | Dose=10uM, 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1A, CACNA1B, CACNA1C, CACNA1S |
| EB-11-MR93_1uM | Dose=1uM, 7beta,25-Dihydroxycholesterol |
| HE-34-ZC14_10uM | Dose=10uM |
| BF-29-LU75_0.1uM | Dose=0.1uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| SB-94-ZA83_0.01uM | Dose=0.01uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| VA-11-NO89_0.01uM | Dose=0.01uM, 6-Hydroxy-1,3-benzothiazole-2-sulfonamide, Carbonic anhydrase type I inhibitor;carbonic anhydrase type II inhibitor targeting CA1, CA4, CA5A, CA5B, CA3, CA8, CA11, CA10 |
| FC-36-SU62_10uM | Dose=10uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| HA-38-ML65_10uM | Dose=10uM |
| AD-42-US78_10uM | Dose=10uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3 |
| ME-62-IQ37_0.1uM | Dose=0.1uM, WY 47288, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| AE-28-IQ88_10uM | Dose=10uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| DD-73-IP88_1uM | Dose=1uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| CB-13-ZM26_0.1uM | Dose=0.1uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA |
| JA-42-MU37_0.01uM | Dose=0.01uM |
| FE-72-KZ75_0.1uM | Dose=0.1uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3 |
| CC-20-FN31_10uM | Dose=10uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| DE-52-BS63_0.1uM | Dose=0.1uM, PAK1 gene inhibitor targeting PAK1 |
| FF-46-CU92_0.01uM | Dose=0.01uM |
| NC-35-BF58_0.01uM | Dose=0.01uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
| CB-42-EI79_0.01uM | Dose=0.01uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1 |
| BD-18-XC74_10uM | Dose=10uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| BC-56-BB82_1uM | Dose=1uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2 |
| KD-14-RS67_0.01uM | Dose=0.01uM, 1-[4-(2,3-Dimethoxybenzoyl)piperazin-1-yl]-2-(3-methylphenoxy)ethanone, antagonist of CBX7ChD/methyl-lysine binding by blocking H3K27me3 binding;CBX7ChD antagonist targeting CBX7 |
| HB-45-XQ45_10uM | Dose=10uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| AC-36-SY22_0.01uM | Dose=0.01uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| AB-80-CK34_1uM | Dose=1uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| BD-01-RI07_0.01uM | Dose=0.01uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC |
| ME-54-JY76_0.01uM | Dose=0.01uM |
| CF-61-EH59_0.1uM | Dose=0.1uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| AD-43-XJ59_10uM | Dose=10uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| KC-93-NH98_10uM | Dose=10uM, Acea 1011, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1 |
| JF-84-QZ64_0.01uM | Dose=0.01uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2 |
| JA-95-PQ25_0.1uM | Dose=0.1uM, Tocopherol Nicotinate |
| HA-83-MI31_1uM | Dose=1uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| IB-14-XS97_0.1uM | Dose=0.1uM, Pomalidomide-6-OH, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| BA-02-FS63_1uM | Dose=1uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| LB-76-JJ80_1uM | Dose=1uM, 1H-Isoindol-1-one, 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| FA-94-QJ71_1uM | Dose=1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1 |
| GF-02-ER50_10uM | Dose=10uM, Ethane-1,2-diyl dicarbamimidothioate |
| IF-92-OK68_10uM | Dose=10uM, Ethyl 4-(methylamino)-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3 |
| FC-15-XG61_10uM | Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| XA-12-UL84_1uM | Dose=1uM |
| BD-81-FB30_1uM | Dose=1uM |
| AB-10-RE65_10uM | Dose=10uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| LE-39-LB33_10uM | Dose=10uM, Chlorothiazide, SLC12A3 inhibitor;CA4 inhibitor;CA1 inhibitor;CA2 inhibitor targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, SLC12A3, CA5B, CA10 |
| BE-36-FY37_0.1uM | Dose=0.1uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| FA-94-QJ71_0.1uM | Dose=0.1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1 |
| AA-15-VA57_1uM | Dose=1uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| FF-01-OH44_0.1uM | Dose=0.1uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38 |
| IE-34-IW27_10uM | Dose=10uM, 3-((4-(Trifluoromethyl)Phenyl)Amino)Benzoic Acid, AKR1C3 inhibitor targeting AKR1C3 |
| GE-34-TW62_1uM | Dose=1uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF |
| BD-85-VR28_1uM | Dose=1uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol |
| FA-47-IB34_0.01uM | Dose=0.01uM |
| UA-17-QS18_10uM | Dose=10uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2 |
| AA-85-LB25_1uM | Dose=1uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| RA-25-VV91_0.01uM | Dose=0.01uM |
| EA-86-YK48_1uM | Dose=1uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1 |
| JD-62-TK68_1uM | Dose=1uM |
| UC-20-ZV24_0.01uM | Dose=0.01uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4 |
| DE-11-PO61_10uM | Dose=10uM, (S)-N-(8-((2-Amino-4-methylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)cyclopropanecarboxamide, AP2-Associated Protein Kinase 1 (AAK1) Inhibitors targeting AAK1 |
| DB-80-QN16_0.01uM | Dose=0.01uM, Valpromide |
| BA-56-QV45_0.1uM | Dose=0.1uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1 |
| BE-37-ZF44_10uM | Dose=10uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| BC-94-GN01_0.1uM | Dose=0.1uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1 |
| IF-43-EO10_1uM | Dose=1uM |
| TA-25-KO99_0.1uM | Dose=0.1uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4 |
| EB-08-WP80_1uM | Dose=1uM |
| S0-EE-WJKI_0.01uM | Dose=0.01uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL |
| AD-26-RY42_0.1uM | Dose=0.1uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| EB-98-OI08_10uM | Dose=10uM |
| AA-58-JC44_1uM | Dose=1uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2 |
| DB-55-UX87_10uM | Dose=10uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2 |
| FD-19-TD14_0.1uM | Dose=0.1uM |
| BF-69-DN58_10uM | Dose=10uM |
| JA-02-IU07_0.1uM | Dose=0.1uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5 |
| EA-73-MI41_10uM | Dose=10uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B |
| HE-68-XL70_1uM | Dose=1uM, 1,2,5-Thiadiazolidin-3-one, 5-[4-(cyclohexylmethyl)-2-fluoro-6-hydroxyphenyl]-, 1,1-dioxide, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1 |
| LE-33-GL18_1uM | Dose=1uM, 3-(4-Tert-butylbenzenesulfonamido)thiophene-2-carboxylic acid, Chemokine CCR9 Receptor Antagonists targeting CCR9 |
| BB-77-QQ71_0.1uM | Dose=0.1uM, Ricolinostat, HDAC6 targeting HDAC6 |
| CB-44-FA25_0.1uM | Dose=0.1uM, N-Tosyl-L-phenylalanyl chloromethyl ketone |
| DD-55-AU25_10uM | Dose=10uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| BB-08-WM33_0.1uM | Dose=0.1uM, AM 281, CNR1 antagonist targeting CNR1 |
| RA-49-ZB08_0.1uM | Dose=0.1uM |
| BC-82-PP66_0.1uM | Dose=0.1uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| KE-86-QG38_0.1uM | Dose=0.1uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-thiomorpholin-4-ylimidazo[1,2-a]pyridin-8-amine, dipeptidyl-peptidase II (DPP7) inhibitor;Fibroblast Activation Protein alpha subunit (FAP) Inhibitor;dipeptidyl-peptidase IV (DPP4) inhibitor targeting DPP4 |
| DA-27-BW40_0.01uM | Dose=0.01uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| AA-67-TF79_0.1uM | Dose=0.1uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1 |
| AD-53-VC77_10uM | Dose=10uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-[[(6S)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| FE-99-RJ28_10uM | Dose=10uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1 |
| GE-77-FY84_1uM | Dose=1uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| DF-03-OP38_1uM | Dose=1uM |
| BF-63-NG22_10uM | Dose=10uM, Tankyrase 2 (TNKS2) Inhibitors;Tankyrase 1 (TNKS1) Inhibitors targeting TNKS, TNKS2 |
| HC-48-BS22_0.01uM | Dose=0.01uM |
| GA-30-HJ41_0.01uM | Dose=0.01uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| BF-94-NX85_10uM | Dose=10uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3 |
| ID-26-HX79_10uM | Dose=10uM, N-(3-Chloro-5-Fluorophenyl)-4-Nitro-2,1,3-Benzoxadiazol-5-Amine, HIF-2;HIF-2 Inhibitor targeting EPAS1 |
| TF-36-BS66_10uM | Dose=10uM, (3S,8S,9S,10R,13S,14S,17R)-17-[(2S)-1-hydroxypropan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol, Cholesterol Biosynthesis Inhibitors; Delta(24)-Sterol Reductase (DHCR24) Inhibitors targeting DHCR24 |
| AF-76-FL46_0.1uM | Dose=0.1uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN |
| JB-82-SK68_0.01uM | Dose=0.01uM, Oxyfenthiin |
| CD-62-GL56_0.1uM | Dose=0.1uM, Fenesin |
| ZE-46-XH09_0.01uM | Dose=0.01uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide |
| JA-01-GQ75_0.1uM | Dose=0.1uM, NS 1652, Chloride Channel Blockers targeting GRIK1 |
| BA-98-JJ31_0.01uM | Dose=0.01uM, Quinine |
| RC-62-LC43_0.1uM | Dose=0.1uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One |
| BA-23-MC77_10uM | Dose=10uM, Oxcarbazepine, Sodium Channel Blockers targeting AQP4, SCN5A |
| AD-54-IH37_10uM | Dose=10uM, Entacapone, COMT Inhibitors targeting COMT |
| FA-57-CO50_10uM | Dose=10uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| GB-33-FW25_1uM | Dose=1uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT |
| YF-46-CA32_0.01uM | Dose=0.01uM |
| ID-12-NA84_0.1uM | Dose=0.1uM, 1-(2-Methoxyphenyl)-4-(3-phenylpropyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AC-42-SI74_1uM | Dose=1uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| GB-72-BR65_1uM | Dose=1uM, Opc 14117 |
| FC-31-HE22_10uM | Dose=10uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1 |
| WA-43-MP01_1uM | Dose=1uM, 2-phenyl-1,2-benzisothiazol-3-(2H)-one |
| DA-54-NN76_0.01uM | Dose=0.01uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| CC-17-JL38_0.1uM | Dose=0.1uM, Ilk-IN-1 targeting ILK |
| AD-85-ME82_0.01uM | Dose=0.01uM, 15-O-Desmethylascomycin |
| CE-15-YU05_0.01uM | Dose=0.01uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| BA-16-AB67_0.01uM | Dose=0.01uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| AC-45-EE32_0.01uM | Dose=0.01uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| CF-87-AS90_1uM | Dose=1uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| BA-46-RB17_0.01uM | Dose=0.01uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| AC-95-TK81_10uM | Dose=10uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| HD-41-DX72_0.01uM | Dose=0.01uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1 |
| AC-45-YY00_10uM | Dose=10uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol |
| ZC-09-IW47_0.01uM | Dose=0.01uM, 7-(2,2-Dimethylpropyl)-6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile |
| DE-09-HJ53_0.01uM | Dose=0.01uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| KB-88-OR49_1uM | Dose=1uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| CB-45-VH79_10uM | Dose=10uM |
| BC-10-OR76_0.1uM | Dose=0.1uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| BD-38-QC39_0.01uM | Dose=0.01uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| IE-80-DC24_1uM | Dose=1uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide |
| AF-31-RV78_0.1uM | Dose=0.1uM, targeting NOS3, PAH, TH, TPH1 |
| BF-24-JN36_0.01uM | Dose=0.01uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| BB-99-UN48_10uM | Dose=10uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| ZD-78-BS65_0.1uM | Dose=0.1uM |
| AB-25-XU75_0.1uM | Dose=0.1uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| ZC-47-HL31_10uM | Dose=10uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1 |
| DE-52-BS63_10uM | Dose=10uM, PAK1 gene inhibitor targeting PAK1 |
| JF-30-FW92_1uM | Dose=1uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R |
| DE-37-JV37_0.1uM | Dose=0.1uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| EB-90-BR21_1uM | Dose=1uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| YA-81-YH47_1uM | Dose=1uM |
| AE-37-MC27_0.01uM | Dose=0.01uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| WA-53-FZ40_10uM | Dose=10uM |
| GB-92-MH66_0.1uM | Dose=0.1uM, Ureidosuccinic acid |
| EE-64-WM03_0.01uM | Dose=0.01uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| FE-06-GR60_0.1uM | Dose=0.1uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| BC-22-DS93_0.1uM | Dose=0.1uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| JE-11-UD64_1uM | Dose=1uM, 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-, Dopamine D3 Agonists targeting DRD3 |
| RA-53-JG50_10uM | Dose=10uM, (S)-N-(2,6-Dioxopiperidin-3-yl)undec-10-enamide, Broad Spectrum Chemokine Inhibitors (BSCI) targeting CCR2, CRBN |
| BB-51-ML99_10uM | Dose=10uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53 |
| VE-28-FM71_0.1uM | Dose=0.1uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3 |
| VE-28-FM71_10uM | Dose=10uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3 |
| FB-67-OY39_0.1uM | Dose=0.1uM, Galnon, GALR2 agonist targeting GALR2 |
| AC-45-EE32_1uM | Dose=1uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| AB-61-FY15_10uM | Dose=10uM |
| BF-63-DQ96_0.1uM | Dose=0.1uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| CD-20-GE75_1uM | Dose=1uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| GA-68-KC29_10uM | Dose=10uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6 |
| SB-89-QK94_10uM | Dose=10uM |
| AB-32-WM54_10uM | Dose=10uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG |
| PC-85-EL52_1uM | Dose=1uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139 |
| ED-27-OE11_1uM | Dose=1uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| BD-62-ZF67_0.1uM | Dose=0.1uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| IE-44-GZ79_0.1uM | Dose=0.1uM, 2,3,4,5-Tetra(4-pyridyl)thiophene, Hedgehog Signaling Inhibitors targeting GLI1 |
| HE-84-SC79_0.01uM | Dose=0.01uM |
| FF-06-MA64_10uM | Dose=10uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1 |
| GA-48-JB51_0.1uM | Dose=0.1uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B |
| AC-55-GO91_1uM | Dose=1uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| EA-92-CV45_10uM | Dose=10uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| EE-64-WM03_10uM | Dose=10uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| BA-46-YF32_0.01uM | Dose=0.01uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| HE-34-NJ16_10uM | Dose=10uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9 |
| BC-12-VG35_1uM | Dose=1uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK |
| KE-04-OV29_0.1uM | Dose=0.1uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)- |
| AB-61-FY15_1uM | Dose=1uM |
| QB-42-ET79_0.01uM | Dose=0.01uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1 |
| GF-46-LK68_10uM | Dose=10uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2 |
| AD-89-XG11_1uM | Dose=1uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| PC-49-XP02_0.01uM | Dose=0.01uM |
| AB-90-YR46_0.01uM | Dose=0.01uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| CB-62-TB77_10uM | Dose=10uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2 |
| AD-89-XG11_0.1uM | Dose=0.1uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| DE-37-JV37_10uM | Dose=10uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| DD-47-GB64_10uM | Dose=10uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| DC-43-KF54_0.1uM | Dose=0.1uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| DD-73-IP88_0.01uM | Dose=0.01uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| ZE-11-HK24_0.1uM | Dose=0.1uM, methyl (1R,2R,3S,3aR,8bS)-6-[[(2R,3R,6R)-6-[(1S)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate, EIF4A gene modulator targeting EIF4A1, EIF4A2, EIF4A3 |
| FA-88-II68_0.1uM | Dose=0.1uM |
| AE-07-IZ32_1uM | Dose=1uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2 |
| LC-42-WU67_10uM | Dose=10uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3 |
| FE-94-WT30_10uM | Dose=10uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2 |
| BF-03-RM76_1uM | Dose=1uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2 |
| WF-85-JN16_1uM | Dose=1uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| EE-13-PS05_1uM | Dose=1uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| TD-57-NZ75_0.01uM | Dose=0.01uM |
| HE-80-BQ08_0.01uM | Dose=0.01uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1 |
| GA-09-TM90_10uM | Dose=10uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK |
| AB-02-TI14_1uM | Dose=1uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| CF-31-GE67_1uM | Dose=1uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| RA-14-EK87_0.01uM | Dose=0.01uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one |
| DC-98-HC94_10uM | Dose=10uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| AF-01-FE42_0.1uM | Dose=0.1uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| CA-73-TP18_10uM | Dose=10uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15 |
| GC-60-XQ43_10uM | Dose=10uM, Insulin Receptor Antagonists;IGF-1R Inhibitors targeting IGF1R, INSR |
| HD-99-BT62_1uM | Dose=1uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1 |
| AE-00-WU78_0.1uM | Dose=0.1uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AB-97-BI36_0.1uM | Dose=0.1uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| FA-67-MV22_0.1uM | Dose=0.1uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1 |
| DA-48-NC44_10uM | Dose=10uM |
| CF-68-DM58_10uM | Dose=10uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| BB-42-FF52_0.1uM | Dose=0.1uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ |
| IC-98-UO17_10uM | Dose=10uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5 |
| IF-31-RN78_0.1uM | Dose=0.1uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1 |
| CC-04-YT10_10uM | Dose=10uM |
| LB-68-SH80_0.1uM | Dose=0.1uM, (2S,4R)-1-acetyl-N-(1-(benzo[d]thiazol-2-yl)-5-guanidino-1-oxopentan-2-yl)-4-hydroxypyrrolidine-2-carboxamide, Trypsin Inhibitors;Tryptase Inhibitors targeting PRSS1, PRSS2, PRSS3, TPSAB1, TPSD1, TPSG1, TPSB2 |
| AB-71-NB55_10uM | Dose=10uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14 |
| FC-35-BX82_0.1uM | Dose=0.1uM, Cyclosporin V |
| AA-83-YJ04_10uM | Dose=10uM |
| AC-41-IB85_10uM | Dose=10uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| VF-06-RV33_1uM | Dose=1uM, 3-[(4-chlorophenyl)methyl]-4-methyl-5,7-bis(2H-tetrazol-5-ylmethoxy)chromen-2-one targeting PLN |
| AC-41-IB85_1uM | Dose=1uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| LB-00-NP55_10uM | Dose=10uM, (2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-1-benzofuran-3-one, Sphingosine Kinase Inhibitors targeting SPHK2 |
| HF-33-KS15_0.01uM | Dose=0.01uM, l-Menthol, TRPM8 (TRP-p8;CMR1) Agonists targeting TRPM8 |
| FC-13-VS25_0.01uM | Dose=0.01uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| PF-72-IT39_1uM | Dose=1uM |
| KA-37-GD83_10uM | Dose=10uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
| DC-78-CM38_10uM | Dose=10uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| AE-21-BF25_0.01uM | Dose=0.01uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| LD-39-FL02_0.01uM | Dose=0.01uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside |
| XB-75-YN01_10uM | Dose=10uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV |
| MA-45-US84_0.1uM | Dose=0.1uM, 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, SUV420H1/H2 inhibitor;kmt5b and kmt5c inhibitor targeting KMT5B, KMT5C |
| DA-83-IZ87_0.01uM | Dose=0.01uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| EA-02-ZO63_1uM | Dose=1uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3 |
| BF-44-HD37_1uM | Dose=1uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB |
| KD-88-RE18_0.1uM | Dose=0.1uM |
| BD-60-XA25_10uM | Dose=10uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine |
| BE-70-YH17_1uM | Dose=1uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| AC-94-YX80_0.01uM | Dose=0.01uM, Loratadine |
| LC-40-KC29_10uM | Dose=10uM |
| AA-99-HO76_10uM | Dose=10uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1 |
| BC-43-JW95_0.01uM | Dose=0.01uM, Phenylalanine |
| FC-40-QD52_0.1uM | Dose=0.1uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| DB-93-SW55_0.01uM | Dose=0.01uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| DF-95-CY55_0.1uM | Dose=0.1uM |
| HC-18-NB46_1uM | Dose=1uM, N-Acetyl-6-methoxytryptamine |
| DC-08-CM08_1uM | Dose=1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| CC-56-MO03_0.1uM | Dose=0.1uM, 4-(1H-indol-3-yl)pyrimidin-2-amine |
| FB-33-LI31_0.1uM | Dose=0.1uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile |
| FE-25-GD89_0.1uM | Dose=0.1uM |
| AC-55-GO91_0.1uM | Dose=0.1uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| EE-64-WM03_1uM | Dose=1uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| GD-46-OD81_1uM | Dose=1uM, U 41792 |
| QA-34-PH05_0.01uM | Dose=0.01uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2 |
| NE-27-MD08_10uM | Dose=10uM, N-[1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide, Motilin Receptor Antagonist targeting MLNR |
| ED-62-DB62_0.01uM | Dose=0.01uM |
| BE-89-DG86_0.1uM | Dose=0.1uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| DA-83-VJ09_0.1uM | Dose=0.1uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| XE-18-BC97_10uM | Dose=10uM, 2-Hydroxy-6-[4-methyl-5-(4-methylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]naphthalene-1-carbaldehyde |
| DE-02-BL66_0.1uM | Dose=0.1uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| QF-00-CY91_1uM | Dose=1uM, 3-Phenylacetylamino-2,6-piperidinedione |
| JB-60-JM38_0.1uM | Dose=0.1uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4 |
| FE-09-JD34_0.01uM | Dose=0.01uM, Dot1L-IN-5 |
| MC-30-BS07_0.01uM | Dose=0.01uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG |
| AD-09-MD49_10uM | Dose=10uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR |
| AF-80-GK24_1uM | Dose=1uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| OF-02-BG78_0.01uM | Dose=0.01uM |
| QA-25-HL62_10uM | Dose=10uM, 4-({3-chloro-4-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinoline-3-carbonitrile, Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors targeting MAP2K1 |
| CA-16-ZL71_0.1uM | Dose=0.1uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b |
| EE-26-UK38_0.01uM | Dose=0.01uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A |
| AE-09-IN08_10uM | Dose=10uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3 |
| AC-91-ME22_0.1uM | Dose=0.1uM, (R)-Aminoglutethimide |
| MB-72-YK93_10uM | Dose=10uM |
| AA-15-HO31_10uM | Dose=10uM, Batimastat, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting FCER2, MMP14, MMP16, MMP11, FCER1A, MS4A2, MMP15, MMP17, MMP19, MMP23A, MMP20, MS4A7, MMP27, MMP28, MMP21 |
| AC-10-JK64_0.01uM | Dose=0.01uM |
| BE-16-UV45_10uM | Dose=10uM |
| CF-55-OA12_0.1uM | Dose=0.1uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| TF-04-RX73_0.1uM | Dose=0.1uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile |
| BB-48-VW67_10uM | Dose=10uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| IC-27-TE11_0.1uM | Dose=0.1uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4 |
| OB-61-XZ91_0.01uM | Dose=0.01uM, Neurotrophic Agents targeting ADA, PNP |
| S0-EE-Y737_10uM | Dose=10uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6 |
| NA-00-YS67_1uM | Dose=1uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS |
| DD-30-NA60_10uM | Dose=10uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| JB-89-SI60_0.1uM | Dose=0.1uM, (3s,5r)-N-{[9-(4-Methoxybutyl)-9h-Xanthen-9-Yl]methyl}-5-{[(4-Methylphenyl)sulfonyl]amino}piperidine-3-Carboxamide, Renin Inhibitors targeting REN |
| LE-94-HL75_0.1uM | Dose=0.1uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2 |
| FF-46-OR35_0.01uM | Dose=0.01uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| AC-51-WE57_1uM | Dose=1uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| OA-15-DB28_1uM | Dose=1uM |
| WB-92-FB15_0.01uM | Dose=0.01uM, (2S)-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| GA-53-SC22_0.01uM | Dose=0.01uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| EA-93-KT88_0.1uM | Dose=0.1uM |
| CB-11-GB40_1uM | Dose=1uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| TD-49-MO89_0.1uM | Dose=0.1uM |
| NC-42-UX09_0.1uM | Dose=0.1uM |
| CF-42-OS28_0.01uM | Dose=0.01uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| S0-EE-YRH3_1uM | Dose=1uM, [3-[[4-(aminomethyl)-1-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate, LIMK2 gene inhibitor;LIMK1 gene inhibitor targeting LIMK1, LIMK2 |
| ZC-12-OO11_0.1uM | Dose=0.1uM, 5-(Pyridin-4-YL)-1H-imidazole-2-thiol, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| CB-40-DA30_10uM | Dose=10uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5 |
| NB-58-SA13_0.01uM | Dose=0.01uM |
| SC-72-YW56_0.1uM | Dose=0.1uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5 |
| EA-33-QC97_0.01uM | Dose=0.01uM |
| OB-28-LD05_10uM | Dose=10uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid |
| BF-79-GG96_1uM | Dose=1uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| OB-17-DQ74_0.1uM | Dose=0.1uM, Selinexor, Exportin 1 inhibitor targeting XPO1 |
| RD-89-FH52_0.01uM | Dose=0.01uM |
| JD-48-EV39_0.01uM | Dose=0.01uM, Xanthenone-4-acetic acid |
| CE-02-FZ80_10uM | Dose=10uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1 |
| UE-02-UW61_1uM | Dose=1uM, 4-Methyl-1-(1h-Pyrazol-4-Ylmethyl)-5-[(4-{[6-(2,2,2-Trifluoroethyl)thieno[2,3-D]pyrimidin-4-Yl]amino}piperidin-1-Yl)methyl]-1h-Indole-2-Carbonitrile, Menin inhibitor targeting MEN1 |
| ZB-09-RC84_10uM | Dose=10uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| YE-57-WY37_1uM | Dose=1uM, 2-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]benzamide |
| FC-13-UF39_0.01uM | Dose=0.01uM |
| AC-73-DW50_10uM | Dose=10uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| BD-96-HO33_0.1uM | Dose=0.1uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1 |
| BF-63-DQ96_10uM | Dose=10uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| KA-75-LP02_0.1uM | Dose=0.1uM |
| AD-14-QD12_10uM | Dose=10uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2 |
| GB-93-CC27_10uM | Dose=10uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6 |
| FE-61-DL94_10uM | Dose=10uM |
| IA-76-ZU47_0.01uM | Dose=0.01uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1 |
| QB-69-AR11_0.01uM | Dose=0.01uM, N-[(1S,2R,3S,4R)-4-(2-Chloro-6-cyclopentylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide, Adenosine A1 Agonists targeting ADORA1 |
| AB-09-PR28_0.1uM | Dose=0.1uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE |
| KC-36-DK23_10uM | Dose=10uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1 |
| AC-29-ZR23_1uM | Dose=1uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| AD-30-OK99_1uM | Dose=1uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| NB-21-MW29_0.1uM | Dose=0.1uM |
| EF-80-OD07_1uM | Dose=1uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| NF-53-AH73_0.01uM | Dose=0.01uM, Riociguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| BB-62-MS83_0.01uM | Dose=0.01uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| YA-21-RR66_10uM | Dose=10uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4 |
| NB-17-SQ59_0.1uM | Dose=0.1uM, SDZ-62-434 free, Platelet-Activating Factor Receptor (PAFR) Antagonists targeting PTAFR |
| KC-36-DK23_1uM | Dose=1uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1 |
| XD-03-FM54_0.01uM | Dose=0.01uM |
| DA-63-NP63_10uM | Dose=10uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID |
| PB-13-ZD03_10uM | Dose=10uM, 1-N,3-N-bis(1-methylquinolin-1-ium-6-yl)benzene-1,3-dicarboxamide, DNA G-quadruplex (G4) Ligands;Telomerase Inhibitors targeting TERT |
| JB-72-IH66_10uM | Dose=10uM, CID 49843509, Proteinase activated receptor 2 (PAR2) partial agonist targeting F2RL1 |
| AE-41-GB05_0.01uM | Dose=0.01uM, Ave5638, Known Tryptase inhibitor targeting TPSB2 |
| ED-14-GQ53_0.1uM | Dose=0.1uM, 2-(4-Methylphenoxy)benzoic acid |
| AE-59-ZQ55_1uM | Dose=1uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1 |
| EC-41-PH99_1uM | Dose=1uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide |
| GB-96-WX99_0.1uM | Dose=0.1uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1 |
| AC-17-PC87_10uM | Dose=10uM, Chk2 Inhibitor II targeting CHEK2 |
| IE-28-SY71_0.01uM | Dose=0.01uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one |
| AC-11-BO01_10uM | Dose=10uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1 |
| NE-42-YQ17_1uM | Dose=1uM |
| CA-54-WJ96_0.1uM | Dose=0.1uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| S0-EE-Y9YA_10uM | Dose=10uM, 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine, BUB1 mitotic checkpoint serine/threonine kinase inhibitor targeting BUB1 |
| HE-17-FY34_10uM | Dose=10uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| NB-17-SQ59_10uM | Dose=10uM, SDZ-62-434 free, Platelet-Activating Factor Receptor (PAFR) Antagonists targeting PTAFR |
| JA-23-QE71_10uM | Dose=10uM, [4-(8-chloro-5-methyl-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)piperidin-1-yl]-(1H-indol-6-yl)methanone, AVPR1A antagonist targeting AVPR1A |
| SF-67-CJ22_10uM | Dose=10uM |
| XD-68-MP63_0.01uM | Dose=0.01uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine |
| JF-93-EL43_10uM | Dose=10uM, Shp2 IN-1, SHP2 inhibitor targeting PTPN11 |
| CF-31-GE67_10uM | Dose=10uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| BA-71-BE32_1uM | Dose=1uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| GA-77-MH38_0.01uM | Dose=0.01uM |
| AB-55-HO71_0.1uM | Dose=0.1uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF |
| DD-55-SD64_0.1uM | Dose=0.1uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C |
| JD-00-YJ41_0.01uM | Dose=0.01uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK |
| S0-EE-XZUM_0.1uM | Dose=0.1uM, targeting KDM5B, KDM4B, KDM5A |
| JA-02-IU07_1uM | Dose=1uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5 |
| BD-85-OV63_1uM | Dose=1uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| SA-63-NG30_1uM | Dose=1uM, N-[4-(3-Chlorophenyl)-5-(2-chlorobenzoyl)thiazole-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, Retinoid receptor modulator targeting RORB, RORC |
| QE-11-DP47_0.01uM | Dose=0.01uM, 9-Hydroxycalabaxanthone |
| LD-00-HM58_0.01uM | Dose=0.01uM, 5-[2,3-Bis(Chloranyl)phenyl]-2-[(3~{r},5~{s})-3,5-Dimethylpiperazin-1-Yl]pyrimidin-4-Amine, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A |
| PA-80-RV09_10uM | Dose=10uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1 |
| EF-19-KJ63_10uM | Dose=10uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A |
| AD-29-MQ00_1uM | Dose=1uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| MF-17-BD63_10uM | Dose=10uM, N-[4'-Methyl-2-(pyridin-3-ylamino)-[4,5]bithiazolyl-2'-yl]-acetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| DC-08-CM08_10uM | Dose=10uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| ZD-74-FC07_10uM | Dose=10uM |
| GF-57-MY04_10uM | Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB |
| JD-70-IC84_0.01uM | Dose=0.01uM, Genipin, Free Radical Scavengers;Apoptosis Inhibitors;UCP2 inhibitor;Non-Steroidal Antiinflammatory Drugs targeting UCP2 |
| OD-07-NJ52_10uM | Dose=10uM, 5-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-2,2-diphenyl-pentanenitrile, CCR1 antagonist;Chemokine US28 Receptor Inverse Agonists targeting CCR1 |
| DD-12-RF07_1uM | Dose=1uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| AE-43-UJ94_1uM | Dose=1uM |
| DE-91-FH69_10uM | Dose=10uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| LD-12-GA99_0.01uM | Dose=0.01uM, Diacetyldiphenylurea bisguanylhydrazone, Ribonuclease P Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2 |
| QF-55-QV81_0.01uM | Dose=0.01uM |
| KA-00-HF91_1uM | Dose=1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate |
| AC-55-GO91_0.01uM | Dose=0.01uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| BB-99-UN48_1uM | Dose=1uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| AC-95-TK81_0.01uM | Dose=0.01uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| EA-69-VJ68_0.01uM | Dose=0.01uM |
| ED-79-EW79_0.01uM | Dose=0.01uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5 |
| CB-40-DA30_0.1uM | Dose=0.1uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5 |
| KC-15-HM70_10uM | Dose=10uM, Talarozole, An inhibitor of CYP26 targeting CYP26A1 |
| BA-74-WG29_10uM | Dose=10uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2 |
| BF-77-FT23_10uM | Dose=10uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2 |
| BF-94-NX85_0.01uM | Dose=0.01uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3 |
| MA-88-CA03_10uM | Dose=10uM, 6,7,4'-Trihydroxyisoflavan |
| LF-37-AX51_0.1uM | Dose=0.1uM, 2'-Hydroxy-4'-Methoxychalcone |
| CC-70-BD07_0.1uM | Dose=0.1uM, Voriconazole Impurity 7 |
| TD-49-MO89_1uM | Dose=1uM |
| AC-59-ZD79_0.1uM | Dose=0.1uM, N6-Methyladenosine |
| BB-51-DP49_0.01uM | Dose=0.01uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| GF-57-LR72_0.1uM | Dose=0.1uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| BB-44-SX65_0.1uM | Dose=0.1uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| FA-70-ZG69_10uM | Dose=10uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| ZB-28-SS80_0.1uM | Dose=0.1uM, (3-Cyano-4-{3-[(5-methyl-furan-2-ylmethyl)-sulfamoyl]-5-trifluoromethyl-phenyl}-pyrrol-1-yl)-acetic acid, GPR44 antagonist targeting PTGDR2 |
| LF-86-EA69_10uM | Dose=10uM, N-(3,5-dichlorophenyl)benzenesulfonamide, Dedicator of cytokenesis protein 5 inhibitor targeting DOCK5 |
| FF-96-HL81_1uM | Dose=1uM |
| DF-00-BX35_1uM | Dose=1uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| DE-29-MT22_1uM | Dose=1uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| BF-97-LS55_10uM | Dose=10uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| EC-09-DC91_0.01uM | Dose=0.01uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| KE-18-XY06_0.1uM | Dose=0.1uM, Ibopamine, Dopamine D1 Agonists targeting DRD1 |
| FC-62-AI14_10uM | Dose=10uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ |
| AE-15-KH69_0.01uM | Dose=0.01uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3 |
| DC-93-NP78_0.1uM | Dose=0.1uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN |
| LE-33-GL18_0.1uM | Dose=0.1uM, 3-(4-Tert-butylbenzenesulfonamido)thiophene-2-carboxylic acid, Chemokine CCR9 Receptor Antagonists targeting CCR9 |
| AD-85-ME82_10uM | Dose=10uM, 15-O-Desmethylascomycin |
| HE-55-AG11_1uM | Dose=1uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3 |
| DB-88-VW47_1uM | Dose=1uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3 |
| GC-69-JF03_1uM | Dose=1uM |
| QC-63-VN72_10uM | Dose=10uM |
| JE-47-FU54_1uM | Dose=1uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4 |
| DB-29-HQ45_1uM | Dose=1uM |
| DC-93-NP78_1uM | Dose=1uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN |
| AA-54-WG39_0.01uM | Dose=0.01uM, 4-Aminobenzamide |
| AC-17-PI61_10uM | Dose=10uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6 |
| TD-49-MO89_10uM | Dose=10uM |
| GA-01-EO66_1uM | Dose=1uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1 |
| HB-77-UY14_0.01uM | Dose=0.01uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B |
| AC-40-DU58_1uM | Dose=1uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP |
| HD-96-GX64_10uM | Dose=10uM, Methyl 4-[(3,6-dichloro-2-methoxybenzoyl)amino]benzoate targeting TAS1R1 |
| AC-31-PL89_0.1uM | Dose=0.1uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| AE-13-CX28_1uM | Dose=1uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3 |
| CB-42-EI79_0.1uM | Dose=0.1uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1 |
| WE-41-YO44_10uM | Dose=10uM, N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea, Angiogenesis Inhibitors;Urokinase (u-PA) Inhibitors targeting PLAU |
| HD-40-AK39_0.01uM | Dose=0.01uM, Eliglustat targeting UGCG |
| WC-95-BX35_1uM | Dose=1uM, [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-(4z)-ylidene]-acetic acid |
| CC-91-RO81_10uM | Dose=10uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3 |
| YA-21-RR66_1uM | Dose=1uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4 |
| EA-32-CY22_10uM | Dose=10uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| AA-99-HG96_0.1uM | Dose=0.1uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F |
| QD-32-CW16_0.01uM | Dose=0.01uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R |
| OC-14-JE88_0.01uM | Dose=0.01uM, Sergliflozin Etabonate, SGLT-2 Inhibitors targeting SLC5A2 |
| BB-51-ML99_1uM | Dose=1uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53 |
| PB-66-RW16_10uM | Dose=10uM, PRMT6 gene inhibitor;PRMT6 inhibitor targeting PRMT6 |
| BA-52-FW03_0.1uM | Dose=0.1uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| HD-18-YL30_0.1uM | Dose=0.1uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1 |
| CB-73-MJ69_10uM | Dose=10uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3 |
| GB-27-AY54_1uM | Dose=1uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| FC-40-QD52_1uM | Dose=1uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| UD-07-US73_0.1uM | Dose=0.1uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB |
| GA-97-UL18_10uM | Dose=10uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3 |
| AA-14-DQ28_1uM | Dose=1uM, Estradiol |
| DF-11-IL69_0.01uM | Dose=0.01uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS |
| LB-17-PD08_0.01uM | Dose=0.01uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1 |
| EB-44-GM58_0.01uM | Dose=0.01uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| DD-55-SD64_1uM | Dose=1uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C |
| BA-86-AL61_0.1uM | Dose=0.1uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1 |
| GB-94-XG34_1uM | Dose=1uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN |
| BB-32-IZ10_10uM | Dose=10uM |
| DA-05-NN93_0.01uM | Dose=0.01uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| EA-32-CY22_0.1uM | Dose=0.1uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| AE-36-GL26_0.1uM | Dose=0.1uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide |
| AF-65-CU85_10uM | Dose=10uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6 |
| WB-92-FB15_0.1uM | Dose=0.1uM, (2S)-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| JD-94-BC04_0.01uM | Dose=0.01uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1 |
| AB-23-UX23_1uM | Dose=1uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1 |
| CE-04-HT15_1uM | Dose=1uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1 |
| XA-36-WV33_0.01uM | Dose=0.01uM, Ethyl 4-(3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| HD-68-CB31_1uM | Dose=1uM, N-Methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide targeting CYP2D6 |
| BA-50-HH67_0.1uM | Dose=0.1uM, Tomatidine |
| HB-45-XQ45_0.1uM | Dose=0.1uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| MD-60-WI93_0.1uM | Dose=0.1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR-1 (Flt-1) Inhibitors targeting FLT1 |
| GB-10-QG19_0.1uM | Dose=0.1uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| FA-57-CO50_0.01uM | Dose=0.01uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| RA-14-EK87_1uM | Dose=1uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one |
| S0-EE-Y737_0.1uM | Dose=0.1uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6 |
| DD-44-OX00_1uM | Dose=1uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| FD-35-PQ00_0.1uM | Dose=0.1uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2 |
| AA-67-JI21_1uM | Dose=1uM, Tryptamine |
| CF-82-LL11_10uM | Dose=10uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5 |
| ZA-84-ZC97_10uM | Dose=10uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA |
| KC-99-BS89_10uM | Dose=10uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine |
| GA-13-WB79_1uM | Dose=1uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| CA-44-LT45_1uM | Dose=1uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| FB-32-TL51_10uM | Dose=10uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| CA-84-IJ41_10uM | Dose=10uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| GA-30-HJ41_10uM | Dose=10uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| VD-08-YA83_0.01uM | Dose=0.01uM |
| AC-24-NX95_1uM | Dose=1uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| AD-94-EX35_0.01uM | Dose=0.01uM, Pretomanid |
| HA-30-KD77_1uM | Dose=1uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2 |
| KB-39-DB68_0.1uM | Dose=0.1uM, 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AE-17-IZ62_10uM | Dose=10uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide |
| MF-04-HB41_0.01uM | Dose=0.01uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1 |
| AB-05-FB25_0.01uM | Dose=0.01uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1 |
| HD-85-AJ28_10uM | Dose=10uM, Nelivaptan, DNA-Directed RNA Polymerase Inhibitors targeting AVPR1B |
| JE-04-LS32_1uM | Dose=1uM |
| DB-21-FY25_0.1uM | Dose=0.1uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| LA-09-SS14_0.1uM | Dose=0.1uM, Pcera-1, TNF-alpha Production Inhibitors;IL-10 Production Enhancers;cPLA2a activator targeting PLA2G4A |
| AB-63-UX23_0.01uM | Dose=0.01uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| FA-45-XX32_10uM | Dose=10uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1 |
| DE-91-FH69_1uM | Dose=1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| EB-67-WB79_1uM | Dose=1uM |
| GE-25-DQ65_10uM | Dose=10uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| AB-09-PR28_0.01uM | Dose=0.01uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE |
| AA-09-HG96_10uM | Dose=10uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA |
| DE-82-SC55_0.1uM | Dose=0.1uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP |
| FF-90-JK74_10uM | Dose=10uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A |
| CA-44-LT45_10uM | Dose=10uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| PC-49-XP02_1uM | Dose=1uM |
| EB-82-HZ30_0.1uM | Dose=0.1uM |
| IB-06-YD91_0.1uM | Dose=0.1uM, dual thymidylate synthase and dihydrofolate reductase inhibitors targeting DHFR, FOLR1, GART, SLC19A1, TYMS |
| BD-85-OV63_0.1uM | Dose=0.1uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| JB-76-JD86_0.01uM | Dose=0.01uM, N-[(6-amino-4-methylpyridin-3-yl)methyl]-1-benzylpyrazole-4-carboxamide |
| UA-20-YK17_0.1uM | Dose=0.1uM, (2R)-1-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropan-1-one, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| BB-36-LB57_1uM | Dose=1uM |
| AC-41-MB45_10uM | Dose=10uM |
| DE-27-WV87_0.01uM | Dose=0.01uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| AD-16-OE34_0.1uM | Dose=0.1uM, Octopamine |
| FE-09-JD34_10uM | Dose=10uM, Dot1L-IN-5 |
| S0-EE-WNJC_10uM | Dose=10uM |
| LB-90-DC89_10uM | Dose=10uM, (S)-Albuterol |
| JB-99-UC61_0.01uM | Dose=0.01uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid |
| BA-74-WG29_0.1uM | Dose=0.1uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2 |
| BA-69-TQ80_10uM | Dose=10uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| KD-44-PB06_1uM | Dose=1uM, CID 10461016 |
| TE-67-XP56_0.1uM | Dose=0.1uM, Bms-561392, ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors) targeting ADAM17 |
| XD-44-FJ34_1uM | Dose=1uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| RF-57-OJ02_10uM | Dose=10uM, N-(4-chloro-2-isopropoxybenzyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, GPR3 inverse agonist targeting GPR3 |
| VB-76-UE47_0.01uM | Dose=0.01uM |
| CC-05-MK46_0.01uM | Dose=0.01uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| BD-81-FB30_0.01uM | Dose=0.01uM |
| S0-EE-Y00Z_10uM | Dose=10uM, T-98475, GnRH (LHRH) Antagonists targeting GNRHR |
| FA-56-WH26_1uM | Dose=1uM, Venglustat targeting UGCG |
| AA-27-LG62_10uM | Dose=10uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG |
| BB-44-SX65_0.01uM | Dose=0.01uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| KA-50-OP35_1uM | Dose=1uM |
| FF-22-NB12_10uM | Dose=10uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| AC-22-PZ30_0.1uM | Dose=0.1uM, Eed226, PRC2/EED targeting EED |
| AB-86-XY72_0.1uM | Dose=0.1uM |
| AA-43-TW35_1uM | Dose=1uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B |
| AB-70-GR31_0.1uM | Dose=0.1uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| DA-86-GO43_10uM | Dose=10uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| GA-04-JM33_1uM | Dose=1uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4 |
| LC-03-KY64_10uM | Dose=10uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2 |
| SD-12-UF05_0.01uM | Dose=0.01uM, Phenylsulfamate, Carbonic anhydrase inhibitor targeting CA2 |
| XD-37-GI34_0.01uM | Dose=0.01uM |
| MF-04-HB41_10uM | Dose=10uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1 |
| JD-87-MR82_10uM | Dose=10uM, N-[1,3-Dimethyl-6-[(2r)-2-Methylpiperazin-1-Yl]-2-Oxidanylidene-Benzimidazol-5-Yl]-2-Methoxy-Benzamide, BRPF1 inhibitor;BRPF1 inhibitors targeting BRPF1 |
| PC-87-OG75_0.1uM | Dose=0.1uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile |
| BE-49-AQ65_0.1uM | Dose=0.1uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
| DD-47-GB64_0.1uM | Dose=0.1uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| AD-33-YW85_10uM | Dose=10uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| TC-22-OM27_0.01uM | Dose=0.01uM |
| KD-04-TL80_10uM | Dose=10uM |
| BE-65-HV88_0.1uM | Dose=0.1uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B |
| AA-76-CL76_0.1uM | Dose=0.1uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| MF-81-RJ18_0.1uM | Dose=0.1uM |
| SD-69-IX30_0.1uM | Dose=0.1uM, Etomoxir |
| IA-28-VB61_10uM | Dose=10uM |
| EC-62-HO43_0.1uM | Dose=0.1uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1 |
| JC-03-OI01_10uM | Dose=10uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA |
| FC-58-KP35_0.1uM | Dose=0.1uM, AM-966, LPAR1 antagonist targeting LPAR1 |
| EE-08-SZ54_0.1uM | Dose=0.1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| AD-91-LE02_0.01uM | Dose=0.01uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| BD-80-SK69_1uM | Dose=1uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7 |
| SA-32-CC58_10uM | Dose=10uM, Piperidin-4-yl-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-amine, CDK inhibitors targeting CCNB2, CCNB3 |
| AD-16-HL96_0.01uM | Dose=0.01uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| HA-36-VD41_0.1uM | Dose=0.1uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| GF-46-FA29_10uM | Dose=10uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2 |
| AF-01-FE42_0.01uM | Dose=0.01uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| BB-80-NH42_0.01uM | Dose=0.01uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2 |
| EF-20-MG69_10uM | Dose=10uM, 7,8-Dihydroxyflavone, TRKB Activators targeting NTRK2 |
| JD-01-RA07_0.1uM | Dose=0.1uM, N-(4,6-Dimethylpyrimidin-2-yl)-4-((2-methylbenzyl)amino)benzenesulfonamide, alpha2B-Adrenoceptor Antagonists targeting ADRA2B |
| ID-55-OJ03_0.1uM | Dose=0.1uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10 |
| FC-85-OX77_0.1uM | Dose=0.1uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| HC-94-AQ98_0.1uM | Dose=0.1uM, Roxadustat, hypoxia-inducible factor prolyl hydroxylase inhibitor targeting EGLN1, EGLN2, EGLN3 |
| AC-74-UR36_10uM | Dose=10uM, Apixaban, Known FactorXa inhibitor targeting F10 |
| IF-86-JG83_1uM | Dose=1uM, (S)-2-benzylamino-3-phenyl-1-propanol |
| AE-67-FF84_1uM | Dose=1uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| IC-80-CT90_1uM | Dose=1uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea |
| PB-40-CS17_1uM | Dose=1uM |
| ED-91-LA02_10uM | Dose=10uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B |
| CC-91-VE57_0.01uM | Dose=0.01uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| GE-28-EL65_0.1uM | Dose=0.1uM, 3-O-Methyldopa, DL- |
| CC-84-JQ48_0.1uM | Dose=0.1uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| SB-94-ZA83_0.1uM | Dose=0.1uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| WD-26-EB85_1uM | Dose=1uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1 |
| TC-59-QN21_0.1uM | Dose=0.1uM, SB-332235, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| ME-16-XW76_1uM | Dose=1uM, 1-(3-Benzoylpropyl)-4-benzamidopiperidine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| AB-63-UX23_10uM | Dose=10uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| DB-73-BC12_0.1uM | Dose=0.1uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4 |
| CD-16-KY17_0.01uM | Dose=0.01uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| FB-68-SI43_10uM | Dose=10uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide |
| JB-76-JD86_10uM | Dose=10uM, N-[(6-amino-4-methylpyridin-3-yl)methyl]-1-benzylpyrazole-4-carboxamide |
| FB-95-JD99_10uM | Dose=10uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B |
| YD-59-WM48_0.01uM | Dose=0.01uM, 2-Methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane], CHRM1 agonist targeting CHRM1 |
| LB-14-EI63_0.01uM | Dose=0.01uM, Tolcapone, COMT Inhibitors targeting COMT |
| EB-09-OC36_1uM | Dose=1uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| FF-54-JC89_1uM | Dose=1uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| ID-30-ST90_0.1uM | Dose=0.1uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide |
| AB-09-YX02_10uM | Dose=10uM, p-Coumaric acid |
| CA-66-FY97_0.1uM | Dose=0.1uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| JA-42-MU37_1uM | Dose=1uM |
| UA-06-UV98_0.1uM | Dose=0.1uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB |
| AB-92-GP61_0.1uM | Dose=0.1uM, JTE-607 free base |
| EE-01-FB85_0.1uM | Dose=0.1uM, Indolactam V, PKC agonist targeting PRKCA |
| LC-54-XS57_10uM | Dose=10uM |
| BA-46-QO78_1uM | Dose=1uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| GA-47-MH68_0.01uM | Dose=0.01uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| IE-13-CP28_1uM | Dose=1uM, CLK1 protein kinase inhibitor targeting CLK1, DYRK1A, DYRK2 |
| AB-96-JV50_10uM | Dose=10uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2 |
| AC-97-KP88_1uM | Dose=1uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| GB-98-IZ84_0.01uM | Dose=0.01uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5 |
| DE-42-QB97_1uM | Dose=1uM, N-Acetylserotonin |
| BC-10-OR76_0.01uM | Dose=0.01uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| KA-37-GD83_1uM | Dose=1uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
| EA-73-WI86_10uM | Dose=10uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1 |
| JD-87-KA71_0.1uM | Dose=0.1uM, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethyl-quinazoline, Antimitotic Drugs targeting TUBB |
| IE-46-VU57_0.01uM | Dose=0.01uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1 |
| YF-64-PQ11_10uM | Dose=10uM, Nitisinone, 4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors targeting HPD |
| BE-28-QT65_0.1uM | Dose=0.1uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| UC-58-DM11_1uM | Dose=1uM, Pozanicline, Nicotinic Receptor Partial Agonists targeting CHRNA4, CHRNB2 |
| AA-31-YE07_10uM | Dose=10uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| CC-48-OM48_1uM | Dose=1uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| EA-96-QK68_1uM | Dose=1uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| IA-65-QX27_10uM | Dose=10uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A |
| PB-18-HD85_0.1uM | Dose=0.1uM |
| HD-41-DX72_10uM | Dose=10uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1 |
| DB-41-SH04_0.01uM | Dose=0.01uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3 |
| HC-38-KI38_10uM | Dose=10uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| EA-69-VJ68_10uM | Dose=10uM |
| AE-43-UJ94_0.1uM | Dose=0.1uM |
| OF-32-PT74_1uM | Dose=1uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene |
| AB-63-UX23_1uM | Dose=1uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| HC-11-RK51_0.01uM | Dose=0.01uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| XC-81-LR46_1uM | Dose=1uM |
| OF-32-PT74_10uM | Dose=10uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene |
| QE-03-UA61_10uM | Dose=10uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1 |
| MA-20-ZI33_0.1uM | Dose=0.1uM |
| EA-40-KQ08_0.1uM | Dose=0.1uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| AA-23-FM46_0.01uM | Dose=0.01uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EE-85-SK26_10uM | Dose=10uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| DD-96-DE39_0.1uM | Dose=0.1uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| CE-72-SF92_10uM | Dose=10uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| OF-19-JH77_1uM | Dose=1uM, 2-[1-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-2,2-diphenyl-ethylamino]-acetamide, TACR1 antagonist targeting TACR1 |
| FA-65-UA27_0.1uM | Dose=0.1uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| BD-49-MD69_0.01uM | Dose=0.01uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| HD-51-KD29_1uM | Dose=1uM, 5-bromo-2-N-[4-[3-(propan-2-ylamino)propylamino]phenyl]-4-N-pyridin-2-ylpyrimidine-2,4-diamine, Cyclin-Dependent Kinase Inhibitors targeting CDK4, CDKL5, CDK6 |
| GF-15-LT47_1uM | Dose=1uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3 |
| AB-06-KB32_0.01uM | Dose=0.01uM |
| OA-89-EE65_10uM | Dose=10uM, N-[4-chloro-2-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-4-(trifluoromethoxy)benzenesulfonamide |
| DB-41-IH69_1uM | Dose=1uM |
| JD-50-EC04_10uM | Dose=10uM, 6-(4-Fluorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-amine, EphB4 Inhibitors;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, EPHB4, SRC, ABL2 |
| ZE-58-ZZ82_10uM | Dose=10uM |
| DD-43-WW40_1uM | Dose=1uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| CB-48-WM43_0.1uM | Dose=0.1uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E |
| HC-48-BS22_10uM | Dose=10uM |
| TC-59-QN21_10uM | Dose=10uM, SB-332235, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| PA-57-FX61_1uM | Dose=1uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide |
| DA-33-CX68_10uM | Dose=10uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B |
| JE-27-XK20_0.01uM | Dose=0.01uM, Rifapentine, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| KB-85-KP82_1uM | Dose=1uM, Sch 33303, Mediator Release Inhibitors;Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1 |
| AA-57-FZ47_10uM | Dose=10uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| AA-77-RI81_0.1uM | Dose=0.1uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B |
| XD-03-FM54_10uM | Dose=10uM |
| JF-91-IG96_10uM | Dose=10uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one |
| AE-38-EW82_1uM | Dose=1uM |
| AB-00-IL62_0.01uM | Dose=0.01uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| FE-75-VG41_0.1uM | Dose=0.1uM, Muscarinic M3 Antagonists targeting CHRM3 |
| PA-70-ZC89_0.1uM | Dose=0.1uM |
| GA-13-WB79_0.1uM | Dose=0.1uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| CC-07-DV77_0.1uM | Dose=0.1uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A |
| DC-59-NQ20_0.01uM | Dose=0.01uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| GB-72-BR65_0.01uM | Dose=0.01uM, Opc 14117 |
| DE-29-MT22_10uM | Dose=10uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| S0-EE-Y97N_1uM | Dose=1uM, 4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, ALK2 inhibitor targeting TGFBR2 |
| RF-04-GI28_1uM | Dose=1uM |
| BE-07-IS45_10uM | Dose=10uM, Antalarmin, CRHR1 antagonist targeting CRHR1 |
| GA-16-IU17_1uM | Dose=1uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| IB-23-AO00_10uM | Dose=10uM, 6-Amino-4-[(3-methylphenyl)amino]quinazoline, Inhibitors of Signal Transduction Pathways;Tyrosine Kinase Inhibitors targeting EGFR, TIE1 |
| CB-12-HC20_0.01uM | Dose=0.01uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55 |
| AC-50-JK54_0.01uM | Dose=0.01uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4 |
| YB-54-ET23_0.01uM | Dose=0.01uM, 5-Chloro-2-{2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl}pyridine, JMJD2 Histone Demethylase Inhibitor targeting KDM4C, KDM4E, KDM4B |
| JF-55-EN33_0.1uM | Dose=0.1uM, 3-[6-Amino-5-(3,4,5-Trimethoxyphenyl)pyridin-3-Yl]phenol, ACVRL1 gene inhibitor targeting ACVRL1 |
| TC-02-NZ28_10uM | Dose=10uM |
| DE-69-QQ25_1uM | Dose=1uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| TE-76-FI57_1uM | Dose=1uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2 |
| DB-24-CQ08_1uM | Dose=1uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol |
| BB-28-CT35_0.1uM | Dose=0.1uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ |
| BA-39-LQ60_0.1uM | Dose=0.1uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| UD-09-TN01_10uM | Dose=10uM, Anta XV, Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| GF-58-OL90_0.1uM | Dose=0.1uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| CB-93-YZ07_0.01uM | Dose=0.01uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| AF-76-BV30_0.01uM | Dose=0.01uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| AF-16-IB77_0.1uM | Dose=0.1uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| GD-46-BU97_0.1uM | Dose=0.1uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| GB-90-UG49_0.1uM | Dose=0.1uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B |
| JC-06-ED36_0.1uM | Dose=0.1uM, CDDO-Im, PPARgamma Agonists;Apoptosis Inducers;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Nitric Oxide Production Inhibitors targeting NFE2L2, PPARG, KEAP1 |
| OA-12-SU22_1uM | Dose=1uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| GA-06-UU42_0.01uM | Dose=0.01uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| AE-21-BF25_0.1uM | Dose=0.1uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| JC-52-RH51_1uM | Dose=1uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1 |
| DB-41-IH69_0.1uM | Dose=0.1uM |
| AA-59-HG56_1uM | Dose=1uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B |
| PC-74-OR34_10uM | Dose=10uM, CaV1.3 antagonist-1, CACNA1D calcium channel subunit inhibitor targeting CACNA1D |
| RB-34-TO07_0.1uM | Dose=0.1uM, N'-[4-[[4-[Hydroxybis[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-urea, EHMT2 inhibitor targeting EHMT2 |
| JD-54-BS97_10uM | Dose=10uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO |
| DE-09-HJ53_1uM | Dose=1uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| RC-47-HT31_0.01uM | Dose=0.01uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| DF-00-NA25_0.01uM | Dose=0.01uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES |
| EC-98-YS67_10uM | Dose=10uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| VD-41-XP62_0.1uM | Dose=0.1uM, 3-fluoro-N'-(2-fluorobenzenesulfonyl)-5-(pyridin-2-yl)benzohydrazide targeting KAT6A, KAT6B |
| AE-09-IN08_0.01uM | Dose=0.01uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3 |
| AC-77-BC52_0.01uM | Dose=0.01uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine |
| CB-87-GT98_10uM | Dose=10uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL |
| UD-70-IO77_0.1uM | Dose=0.1uM, 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, PDE10A inhibitor targeting PDE10A |
| UB-79-KN96_10uM | Dose=10uM |
| AB-63-OW35_10uM | Dose=10uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A |
| EA-95-YQ95_0.01uM | Dose=0.01uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6 |
| DE-48-PP80_0.1uM | Dose=0.1uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| RB-42-MC53_10uM | Dose=10uM, 4-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-indol-1-yl}-piperidine-1-carboxylic acid tert-butyl ester, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| EB-83-IM06_10uM | Dose=10uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE |
| RA-53-JG50_1uM | Dose=1uM, (S)-N-(2,6-Dioxopiperidin-3-yl)undec-10-enamide, Broad Spectrum Chemokine Inhibitors (BSCI) targeting CCR2, CRBN |
| DE-79-FD94_0.01uM | Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| GD-39-YG36_10uM | Dose=10uM, CID 137636547 |
| IC-98-UO17_0.1uM | Dose=0.1uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5 |
| S0-EE-Y6YC_10uM | Dose=10uM, N-[5-({[(3-Fluorophenyl)carbamoyl]amino}methyl)-2-Methylphenyl]imidazo[1,2-A]pyridine-3-Carboxamide, DDR2 inhibitor targeting DDR2 |
| DB-80-QN16_0.1uM | Dose=0.1uM, Valpromide |
| VA-39-AQ18_1uM | Dose=1uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R |
| CB-49-OG36_1uM | Dose=1uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1 |
| VB-89-RG34_10uM | Dose=10uM, [(2R)-2-amino-2-methyl-4-[4-[3-(4-phenylphenyl)propanoyl]phenyl]butyl] dihydrogen phosphate, Lysophospholipid Receptor Agonists targeting S1PR1, S1PR5 |
| DE-00-JU18_0.01uM | Dose=0.01uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| IA-38-XE73_10uM | Dose=10uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3 |
| OB-61-XZ91_0.1uM | Dose=0.1uM, Neurotrophic Agents targeting ADA, PNP |
| BC-62-RZ55_0.1uM | Dose=0.1uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4 |
| AB-74-VK99_1uM | Dose=1uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| LD-98-VO32_10uM | Dose=10uM, Gsk2830371, WIP1 inhibitor targeting PPM1D |
| FD-74-LD52_0.01uM | Dose=0.01uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB |
| BC-15-MR23_10uM | Dose=10uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT |
| AD-40-WB93_0.1uM | Dose=0.1uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1 |
| FC-36-SU62_0.1uM | Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| BC-57-KZ72_1uM | Dose=1uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| BD-38-GC64_0.1uM | Dose=0.1uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| JC-99-EF33_10uM | Dose=10uM, 3-({[4-Methyl-5-(Pyridin-4-Yl)-4h-1,2,4-Triazol-3-Yl]methyl}amino)-N-[2-(Trifluoromethyl)benzyl]benzamide, beta adrenergic receptor kinase 1 and 2 targeting GRK2, GRK3, GRK1 |
| S0-EE-Y96U_1uM | Dose=1uM, Jnj-42165279, FAAH inhibitor targeting FAAH |
| FA-10-KQ78_0.01uM | Dose=0.01uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| GB-06-BA49_0.1uM | Dose=0.1uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1 |
| BD-19-MD69_0.01uM | Dose=0.01uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| AA-03-QM41_0.1uM | Dose=0.1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R |
| BA-96-YB32_0.01uM | Dose=0.01uM |
| DD-95-TY80_10uM | Dose=10uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| DB-45-EH09_10uM | Dose=10uM, [[5-Cyano-2-prop-2-ynylsulfanyl-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amino]thiourea, LSD1 inhibitor targeting KDM1A |
| HC-76-SY22_0.01uM | Dose=0.01uM, Sulprostone |
| AC-51-PY60_10uM | Dose=10uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| RE-62-FC93_1uM | Dose=1uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| ND-54-FY31_0.01uM | Dose=0.01uM, 2-Nitrobenzenesulfonamide |
| AD-72-MJ27_0.1uM | Dose=0.1uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| YB-01-IL62_10uM | Dose=10uM, 4-Methyl-3-[(3-nitrophenyl)methyl]-7-pyrimidin-2-yloxychromen-2-one |
| BB-39-YQ35_0.1uM | Dose=0.1uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| LD-22-SA99_1uM | Dose=1uM, (S)-Crizotinib, ALK gene inhibitor,ROS1 gene inhibitor, MET gene inhibitor, NUDT1 gene inhibitor;NUDT1 gene inhibitor targeting NUDT1 |
| ED-05-KX67_0.01uM | Dose=0.01uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| UB-41-DY23_0.1uM | Dose=0.1uM |
| ID-30-NC19_10uM | Dose=10uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R |
| S0-EE-WJKI_1uM | Dose=1uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL |
| KA-50-OP35_0.1uM | Dose=0.1uM |
| HE-11-PK61_1uM | Dose=1uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8 |
| DE-03-NP53_1uM | Dose=1uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| IB-08-VY61_0.01uM | Dose=0.01uM, Rivanicline, Nicotinic alpha4beta2 Agonists;Nicotinic Receptor Agonists targeting CHRNA4, CHRNB2 |
| AC-49-ZR23_0.1uM | Dose=0.1uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| HE-29-OW54_0.1uM | Dose=0.1uM, Camicinal, Motilin Receptor Agonists targeting MLNR |
| BB-74-RX30_10uM | Dose=10uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| GF-16-RR50_10uM | Dose=10uM, Gsk484, PAD4 (Protein-arginine deiminase type-4) substrate competitive reversible inhibitor targeting PADI4 |
| BC-15-BY15_1uM | Dose=1uM |
| NE-37-JX51_0.1uM | Dose=0.1uM |
| AA-67-JI21_0.1uM | Dose=0.1uM, Tryptamine |
| HB-79-CZ36_1uM | Dose=1uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2 |
| HB-24-GP45_1uM | Dose=1uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D |
| LA-86-XT29_0.1uM | Dose=0.1uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2 |
| S0-EE-U3YG_0.01uM | Dose=0.01uM, ACMSD inhibitor targeting ACMSD |
| QB-34-NU46_0.1uM | Dose=0.1uM, (3R,4aR,10aR)-1-methyl-3-[(4-methylpyrimidin-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| JD-58-MV19_1uM | Dose=1uM, mTOR Complex 2 (mTORC2) Inhibitors;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| QB-00-CS87_0.1uM | Dose=0.1uM |
| OD-47-WT51_10uM | Dose=10uM, Ecopipam, selective dopamine D1/D5 receptor antagonist targeting DRD1 |
| LE-39-LB33_1uM | Dose=1uM, Chlorothiazide, SLC12A3 inhibitor;CA4 inhibitor;CA1 inhibitor;CA2 inhibitor targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, SLC12A3, CA5B, CA10 |
| DD-75-HY40_0.1uM | Dose=0.1uM, Celastrol |
| BB-45-NH69_0.01uM | Dose=0.01uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| AE-42-HT01_1uM | Dose=1uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| NC-54-XY91_10uM | Dose=10uM, 1-(4-Chlorophenyl)-5-cyclohexylpyrazolo[3,4-d]pyrimidin-4-one |
| EC-81-BA87_0.01uM | Dose=0.01uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| PC-05-MI00_0.01uM | Dose=0.01uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2 |
| SE-15-AV21_1uM | Dose=1uM, 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea, Eukaryotic Translation Initiation Factor 2-alpha Kinase 1 (HRI) Activators targeting EIF2AK1 |
| QB-00-CS87_0.01uM | Dose=0.01uM |
| BE-36-XE09_0.1uM | Dose=0.1uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| BF-95-KA82_0.1uM | Dose=0.1uM, SOAT-1 inhibitor |
| JC-03-OI01_1uM | Dose=1uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA |
| GA-66-XX49_10uM | Dose=10uM |
| ND-39-PO34_1uM | Dose=1uM, n-(1-Methylbenzo[f]quinazolin-3-yl)guanidine targeting NPY1R, NPFFR1 |
| PD-74-VS77_10uM | Dose=10uM |
| JD-10-HW02_1uM | Dose=1uM |
| BC-43-JW95_0.1uM | Dose=0.1uM, Phenylalanine |
| BB-17-GC12_10uM | Dose=10uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2 |
| S0-EE-Y96U_0.01uM | Dose=0.01uM, Jnj-42165279, FAAH inhibitor targeting FAAH |
| CA-48-SW47_0.01uM | Dose=0.01uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| EC-08-AP40_1uM | Dose=1uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP |
| XA-88-GW50_10uM | Dose=10uM |
| GE-28-EL65_0.01uM | Dose=0.01uM, 3-O-Methyldopa, DL- |
| BC-22-DS93_10uM | Dose=10uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| AC-45-EE32_0.1uM | Dose=0.1uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| FE-16-UK58_1uM | Dose=1uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| BB-08-WM33_10uM | Dose=10uM, AM 281, CNR1 antagonist targeting CNR1 |
| EA-17-BY69_0.1uM | Dose=0.1uM |
| BD-78-MJ16_0.1uM | Dose=0.1uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| GB-39-OF03_0.01uM | Dose=0.01uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| CC-04-YT10_0.01uM | Dose=0.01uM |
| PA-15-CI45_10uM | Dose=10uM, ethyl 4-[[(2S)-2-aminopropanoyl]amino]-5-[4-(3,5-dichlorophenyl)phenyl]-2,3-dihydroxypentanoate, Ubiquitin-Conjugating Enzyme E2 R1 (CDC34) Inhibitors targeting CDC34 |
| SB-94-ZA83_1uM | Dose=1uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| JD-38-MY26_0.1uM | Dose=0.1uM, FTY720 (R)-Phosphate, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR1, S1PR3, S1PR4 |
| HE-16-PO98_0.01uM | Dose=0.01uM, Azd-5153, inhibitor of BRD4 targeting BRD4 |
| AB-40-HA80_10uM | Dose=10uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| XE-45-YU38_1uM | Dose=1uM |
| SA-63-NG30_0.1uM | Dose=0.1uM, N-[4-(3-Chlorophenyl)-5-(2-chlorobenzoyl)thiazole-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, Retinoid receptor modulator targeting RORB, RORC |
| BE-45-XA42_0.1uM | Dose=0.1uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1 |
| BC-34-IH52_0.01uM | Dose=0.01uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| QF-09-IK44_0.01uM | Dose=0.01uM, Aryl carbamate analog 1 |
| HC-94-AQ98_0.01uM | Dose=0.01uM, Roxadustat, hypoxia-inducible factor prolyl hydroxylase inhibitor targeting EGLN1, EGLN2, EGLN3 |
| DA-05-NN93_1uM | Dose=1uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| WF-31-RY78_0.01uM | Dose=0.01uM, (3H)granisetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| OB-28-LD05_0.01uM | Dose=0.01uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid |
| GA-43-FL03_0.01uM | Dose=0.01uM, Aliskiren, Renin Inhibitors targeting REN |
| UC-20-ZV24_1uM | Dose=1uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4 |
| PA-93-BD53_1uM | Dose=1uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC |
| AD-31-GO06_1uM | Dose=1uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| EF-01-LB20_0.1uM | Dose=0.1uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| KE-47-IA01_0.01uM | Dose=0.01uM, Pci-34051, HDAC8 inhibitor targeting HDAC8 |
| DD-42-PC65_0.1uM | Dose=0.1uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| PA-84-RB96_10uM | Dose=10uM, 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one |
| BD-85-VR28_0.01uM | Dose=0.01uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol |
| OE-18-ZX28_10uM | Dose=10uM |
| BA-34-BQ43_1uM | Dose=1uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB |
| EA-90-PK44_1uM | Dose=1uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| DC-02-OP01_0.01uM | Dose=0.01uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5 |
| IA-76-YQ42_0.01uM | Dose=0.01uM, 2-{[4-(dimethylamino)benzene](2-methylpropyl)sulfonamido}-N-hydroxyacetamide |
| DE-27-WV87_0.1uM | Dose=0.1uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| FF-61-PA27_10uM | Dose=10uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD |
| QB-29-GK19_0.01uM | Dose=0.01uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL |
| AA-98-FJ71_0.1uM | Dose=0.1uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| HC-76-SY22_0.1uM | Dose=0.1uM, Sulprostone |
| VB-48-KG22_1uM | Dose=1uM, 6,8-Dimercapto-2-hydroxypurine |
| JD-48-EV39_1uM | Dose=1uM, Xanthenone-4-acetic acid |
| BC-30-IU38_10uM | Dose=10uM, N-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide, Apoptosis Inducers;IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKG |
| AB-90-YR46_10uM | Dose=10uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| GA-01-EO66_0.1uM | Dose=0.1uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1 |
| CB-12-HC20_10uM | Dose=10uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55 |
| QE-35-YE15_10uM | Dose=10uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine |
| GA-51-DD14_10uM | Dose=10uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| HD-28-QL60_10uM | Dose=10uM, (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine, Na+/H+ Exchanger type 3 (NHE-3) Inhibitors targeting SLC9A3 |
| LB-76-JJ80_0.1uM | Dose=0.1uM, 1H-Isoindol-1-one, 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| BD-39-KG21_10uM | Dose=10uM, Selegiline, MAO-B Inhibitors targeting MAOB |
| DA-39-AJ98_0.1uM | Dose=0.1uM, Metylperon, DRD2 antagonist targeting DRD2 |
| GB-16-SU72_10uM | Dose=10uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| DE-69-QQ25_0.01uM | Dose=0.01uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| GC-42-LL86_0.01uM | Dose=0.01uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| EE-60-CG74_1uM | Dose=1uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| YE-02-BO16_0.1uM | Dose=0.1uM, 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester, Anxiolytics targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| FE-64-KC49_0.01uM | Dose=0.01uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| AA-72-QI84_10uM | Dose=10uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| FA-70-ZG69_0.1uM | Dose=0.1uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| OB-28-LD05_1uM | Dose=1uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid |
| GF-03-HI41_0.01uM | Dose=0.01uM, RS 39604, HTR4 antagonist targeting HTR4 |
| BA-40-IU73_0.1uM | Dose=0.1uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR |
| SF-77-LC15_1uM | Dose=1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-10,10-dimethyl-2-oxa-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| OF-32-PT74_0.01uM | Dose=0.01uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene |
| ID-12-GA19_0.1uM | Dose=0.1uM, Apoptosis Inducers;Polyamine Oxidase Inhibitors targeting SMOX |
| ME-77-XX06_10uM | Dose=10uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide |
| JA-82-EV20_10uM | Dose=10uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1 |
| BD-40-EK64_10uM | Dose=10uM, Terbuficin, LDL Antioxidants targeting ABCA1 |
| HA-99-UT82_0.01uM | Dose=0.01uM |
| QF-09-IK44_10uM | Dose=10uM, Aryl carbamate analog 1 |
| AB-96-JV50_1uM | Dose=1uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2 |
| CC-88-JZ09_0.1uM | Dose=0.1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| DA-18-QP05_1uM | Dose=1uM |
| BA-16-AB67_0.1uM | Dose=0.1uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| BA-02-RI19_0.1uM | Dose=0.1uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| JF-30-FM28_10uM | Dose=10uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1 |
| FB-67-PL18_10uM | Dose=10uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| FC-20-EQ58_0.1uM | Dose=0.1uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| JE-11-UD64_0.01uM | Dose=0.01uM, 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-, Dopamine D3 Agonists targeting DRD3 |
| AE-06-FY47_1uM | Dose=1uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| YC-45-JD42_0.1uM | Dose=0.1uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate |
| EC-14-UM93_1uM | Dose=1uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| UF-55-NA30_1uM | Dose=1uM, 3-[[2-(3-Aminophenyl)-[1,3]oxazolo[5,4-d]pyrimidin-7-yl]amino]phenol |
| BB-69-YQ35_0.1uM | Dose=0.1uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| EB-11-MR93_10uM | Dose=10uM, 7beta,25-Dihydroxycholesterol |
| AE-05-GR23_10uM | Dose=10uM, Gnf-5, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, ABL2 |
| AB-92-LS83_0.01uM | Dose=0.01uM, Flurbiprofen targeting SC5D |
| NB-21-MW29_0.01uM | Dose=0.01uM |
| UF-44-NQ36_0.1uM | Dose=0.1uM, Argipressin tannate, AVPR1A agonist targeting AVPR1A |
| EE-47-TB79_10uM | Dose=10uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-[2-(4-methoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein 7 Inhibitors targeting KLK7 |
| GA-48-JB51_10uM | Dose=10uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B |
| AE-42-HT01_0.01uM | Dose=0.01uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| FE-69-HJ93_0.1uM | Dose=0.1uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| BA-98-JJ31_1uM | Dose=1uM, Quinine |
| RD-37-PW33_1uM | Dose=1uM, BAX activator targeting BAX |
| EF-83-OP68_10uM | Dose=10uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR |
| CD-70-GD72_1uM | Dose=1uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CF-82-FS38_1uM | Dose=1uM |
| KB-85-KP82_0.01uM | Dose=0.01uM, Sch 33303, Mediator Release Inhibitors;Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1 |
| GB-64-HC34_1uM | Dose=1uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| FF-90-JK74_0.01uM | Dose=0.01uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A |
| DA-11-GV88_10uM | Dose=10uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| RE-62-FC93_0.1uM | Dose=0.1uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| XA-88-GW50_0.1uM | Dose=0.1uM |
| EE-99-ZM45_0.1uM | Dose=0.1uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H |
| BC-19-GQ25_10uM | Dose=10uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC |
| PC-49-XP02_10uM | Dose=10uM |
| GB-90-UG49_10uM | Dose=10uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B |
| AC-49-ZR23_0.01uM | Dose=0.01uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| BA-90-AA10_0.01uM | Dose=0.01uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| KC-48-OO62_1uM | Dose=1uM, PKC theta inhibitor targeting PRKCQ |
| JD-54-BS97_0.1uM | Dose=0.1uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO |
| WC-67-DI84_0.1uM | Dose=0.1uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide |
| BB-82-TP51_0.01uM | Dose=0.01uM, Tegobuvir |
| CA-31-EL19_10uM | Dose=10uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM |
| DA-27-BW20_1uM | Dose=1uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| DA-62-QB27_0.01uM | Dose=0.01uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| AE-28-IQ88_0.1uM | Dose=0.1uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| FA-47-JB44_0.1uM | Dose=0.1uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183 |
| DA-35-ZK21_0.01uM | Dose=0.01uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| OB-46-IM27_1uM | Dose=1uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide |
| BB-19-ZK81_0.1uM | Dose=0.1uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH |
| UE-76-JL04_1uM | Dose=1uM |
| AD-12-YF12_10uM | Dose=10uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2 |
| JA-42-NH96_0.1uM | Dose=0.1uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS |
| CC-90-FE70_0.01uM | Dose=0.01uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| EF-22-PB37_0.01uM | Dose=0.01uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| PE-69-DO79_0.1uM | Dose=0.1uM, N-phenylaminosulfonamide, carbonic anhydrase inhibitor targeting CA1 |
| BA-41-VY30_10uM | Dose=10uM, 2-methyl-5-HT targeting HTR1F |
| FB-99-SM50_0.1uM | Dose=0.1uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| FE-82-WB22_0.01uM | Dose=0.01uM, MRT67307 HCl targeting ULK1 |
| KE-86-QG38_10uM | Dose=10uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-thiomorpholin-4-ylimidazo[1,2-a]pyridin-8-amine, dipeptidyl-peptidase II (DPP7) inhibitor;Fibroblast Activation Protein alpha subunit (FAP) Inhibitor;dipeptidyl-peptidase IV (DPP4) inhibitor targeting DPP4 |
| HA-29-PM90_0.01uM | Dose=0.01uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| BD-38-GC64_10uM | Dose=10uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| FD-88-CF51_0.01uM | Dose=0.01uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| AD-91-LE02_1uM | Dose=1uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| RE-99-TA30_0.01uM | Dose=0.01uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R |
| CD-20-GE75_0.01uM | Dose=0.01uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| AC-73-DW50_0.01uM | Dose=0.01uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| BA-52-FW03_1uM | Dose=1uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| SC-25-HE80_1uM | Dose=1uM, 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-methylphenyl]-3-(trifluoromethyl)benzamide, DDR tyrosine kinase receptor inhibitor targeting DDR1, DDR2 |
| AC-43-ZC52_10uM | Dose=10uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3 |
| AA-97-XP63_10uM | Dose=10uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4 |
| ZB-93-OS38_10uM | Dose=10uM, 1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine |
| BF-61-IO76_0.01uM | Dose=0.01uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| QA-67-IM54_0.1uM | Dose=0.1uM, CID 118626505 |
| TC-66-CI47_1uM | Dose=1uM |
| DA-66-OE69_0.01uM | Dose=0.01uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| JB-65-ON98_10uM | Dose=10uM |
| PA-57-FX61_0.1uM | Dose=0.1uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide |
| FE-16-UK58_0.1uM | Dose=0.1uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| OA-15-DB28_0.01uM | Dose=0.01uM |
| AF-23-RM26_0.1uM | Dose=0.1uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR |
| CC-18-YW57_0.1uM | Dose=0.1uM |
| KB-77-BA46_10uM | Dose=10uM, 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide, p38 MAPK Inhibitors targeting MAPK14 |
| HB-51-FH64_0.01uM | Dose=0.01uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3 |
| DD-55-AU25_0.1uM | Dose=0.1uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| HB-13-XB94_0.1uM | Dose=0.1uM, Basimglurant, MGLUR5 NAM targeting GRM5 |
| HE-10-QN66_0.1uM | Dose=0.1uM, Cytoxazone |
| AA-10-BH32_10uM | Dose=10uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP |
| HE-14-AT80_0.1uM | Dose=0.1uM, Filgotinib targeting JAK1, JAK2, JAK3, TYK2 |
| CA-48-JF51_0.1uM | Dose=0.1uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| EA-61-RR63_1uM | Dose=1uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| RF-36-EI47_0.01uM | Dose=0.01uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2 |
| BC-20-WA90_0.1uM | Dose=0.1uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| LE-55-RW34_10uM | Dose=10uM, [(E)-[9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-ylidene]amino] 5-bromothiophene-2-carboxylate, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TNF-alpha Production Inhibitors targeting PTGS1, PTGS2 |
| DD-28-MZ39_10uM | Dose=10uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO |
| EA-33-QC97_1uM | Dose=1uM |
| BA-59-EN38_1uM | Dose=1uM |
| CB-46-FO63_10uM | Dose=10uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| VD-08-TC47_1uM | Dose=1uM, Tesaglitazar, PPARgamma Agonists;Insulin Sensitizers;PPARalpha Agonists targeting PPARA, PPARG |
| ZE-46-XH09_0.1uM | Dose=0.1uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide |
| DF-32-EL16_0.1uM | Dose=0.1uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1 |
| CA-43-WF29_1uM | Dose=1uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| CA-66-FY97_1uM | Dose=1uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| S0-EE-XXLY_1uM | Dose=1uM, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(3S)-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]urea, CDK8 inhibitor targeting CDK8 |
| DA-33-CW45_0.01uM | Dose=0.01uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2 |
| BF-41-MV83_0.01uM | Dose=0.01uM, Edaravone |
| DB-62-ES23_10uM | Dose=10uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| SD-51-LL22_1uM | Dose=1uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1 |
| XD-44-FJ34_0.01uM | Dose=0.01uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| AC-78-GT35_10uM | Dose=10uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1 |
| EB-09-JJ93_1uM | Dose=1uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A |
| MC-60-AC74_10uM | Dose=10uM, 1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid, IGFBP1-6 Inhibitor targeting IGFBP4 |
| FE-16-UK58_0.01uM | Dose=0.01uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| FD-67-GI76_1uM | Dose=1uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2 |
| UE-90-AA63_1uM | Dose=1uM |
| EA-40-KQ08_10uM | Dose=10uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| EA-25-VD74_10uM | Dose=10uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| ME-62-IQ37_1uM | Dose=1uM, WY 47288, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| IB-80-NT15_1uM | Dose=1uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| KE-93-TR02_10uM | Dose=10uM, Emate, Steryl Sulfatase Inhibitors;Estrogen Receptor (ER) Agonists targeting STS |
| AC-00-KV26_10uM | Dose=10uM, N,N,N-trimethylglycinium |
| ED-25-BD54_0.01uM | Dose=0.01uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| FE-22-JV50_0.1uM | Dose=0.1uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD |
| AB-17-WP43_0.1uM | Dose=0.1uM, Loperamide, mu-Opioid Agonists targeting OPRM1 |
| AF-31-RV78_10uM | Dose=10uM, targeting NOS3, PAH, TH, TPH1 |
| LB-67-FA06_1uM | Dose=1uM |
| ID-31-PA82_0.01uM | Dose=0.01uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1 |
| HA-82-XO48_10uM | Dose=10uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK |
| JC-24-MC69_0.1uM | Dose=0.1uM, [4-(4-Phenylphenyl)-1-triazolyl]-(1-pyrrolidinyl)methanone, Acylaminoacyl peptidase inhibitor targeting APEH |
| ID-70-SM63_0.1uM | Dose=0.1uM, Masoprocol, IGF-1R Phosphorylation Inhibitors;ER stress inducer;Lipoxygenase Inhibitors targeting ALOX5, ALOX15 |
| CE-52-XV55_0.1uM | Dose=0.1uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A |
| FA-90-DR66_10uM | Dose=10uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| EC-56-YK73_10uM | Dose=10uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2 |
| MF-41-QM60_1uM | Dose=1uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9 |
| AD-83-MW95_0.01uM | Dose=0.01uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| BB-73-ZW70_10uM | Dose=10uM |
| DD-30-SX80_0.1uM | Dose=0.1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| YF-57-HO38_10uM | Dose=10uM, Abecarnil, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB3, GABRG2 |
| JB-65-ON98_0.01uM | Dose=0.01uM |
| BC-02-WF67_0.1uM | Dose=0.1uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2 |
| NE-29-VB58_1uM | Dose=1uM, L 692429, GHS Receptor Antagonists;GHSR agonist targeting GHSR |
| FD-29-MM50_0.01uM | Dose=0.01uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| XD-68-MP63_10uM | Dose=10uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine |
| BD-15-VR68_0.1uM | Dose=0.1uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1 |
| LF-64-NB46_10uM | Dose=10uM, Fti 277, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| AE-94-ZD47_0.1uM | Dose=0.1uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| HC-95-WQ65_0.1uM | Dose=0.1uM, Monomethyl Fumarate |
| OF-47-EQ74_1uM | Dose=1uM |
| BE-45-VH04_0.1uM | Dose=0.1uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate |
| JC-67-FV32_10uM | Dose=10uM, 4-[4-(2-Pyrrolidin-1-ylethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine-6-carboxamide targeting SIRT2, SIRT3, SIRT1 |
| IF-75-AJ33_1uM | Dose=1uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1 |
| YE-45-AD07_10uM | Dose=10uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS |
| UA-56-RO11_0.01uM | Dose=0.01uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3 |
| AB-11-MO96_0.1uM | Dose=0.1uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| AA-77-MP68_10uM | Dose=10uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| EC-37-MB09_0.01uM | Dose=0.01uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| LB-67-FA06_0.01uM | Dose=0.01uM |
| EB-92-TL51_0.01uM | Dose=0.01uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| S0-EE-WHDK_0.1uM | Dose=0.1uM, 2-(6-aminopurin-9-yl)-N-[(4-sulfamoylphenyl)methyl]acetamide targeting CA2, CA9 |
| ED-02-CL76_0.1uM | Dose=0.1uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT |
| FE-10-KQ78_0.01uM | Dose=0.01uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| EE-45-YQ15_10uM | Dose=10uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7 |
| CE-77-JB44_10uM | Dose=10uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| EE-32-EY37_0.01uM | Dose=0.01uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2 |
| CB-68-SP90_0.1uM | Dose=0.1uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| NC-01-ET52_1uM | Dose=1uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD |
| AA-30-BE85_1uM | Dose=1uM, 4,7-Dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one, EWS-FLI1 Inhibitors targeting EWSR1, FLI1 |
| ID-31-PA82_1uM | Dose=1uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1 |
| LE-65-RW44_1uM | Dose=1uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3 |
| OE-31-YC41_0.01uM | Dose=0.01uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2 |
| HF-76-AK33_0.1uM | Dose=0.1uM, VU0409551, GRM5 positive allosteric modulator targeting GRM5 |
| QF-71-QI30_1uM | Dose=1uM, 4-Dimethylamino-N-(7-hydroxycarbamoyl-heptyl)-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| UF-55-NA30_0.1uM | Dose=0.1uM, 3-[[2-(3-Aminophenyl)-[1,3]oxazolo[5,4-d]pyrimidin-7-yl]amino]phenol |
| FD-88-CF51_10uM | Dose=10uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| OF-28-PH15_1uM | Dose=1uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3 |
| AE-90-RS19_0.01uM | Dose=0.01uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5 |
| HD-26-KX74_0.01uM | Dose=0.01uM |
| DE-48-HZ49_0.1uM | Dose=0.1uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2 |
| AC-73-DW50_0.1uM | Dose=0.1uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| XC-50-TN39_10uM | Dose=10uM |
| SD-12-UF05_1uM | Dose=1uM, Phenylsulfamate, Carbonic anhydrase inhibitor targeting CA2 |
| CA-68-TC79_0.01uM | Dose=0.01uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| BC-57-KZ72_0.01uM | Dose=0.01uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| DD-30-SX80_1uM | Dose=1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| AA-01-XV28_0.01uM | Dose=0.01uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| NC-73-QU79_0.1uM | Dose=0.1uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| S0-EE-Y6Y9_10uM | Dose=10uM, 6-chloro-N-(1-ethylpiperidin-4-yl)-1,2,3,4-tetrahydroacridin-9-amine |
| BB-05-NK66_10uM | Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| CF-03-QN99_0.1uM | Dose=0.1uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8 |
| UE-90-AA63_0.01uM | Dose=0.01uM |
| CB-24-FA25_0.01uM | Dose=0.01uM, Spiperone |
| FA-71-UB40_0.01uM | Dose=0.01uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid |
| UB-28-WW60_10uM | Dose=10uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol |
| CE-18-AP15_0.1uM | Dose=0.1uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BB-32-IZ10_1uM | Dose=1uM |
| RA-03-RQ19_0.01uM | Dose=0.01uM, 3-(6-fluoropyridin-3-yl)-2-(4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)pyridine, QPCT inhibitor targeting QPCT |
| HE-84-SC79_1uM | Dose=1uM |
| S0-EE-XZUM_1uM | Dose=1uM, targeting KDM5B, KDM4B, KDM5A |
| DB-21-FY25_10uM | Dose=10uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| BD-50-HU68_1uM | Dose=1uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2 |
| DB-40-HA40_1uM | Dose=1uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| ME-60-RF56_0.1uM | Dose=0.1uM, N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]benzamide, Serotonin Antagonists targeting HTR1A |
| YC-32-MB85_10uM | Dose=10uM, N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Inhibitors of Signal Transduction Pathways;Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2 |
| DA-83-IZ87_10uM | Dose=10uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| AB-70-GR31_1uM | Dose=1uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| BC-02-SI44_10uM | Dose=10uM, Importazole, Importin beta inhibitor targeting KPNB1 |
| CD-90-SN76_1uM | Dose=1uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1 |
| GD-59-OG21_0.01uM | Dose=0.01uM, Stavudine |
| IC-98-UO17_1uM | Dose=1uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5 |
| AD-16-OE34_10uM | Dose=10uM, Octopamine |
| UF-85-NE30_0.01uM | Dose=0.01uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile |
| XA-88-GW50_1uM | Dose=1uM |
| LC-42-WU67_0.1uM | Dose=0.1uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3 |
| FD-81-SU40_10uM | Dose=10uM, Methoxyamine |
| QF-05-OL72_10uM | Dose=10uM |
| EF-52-ML96_10uM | Dose=10uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2 |
| LD-37-JE11_0.1uM | Dose=0.1uM, SR7826, Limk1 inhibitor targeting LIMK1 |
| SD-15-WR01_1uM | Dose=1uM, 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoic acid, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| JF-25-NM40_10uM | Dose=10uM |
| HE-18-HV99_10uM | Dose=10uM |
| CB-88-LG34_1uM | Dose=1uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| AA-02-FS13_10uM | Dose=10uM, Benzylhydrazine |
| MD-17-VD78_1uM | Dose=1uM |
| FA-36-VA24_0.1uM | Dose=0.1uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea |
| JA-98-CL60_0.1uM | Dose=0.1uM, 2-Acetamido-3-[[1,4,4a,5,6,6a,7,12,12a,12b-decahydro-4a,8,12a,12b-tetrahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracene-6a-yl]thio]propionic acid, Endothelin Receptor Antagonists targeting EDNRA |
| JA-26-YQ32_1uM | Dose=1uM, Bentiromide, Pancreatic trypsin inhibitor targeting HPN |
| FF-06-MA64_0.1uM | Dose=0.1uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1 |
| UB-76-QL04_10uM | Dose=10uM, 3-[[2-[6-(2-methoxyethylamino)pyrimidin-4-yl]-1,2,4-triazol-3-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide |
| FA-56-WH26_0.1uM | Dose=0.1uM, Venglustat targeting UGCG |
| DA-42-BI19_1uM | Dose=1uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB |
| DE-48-PP80_10uM | Dose=10uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| AA-56-JY17_10uM | Dose=10uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1 |
| AB-05-FB25_0.1uM | Dose=0.1uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1 |
| PA-57-FX61_0.01uM | Dose=0.01uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide |
| DB-82-PI34_0.01uM | Dose=0.01uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4 |
| CD-07-GB34_10uM | Dose=10uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F |
| OB-28-LD05_0.1uM | Dose=0.1uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid |
| LC-57-RH78_10uM | Dose=10uM, K(ATP) Channel Blockers targeting ABCC8, ABCC9, KCNJ8, KCNJ11 |
| LA-93-IR67_0.1uM | Dose=0.1uM, N-(6-Tetradecanamidobenzo[d]thiazol-2-yl)benzamide, Ceramide Kinase Inhibitors targeting CERK |
| DB-34-QA60_1uM | Dose=1uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| DD-30-SX80_0.01uM | Dose=0.01uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| AD-65-WK61_0.1uM | Dose=0.1uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P |
| BC-26-LE04_0.1uM | Dose=0.1uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| HB-36-FN80_0.1uM | Dose=0.1uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AD-55-WK61_10uM | Dose=10uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1 |
| BD-38-GC64_0.01uM | Dose=0.01uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| AA-38-TT50_10uM | Dose=10uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| LF-14-KL05_10uM | Dose=10uM, 1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamine, Urotensin II receptor inhibitor targeting UTS2R |
| AB-41-IO16_0.1uM | Dose=0.1uM |
| CE-18-AP85_1uM | Dose=1uM |
| EC-34-FT85_10uM | Dose=10uM, Nibr-0213 targeting S1PR1 |
| PA-70-ZC89_10uM | Dose=10uM |
| BB-03-FT18_10uM | Dose=10uM, Tmp269 targeting HDAC9, HDAC4, HDAC5, HDAC7 |
| TA-57-FF07_1uM | Dose=1uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl |
| ME-73-FK70_0.1uM | Dose=0.1uM, 5-Iodo-6-amino-1,2-benzopyrone, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| IC-23-YE16_1uM | Dose=1uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide |
| JC-96-ID26_0.1uM | Dose=0.1uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A |
| ED-31-AA47_10uM | Dose=10uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2 |
| GF-46-LK68_0.1uM | Dose=0.1uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2 |
| BA-77-NI61_0.01uM | Dose=0.01uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine |
| AF-48-FX20_1uM | Dose=1uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| YD-21-ZR41_1uM | Dose=1uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2 |
| SA-63-NG30_10uM | Dose=10uM, N-[4-(3-Chlorophenyl)-5-(2-chlorobenzoyl)thiazole-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, Retinoid receptor modulator targeting RORB, RORC |
| JC-47-KK95_0.1uM | Dose=0.1uM, 4-(2-Cyano-5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid |
| S0-EE-Y96T_1uM | Dose=1uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A |
| FE-75-VG41_0.01uM | Dose=0.01uM, Muscarinic M3 Antagonists targeting CHRM3 |
| CA-61-VV83_0.01uM | Dose=0.01uM |
| GD-39-YG36_0.01uM | Dose=0.01uM, CID 137636547 |
| LC-54-XS57_1uM | Dose=1uM |
| LA-21-GQ75_1uM | Dose=1uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR |
| AA-14-DQ28_0.01uM | Dose=0.01uM, Estradiol |
| GF-72-OO48_0.1uM | Dose=0.1uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| FE-29-XM40_1uM | Dose=1uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2 |
| LA-69-OL77_0.1uM | Dose=0.1uM, 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one, NR2B Antagonists targeting GRIN2B |
| CA-56-GE89_1uM | Dose=1uM, 7-Deaza-2'-C-ethynyladenosine |
| MB-53-WO35_10uM | Dose=10uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5 |
| AA-42-XZ05_0.01uM | Dose=0.01uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4 |
| JB-89-SI60_1uM | Dose=1uM, (3s,5r)-N-{[9-(4-Methoxybutyl)-9h-Xanthen-9-Yl]methyl}-5-{[(4-Methylphenyl)sulfonyl]amino}piperidine-3-Carboxamide, Renin Inhibitors targeting REN |
| S0-EE-YRH3_0.1uM | Dose=0.1uM, [3-[[4-(aminomethyl)-1-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate, LIMK2 gene inhibitor;LIMK1 gene inhibitor targeting LIMK1, LIMK2 |
| ME-11-OJ38_0.01uM | Dose=0.01uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4 |
| MF-65-HS14_1uM | Dose=1uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one |
| BF-41-MV83_0.1uM | Dose=0.1uM, Edaravone |
| AC-71-YF45_1uM | Dose=1uM |
| BA-46-QO78_0.1uM | Dose=0.1uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| CB-38-AW77_10uM | Dose=10uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1 |
| ID-43-YL08_1uM | Dose=1uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3 |
| AB-79-ZD24_0.1uM | Dose=0.1uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4 |
| GE-84-VZ24_0.1uM | Dose=0.1uM, 8-[5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chroman-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one, Phospholipase A2 (PLA2) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PLA2G10 |
| CD-35-BD44_1uM | Dose=1uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| IF-81-QQ90_0.1uM | Dose=0.1uM, Dmppo, Phosphodiesterase Inhibitors targeting PDE5A |
| NC-27-AD53_0.01uM | Dose=0.01uM, Azd-1480, Jak2 Inhibitors targeting JAK1, JAK2 |
| EB-44-GM58_0.1uM | Dose=0.1uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| EB-98-OI08_1uM | Dose=1uM |
| FD-67-GI76_0.01uM | Dose=0.01uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2 |
| FA-94-QJ71_10uM | Dose=10uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1 |
| UE-50-KK32_0.1uM | Dose=0.1uM, 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile |
| TD-57-NZ75_0.1uM | Dose=0.1uM |
| AC-45-YY00_1uM | Dose=1uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol |
| KD-88-RE18_1uM | Dose=1uM |
| CF-68-DM58_1uM | Dose=1uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| SB-28-EJ14_0.1uM | Dose=0.1uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2 |
| DB-78-NM13_10uM | Dose=10uM, Telenzepine, CHRM1 antagonist targeting CHRM1 |
| EC-18-TF61_10uM | Dose=10uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1 |
| GB-33-FW25_0.1uM | Dose=0.1uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT |
| BB-45-NH69_0.1uM | Dose=0.1uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| ME-60-RF56_1uM | Dose=1uM, N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]benzamide, Serotonin Antagonists targeting HTR1A |
| AD-20-YO14_0.1uM | Dose=0.1uM, Ars-1620 targeting KRAS |
| KC-36-DK23_0.1uM | Dose=0.1uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1 |
| CA-72-UL91_0.1uM | Dose=0.1uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| GF-19-NZ91_0.1uM | Dose=0.1uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| TC-94-QN39_1uM | Dose=1uM, Iferanserin |
| GC-81-IA52_10uM | Dose=10uM, 2-(2-hydroxy-(1,1'-biphenyl)-3-yl)-1H-1,3-benzodiazole-5-carboximidamide, Urokinase (u-PA) Inhibitors;Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting F2, PLAT, PLAU, F10, PLG |
| AE-37-MC27_10uM | Dose=10uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| VD-08-TC47_0.1uM | Dose=0.1uM, Tesaglitazar, PPARgamma Agonists;Insulin Sensitizers;PPARalpha Agonists targeting PPARA, PPARG |
| MD-09-FE75_0.1uM | Dose=0.1uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2 |
| GA-66-XX49_1uM | Dose=1uM |
| KA-75-LP02_0.01uM | Dose=0.01uM |
| BA-74-BQ33_0.1uM | Dose=0.1uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG |
| FA-10-KQ78_1uM | Dose=1uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| CA-48-SW47_1uM | Dose=1uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| LE-65-RW44_0.1uM | Dose=0.1uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3 |
| EF-85-DA07_0.01uM | Dose=0.01uM |
| MF-20-QI53_1uM | Dose=1uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2 |
| BD-60-ZK54_10uM | Dose=10uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| AE-43-WW30_10uM | Dose=10uM, Hyoscyamine, Muscarinic receptor antagonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| DD-61-DY35_10uM | Dose=10uM |
| ME-73-FK70_0.01uM | Dose=0.01uM, 5-Iodo-6-amino-1,2-benzopyrone, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| RB-34-TO07_1uM | Dose=1uM, N'-[4-[[4-[Hydroxybis[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-urea, EHMT2 inhibitor targeting EHMT2 |
| JB-82-SK68_0.1uM | Dose=0.1uM, Oxyfenthiin |
| FB-56-IR20_0.1uM | Dose=0.1uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2 |
| ED-39-VX22_1uM | Dose=1uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| ZE-58-ZZ82_0.01uM | Dose=0.01uM |
| DF-95-CY55_0.01uM | Dose=0.01uM |
| RC-47-HT31_10uM | Dose=10uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| JA-95-PQ25_1uM | Dose=1uM, Tocopherol Nicotinate |
| KC-99-BS89_1uM | Dose=1uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine |
| TC-32-HZ53_0.1uM | Dose=0.1uM, N-[2-[2-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetamide, CCR1 antagonist targeting CCR1 |
| DD-65-SA37_10uM | Dose=10uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4 |
| VA-57-TF22_10uM | Dose=10uM |
| S0-EE-XMWH_0.01uM | Dose=0.01uM, 4-[4-(1-Benzofuran-5-Yl)phenyl]-5-{[(3s)-1-(Cyclopropylcarbonyl)pyrrolidin-3-Yl]methyl}-2,4-Dihydro-3h-1,2,4-Triazol-3-One, FAS inhibitor targeting FASN |
| WD-73-QC55_1uM | Dose=1uM, Pirenoxine |
| DF-57-FI46_0.1uM | Dose=0.1uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1 |
| FE-75-VG41_1uM | Dose=1uM, Muscarinic M3 Antagonists targeting CHRM3 |
| NE-37-JX51_1uM | Dose=1uM |
| BC-88-KT45_1uM | Dose=1uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| AC-24-NX95_10uM | Dose=10uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| BB-49-OQ60_10uM | Dose=10uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12 |
| ND-57-WU44_10uM | Dose=10uM, (2S,3R,4R)-3-hydroxy-4-[(4-phenylphenyl)methoxy]pyrrolidine-2-carboxylic acid, Anti-ASCT2 (Neutral Amino Acid Transporter) targeting SLC1A4, SLC1A5 |
| HA-22-CY42_0.01uM | Dose=0.01uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DB-40-GN91_1uM | Dose=1uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| OE-23-XH48_1uM | Dose=1uM, Glpg-1837, CFTR modulator targeting CFTR |
| EE-16-RH01_0.1uM | Dose=0.1uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3 |
| GF-57-LR72_1uM | Dose=1uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| ND-85-OJ63_0.1uM | Dose=0.1uM, Ezutromid, UTRN (Utrophin gene) Expression Enhancers targeting AHR |
| HA-08-IL05_10uM | Dose=10uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| ZB-42-PL54_1uM | Dose=1uM |
| AC-92-HS43_10uM | Dose=10uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4 |
| AB-02-CF97_0.1uM | Dose=0.1uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| YA-52-FO46_10uM | Dose=10uM, N-(2-chlorobenzyl)-2-(N-(4-isobutoxy-3-methoxybenzyl)-4-((4-methylpiperazin-1-yl)methyl)phenylsulfonamido)acetamide, BDKRB1 antagonist;Non-Opioid Analgesics targeting BDKRB1 |
| EB-89-KM10_0.01uM | Dose=0.01uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| KA-14-VZ39_10uM | Dose=10uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3 |
| UB-83-HM84_0.1uM | Dose=0.1uM, Dexamethasone Pivalate |
| PC-86-EW46_0.01uM | Dose=0.01uM, FG-2216, EGLN1 gene inhibitor targeting EGLN1, P4HA1, P4HB, P4HA2, P4HA3 |
| JB-28-VO37_0.1uM | Dose=0.1uM, 7-[(1R)-2-[[(1R,2R)-2-(3-ethoxyphenyl)cyclopentyl]amino]-1-hydroxyethyl]-4-hydroxy-3H-1,3-benzothiazol-2-one |
| TD-09-SX65_0.01uM | Dose=0.01uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2 |
| GA-61-GX82_0.1uM | Dose=0.1uM, Abeorphine |
| CE-24-LQ98_0.1uM | Dose=0.1uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide |
| OA-80-YT10_0.01uM | Dose=0.01uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3 |
| LA-24-RZ79_10uM | Dose=10uM, (2S,3R,4R,5S,6R)-2-[4-cyclopropyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2 |
| GD-72-XO18_0.01uM | Dose=0.01uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| AA-77-RI81_0.01uM | Dose=0.01uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B |
| ED-05-KX67_1uM | Dose=1uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| JA-88-IO52_0.1uM | Dose=0.1uM |
| UE-50-KK32_1uM | Dose=1uM, 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile |
| FC-40-QD52_10uM | Dose=10uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| BC-82-PP66_0.01uM | Dose=0.01uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| JF-30-FM28_0.1uM | Dose=0.1uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1 |
| ED-62-DB62_1uM | Dose=1uM |
| FF-01-OH44_10uM | Dose=10uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38 |
| BA-28-JD87_0.1uM | Dose=0.1uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| EB-92-TL51_0.1uM | Dose=0.1uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| AE-54-BN96_0.01uM | Dose=0.01uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3 |
| AC-49-NG46_0.01uM | Dose=0.01uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| AE-38-EW82_0.01uM | Dose=0.01uM |
| DB-40-GN91_10uM | Dose=10uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| BD-81-FB30_0.1uM | Dose=0.1uM |
| FA-88-II68_0.01uM | Dose=0.01uM |
| BA-60-DR11_1uM | Dose=1uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| BB-82-TP51_10uM | Dose=10uM, Tegobuvir |
| AC-97-KP88_0.1uM | Dose=0.1uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| BB-50-CR51_10uM | Dose=10uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT |
| FB-29-KC76_0.01uM | Dose=0.01uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5 |
| ZB-33-MZ40_0.01uM | Dose=0.01uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1 |
| IB-56-JN40_1uM | Dose=1uM, Y-33075, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| DA-15-PU65_1uM | Dose=1uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| PA-80-RV09_1uM | Dose=1uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1 |
| EE-13-PS05_0.1uM | Dose=0.1uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| DA-83-VJ09_10uM | Dose=10uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| ME-60-RF56_10uM | Dose=10uM, N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]benzamide, Serotonin Antagonists targeting HTR1A |
| EF-16-GV25_10uM | Dose=10uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1 |
| GB-11-PX47_10uM | Dose=10uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3 |
| CD-84-BU23_0.1uM | Dose=0.1uM, Oseltamivir |
| QB-87-TC65_10uM | Dose=10uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1 |
| DD-66-VY52_1uM | Dose=1uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3 |
| AC-56-ZV05_10uM | Dose=10uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK |
| DE-42-QB97_0.1uM | Dose=0.1uM, N-Acetylserotonin |
| AC-38-WM38_0.1uM | Dose=0.1uM |
| FD-19-TD14_0.01uM | Dose=0.01uM |
| ID-30-ST90_0.01uM | Dose=0.01uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide |
| CE-09-ZT22_10uM | Dose=10uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2 |
| OC-41-DF58_10uM | Dose=10uM, Oprea1_571617, inhibitor of dna ligase IV targeting LIG4 |
| AF-40-QU33_10uM | Dose=10uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| QE-76-HF95_1uM | Dose=1uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2 |
| BB-75-JK26_10uM | Dose=10uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| AE-19-ZK31_0.01uM | Dose=0.01uM, Prinomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9, MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| SF-32-RC78_0.01uM | Dose=0.01uM, MAP3K5 gene inhibitor targeting MAP3K5 |
| AB-96-XV75_10uM | Dose=10uM, Dapsone |
| DE-28-ZP75_0.01uM | Dose=0.01uM, Deserpidine |
| NB-24-VE53_10uM | Dose=10uM, Tebanicline, Nicotinic Receptor Agonists targeting CHRNA3, CHRNA4 |
| GC-02-TV70_1uM | Dose=1uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| FB-85-ND09_10uM | Dose=10uM |
| WE-48-PP43_1uM | Dose=1uM, (1S,2R)-2-[[9-ethyl-6-(4-piperidin-1-ylsulfonylanilino)purin-2-yl]amino]cyclohexane-1-carboxamide, Protein Kinase Inhibitors targeting SRC |
| AB-25-XU75_0.01uM | Dose=0.01uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| MA-88-CA03_0.01uM | Dose=0.01uM, 6,7,4'-Trihydroxyisoflavan |
| EA-92-CV45_0.01uM | Dose=0.01uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| OE-67-XG40_10uM | Dose=10uM, Benzamide, N-[4-methyl-3-[[4-(6-methyl-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KIT |
| DA-91-NR73_0.01uM | Dose=0.01uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester |
| DA-17-XI26_10uM | Dose=10uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2 |
| IB-87-IU44_0.1uM | Dose=0.1uM, Thymol |
| DD-77-GV27_10uM | Dose=10uM, Fluspirilene, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| AB-40-HA80_1uM | Dose=1uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| FC-68-LJ11_0.1uM | Dose=0.1uM |
| PC-62-AQ92_0.01uM | Dose=0.01uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD |
| BB-77-IG67_0.01uM | Dose=0.01uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| NE-00-JZ19_0.01uM | Dose=0.01uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ |
| BD-41-DB55_10uM | Dose=10uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3 |
| DC-78-CM38_0.01uM | Dose=0.01uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| AE-61-UO01_0.1uM | Dose=0.1uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| LC-20-LZ39_10uM | Dose=10uM, 2,4-Dichlorobenzyl carbamimidothioate, Angiogenesis Inhibitors;MreB Polymerization Inhibitors targeting IDO1 |
| EB-90-BR21_0.1uM | Dose=0.1uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| CD-13-QZ32_1uM | Dose=1uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| IB-59-SI50_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[[2-(5-phenylmethoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| FA-91-OA82_0.1uM | Dose=0.1uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7 |
| AE-94-OX50_10uM | Dose=10uM, N-(2,6-Dichloro-pyridin-4-yl)-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide, S1PR2 antagonist;S1PR4 antagonist targeting S1PR4 |
| KF-37-OX16_0.01uM | Dose=0.01uM, N-[4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazol-2-yl]acetamide, TNF-alpha Production Inhibitors;Inhibitors of Signal Transduction Pathways;Adenosine A3 Antagonists;p38 MAPK Inhibitors targeting ADORA3, MAPK13 |
| S0-EE-Y79N_1uM | Dose=1uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4 |
| EF-33-QP63_0.1uM | Dose=0.1uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| BE-13-XC52_0.01uM | Dose=0.01uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| AB-40-HA80_0.1uM | Dose=0.1uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| BF-02-QT56_10uM | Dose=10uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS |
| NC-52-HX69_10uM | Dose=10uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1 |
| FB-06-IU47_10uM | Dose=10uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10 |
| OB-65-AI50_0.01uM | Dose=0.01uM, Rgfp966, HDAC3 active-site competitive inhibitor;HDAC3 targeting HDAC3 |
| BA-95-YU85_0.01uM | Dose=0.01uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| BB-72-TP61_10uM | Dose=10uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide |
| BD-83-QC82_1uM | Dose=1uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| CD-10-LX95_10uM | Dose=10uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2 |
| JD-54-BS97_0.01uM | Dose=0.01uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO |
| YA-81-YH47_10uM | Dose=10uM |
| MB-46-BT89_10uM | Dose=10uM, 4-Hydroxy-3,5-dimethoxycinnamic acid, GABA(A) Receptor Agonists;Alleviation of Cartilage Destruction;Antioxidants targeting KEAP1 |
| ED-93-KF69_10uM | Dose=10uM, 3-(2-Aminoethyl)adamantan-1-ol |
| AB-78-RM53_0.1uM | Dose=0.1uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1 |
| AA-91-SB25_10uM | Dose=10uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK |
| OA-74-FH10_10uM | Dose=10uM, Losartan Carboxaldehyde, Cyclooxygenase-2 Inhibitors;Angiotensin AT1 Antagonists targeting AGTR1, PTGS2 |
| KE-53-DB74_1uM | Dose=1uM, N-[4-Methyl-2-(morpholin-4-YL)quinolin-6-YL]furan-2-carboxamide |
| KA-73-PR92_0.1uM | Dose=0.1uM |
| CE-21-UO81_0.01uM | Dose=0.01uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| MF-04-HB41_0.1uM | Dose=0.1uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1 |
| BA-77-IP18_0.01uM | Dose=0.01uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| JC-03-OI01_0.01uM | Dose=0.01uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA |
| CB-13-WC72_0.01uM | Dose=0.01uM |
| VE-22-XI52_10uM | Dose=10uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| UA-17-QS18_1uM | Dose=1uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2 |
| AD-31-PI82_10uM | Dose=10uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2 |
| CB-13-ZM96_1uM | Dose=1uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine |
| RF-04-GI28_0.01uM | Dose=0.01uM |
| FC-64-QJ96_0.1uM | Dose=0.1uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| BD-81-LB65_1uM | Dose=1uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1 |
| GF-14-RF56_10uM | Dose=10uM |
| ME-61-RC56_10uM | Dose=10uM, Suronacrine, Acetylcholinesterase Inhibitors;Norepinephrine Reuptake Inhibitors targeting ACHE |
| AD-86-ES28_1uM | Dose=1uM, LY2033298, M4 positive allosteric modulator targeting CHRM4 |
| HD-41-DX72_0.1uM | Dose=0.1uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1 |
| LA-21-GQ75_0.1uM | Dose=0.1uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR |
| AD-11-RL84_0.1uM | Dose=0.1uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| IB-14-YP50_0.1uM | Dose=0.1uM, Sar405, VPS34 inhibitor targeting PIK3C3 |
| GD-98-WZ24_0.01uM | Dose=0.01uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| SC-17-WW78_10uM | Dose=10uM, 2-[[4-(4-cyano-1-methylpiperidin-4-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile, MAP3K12 (DLK) Inhibitors targeting MAP3K12 |
| MA-06-DJ95_1uM | Dose=1uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7 |
| HB-98-OB36_10uM | Dose=10uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| ZD-74-FC07_1uM | Dose=1uM |
| LB-76-JJ80_0.01uM | Dose=0.01uM, 1H-Isoindol-1-one, 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| AE-90-RS19_10uM | Dose=10uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5 |
| BA-06-RE84_0.01uM | Dose=0.01uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| GA-51-DD14_1uM | Dose=1uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| JE-61-XN48_1uM | Dose=1uM, HC-030031, TRPA1 Antagonists targeting TRPA1 |
| HC-94-AQ98_10uM | Dose=10uM, Roxadustat, hypoxia-inducible factor prolyl hydroxylase inhibitor targeting EGLN1, EGLN2, EGLN3 |
| BD-68-ZT55_10uM | Dose=10uM, Triclosan |
| DD-96-VY72_10uM | Dose=10uM |
| AD-84-LG49_1uM | Dose=1uM |
| CA-23-BW20_0.01uM | Dose=0.01uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2 |
| HD-68-CB31_0.1uM | Dose=0.1uM, N-Methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide targeting CYP2D6 |
| IE-46-OA29_1uM | Dose=1uM, 6-Fluoro-3-((1E)-2-(3-pyridinyl)ethenyl)-1H-indole, Tryptophan 2,3 dioxygenase inhibitor targeting TDO2 |
| TC-66-CI47_0.01uM | Dose=0.01uM |
| CE-72-GF32_0.01uM | Dose=0.01uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| KE-04-OV29_10uM | Dose=10uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)- |
| GF-73-HI61_0.01uM | Dose=0.01uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| FB-68-SI43_1uM | Dose=1uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide |
| BA-16-AB67_1uM | Dose=1uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| CB-72-CP81_10uM | Dose=10uM |
| GB-96-WX99_10uM | Dose=10uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1 |
| BD-81-FB30_10uM | Dose=10uM |
| JF-30-FW92_0.1uM | Dose=0.1uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R |
| AC-31-AY35_10uM | Dose=10uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| YA-82-VS66_10uM | Dose=10uM, 2-(4-Chlorobenzoyl)-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-1,2,3,4-tetrahydroisoquinoline, NMDA NR2C Receptor Ligands;NMDA NR2D Receptor Ligands targeting GRIN2C, GRIN2D |
| FD-67-GI76_0.1uM | Dose=0.1uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2 |
| EC-07-ZB49_0.01uM | Dose=0.01uM, ML-9 free base |
| HE-10-QN66_1uM | Dose=1uM, Cytoxazone |
| XD-03-FM54_0.1uM | Dose=0.1uM |
| FD-05-QX72_0.01uM | Dose=0.01uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11 |
| JD-61-EG41_10uM | Dose=10uM, 5-chloro-N-(2-methoxyphenyl)-3-methyl-1-benzothiophene-2-sulfonamide, CDK5/p25 Inhibitors targeting CDK5 |
| AA-84-BX70_1uM | Dose=1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| LB-11-CG51_0.1uM | Dose=0.1uM, Ibrutinib Racemate, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK |
| HC-06-EN50_1uM | Dose=1uM |
| BC-52-WF67_0.01uM | Dose=0.01uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| AD-29-MQ00_10uM | Dose=10uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| TF-09-RD17_0.01uM | Dose=0.01uM, Avasimibe, ACAT Inhibitor targeting SOAT1, SOAT2 |
| CB-92-FS28_10uM | Dose=10uM |
| S0-EE-WNJ9_1uM | Dose=1uM, 2-N-methyl-6-[(1S)-1-phenylethyl]-4-N-(1H-pyrazol-4-yl)pyridine-2,4-dicarboxamide targeting BRD4 |
| HB-13-XB94_1uM | Dose=1uM, Basimglurant, MGLUR5 NAM targeting GRM5 |
| IF-43-EO10_0.01uM | Dose=0.01uM |
| JB-99-UC61_0.1uM | Dose=0.1uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid |
| DB-20-QK39_0.01uM | Dose=0.01uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| KD-30-SM33_10uM | Dose=10uM, Pyridoxamine |
| HC-14-FM48_0.1uM | Dose=0.1uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| DE-02-BL66_1uM | Dose=1uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| HC-18-NB46_0.01uM | Dose=0.01uM, N-Acetyl-6-methoxytryptamine |
| BE-28-WW67_1uM | Dose=1uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| HC-86-IA49_10uM | Dose=10uM |
| AE-05-CB45_0.1uM | Dose=0.1uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| DB-34-QA60_0.1uM | Dose=0.1uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| XE-99-WG54_0.1uM | Dose=0.1uM, Bvryltbigiaadd-uhfffaoysa- |
| VC-19-YG34_0.1uM | Dose=0.1uM, 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, Flt3 (FLK2/STK1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting CHUK, FLT3, IKBKB, IKBKG |
| AC-94-SN51_10uM | Dose=10uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1 |
| EC-70-XX20_0.1uM | Dose=0.1uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5 |
| FC-82-WB67_0.1uM | Dose=0.1uM, Lycopene |
| XD-53-KC50_0.01uM | Dose=0.01uM |
| HA-27-FV67_0.1uM | Dose=0.1uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4 |
| KE-53-DB74_0.01uM | Dose=0.01uM, N-[4-Methyl-2-(morpholin-4-YL)quinolin-6-YL]furan-2-carboxamide |
| BD-36-VB52_0.1uM | Dose=0.1uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| AB-30-DA10_0.1uM | Dose=0.1uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2 |
| BF-00-PE90_0.1uM | Dose=0.1uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2 |
| HC-76-PX74_10uM | Dose=10uM |
| AD-11-FZ23_10uM | Dose=10uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| GA-88-CF36_0.01uM | Dose=0.01uM, Brusatol |
| EC-67-PV87_0.1uM | Dose=0.1uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| BD-10-ZH17_1uM | Dose=1uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR |
| LE-31-QT97_0.1uM | Dose=0.1uM, N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide, Melatonin Antagonists targeting MTNR1B, MTNR1A |
| KB-57-TK65_10uM | Dose=10uM, Altenusin, Neutral Sphingomyelinase (N-SMase) Inhibitors;HIV Integrase Inhibitors targeting SMPD2 |
| GF-02-ER50_1uM | Dose=1uM, Ethane-1,2-diyl dicarbamimidothioate |
| BA-69-TQ80_0.1uM | Dose=0.1uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| AD-70-DU18_0.01uM | Dose=0.01uM |
| AC-43-ZC52_0.1uM | Dose=0.1uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3 |
| CE-85-KN13_0.01uM | Dose=0.01uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| GD-98-WZ24_1uM | Dose=1uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| YB-18-SI56_0.1uM | Dose=0.1uM |
| EB-92-TL51_10uM | Dose=10uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| AF-48-FX20_0.1uM | Dose=0.1uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| AC-40-DU58_0.1uM | Dose=0.1uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP |
| MD-86-UW46_0.1uM | Dose=0.1uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide |
| CE-72-GF32_10uM | Dose=10uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| BC-75-FA82_1uM | Dose=1uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| DA-20-VR86_10uM | Dose=10uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN |
| BC-22-DS93_1uM | Dose=1uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BB-17-GC12_0.1uM | Dose=0.1uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2 |
| CB-73-MJ69_0.1uM | Dose=0.1uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3 |
| PA-09-IB98_1uM | Dose=1uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one |
| RA-14-EK87_0.1uM | Dose=0.1uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one |
| BE-68-LK29_0.1uM | Dose=0.1uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9 |
| AD-11-FZ23_0.1uM | Dose=0.1uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| DD-71-LY65_1uM | Dose=1uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| YF-47-HO48_0.01uM | Dose=0.01uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC |
| EF-14-GN61_10uM | Dose=10uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9 |
| BA-90-AA10_1uM | Dose=1uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| BB-29-VD14_0.01uM | Dose=0.01uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3 |
| TC-94-QN39_0.01uM | Dose=0.01uM, Iferanserin |
| BD-98-XW77_10uM | Dose=10uM |
| CD-70-GD72_0.01uM | Dose=0.01uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| PC-44-DH10_0.1uM | Dose=0.1uM, (1R,3S,6S,10S,11R)-7-[(dimethylamino)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA |
| KF-73-PY04_10uM | Dose=10uM, Gsk 932121, P. falciparum Cytochrome b-c1 Complex (Complex III subunit 3) Inhibitors;Electron Transport Chain Inhibitors targeting UQCRC1 |
| AD-19-GH34_10uM | Dose=10uM, Gsk-lsd1, KDM1A/B targeting KDM1A |
| HC-15-LT47_0.1uM | Dose=0.1uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| OC-55-QZ56_0.01uM | Dose=0.01uM, Icrf 193 |
| AE-59-ZQ55_0.1uM | Dose=0.1uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1 |
| JA-85-CW09_0.1uM | Dose=0.1uM, 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK Inhibitors targeting CCND2, CCND3 |
| DB-63-TM61_0.01uM | Dose=0.01uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| OF-98-RK57_0.1uM | Dose=0.1uM, Propiverine, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| BC-15-BY15_10uM | Dose=10uM |
| WD-86-NH64_0.01uM | Dose=0.01uM |
| BE-48-IT75_1uM | Dose=1uM |
| BF-44-HD37_0.1uM | Dose=0.1uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB |
| AA-45-BL29_10uM | Dose=10uM, DL-Tyrosine |
| BD-63-KJ69_0.01uM | Dose=0.01uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| DE-14-EG14_0.1uM | Dose=0.1uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| FE-49-ZJ78_1uM | Dose=1uM |
| BF-94-NX85_1uM | Dose=1uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3 |
| CB-77-KL88_0.1uM | Dose=0.1uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| RD-96-AM02_10uM | Dose=10uM |
| XB-75-YN01_1uM | Dose=1uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV |
| PA-39-SH87_0.01uM | Dose=0.01uM, 2-[6-[(Quinolin-2-yl)methoxy]naphthalen-2-yl]propanoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs;Leukotriene Antagonists targeting ALOX5 |
| AB-44-GQ28_0.1uM | Dose=0.1uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A |
| ID-26-HX79_0.1uM | Dose=0.1uM, N-(3-Chloro-5-Fluorophenyl)-4-Nitro-2,1,3-Benzoxadiazol-5-Amine, HIF-2;HIF-2 Inhibitor targeting EPAS1 |
| DD-44-OX00_0.1uM | Dose=0.1uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| ED-26-RU42_1uM | Dose=1uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| KA-58-YE68_1uM | Dose=1uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B |
| UD-78-YQ06_0.1uM | Dose=0.1uM, CID 91826512, Tip60 (KAT5) inhibitor targeting KAT5 |
| BB-69-YQ35_1uM | Dose=1uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| CB-25-VR83_1uM | Dose=1uM |
| EA-61-RR63_10uM | Dose=10uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| WD-62-UB45_10uM | Dose=10uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3 |
| KD-30-SM33_0.1uM | Dose=0.1uM, Pyridoxamine |
| AB-83-EW00_0.01uM | Dose=0.01uM, 1,3-Dipropyl-7-methylxanthine |
| HE-84-SC79_0.1uM | Dose=0.1uM |
| AA-86-YV75_1uM | Dose=1uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| IA-38-XE73_0.01uM | Dose=0.01uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3 |
| GC-46-AX49_0.1uM | Dose=0.1uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13 |
| DD-61-DY35_1uM | Dose=1uM |
| FC-67-SZ42_0.1uM | Dose=0.1uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| FE-82-MY37_0.01uM | Dose=0.01uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| DB-20-QK39_1uM | Dose=1uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| BC-72-DZ30_0.1uM | Dose=0.1uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1 |
| AA-44-BX20_10uM | Dose=10uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| XC-61-SE50_0.1uM | Dose=0.1uM, A-971432, selective agonist of sphingosine-1-phosphate receptor 5 (S1PR5) targeting S1PR5 |
| CE-52-SB42_10uM | Dose=10uM, 1-Aminobenzotriazole, Cytochrome P450 Inhibitors targeting CYP2W1 |
| VA-84-EQ91_0.1uM | Dose=0.1uM, [(2R,3R,5R,10S,11R,12R,13R,14S,17R)-2,3,11-trihydroxy-4,4,10,13-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-12-yl] acetate, Elastase Inhibitors targeting PI3 |
| BB-79-GA42_0.01uM | Dose=0.01uM, Pratol |
| CB-52-IL46_1uM | Dose=1uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| WC-95-BX35_0.1uM | Dose=0.1uM, [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-(4z)-ylidene]-acetic acid |
| ME-42-RD46_1uM | Dose=1uM, 2-[2-[[3-amino-5-[3-[(1S)-1-amino-2-hydroxyethyl]phenyl]phenyl]methoxy]phenyl]acetic acid, Complement factor D inhibitor targeting CFD |
| SD-15-WR01_0.01uM | Dose=0.01uM, 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoic acid, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| YB-01-IL62_1uM | Dose=1uM, 4-Methyl-3-[(3-nitrophenyl)methyl]-7-pyrimidin-2-yloxychromen-2-one |
| GE-40-GQ38_0.01uM | Dose=0.01uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| DB-29-HQ45_0.1uM | Dose=0.1uM |
| BD-93-AM31_1uM | Dose=1uM, Veliparib targeting PARP1, PARP2 |
| UE-76-JL04_0.1uM | Dose=0.1uM |
| PA-25-OV46_0.1uM | Dose=0.1uM, Bjb-432 |
| BF-26-MB27_1uM | Dose=1uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG |
| KA-50-OP35_10uM | Dose=10uM |
| EC-81-BA87_10uM | Dose=10uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| OC-53-QX76_10uM | Dose=10uM, N-[2-(3-chlorophenyl)ethyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| XB-35-TO54_1uM | Dose=1uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4 |
| EC-72-RE74_0.01uM | Dose=0.01uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L |
| AC-37-OZ52_0.1uM | Dose=0.1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| MC-30-BS07_0.1uM | Dose=0.1uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG |
| AC-21-IE62_1uM | Dose=1uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| PA-80-RV09_0.01uM | Dose=0.01uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1 |
| IE-04-SI43_10uM | Dose=10uM, 4-Tert-butyl-2-[[4-(pyridin-4-ylmethyl)phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Antagonists;Mineralocorticoid Receptor (MR) Antagonists;Drugs Acting on Estrogen Receptors (ER) targeting AR, NR3C2, PGR |
| DD-42-PC65_0.01uM | Dose=0.01uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| CC-62-XM29_0.01uM | Dose=0.01uM, Skf-81297, DRD1 agonist targeting DRD1 |
| BE-64-ZN31_10uM | Dose=10uM, Enzalutamide, Androgen Receptor Antagonists targeting AR |
| CE-72-SF92_0.01uM | Dose=0.01uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| BA-77-IP18_10uM | Dose=10uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| AD-88-WG84_10uM | Dose=10uM, 2-Bromo-N-(3-butyramidophenyl)benzamide, PAR-1 antagonist targeting F2R |
| WF-96-ME07_10uM | Dose=10uM, Cur 61414, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| SA-31-AZ46_10uM | Dose=10uM, PKM2 activator 3, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM |
| DB-54-ZQ73_10uM | Dose=10uM |
| AF-42-MP86_0.1uM | Dose=0.1uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide |
| GB-69-YC71_1uM | Dose=1uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3 |
| CE-38-KX20_0.01uM | Dose=0.01uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| JA-42-NH96_10uM | Dose=10uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS |
| LB-70-YM83_0.01uM | Dose=0.01uM |
| GB-93-CC27_1uM | Dose=1uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6 |
| GA-53-SC22_0.1uM | Dose=0.1uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| DB-05-UK61_10uM | Dose=10uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1 |
| EF-22-PB37_10uM | Dose=10uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| DF-32-EL16_10uM | Dose=10uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1 |
| GB-90-UG49_0.01uM | Dose=0.01uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B |
| AC-36-SY22_0.1uM | Dose=0.1uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| QF-00-CY91_0.1uM | Dose=0.1uM, 3-Phenylacetylamino-2,6-piperidinedione |
| IB-78-AY41_0.01uM | Dose=0.01uM, 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Cyclooxygenase-2 Inhibitors targeting SC5D |
| CB-01-MR53_10uM | Dose=10uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| NE-92-EU87_0.1uM | Dose=0.1uM, Abl127, Protein Phosphatase Methylesterase 1 Inhibitor targeting PPME1 |
| HE-01-ND39_10uM | Dose=10uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| FB-32-TL51_0.1uM | Dose=0.1uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| FA-17-JZ87_0.1uM | Dose=0.1uM, Valdecoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| PD-71-MW24_0.1uM | Dose=0.1uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA |
| JA-32-HE94_1uM | Dose=1uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT |
| SB-29-ZH97_1uM | Dose=1uM, Tetrahydrouridine, CDA gene inhibitor targeting CDA |
| ZA-84-ZC97_0.1uM | Dose=0.1uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA |
| HB-16-NO83_10uM | Dose=10uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S |
| DB-77-AV67_1uM | Dose=1uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate |
| CA-96-UO48_10uM | Dose=10uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| JE-55-OJ53_0.1uM | Dose=0.1uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile |
| CE-74-KU68_0.1uM | Dose=0.1uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| AC-21-IE62_0.1uM | Dose=0.1uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| RD-96-AM02_0.01uM | Dose=0.01uM |
| FD-91-OK66_0.1uM | Dose=0.1uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| BB-74-RX30_0.1uM | Dose=0.1uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| DC-72-IB32_10uM | Dose=10uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A |
| IC-72-HR20_1uM | Dose=1uM, 3-Hydroxykynurenine |
| WC-81-BR91_1uM | Dose=1uM, Bisanilinopyrimidine, 3d |
| CB-52-IL46_10uM | Dose=10uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| XE-99-WG54_10uM | Dose=10uM, Bvryltbigiaadd-uhfffaoysa- |
| OC-12-KT94_0.1uM | Dose=0.1uM, Sch 40120, Lipoxygenase Inhibitors;Mediator Release Inhibitors targeting ALOX5 |
| CA-43-YM01_1uM | Dose=1uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R |
| HB-24-AP80_1uM | Dose=1uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| AA-09-HG96_0.1uM | Dose=0.1uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA |
| FB-67-OY39_1uM | Dose=1uM, Galnon, GALR2 agonist targeting GALR2 |
| AA-16-HV95_1uM | Dose=1uM |
| DA-35-ZK21_0.1uM | Dose=0.1uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| AA-54-WG39_0.1uM | Dose=0.1uM, 4-Aminobenzamide |
| CC-29-RG66_0.01uM | Dose=0.01uM |
| CC-42-ZV45_0.1uM | Dose=0.1uM, (S)-2-amino-5-phosphonopentanoic acid |
| CC-91-RO81_0.1uM | Dose=0.1uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3 |
| JB-91-QG66_10uM | Dose=10uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[4-fluoro-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| CE-37-XI06_0.1uM | Dose=0.1uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| EA-90-PK44_0.1uM | Dose=0.1uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| KB-17-DU74_0.01uM | Dose=0.01uM, SR8278, REV-ERB anatagonist targeting NR1D1 |
| DA-86-GO43_0.01uM | Dose=0.01uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| LC-43-SE41_0.1uM | Dose=0.1uM, PRX-08066 free base, 5-HT2B Antagonists targeting HTR2B |
| HF-51-NR28_1uM | Dose=1uM, 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide, ARP2/3 Complex inhibitor targeting ACTR3, ACTR2 |
| BC-75-FA82_0.1uM | Dose=0.1uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| BC-28-NG89_0.1uM | Dose=0.1uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists |
| BE-61-OB65_1uM | Dose=1uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| GC-57-HV87_1uM | Dose=1uM |
| CC-08-JZ09_0.01uM | Dose=0.01uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4 |
| BA-97-CI76_10uM | Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate |
| KE-73-XV62_0.1uM | Dose=0.1uM, Tubercidin |
| QC-12-DW06_1uM | Dose=1uM, 4-Phenyl-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]piperidine-4-carboxamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| FB-68-SI43_0.01uM | Dose=0.01uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide |
| AF-13-LM61_0.01uM | Dose=0.01uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B |
| LF-92-IK63_1uM | Dose=1uM, 2-{[4-Amino-3-(3-Fluoro-4-Hydroxyphenyl)-1h-Pyrazolo[3,4-D]pyrimidin-1-Yl]methyl}-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD, PIK3CG |
| YC-27-PB87_10uM | Dose=10uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5 |
| HF-67-IR57_1uM | Dose=1uM |
| UB-40-KU41_1uM | Dose=1uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide |
| FD-19-TD14_1uM | Dose=1uM |
| DF-32-EL16_1uM | Dose=1uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1 |
| FA-20-GU88_0.1uM | Dose=0.1uM, N-(4-Cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-acetamide, Adenosine A2B Antagonists targeting ADORA2B |
| IC-76-JU42_1uM | Dose=1uM |
| SA-49-SD47_0.1uM | Dose=0.1uM, (3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, ADORA2A agonist;ADORA2B agonist targeting ADORA2A, ADORA2B |
| LB-90-DC89_0.1uM | Dose=0.1uM, (S)-Albuterol |
| EB-85-DG91_0.01uM | Dose=0.01uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| SD-69-IX30_1uM | Dose=1uM, Etomoxir |
| CD-12-NI84_0.1uM | Dose=0.1uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| AB-35-RU30_0.01uM | Dose=0.01uM |
| DD-96-DE39_10uM | Dose=10uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| MD-49-BL92_10uM | Dose=10uM, N-[5-(7-chloroquinolin-4-yl)sulfanyl-1,3,4-thiadiazol-2-yl]acetamide |
| HB-69-CT62_10uM | Dose=10uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| CB-69-DJ58_0.1uM | Dose=0.1uM, Midafotel, NMDA Antagonists targeting GRIN1 |
| GD-07-HO70_1uM | Dose=1uM |
| AA-47-BS40_1uM | Dose=1uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| RC-47-HT31_0.1uM | Dose=0.1uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| AD-14-QD12_1uM | Dose=1uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2 |
| DD-91-OY40_0.1uM | Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| SF-32-RC78_1uM | Dose=1uM, MAP3K5 gene inhibitor targeting MAP3K5 |
| AE-62-QI94_10uM | Dose=10uM, Zankiren, Renin Inhibitors targeting REN |
| BD-98-TG79_1uM | Dose=1uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| EB-47-BB89_10uM | Dose=10uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3 |
| CB-46-FO63_0.1uM | Dose=0.1uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| S0-EE-XZUM_10uM | Dose=10uM, targeting KDM5B, KDM4B, KDM5A |
| IE-38-FB31_0.01uM | Dose=0.01uM |
| EE-66-CK83_1uM | Dose=1uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| AE-06-FY47_0.01uM | Dose=0.01uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| IB-42-HL06_0.1uM | Dose=0.1uM, N-((1R,3aS,3bS,9aR,9bS,11aR)-9a,11a-dimethyl-1-((2R)-6-methylheptan-2-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta(a)phenanthren-7-ylidene)hydroxylamine, neuroprotective;Mitochondrial VDAC channel blocker targeting VDAC1 |
| LA-93-IR67_10uM | Dose=10uM, N-(6-Tetradecanamidobenzo[d]thiazol-2-yl)benzamide, Ceramide Kinase Inhibitors targeting CERK |
| CE-10-WA05_10uM | Dose=10uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide |
| CE-18-CG29_0.1uM | Dose=0.1uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1 |
| QE-98-XD90_0.01uM | Dose=0.01uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine |
| BD-58-PT20_1uM | Dose=1uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2 |
| LE-55-RW34_0.1uM | Dose=0.1uM, [(E)-[9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-ylidene]amino] 5-bromothiophene-2-carboxylate, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TNF-alpha Production Inhibitors targeting PTGS1, PTGS2 |
| EC-49-OQ85_0.1uM | Dose=0.1uM |
| EB-67-WB79_0.1uM | Dose=0.1uM |
| GC-09-XF08_0.01uM | Dose=0.01uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| AF-10-QK79_10uM | Dose=10uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AA-58-JC44_0.1uM | Dose=0.1uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2 |
| KB-04-AF26_10uM | Dose=10uM |
| AB-02-CF97_10uM | Dose=10uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| LB-70-YM83_10uM | Dose=10uM |
| IA-14-WP20_0.1uM | Dose=0.1uM, Tazarotene, Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists targeting ODC1, RARB, RARG |
| BD-80-SK69_0.1uM | Dose=0.1uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7 |
| MF-62-JR25_0.1uM | Dose=0.1uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| JC-63-BE61_0.01uM | Dose=0.01uM |
| CD-96-HO43_1uM | Dose=1uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ |
| BA-10-WH72_10uM | Dose=10uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9 |
| AD-52-UZ45_1uM | Dose=1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| DB-18-UF01_0.01uM | Dose=0.01uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| GB-14-AJ76_0.01uM | Dose=0.01uM |
| TA-82-BQ12_1uM | Dose=1uM, CU-Cpt22, TLR1/2 complex inhibitor targeting TLR1, TLR2 |
| UB-21-MV06_1uM | Dose=1uM, 7-amino-6-(1H-benzo[d]imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-5(4H)-one, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| KB-48-GH25_0.1uM | Dose=0.1uM, 2-[3-[(4-Methylphenyl)carbamoyl]-4-piperidin-1-ylphenyl]indazole-6-carboxylic acid |
| YA-61-RR36_1uM | Dose=1uM |
| DE-58-OW37_1uM | Dose=1uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L |
| OD-30-UF61_1uM | Dose=1uM |
| BE-61-OB65_0.1uM | Dose=0.1uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| AE-18-ZM98_0.1uM | Dose=0.1uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| CD-96-HO43_0.1uM | Dose=0.1uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ |
| NE-93-AH13_0.01uM | Dose=0.01uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one |
| AE-32-NZ70_0.1uM | Dose=0.1uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2 |
| YD-21-ZR41_0.1uM | Dose=0.1uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2 |
| AA-56-AB37_0.01uM | Dose=0.01uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1 |
| XB-35-TO54_0.1uM | Dose=0.1uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4 |
| DA-85-SU90_10uM | Dose=10uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1 |
| ME-16-XW76_0.1uM | Dose=0.1uM, 1-(3-Benzoylpropyl)-4-benzamidopiperidine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| JA-85-SW39_0.1uM | Dose=0.1uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2 |
| IB-08-VY61_0.1uM | Dose=0.1uM, Rivanicline, Nicotinic alpha4beta2 Agonists;Nicotinic Receptor Agonists targeting CHRNA4, CHRNB2 |
| BA-88-HT15_0.01uM | Dose=0.01uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| BB-39-DQ95_1uM | Dose=1uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7 |
| AA-14-DQ28_0.1uM | Dose=0.1uM, Estradiol |
| BA-64-PX65_0.1uM | Dose=0.1uM, Carnosine |
| CE-88-RJ81_0.01uM | Dose=0.01uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| JD-47-WR37_10uM | Dose=10uM |
| JA-42-MU37_10uM | Dose=10uM |
| ID-32-NA94_10uM | Dose=10uM, Ggti 298, Farnesyl Transferase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting FNTA, PGGT1B |
| S0-EE-Y6Y9_1uM | Dose=1uM, 6-chloro-N-(1-ethylpiperidin-4-yl)-1,2,3,4-tetrahydroacridin-9-amine |
| DE-48-PP80_1uM | Dose=1uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| TE-76-FI57_0.1uM | Dose=0.1uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2 |
| FA-43-TP28_1uM | Dose=1uM, Doxapram targeting KCNK3, KCNK9 |
| KA-46-YG68_10uM | Dose=10uM, 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors targeting CAMK2A, CAMK2B, FYN, MAPK13, CAMK2G |
| EE-60-CG74_0.01uM | Dose=0.01uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| IA-80-OW42_0.1uM | Dose=0.1uM, N-(3-Ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline, Cathepsin B Inhibitors targeting CTSB |
| JD-61-EG41_0.1uM | Dose=0.1uM, 5-chloro-N-(2-methoxyphenyl)-3-methyl-1-benzothiophene-2-sulfonamide, CDK5/p25 Inhibitors targeting CDK5 |
| GC-69-JF03_0.01uM | Dose=0.01uM |
| FD-80-EG54_10uM | Dose=10uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| ME-54-JY76_0.1uM | Dose=0.1uM |
| VA-71-JY23_10uM | Dose=10uM |
| BA-56-QV45_0.01uM | Dose=0.01uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1 |
| S0-EE-YAXR_1uM | Dose=1uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84 |
| CD-62-GL56_0.01uM | Dose=0.01uM, Fenesin |
| VB-92-JQ72_10uM | Dose=10uM, N-[1-[[1-(2-fluoroethyl)piperidin-4-yl]-phenylmethyl]pyrazol-4-yl]-6,6-dimethyl-1,4,5,7-tetrahydroindazole-3-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK |
| BD-85-OV63_10uM | Dose=10uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| CD-47-BV87_10uM | Dose=10uM, Atomoxetine, Norepinephrine Transporter (NET) Inhibitors targeting SLC6A2 |
| OD-09-LH57_0.1uM | Dose=0.1uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester |
| CC-04-WK34_10uM | Dose=10uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1 |
| ND-54-FY31_0.1uM | Dose=0.1uM, 2-Nitrobenzenesulfonamide |
| DC-22-HS83_0.1uM | Dose=0.1uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AA-56-JY17_0.1uM | Dose=0.1uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1 |
| CB-77-KL88_10uM | Dose=10uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AE-28-IQ88_0.01uM | Dose=0.01uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| UB-28-WW60_0.01uM | Dose=0.01uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol |
| BA-26-GI09_0.01uM | Dose=0.01uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR |
| DC-98-HC94_0.1uM | Dose=0.1uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| BF-08-RW47_0.01uM | Dose=0.01uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D |
| CC-44-MG29_0.1uM | Dose=0.1uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CC-14-WK34_0.1uM | Dose=0.1uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| AE-52-FP96_0.1uM | Dose=0.1uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| LA-57-ZX71_0.01uM | Dose=0.01uM, Epz015666, PRMT5 gene inhibitor;SAM-cooperative (uncompetitive) inhibition of methyltransferase function;Epizyme SAM cooperative PRMT5 inhibitor (aka EPZ01566 / GSK3235025) targeting PRMT5 |
| AC-83-LN99_0.1uM | Dose=0.1uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3 |
| AA-10-VR76_10uM | Dose=10uM, Hexachlorophene, Autotaxin) Inhibitors;Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2, SDHD |
| UC-21-PY73_10uM | Dose=10uM, Ro 46-2005, Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| WA-03-IF37_1uM | Dose=1uM, 5-[[4-(3-bromo-4-ethylanilino)phthalazin-1-yl]methyl]-1H-pyridin-2-one, Cytochrome P450 CYP2C9 Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Angiogenesis Inhibitors targeting CYP2C9, CYP3A4, KDR, MUSK |
| AE-73-KX58_10uM | Dose=10uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2 |
| IC-15-FM25_10uM | Dose=10uM, 2,4-Dioxo-6-phenylamino-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid phenylamide, SAPK1b (JNK3) Inhibitors targeting MAPK10 |
| QC-10-TY16_0.1uM | Dose=0.1uM, Ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate, Carnitine O-Palmitoyltransferase Inhibitors;Antioxidants targeting CPT1A, CPT1B |
| HE-10-QN66_0.01uM | Dose=0.01uM, Cytoxazone |
| AB-01-UY50_1uM | Dose=1uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| GB-45-YG91_0.01uM | Dose=0.01uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| FA-43-XS35_10uM | Dose=10uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6 |
| GD-79-JJ38_10uM | Dose=10uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| LE-01-MT37_10uM | Dose=10uM, N-[5-[[6-(2-hydroxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide, CDK1/2 inhibitor targeting CCNA1 |
| BB-82-TP51_0.1uM | Dose=0.1uM, Tegobuvir |
| AB-01-UY50_0.1uM | Dose=0.1uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| DB-63-TM61_1uM | Dose=1uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| AD-72-MJ27_0.01uM | Dose=0.01uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| KC-21-PG56_10uM | Dose=10uM, N-[4-[[3-(hydroxyamino)-3-oxopropyl]-[2-(4-methoxyphenyl)ethyl]sulfamoyl]phenyl]benzamide, Mammalian Tolloid-like 1 Protein (TLL1) inhibitor;Procollagen C Peptidase (BMP1) inhibitor;Mammalian Tolloid-like 2 Protein (TLL2) Inhibitor targeting BMP1 |
| KD-38-KY71_1uM | Dose=1uM, CID 44542178, NPFFR2 agonist, GIRK 1/4 blocker targeting NPFFR2 |
| BE-41-AV63_1uM | Dose=1uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| DE-91-FH69_0.01uM | Dose=0.01uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| PE-58-WU11_0.1uM | Dose=0.1uM |
| AB-09-YX02_0.01uM | Dose=0.01uM, p-Coumaric acid |
| CD-20-GE75_0.1uM | Dose=0.1uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| SB-92-FF15_10uM | Dose=10uM, 1-[2-(1-Hydroxymethyl-cyclopentylamino)-acetyl]-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| RE-99-TA30_0.1uM | Dose=0.1uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R |
| AC-18-DC84_0.1uM | Dose=0.1uM, 7-Nitroindazole |
| NE-92-EU87_0.01uM | Dose=0.01uM, Abl127, Protein Phosphatase Methylesterase 1 Inhibitor targeting PPME1 |
| WC-38-CZ02_1uM | Dose=1uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol |
| BC-38-UW37_10uM | Dose=10uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH |
| DA-59-ZD74_10uM | Dose=10uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| GD-79-JJ38_1uM | Dose=1uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| YB-30-EK42_10uM | Dose=10uM |
| EB-09-JJ93_0.1uM | Dose=0.1uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A |
| HA-33-ZI46_1uM | Dose=1uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| LE-41-QT17_10uM | Dose=10uM, 2,2-dimethyl-5-(morpholin-4-yl)-N-(pyridin-3-ylmethyl)-1,4-dihydro-2H-pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-8-amine, Phosphodiesterase PDE4D Inhibitors;Phosphodiesterase PDE4B Inhibitors;Phosphodiesterase PDE4A Inhibitors targeting PDE4A, PDE4B, PDE4D |
| AA-22-SF72_0.01uM | Dose=0.01uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET |
| AB-86-XY72_0.01uM | Dose=0.01uM |
| AA-22-FS33_10uM | Dose=10uM, Vatalanib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors;VEGFR-1 (Flt-1) Inhibitors;KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways;Aromatase Inhibitors;Angiogenesis Inhibitors targeting FLT1, KDR, KIT |
| OD-09-LH57_1uM | Dose=1uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester |
| ND-15-RC31_0.1uM | Dose=0.1uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1 |
| HE-68-XL70_10uM | Dose=10uM, 1,2,5-Thiadiazolidin-3-one, 5-[4-(cyclohexylmethyl)-2-fluoro-6-hydroxyphenyl]-, 1,1-dioxide, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1 |
| KE-47-IA01_10uM | Dose=10uM, Pci-34051, HDAC8 inhibitor targeting HDAC8 |
| UC-68-LC67_10uM | Dose=10uM, N-Cyclopropyl-N-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine, Known USP14 inhibitor targeting USP14 |
| FC-58-KP35_10uM | Dose=10uM, AM-966, LPAR1 antagonist targeting LPAR1 |
| EC-17-MF19_0.01uM | Dose=0.01uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| AC-55-XA97_0.01uM | Dose=0.01uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| XF-42-ES96_0.01uM | Dose=0.01uM, (1-(4-Nitrophenyl)piperidin-3-yl)methanol, CDK Inhibitors targeting CCND2, CCND3, CDK6 |
| BE-38-UW72_0.1uM | Dose=0.1uM |
| AB-92-GP61_1uM | Dose=1uM, JTE-607 free base |
| KC-35-MF93_1uM | Dose=1uM |
| JF-62-LU77_0.1uM | Dose=0.1uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN |
| DD-15-VH74_10uM | Dose=10uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1 |
| JE-61-EQ70_0.01uM | Dose=0.01uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine |
| KE-68-FV64_0.01uM | Dose=0.01uM, 1-(4-Tert-butylphenyl)sulfonylindole-5-carbonitrile, CCR9 antagonist targeting CCR9 |
| GA-59-RW04_0.1uM | Dose=0.1uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| EC-98-KI28_10uM | Dose=10uM, CID 196804 |
| BC-56-BB82_10uM | Dose=10uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2 |
| MD-60-WI93_10uM | Dose=10uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR-1 (Flt-1) Inhibitors targeting FLT1 |
| EE-49-CD29_0.1uM | Dose=0.1uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| BA-60-DR11_0.01uM | Dose=0.01uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| DE-02-BL66_0.01uM | Dose=0.01uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| DB-51-UO66_10uM | Dose=10uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2 |
| ED-25-BD54_0.1uM | Dose=0.1uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| AE-18-RD27_0.1uM | Dose=0.1uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E |
| JA-62-XU82_1uM | Dose=1uM, benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-phenylethyl]carbamate, Cathepsin K Inhibitors;Cathepsin S Inhibitors;Cathepsin L Inhibitors targeting CTSK, CTSL, CTSS |
| AE-03-BM76_0.01uM | Dose=0.01uM, Gamma-Aminobutyric Acid targeting GABRR1 |
| BC-45-VY95_10uM | Dose=10uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B |
| BC-74-QN56_1uM | Dose=1uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| JA-23-RY79_0.01uM | Dose=0.01uM |
| GF-72-OO48_10uM | Dose=10uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| UA-91-HL97_10uM | Dose=10uM |
| CA-17-XB39_0.01uM | Dose=0.01uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3 |
| CE-18-AP15_1uM | Dose=1uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| IA-48-KI53_0.01uM | Dose=0.01uM, Vinaxanthone, semaphorin inhibitor targeting SEMA3A |
| AA-81-CY65_0.1uM | Dose=0.1uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3 |
| DA-33-CX68_0.1uM | Dose=0.1uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B |
| IE-38-FB31_1uM | Dose=1uM |
| JD-00-TT75_0.1uM | Dose=0.1uM, 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid, Lactate dehydrogenase inhibitor targeting LDHA, LDHB |
| XA-36-WV33_0.1uM | Dose=0.1uM, Ethyl 4-(3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| GE-63-WI86_1uM | Dose=1uM, Nesbuvir |
| AB-04-MQ83_10uM | Dose=10uM |
| EC-34-FT85_0.1uM | Dose=0.1uM, Nibr-0213 targeting S1PR1 |
| CD-26-MB82_1uM | Dose=1uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| CE-77-JB44_0.01uM | Dose=0.01uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| AB-04-NN16_0.1uM | Dose=0.1uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G |
| AB-84-PK04_0.01uM | Dose=0.01uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| FE-82-JV20_0.1uM | Dose=0.1uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2 |
| EC-60-IX15_10uM | Dose=10uM, 3',4',7-Trihydroxyisoflavone, Tyrosinase Inhibitors;Melanin Inhibitors;Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF, TYR |
| BA-02-FS63_10uM | Dose=10uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| AB-44-GQ28_10uM | Dose=10uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A |
| OF-02-BG78_0.1uM | Dose=0.1uM |
| ZB-67-SE99_10uM | Dose=10uM |
| CE-36-KR60_0.01uM | Dose=0.01uM, Hydroxychloroquine |
| BE-50-RK99_0.01uM | Dose=0.01uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| GB-69-YC71_0.1uM | Dose=0.1uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3 |
| XA-40-AD40_0.01uM | Dose=0.01uM, Methyl (3E)-4-phenyl-3-butenoate targeting PAM |
| NC-85-PZ41_0.1uM | Dose=0.1uM, Mln-4760, Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors targeting ACE2 |
| AE-38-QT35_10uM | Dose=10uM, ML324, KDM4E targeting KDM4E |
| WC-89-JT40_0.01uM | Dose=0.01uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10 |
| RD-90-DS77_10uM | Dose=10uM, Genistin |
| BB-73-ZW70_0.01uM | Dose=0.01uM |
| IC-27-TE11_0.01uM | Dose=0.01uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4 |
| AC-22-PZ30_1uM | Dose=1uM, Eed226, PRC2/EED targeting EED |
| PD-31-RP17_10uM | Dose=10uM |
| CA-66-YB17_1uM | Dose=1uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A |
| HE-43-BS90_0.01uM | Dose=0.01uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BA-31-KY85_10uM | Dose=10uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14 |
| AE-00-NY23_0.01uM | Dose=0.01uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| ED-81-ZH14_10uM | Dose=10uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK |
| CC-86-IO63_0.1uM | Dose=0.1uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6 |
| BC-88-KT45_0.01uM | Dose=0.01uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| BB-52-UP66_10uM | Dose=10uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| QF-09-IK44_1uM | Dose=1uM, Aryl carbamate analog 1 |
| GC-09-XF08_1uM | Dose=1uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| AC-65-TK51_1uM | Dose=1uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D |
| AC-70-KV26_0.01uM | Dose=0.01uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| AC-98-UW57_1uM | Dose=1uM, Suplatast |
| BA-52-FW03_10uM | Dose=10uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BD-18-FM58_1uM | Dose=1uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| IA-35-KC86_0.01uM | Dose=0.01uM, L-lobeline free base |
| FC-15-XG61_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| KD-50-WP70_0.1uM | Dose=0.1uM, N-(3,4-dichlorophenyl)guanidine, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| DA-56-CH26_10uM | Dose=10uM, N-(1-(3-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| AA-87-MP18_0.1uM | Dose=0.1uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5 |
| AB-31-VZ28_10uM | Dose=10uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A |
| BD-41-DI77_0.1uM | Dose=0.1uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A |
| OD-30-UF61_0.1uM | Dose=0.1uM |
| TA-25-KO99_1uM | Dose=1uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4 |
| AA-57-CF49_10uM | Dose=10uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1 |
| JF-76-BD96_1uM | Dose=1uM, 1-(4-Chlorophenyl)-N-[3-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1H-pyrazole-4-carboxamide |
| WE-69-LT10_0.1uM | Dose=0.1uM |
| KF-18-RY71_0.1uM | Dose=0.1uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4 |
| LA-31-YT57_0.1uM | Dose=0.1uM, 9-Chloro-2-(2-fluorophenyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-ol, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG1, GABRG2, GABRG3 |
| BD-63-JC77_10uM | Dose=10uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester |
| EC-08-KS82_0.1uM | Dose=0.1uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C |
| AB-17-WP43_0.01uM | Dose=0.01uM, Loperamide, mu-Opioid Agonists targeting OPRM1 |
| OF-28-PH15_0.01uM | Dose=0.01uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3 |
| CF-50-MN16_0.1uM | Dose=0.1uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1 |
| HE-43-BS90_10uM | Dose=10uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| CB-15-RU50_10uM | Dose=10uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| AB-09-YX02_1uM | Dose=1uM, p-Coumaric acid |
| XE-69-AT35_10uM | Dose=10uM, Nocardimicin A |
| WD-08-QT63_10uM | Dose=10uM |
| KB-37-OO25_0.01uM | Dose=0.01uM, Tovinontrine targeting PDE9A |
| MA-06-DJ95_0.1uM | Dose=0.1uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7 |
| PA-09-IB98_0.1uM | Dose=0.1uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one |
| BE-37-ZF44_1uM | Dose=1uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| GF-15-LT47_0.01uM | Dose=0.01uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3 |
| FB-86-IO73_1uM | Dose=1uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| WA-03-IF37_0.1uM | Dose=0.1uM, 5-[[4-(3-bromo-4-ethylanilino)phthalazin-1-yl]methyl]-1H-pyridin-2-one, Cytochrome P450 CYP2C9 Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Angiogenesis Inhibitors targeting CYP2C9, CYP3A4, KDR, MUSK |
| XC-65-XN91_1uM | Dose=1uM, 6-(Propylamino)nicotinic acid, GPR109A agonist targeting HCAR2 |
| AB-63-HD20_0.01uM | Dose=0.01uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| CC-93-RP38_0.01uM | Dose=0.01uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| KB-77-BA46_1uM | Dose=1uM, 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide, p38 MAPK Inhibitors targeting MAPK14 |
| JC-67-FV32_0.1uM | Dose=0.1uM, 4-[4-(2-Pyrrolidin-1-ylethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine-6-carboxamide targeting SIRT2, SIRT3, SIRT1 |
| NC-35-BF58_1uM | Dose=1uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
| JC-52-RH51_0.01uM | Dose=0.01uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1 |
| AF-28-FX20_10uM | Dose=10uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2 |
| HC-19-UZ81_0.1uM | Dose=0.1uM, Galgravin |
| GC-32-SH41_10uM | Dose=10uM, MMP3 inhibitor 2 |
| MB-48-VA23_1uM | Dose=1uM, 9-Benzyl-2-methyl-4-phenyl-5-oxa-1,2,9-triazaspiro[5.5]undecane, Vascular adhesion molecule antagonists targeting AOC3 |
| AA-18-GQ83_1uM | Dose=1uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| BA-75-VA57_1uM | Dose=1uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2 |
| DC-59-NQ20_1uM | Dose=1uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| DF-85-QA87_0.01uM | Dose=0.01uM, Htfmt, HRH1 agonist targeting HRH1 |
| MA-20-ZI33_0.01uM | Dose=0.01uM |
| FE-19-OW54_10uM | Dose=10uM, Fenofibric Acid |
| YA-81-YH47_0.01uM | Dose=0.01uM |
| JD-61-EG41_0.01uM | Dose=0.01uM, 5-chloro-N-(2-methoxyphenyl)-3-methyl-1-benzothiophene-2-sulfonamide, CDK5/p25 Inhibitors targeting CDK5 |
| AC-49-ZR23_10uM | Dose=10uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| TD-69-UA90_10uM | Dose=10uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| KC-87-DN47_0.01uM | Dose=0.01uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR |
| WF-76-NV73_10uM | Dose=10uM, Cxl-1020, activation for sGC, oxidation of sulfides for others targeting ATP2A2, CTSB, GAPDH, GUCY1A1, PLN |
| AA-01-XV28_1uM | Dose=1uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| AA-91-WB95_10uM | Dose=10uM |
| GD-51-SU60_0.01uM | Dose=0.01uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| ND-54-NO97_0.1uM | Dose=0.1uM, 3-Epioleanolic acid |
| BC-74-QN56_0.1uM | Dose=0.1uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| FE-19-SC91_1uM | Dose=1uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6 |
| EA-81-CR68_10uM | Dose=10uM |
| RA-44-SU16_0.1uM | Dose=0.1uM, H4 Receptor antagonist 1, HRH4 antagonist targeting HRH4 |
| YD-71-BE10_0.1uM | Dose=0.1uM, Sgk1-IN-1, Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitors targeting SGK1, SGK2 |
| BE-10-NK39_10uM | Dose=10uM, Nbi-30775, CRF1 Antagonists targeting CRHR1 |
| SB-89-QK94_0.01uM | Dose=0.01uM |
| OC-40-XI13_0.01uM | Dose=0.01uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12 |
| CE-18-ZM38_0.1uM | Dose=0.1uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ |
| KA-35-YF58_1uM | Dose=1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AB-16-LY07_10uM | Dose=10uM, Nortriptyline, K(ir) 4.1 Blockers targeting KCNJ10 |
| CF-22-IS33_10uM | Dose=10uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL |
| CE-72-GF32_1uM | Dose=1uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| AD-84-LG49_10uM | Dose=10uM |
| AF-33-AM86_0.01uM | Dose=0.01uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| BB-62-SZ35_0.1uM | Dose=0.1uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| CA-60-RU13_0.01uM | Dose=0.01uM |
| BF-41-MV83_10uM | Dose=10uM, Edaravone |
| AF-81-IV73_0.01uM | Dose=0.01uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13 |
| BA-71-BE32_10uM | Dose=10uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| BE-47-IP08_0.1uM | Dose=0.1uM, Acifran, GPR109A agonist targeting HCAR2 |
| QE-18-WG07_0.01uM | Dose=0.01uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2 |
| CB-16-SY72_0.01uM | Dose=0.01uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| RA-18-CU16_0.1uM | Dose=0.1uM |
| EC-86-EK93_1uM | Dose=1uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4 |
| BD-69-YD09_10uM | Dose=10uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4 |
| HD-29-PZ41_0.01uM | Dose=0.01uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one |
| JE-86-QG78_0.01uM | Dose=0.01uM, Ibrolipim |
| XD-50-BD50_0.1uM | Dose=0.1uM, 2-(4-Amylcinnamoyl)amino-4-chlorobenzoic acid, Phospholipase A2 (PLA2) Inhibitors targeting PLA2G10 |
| NE-29-VB58_0.01uM | Dose=0.01uM, L 692429, GHS Receptor Antagonists;GHSR agonist targeting GHSR |
| DB-40-HA40_0.1uM | Dose=0.1uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| OC-59-JO99_10uM | Dose=10uM, N-[(2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-methoxybut-2-ynoxy)benzamide |
| JF-25-NM40_0.01uM | Dose=0.01uM |
| DA-88-JF21_0.1uM | Dose=0.1uM, FG-9041 targeting GRIA4 |
| LA-10-VZ79_1uM | Dose=1uM, AZ-628, Raf kinase B Inhibitors;Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| DA-33-BM26_1uM | Dose=1uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| CD-80-ZD47_0.01uM | Dose=0.01uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT |
| HD-00-AG74_10uM | Dose=10uM |
| BD-63-JC77_0.01uM | Dose=0.01uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester |
| AD-30-SU93_0.1uM | Dose=0.1uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| DD-24-TT70_10uM | Dose=10uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AA-68-MW92_1uM | Dose=1uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| LD-00-HM58_0.1uM | Dose=0.1uM, 5-[2,3-Bis(Chloranyl)phenyl]-2-[(3~{r},5~{s})-3,5-Dimethylpiperazin-1-Yl]pyrimidin-4-Amine, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A |
| EA-96-QK68_10uM | Dose=10uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| NE-94-VE83_10uM | Dose=10uM |
| TC-32-HZ53_10uM | Dose=10uM, N-[2-[2-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetamide, CCR1 antagonist targeting CCR1 |
| DC-84-CJ21_0.1uM | Dose=0.1uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3 |
| AB-15-XR48_0.1uM | Dose=0.1uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B |
| DE-27-WV87_10uM | Dose=10uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| WC-49-TQ48_0.1uM | Dose=0.1uM |
| AC-22-PZ30_10uM | Dose=10uM, Eed226, PRC2/EED targeting EED |
| XF-24-NT53_0.1uM | Dose=0.1uM, Bms-599626, HER4 (erbB4) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;HER3 (erbB3) Inhibitors targeting EGFR, ERBB2, ERBB3, ERBB4 |
| IB-14-YP50_10uM | Dose=10uM, Sar405, VPS34 inhibitor targeting PIK3C3 |
| CC-55-CD84_0.01uM | Dose=0.01uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| DD-49-YG96_1uM | Dose=1uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| AA-91-WB95_0.01uM | Dose=0.01uM |
| ZD-43-CS43_0.01uM | Dose=0.01uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B |
| MB-48-VA23_10uM | Dose=10uM, 9-Benzyl-2-methyl-4-phenyl-5-oxa-1,2,9-triazaspiro[5.5]undecane, Vascular adhesion molecule antagonists targeting AOC3 |
| GC-08-VP20_0.1uM | Dose=0.1uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| AB-71-NB55_0.1uM | Dose=0.1uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14 |
| EF-73-IP33_0.1uM | Dose=0.1uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| BA-87-NF64_1uM | Dose=1uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| S0-EE-Y737_0.01uM | Dose=0.01uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6 |
| ED-00-OH22_0.1uM | Dose=0.1uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT |
| IF-86-JG83_0.01uM | Dose=0.01uM, (S)-2-benzylamino-3-phenyl-1-propanol |
| DC-61-QV78_0.01uM | Dose=0.01uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2 |
| EC-90-QX75_10uM | Dose=10uM, N-[5-cyano-4-[(2S)-2-methoxypropoxy]pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, FGFR4 gene inhibitor targeting FGFR4 |
| BC-72-DZ30_10uM | Dose=10uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1 |
| AB-95-LH34_0.1uM | Dose=0.1uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK |
| PE-68-QD35_10uM | Dose=10uM, Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate, TGFBR2 degrador targeting TGFBR2 |
| JF-30-FM28_1uM | Dose=1uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1 |
| NB-62-DN30_10uM | Dose=10uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB |
| FA-30-KQ38_0.1uM | Dose=0.1uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB |
| ME-93-CO85_1uM | Dose=1uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine |
| CA-25-LR28_1uM | Dose=1uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| BF-00-PE90_0.01uM | Dose=0.01uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2 |
| EF-33-QP63_1uM | Dose=1uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| KA-54-QW27_0.01uM | Dose=0.01uM, Phosphodiesterase V (PDE5A) Inhibitors;GPR35 agonist targeting GPR35, PDE6A, PDE5A, ENPP6 |
| S0-EE-YGIT_0.1uM | Dose=0.1uM, 1-(4-Chlorophenoxy)-3-[[1-[(2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]methyl-methylamino]propan-2-ol, TLR-4 antagonist targeting TLR4 |
| QA-34-BH60_0.01uM | Dose=0.01uM, rac-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide |
| CB-20-ND22_1uM | Dose=1uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| FC-64-QJ96_0.01uM | Dose=0.01uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AC-29-ZR23_0.1uM | Dose=0.1uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| PA-25-OV46_1uM | Dose=1uM, Bjb-432 |
| ZD-15-SG14_0.1uM | Dose=0.1uM, 5,5'-Diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde |
| LA-93-IR67_1uM | Dose=1uM, N-(6-Tetradecanamidobenzo[d]thiazol-2-yl)benzamide, Ceramide Kinase Inhibitors targeting CERK |
| CC-70-BD07_10uM | Dose=10uM, Voriconazole Impurity 7 |
| AA-89-HG56_0.01uM | Dose=0.01uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A |
| AE-36-JB67_10uM | Dose=10uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| BC-08-RC39_0.01uM | Dose=0.01uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3 |
| MB-46-BT89_0.01uM | Dose=0.01uM, 4-Hydroxy-3,5-dimethoxycinnamic acid, GABA(A) Receptor Agonists;Alleviation of Cartilage Destruction;Antioxidants targeting KEAP1 |
| DD-41-AE67_1uM | Dose=1uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| PB-09-OE00_0.01uM | Dose=0.01uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| NB-75-RF23_10uM | Dose=10uM |
| DC-22-HS83_1uM | Dose=1uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AD-20-YO14_10uM | Dose=10uM, Ars-1620 targeting KRAS |
| GC-57-HV87_0.01uM | Dose=0.01uM |
| BC-95-MO06_1uM | Dose=1uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D |
| AE-64-KN26_0.01uM | Dose=0.01uM |
| DA-17-XI26_1uM | Dose=1uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2 |
| DD-55-AU25_1uM | Dose=1uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| AA-56-DV95_10uM | Dose=10uM |
| LF-33-KO15_1uM | Dose=1uM, 9-Isopropyl-N-[3-(trifluoromethyl)benzyl]-9H-purin-6-amine, Casein kinase-I alpha inhibitor;Casein kinase-I delta inhibitor targeting CSNK1A1, CSNK1D |
| PA-40-NS72_0.1uM | Dose=0.1uM, Oseltamivir Acid |
| BD-78-MJ16_1uM | Dose=1uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| KE-73-XV62_0.01uM | Dose=0.01uM, Tubercidin |
| BD-81-LB65_0.1uM | Dose=0.1uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1 |
| UA-44-EN14_0.01uM | Dose=0.01uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone |
| EE-83-RW10_0.01uM | Dose=0.01uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1 |
| CE-39-DG56_10uM | Dose=10uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| MB-53-WO35_0.1uM | Dose=0.1uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5 |
| TA-36-PC58_0.1uM | Dose=0.1uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5 |
| BB-25-NU80_0.1uM | Dose=0.1uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| EE-77-XO60_10uM | Dose=10uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol |
| GD-46-OD81_0.01uM | Dose=0.01uM, U 41792 |
| BD-48-ZT65_10uM | Dose=10uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| BE-41-AV63_0.01uM | Dose=0.01uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| PA-40-HC94_10uM | Dose=10uM |
| CE-77-JB44_1uM | Dose=1uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| DF-75-MR73_10uM | Dose=10uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4 |
| EA-96-QK68_0.1uM | Dose=0.1uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| IC-43-CV07_10uM | Dose=10uM |
| EB-82-HZ30_1uM | Dose=1uM |
| TC-67-HF87_0.01uM | Dose=0.01uM |
| BD-38-QC39_0.1uM | Dose=0.1uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| HC-74-FM38_0.01uM | Dose=0.01uM |
| EA-61-RR63_0.1uM | Dose=0.1uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AA-43-BW50_10uM | Dose=10uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3 |
| AA-47-BS40_0.1uM | Dose=0.1uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| ED-93-KF69_1uM | Dose=1uM, 3-(2-Aminoethyl)adamantan-1-ol |
| PD-14-CH80_10uM | Dose=10uM |
| IA-35-KC86_0.1uM | Dose=0.1uM, L-lobeline free base |
| BA-69-TQ80_0.01uM | Dose=0.01uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| SC-72-YW56_0.01uM | Dose=0.01uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5 |
| BB-39-YQ35_0.01uM | Dose=0.01uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| GA-16-IU17_0.01uM | Dose=0.01uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| BD-48-ZT65_0.1uM | Dose=0.1uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| GD-33-XB49_1uM | Dose=1uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| AA-98-FJ71_0.01uM | Dose=0.01uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| AF-76-BV30_0.1uM | Dose=0.1uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| ZE-14-BN99_0.1uM | Dose=0.1uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19 |
| RA-23-IX31_0.1uM | Dose=0.1uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1 |
| IA-03-BO30_0.1uM | Dose=0.1uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2 |
| ZB-92-PL24_10uM | Dose=10uM, Palonosetron, 5-HT3 Antagonists targeting HTR3A |
| BF-08-RW47_0.1uM | Dose=0.1uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D |
| CC-90-FE70_0.1uM | Dose=0.1uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| OF-47-EQ74_10uM | Dose=10uM |
| AF-73-HJ84_0.01uM | Dose=0.01uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| EF-14-GN61_0.01uM | Dose=0.01uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9 |
| DF-57-FI46_10uM | Dose=10uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1 |
| AA-77-MP68_1uM | Dose=1uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| DF-95-CY55_1uM | Dose=1uM |
| FD-79-TC61_0.1uM | Dose=0.1uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| AC-73-DW50_1uM | Dose=1uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| BA-39-LQ60_1uM | Dose=1uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| ZE-53-LS38_1uM | Dose=1uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine |
| FC-82-WB67_10uM | Dose=10uM, Lycopene |
| CC-90-EX35_10uM | Dose=10uM |
| JF-79-OI50_1uM | Dose=1uM, FK 409, Soluble Guanylyl Cyclase (sGC) Activators;Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| AC-55-CK61_0.1uM | Dose=0.1uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2 |
| ID-37-UU19_0.1uM | Dose=0.1uM, 5-[[4-[3-(trifluoromethyl)anilino]phthalazin-1-yl]methyl]-1H-pyridin-2-one |
| ZC-47-HL31_1uM | Dose=1uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1 |
| BF-31-BY55_1uM | Dose=1uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| WE-43-PZ45_0.01uM | Dose=0.01uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone |
| EC-07-ZB49_10uM | Dose=10uM, ML-9 free base |
| BC-52-WF67_0.1uM | Dose=0.1uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| KA-35-YF58_0.01uM | Dose=0.01uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| FB-56-SR65_10uM | Dose=10uM, Arginine |
| BE-42-WI29_1uM | Dose=1uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| HC-04-ZM18_0.1uM | Dose=0.1uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| TE-16-VT54_0.1uM | Dose=0.1uM, Atglistatin, Patatin like phospholipase protein inhibitor targeting PNPLA2 |
| AA-33-DN24_1uM | Dose=1uM, Olprinone |
| CF-55-OA12_10uM | Dose=10uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| CC-15-TX17_10uM | Dose=10uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10 |
| PD-50-SI33_10uM | Dose=10uM, N-(1-(3-methoxypropyl)-5-((phenylamino)methyl)-1H-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK |
| RA-89-RR01_0.1uM | Dose=0.1uM, Bms-906024, Gamma-secretase inhibitor;gamma secretase inhibitor targeting PSEN1 |
| OA-62-NJ00_1uM | Dose=1uM |
| GD-27-UE16_10uM | Dose=10uM, GPR41 agonist-1, GPR41 agonist targeting FFAR3 |
| CE-77-JB44_0.1uM | Dose=0.1uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| VD-08-YA83_0.1uM | Dose=0.1uM |
| AB-73-ZX03_0.1uM | Dose=0.1uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5 |
| BB-69-YQ35_0.01uM | Dose=0.01uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| CB-05-AU50_0.01uM | Dose=0.01uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1 |
| JF-16-BD66_1uM | Dose=1uM, Gsk-690693, PKB gamma/Akt3 Inhibitors;Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors targeting AKT1, AKT2, DAPK3, PRKG1, PRKX, AKT3, PAK6 |
| CE-68-CC69_0.01uM | Dose=0.01uM |
| BD-99-DU20_1uM | Dose=1uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| EA-73-WI86_1uM | Dose=1uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1 |
| AC-18-DC84_10uM | Dose=10uM, 7-Nitroindazole |
| AC-76-BB02_1uM | Dose=1uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14 |
| AA-50-FY68_10uM | Dose=10uM |
| AE-18-RD27_0.01uM | Dose=0.01uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E |
| DF-32-MM89_10uM | Dose=10uM, Dihydropyrimidine Dehydrogenase Inhibitors targeting DPYD |
| WC-49-TQ48_0.01uM | Dose=0.01uM |
| BE-45-VH04_0.01uM | Dose=0.01uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate |
| CA-57-TC62_1uM | Dose=1uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1 |
| SF-32-RC78_0.1uM | Dose=0.1uM, MAP3K5 gene inhibitor targeting MAP3K5 |
| MB-67-UU04_10uM | Dose=10uM, 6-[4-[2-(3-Fluoropyridin-4-yl)imidazo[4,5-b]pyridin-3-yl]piperidin-1-yl]sulfonyl-2-methyl-1,3-benzoxazole, CFTR Modulator targeting CFTR |
| AE-52-FP96_0.01uM | Dose=0.01uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| HD-91-YX62_1uM | Dose=1uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile |
| AF-06-AY37_10uM | Dose=10uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| GA-16-IU17_0.1uM | Dose=0.1uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| IC-28-HS37_0.1uM | Dose=0.1uM, Nvs-cecr2-1, CECR2 inhibitor;CECR2 inhbitor targeting CECR2 |
| FA-47-IB34_1uM | Dose=1uM |
| AA-31-YE07_0.1uM | Dose=0.1uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| HA-38-ML65_1uM | Dose=1uM |
| HD-41-DX72_1uM | Dose=1uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1 |
| BB-08-WM33_0.01uM | Dose=0.01uM, AM 281, CNR1 antagonist targeting CNR1 |
| TF-23-DD23_0.1uM | Dose=0.1uM, PF-4708671, Antagonist of S6K targeting RPS6KB1 |
| CF-90-DA50_0.1uM | Dose=0.1uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1 |
| CF-83-HM41_0.01uM | Dose=0.01uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA |
| AC-57-ZF49_0.1uM | Dose=0.1uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| BB-62-SZ35_1uM | Dose=1uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| DA-10-VU83_10uM | Dose=10uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2 |
| OE-68-FR64_1uM | Dose=1uM, n-(2,6-Diethylphenyl)-homophthalimide, Puromycin-Sensitive Aminopeptidase Inhibitors targeting ANPEP, NPEPPS |
| TD-31-KS49_0.1uM | Dose=0.1uM, Sertindole, Dopamine D2 Antagonists;5-HT2A Antagonists targeting ADRA1B, HTR1E, HTR1F |
| JE-43-OY99_0.1uM | Dose=0.1uM |
| DF-56-GR45_0.1uM | Dose=0.1uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| NB-62-DN30_0.01uM | Dose=0.01uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB |
| AA-22-UI44_0.01uM | Dose=0.01uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| DF-03-OP38_0.01uM | Dose=0.01uM |
| BB-53-SW55_10uM | Dose=10uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| UD-70-IO77_1uM | Dose=1uM, 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, PDE10A inhibitor targeting PDE10A |
| AE-56-RB57_1uM | Dose=1uM |
| LB-11-CG51_10uM | Dose=10uM, Ibrutinib Racemate, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK |
| EC-07-ZB49_0.1uM | Dose=0.1uM, ML-9 free base |
| OD-96-ZC58_0.01uM | Dose=0.01uM, Mdl-29951, NMDA Glycine-Site Antagonists;Fructose-1,6-Bisphosphatase Inhibitors;GPR17 gene modulator targeting FBP1, GPR17 |
| BE-48-TM93_0.01uM | Dose=0.01uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R |
| DF-84-RT50_1uM | Dose=1uM |
| CE-25-VD54_10uM | Dose=10uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A |
| WF-85-JN16_10uM | Dose=10uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| TC-32-HZ53_1uM | Dose=1uM, N-[2-[2-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetamide, CCR1 antagonist targeting CCR1 |
| ED-05-KX67_10uM | Dose=10uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| BF-72-LI04_10uM | Dose=10uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| OA-51-KF88_1uM | Dose=1uM, Lodoxamide targeting ARRB2, GPR35 |
| CE-18-ZM38_0.01uM | Dose=0.01uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ |
| BA-60-RH02_1uM | Dose=1uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1 |
| SE-92-BP29_0.01uM | Dose=0.01uM |
| LB-90-DC89_1uM | Dose=1uM, (S)-Albuterol |
| JB-14-ZM03_0.1uM | Dose=0.1uM, Idronoxil, Apoptosis Inducers;BIRC4 Expression Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Inhibitors of Signal Transduction Pathways;Sphingosine Kinase Inhibitors targeting ENOX2, SPHK2 |
| DA-42-BI19_0.1uM | Dose=0.1uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB |
| CF-83-PM81_0.01uM | Dose=0.01uM |
| ZE-58-ZZ82_1uM | Dose=1uM |
| AE-32-UP21_1uM | Dose=1uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| FF-06-MO73_0.1uM | Dose=0.1uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3 |
| VA-03-RM19_10uM | Dose=10uM, N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide, 5-hydroxytryptamine receptor 1F receptor agonist targeting HTR1F |
| BD-45-EU45_10uM | Dose=10uM, 3-fluoro-4-[(5S)-7-[(4-fluorophenyl)methyl]-6-oxo-5-propyl-8H-imidazo[1,5-a]pyrazin-5-yl]benzonitrile |
| HA-53-FL63_0.1uM | Dose=0.1uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| OE-23-XH48_0.1uM | Dose=0.1uM, Glpg-1837, CFTR modulator targeting CFTR |
| HC-01-FD24_0.1uM | Dose=0.1uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol |
| BB-25-NU80_0.01uM | Dose=0.01uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| QF-09-IK44_0.1uM | Dose=0.1uM, Aryl carbamate analog 1 |
| ED-33-YZ72_0.1uM | Dose=0.1uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300 |
| PF-84-RH50_0.01uM | Dose=0.01uM |
| CA-43-WF29_10uM | Dose=10uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| YC-27-PB87_0.1uM | Dose=0.1uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5 |
| HE-17-FY34_0.1uM | Dose=0.1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| MB-35-NZ76_0.1uM | Dose=0.1uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone) |
| UE-90-AA63_0.1uM | Dose=0.1uM |
| AC-93-OJ74_10uM | Dose=10uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| JD-12-YK78_10uM | Dose=10uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| OC-21-IP52_1uM | Dose=1uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide |
| UA-06-UV98_1uM | Dose=1uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB |
| JA-46-LK88_1uM | Dose=1uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3 |
| BC-15-EL49_0.01uM | Dose=0.01uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| WD-97-SF27_10uM | Dose=10uM, 2-(((2-chloro-3-(2-methylpyridin-3-yl)-1-benzothiophen-5-yl)carbamoyl)amino)-N-(3-(methyl((3R)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-3-yl)amino)propyl)acetamide targeting DOT1L |
| AA-17-RC87_1uM | Dose=1uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| DE-93-IC37_0.01uM | Dose=0.01uM, Protein Tyrosine Phosphatase PTP-1C Inhibitors;Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1, PTPN6, PTPN11 |
| CE-95-YX02_0.01uM | Dose=0.01uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3 |
| VA-39-AQ18_0.1uM | Dose=0.1uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R |
| BF-31-BY55_10uM | Dose=10uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| AD-11-FZ23_0.01uM | Dose=0.01uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| LE-81-PG11_10uM | Dose=10uM, N-Methyl-N-((2-(1-(2-(methylamino)ethyl)piperidin-4-yl)pyridin-4-yl)methyl)-3-phenoxybenzamide, inhibitor of PRMT4 targeting CARM1 |
| LF-85-QP07_10uM | Dose=10uM, (5,6-Dimethyl-thieno[2,3-d]pyrimidin-4-ylsulfanyl)-acetic acid, Palmitoleoyl-Protein Carboxylesterase NOTUM Inhibitors targeting NOTUM |
| HF-82-PE14_10uM | Dose=10uM |
| AD-98-UM13_10uM | Dose=10uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E |
| ZB-67-SE99_0.1uM | Dose=0.1uM |
| KA-92-WY22_1uM | Dose=1uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1 |
| DB-41-SH04_0.1uM | Dose=0.1uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3 |
| DD-77-OI11_10uM | Dose=10uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2 |
| XF-42-ES96_1uM | Dose=1uM, (1-(4-Nitrophenyl)piperidin-3-yl)methanol, CDK Inhibitors targeting CCND2, CCND3, CDK6 |
| AE-06-JY57_0.01uM | Dose=0.01uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| HF-25-LA47_1uM | Dose=1uM, Cathepsin inhibitor 1, Cathepsin L Inhibitors targeting CTSL, CTSV, CTSL3P |
| AA-01-JO26_1uM | Dose=1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| BA-87-NF64_10uM | Dose=10uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| GE-28-EL65_1uM | Dose=1uM, 3-O-Methyldopa, DL- |
| FE-37-OL13_1uM | Dose=1uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| DC-91-ME12_0.01uM | Dose=0.01uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| LB-18-LH35_0.1uM | Dose=0.1uM, Flobufen, Lipoxygenase Inhibitors;Leukotriene BLT (LTB4) Antagonists;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, LTB4R, PTGS1, PTGS2, LTB4R2 |
| DD-99-WQ55_0.01uM | Dose=0.01uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)- |
| AA-79-SX47_0.1uM | Dose=0.1uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2 |
| WE-43-PZ45_0.1uM | Dose=0.1uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone |
| GB-84-KP45_0.01uM | Dose=0.01uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| ND-54-FY31_10uM | Dose=10uM, 2-Nitrobenzenesulfonamide |
| BF-49-KQ10_10uM | Dose=10uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA |
| RA-18-CU16_0.01uM | Dose=0.01uM |
| JA-63-WB39_1uM | Dose=1uM |
| AA-20-DK54_0.1uM | Dose=0.1uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| CF-65-GU65_0.01uM | Dose=0.01uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| AD-10-ZS64_0.01uM | Dose=0.01uM, Ivabradine |
| CB-97-LV32_1uM | Dose=1uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1 |
| OF-02-BG78_1uM | Dose=1uM |
| GB-56-TN25_1uM | Dose=1uM |
| YF-64-PQ11_0.01uM | Dose=0.01uM, Nitisinone, 4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors targeting HPD |
| CB-24-AT90_0.1uM | Dose=0.1uM, Monensin |
| XC-13-LW13_1uM | Dose=1uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile |
| CF-90-DA50_1uM | Dose=1uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1 |
| LD-14-PB06_1uM | Dose=1uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET |
| HD-29-LW24_0.1uM | Dose=0.1uM, Mocetinostat, Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;HDAC1/2 targeting HDAC1, HDAC2, HDAC3 |
| GE-14-EF51_10uM | Dose=10uM, LL-Z1272.Episilon. targeting FNTB |
| JB-72-IH66_1uM | Dose=1uM, CID 49843509, Proteinase activated receptor 2 (PAR2) partial agonist targeting F2RL1 |
| JF-74-GS02_0.01uM | Dose=0.01uM, alpha-Trifluoromethyl-alpha-hydroxybenzeneacetamide, T-Type Calcium Channel Blockers targeting KCNK3, KCNK9 |
| DA-86-GO43_0.1uM | Dose=0.1uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| IE-38-FB31_0.1uM | Dose=0.1uM |
| PD-11-LM65_1uM | Dose=1uM, Acifluorfen |
| GB-73-QS80_0.1uM | Dose=0.1uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| CB-59-FD39_10uM | Dose=10uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| KA-58-YE68_0.01uM | Dose=0.01uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B |
| CB-80-CK24_0.01uM | Dose=0.01uM, F1174-1718 |
| DD-96-DE39_1uM | Dose=1uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| VB-76-UE47_10uM | Dose=10uM |
| BA-39-OX47_0.01uM | Dose=0.01uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| BD-80-SK69_0.01uM | Dose=0.01uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7 |
| AE-89-KX47_1uM | Dose=1uM |
| HC-95-WQ65_10uM | Dose=10uM, Monomethyl Fumarate |
| HD-90-HQ28_0.01uM | Dose=0.01uM, 2-[[(3R)-pyrrolidin-3-yl]methylamino]-9-[[2-(trifluoromethoxy)phenyl]methyl]-7H-purin-8-one, PKC theta inhibitor targeting PRKCQ |
| HD-85-AJ28_1uM | Dose=1uM, Nelivaptan, DNA-Directed RNA Polymerase Inhibitors targeting AVPR1B |
| ZB-42-PL54_0.01uM | Dose=0.01uM |
| AC-55-CK61_0.01uM | Dose=0.01uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2 |
| ED-10-ED67_0.01uM | Dose=0.01uM, Dcebio |
| BE-89-DG86_0.01uM | Dose=0.01uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| DA-23-IF64_10uM | Dose=10uM, Lufironil, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| EA-73-MI41_1uM | Dose=1uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B |
| BB-43-YQ76_1uM | Dose=1uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| EA-25-VD74_0.1uM | Dose=0.1uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| AC-42-LW33_0.01uM | Dose=0.01uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one |
| JD-00-TT75_10uM | Dose=10uM, 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid, Lactate dehydrogenase inhibitor targeting LDHA, LDHB |
| DF-00-BU08_0.1uM | Dose=0.1uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4 |
| LE-33-GL18_0.01uM | Dose=0.01uM, 3-(4-Tert-butylbenzenesulfonamido)thiophene-2-carboxylic acid, Chemokine CCR9 Receptor Antagonists targeting CCR9 |
| DA-48-NC44_1uM | Dose=1uM |
| JF-30-FM28_0.01uM | Dose=0.01uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1 |
| AA-19-EX72_1uM | Dose=1uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A |
| CB-68-SP90_10uM | Dose=10uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| GF-32-FY02_0.01uM | Dose=0.01uM |
| GA-32-TO88_0.01uM | Dose=0.01uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9 |
| ND-35-VF18_0.1uM | Dose=0.1uM, (4-{[(5-{[(3-Chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, PTGER4 agonist;Prostanoid EP4 Agonists targeting PTGER4 |
| JF-93-EL43_0.1uM | Dose=0.1uM, Shp2 IN-1, SHP2 inhibitor targeting PTPN11 |
| AE-32-UP21_0.1uM | Dose=0.1uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| CC-31-VS31_1uM | Dose=1uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1 |
| XC-68-NP33_0.1uM | Dose=0.1uM, 1-(3-Phenylpropyl)-4-[[(4R)-2-(3-pyridyl)thiazolidin-4-yl]carbonyl]piperazine, PTAFR antagonist targeting PTAFR |
| KC-36-DK23_0.01uM | Dose=0.01uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1 |
| AB-74-VK99_0.01uM | Dose=0.01uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| GF-84-NF76_0.1uM | Dose=0.1uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1 |
| AB-23-MN29_1uM | Dose=1uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A |
| UD-03-SW43_10uM | Dose=10uM |
| UA-06-UV98_0.01uM | Dose=0.01uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB |
| CE-96-CZ90_10uM | Dose=10uM |
| DB-54-GQ68_0.1uM | Dose=0.1uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| YC-57-OY42_1uM | Dose=1uM, SB-267268, Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha-V/beta-3 antagonist, integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3 |
| KC-99-BS89_0.01uM | Dose=0.01uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine |
| RB-18-SX73_10uM | Dose=10uM |
| HE-99-KP87_0.01uM | Dose=0.01uM, {4-[4-(4-Isopropoxyphenyl)-5-(4-trifluoromethoxyphenyl)thiazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARD |
| HC-20-JJ81_10uM | Dose=10uM, 1-[[6-(2-Hydroxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| NE-14-AO67_10uM | Dose=10uM |
| HD-22-GO73_1uM | Dose=1uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2 |
| NC-52-AG88_1uM | Dose=1uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1 |
| CB-20-ND22_10uM | Dose=10uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| AA-02-FS13_0.1uM | Dose=0.1uM, Benzylhydrazine |
| AD-42-US78_0.01uM | Dose=0.01uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3 |
| CD-16-KY17_1uM | Dose=1uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| BB-41-XE67_0.01uM | Dose=0.01uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| AA-42-XZ05_10uM | Dose=10uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4 |
| OB-20-LP90_0.1uM | Dose=0.1uM, CID 11957585, OXTR antagonist targeting OXTR |
| FC-05-LX47_1uM | Dose=1uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| DD-85-WO51_0.1uM | Dose=0.1uM |
| DE-14-EG14_10uM | Dose=10uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| GE-68-FZ64_0.1uM | Dose=0.1uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA |
| LF-45-MW04_10uM | Dose=10uM, SB-408124, Orexin 1 receptor antagonist targeting HCRTR1 |
| EA-86-YK48_0.1uM | Dose=0.1uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1 |
| CB-83-LF14_0.1uM | Dose=0.1uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BF-29-LU75_0.01uM | Dose=0.01uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| AB-17-LS35_0.1uM | Dose=0.1uM, Prostanoid TP Antagonists |
| DE-27-WV67_1uM | Dose=1uM |
| DC-70-EK34_0.01uM | Dose=0.01uM, BF-844, CLRN stabilizer targeting CLRN1 |
| FA-91-OA82_10uM | Dose=10uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7 |
| WE-41-YO44_0.1uM | Dose=0.1uM, N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea, Angiogenesis Inhibitors;Urokinase (u-PA) Inhibitors targeting PLAU |
| FE-36-XA09_0.01uM | Dose=0.01uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3 |
| CE-72-GF32_0.1uM | Dose=0.1uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| SE-92-BP29_0.1uM | Dose=0.1uM |
| HB-24-GP45_0.1uM | Dose=0.1uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D |
| AC-02-SI74_0.1uM | Dose=0.1uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E |
| BD-70-PH02_1uM | Dose=1uM |
| HA-53-FL63_0.01uM | Dose=0.01uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| HB-43-TI61_0.1uM | Dose=0.1uM, Travoprost, Prostanoid FP Agonists targeting PTGFR |
| YD-59-WM48_1uM | Dose=1uM, 2-Methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane], CHRM1 agonist targeting CHRM1 |
| ED-33-YZ72_0.01uM | Dose=0.01uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300 |
| LC-11-GG16_0.1uM | Dose=0.1uM |
| CA-90-RU33_1uM | Dose=1uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| AE-89-KX47_0.1uM | Dose=0.1uM |
| CE-72-SF92_0.1uM | Dose=0.1uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| AA-67-TF79_10uM | Dose=10uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1 |
| HB-29-DM15_10uM | Dose=10uM, 4-(4-Guanidinobenzoyloxy)phenylacetate |
| SB-89-QK94_0.1uM | Dose=0.1uM |
| CB-92-FS28_1uM | Dose=1uM |
| AC-80-DI95_0.1uM | Dose=0.1uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| KE-28-MO72_0.01uM | Dose=0.01uM, N-[3-[[1-[6-[2-(dimethylamino)ethylamino]pyrimidin-4-yl]imidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide |
| ID-30-NC19_0.01uM | Dose=0.01uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R |
| GC-29-JC76_10uM | Dose=10uM, 1-[4-(4-Benzhydryl-piperazin-1-yl)-3-cyano-phenyl]-3-(3,5-dimethyl-isoxazol-4-yl)-urea, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| AD-92-QZ55_1uM | Dose=1uM, Tmc-353121 |
| FE-56-PV35_1uM | Dose=1uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B |
| VB-92-JQ72_0.1uM | Dose=0.1uM, N-[1-[[1-(2-fluoroethyl)piperidin-4-yl]-phenylmethyl]pyrazol-4-yl]-6,6-dimethyl-1,4,5,7-tetrahydroindazole-3-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK |
| AB-33-VM36_0.1uM | Dose=0.1uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS |
| BA-95-YU85_0.1uM | Dose=0.1uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| BF-02-QT56_0.1uM | Dose=0.1uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS |
| DE-99-OT37_10uM | Dose=10uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| AA-72-QI84_0.1uM | Dose=0.1uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| BA-86-YY52_0.01uM | Dose=0.01uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C |
| HF-29-JW14_0.1uM | Dose=0.1uM, Latrepirdine, NMDA Antagonists;5-HT6 Antagonists targeting HTR6 |
| AF-41-QY60_1uM | Dose=1uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| BC-39-JG96_0.01uM | Dose=0.01uM, Gemfibrozil, PPARalpha Agonists targeting PPARA |
| BA-72-YP01_0.1uM | Dose=0.1uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1 |
| DB-21-FY75_0.1uM | Dose=0.1uM, CID 67042933, CDK9 inhibitor targeting CDK9 |
| EB-07-JB09_0.1uM | Dose=0.1uM |
| FB-29-KC76_0.1uM | Dose=0.1uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5 |
| BB-93-VT73_0.1uM | Dose=0.1uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1 |
| UE-76-JL04_10uM | Dose=10uM |
| IF-06-KQ42_10uM | Dose=10uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4 |
| UE-01-HV71_1uM | Dose=1uM |
| CE-74-KU68_10uM | Dose=10uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| TC-94-QN39_0.1uM | Dose=0.1uM, Iferanserin |
| GA-77-MH38_1uM | Dose=1uM |
| AD-06-OB47_0.1uM | Dose=0.1uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| CB-13-WC72_0.1uM | Dose=0.1uM |
| DB-41-OE47_10uM | Dose=10uM |
| KB-57-TK65_0.1uM | Dose=0.1uM, Altenusin, Neutral Sphingomyelinase (N-SMase) Inhibitors;HIV Integrase Inhibitors targeting SMPD2 |
| BE-36-FY37_0.01uM | Dose=0.01uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| ZE-37-PE19_10uM | Dose=10uM, 6,8-Dichloro-7-methoxy-9H-beta-carboline targeting CHUK |
| GE-54-IF41_0.1uM | Dose=0.1uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3 |
| IC-43-CV07_1uM | Dose=1uM |
| AB-35-RU30_1uM | Dose=1uM |
| DC-13-RZ62_10uM | Dose=10uM, Ubidecarenone |
| BC-20-WA90_0.01uM | Dose=0.01uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| UB-41-DY23_1uM | Dose=1uM |
| NA-00-YS67_0.01uM | Dose=0.01uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS |
| EB-89-KM10_1uM | Dose=1uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| DA-15-PU65_0.1uM | Dose=0.1uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| YE-55-YX75_10uM | Dose=10uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4 |
| UB-28-WW60_1uM | Dose=1uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol |
| FB-99-SM50_10uM | Dose=10uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| UA-56-RO11_10uM | Dose=10uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3 |
| IA-48-KI53_0.1uM | Dose=0.1uM, Vinaxanthone, semaphorin inhibitor targeting SEMA3A |
| ZE-45-CG69_1uM | Dose=1uM |
| ED-15-OX47_10uM | Dose=10uM, Dimaprit, HRH2 agonist targeting HRH2 |
| BD-19-MD69_0.1uM | Dose=0.1uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| RE-04-MV24_0.1uM | Dose=0.1uM, Catpb, GPR43 antagonist targeting FFAR2 |
| IB-42-HL06_1uM | Dose=1uM, N-((1R,3aS,3bS,9aR,9bS,11aR)-9a,11a-dimethyl-1-((2R)-6-methylheptan-2-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta(a)phenanthren-7-ylidene)hydroxylamine, neuroprotective;Mitochondrial VDAC channel blocker targeting VDAC1 |
| DC-81-PH69_0.1uM | Dose=0.1uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1 |
| BC-95-MO06_0.01uM | Dose=0.01uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D |
| FB-67-OY39_0.01uM | Dose=0.01uM, Galnon, GALR2 agonist targeting GALR2 |
| BB-31-EB45_0.01uM | Dose=0.01uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1 |
| OE-89-FS84_10uM | Dose=10uM, Glycolysis pathway inhibitor targeting PFKFB3, PFKFB4 |
| AA-56-AB37_0.1uM | Dose=0.1uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1 |
| BE-41-AV63_0.1uM | Dose=0.1uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| IC-79-JZ26_0.01uM | Dose=0.01uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide |
| LA-24-RZ79_0.1uM | Dose=0.1uM, (2S,3R,4R,5S,6R)-2-[4-cyclopropyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2 |
| EB-11-MR93_0.01uM | Dose=0.01uM, 7beta,25-Dihydroxycholesterol |
| UE-41-CL72_1uM | Dose=1uM, N-(7-hydroxy-1-naphthyl)-N'-[3-(methylthio)phenyl]urea, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting P2RX1, TRPV1 |
| AC-93-QD45_0.1uM | Dose=0.1uM, targeting CGAS |
| HE-09-WC21_0.1uM | Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| FB-20-YQ23_0.1uM | Dose=0.1uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R |
| GC-07-UO80_10uM | Dose=10uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68 |
| PC-04-TO77_0.01uM | Dose=0.01uM |
| GE-98-ZI68_1uM | Dose=1uM |
| VE-15-RK04_10uM | Dose=10uM, Eudistomin N targeting CHUK |
| SF-77-LC15_0.01uM | Dose=0.01uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-10,10-dimethyl-2-oxa-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| HD-96-GX64_1uM | Dose=1uM, Methyl 4-[(3,6-dichloro-2-methoxybenzoyl)amino]benzoate targeting TAS1R1 |
| AA-77-MP68_0.01uM | Dose=0.01uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| CD-89-CG91_0.01uM | Dose=0.01uM |
| CF-61-EH59_0.01uM | Dose=0.01uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| BE-61-OB65_10uM | Dose=10uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| EB-52-HZ20_1uM | Dose=1uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1 |
| DC-08-CM08_0.01uM | Dose=0.01uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| AB-87-II61_0.01uM | Dose=0.01uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| S0-EE-Y9S3_0.1uM | Dose=0.1uM, PF-06471553, MOGAT 3 inhibitor targeting MOGAT3 |
| PD-14-CH80_0.01uM | Dose=0.01uM |
| AC-98-QW77_0.1uM | Dose=0.1uM, CGC-11047 free base |
| TC-45-JH72_0.1uM | Dose=0.1uM, Vesamicol targeting SLC18A3 |
| IA-77-NA41_10uM | Dose=10uM, 6-(4-((diethylamino)methyl)benzyl)-7-neopentyl-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK |
| RA-03-RQ19_10uM | Dose=10uM, 3-(6-fluoropyridin-3-yl)-2-(4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)pyridine, QPCT inhibitor targeting QPCT |
| AA-77-RI81_1uM | Dose=1uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B |
| AB-39-ED84_10uM | Dose=10uM, (+)-Ketoconazole, Antifungal;CYP inhibitor targeting CYP2D6, CYP3A5, CYP24A1, CYP21A2 |
| CA-60-LK14_0.1uM | Dose=0.1uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| BB-47-YI31_0.1uM | Dose=0.1uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| CE-03-PW65_10uM | Dose=10uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8 |
| QC-22-LC33_10uM | Dose=10uM, 4-fluoro-N-[4-(piperidin-1-ylcarbonyl)phenyl]benzamide |
| AB-64-ZX70_1uM | Dose=1uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| AA-98-MW52_0.1uM | Dose=0.1uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2 |
| BF-72-LI04_1uM | Dose=1uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| FE-09-JD34_1uM | Dose=1uM, Dot1L-IN-5 |
| AB-78-RM53_10uM | Dose=10uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1 |
| ID-96-UX79_0.01uM | Dose=0.01uM, Vaniprevir |
| RA-44-SU16_0.01uM | Dose=0.01uM, H4 Receptor antagonist 1, HRH4 antagonist targeting HRH4 |
| IB-96-PK68_0.1uM | Dose=0.1uM |
| GD-72-XO18_1uM | Dose=1uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| UB-83-HM84_1uM | Dose=1uM, Dexamethasone Pivalate |
| CB-38-AW77_0.1uM | Dose=0.1uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1 |
| FA-77-LS25_0.1uM | Dose=0.1uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| UD-50-IU51_10uM | Dose=10uM, Geranyl biphosphonate |
| GA-23-VF89_1uM | Dose=1uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| HA-83-MI31_0.01uM | Dose=0.01uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| KB-46-EJ60_1uM | Dose=1uM |
| NA-07-JX31_1uM | Dose=1uM |
| KD-88-RE18_0.01uM | Dose=0.01uM |
| GE-47-OO30_0.01uM | Dose=0.01uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3 |
| YE-01-JU83_0.1uM | Dose=0.1uM, N-p-Tolyl-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| TC-91-SL57_1uM | Dose=1uM |
| KC-15-HM70_0.01uM | Dose=0.01uM, Talarozole, An inhibitor of CYP26 targeting CYP26A1 |
| AE-78-XJ76_1uM | Dose=1uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| KA-58-YE68_0.1uM | Dose=0.1uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B |
| DB-92-FB02_1uM | Dose=1uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK |
| IB-30-KN41_0.1uM | Dose=0.1uM, ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, Known Thrombin inhibitor targeting F2 |
| EE-61-NU30_1uM | Dose=1uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7 |
| CB-13-ZM26_10uM | Dose=10uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA |
| CC-20-FN31_0.1uM | Dose=0.1uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| FA-10-DN36_0.1uM | Dose=0.1uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B |
| PA-53-BA36_0.1uM | Dose=0.1uM, Wx-uk1 free base, Urokinase (u-PA) Inhibitors targeting PLAU, PLG |
| TF-04-RX73_10uM | Dose=10uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile |
| EC-67-PV87_0.01uM | Dose=0.01uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| DE-28-ZP75_0.1uM | Dose=0.1uM, Deserpidine |
| AB-80-CK34_0.01uM | Dose=0.01uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| BD-36-VB52_1uM | Dose=1uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| GC-06-BU42_10uM | Dose=10uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD |
| VE-22-XI52_0.1uM | Dose=0.1uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| AF-33-AM86_10uM | Dose=10uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| LD-37-JE11_1uM | Dose=1uM, SR7826, Limk1 inhibitor targeting LIMK1 |
| BB-28-CT35_10uM | Dose=10uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ |
| MC-30-BS07_1uM | Dose=1uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG |
| RB-18-SX73_0.1uM | Dose=0.1uM |
| BF-59-OR93_0.1uM | Dose=0.1uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| KC-77-HN47_0.01uM | Dose=0.01uM, GABA(A) BZ Site Receptor Partial Agonists |
| FE-82-JV20_0.01uM | Dose=0.01uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2 |
| CE-23-HP88_0.01uM | Dose=0.01uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AC-50-FR41_0.01uM | Dose=0.01uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| MA-31-VM30_1uM | Dose=1uM, Sabeluzole |
| GA-66-IX54_0.1uM | Dose=0.1uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| DF-00-BX35_0.01uM | Dose=0.01uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| AC-99-ZN13_10uM | Dose=10uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| AE-62-QI94_0.1uM | Dose=0.1uM, Zankiren, Renin Inhibitors targeting REN |
| KA-82-CN45_10uM | Dose=10uM, morpholinocarbonyl-Phe-hPhe-CH2F, m-Calpain (Calpain-2) Inhibitors;Cathepsin B Inhibitors;Cathepsin L Inhibitors targeting CAPN2, CTSB, CTSL |
| SE-81-RI20_0.01uM | Dose=0.01uM |
| UE-90-KK72_10uM | Dose=10uM |
| HA-81-VN33_10uM | Dose=10uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4 |
| EE-99-ZM45_0.01uM | Dose=0.01uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H |
| BB-69-WN73_0.1uM | Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| MB-35-NZ76_1uM | Dose=1uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone) |
| PE-86-SC73_10uM | Dose=10uM, PF-543, SPHK1 inhibitor targeting SPHK1 |
| DB-73-KP48_10uM | Dose=10uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN |
| BC-97-SZ42_10uM | Dose=10uM, (R)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine, Known Gamma secretase modulator targeting PSEN2 |
| KE-41-JG66_10uM | Dose=10uM, 6-[(2-{[4-(4-Bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile |
| YA-85-VH07_0.1uM | Dose=0.1uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1 |
| KB-45-CF78_0.01uM | Dose=0.01uM, 2-Benzyl-4H-3,1-benzoxazin-4-one |
| CA-48-CT20_10uM | Dose=10uM |
| AF-76-AY17_0.1uM | Dose=0.1uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| WF-85-JN16_0.1uM | Dose=0.1uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| SC-59-TX35_0.01uM | Dose=0.01uM |
| FF-61-BU95_0.1uM | Dose=0.1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB |
| AF-41-BY55_10uM | Dose=10uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2 |
| IA-80-OW42_1uM | Dose=1uM, N-(3-Ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline, Cathepsin B Inhibitors targeting CTSB |
| EE-02-BO83_0.01uM | Dose=0.01uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| NB-31-SG91_10uM | Dose=10uM, 6-O-Methyl Mycophenolic Acid Methyl Ester |
| AB-02-CF97_0.01uM | Dose=0.01uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| ZD-23-ZF57_1uM | Dose=1uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2 |
| KB-59-KM40_10uM | Dose=10uM |
| AA-15-VA57_10uM | Dose=10uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| CC-85-AY05_0.01uM | Dose=0.01uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB |
| KE-30-PJ81_10uM | Dose=10uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| MB-50-ZI28_0.01uM | Dose=0.01uM, (4S)-4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one |
| CC-90-FE70_1uM | Dose=1uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| JD-95-WC21_0.01uM | Dose=0.01uM, 2-(2-hydroxyphenyl)-3-phenethylquinazolin-4(3H)-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| BC-87-PJ84_1uM | Dose=1uM, Urapidil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| KE-30-PJ81_1uM | Dose=1uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| AC-70-KV26_0.1uM | Dose=0.1uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| BF-79-GG96_10uM | Dose=10uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| FC-22-VC55_1uM | Dose=1uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR |
| DD-47-GB64_1uM | Dose=1uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| AA-44-BX20_1uM | Dose=1uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| FE-94-WT30_0.01uM | Dose=0.01uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2 |
| FF-22-NB12_0.1uM | Dose=0.1uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| SA-32-CC58_1uM | Dose=1uM, Piperidin-4-yl-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-amine, CDK inhibitors targeting CCNB2, CCNB3 |
| WA-06-QR58_10uM | Dose=10uM, [(E)-(2-hydroxy-5-phenylphenyl)methylideneamino]thiourea targeting CDK5R1 |
| TC-22-OM27_1uM | Dose=1uM |
| LF-64-NB46_1uM | Dose=1uM, Fti 277, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| AC-21-PO16_10uM | Dose=10uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate |
| DD-26-RY82_1uM | Dose=1uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR |
| LA-44-KW22_0.1uM | Dose=0.1uM, targeting GSK3B |
| QD-32-CW16_1uM | Dose=1uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R |
| DD-89-WQ95_0.01uM | Dose=0.01uM |
| CB-49-OG36_0.1uM | Dose=0.1uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1 |
| RA-01-US54_0.01uM | Dose=0.01uM |
| FF-61-BU95_10uM | Dose=10uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB |
| CB-52-IL46_0.01uM | Dose=0.01uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| BB-84-DG64_0.01uM | Dose=0.01uM |
| JB-14-TF61_0.01uM | Dose=0.01uM, Plerixafor, HIV Attachment Inhibitors;Chelating Agents;CXCR4 antagonist;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4 |
| SE-89-DO49_0.1uM | Dose=0.1uM, [4-[[(3R)-7-(5-cyanofuran-2-yl)-4-(4-methoxyphenyl)sulfonyl-1-[(3-methylimidazol-4-yl)methyl]-3,5-dihydro-2H-1,4-benzodiazepin-3-yl]methyl]phenyl] N-benzylcarbamate, Rab GGTase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting RABGGTA, RABGGTB |
| AB-12-PP61_0.1uM | Dose=0.1uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2 |
| BF-79-GG96_0.1uM | Dose=0.1uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| BE-66-UB12_0.1uM | Dose=0.1uM |
| ID-31-AD14_0.01uM | Dose=0.01uM, 3-(3,4-dimethoxyphenyl)-N-(3-morpholin-4-ylpropyl)pyrazolo[1,5-a]pyrimidin-5-amine |
| HE-29-OW54_10uM | Dose=10uM, Camicinal, Motilin Receptor Agonists targeting MLNR |
| AB-78-RM53_0.01uM | Dose=0.01uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1 |
| NA-07-JX31_0.01uM | Dose=0.01uM |
| RD-66-DP49_0.1uM | Dose=0.1uM, 2-[(1-Methyl-2-Oxidanyl-4-Oxidanylidene-Quinolin-3-Yl)carbonylamino]ethanoic Acid, Prolyl 4-Hydroxylase Inhibitors;Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| LE-94-HL75_0.01uM | Dose=0.01uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2 |
| FD-88-CF51_0.1uM | Dose=0.1uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| XC-50-TN39_0.1uM | Dose=0.1uM |
| AA-92-NW83_0.1uM | Dose=0.1uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| AB-14-GQ48_0.1uM | Dose=0.1uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| IE-02-TR35_1uM | Dose=1uM, (S)-N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, NPSR1 antagonist targeting NPSR1 |
| BC-43-HJ69_1uM | Dose=1uM, Phenelzine, MAO Inhibitors targeting MAOA |
| AB-04-MQ83_0.01uM | Dose=0.01uM |
| HA-82-XO48_0.01uM | Dose=0.01uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK |
| KD-44-PB06_0.01uM | Dose=0.01uM, CID 10461016 |
| OA-62-NJ00_0.01uM | Dose=0.01uM |
| HB-43-TI61_1uM | Dose=1uM, Travoprost, Prostanoid FP Agonists targeting PTGFR |
| HB-45-XQ45_0.01uM | Dose=0.01uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| UB-40-KU41_0.01uM | Dose=0.01uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide |
| CA-31-EL19_1uM | Dose=1uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM |
| IA-95-KW09_10uM | Dose=10uM, (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester, Leukotriene Antagonists targeting CYSLTR1 |
| GC-08-VP20_10uM | Dose=10uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| TC-80-LY86_10uM | Dose=10uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid |
| HD-18-YL30_0.01uM | Dose=0.01uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1 |
| YE-46-YA12_0.01uM | Dose=0.01uM, 2-(4-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1 |
| DF-84-RT50_0.01uM | Dose=0.01uM |
| GB-37-WI36_0.01uM | Dose=0.01uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| OB-01-DJ93_10uM | Dose=10uM, Mardepodect, Phosphodiesterase 10A Inhibitors targeting PDE10A |
| QF-41-QW99_0.01uM | Dose=0.01uM, Fdl169, CFTR corrector targeting CFTR |
| GC-86-TD91_1uM | Dose=1uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| GE-47-OO30_0.1uM | Dose=0.1uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3 |
| CB-16-JO93_1uM | Dose=1uM |
| OF-37-IT01_0.01uM | Dose=0.01uM |
| YD-59-WM48_0.1uM | Dose=0.1uM, 2-Methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane], CHRM1 agonist targeting CHRM1 |
| FC-36-SU62_1uM | Dose=1uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| JF-14-JC89_0.1uM | Dose=0.1uM, Halicin, SAPK1c (JNK1) Inhibitors targeting MAPK8 |
| CC-29-RG66_0.1uM | Dose=0.1uM |
| XB-39-YT35_1uM | Dose=1uM, 4-[[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide, OPRD1 agonist targeting OPRD1 |
| AC-33-YJ09_10uM | Dose=10uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| RA-18-CU16_10uM | Dose=10uM |
| DF-84-RT50_0.1uM | Dose=0.1uM |
| AA-98-PM63_0.1uM | Dose=0.1uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| JA-38-XE73_0.1uM | Dose=0.1uM |
| CB-36-QH71_0.1uM | Dose=0.1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| ME-47-KQ59_0.01uM | Dose=0.01uM, 4-(3-benzyl-4-{[5-(2-fluorophenyl)furan-2-yl]methylidene}-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid targeting BTRC |
| KA-63-FH23_1uM | Dose=1uM, Cgp 77675, Src Kinase Inhibitors targeting SRC |
| ED-11-BL19_0.1uM | Dose=0.1uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A |
| MC-36-PM07_0.1uM | Dose=0.1uM, Pd 150606, Calpain Inhibitors targeting CAPN1 |
| CA-66-GI09_0.1uM | Dose=0.1uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR |
| NB-24-VE53_0.1uM | Dose=0.1uM, Tebanicline, Nicotinic Receptor Agonists targeting CHRNA3, CHRNA4 |
| EF-75-JG46_10uM | Dose=10uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F |
| PB-18-HD85_1uM | Dose=1uM |
| AE-38-LX10_0.01uM | Dose=0.01uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| KA-53-KV02_1uM | Dose=1uM, 3-(phenylsulfonyl)-N-((tetrahydrofuran-2-yl)methyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine, HTR6 antagonist;5-HT6 Antagonists targeting HTR6 |
| DC-22-HS83_10uM | Dose=10uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AC-59-ZD79_10uM | Dose=10uM, N6-Methyladenosine |
| DA-18-QP05_10uM | Dose=10uM |
| AE-00-WU78_10uM | Dose=10uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E |
| BF-61-IO76_1uM | Dose=1uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| PE-58-WU11_0.01uM | Dose=0.01uM |
| WD-08-QT63_1uM | Dose=1uM |
| FE-12-TO68_1uM | Dose=1uM |
| EB-18-PP65_0.1uM | Dose=0.1uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK |
| FB-99-SM50_1uM | Dose=1uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| HA-10-LJ21_0.01uM | Dose=0.01uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88 |
| HA-88-JB21_10uM | Dose=10uM, 1,5-Dihydroxyisoquinoline, PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| BC-61-ZY95_0.01uM | Dose=0.01uM |
| DD-42-PC65_1uM | Dose=1uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| BA-40-IU73_1uM | Dose=1uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR |
| DC-84-CJ21_1uM | Dose=1uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3 |
| CD-90-SN76_0.1uM | Dose=0.1uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1 |
| S0-EE-XMXE_0.01uM | Dose=0.01uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2 |
| AD-86-ES28_0.1uM | Dose=0.1uM, LY2033298, M4 positive allosteric modulator targeting CHRM4 |
| AE-04-SN76_0.1uM | Dose=0.1uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6 |
| HF-00-QG19_0.1uM | Dose=0.1uM, R-Psop, Neuromedin U Receptor 2 (NMU2) Ligands targeting NMUR2 |
| AA-67-FZ57_10uM | Dose=10uM, Isothiourea-1a, HIV Attachment Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4 |
| HA-81-VN33_1uM | Dose=1uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4 |
| YB-79-DM48_10uM | Dose=10uM, 3-Octadecyloxy-2-methoxypropylphosphonocholine, Angiogenesis Inhibitors;Lipid Homeostasis Modulator;Membrane Metabolism Inhibitor;CoA-Independent Transacyclase (CoA-IT) Inhibitors targeting PNPLA4, PLCB1, PNPLA2, PNPLA3 |
| DD-41-AE67_0.01uM | Dose=0.01uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| QB-34-NU46_0.01uM | Dose=0.01uM, (3R,4aR,10aR)-1-methyl-3-[(4-methylpyrimidin-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| FE-31-JU80_10uM | Dose=10uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid |
| LA-21-GQ75_0.01uM | Dose=0.01uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR |
| LE-60-VC29_1uM | Dose=1uM, N-(2,4-dichlorobenzyl)-1-benzyl-5-oxopyrrolidine-3-carboxamide, P2X7 Receptor Antagonists targeting P2RX7 |
| EE-60-CG74_10uM | Dose=10uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| OB-15-UL37_10uM | Dose=10uM, [(1S)-1-[ethyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]ethyl]phosphonic acid targeting GRIA4 |
| FA-12-QB17_0.1uM | Dose=0.1uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2 |
| VA-15-ZR21_0.01uM | Dose=0.01uM |
| AD-02-XI19_0.01uM | Dose=0.01uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT |
| DF-70-CD57_0.01uM | Dose=0.01uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2 |
| NC-54-XY91_0.01uM | Dose=0.01uM, 1-(4-Chlorophenyl)-5-cyclohexylpyrazolo[3,4-d]pyrimidin-4-one |
| EB-82-QI99_1uM | Dose=1uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| HD-89-HC56_1uM | Dose=1uM, eIF4A3-IN-2 targeting EIF4A3 |
| EC-72-RE74_0.1uM | Dose=0.1uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L |
| IA-41-GR68_0.1uM | Dose=0.1uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP |
| UD-16-YL39_10uM | Dose=10uM, 3-amino-N-(5-benzoyl-2-piperazin-1-ylphenyl)pyrazine-2-carboxamide |
| DE-28-XP50_10uM | Dose=10uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| MD-91-JM80_10uM | Dose=10uM, N-methyl-2-(4-phenylmethoxypiperidin-1-yl)ethanamine, PRMT4/6 inhibitor;PRMT4 and PRMT6 inhibitor targeting CARM1, PRMT6 |
| CA-63-LW25_0.1uM | Dose=0.1uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| EB-97-AV17_1uM | Dose=1uM, Diphenylamine-2,2'-dicarboxylic acid |
| CA-88-FC74_10uM | Dose=10uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4 |
| IF-43-EO10_10uM | Dose=10uM |
| AA-47-BS40_10uM | Dose=10uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| OE-78-XD40_0.1uM | Dose=0.1uM, (+)-Dibenzoyl-D-tartaric acid, Dopamine D3 Antagonists targeting DRD3 |
| KC-95-ZW49_1uM | Dose=1uM, 2-thiophen-2-ylethyl (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoate, 12-Lipoxygenase Inhibitors targeting ALOX12 |
| IA-27-CK10_0.1uM | Dose=0.1uM, Sch 28080, Reversible H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| AC-77-BC52_10uM | Dose=10uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine |
| MB-86-VG83_0.1uM | Dose=0.1uM, N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, BRD7/9 inhbitor;BRD9 inhibitor;BRD7/9 Bromodomain Inhibitor targeting BRD7, BRD9 |
| HA-51-DA67_0.1uM | Dose=0.1uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR |
| BD-33-HT38_1uM | Dose=1uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| DD-31-LY65_0.1uM | Dose=0.1uM, Menatetrenone |
| AA-34-SG19_10uM | Dose=10uM, Abitesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| QB-42-ET79_1uM | Dose=1uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1 |
| IF-78-GO12_0.1uM | Dose=0.1uM, Acetaminophen, Cyclooxygenase-3 Inhibitors targeting PTGS1 |
| OE-78-TD20_1uM | Dose=1uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1 |
| HA-33-ZI46_10uM | Dose=10uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| KA-81-AG66_0.1uM | Dose=0.1uM, Alvocidib, CDK9 inhibitor targeting CDK9, CCNB2 |
| CE-52-XV55_1uM | Dose=1uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A |
| AB-37-JM16_10uM | Dose=10uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB |
| CA-96-UO48_1uM | Dose=1uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| ZE-13-SI09_10uM | Dose=10uM, (1-Amino-2-cyclohexylethyl)phosphonic acid, Leucine Aminopeptidase inhibitor targeting LAP3 |
| YB-74-BG62_0.01uM | Dose=0.01uM, Dopamine D2/3 receptor partial agonist targeting DRD3 |
| HB-92-XE24_1uM | Dose=1uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| BF-13-HM71_0.01uM | Dose=0.01uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| FA-57-CO50_1uM | Dose=1uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| DC-08-KP05_0.01uM | Dose=0.01uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| AA-15-VA57_0.01uM | Dose=0.01uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| CF-97-KZ12_0.01uM | Dose=0.01uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| GB-45-CJ58_0.1uM | Dose=0.1uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C |
| BA-10-WH12_10uM | Dose=10uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| FF-08-DP35_1uM | Dose=1uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2 |
| LC-03-KY64_0.01uM | Dose=0.01uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2 |
| CB-42-EI79_1uM | Dose=1uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1 |
| GF-90-DG49_0.1uM | Dose=0.1uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| HF-00-QG19_1uM | Dose=1uM, R-Psop, Neuromedin U Receptor 2 (NMU2) Ligands targeting NMUR2 |
| GE-68-FZ64_0.01uM | Dose=0.01uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA |
| LC-83-NR62_0.01uM | Dose=0.01uM, (3R)-N~2~-(cyclopropylmethyl)-N~1~-hydroxy-3-(3-hydroxybenzyl)-N~4~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-L-aspartamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5 |
| LB-24-KP05_1uM | Dose=1uM, Oxalylglycine, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| JE-86-QG78_0.1uM | Dose=0.1uM, Ibrolipim |
| KD-00-UJ81_0.1uM | Dose=0.1uM, 3-anilinoisoquinolin-1(2H)-one |
| ED-14-GQ53_0.01uM | Dose=0.01uM, 2-(4-Methylphenoxy)benzoic acid |
| JE-11-UD64_10uM | Dose=10uM, 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-, Dopamine D3 Agonists targeting DRD3 |
| ME-31-RM40_0.01uM | Dose=0.01uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| ID-12-NA84_0.01uM | Dose=0.01uM, 1-(2-Methoxyphenyl)-4-(3-phenylpropyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| QD-13-FQ44_0.1uM | Dose=0.1uM, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, PDCD1, PDE1A, PDE1C, PDE4C, PDE6A, PDE6C, PDE6D, PDE6G, PDE6H, PDE8A, PDE9A, PDE6B, PDE8B |
| BE-07-IS45_0.1uM | Dose=0.1uM, Antalarmin, CRHR1 antagonist targeting CRHR1 |
| AB-27-LS15_10uM | Dose=10uM, bisindolylmaleimide VIII, Protein Kinase C (PKC) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CAMK2D, PRKCA |
| DA-49-ZD74_10uM | Dose=10uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| MA-31-VM30_0.01uM | Dose=0.01uM, Sabeluzole |
| HB-19-DP22_1uM | Dose=1uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| HA-22-YE24_0.1uM | Dose=0.1uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR |
| BA-39-LQ60_0.01uM | Dose=0.01uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| MC-51-BT07_10uM | Dose=10uM, Cx516, AMPA Receptor Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AC-59-ZD79_0.01uM | Dose=0.01uM, N6-Methyladenosine |
| BD-85-GY20_1uM | Dose=1uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| IC-61-PQ10_0.1uM | Dose=0.1uM, Coumate, Steryl Sulfatase Inhibitors targeting STS |
| KA-51-CQ55_1uM | Dose=1uM, N-Cyclohexyl-4-(4-phenyl-1-(piperazin-1-yl)-2,6-naphthyridin-3-yl)pyridin-2-amine, PKD inhibitor targeting PRKD1 |
| OA-16-KC73_0.01uM | Dose=0.01uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1 |
| EA-32-CY22_0.01uM | Dose=0.01uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| MF-41-QM60_10uM | Dose=10uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9 |
| AE-72-UP91_0.1uM | Dose=0.1uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| DE-73-EF24_0.01uM | Dose=0.01uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| PE-68-QD35_0.1uM | Dose=0.1uM, Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate, TGFBR2 degrador targeting TGFBR2 |
| S0-EE-X3ZZ_0.1uM | Dose=0.1uM, Pesampator targeting GRIA1 |
| DD-85-KU00_10uM | Dose=10uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| CA-60-RU13_1uM | Dose=1uM |
| FF-01-OH44_1uM | Dose=1uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38 |
| BC-09-XQ45_1uM | Dose=1uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2 |
| GB-51-MD79_10uM | Dose=10uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG |
| HA-57-XH23_10uM | Dose=10uM |
| LF-92-IK63_0.01uM | Dose=0.01uM, 2-{[4-Amino-3-(3-Fluoro-4-Hydroxyphenyl)-1h-Pyrazolo[3,4-D]pyrimidin-1-Yl]methyl}-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD, PIK3CG |
| AC-14-JQ68_1uM | Dose=1uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| IB-26-FG03_0.1uM | Dose=0.1uM, 3-(2-amino-2-methylpropyl)-1H-indol-5-ol |
| EE-49-CD29_0.01uM | Dose=0.01uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| FC-67-SZ42_10uM | Dose=10uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| GB-27-AY54_0.1uM | Dose=0.1uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| DF-45-GA42_1uM | Dose=1uM, SB 224289, HTR1B antagonist targeting HTR1B |
| EF-62-IO23_0.01uM | Dose=0.01uM |
| OA-54-FL10_0.01uM | Dose=0.01uM |
| HD-28-QL60_0.1uM | Dose=0.1uM, (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine, Na+/H+ Exchanger type 3 (NHE-3) Inhibitors targeting SLC9A3 |
| DA-60-KU38_0.01uM | Dose=0.01uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| ED-32-VE54_1uM | Dose=1uM, Thiosalicylic Acid |
| ME-93-CO85_0.01uM | Dose=0.01uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine |
| AD-54-FG24_0.01uM | Dose=0.01uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB |
| AC-41-IB85_0.1uM | Dose=0.1uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| CF-56-LO98_0.01uM | Dose=0.01uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| MB-49-LL22_1uM | Dose=1uM, Pinometostat, Dot1L / KMT4;Dot1L inhibitor targeting DOT1L |
| BD-12-CM09_0.01uM | Dose=0.01uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3 |
| GF-81-MU70_0.1uM | Dose=0.1uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3 |
| WA-98-CM36_0.01uM | Dose=0.01uM, 5-chloro-N-(5-chloro-2-hydroxy-phenyl)-2-methoxy-benzamide, KCNMA1 gene stimulator;BKca channel opener targeting KCNMA1 |
| LA-69-OL77_0.01uM | Dose=0.01uM, 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one, NR2B Antagonists targeting GRIN2B |
| EA-22-SB72_0.1uM | Dose=0.1uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R |
| AC-93-LT43_1uM | Dose=1uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2 |
| XD-50-BD50_0.01uM | Dose=0.01uM, 2-(4-Amylcinnamoyl)amino-4-chlorobenzoic acid, Phospholipase A2 (PLA2) Inhibitors targeting PLA2G10 |
| DE-15-GD59_1uM | Dose=1uM |
| LC-54-XS57_0.01uM | Dose=0.01uM |
| CC-37-QW80_1uM | Dose=1uM |
| UA-06-UV98_10uM | Dose=10uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB |
| AA-72-QI84_0.01uM | Dose=0.01uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| BC-26-LE04_1uM | Dose=1uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| AE-05-CB45_1uM | Dose=1uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| UF-61-QB73_1uM | Dose=1uM, (S)-1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropan-1-ol, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors targeting CYP17A1 |
| S0-EE-X9NZ_10uM | Dose=10uM, Methyl 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoate, Retinol-Binding Protein 4 Inhibitors targeting RBP4 |
| XD-01-OY13_0.01uM | Dose=0.01uM, Cvt-12012, SCD1) Inhibitors;Stearoyl-CoA Desaturase (delta-9 Desaturase;SCD targeting SCD |
| CA-26-BI29_1uM | Dose=1uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR |
| WC-75-IK59_10uM | Dose=10uM, 8-(4-hydroxybutyl)-1-methyl-7-phenyl-1H-imidazo[1,2-a]purine-2,4(3H,8H)-dione, EphB4 Inhibitors targeting EPHB4 |
| HF-36-FK93_0.01uM | Dose=0.01uM, (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide, SPHK1 inhibitor targeting SPHK1 |
| HB-43-TI61_10uM | Dose=10uM, Travoprost, Prostanoid FP Agonists targeting PTGFR |
| CA-26-UY62_0.01uM | Dose=0.01uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| NF-19-JL47_1uM | Dose=1uM, 2-Amino-5-[(1-Methoxy-2-Methylindolizin-3-Yl)carbonyl]benzoic Acid, Allosteric inhibitor binding extracellular domain targeting FGFR3, FGFR2, FGFR4 |
| BE-42-IC00_0.1uM | Dose=0.1uM, Zygosporin A, actin polymerization targeting ACTA1 |
| LE-40-JW92_1uM | Dose=1uM |
| LB-67-FA06_0.1uM | Dose=0.1uM |
| FA-06-GA39_0.01uM | Dose=0.01uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR |
| JA-74-VZ14_10uM | Dose=10uM, CID 25108278, PAR2 Agonists;F2RL1 agonist targeting F2RL1 |
| SA-03-IQ14_0.1uM | Dose=0.1uM |
| JC-67-FV32_1uM | Dose=1uM, 4-[4-(2-Pyrrolidin-1-ylethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine-6-carboxamide targeting SIRT2, SIRT3, SIRT1 |
| HB-75-KT12_1uM | Dose=1uM |
| HA-99-UT82_0.1uM | Dose=0.1uM |
| CC-88-JZ09_10uM | Dose=10uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| BB-36-LB57_0.01uM | Dose=0.01uM |
| EA-73-MI41_0.1uM | Dose=0.1uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B |
| BE-47-IP08_10uM | Dose=10uM, Acifran, GPR109A agonist targeting HCAR2 |
| CF-35-NN63_1uM | Dose=1uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| EF-46-LK88_0.01uM | Dose=0.01uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate |
| SD-12-UF05_0.1uM | Dose=0.1uM, Phenylsulfamate, Carbonic anhydrase inhibitor targeting CA2 |
| DB-11-SS01_0.1uM | Dose=0.1uM, Thal-sns-032 targeting CDK9 |
| DD-36-YH76_0.01uM | Dose=0.01uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| CB-77-KL88_1uM | Dose=1uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| BA-44-SG89_1uM | Dose=1uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD |
| MF-04-HB41_1uM | Dose=1uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1 |
| KA-73-PR92_10uM | Dose=10uM |
| FD-79-KT27_10uM | Dose=10uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| AD-85-ME82_0.1uM | Dose=0.1uM, 15-O-Desmethylascomycin |
| GF-57-LR72_0.01uM | Dose=0.01uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| FE-06-GR60_0.01uM | Dose=0.01uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| AB-12-IS33_10uM | Dose=10uM, Melphalan |
| AD-27-JS45_10uM | Dose=10uM, 4-Methylhistamine, HRH4 agonist targeting HRH4 |
| VA-39-AQ18_10uM | Dose=10uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R |
| ND-15-RC31_0.01uM | Dose=0.01uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1 |
| RF-05-PV01_0.01uM | Dose=0.01uM, 6-Chloro-3-((4-methylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one, SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4, PBRM1 |
| HC-18-NB46_10uM | Dose=10uM, N-Acetyl-6-methoxytryptamine |
| AC-58-RM63_0.1uM | Dose=0.1uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2 |
| FF-55-AD09_10uM | Dose=10uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183 |
| AD-51-ZE47_0.01uM | Dose=0.01uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| BF-94-CQ58_0.01uM | Dose=0.01uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DA-17-YW85_10uM | Dose=10uM, Tgba01AD |
| JF-91-IG96_0.01uM | Dose=0.01uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one |
| ID-30-NC19_1uM | Dose=1uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R |
| HC-18-NB46_0.1uM | Dose=0.1uM, N-Acetyl-6-methoxytryptamine |
| AD-99-SN88_0.01uM | Dose=0.01uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| BE-48-IT75_10uM | Dose=10uM |
| NF-27-AQ24_10uM | Dose=10uM, GR 46611, HTR1D agonist targeting HTR1D |
| AE-79-LG46_1uM | Dose=1uM, Gepirone |
| JA-80-KW72_0.1uM | Dose=0.1uM, 9-[(2-Methyl-1,2,4-triazol-3-yl)methoxy]-6-phenyl-4,5,7,8-tetrazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraene targeting GABRA2, GABRA3 |
| AB-11-QV43_1uM | Dose=1uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| AF-71-GL94_0.1uM | Dose=0.1uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide |
| IA-95-KW09_0.1uM | Dose=0.1uM, (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester, Leukotriene Antagonists targeting CYSLTR1 |
| CB-59-FD39_0.1uM | Dose=0.1uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| ED-35-EX82_0.1uM | Dose=0.1uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO |
| AC-57-ZF49_1uM | Dose=1uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| GB-27-AY54_10uM | Dose=10uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| EC-17-MF19_10uM | Dose=10uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| FC-68-LJ11_1uM | Dose=1uM |
| FD-49-XC21_0.1uM | Dose=0.1uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| DC-45-WU45_0.1uM | Dose=0.1uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2 |
| FE-19-OW54_0.01uM | Dose=0.01uM, Fenofibric Acid |
| IA-94-MZ54_10uM | Dose=10uM, BC-1215, FBXO3 gene inhibitor targeting FBXO3 |
| AW-15-2439_0.1uM | Dose=0.1uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| BA-73-MC77_10uM | Dose=10uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1 |
| AD-89-LX67_10uM | Dose=10uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| MF-17-BD63_0.1uM | Dose=0.1uM, N-[4'-Methyl-2-(pyridin-3-ylamino)-[4,5]bithiazolyl-2'-yl]-acetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| IC-08-NY46_0.1uM | Dose=0.1uM, N-(3-phenoxycinnamyl)acetohydroxamic acid |
| S0-EE-Y96U_10uM | Dose=10uM, Jnj-42165279, FAAH inhibitor targeting FAAH |
| IA-37-FR87_0.1uM | Dose=0.1uM, Pexacerfont, CRF1 Antagonists targeting CRHR1 |
| AA-98-HX85_0.1uM | Dose=0.1uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| AA-12-SS68_0.1uM | Dose=0.1uM |
| SB-75-TY18_0.1uM | Dose=0.1uM |
| AE-95-KU30_1uM | Dose=1uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C |
| CD-84-BU23_0.01uM | Dose=0.01uM, Oseltamivir |
| OA-15-DB28_10uM | Dose=10uM |
| SC-59-TX35_0.1uM | Dose=0.1uM |
| AC-31-SL44_10uM | Dose=10uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B |
| CD-41-RE87_0.1uM | Dose=0.1uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R |
| JB-08-BL30_0.1uM | Dose=0.1uM, 3-{1-[3-(biphenyl-4-ylamino)-3-oxopropyl]-1H-1,2,3-triazol-4-yl}-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| CB-46-FO63_0.01uM | Dose=0.01uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| IF-22-EA89_0.1uM | Dose=0.1uM, Gusperimus |
| CE-88-RJ81_0.1uM | Dose=0.1uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| XA-88-GW50_0.01uM | Dose=0.01uM |
| KC-07-HN67_1uM | Dose=1uM, Ormetoprim, P2X2/3 Receptor Antagonists;P2X3 Receptor Antagonists targeting P2RX3 |
| UF-98-OM26_10uM | Dose=10uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| NC-85-PZ41_0.01uM | Dose=0.01uM, Mln-4760, Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors targeting ACE2 |
| GE-29-BW04_10uM | Dose=10uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A |
| BE-61-CB85_1uM | Dose=1uM |
| IE-49-AI35_0.01uM | Dose=0.01uM, Sovateltide, EDNRB agonist targeting EDNRB |
| BC-15-MR23_0.01uM | Dose=0.01uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT |
| ED-25-BD54_10uM | Dose=10uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| DE-20-VX20_1uM | Dose=1uM |
| AF-30-GH67_0.1uM | Dose=0.1uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| BC-25-VR48_0.1uM | Dose=0.1uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB |
| UF-14-LK87_0.01uM | Dose=0.01uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1 |
| KD-31-TU05_1uM | Dose=1uM, Lesinurad targeting SLC22A11, SLC22A12 |
| BD-99-DU20_0.01uM | Dose=0.01uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| YD-38-CI01_1uM | Dose=1uM, 4-Amino-5-chloro-2-methoxy-benzoic acid 2-pyrrolidin-1-yl-ethyl ester, HTR4 agonist targeting HTR4 |
| MD-09-FE75_10uM | Dose=10uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2 |
| WC-82-YS26_0.01uM | Dose=0.01uM, 4-[5-(2-methylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine |
| BD-47-DS20_1uM | Dose=1uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| RB-61-DW99_10uM | Dose=10uM, N-Methyl-1-(5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl)methanamine, ATP4A blocker, ATP4B blocker targeting ATP4A, ATP4B |
| FB-06-IU47_0.1uM | Dose=0.1uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10 |
| HA-72-NR60_10uM | Dose=10uM |
| GE-40-VJ66_10uM | Dose=10uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2 |
| YC-83-VF72_0.1uM | Dose=0.1uM |
| YE-80-LN04_0.1uM | Dose=0.1uM |
| KE-37-MN32_1uM | Dose=1uM, Psammaplin D, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BE-25-UR78_0.1uM | Dose=0.1uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB |
| HA-29-PM90_0.1uM | Dose=0.1uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| XC-81-LR46_0.01uM | Dose=0.01uM |
| LC-96-WR85_1uM | Dose=1uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17 |
| JB-35-RC26_1uM | Dose=1uM, Valopicitabine |
| VD-08-YA83_1uM | Dose=1uM |
| JD-81-YX02_0.01uM | Dose=0.01uM, Jnj-7706621, Aurora Kinase Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting CDK1, CDK2, AURKA, CCNA1 |
| NA-00-YS67_10uM | Dose=10uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS |
| WD-62-UB45_0.01uM | Dose=0.01uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3 |
| IC-79-JZ26_0.1uM | Dose=0.1uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide |
| OD-30-JC39_10uM | Dose=10uM, S-propyl 3-(3,4-dihydroxyphenyl)propanethioate, NFE2L2 stimulator/agonist targeting NFE2L2 |
| HC-01-CN33_0.1uM | Dose=0.1uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile |
| BE-71-AV63_0.1uM | Dose=0.1uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3 |
| OE-50-VB46_0.01uM | Dose=0.01uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2 |
| IA-41-GR68_1uM | Dose=1uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP |
| LB-24-KP05_0.01uM | Dose=0.01uM, Oxalylglycine, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| CB-99-OG76_0.01uM | Dose=0.01uM |
| ME-77-XX06_1uM | Dose=1uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide |
| GF-72-OO48_1uM | Dose=1uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| NC-94-LE33_0.1uM | Dose=0.1uM, Lomeguatrib, MGMT gene inhibitor targeting MGMT |
| FC-98-AJ86_0.1uM | Dose=0.1uM, Trimebutine |
| CC-37-QW80_10uM | Dose=10uM |
| S0-EE-WIZB_10uM | Dose=10uM, Glpg-2451 targeting CFTR |
| BF-00-PE90_10uM | Dose=10uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2 |
| OF-28-PH15_10uM | Dose=10uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3 |
| DE-20-VX20_0.01uM | Dose=0.01uM |
| FD-35-PQ00_0.01uM | Dose=0.01uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2 |
| FC-67-SZ42_0.01uM | Dose=0.01uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| NC-06-IT89_0.1uM | Dose=0.1uM, Trientine, Chelating Agents;Telomerase Inhibitors targeting TERT |
| CC-20-FN31_0.01uM | Dose=0.01uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| CC-49-CQ25_1uM | Dose=1uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CA-98-SW47_0.1uM | Dose=0.1uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A |
| DE-17-IZ77_0.1uM | Dose=0.1uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B |
| AF-16-IB77_0.01uM | Dose=0.01uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| RC-47-LT41_0.01uM | Dose=0.01uM |
| AE-21-GE72_0.01uM | Dose=0.01uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| GE-77-IH08_1uM | Dose=1uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| XD-37-GI34_0.1uM | Dose=0.1uM |
| IF-75-AJ33_0.1uM | Dose=0.1uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1 |
| MB-32-LQ97_10uM | Dose=10uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1 |
| BF-69-DN58_1uM | Dose=1uM |
| LE-48-SO37_10uM | Dose=10uM, 4-[(3-chlorophenyl)methoxy]-1-methyl-5-pyridin-3-yl-3H-indol-2-one |
| CD-47-YL43_0.1uM | Dose=0.1uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B |
| ID-00-IC14_0.1uM | Dose=0.1uM |
| DD-08-NW42_10uM | Dose=10uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1 |
| CE-04-OJ56_10uM | Dose=10uM, 2-(2-Aminoethyl)pyridine |
| KA-71-CQ35_10uM | Dose=10uM, 1-(4-tert.Butyl-benzenesulfonyl)-5-chloro-1H-indole-2-carboxylic acid, CCR9 chemokine antagonist targeting CCR9 |
| AD-70-DU18_0.1uM | Dose=0.1uM |
| CB-20-ND22_0.01uM | Dose=0.01uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| JB-63-NV02_10uM | Dose=10uM, 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| ZC-09-IW47_0.1uM | Dose=0.1uM, 7-(2,2-Dimethylpropyl)-6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile |
| UB-79-KN96_0.1uM | Dose=0.1uM |
| QF-97-LC45_0.1uM | Dose=0.1uM |
| AF-19-KN63_0.01uM | Dose=0.01uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR |
| TA-25-ZO44_10uM | Dose=10uM, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, Protein Kinase B (PKB/Akt) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting PDPK1 |
| CE-37-XI06_1uM | Dose=1uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| BB-77-IG67_0.1uM | Dose=0.1uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| DF-56-GR45_10uM | Dose=10uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| DA-88-JF21_10uM | Dose=10uM, FG-9041 targeting GRIA4 |
| CC-41-SI77_10uM | Dose=10uM, 5-(2-chloro-4-cyclopropylphenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-4-methyl-1,2-oxazole-3-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1 |
| QF-00-CY91_0.01uM | Dose=0.01uM, 3-Phenylacetylamino-2,6-piperidinedione |
| DD-82-HB82_10uM | Dose=10uM, Prodipine targeting CYP2D6 |
| BE-28-QT65_1uM | Dose=1uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| AA-48-GT70_1uM | Dose=1uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT |
| CA-56-GE89_0.01uM | Dose=0.01uM, 7-Deaza-2'-C-ethynyladenosine |
| LE-94-HL75_1uM | Dose=1uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2 |
| CC-86-IO63_1uM | Dose=1uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6 |
| BB-43-YQ76_0.01uM | Dose=0.01uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| S0-EE-YFM9_0.01uM | Dose=0.01uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K |
| AA-02-FS13_0.01uM | Dose=0.01uM, Benzylhydrazine |
| EF-75-JG46_0.01uM | Dose=0.01uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F |
| IF-81-QQ90_10uM | Dose=10uM, Dmppo, Phosphodiesterase Inhibitors targeting PDE5A |
| HA-51-DA67_1uM | Dose=1uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR |
| IB-96-PK68_10uM | Dose=10uM |
| KB-04-AF26_0.01uM | Dose=0.01uM |
| NC-42-UX09_0.01uM | Dose=0.01uM |
| AB-15-XR48_10uM | Dose=10uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B |
| PA-64-LE28_10uM | Dose=10uM, BN-82451, Lipid Peroxidation Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants;Sodium Channel Blockers targeting PTGS1, PTGS2, SCN1A, SCN2A, SCN3A |
| BF-31-BY55_0.01uM | Dose=0.01uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| HA-72-NR60_1uM | Dose=1uM |
| VA-15-ZR21_10uM | Dose=10uM |
| OB-44-HO47_1uM | Dose=1uM |
| SA-49-SD47_10uM | Dose=10uM, (3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, ADORA2A agonist;ADORA2B agonist targeting ADORA2A, ADORA2B |
| GB-81-GK41_1uM | Dose=1uM, QX-314, BLMH gene inhibitor targeting BLM |
| QA-87-NQ04_1uM | Dose=1uM, 5-(Methylamino)-2-(naphthalen-1-yl)-1,3-oxazole-4-carbonitrile, ALOX15 gene inhibitor targeting ALOX15 |
| OB-71-IZ36_0.1uM | Dose=0.1uM, 5-m-Tolyloxyuracil, Lyn Kinase Activators targeting LYN |
| CB-73-HZ47_0.1uM | Dose=0.1uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| DB-92-FB02_10uM | Dose=10uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK |
| BA-90-AA10_0.1uM | Dose=0.1uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| QE-76-HF95_10uM | Dose=10uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2 |
| EC-95-BQ25_10uM | Dose=10uM, 2-(5-Oxo-5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-7-yl)-propionic acid, DNA Polymerase Inhibitors;ATPase Inhibitors targeting REV3L |
| OB-77-XJ02_0.01uM | Dose=0.01uM, Erythrodiol, IL-1beta Production Inhibitors;IL-6 Production Inhibitors targeting IL1B, IL6 |
| GD-39-YG36_1uM | Dose=1uM, CID 137636547 |
| AA-27-TF89_1uM | Dose=1uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| EF-99-HJ48_1uM | Dose=1uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| UE-41-CL72_0.01uM | Dose=0.01uM, N-(7-hydroxy-1-naphthyl)-N'-[3-(methylthio)phenyl]urea, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting P2RX1, TRPV1 |
| DD-34-AN51_0.01uM | Dose=0.01uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| AW-16-2259_10uM | Dose=10uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB |
| QA-07-KC40_0.01uM | Dose=0.01uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| ND-06-AJ85_0.1uM | Dose=0.1uM, N-[7-[1-[[2-(4-chlorophenyl)-6-fluorophenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2 |
| FD-79-KT27_0.1uM | Dose=0.1uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| BD-63-JC77_0.1uM | Dose=0.1uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester |
| KA-92-WY22_0.1uM | Dose=0.1uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1 |
| AA-91-SB25_0.01uM | Dose=0.01uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK |
| AF-23-RM26_10uM | Dose=10uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR |
| JE-61-XN48_0.1uM | Dose=0.1uM, HC-030031, TRPA1 Antagonists targeting TRPA1 |
| JB-65-ON98_1uM | Dose=1uM |
| QA-98-TQ46_0.1uM | Dose=0.1uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one |
| DA-62-QB27_0.1uM | Dose=0.1uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| AF-28-FX20_0.1uM | Dose=0.1uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2 |
| OD-03-CA36_1uM | Dose=1uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide |
| DB-80-CD47_0.01uM | Dose=0.01uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT |
| EB-92-TL51_1uM | Dose=1uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| DE-69-QQ25_0.1uM | Dose=0.1uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| MB-32-LQ97_0.01uM | Dose=0.01uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1 |
| AC-95-TK81_1uM | Dose=1uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| QE-83-LG95_10uM | Dose=10uM, Zotepine, Dopamine D2 Antagonists;Adrenergic receptor modulator;Serotonin Antagonists targeting ADRA1B, HTR1E, HTR1F |
| AA-72-JP86_0.1uM | Dose=0.1uM, Delamanid |
| BF-96-PY22_0.01uM | Dose=0.01uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| BB-01-IO76_1uM | Dose=1uM, Aspartic Acid |
| BE-16-VM54_1uM | Dose=1uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC |
| BF-69-DX62_10uM | Dose=10uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| BB-63-AW70_10uM | Dose=10uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| S0-EE-X9LZ_10uM | Dose=10uM, N-[1-[6-(3-methoxyphenyl)pyrimidin-4-yl]piperidin-4-yl]-N-methyl-7-oxo-6-prop-2-enyl-1H-pyrrolo[2,3-c]pyridine-4-carboxamide, Inhibitor of CERC2 targeting CECR2 |
| ED-43-XF39_1uM | Dose=1uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5 |
| AC-50-JK54_1uM | Dose=1uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4 |
| AA-48-GT70_10uM | Dose=10uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT |
| XD-68-MP63_1uM | Dose=1uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine |
| XD-27-EB72_10uM | Dose=10uM, PRC2/EZH2 targeting EZH2 |
| BB-83-OX58_0.1uM | Dose=0.1uM |
| KC-32-GO33_0.1uM | Dose=0.1uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7 |
| CF-15-FD69_1uM | Dose=1uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12 |
| IC-07-VY79_0.01uM | Dose=0.01uM, Formoterol, ADRB2 agonist targeting ADRB2 |
| HF-79-EC41_0.01uM | Dose=0.01uM, Blu-9931, FGFR4 inhibior targeting FGFR4 |
| GF-15-LT47_0.1uM | Dose=0.1uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3 |
| DD-82-GV50_0.1uM | Dose=0.1uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| FC-15-XG61_0.1uM | Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| VE-22-XI52_1uM | Dose=1uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| BE-61-CB85_10uM | Dose=10uM |
| DE-10-AU63_1uM | Dose=1uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR |
| WE-69-LT10_0.01uM | Dose=0.01uM |
| HA-99-PM50_0.1uM | Dose=0.1uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| BB-26-JS03_10uM | Dose=10uM |
| BB-49-OQ60_0.01uM | Dose=0.01uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12 |
| BD-48-ZT65_0.01uM | Dose=0.01uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| CA-53-TT18_0.1uM | Dose=0.1uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A |
| MF-20-QI53_10uM | Dose=10uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2 |
| JC-96-ID26_1uM | Dose=1uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A |
| EB-85-JN83_10uM | Dose=10uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| JB-65-ON98_0.1uM | Dose=0.1uM |
| AE-15-KH69_10uM | Dose=10uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3 |
| QC-49-CA55_0.1uM | Dose=0.1uM |
| FA-10-KQ78_0.1uM | Dose=0.1uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| DC-31-WP64_10uM | Dose=10uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| HD-91-YX62_0.01uM | Dose=0.01uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile |
| AA-70-DH87_0.1uM | Dose=0.1uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B |
| NF-19-JL47_0.01uM | Dose=0.01uM, 2-Amino-5-[(1-Methoxy-2-Methylindolizin-3-Yl)carbonyl]benzoic Acid, Allosteric inhibitor binding extracellular domain targeting FGFR3, FGFR2, FGFR4 |
| AD-83-MW95_10uM | Dose=10uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| FC-20-EQ58_0.01uM | Dose=0.01uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| JB-35-RC26_10uM | Dose=10uM, Valopicitabine |
| CF-97-AV07_0.01uM | Dose=0.01uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4 |
| KC-45-DZ26_0.1uM | Dose=0.1uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| XD-40-HA98_1uM | Dose=1uM, ;Mammalian Target of Rapamycin (mTOR;FRAP1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting MTOR, IKBKB |
| LA-31-YT57_1uM | Dose=1uM, 9-Chloro-2-(2-fluorophenyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-ol, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG1, GABRG2, GABRG3 |
| CF-57-GW25_10uM | Dose=10uM, Perphenazine, Dopamine Receptor Antagonists targeting DRD2 |
| LD-98-VO32_0.1uM | Dose=0.1uM, Gsk2830371, WIP1 inhibitor targeting PPM1D |
| GF-02-ER50_0.1uM | Dose=0.1uM, Ethane-1,2-diyl dicarbamimidothioate |
| CF-24-PH37_10uM | Dose=10uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10 |
| BB-39-DQ95_10uM | Dose=10uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7 |
| BF-02-AC35_0.1uM | Dose=0.1uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| AD-50-WA90_1uM | Dose=1uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| XC-12-SL04_10uM | Dose=10uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1 |
| BB-65-SY95_0.01uM | Dose=0.01uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| CB-29-KG96_10uM | Dose=10uM |
| AC-10-PK69_10uM | Dose=10uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| CC-21-IE22_0.1uM | Dose=0.1uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1 |
| AA-85-LB25_0.01uM | Dose=0.01uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| JF-79-OI50_0.1uM | Dose=0.1uM, FK 409, Soluble Guanylyl Cyclase (sGC) Activators;Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| BD-02-US28_0.1uM | Dose=0.1uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2 |
| KC-15-HM70_0.1uM | Dose=0.1uM, Talarozole, An inhibitor of CYP26 targeting CYP26A1 |
| EB-55-VD69_0.01uM | Dose=0.01uM, (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide |
| KB-17-PN92_0.01uM | Dose=0.01uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate |
| DE-85-FR73_1uM | Dose=1uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| VA-11-NO89_0.1uM | Dose=0.1uM, 6-Hydroxy-1,3-benzothiazole-2-sulfonamide, Carbonic anhydrase type I inhibitor;carbonic anhydrase type II inhibitor targeting CA1, CA4, CA5A, CA5B, CA3, CA8, CA11, CA10 |
| AA-01-XV28_0.1uM | Dose=0.1uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| DF-80-BU28_1uM | Dose=1uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1 |
| FF-10-JX55_1uM | Dose=1uM |
| IB-56-BR35_0.01uM | Dose=0.01uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3 |
| PA-25-OV46_0.01uM | Dose=0.01uM, Bjb-432 |
| EC-72-RE74_10uM | Dose=10uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L |
| BF-54-GX35_0.01uM | Dose=0.01uM |
| CA-48-JF51_10uM | Dose=10uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| DC-49-EJ23_10uM | Dose=10uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6 |
| PA-15-CP52_10uM | Dose=10uM, (3aS,9bS)-2-(1-benzofuran-5-sulfonyl)-5-methyl-1H,2H,3H,3aH,4H,5H,9bH-pyrrolo[3,4-c]1,6-naphthyridin-4-one targeting GLRA1, GLRA2, GLRA3, GLRA4 |
| GB-01-UN23_0.1uM | Dose=0.1uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| CD-05-PU90_0.1uM | Dose=0.1uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3 |
| EA-81-CR68_0.01uM | Dose=0.01uM |
| BB-21-KE77_10uM | Dose=10uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1 |
| BC-33-BM51_0.01uM | Dose=0.01uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| BA-46-RB17_10uM | Dose=10uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| SB-87-LQ34_10uM | Dose=10uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10 |
| AC-98-QW77_0.01uM | Dose=0.01uM, CGC-11047 free base |
| BA-28-JD87_10uM | Dose=10uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| XC-12-SL04_0.01uM | Dose=0.01uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1 |
| NF-64-RE03_10uM | Dose=10uM, 3-(3-Bromo-5-methoxy-4-(octyloxy)benzylamino)propylphosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| DA-27-BW20_0.01uM | Dose=0.01uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| FF-32-LL81_0.1uM | Dose=0.1uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1 |
| RA-89-RR01_1uM | Dose=1uM, Bms-906024, Gamma-secretase inhibitor;gamma secretase inhibitor targeting PSEN1 |
| IB-94-WM88_1uM | Dose=1uM, Ethyl 4-[2-(4,6-dimethyl-3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)acetyl]piperazine-1-carboxylate, DTYMK inhibitor targeting DTYMK |
| GA-66-IX54_0.01uM | Dose=0.01uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| KB-04-AF26_1uM | Dose=1uM |
| FE-59-BC81_1uM | Dose=1uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| VA-48-TW80_10uM | Dose=10uM, GABA receptor ligand targeting GABRA2 |
| DC-78-CM38_0.1uM | Dose=0.1uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| GD-98-WZ24_0.1uM | Dose=0.1uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| FA-45-XX32_0.1uM | Dose=0.1uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1 |
| AA-46-HS88_0.01uM | Dose=0.01uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AA-68-MW92_0.01uM | Dose=0.01uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| GB-11-PX47_0.1uM | Dose=0.1uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3 |
| GD-17-GR17_0.1uM | Dose=0.1uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| TC-16-ZS56_0.1uM | Dose=0.1uM, Recilisib |
| NB-31-SG91_0.01uM | Dose=0.01uM, 6-O-Methyl Mycophenolic Acid Methyl Ester |
| GA-53-SC22_1uM | Dose=1uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| DE-57-XI06_0.01uM | Dose=0.01uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2 |
| UB-40-KU41_10uM | Dose=10uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide |
| BB-94-HN41_10uM | Dose=10uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1 |
| GB-14-AJ76_1uM | Dose=1uM |
| VD-08-YA83_10uM | Dose=10uM |
| DA-67-HS65_0.1uM | Dose=0.1uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2 |
| BD-97-PP33_1uM | Dose=1uM, Sonlicromanol |
| HD-26-KX74_0.1uM | Dose=0.1uM |
| AE-73-KX58_0.01uM | Dose=0.01uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2 |
| MB-49-LL22_0.1uM | Dose=0.1uM, Pinometostat, Dot1L / KMT4;Dot1L inhibitor targeting DOT1L |
| KF-73-PY04_0.1uM | Dose=0.1uM, Gsk 932121, P. falciparum Cytochrome b-c1 Complex (Complex III subunit 3) Inhibitors;Electron Transport Chain Inhibitors targeting UQCRC1 |
| AB-86-XY72_10uM | Dose=10uM |
| BA-24-BX40_10uM | Dose=10uM, 2-(2-Imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone targeting ATAD5 |
| EB-70-JQ38_0.1uM | Dose=0.1uM, Z-Phe-DL-Ala-fluoromethylketone |
| BD-23-MT28_10uM | Dose=10uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR |
| BA-98-JJ31_0.1uM | Dose=0.1uM, Quinine |
| BA-39-LQ60_10uM | Dose=10uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| CB-02-XL81_10uM | Dose=10uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| AF-53-GC97_10uM | Dose=10uM |
| ZE-14-BN99_10uM | Dose=10uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19 |
| XF-24-NT53_10uM | Dose=10uM, Bms-599626, HER4 (erbB4) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;HER3 (erbB3) Inhibitors targeting EGFR, ERBB2, ERBB3, ERBB4 |
| ED-62-DB62_10uM | Dose=10uM |
| FC-22-ZV65_1uM | Dose=1uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2 |
| TD-33-TT56_0.01uM | Dose=0.01uM |
| SF-48-KT63_10uM | Dose=10uM, 4-((Aminosulfonyl)amino)benzenesulfonamide |
| PE-86-SC73_1uM | Dose=1uM, PF-543, SPHK1 inhibitor targeting SPHK1 |
| GD-63-XB79_0.01uM | Dose=0.01uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| AB-96-XV75_0.01uM | Dose=0.01uM, Dapsone |
| BA-06-RE84_1uM | Dose=1uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| OC-41-DF58_0.01uM | Dose=0.01uM, Oprea1_571617, inhibitor of dna ligase IV targeting LIG4 |
| YB-83-AS93_10uM | Dose=10uM, 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4, PRKCH, PRKCZ |
| AB-09-NX37_10uM | Dose=10uM, 6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one, Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2, NURR1) Agonists targeting NR4A2 |
| IE-44-GZ79_0.01uM | Dose=0.01uM, 2,3,4,5-Tetra(4-pyridyl)thiophene, Hedgehog Signaling Inhibitors targeting GLI1 |
| LE-41-QT17_0.01uM | Dose=0.01uM, 2,2-dimethyl-5-(morpholin-4-yl)-N-(pyridin-3-ylmethyl)-1,4-dihydro-2H-pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-8-amine, Phosphodiesterase PDE4D Inhibitors;Phosphodiesterase PDE4B Inhibitors;Phosphodiesterase PDE4A Inhibitors targeting PDE4A, PDE4B, PDE4D |
| WD-86-NH64_10uM | Dose=10uM |
| S0-EE-XYMJ_0.1uM | Dose=0.1uM, Gsk1331268, mgluR2 Positive Allosteric Modulator;postive allosteric modulator targeting GRM2 |
| IE-19-LI00_1uM | Dose=1uM, Bis-indolylmaleimide deriv. 8d, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| DF-70-CD57_0.1uM | Dose=0.1uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2 |
| AE-57-PS55_10uM | Dose=10uM, 4-[[2-[[(1S,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide, CSF1R gene antagonist targeting CSF1R |
| JF-39-BZ76_10uM | Dose=10uM, Vs-4718, FAK inhibitor targeting PTK2 |
| QB-34-NU46_1uM | Dose=1uM, (3R,4aR,10aR)-1-methyl-3-[(4-methylpyrimidin-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| AC-77-BC52_1uM | Dose=1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine |
| NE-29-VB58_0.1uM | Dose=0.1uM, L 692429, GHS Receptor Antagonists;GHSR agonist targeting GHSR |
| SB-74-OD45_0.01uM | Dose=0.01uM, N-1-(Fur-3-ylethyl)-N-hydroxyurea, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| HA-30-KD77_10uM | Dose=10uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2 |
| KE-41-JG66_1uM | Dose=1uM, 6-[(2-{[4-(4-Bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile |
| CE-19-PD79_0.01uM | Dose=0.01uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| FB-12-UL66_0.01uM | Dose=0.01uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| BE-15-IE57_0.01uM | Dose=0.01uM, 2-(Butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno(2,3-b)pyridin-3-amine, Prostaglandin-degrading enzyme 15-PGDH inhibitor;inhibitor of the prostaglandin-degrading enzyme 15-PGDH targeting HPGD |
| GA-89-ZT62_0.01uM | Dose=0.01uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS |
| WF-76-NV73_0.1uM | Dose=0.1uM, Cxl-1020, activation for sGC, oxidation of sulfides for others targeting ATP2A2, CTSB, GAPDH, GUCY1A1, PLN |
| DE-57-XI06_10uM | Dose=10uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2 |
| S0-EE-YGIT_1uM | Dose=1uM, 1-(4-Chlorophenoxy)-3-[[1-[(2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]methyl-methylamino]propan-2-ol, TLR-4 antagonist targeting TLR4 |
| CB-12-BV05_0.1uM | Dose=0.1uM |
| AE-32-UP21_10uM | Dose=10uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| OF-98-RK57_10uM | Dose=10uM, Propiverine, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| BA-86-YY52_0.1uM | Dose=0.1uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C |
| NC-28-YK77_10uM | Dose=10uM, (4S)-4-[(1R)-2-[[1-(4-tert-butylpyridin-2-yl)cyclopropyl]amino]-1-hydroxyethyl]-18-methyl-3,15,17-triazatricyclo[14.3.1.16,10]henicosa-1(20),6,8,10(21),16,18-hexaen-2-one |
| AD-28-GJ71_0.1uM | Dose=0.1uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A |
| BD-07-IW65_0.1uM | Dose=0.1uM |
| NB-58-SA13_0.1uM | Dose=0.1uM |
| IE-80-DC24_0.01uM | Dose=0.01uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide |
| AD-51-ZE47_0.1uM | Dose=0.1uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| CA-48-SW47_0.1uM | Dose=0.1uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| IC-23-YE16_0.1uM | Dose=0.1uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide |
| XC-12-SL04_0.1uM | Dose=0.1uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1 |
| CB-59-ZX97_10uM | Dose=10uM |
| GC-73-YI26_1uM | Dose=1uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2 |
| HE-15-UQ55_0.01uM | Dose=0.01uM |
| CB-16-JO93_10uM | Dose=10uM |
| AE-87-GP03_0.1uM | Dose=0.1uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4 |
| AB-64-ZX70_0.1uM | Dose=0.1uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| OC-40-XI13_10uM | Dose=10uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12 |
| AC-24-NX95_0.1uM | Dose=0.1uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| BF-02-AC95_10uM | Dose=10uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| MD-84-YS12_0.1uM | Dose=0.1uM, 2,4-dichloro-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamoyl]benzamide, PCTP (StARD2) Inhibitor targeting PCTP |
| HF-25-LA47_10uM | Dose=10uM, Cathepsin inhibitor 1, Cathepsin L Inhibitors targeting CTSL, CTSV, CTSL3P |
| PA-15-CI45_0.01uM | Dose=0.01uM, ethyl 4-[[(2S)-2-aminopropanoyl]amino]-5-[4-(3,5-dichlorophenyl)phenyl]-2,3-dihydroxypentanoate, Ubiquitin-Conjugating Enzyme E2 R1 (CDC34) Inhibitors targeting CDC34 |
| KD-44-PB06_10uM | Dose=10uM, CID 10461016 |
| EB-30-VD02_1uM | Dose=1uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2 |
| FB-12-UL66_0.1uM | Dose=0.1uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| HF-82-PE14_0.01uM | Dose=0.01uM |
| CB-99-OG76_1uM | Dose=1uM |
| CE-36-HY42_10uM | Dose=10uM |
| QE-03-UA61_0.01uM | Dose=0.01uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1 |
| JC-26-DD86_0.1uM | Dose=0.1uM, 1-[6-(4-Methylphenyl)-[1,3]oxazolo[4,5-b]pyridin-2-yl]-6-phenylhexan-1-one, dual diacyglycerol lipase alpha and beta reversible inhibitor targeting DAGLA, DAGLB |
| AC-54-FR31_0.1uM | Dose=0.1uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG |
| AD-50-WA90_0.01uM | Dose=0.01uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AA-40-IA00_1uM | Dose=1uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1 |
| IA-37-FR87_0.01uM | Dose=0.01uM, Pexacerfont, CRF1 Antagonists targeting CRHR1 |
| S0-EE-XYMJ_1uM | Dose=1uM, Gsk1331268, mgluR2 Positive Allosteric Modulator;postive allosteric modulator targeting GRM2 |
| BE-67-QZ92_0.1uM | Dose=0.1uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B |
| UA-44-EN14_10uM | Dose=10uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone |
| CC-58-DF11_0.1uM | Dose=0.1uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5 |
| DE-90-RU43_0.1uM | Dose=0.1uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP |
| ED-14-GQ53_1uM | Dose=1uM, 2-(4-Methylphenoxy)benzoic acid |
| LB-70-YM83_0.1uM | Dose=0.1uM |
| PC-68-DU31_0.1uM | Dose=0.1uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1 |
| PA-75-VL17_0.01uM | Dose=0.01uM |
| AB-92-LS83_0.1uM | Dose=0.1uM, Flurbiprofen targeting SC5D |
| IA-03-BO30_1uM | Dose=1uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2 |
| GA-89-ZT62_1uM | Dose=1uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS |
| NC-14-ES72_10uM | Dose=10uM |
| JF-14-JC89_10uM | Dose=10uM, Halicin, SAPK1c (JNK1) Inhibitors targeting MAPK8 |
| SC-76-YF40_10uM | Dose=10uM |
| LE-50-AP60_10uM | Dose=10uM |
| AD-55-EA62_0.1uM | Dose=0.1uM, D-AP4 |
| EF-01-LB20_0.01uM | Dose=0.01uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| BB-19-ZK81_1uM | Dose=1uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH |
| AE-21-BF25_1uM | Dose=1uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| BA-41-QF30_10uM | Dose=10uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide |
| AC-98-UW57_0.01uM | Dose=0.01uM, Suplatast |
| ED-98-UI13_0.1uM | Dose=0.1uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E |
| HC-48-BS22_1uM | Dose=1uM |
| NB-62-DN30_1uM | Dose=1uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB |
| GC-35-PT27_1uM | Dose=1uM, MMP-9 (Gelatinase B) Inhibitors |
| CD-63-FZ67_0.1uM | Dose=0.1uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| XF-76-GE52_10uM | Dose=10uM |
| UC-19-KX65_0.01uM | Dose=0.01uM |
| AD-18-VX25_1uM | Dose=1uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18 |
| LB-68-SH80_1uM | Dose=1uM, (2S,4R)-1-acetyl-N-(1-(benzo[d]thiazol-2-yl)-5-guanidino-1-oxopentan-2-yl)-4-hydroxypyrrolidine-2-carboxamide, Trypsin Inhibitors;Tryptase Inhibitors targeting PRSS1, PRSS2, PRSS3, TPSAB1, TPSD1, TPSG1, TPSB2 |
| DA-75-KD59_1uM | Dose=1uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17 |
| TA-25-KO99_0.01uM | Dose=0.01uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4 |
| EB-97-AV17_0.01uM | Dose=0.01uM, Diphenylamine-2,2'-dicarboxylic acid |
| DF-26-EY87_0.01uM | Dose=0.01uM |
| SB-29-AN01_1uM | Dose=1uM, benzyl (2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carboxylate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| GF-19-OF53_0.1uM | Dose=0.1uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5 |
| BD-04-NG34_0.1uM | Dose=0.1uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2 |
| CB-83-ZW70_10uM | Dose=10uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| DA-80-IV36_1uM | Dose=1uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| AB-04-NN16_0.01uM | Dose=0.01uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G |
| HB-01-ZU75_10uM | Dose=10uM |
| PF-72-IT39_0.01uM | Dose=0.01uM |
| AE-38-LX10_1uM | Dose=1uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| CE-10-WA05_0.01uM | Dose=0.01uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide |
| DC-81-PH69_1uM | Dose=1uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1 |
| CD-12-NI84_10uM | Dose=10uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| S0-EE-XMWH_1uM | Dose=1uM, 4-[4-(1-Benzofuran-5-Yl)phenyl]-5-{[(3s)-1-(Cyclopropylcarbonyl)pyrrolidin-3-Yl]methyl}-2,4-Dihydro-3h-1,2,4-Triazol-3-One, FAS inhibitor targeting FASN |
| JE-72-KV75_1uM | Dose=1uM, 6-Chloro-2-(2-Fluoro-4,5-Dimethoxyphenyl)-N-(Piperidin-4-Ylmethyl)-3h-Imidazo[4,5-B]pyridin-7-Amine, JAK1 selective inhibitors targeting CDK2, JAK1, AURKB |
| OB-77-XJ02_10uM | Dose=10uM, Erythrodiol, IL-1beta Production Inhibitors;IL-6 Production Inhibitors targeting IL1B, IL6 |
| DC-93-WC67_10uM | Dose=10uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2 |
| DA-07-LL18_0.01uM | Dose=0.01uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| CC-42-ZV45_0.01uM | Dose=0.01uM, (S)-2-amino-5-phosphonopentanoic acid |
| KF-00-NW62_0.01uM | Dose=0.01uM, 6-[(2-Aminopyridin-3-yl)methylamino]-1,3-bis[(4-methoxyphenyl)methyl]-1,3,5-triazine-2,4-dione, Prokineticin 1 Receptor (PKR1) Antagonist targeting PROKR1 |
| NE-94-VE83_1uM | Dose=1uM |
| GA-79-ZF28_10uM | Dose=10uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4 |
| RE-97-MC55_1uM | Dose=1uM, 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCG |
| RE-97-MC55_0.1uM | Dose=0.1uM, 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCG |
| AD-54-FG24_0.1uM | Dose=0.1uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB |
| PB-13-ZD03_0.01uM | Dose=0.01uM, 1-N,3-N-bis(1-methylquinolin-1-ium-6-yl)benzene-1,3-dicarboxamide, DNA G-quadruplex (G4) Ligands;Telomerase Inhibitors targeting TERT |
| DB-32-FS68_0.01uM | Dose=0.01uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AC-67-PZ77_10uM | Dose=10uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1 |
| IF-06-KQ42_1uM | Dose=1uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4 |
| AF-76-AY17_0.01uM | Dose=0.01uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| DB-58-ZC04_0.01uM | Dose=0.01uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2 |
| BE-69-RD44_0.1uM | Dose=0.1uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1 |
| CA-73-TP18_1uM | Dose=1uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15 |
| NA-30-HS87_0.1uM | Dose=0.1uM, Gsk-J4, KDM6A gene inhibitor, KDM6B gene inhibitor;pan-KDM6 family (KDM6A / KDM6B / UTY);Histone demethylation inhibitors targeting KDM6A, KDM6B |
| FB-56-IR20_0.01uM | Dose=0.01uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2 |
| DE-62-FI29_0.01uM | Dose=0.01uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| GC-46-AX49_1uM | Dose=1uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13 |
| KA-73-PR92_0.01uM | Dose=0.01uM |
| AC-31-PL89_1uM | Dose=1uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| UA-56-RO11_0.1uM | Dose=0.1uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3 |
| GC-42-LL86_0.1uM | Dose=0.1uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| BA-75-VA57_0.1uM | Dose=0.1uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2 |
| HD-99-BT62_0.01uM | Dose=0.01uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1 |
| NA-07-JX31_10uM | Dose=10uM |
| BE-64-ZN31_1uM | Dose=1uM, Enzalutamide, Androgen Receptor Antagonists targeting AR |
| AA-92-NW83_0.01uM | Dose=0.01uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| KA-54-MB31_0.01uM | Dose=0.01uM, 3-Amino-3,4-dihydro-1-hydroxy-2(1H)-quinolinone, Kynurenine Aminotransferase II (KAT II) Inhibitors targeting AADAT |
| RC-62-LC43_10uM | Dose=10uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One |
| BE-24-LQ28_10uM | Dose=10uM |
| BD-41-DB55_0.01uM | Dose=0.01uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3 |
| HA-57-XH23_0.01uM | Dose=0.01uM |
| KA-73-PR92_1uM | Dose=1uM |
| BC-43-PD20_1uM | Dose=1uM, GPR52 agonist-1, GPR52 agonist targeting GPR52 |
| DF-75-MR73_0.01uM | Dose=0.01uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4 |
| BC-94-GN01_0.01uM | Dose=0.01uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1 |
| AC-10-PK69_0.1uM | Dose=0.1uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| BD-69-GX17_0.1uM | Dose=0.1uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| ZB-54-WT28_0.1uM | Dose=0.1uM, 6-(3-Fluorophenyl)-N-[1-(2,2,2-Trifluoroethyl)piperidin-4-Yl]pyridine-3-Carboxamide, Hematopoietic Prostaglandin D Synthase Inhibitor targeting HPGDS |
| S0-EE-YGIT_10uM | Dose=10uM, 1-(4-Chlorophenoxy)-3-[[1-[(2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]methyl-methylamino]propan-2-ol, TLR-4 antagonist targeting TLR4 |
| IC-86-MA49_0.1uM | Dose=0.1uM, 2-Adamantanecarbonyl-arg-phe-NH2 trifluoroacetate, Neuropeptide FF Receptor Antagonists targeting NPFFR1 |
| HC-69-UG51_10uM | Dose=10uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR |
| EC-17-VB09_10uM | Dose=10uM, Pyridazine, 4,6-diphenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)- |
| FC-05-ID99_10uM | Dose=10uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET |
| DB-41-OE47_0.01uM | Dose=0.01uM |
| PA-39-SH87_1uM | Dose=1uM, 2-[6-[(Quinolin-2-yl)methoxy]naphthalen-2-yl]propanoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs;Leukotriene Antagonists targeting ALOX5 |
| JF-37-AR97_0.01uM | Dose=0.01uM, {4'-[3-Methyl-4-((s)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid |
| WD-86-NH64_1uM | Dose=1uM |
| JA-23-RY79_10uM | Dose=10uM |
| OD-13-IE31_0.01uM | Dose=0.01uM |
| PD-31-RP17_1uM | Dose=1uM |
| FE-26-GO83_10uM | Dose=10uM, methyl 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoate |
| DB-63-TM61_10uM | Dose=10uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| QF-41-QW99_0.1uM | Dose=0.1uM, Fdl169, CFTR corrector targeting CFTR |
| SC-59-TX35_1uM | Dose=1uM |
| BF-19-KU00_0.01uM | Dose=0.01uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS |
| EC-18-TF61_1uM | Dose=1uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1 |
| AA-42-XZ05_1uM | Dose=1uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4 |
| DC-96-HY67_0.01uM | Dose=0.01uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1 |
| UD-20-ER54_1uM | Dose=1uM, Paprazine, uncompetitive inhibitor targeting GAA |
| AA-31-OE22_10uM | Dose=10uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione |
| WB-48-OF09_10uM | Dose=10uM |
| AD-50-WA90_0.1uM | Dose=0.1uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| RB-18-SX73_1uM | Dose=1uM |
| DB-54-ZQ73_0.1uM | Dose=0.1uM |
| JB-75-NC66_0.1uM | Dose=0.1uM, 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, HSP70 co-inducer or chaperone targeting HSPA1A |
| HF-57-QB74_1uM | Dose=1uM, Ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate, steroidogenic factor 1 inhibitor;NR5A1 inhibitor targeting NR5A1 |
| AE-95-KU30_0.01uM | Dose=0.01uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C |
| DD-08-NW42_1uM | Dose=1uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1 |
| LB-03-JV32_1uM | Dose=1uM, 1-carbamimidamido-N-(4-methylphenyl)methanimidamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| YA-61-RR36_10uM | Dose=10uM |
| OE-31-YC41_10uM | Dose=10uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2 |
| DD-01-VE87_10uM | Dose=10uM |
| FD-15-HD09_1uM | Dose=1uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU |
| AB-82-EP26_0.01uM | Dose=0.01uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| AE-28-WC14_10uM | Dose=10uM, Trichlorfon, Butyrylcholinesterase Inhibitors targeting BCHE |
| RD-39-ZE95_0.01uM | Dose=0.01uM, 3,4-Dichloro-1-benzothiophene-2-carbohydrazide, inhibitor of OGG1 targeting OGG1 |
| HC-38-KI38_1uM | Dose=1uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| BC-80-FK74_0.1uM | Dose=0.1uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| WB-92-TT14_1uM | Dose=1uM |
| BA-34-BQ43_10uM | Dose=10uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB |
| GA-61-GX82_10uM | Dose=10uM, Abeorphine |
| BC-28-NG89_10uM | Dose=10uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists |
| AF-01-FE42_1uM | Dose=1uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| VE-33-MT21_0.1uM | Dose=0.1uM, Gdc-0834, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK |
| BF-95-KA82_0.01uM | Dose=0.01uM, SOAT-1 inhibitor |
| NB-58-SA13_1uM | Dose=1uM |
| BE-59-WG31_0.1uM | Dose=0.1uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| AB-15-FB25_10uM | Dose=10uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1 |
| DE-34-DT75_10uM | Dose=10uM, NG5DD6UA5D, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers;Caspase 8 Activators;Caspase 3 Activators;Angiogenesis Inhibitors;Caspase 9 Activators targeting BIRC2, XIAP |
| DE-57-JI61_0.1uM | Dose=0.1uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2 |
| GC-15-JX22_10uM | Dose=10uM |
| AF-62-PI84_1uM | Dose=1uM, Ethanone, 1-[1,1'-biphenyl]-4-yl-2-(1H-1,2,4-triazol-1-yl)-, Heme Oxygenase 1 (HO-1) Inhibitors targeting HMOX1 |
| DE-80-BU08_0.01uM | Dose=0.01uM, DC_AC50, ATOX1 inhibitor targeting ATOX1 |
| EF-75-JG46_0.1uM | Dose=0.1uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F |
| BD-25-SA37_1uM | Dose=1uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| OB-46-IM27_0.1uM | Dose=0.1uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide |
| YA-71-LR91_0.01uM | Dose=0.01uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-2-[4-(2-methyltetrazol-5-yl)phenyl]acetamide |
| AA-90-AU53_0.1uM | Dose=0.1uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| OF-05-CB18_0.1uM | Dose=0.1uM |
| WB-48-OF09_0.01uM | Dose=0.01uM |
| QF-97-LC45_1uM | Dose=1uM |
| BD-60-XA25_0.01uM | Dose=0.01uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine |
| CC-21-IE22_10uM | Dose=10uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1 |
| JA-85-CW09_1uM | Dose=1uM, 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK Inhibitors targeting CCND2, CCND3 |
| CE-03-PW65_1uM | Dose=1uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8 |
| CD-47-YL43_10uM | Dose=10uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B |
| BB-39-YQ35_10uM | Dose=10uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| BD-18-XC74_1uM | Dose=1uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| CD-59-MG26_0.1uM | Dose=0.1uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| NE-55-KI60_0.1uM | Dose=0.1uM, Matrix Metalloproteinase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AA-84-BX70_0.01uM | Dose=0.01uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| RC-14-PH60_0.1uM | Dose=0.1uM, Lin28-let-7a antagonist 1 targeting LIN28A |
| CA-07-KS70_10uM | Dose=10uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1 |
| DE-37-JV37_1uM | Dose=1uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| HB-29-DM15_0.01uM | Dose=0.01uM, 4-(4-Guanidinobenzoyloxy)phenylacetate |
| AD-20-YO14_0.01uM | Dose=0.01uM, Ars-1620 targeting KRAS |
| JD-81-YX02_0.1uM | Dose=0.1uM, Jnj-7706621, Aurora Kinase Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting CDK1, CDK2, AURKA, CCNA1 |
| HB-72-BR75_10uM | Dose=10uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3 |
| S0-EE-YMWJ_0.01uM | Dose=0.01uM, TX1-85-1, ERBB3 covalent inhibitor targeting ERBB3 |
| KF-38-DH25_1uM | Dose=1uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2 |
| AB-41-VZ28_0.1uM | Dose=0.1uM, Neostigmine, Acetylcholinesterase Inhibitors targeting ACHE |
| EA-33-QC97_0.1uM | Dose=0.1uM |
| AD-55-WK61_1uM | Dose=1uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1 |
| BC-10-SB73_0.1uM | Dose=0.1uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14 |
| AA-22-SF72_0.1uM | Dose=0.1uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET |
| UD-16-YL39_0.01uM | Dose=0.01uM, 3-amino-N-(5-benzoyl-2-piperazin-1-ylphenyl)pyrazine-2-carboxamide |
| RB-80-RO52_0.01uM | Dose=0.01uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1 |
| IE-46-VU57_10uM | Dose=10uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1 |
| MA-88-CA03_0.1uM | Dose=0.1uM, 6,7,4'-Trihydroxyisoflavan |
| IA-75-LQ65_10uM | Dose=10uM, Enasidenib, IDH2 R140Q mutant inhibitor targeting IDH2 |
| HA-33-ZI46_0.01uM | Dose=0.01uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AE-94-ZD47_10uM | Dose=10uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| BA-77-NI61_1uM | Dose=1uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine |
| QD-39-YV36_0.1uM | Dose=0.1uM, (1S,3S)-3-amino-4-(2,2,2-trifluoro-1-trifluoromethylethylidene)cyclopentane, OAT inhibitor targeting OAT |
| BC-88-KT45_0.1uM | Dose=0.1uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| UF-85-NE30_1uM | Dose=1uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile |
| XD-53-KC50_1uM | Dose=1uM |
| VE-11-PV61_1uM | Dose=1uM, Tak-259, Orally Active α1D Adrenoceptor targeting ADRA1D |
| IE-13-CP28_0.1uM | Dose=0.1uM, CLK1 protein kinase inhibitor targeting CLK1, DYRK1A, DYRK2 |
| IC-05-AW29_10uM | Dose=10uM, Malotilate |
| EB-70-JQ38_0.01uM | Dose=0.01uM, Z-Phe-DL-Ala-fluoromethylketone |
| ID-26-HX79_0.01uM | Dose=0.01uM, N-(3-Chloro-5-Fluorophenyl)-4-Nitro-2,1,3-Benzoxadiazol-5-Amine, HIF-2;HIF-2 Inhibitor targeting EPAS1 |
| NB-92-BG38_0.1uM | Dose=0.1uM, 5-HT7 agonist 2, HTR7 agonist targeting HTR7 |
| AC-00-KV26_0.01uM | Dose=0.01uM, N,N,N-trimethylglycinium |
| S0-EE-U3YG_1uM | Dose=1uM, ACMSD inhibitor targeting ACMSD |
| IE-28-SY71_10uM | Dose=10uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one |
| JA-23-RY79_0.1uM | Dose=0.1uM |
| HC-86-IA49_0.01uM | Dose=0.01uM |
| IC-05-WD74_1uM | Dose=1uM, N-[(2,6-dimethylphenyl)methyl]-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine, HRI Kinase inhibitor targeting EIF2AK1 |
| AF-65-CU85_0.1uM | Dose=0.1uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6 |
| DB-67-IP73_10uM | Dose=10uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5 |
| WB-92-TT14_10uM | Dose=10uM |
| QD-13-FQ44_10uM | Dose=10uM, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, PDCD1, PDE1A, PDE1C, PDE4C, PDE6A, PDE6C, PDE6D, PDE6G, PDE6H, PDE8A, PDE9A, PDE6B, PDE8B |
| BA-68-FJ41_0.1uM | Dose=0.1uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| CC-84-JQ48_1uM | Dose=1uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| AD-91-FB70_1uM | Dose=1uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2 |
| BC-32-DI69_1uM | Dose=1uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1 |
| CC-21-IE22_0.01uM | Dose=0.01uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1 |
| KC-86-UD16_1uM | Dose=1uM |
| HA-08-IL05_0.01uM | Dose=0.01uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| CD-59-PT17_1uM | Dose=1uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1 |
| JF-55-EN33_1uM | Dose=1uM, 3-[6-Amino-5-(3,4,5-Trimethoxyphenyl)pyridin-3-Yl]phenol, ACVRL1 gene inhibitor targeting ACVRL1 |
| HB-96-QD61_1uM | Dose=1uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4 |
| AC-76-BB02_0.1uM | Dose=0.1uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14 |
| GC-61-BD64_0.1uM | Dose=0.1uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| EF-43-OP88_0.1uM | Dose=0.1uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD |
| PC-44-DH10_1uM | Dose=1uM, (1R,3S,6S,10S,11R)-7-[(dimethylamino)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA |
| BF-69-DN58_0.01uM | Dose=0.01uM |
| AD-30-TH82_1uM | Dose=1uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1 |
| KA-37-GD83_0.1uM | Dose=0.1uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
| BB-51-DP49_10uM | Dose=10uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| AA-91-WB95_1uM | Dose=1uM |
| MA-42-UX14_10uM | Dose=10uM |
| CB-15-RU50_1uM | Dose=1uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| KE-06-DQ22_0.01uM | Dose=0.01uM, 3-(2-carboxyethyl)-4-iodo-1H-indole-2-carboxylic acid |
| AF-12-IW93_0.1uM | Dose=0.1uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| NB-61-FT12_1uM | Dose=1uM, N-Salicyloyltryptamine, Potassium Channel Modulators;Sodium Channel Blockers;L-Type Calcium Channel Blockers targeting KCND3 |
| BC-26-LE04_0.01uM | Dose=0.01uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| KB-37-OO25_0.1uM | Dose=0.1uM, Tovinontrine targeting PDE9A |
| KC-32-GO33_0.01uM | Dose=0.01uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7 |
| DC-17-EL33_0.1uM | Dose=0.1uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| RA-25-VV91_0.1uM | Dose=0.1uM |
| EC-98-YS67_0.01uM | Dose=0.01uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| CB-92-VC05_0.1uM | Dose=0.1uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R |
| YC-32-MB85_0.1uM | Dose=0.1uM, N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Inhibitors of Signal Transduction Pathways;Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2 |
| EC-40-DQ58_10uM | Dose=10uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4 |
| BD-18-MM33_0.1uM | Dose=0.1uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BC-03-OQ01_0.01uM | Dose=0.01uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM |
| OA-10-PB21_0.01uM | Dose=0.01uM, Tiospirone, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| AB-96-XV75_0.1uM | Dose=0.1uM, Dapsone |
| FB-85-ND09_1uM | Dose=1uM |
| BB-43-YQ76_0.1uM | Dose=0.1uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| AC-97-KP88_0.01uM | Dose=0.01uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| CB-29-KG96_0.1uM | Dose=0.1uM |
| BD-44-FH87_0.1uM | Dose=0.1uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1 |
| AB-01-NB05_0.1uM | Dose=0.1uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG |
| PB-40-YB26_0.1uM | Dose=0.1uM, SIRT1 gene inhibitor;Histone Deacetylase SIRT2 Inhibitors targeting SIRT2, SIRT1 |
| CB-84-FA85_10uM | Dose=10uM |
| HF-35-HT37_10uM | Dose=10uM |
| BB-62-SZ35_0.01uM | Dose=0.01uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| IB-96-PK68_0.01uM | Dose=0.01uM |
| BD-85-IA32_1uM | Dose=1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| QE-04-BY06_10uM | Dose=10uM, (5,5-Dioxo-4H-thieno[3,2-c]thiochromen-2-yl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone, LYPLA2 gene inhibitor targeting LYPLA2 |
| FA-16-KA99_10uM | Dose=10uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea |
| HE-29-OW54_0.01uM | Dose=0.01uM, Camicinal, Motilin Receptor Agonists targeting MLNR |
| OE-50-VB46_10uM | Dose=10uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AB-82-ES53_1uM | Dose=1uM, Quercetin targeting SULT1A1 |
| AA-46-GL76_0.01uM | Dose=0.01uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| BD-94-KU93_10uM | Dose=10uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| FE-64-KC49_10uM | Dose=10uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| BB-85-NU70_10uM | Dose=10uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ |
| JD-12-CE09_1uM | Dose=1uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| HA-50-AT10_0.01uM | Dose=0.01uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2 |
| BF-49-IA57_1uM | Dose=1uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2 |
| DF-40-CD57_1uM | Dose=1uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1 |
| WB-33-KW88_0.01uM | Dose=0.01uM |
| CA-90-RU33_0.01uM | Dose=0.01uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| CE-35-LA42_1uM | Dose=1uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide |
| SC-02-RZ08_10uM | Dose=10uM, N-[(E)-[4-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]phenyl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine, CXCR4 antagonist targeting CXCR4 |
| KE-89-TF43_1uM | Dose=1uM, 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one, PDE9A gene inhibitor targeting PDE9A |
| BA-28-JD87_1uM | Dose=1uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| HD-29-PZ41_0.1uM | Dose=0.1uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one |
| MB-35-NZ76_10uM | Dose=10uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone) |
| GA-30-HJ41_1uM | Dose=1uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| WE-69-LT10_1uM | Dose=1uM |
| AD-55-EA62_0.01uM | Dose=0.01uM, D-AP4 |
| NB-48-NL30_10uM | Dose=10uM, 4-[[3-(4-cyanophenyl)-5-methylpyrazol-1-yl]methyl]-N-ethylbenzamide targeting AR |
| EC-01-PH79_0.01uM | Dose=0.01uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| OD-03-CA36_0.1uM | Dose=0.1uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide |
| GE-63-WI86_0.01uM | Dose=0.01uM, Nesbuvir |
| AC-94-YX80_1uM | Dose=1uM, Loratadine |
| AE-91-BF25_10uM | Dose=10uM, Imetit, HRH3 agonist targeting HRH3 |
| CC-91-RO81_0.01uM | Dose=0.01uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3 |
| TA-36-PC58_10uM | Dose=10uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5 |
| BB-37-LS05_10uM | Dose=10uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| CA-54-WJ96_0.01uM | Dose=0.01uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| AB-31-VZ28_0.1uM | Dose=0.1uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A |
| VB-92-JQ72_1uM | Dose=1uM, N-[1-[[1-(2-fluoroethyl)piperidin-4-yl]-phenylmethyl]pyrazol-4-yl]-6,6-dimethyl-1,4,5,7-tetrahydroindazole-3-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK |
| ED-43-XF39_10uM | Dose=10uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5 |
| AB-06-KB32_0.1uM | Dose=0.1uM |
| OC-21-IP52_0.01uM | Dose=0.01uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide |
| MB-83-RV32_10uM | Dose=10uM, N-1,2,3-Benzothiadiazol-6-yl-N'-[2-oxo-2-(1-piperidinyl)ethyl]urea, allosteric PRMT3 inhibitor;PRMT3 targeting PRMT3 |
| AB-04-MQ83_0.1uM | Dose=0.1uM |
| DD-89-MJ03_10uM | Dose=10uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| AD-66-NV75_0.01uM | Dose=0.01uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| IA-35-VT87_0.1uM | Dose=0.1uM, Gka-50, Glucose Lowering Agents;Glucokinase Activators targeting GCK |
| EB-97-AV17_10uM | Dose=10uM, Diphenylamine-2,2'-dicarboxylic acid |
| NF-53-AH73_0.1uM | Dose=0.1uM, Riociguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| AC-98-UW57_0.1uM | Dose=0.1uM, Suplatast |
| BC-33-BM51_0.1uM | Dose=0.1uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| AE-56-RB57_0.1uM | Dose=0.1uM |
| ND-66-KW81_1uM | Dose=1uM, A-161906, TNF-alpha Production Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| UE-78-EW35_0.01uM | Dose=0.01uM, 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole, HTR2A antagonist targeting HTR2A |
| FA-77-YL98_0.01uM | Dose=0.01uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| LC-21-LG46_0.01uM | Dose=0.01uM |
| UB-41-DY23_10uM | Dose=10uM |
| CD-07-GB34_1uM | Dose=1uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F |
| AF-10-QK79_1uM | Dose=1uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| EB-07-JB09_1uM | Dose=1uM |
| LF-30-FP85_10uM | Dose=10uM, 2-Chloro-5-[3-(5-chloro-2-methoxy-pyridin-4-yl)-1h-indole-6-carbonyl]-benzenesulfonamide |
| KE-04-OV29_0.01uM | Dose=0.01uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)- |
| NB-89-OV56_0.1uM | Dose=0.1uM, PF 04802367, GSK3a/b inhibitor targeting GSK3B, GSK3A |
| YB-30-EK42_1uM | Dose=1uM |
| JC-76-VX29_10uM | Dose=10uM, 7-Nitro-1,2,3,4-tetrahydroisoquinoline, phenylethanolamine N-methyltransferase inhibitor targeting PNMT |
| CB-45-VH79_1uM | Dose=1uM |
| LE-08-BO67_1uM | Dose=1uM, 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide, Muscarinic M5 receptor antagonist targeting CHRM5 |
| YB-79-RC04_10uM | Dose=10uM, 7-[(1R,2S,3E,5Z)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-(3-methylphenyl)octa-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid, Phospholipase A2 (PLA2) Inhibitors;Leukotriene Antagonists targeting PLA2G10 |
| AB-61-FY15_0.01uM | Dose=0.01uM |
| DB-80-QN16_10uM | Dose=10uM, Valpromide |
| GE-17-FE71_0.01uM | Dose=0.01uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR |
| EA-60-LN91_10uM | Dose=10uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1 |
| TE-67-XP56_10uM | Dose=10uM, Bms-561392, ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors) targeting ADAM17 |
| GE-98-ZI68_0.01uM | Dose=0.01uM |
| BD-33-HT38_0.01uM | Dose=0.01uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| MD-92-KD16_0.1uM | Dose=0.1uM, 1-Methyl-2-[(2-methyl-6-propan-2-ylphenyl)methylcarbamoyl]-3-oxoindazole-7-carboxylic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| BD-33-HT38_10uM | Dose=10uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| BC-15-EL49_0.1uM | Dose=0.1uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| JE-04-LS32_0.1uM | Dose=0.1uM |
| FC-62-AI14_0.01uM | Dose=0.01uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ |
| ED-84-WW97_0.1uM | Dose=0.1uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5 |
| NE-94-VE83_0.1uM | Dose=0.1uM |
| VF-12-MF80_0.1uM | Dose=0.1uM, 2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide, Adenosine A2B Agonists targeting ADORA2B |
| AF-16-IB77_1uM | Dose=1uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| DF-46-QE34_0.1uM | Dose=0.1uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1 |
| HC-43-CV47_0.01uM | Dose=0.01uM, Bergapten |
| UF-28-DW05_10uM | Dose=10uM, 5-[3-(5-aminopentyl)-5-(1H-indol-3-ylmethyl)-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(4-aminophenoxy)benzonitrile, Somatostatin SRIF1A (sst2) Agonists targeting SSTR2 |
| MA-43-MR37_0.1uM | Dose=0.1uM |
| UA-91-HL97_1uM | Dose=1uM |
| AE-32-UP21_0.01uM | Dose=0.01uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| S0-EE-YC7H_0.01uM | Dose=0.01uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6 |
| AD-51-ZE47_10uM | Dose=10uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| AB-11-AY75_10uM | Dose=10uM, 5-(2,5-Dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid, Pin1 Inhibitors targeting PIN1 |
| AB-40-HA80_0.01uM | Dose=0.01uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| FB-67-PL18_0.1uM | Dose=0.1uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| KA-37-GD83_0.01uM | Dose=0.01uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
| AB-35-RU30_0.1uM | Dose=0.1uM |
| WD-26-EB85_0.1uM | Dose=0.1uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1 |
| BE-48-TM93_0.1uM | Dose=0.1uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R |
| ED-87-UE76_10uM | Dose=10uM, CP-122721, Neurokinin 1 receptor antagonist;Tachykinin NK1 Antagonists targeting CYP2D6 |
| JC-47-KK95_0.01uM | Dose=0.01uM, 4-(2-Cyano-5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid |
| JD-87-MR82_0.01uM | Dose=0.01uM, N-[1,3-Dimethyl-6-[(2r)-2-Methylpiperazin-1-Yl]-2-Oxidanylidene-Benzimidazol-5-Yl]-2-Methoxy-Benzamide, BRPF1 inhibitor;BRPF1 inhibitors targeting BRPF1 |
| FB-86-IO73_10uM | Dose=10uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| CE-95-YX02_0.1uM | Dose=0.1uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3 |
| AC-92-HS43_0.1uM | Dose=0.1uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4 |
| DB-78-NM13_0.1uM | Dose=0.1uM, Telenzepine, CHRM1 antagonist targeting CHRM1 |
| EE-78-ES92_10uM | Dose=10uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A |
| AA-16-HV95_10uM | Dose=10uM |
| RF-04-GI28_0.1uM | Dose=0.1uM |
| OA-54-FL10_1uM | Dose=1uM |
| FF-07-FL63_1uM | Dose=1uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| DB-34-QA60_0.01uM | Dose=0.01uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| LB-72-WN85_0.1uM | Dose=0.1uM |
| HC-01-CN33_0.01uM | Dose=0.01uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile |
| KB-24-KS32_1uM | Dose=1uM, {3,5-Dimethyl-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenoxy}-acetic acid |
| AD-54-IH37_0.1uM | Dose=0.1uM, Entacapone, COMT Inhibitors targeting COMT |
| AB-41-IO16_0.01uM | Dose=0.01uM |
| FD-85-SX37_10uM | Dose=10uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2 |
| GA-94-KZ19_0.1uM | Dose=0.1uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2 |
| BB-28-CT35_0.01uM | Dose=0.01uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ |
| DB-24-CQ08_0.01uM | Dose=0.01uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol |
| PC-85-EL52_0.01uM | Dose=0.01uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139 |
| PE-58-WU11_1uM | Dose=1uM |
| QC-15-WY38_10uM | Dose=10uM, TRKA Inhibitors targeting NTRK1 |
| AB-44-GQ28_0.01uM | Dose=0.01uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A |
| BC-52-WF67_1uM | Dose=1uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| AC-53-YM36_1uM | Dose=1uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK |
| TD-69-UA90_0.01uM | Dose=0.01uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| LC-42-WU67_1uM | Dose=1uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3 |
| DF-93-BT88_1uM | Dose=1uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C |
| MB-72-YK93_0.1uM | Dose=0.1uM |
| BD-19-MD69_1uM | Dose=1uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| QD-39-YV36_1uM | Dose=1uM, (1S,3S)-3-amino-4-(2,2,2-trifluoro-1-trifluoromethylethylidene)cyclopentane, OAT inhibitor targeting OAT |
| AD-29-IG16_1uM | Dose=1uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1 |
| CF-68-DM58_0.01uM | Dose=0.01uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| BF-94-CQ58_10uM | Dose=10uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| AC-21-PO16_1uM | Dose=1uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate |
| LD-14-PB06_0.1uM | Dose=0.1uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET |
| WF-20-QN39_0.1uM | Dose=0.1uM, Diethylstilbestrol Dipropionate, Estrogen Receptor Agonist targeting ESR1 |
| EE-04-QG34_10uM | Dose=10uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1 |
| CB-73-HZ47_0.01uM | Dose=0.01uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| OD-47-WT51_1uM | Dose=1uM, Ecopipam, selective dopamine D1/D5 receptor antagonist targeting DRD1 |
| LF-35-CP32_1uM | Dose=1uM, Adinazolam, Peripheral-type benzodiazepine receptors potentiator targeting TSPO |
| GC-74-QF56_0.01uM | Dose=0.01uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| BD-59-MG06_0.1uM | Dose=0.1uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| DC-93-RZ62_10uM | Dose=10uM |
| BB-79-GA42_0.1uM | Dose=0.1uM, Pratol |
| EC-86-EK93_0.1uM | Dose=0.1uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4 |
| UD-16-YL39_0.1uM | Dose=0.1uM, 3-amino-N-(5-benzoyl-2-piperazin-1-ylphenyl)pyrazine-2-carboxamide |
| BD-85-OV63_0.01uM | Dose=0.01uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| CA-72-UL91_0.01uM | Dose=0.01uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| AF-31-RV78_1uM | Dose=1uM, targeting NOS3, PAH, TH, TPH1 |
| FB-51-DL49_10uM | Dose=10uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4 |
| BA-70-LV41_0.1uM | Dose=0.1uM, Rosmarinic acid, Angiogenesis Inhibitors;4-aminobutyrate transaminase inhibitor;Antioxidants targeting ABAT |
| AF-99-HA02_0.1uM | Dose=0.1uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| EE-83-RW10_0.1uM | Dose=0.1uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1 |
| EC-62-NP61_10uM | Dose=10uM, 4'-(3,6,9,12-Tetraoxapentadec-14-yn-1-yloxy)-[1,1'-biphenyl]-4-yl sulfurofluoridate, CRABP2 inhibitor targeting CRABP2 |
| XC-86-SR58_10uM | Dose=10uM |
| AA-99-PN83_1uM | Dose=1uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide |
| ZE-37-PE19_0.1uM | Dose=0.1uM, 6,8-Dichloro-7-methoxy-9H-beta-carboline targeting CHUK |
| AA-99-HG96_10uM | Dose=10uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F |
| BD-98-XW77_0.01uM | Dose=0.01uM |
| BA-13-CC32_0.01uM | Dose=0.01uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BE-16-UV45_1uM | Dose=1uM |
| BD-27-CC87_1uM | Dose=1uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13 |
| BA-15-LA22_0.1uM | Dose=0.1uM |
| ZE-46-XH09_1uM | Dose=1uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide |
| DA-80-IV36_10uM | Dose=10uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| NB-92-BG38_0.01uM | Dose=0.01uM, 5-HT7 agonist 2, HTR7 agonist targeting HTR7 |
| NC-62-VG98_10uM | Dose=10uM, 5-Chloro-2-(mesitylamino)benzamide, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR4, S1PR5 |
| IC-08-NY46_10uM | Dose=10uM, N-(3-phenoxycinnamyl)acetohydroxamic acid |
| UE-90-KK72_0.1uM | Dose=0.1uM |
| QB-88-PG52_0.1uM | Dose=0.1uM, 2-Benzyloxy-4H-3,1-benzoxazin-4-one, Cathepsin G inhibitor targeting CTSG |
| AF-81-IV73_0.1uM | Dose=0.1uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13 |
| BE-49-XN43_10uM | Dose=10uM |
| DA-35-ZK21_10uM | Dose=10uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| KC-54-AS32_10uM | Dose=10uM, Miridesap, Antiamyloidogenic Agents;Anti-Human Serum Amyloid P (Anti-SAP) targeting APCS |
| AC-36-FB52_0.01uM | Dose=0.01uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| WB-92-TT14_0.01uM | Dose=0.01uM |
| AD-42-OW73_0.01uM | Dose=0.01uM, SB 415286 targeting GSK3A, GSK3B |
| OD-13-IE31_10uM | Dose=10uM |
| AE-95-HR68_1uM | Dose=1uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2 |
| QE-76-HF95_0.1uM | Dose=0.1uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2 |
| AB-02-CF97_1uM | Dose=1uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| WA-98-CM36_10uM | Dose=10uM, 5-chloro-N-(5-chloro-2-hydroxy-phenyl)-2-methoxy-benzamide, KCNMA1 gene stimulator;BKca channel opener targeting KCNMA1 |
| GD-23-GS20_1uM | Dose=1uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2 |
| PC-63-CH43_10uM | Dose=10uM, 1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide, PARG inhibitor targeting PARG |
| CF-50-QK79_0.1uM | Dose=0.1uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2 |
| GE-58-RW27_0.1uM | Dose=0.1uM, Fomepizole |
| EA-07-RB34_10uM | Dose=10uM |
| CC-90-NK44_0.1uM | Dose=0.1uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| EE-59-HC06_10uM | Dose=10uM, 1,2,3,4-Tetrahydroisoquinoline-2-sulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type XIV Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA14 |
| BF-13-HM71_0.1uM | Dose=0.1uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| AC-51-PY60_1uM | Dose=1uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| CC-62-XM29_0.1uM | Dose=0.1uM, Skf-81297, DRD1 agonist targeting DRD1 |
| BB-27-MC77_1uM | Dose=1uM |
| EE-85-SK26_0.01uM | Dose=0.01uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| DD-30-NA60_0.01uM | Dose=0.01uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| GE-26-BO33_0.01uM | Dose=0.01uM, USP7/USP47 inhibitor targeting USP7 |
| GC-02-TV70_10uM | Dose=10uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| GF-19-NZ91_1uM | Dose=1uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| AB-73-SW45_0.1uM | Dose=0.1uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| EE-98-PF86_0.01uM | Dose=0.01uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| FB-56-IR20_10uM | Dose=10uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2 |
| AC-02-SI74_1uM | Dose=1uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EE-66-CK83_0.01uM | Dose=0.01uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| BA-74-EG74_10uM | Dose=10uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD |
| ME-77-TQ29_0.1uM | Dose=0.1uM, N,N'-bis-(2-hydroxybenzyl)-2,5-diamino-2,5-dimethyl-hexane, TRPA1 Antagonists targeting TRPA1 |
| DE-85-FR73_0.1uM | Dose=0.1uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| BE-16-VM54_10uM | Dose=10uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC |
| OE-23-XH48_10uM | Dose=10uM, Glpg-1837, CFTR modulator targeting CFTR |
| HF-36-FK93_1uM | Dose=1uM, (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide, SPHK1 inhibitor targeting SPHK1 |
| QB-87-TC65_1uM | Dose=1uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1 |
| IC-91-IX22_1uM | Dose=1uM, 1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Angiogenesis Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;EphB4 Inhibitors targeting CAMK2B, EPHB4, FYN, MAPK13, CAMK2G |
| KC-35-MF93_10uM | Dose=10uM |
| AE-94-ZD47_0.01uM | Dose=0.01uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| AC-21-PO16_0.01uM | Dose=0.01uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate |
| OC-10-FB51_10uM | Dose=10uM |
| JA-62-XU82_0.01uM | Dose=0.01uM, benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-phenylethyl]carbamate, Cathepsin K Inhibitors;Cathepsin S Inhibitors;Cathepsin L Inhibitors targeting CTSK, CTSL, CTSS |
| DD-77-OI11_0.1uM | Dose=0.1uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2 |
| GA-66-XX49_0.1uM | Dose=0.1uM |
| BE-07-XF09_0.1uM | Dose=0.1uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2 |
| AA-98-HX85_1uM | Dose=1uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| FE-22-JV50_1uM | Dose=1uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD |
| CE-20-VA70_0.1uM | Dose=0.1uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| BE-68-LK29_10uM | Dose=10uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9 |
| AA-31-OE22_1uM | Dose=1uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione |
| TA-34-CK62_0.1uM | Dose=0.1uM, 3-[[4-[2-(3-Chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propanamide, CDK1 Inhibitors targeting CDK1 |
| DD-96-VY72_0.01uM | Dose=0.01uM |
| CE-35-LA42_0.01uM | Dose=0.01uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide |
| TC-36-AL79_10uM | Dose=10uM, Duloxetine, Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting CYP2D6, SLC6A2, SLC6A4 |
| JF-84-QZ64_10uM | Dose=10uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2 |
| AB-95-LH34_10uM | Dose=10uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK |
| BB-53-SW55_0.01uM | Dose=0.01uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| BB-86-BE19_0.1uM | Dose=0.1uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| AF-89-AD94_10uM | Dose=10uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7 |
| EF-83-OP68_1uM | Dose=1uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR |
| BD-41-DI77_1uM | Dose=1uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A |
| BE-66-GV20_0.01uM | Dose=0.01uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F |
| DB-28-SP20_1uM | Dose=1uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4 |
| BE-13-XC52_1uM | Dose=1uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| AD-51-FB60_10uM | Dose=10uM, 1-C-Ethylaminoadamantane |
| DC-99-NQ50_0.01uM | Dose=0.01uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| AA-99-HG96_1uM | Dose=1uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F |
| FA-71-UB40_0.1uM | Dose=0.1uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid |
| CC-68-YZ44_0.1uM | Dose=0.1uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CA-06-FY97_1uM | Dose=1uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119 |
| NE-42-YQ17_10uM | Dose=10uM |
| CC-20-ZO24_10uM | Dose=10uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| BA-02-RI19_10uM | Dose=10uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| EF-64-HJ41_10uM | Dose=10uM, LY 255283, LTB4R2 antagonist targeting LTB4R2 |
| BB-01-IO76_10uM | Dose=10uM, Aspartic Acid |
| UF-27-OP66_10uM | Dose=10uM, 5-[3-(4-Chlorophenyl)-1H-Indazol-5-Yl]-2H-1,2,3,4-Tetrazole, SAPK1a (JNK2) Inhibitors targeting MAPK9 |
| LB-54-MZ19_0.1uM | Dose=0.1uM, Cetilistat, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Pancreatic Triacylglycerol Lipase Inhibitors targeting LIPC, LIPE, PNLIP, LIPG, LIPF |
| GD-59-OG21_10uM | Dose=10uM, Stavudine |
| JE-31-PK61_10uM | Dose=10uM, 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, PDE9a inhibitor targeting PDE9A |
| ZB-09-RC84_0.01uM | Dose=0.01uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| HF-29-JW14_10uM | Dose=10uM, Latrepirdine, NMDA Antagonists;5-HT6 Antagonists targeting HTR6 |
| BF-79-GG96_0.01uM | Dose=0.01uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| UD-07-US73_0.01uM | Dose=0.01uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB |
| BA-86-YY52_1uM | Dose=1uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C |
| GB-19-AP57_0.01uM | Dose=0.01uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| NC-62-VG98_0.1uM | Dose=0.1uM, 5-Chloro-2-(mesitylamino)benzamide, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR4, S1PR5 |
| BF-49-QA17_10uM | Dose=10uM, Vaf347 |
| DA-49-ZD74_0.01uM | Dose=0.01uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| KE-28-DL25_1uM | Dose=1uM, Methyl 4-[[2,3-dioxo-4-propan-2-yl-7-(trifluoromethyl)quinoxalin-1-yl]methyl]benzoate, Phosphodiesterase PDE4B Inhibitors targeting PDE4B |
| DE-85-LX22_0.01uM | Dose=0.01uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| BF-49-KQ10_0.1uM | Dose=0.1uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA |
| EC-98-YS67_0.1uM | Dose=0.1uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| UE-58-EW15_1uM | Dose=1uM, (E)-1-(4-Hydroxy-3,5-dimethoxyphenyl)-7-phenylhept-1-en-3-one, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| BB-28-MC54_0.01uM | Dose=0.01uM, GPBAR1 agonist targeting GPBAR1 |
| EF-46-LK88_1uM | Dose=1uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate |
| LD-00-HM58_1uM | Dose=1uM, 5-[2,3-Bis(Chloranyl)phenyl]-2-[(3~{r},5~{s})-3,5-Dimethylpiperazin-1-Yl]pyrimidin-4-Amine, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A |
| JA-01-GQ75_0.01uM | Dose=0.01uM, NS 1652, Chloride Channel Blockers targeting GRIK1 |
| BA-98-JJ31_10uM | Dose=10uM, Quinine |
| ZC-74-FT18_0.1uM | Dose=0.1uM, CID 25225521, Orexin 2 receptor antagonist targeting HCRTR2 |
| AC-76-BB72_10uM | Dose=10uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1 |
| YC-27-PB87_1uM | Dose=1uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5 |
| DD-08-BT45_10uM | Dose=10uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| HD-28-QL60_1uM | Dose=1uM, (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine, Na+/H+ Exchanger type 3 (NHE-3) Inhibitors targeting SLC9A3 |
| DD-85-KU00_0.1uM | Dose=0.1uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| IC-43-CV07_0.1uM | Dose=0.1uM |
| DD-12-RF07_10uM | Dose=10uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| HE-01-ND39_1uM | Dose=1uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| HB-01-ZU75_0.1uM | Dose=0.1uM |
| LC-96-WR85_0.1uM | Dose=0.1uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17 |
| ME-77-XX06_0.01uM | Dose=0.01uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide |
| LF-64-NB46_0.01uM | Dose=0.01uM, Fti 277, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| QC-32-ZC28_0.01uM | Dose=0.01uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid |
| FB-62-GL41_10uM | Dose=10uM, 3-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]benzoic acid, Nurr1 Receptor Activators targeting NR4A2 |
| XD-37-GI34_10uM | Dose=10uM |
| DE-24-AX80_0.01uM | Dose=0.01uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| HC-26-PX74_1uM | Dose=1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid |
| EE-08-FF71_0.1uM | Dose=0.1uM, Levofloxacin |
| JA-23-RY79_1uM | Dose=1uM |
| IB-06-YD91_1uM | Dose=1uM, dual thymidylate synthase and dihydrofolate reductase inhibitors targeting DHFR, FOLR1, GART, SLC19A1, TYMS |
| HF-79-EC41_0.1uM | Dose=0.1uM, Blu-9931, FGFR4 inhibior targeting FGFR4 |
| TE-87-FM14_10uM | Dose=10uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid |
| EA-09-HM95_1uM | Dose=1uM |
| BA-28-XM73_0.1uM | Dose=0.1uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide |
| DB-21-FY25_0.01uM | Dose=0.01uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DA-19-JA87_0.1uM | Dose=0.1uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1 |
| AD-66-NO48_1uM | Dose=1uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| AD-92-QZ55_0.1uM | Dose=0.1uM, Tmc-353121 |
| CB-24-FA25_1uM | Dose=1uM, Spiperone |
| DB-40-GN91_0.1uM | Dose=0.1uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| QB-69-QH67_10uM | Dose=10uM, 1,3-Benzothiazol-2-yl-[5-(4-chlorophenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone, TOP2A catalytic inhibitor targeting TOP2A |
| AA-54-WG39_10uM | Dose=10uM, 4-Aminobenzamide |
| OA-89-EE65_0.1uM | Dose=0.1uM, N-[4-chloro-2-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-4-(trifluoromethoxy)benzenesulfonamide |
| ZD-74-FC07_0.01uM | Dose=0.01uM |
| AB-04-HG24_0.01uM | Dose=0.01uM |
| NE-45-SF73_0.1uM | Dose=0.1uM |
| AW-10-0667_10uM | Dose=10uM, Clofibrate |
| AF-40-QU33_1uM | Dose=1uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| SE-92-BP29_1uM | Dose=1uM |
| AB-63-OW35_1uM | Dose=1uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A |
| CA-57-TC62_10uM | Dose=10uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1 |
| DC-22-OP01_0.01uM | Dose=0.01uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4 |
| DB-20-QK39_10uM | Dose=10uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| GB-11-PX47_0.01uM | Dose=0.01uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3 |
| AC-76-BB72_0.1uM | Dose=0.1uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1 |
| GE-25-YQ75_10uM | Dose=10uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2 |
| HB-29-DM15_1uM | Dose=1uM, 4-(4-Guanidinobenzoyloxy)phenylacetate |
| DA-20-VR86_0.01uM | Dose=0.01uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN |
| BA-75-MA47_10uM | Dose=10uM, Selurampanel, AMPA Antagonists targeting GRIA1 |
| IC-96-AX39_0.01uM | Dose=0.01uM, Sivelestat, Elastase inhibitor;Leukocyte Elastase Inhibitors targeting CELA1, ELANE |
| DB-00-QN66_0.01uM | Dose=0.01uM |
| GE-14-EF51_0.01uM | Dose=0.01uM, LL-Z1272.Episilon. targeting FNTB |
| AA-48-XT80_0.01uM | Dose=0.01uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine |
| AB-21-MV93_0.1uM | Dose=0.1uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4 |
| S0-EE-WW96_10uM | Dose=10uM, eCF506 targeting FYN, SRC, YES1 |
| LA-69-OL77_10uM | Dose=10uM, 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one, NR2B Antagonists targeting GRIN2B |
| RF-05-PV01_0.1uM | Dose=0.1uM, 6-Chloro-3-((4-methylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one, SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4, PBRM1 |
| BD-68-PM33_1uM | Dose=1uM, Crt 0066101, protein kinase d inhibitor targeting PKD1 |
| AB-83-EW00_1uM | Dose=1uM, 1,3-Dipropyl-7-methylxanthine |
| ME-73-FK70_10uM | Dose=10uM, 5-Iodo-6-amino-1,2-benzopyrone, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| AE-28-LX10_0.01uM | Dose=0.01uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| CD-47-YL43_0.01uM | Dose=0.01uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B |
| PD-34-SO87_10uM | Dose=10uM, N-(2-((3-(dimethylamino)propyl)(methyl)amino)-5-(trifluoromethyl)phenyl)-2-fluoro-5-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)benzamide, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK |
| S0-EE-Y6WJ_0.1uM | Dose=0.1uM, 4-(2-Amino-1,3-benzothiazol-6-yl)-1-(cyclopropylmethyl)pyridin-2-one, PI4KA gene inhibitor targeting PI4KA |
| HC-43-CV47_1uM | Dose=1uM, Bergapten |
| UA-39-TN76_10uM | Dose=10uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2 |
| RA-14-EK87_10uM | Dose=10uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one |
| EF-16-GV25_1uM | Dose=1uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1 |
| EE-02-BO83_0.1uM | Dose=0.1uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| EF-99-HJ48_0.1uM | Dose=0.1uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| HA-10-LJ21_1uM | Dose=1uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88 |
| DA-39-AJ98_1uM | Dose=1uM, Metylperon, DRD2 antagonist targeting DRD2 |
| BD-45-WH14_1uM | Dose=1uM, HC067047, TRPV4 gene inhibitor targeting TRPV4 |
| GD-59-OG21_0.1uM | Dose=0.1uM, Stavudine |
| JA-17-JV87_10uM | Dose=10uM, Tegafur, Cytochrome P450 CYP2A6 inhibitor targeting CYP2A6 |
| CB-11-GB40_0.01uM | Dose=0.01uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| KB-85-KP82_0.1uM | Dose=0.1uM, Sch 33303, Mediator Release Inhibitors;Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1 |
| NE-34-OZ69_1uM | Dose=1uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1 |
| IA-65-QX27_1uM | Dose=1uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A |
| HE-99-KP87_0.1uM | Dose=0.1uM, {4-[4-(4-Isopropoxyphenyl)-5-(4-trifluoromethoxyphenyl)thiazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARD |
| CA-66-YB17_0.1uM | Dose=0.1uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A |
| SC-76-YF40_0.01uM | Dose=0.01uM |
| AA-90-AU53_10uM | Dose=10uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| CD-54-FJ31_10uM | Dose=10uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT |
| FA-03-CZ62_10uM | Dose=10uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| BE-58-FC64_0.1uM | Dose=0.1uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D |
| LE-48-SO37_0.1uM | Dose=0.1uM, 4-[(3-chlorophenyl)methoxy]-1-methyl-5-pyridin-3-yl-3H-indol-2-one |
| ED-62-GS43_10uM | Dose=10uM, APLNR agonist targeting APLNR |
| BA-04-IG64_10uM | Dose=10uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| RC-14-PH60_1uM | Dose=1uM, Lin28-let-7a antagonist 1 targeting LIN28A |
| CA-98-SW47_10uM | Dose=10uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A |
| BE-16-UV45_0.01uM | Dose=0.01uM |
| LA-09-SS14_1uM | Dose=1uM, Pcera-1, TNF-alpha Production Inhibitors;IL-10 Production Enhancers;cPLA2a activator targeting PLA2G4A |
| FB-12-UL66_10uM | Dose=10uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| KA-52-MX24_0.1uM | Dose=0.1uM |
| CD-84-FJ21_0.01uM | Dose=0.01uM, Dpn 205-734 |
| PC-34-YF76_0.1uM | Dose=0.1uM, 1-[2-(2-Tert-butylanilino)pyridin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea, P2Y Antagonist targeting P2RY1 |
| FB-06-IU47_0.01uM | Dose=0.01uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10 |
| JB-82-MH86_10uM | Dose=10uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| UD-49-HQ53_0.1uM | Dose=0.1uM, 6-[(1S)-1-hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methoxypyridine-3-carbonitrile, KCNJ1 inhibitor;KCNJ1 gene inhibitor targeting KCNJ1 |
| BD-90-DK64_1uM | Dose=1uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1 |
| HD-08-BP45_0.01uM | Dose=0.01uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12 |
| BD-70-PH02_10uM | Dose=10uM |
| JB-81-XD04_0.1uM | Dose=0.1uM, N-Benzylphenethylamine targeting FARS2 |
| CF-56-LO98_10uM | Dose=10uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| AD-42-OW73_10uM | Dose=10uM, SB 415286 targeting GSK3A, GSK3B |
| CE-19-PD79_0.1uM | Dose=0.1uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| AC-55-XA97_0.1uM | Dose=0.1uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| CA-61-VV83_10uM | Dose=10uM |
| FA-79-WC91_0.01uM | Dose=0.01uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ |
| JD-50-EC04_1uM | Dose=1uM, 6-(4-Fluorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-amine, EphB4 Inhibitors;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, EPHB4, SRC, ABL2 |
| IC-86-MA49_1uM | Dose=1uM, 2-Adamantanecarbonyl-arg-phe-NH2 trifluoroacetate, Neuropeptide FF Receptor Antagonists targeting NPFFR1 |
| HF-51-NR28_0.01uM | Dose=0.01uM, 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide, ARP2/3 Complex inhibitor targeting ACTR3, ACTR2 |
| YF-46-CA32_10uM | Dose=10uM |
| IB-92-XA34_1uM | Dose=1uM, 3-Methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine, Anxiolytics targeting GABRA1 |
| AE-70-QB23_1uM | Dose=1uM, Trifluperidol targeting CYP2D6 |
| BE-79-QU25_0.01uM | Dose=0.01uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| ZD-09-WT25_0.01uM | Dose=0.01uM, 4-(Cyclopropylmethyl)-5-[2-(piperidin-4-ylamino)pyrimidin-4-yl]pyrimidin-2-amine |
| BA-74-WG29_1uM | Dose=1uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2 |
| AC-70-KV26_10uM | Dose=10uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| DA-80-IV36_0.1uM | Dose=0.1uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| BE-45-XA42_1uM | Dose=1uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1 |
| MA-67-FQ44_0.01uM | Dose=0.01uM, 1-Hydroxy-2-naphthoyl-Arg-Pro amide targeting TPSAB1, TPSD1, TPSG1, TPSB2 |
| CF-83-HM41_0.1uM | Dose=0.1uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA |
| BD-33-HT38_0.1uM | Dose=0.1uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| FA-06-GA39_0.1uM | Dose=0.1uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR |
| LC-83-NR62_10uM | Dose=10uM, (3R)-N~2~-(cyclopropylmethyl)-N~1~-hydroxy-3-(3-hydroxybenzyl)-N~4~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-L-aspartamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5 |
| JF-08-NB76_10uM | Dose=10uM, 4-[(2E)-3-phenylprop-2-en-1-yl]-N-(4-sulfamoylphenyl)piperazine-1-carbothioamide, CTNNBIP1 gene inhibitor targeting CTNNB1, TCF4 |
| BD-73-TX58_0.01uM | Dose=0.01uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8 |
| PD-94-WO47_0.1uM | Dose=0.1uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1 |
| ID-96-UX79_1uM | Dose=1uM, Vaniprevir |
| LC-42-WU67_0.01uM | Dose=0.01uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3 |
| LC-78-EV09_10uM | Dose=10uM |
| BD-36-VB52_0.01uM | Dose=0.01uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| ED-10-ED67_1uM | Dose=1uM, Dcebio |
| XE-18-BC97_0.01uM | Dose=0.01uM, 2-Hydroxy-6-[4-methyl-5-(4-methylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]naphthalene-1-carbaldehyde |
| GC-82-RV65_0.1uM | Dose=0.1uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B |
| CE-96-JE44_10uM | Dose=10uM, A438079, P2X7 Receptor Antagonists targeting P2RX7 |
| GB-11-TA37_0.01uM | Dose=0.01uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| BD-22-KS33_0.1uM | Dose=0.1uM, Aptazapine, ADRA2A antagonist targeting ADRA2A |
| AE-54-BN96_1uM | Dose=1uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3 |
| QA-67-IM54_10uM | Dose=10uM, CID 118626505 |
| IB-87-ZR37_1uM | Dose=1uM, 6-Chloro-2-[(4-chlorophenyl)methylsulfanyl]-1-(4-ethoxyphenyl)benzimidazole, Free Fatty Acid Receptor 1 (FFAR1;GPR40) Antagonists targeting FFAR1 |
| OC-12-KT94_1uM | Dose=1uM, Sch 40120, Lipoxygenase Inhibitors;Mediator Release Inhibitors targeting ALOX5 |
| AF-83-BX08_0.1uM | Dose=0.1uM |
| FD-55-XG26_10uM | Dose=10uM |
| EA-06-CH36_0.1uM | Dose=0.1uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| BD-50-HU68_0.1uM | Dose=0.1uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2 |
| CC-56-MO03_0.01uM | Dose=0.01uM, 4-(1H-indol-3-yl)pyrimidin-2-amine |
| FF-10-JX55_0.01uM | Dose=0.01uM |
| KB-48-GH25_1uM | Dose=1uM, 2-[3-[(4-Methylphenyl)carbamoyl]-4-piperidin-1-ylphenyl]indazole-6-carboxylic acid |
| BA-84-WN26_0.01uM | Dose=0.01uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| HE-95-KK46_1uM | Dose=1uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A |
| WB-38-DZ32_10uM | Dose=10uM, Isatin Sulfonamide 34, Caspase 7 Inhibitors;Apoptosis Inhibitors;Caspase 3 Inhibitors targeting CASP3, CASP7 |
| AC-82-PZ00_10uM | Dose=10uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C |
| CF-90-DA50_10uM | Dose=10uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1 |
| HA-29-ZM35_10uM | Dose=10uM |
| VB-27-PZ25_1uM | Dose=1uM, 4-(3-bromophenyl)-1H-1,2,3-triazole, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2 |
| BC-21-EB65_10uM | Dose=10uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| AB-72-EP76_1uM | Dose=1uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2 |
| LE-50-NZ39_0.01uM | Dose=0.01uM |
| AA-76-VE74_1uM | Dose=1uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| FE-27-XB49_10uM | Dose=10uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP |
| VA-15-ZR21_1uM | Dose=1uM |
| AC-80-DI95_1uM | Dose=1uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| YB-79-RC04_1uM | Dose=1uM, 7-[(1R,2S,3E,5Z)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-(3-methylphenyl)octa-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid, Phospholipase A2 (PLA2) Inhibitors;Leukotriene Antagonists targeting PLA2G10 |
| YC-27-PB87_0.01uM | Dose=0.01uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5 |
| AE-87-GP03_1uM | Dose=1uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4 |
| EB-85-JN83_0.01uM | Dose=0.01uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| GE-40-VJ66_1uM | Dose=1uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2 |
| AE-52-FP96_10uM | Dose=10uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| XB-39-YT35_10uM | Dose=10uM, 4-[[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide, OPRD1 agonist targeting OPRD1 |
| OC-25-TL77_10uM | Dose=10uM, Methyl 3-(2-phenylacetamido)thiophene-2-carboxylate |
| AD-11-HV98_1uM | Dose=1uM, Balicatib, Cathepsin K Inhibitors targeting CTSK |
| MD-91-JM80_0.01uM | Dose=0.01uM, N-methyl-2-(4-phenylmethoxypiperidin-1-yl)ethanamine, PRMT4/6 inhibitor;PRMT4 and PRMT6 inhibitor targeting CARM1, PRMT6 |
| VF-03-AC40_0.01uM | Dose=0.01uM, 3-chloro-N-[(E)-[1-[4-(trifluoromethoxy)phenyl]pyrrol-2-yl]methylideneamino]-5-(trifluoromethyl)pyridin-2-amine |
| NA-42-JG03_0.1uM | Dose=0.1uM, (3S,6S,8aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-(2-phenylethyl)-2,3,6,7,8,8a-hexahydro-1H-indolizine-3-carboxamide |
| QE-48-NG07_0.01uM | Dose=0.01uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-[4-[[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-(diaminomethylideneamino)-1,3,5-triazin-2-yl]amino]anilino]-1,3,5-triazin-2-yl]guanidine, NPR1 agonist of the extracellular domain targeting NPR1 |
| LC-40-KC29_0.01uM | Dose=0.01uM |
| LC-11-GG16_0.01uM | Dose=0.01uM |
| DB-77-AV67_10uM | Dose=10uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate |
| HF-07-ER47_0.1uM | Dose=0.1uM, 1H-Indole, 3-(3-pyridinylmethyl)- |
| ID-13-PY29_10uM | Dose=10uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B |
| S0-EE-Y6YC_0.1uM | Dose=0.1uM, N-[5-({[(3-Fluorophenyl)carbamoyl]amino}methyl)-2-Methylphenyl]imidazo[1,2-A]pyridine-3-Carboxamide, DDR2 inhibitor targeting DDR2 |
| BC-01-WO51_10uM | Dose=10uM, 2-[[(2S)-2-aminopropanoyl]amino]ethyl N-[4-(3-chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]carbamate |
| CB-68-GZ09_10uM | Dose=10uM, SB-204741, HTR2B antagonist targeting HTR2B |
| LE-81-PG11_0.1uM | Dose=0.1uM, N-Methyl-N-((2-(1-(2-(methylamino)ethyl)piperidin-4-yl)pyridin-4-yl)methyl)-3-phenoxybenzamide, inhibitor of PRMT4 targeting CARM1 |
| AC-29-ZR23_10uM | Dose=10uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| SF-77-LC15_0.1uM | Dose=0.1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-10,10-dimethyl-2-oxa-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| KB-72-ID36_10uM | Dose=10uM, Tolimidone, Lyn kinase activator;Lyn Kinase Activators targeting LYN |
| OC-21-IP52_0.1uM | Dose=0.1uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide |
| FD-29-MM50_1uM | Dose=1uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| XD-68-MP63_0.1uM | Dose=0.1uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine |
| LF-50-IZ49_1uM | Dose=1uM, Alendronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors;Protein Tyrosine Phosphatase (PTP) Inhibitors targeting FDPS, FDFT1 |
| OA-46-YF15_0.1uM | Dose=0.1uM, H-Asp-Glu-Val-Asp-al, Apoptosis Inhibitors;Caspase 3 Inhibitors;Caspase 8 Inhibitors targeting CASP3, CASP8 |
| OF-19-JH77_10uM | Dose=10uM, 2-[1-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-2,2-diphenyl-ethylamino]-acetamide, TACR1 antagonist targeting TACR1 |
| EB-83-IM06_1uM | Dose=1uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE |
| PA-09-IB98_10uM | Dose=10uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one |
| GB-92-JY12_0.01uM | Dose=0.01uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3 |
| CA-60-RU13_10uM | Dose=10uM |
| GC-46-CA74_1uM | Dose=1uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R |
| FE-58-ES32_10uM | Dose=10uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine |
| AD-65-WK61_10uM | Dose=10uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P |
| BD-68-PM33_10uM | Dose=10uM, Crt 0066101, protein kinase d inhibitor targeting PKD1 |
| WB-48-EF24_1uM | Dose=1uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1 |
| DE-28-BW67_0.01uM | Dose=0.01uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| CE-00-EK89_0.1uM | Dose=0.1uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| CF-35-NN63_0.1uM | Dose=0.1uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| CF-55-OA12_0.01uM | Dose=0.01uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| AF-16-GB72_1uM | Dose=1uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3 |
| PC-68-HN64_0.1uM | Dose=0.1uM, 3-(6-fluoro-1H-1,3-benzodiazol-2-yl)-5-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrazin-2-amine, c-Met) Inhibitors;AXL Kinase Inhibitors;HGFR (MET targeting AXL, MET |
| OC-25-TL77_0.01uM | Dose=0.01uM, Methyl 3-(2-phenylacetamido)thiophene-2-carboxylate |
| CE-48-TP40_1uM | Dose=1uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AC-67-TM11_0.1uM | Dose=0.1uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48 |
| DB-88-VW47_0.01uM | Dose=0.01uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3 |
| BC-84-BQ58_1uM | Dose=1uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1 |
| PC-86-EW46_1uM | Dose=1uM, FG-2216, EGLN1 gene inhibitor targeting EGLN1, P4HA1, P4HB, P4HA2, P4HA3 |
| JB-82-SK68_10uM | Dose=10uM, Oxyfenthiin |
| BE-81-QL64_0.01uM | Dose=0.01uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| AD-55-EA62_1uM | Dose=1uM, D-AP4 |
| EF-33-QP63_0.01uM | Dose=0.01uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| RC-74-NK42_1uM | Dose=1uM |
| WB-33-KW88_0.1uM | Dose=0.1uM |
| AC-57-ZF49_0.01uM | Dose=0.01uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| VA-06-DB75_0.01uM | Dose=0.01uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA |
| CA-88-FC74_1uM | Dose=1uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4 |
| CC-30-TN36_0.1uM | Dose=0.1uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B |
| CA-25-LR28_0.1uM | Dose=0.1uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| DA-39-AJ98_10uM | Dose=10uM, Metylperon, DRD2 antagonist targeting DRD2 |
| GB-16-SU72_0.1uM | Dose=0.1uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| NF-64-RE03_0.1uM | Dose=0.1uM, 3-(3-Bromo-5-methoxy-4-(octyloxy)benzylamino)propylphosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| HF-07-ER47_0.01uM | Dose=0.01uM, 1H-Indole, 3-(3-pyridinylmethyl)- |
| BC-02-WF67_1uM | Dose=1uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2 |
| EA-30-ZX90_0.1uM | Dose=0.1uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| DD-31-LY65_0.01uM | Dose=0.01uM, Menatetrenone |
| BB-83-OX58_1uM | Dose=1uM |
| GE-34-TW62_0.01uM | Dose=0.01uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF |
| BB-83-OX58_10uM | Dose=10uM |
| CB-97-LV32_0.1uM | Dose=0.1uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1 |
| DE-17-IZ77_0.01uM | Dose=0.01uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B |
| YB-79-DM48_0.1uM | Dose=0.1uM, 3-Octadecyloxy-2-methoxypropylphosphonocholine, Angiogenesis Inhibitors;Lipid Homeostasis Modulator;Membrane Metabolism Inhibitor;CoA-Independent Transacyclase (CoA-IT) Inhibitors targeting PNPLA4, PLCB1, PNPLA2, PNPLA3 |
| HA-29-PM90_1uM | Dose=1uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| HE-18-HV99_1uM | Dose=1uM |
| GC-57-HV87_0.1uM | Dose=0.1uM |
| TA-48-MG12_0.1uM | Dose=0.1uM |
| AD-72-OW33_10uM | Dose=10uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid |
| SA-43-QT61_1uM | Dose=1uM, 2-Benzyl-5-(2,5-dichloro-phenyl)-2H-[1,2,4]triazole-3-thiol, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| TC-67-HF87_0.1uM | Dose=0.1uM |
| JA-38-XE73_10uM | Dose=10uM |
| LA-09-SS14_10uM | Dose=10uM, Pcera-1, TNF-alpha Production Inhibitors;IL-10 Production Enhancers;cPLA2a activator targeting PLA2G4A |
| GE-97-UL88_10uM | Dose=10uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide |
| CD-54-FJ31_1uM | Dose=1uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT |
| MA-42-UX14_0.01uM | Dose=0.01uM |
| RC-74-NK42_10uM | Dose=10uM |
| BB-04-KA05_10uM | Dose=10uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| CB-25-VR83_0.01uM | Dose=0.01uM |
| NF-64-RE03_0.01uM | Dose=0.01uM, 3-(3-Bromo-5-methoxy-4-(octyloxy)benzylamino)propylphosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| DD-08-BT45_0.1uM | Dose=0.1uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| AE-28-LX10_1uM | Dose=1uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| DB-78-NM13_1uM | Dose=1uM, Telenzepine, CHRM1 antagonist targeting CHRM1 |
| OC-14-JE88_0.1uM | Dose=0.1uM, Sergliflozin Etabonate, SGLT-2 Inhibitors targeting SLC5A2 |
| YB-18-SI56_1uM | Dose=1uM |
| ED-71-GA72_0.1uM | Dose=0.1uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1 |
| EF-33-IW50_0.01uM | Dose=0.01uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2 |
| TD-40-ZR64_1uM | Dose=1uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-cyclopropylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide |
| PF-84-RH50_1uM | Dose=1uM |
| ME-54-JY76_1uM | Dose=1uM |
| GE-63-WI86_0.1uM | Dose=0.1uM, Nesbuvir |
| JD-74-IP25_0.1uM | Dose=0.1uM, Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors |
| NC-42-UX09_1uM | Dose=1uM |
| AE-52-NW93_0.1uM | Dose=0.1uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| QB-06-VC83_0.01uM | Dose=0.01uM, 4-(furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide, GPR41 agonist targeting FFAR3 |
| AF-42-MP86_1uM | Dose=1uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide |
| GD-41-HR28_1uM | Dose=1uM |
| DB-58-ZC04_10uM | Dose=10uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2 |
| FA-23-LP18_1uM | Dose=1uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| DA-17-XI26_0.1uM | Dose=0.1uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2 |
| AA-79-SX47_0.01uM | Dose=0.01uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2 |
| AE-38-EW82_0.1uM | Dose=0.1uM |
| DA-20-OX15_10uM | Dose=10uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9 |
| KB-45-CF78_0.1uM | Dose=0.1uM, 2-Benzyl-4H-3,1-benzoxazin-4-one |
| CE-36-HY42_1uM | Dose=1uM |
| ED-81-ZH14_0.01uM | Dose=0.01uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK |
| EB-08-WP80_0.01uM | Dose=0.01uM |
| TD-35-IE25_1uM | Dose=1uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP |
| RA-03-RQ19_0.1uM | Dose=0.1uM, 3-(6-fluoropyridin-3-yl)-2-(4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)pyridine, QPCT inhibitor targeting QPCT |
| AA-68-OJ16_0.01uM | Dose=0.01uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| DF-80-BU28_0.1uM | Dose=0.1uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1 |
| DA-33-CW45_1uM | Dose=1uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2 |
| MA-67-FQ44_0.1uM | Dose=0.1uM, 1-Hydroxy-2-naphthoyl-Arg-Pro amide targeting TPSAB1, TPSD1, TPSG1, TPSB2 |
| XC-13-LW13_0.1uM | Dose=0.1uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile |
| JA-01-GQ75_10uM | Dose=10uM, NS 1652, Chloride Channel Blockers targeting GRIK1 |
| FD-13-TF49_0.01uM | Dose=0.01uM |
| CE-36-KR60_0.1uM | Dose=0.1uM, Hydroxychloroquine |
| AC-49-NG46_1uM | Dose=1uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| AA-91-WB95_0.1uM | Dose=0.1uM |
| DE-73-EF24_0.1uM | Dose=0.1uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| OB-17-DQ74_0.01uM | Dose=0.01uM, Selinexor, Exportin 1 inhibitor targeting XPO1 |
| FD-74-LD52_1uM | Dose=1uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB |
| BB-84-DG64_0.1uM | Dose=0.1uM |
| FF-59-KC06_0.1uM | Dose=0.1uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B |
| KB-92-MK13_0.1uM | Dose=0.1uM, 4-Cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonitrile, TNF-alpha Production Inhibitors;Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8 |
| AD-20-CH42_10uM | Dose=10uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42 |
| PB-40-YB26_1uM | Dose=1uM, SIRT1 gene inhibitor;Histone Deacetylase SIRT2 Inhibitors targeting SIRT2, SIRT1 |
| CA-53-TT18_1uM | Dose=1uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A |
| ZE-79-HJ46_0.01uM | Dose=0.01uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide |
| AA-33-DN24_10uM | Dose=10uM, Olprinone |
| IC-72-TE79_10uM | Dose=10uM |
| GB-92-MH66_1uM | Dose=1uM, Ureidosuccinic acid |
| CC-29-RG66_10uM | Dose=10uM |
| GA-07-NB64_0.1uM | Dose=0.1uM, (1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate, Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| DE-79-FD94_0.1uM | Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| GE-40-GQ38_1uM | Dose=1uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| QF-41-QW99_1uM | Dose=1uM, Fdl169, CFTR corrector targeting CFTR |
| OC-14-JE88_1uM | Dose=1uM, Sergliflozin Etabonate, SGLT-2 Inhibitors targeting SLC5A2 |
| BE-85-CH49_10uM | Dose=10uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2 |
| GE-77-IH08_0.1uM | Dose=0.1uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| PF-72-IT39_0.1uM | Dose=0.1uM |
| DD-12-RF07_0.01uM | Dose=0.01uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| DE-02-BL66_10uM | Dose=10uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| AF-19-KN63_0.1uM | Dose=0.1uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR |
| CC-88-JZ09_1uM | Dose=1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| RB-43-AX96_1uM | Dose=1uM, PC-190723 |
| IC-60-AG74_10uM | Dose=10uM, Ucph-101, SLC1A3 - EAAT1/GLAST inhibitor targeting SLC1A3 |
| HF-07-ER47_1uM | Dose=1uM, 1H-Indole, 3-(3-pyridinylmethyl)- |
| OD-47-WT51_0.1uM | Dose=0.1uM, Ecopipam, selective dopamine D1/D5 receptor antagonist targeting DRD1 |
| JB-14-ZM03_0.01uM | Dose=0.01uM, Idronoxil, Apoptosis Inducers;BIRC4 Expression Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Inhibitors of Signal Transduction Pathways;Sphingosine Kinase Inhibitors targeting ENOX2, SPHK2 |
| HA-29-PM90_10uM | Dose=10uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| FE-22-JV50_0.01uM | Dose=0.01uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD |
| RA-00-KI98_0.01uM | Dose=0.01uM, N-[1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-5-methoxypyridine-3-carboxamide, Blk tyrosine kinase inhibitor targeting EGFR |
| IA-76-YQ42_0.1uM | Dose=0.1uM, 2-{[4-(dimethylamino)benzene](2-methylpropyl)sulfonamido}-N-hydroxyacetamide |
| BC-53-HT63_10uM | Dose=10uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| CB-55-GX92_1uM | Dose=1uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2 |
| AA-17-RC87_10uM | Dose=10uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| SE-76-JI27_0.1uM | Dose=0.1uM, Pyridine-2-carboxylic acid {(S)-3-[(3,5-bis-trifluoromethyl-benzoyl)-methyl-amino]-4-phenyl-butyl}-amide, Orexin OX-2 Antagonists targeting HCRTR2 |
| HD-68-CB31_0.01uM | Dose=0.01uM, N-Methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide targeting CYP2D6 |
| OF-47-EQ74_0.01uM | Dose=0.01uM |
| FA-03-CZ62_0.1uM | Dose=0.1uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AB-21-MV93_0.01uM | Dose=0.01uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4 |
| AD-77-UF99_10uM | Dose=10uM, (R)-1-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol, TRKB Inhibitors;ALK Inhibitors;TRKA Inhibitors targeting ALK, NTRK1, NTRK2 |
| AD-11-HV98_0.1uM | Dose=0.1uM, Balicatib, Cathepsin K Inhibitors targeting CTSK |
| AD-20-YO14_1uM | Dose=1uM, Ars-1620 targeting KRAS |
| CD-07-GB34_0.1uM | Dose=0.1uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F |
| EE-35-XA42_10uM | Dose=10uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide |
| FA-39-ZT32_1uM | Dose=1uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6 |
| AE-00-NY23_1uM | Dose=1uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| VD-08-TC47_10uM | Dose=10uM, Tesaglitazar, PPARgamma Agonists;Insulin Sensitizers;PPARalpha Agonists targeting PPARA, PPARG |
| FB-84-TJ61_1uM | Dose=1uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D |
| BD-94-KU93_0.1uM | Dose=0.1uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| HB-79-CT92_1uM | Dose=1uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2 |
| LA-25-VT07_0.01uM | Dose=0.01uM, Dmxb-A, Nicotinic alpha7 Partial Agonists targeting CHRNA7 |
| HB-13-XB94_0.01uM | Dose=0.01uM, Basimglurant, MGLUR5 NAM targeting GRM5 |
| NA-16-OJ70_0.01uM | Dose=0.01uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| CE-15-DU45_0.1uM | Dose=0.1uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3 |
| AA-24-SQ13_10uM | Dose=10uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1 |
| IA-65-QX27_0.01uM | Dose=0.01uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A |
| QE-76-HF95_0.01uM | Dose=0.01uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2 |
| DB-05-UK61_0.01uM | Dose=0.01uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1 |
| DB-20-QK39_0.1uM | Dose=0.1uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| BE-49-AQ65_0.01uM | Dose=0.01uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
| EA-00-RN06_1uM | Dose=1uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AB-87-KC82_10uM | Dose=10uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4 |
| ID-37-UU19_0.01uM | Dose=0.01uM, 5-[[4-[3-(trifluoromethyl)anilino]phthalazin-1-yl]methyl]-1H-pyridin-2-one |
| CE-74-KU68_0.01uM | Dose=0.01uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| HB-95-ZG66_10uM | Dose=10uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR |
| DA-86-GO43_1uM | Dose=1uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| AB-34-RQ73_1uM | Dose=1uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| BB-45-NH69_1uM | Dose=1uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| GB-92-MH66_10uM | Dose=10uM, Ureidosuccinic acid |
| BD-68-ZT55_0.01uM | Dose=0.01uM, Triclosan |
| PC-04-TO77_0.1uM | Dose=0.1uM |
| RF-05-PV01_10uM | Dose=10uM, 6-Chloro-3-((4-methylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one, SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4, PBRM1 |
| EC-12-AY12_0.01uM | Dose=0.01uM, Lisofylline |
| GB-72-BR65_0.1uM | Dose=0.1uM, Opc 14117 |
| DC-11-AR68_0.1uM | Dose=0.1uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB |
| UC-20-ZV24_0.1uM | Dose=0.1uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4 |
| YB-83-AS93_0.1uM | Dose=0.1uM, 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4, PRKCH, PRKCZ |
| TA-21-GI75_1uM | Dose=1uM, 2-[[5-(2,6-Dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid, NTSR1 antagonist;NTSR2 antagonist;Neurotensin Antagonists targeting NTSR1, NTSR2 |
| MB-50-ZI28_0.1uM | Dose=0.1uM, (4S)-4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one |
| DD-16-RV85_0.1uM | Dose=0.1uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1 |
| DA-58-LZ09_1uM | Dose=1uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13 |
| EF-84-QW37_1uM | Dose=1uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR |
| BD-01-RI07_1uM | Dose=1uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC |
| HA-03-TL98_10uM | Dose=10uM, Ornithine Decarboxylase Inhibitors;Antimetabolites targeting ODC1 |
| AB-82-EP26_0.1uM | Dose=0.1uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| XE-45-YU38_10uM | Dose=10uM |
| AC-22-PZ30_0.01uM | Dose=0.01uM, Eed226, PRC2/EED targeting EED |
| GD-39-YG36_0.1uM | Dose=0.1uM, CID 137636547 |
| IC-18-TY61_0.01uM | Dose=0.01uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD |
| JE-86-QG78_10uM | Dose=10uM, Ibrolipim |
| LA-57-ZX71_0.1uM | Dose=0.1uM, Epz015666, PRMT5 gene inhibitor;SAM-cooperative (uncompetitive) inhibition of methyltransferase function;Epizyme SAM cooperative PRMT5 inhibitor (aka EPZ01566 / GSK3235025) targeting PRMT5 |
| PD-94-WO47_0.01uM | Dose=0.01uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1 |
| XD-18-IF89_0.01uM | Dose=0.01uM, Humulone, Apoptosis Inducers;AP-1 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Antioxidants targeting PTGS2, JUN |
| FE-72-KZ75_10uM | Dose=10uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3 |
| DD-33-XP23_0.01uM | Dose=0.01uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| JB-09-SI50_0.01uM | Dose=0.01uM, 3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCG |
| IB-23-AO00_0.1uM | Dose=0.1uM, 6-Amino-4-[(3-methylphenyl)amino]quinazoline, Inhibitors of Signal Transduction Pathways;Tyrosine Kinase Inhibitors targeting EGFR, TIE1 |
| KE-30-PJ81_0.1uM | Dose=0.1uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| FD-20-DQ38_1uM | Dose=1uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| GD-90-RA90_10uM | Dose=10uM, SIS3 free base targeting SMAD3 |
| OF-63-KD88_0.1uM | Dose=0.1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethyl ethyl carbonate |
| OE-78-XD40_1uM | Dose=1uM, (+)-Dibenzoyl-D-tartaric acid, Dopamine D3 Antagonists targeting DRD3 |
| IB-26-FG03_1uM | Dose=1uM, 3-(2-amino-2-methylpropyl)-1H-indol-5-ol |
| LE-39-LB33_0.1uM | Dose=0.1uM, Chlorothiazide, SLC12A3 inhibitor;CA4 inhibitor;CA1 inhibitor;CA2 inhibitor targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, SLC12A3, CA5B, CA10 |
| DB-73-KP48_1uM | Dose=1uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN |
| DA-29-ZD04_1uM | Dose=1uM, Losartan, AGTR1 gene inhibitor targeting AGTR1 |
| PB-40-CS17_0.01uM | Dose=0.01uM |
| UF-28-DW05_0.1uM | Dose=0.1uM, 5-[3-(5-aminopentyl)-5-(1H-indol-3-ylmethyl)-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(4-aminophenoxy)benzonitrile, Somatostatin SRIF1A (sst2) Agonists targeting SSTR2 |
| EA-33-QC97_10uM | Dose=10uM |
| DE-24-AX80_10uM | Dose=10uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| OA-46-YF15_0.01uM | Dose=0.01uM, H-Asp-Glu-Val-Asp-al, Apoptosis Inhibitors;Caspase 3 Inhibitors;Caspase 8 Inhibitors targeting CASP3, CASP8 |
| GA-94-KZ19_1uM | Dose=1uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2 |
| AE-21-GE72_0.1uM | Dose=0.1uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| FF-35-JG06_0.01uM | Dose=0.01uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| CC-47-VS90_0.1uM | Dose=0.1uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| NA-29-UI75_1uM | Dose=1uM, Casp8-IN-1, covalent modifier of catalytic cysteine of pro-CASP8 targeting CASP8 |
| GE-77-IH08_10uM | Dose=10uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| IB-80-NT65_0.1uM | Dose=0.1uM |
| CE-03-PW65_0.1uM | Dose=0.1uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8 |
| AF-11-IL39_0.1uM | Dose=0.1uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2 |
| ED-27-OE11_0.01uM | Dose=0.01uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| SB-89-QK94_1uM | Dose=1uM |
| YE-02-BO16_10uM | Dose=10uM, 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester, Anxiolytics targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| BA-30-VU53_0.01uM | Dose=0.01uM |
| CA-31-EV03_10uM | Dose=10uM |
| AC-59-ZD79_1uM | Dose=1uM, N6-Methyladenosine |
| BC-72-DZ30_1uM | Dose=1uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1 |
| ID-07-YY69_0.1uM | Dose=0.1uM, 2-{[2-amino-5-cyano-6-(methylsulfanyl)pyrimidin-4-yl]sulfanyl}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| EC-08-AP40_10uM | Dose=10uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP |
| JB-58-VY51_0.1uM | Dose=0.1uM, Thymidine, Thymidine kinase 1 ligand;Thymidine kinase 2 ligand targeting TK1, TYMP, TK2 |
| HA-50-AT10_1uM | Dose=1uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2 |
| BB-75-JK26_0.01uM | Dose=0.01uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| RA-44-SU16_10uM | Dose=10uM, H4 Receptor antagonist 1, HRH4 antagonist targeting HRH4 |
| AB-02-TI14_0.01uM | Dose=0.01uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| JE-47-FU54_10uM | Dose=10uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4 |
| GD-59-QF63_1uM | Dose=1uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| SA-43-QT61_0.1uM | Dose=0.1uM, 2-Benzyl-5-(2,5-dichloro-phenyl)-2H-[1,2,4]triazole-3-thiol, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| AD-41-WB70_1uM | Dose=1uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| UA-44-EN14_1uM | Dose=1uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone |
| KD-38-KY71_0.01uM | Dose=0.01uM, CID 44542178, NPFFR2 agonist, GIRK 1/4 blocker targeting NPFFR2 |
| CC-15-TX17_1uM | Dose=1uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10 |
| SC-76-YF40_1uM | Dose=1uM |
| HE-99-KP87_1uM | Dose=1uM, {4-[4-(4-Isopropoxyphenyl)-5-(4-trifluoromethoxyphenyl)thiazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARD |
| MB-15-ZF03_1uM | Dose=1uM |
| AB-53-AW00_0.01uM | Dose=0.01uM, Deferasirox |
| SA-28-ZT78_10uM | Dose=10uM, Gavestinel, NMDA Glycine-Site Antagonists targeting GRIN1 |
| S0-EE-U3YG_10uM | Dose=10uM, ACMSD inhibitor targeting ACMSD |
| LB-24-DV44_0.01uM | Dose=0.01uM |
| HA-82-OO58_10uM | Dose=10uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB |
| HE-34-NJ16_0.01uM | Dose=0.01uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9 |
| CE-36-KR60_10uM | Dose=10uM, Hydroxychloroquine |
| JA-82-EV20_0.1uM | Dose=0.1uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1 |
| AE-18-ZM98_0.01uM | Dose=0.01uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| CA-60-LK14_0.01uM | Dose=0.01uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| AD-89-LX67_0.01uM | Dose=0.01uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| HD-16-HN20_0.01uM | Dose=0.01uM |
| UE-13-LK75_0.01uM | Dose=0.01uM, RN486, reversible BTK inhibitor targeting BTK |
| YA-81-YH47_0.1uM | Dose=0.1uM |
| DF-13-OP48_10uM | Dose=10uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol |
| LB-67-JK40_1uM | Dose=1uM |
| MF-62-JR25_0.01uM | Dose=0.01uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| LE-50-NZ39_10uM | Dose=10uM |
| AA-33-DN24_0.1uM | Dose=0.1uM, Olprinone |
| PA-53-BA36_0.01uM | Dose=0.01uM, Wx-uk1 free base, Urokinase (u-PA) Inhibitors targeting PLAU, PLG |
| XB-53-OZ95_0.1uM | Dose=0.1uM |
| KE-74-EB71_1uM | Dose=1uM, 2,3-Dihydroxypropyl dodecanoate |
| BA-53-FM66_0.01uM | Dose=0.01uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN |
| FB-67-OY39_10uM | Dose=10uM, Galnon, GALR2 agonist targeting GALR2 |
| AC-90-QA75_1uM | Dose=1uM, Benzenesulfonamide, 4-amino-3,5-dichloro- |
| OA-80-YT10_1uM | Dose=1uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3 |
| AB-17-DF74_0.01uM | Dose=0.01uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL |
| GD-43-TP28_0.1uM | Dose=0.1uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2 |
| YB-74-BG62_0.1uM | Dose=0.1uM, Dopamine D2/3 receptor partial agonist targeting DRD3 |
| AD-72-RI24_1uM | Dose=1uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| CF-98-KM73_0.01uM | Dose=0.01uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| JB-74-LJ21_10uM | Dose=10uM, 4-Amino-N-[(1S)-1-cyano-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl]tetrahydro-2H-pyran-4-carboxamide, cathepsin C (DPP1) inhibitor targeting CTSC |
| AA-07-BW60_0.1uM | Dose=0.1uM, Moclobemide, MAO-A Inhibitors targeting MAOA |
| BE-31-XV38_0.01uM | Dose=0.01uM, Camptothecin, topoisomerase I targeting TOP1 |
| CC-20-FN31_1uM | Dose=1uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| CD-88-UF56_0.1uM | Dose=0.1uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| ED-93-KF69_0.1uM | Dose=0.1uM, 3-(2-Aminoethyl)adamantan-1-ol |
| BD-59-MG06_1uM | Dose=1uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| AA-69-TD29_0.1uM | Dose=0.1uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1 |
| CF-98-KM73_10uM | Dose=10uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| IA-41-GR68_0.01uM | Dose=0.01uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP |
| BB-51-DP49_1uM | Dose=1uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| FF-32-LL81_0.01uM | Dose=0.01uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1 |
| DB-34-KT45_10uM | Dose=10uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| AD-70-DU18_1uM | Dose=1uM |
| KF-38-DH25_10uM | Dose=10uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2 |
| JE-31-PK61_0.1uM | Dose=0.1uM, 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, PDE9a inhibitor targeting PDE9A |
| SB-16-SI72_10uM | Dose=10uM, 8-pCPT-2'-O-Me-cAMP, PDE2A Inhibitor;RAPGEF3 activator;Activator of Epac targeting RAPGEF3, PDE2A |
| TC-66-CI47_0.1uM | Dose=0.1uM |
| GD-23-GS20_0.1uM | Dose=0.1uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2 |
| QD-32-CW16_0.1uM | Dose=0.1uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R |
| BB-25-NU80_10uM | Dose=10uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| HA-88-EI28_0.01uM | Dose=0.01uM |
| BD-59-MG06_10uM | Dose=10uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| EC-87-ZB49_10uM | Dose=10uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1 |
| SB-29-ZH97_0.01uM | Dose=0.01uM, Tetrahydrouridine, CDA gene inhibitor targeting CDA |
| OC-21-IP52_10uM | Dose=10uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide |
| FD-46-HV00_10uM | Dose=10uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid |
| CD-75-QY45_10uM | Dose=10uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| CC-84-JQ48_0.01uM | Dose=0.01uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| NA-22-BX39_0.1uM | Dose=0.1uM, 5,8-Dihydroxy-3-methyl-4-(9H)-naphtho(2,3-c)furanone, ELAVL1 gene inhibitor targeting ELAVL1, MYLK |
| DA-91-NR73_0.1uM | Dose=0.1uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester |
| RD-90-DS77_0.1uM | Dose=0.1uM, Genistin |
| NC-01-ET52_10uM | Dose=10uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD |
| HC-97-AH03_0.01uM | Dose=0.01uM, (S)-3-(3,4-Dimethoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists;Integrin binder targeting ITGA4, ITGB1 |
| SE-29-ZA15_1uM | Dose=1uM, UT-B-IN-1, Urea transporter inhibitor targeting SLC14A1, SLC14A2 |
| GE-25-YQ75_0.01uM | Dose=0.01uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2 |
| AA-66-YY32_10uM | Dose=10uM, Serazapine, 5-HT2A Antagonists targeting HTR2A |
| AA-89-HG56_1uM | Dose=1uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A |
| EB-85-DG91_1uM | Dose=1uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| IB-80-NT15_0.01uM | Dose=0.01uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| UB-83-HM84_0.01uM | Dose=0.01uM, Dexamethasone Pivalate |
| PA-31-HP87_10uM | Dose=10uM, Ethyl 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate, KDM6 inhibitor targeting KDM6A, UTY, KDM6B |
| BA-73-MC77_0.1uM | Dose=0.1uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1 |
| TC-69-EY43_10uM | Dose=10uM, PF-06761281 targeting SLC13A5 |
| BA-46-YF32_10uM | Dose=10uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| BA-39-OX47_1uM | Dose=1uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| GA-53-SC22_10uM | Dose=10uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| XA-82-BM12_10uM | Dose=10uM, TLR2/4 pathway antagonist targeting TLR2, TLR4 |
| DF-74-MG39_0.01uM | Dose=0.01uM, N-(2-Methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide targeting HDAC9, HDAC4, HDAC5, HDAC7 |
| JC-63-BE61_0.1uM | Dose=0.1uM |
| S0-EE-XFDA_0.01uM | Dose=0.01uM, Unii-4P8laf78C2, ClC-7 Channel Blockers;Bone Resorption Inhibitors targeting CLCN7 |
| MC-43-PK30_10uM | Dose=10uM, Acebilustat, inhibition of leukotriene A4 hydrolase targeting LTA4H |
| RB-43-AX96_0.01uM | Dose=0.01uM, PC-190723 |
| RB-61-DW99_0.1uM | Dose=0.1uM, N-Methyl-1-(5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl)methanamine, ATP4A blocker, ATP4B blocker targeting ATP4A, ATP4B |
| LC-20-LZ39_0.1uM | Dose=0.1uM, 2,4-Dichlorobenzyl carbamimidothioate, Angiogenesis Inhibitors;MreB Polymerization Inhibitors targeting IDO1 |
| DC-28-NF06_10uM | Dose=10uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A |
| ME-77-XX06_0.1uM | Dose=0.1uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide |
| AE-53-IJ74_10uM | Dose=10uM, Desipramine, Norepinephrine Transporter (NET) Inhibitors;Sodium Channel Blockers targeting SLC6A2 |
| CA-26-BI29_0.01uM | Dose=0.01uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR |
| GC-83-NL88_10uM | Dose=10uM, SC-58125, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| JD-87-MR82_0.1uM | Dose=0.1uM, N-[1,3-Dimethyl-6-[(2r)-2-Methylpiperazin-1-Yl]-2-Oxidanylidene-Benzimidazol-5-Yl]-2-Methoxy-Benzamide, BRPF1 inhibitor;BRPF1 inhibitors targeting BRPF1 |
| FF-35-JG06_10uM | Dose=10uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| AA-19-EX72_0.01uM | Dose=0.01uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A |
| YF-64-PQ11_0.1uM | Dose=0.1uM, Nitisinone, 4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors targeting HPD |
| BD-26-EO58_0.1uM | Dose=0.1uM, Norharman, Indoleamine 2,3-dioxygenase Inhibitors;MAO-B Inhibitors targeting IDO1, MAOB |
| BC-52-WF67_10uM | Dose=10uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| CB-77-KL88_0.01uM | Dose=0.01uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| JC-22-WH91_10uM | Dose=10uM, 1-[4-[2-(4-Chlorophenyl)propan-2-yl]phenyl]-5-methyl-1,2,4-triazole-3-carboxamide |
| S0-EE-XFA6_10uM | Dose=10uM, P2Y13 (GPR86; GPR94) Receptor Agonists targeting P2RY13 |
| EC-49-OQ85_0.01uM | Dose=0.01uM |
| VB-27-PZ25_0.1uM | Dose=0.1uM, 4-(3-bromophenyl)-1H-1,2,3-triazole, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2 |
| BA-41-VY30_0.01uM | Dose=0.01uM, 2-methyl-5-HT targeting HTR1F |
| DF-70-CD57_1uM | Dose=1uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2 |
| FC-31-HE22_0.01uM | Dose=0.01uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1 |
| AA-50-FY68_0.1uM | Dose=0.1uM |
| BE-29-DG26_10uM | Dose=10uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C |
| RD-35-DE45_0.01uM | Dose=0.01uM, N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-((1-methylpiperidin-4-yl)oxy)benzamide, SLC5A7 gene inhibitor targeting SLC5A7 |
| MB-53-WO35_0.01uM | Dose=0.01uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5 |
| AE-38-ZM08_10uM | Dose=10uM |
| PA-93-BD53_0.01uM | Dose=0.01uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC |
| LD-98-VO32_1uM | Dose=1uM, Gsk2830371, WIP1 inhibitor targeting PPM1D |
| FE-82-MY37_0.1uM | Dose=0.1uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| VB-76-UE47_0.1uM | Dose=0.1uM |
| CE-66-GR30_1uM | Dose=1uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2 |
| ZB-67-SE99_0.01uM | Dose=0.01uM |
| HF-35-HT37_0.01uM | Dose=0.01uM |
| AA-76-CL76_0.01uM | Dose=0.01uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| FA-52-OO58_0.01uM | Dose=0.01uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9 |
| ZD-15-SG14_1uM | Dose=1uM, 5,5'-Diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde |
| CE-23-HP88_10uM | Dose=10uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AC-44-UR36_0.01uM | Dose=0.01uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT |
| FB-62-JY52_1uM | Dose=1uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO |
| AD-86-XL96_10uM | Dose=10uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| CE-85-KN13_1uM | Dose=1uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| DB-06-HE04_1uM | Dose=1uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF |
| AB-67-SF89_0.1uM | Dose=0.1uM |
| SB-80-CR34_0.01uM | Dose=0.01uM |
| IE-28-SY71_0.1uM | Dose=0.1uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one |
| DF-56-GR45_0.01uM | Dose=0.01uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| EF-46-LK88_0.1uM | Dose=0.1uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate |
| HF-35-HT37_0.1uM | Dose=0.1uM |
| JC-02-ZR15_0.1uM | Dose=0.1uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2 |
| FA-10-KQ78_10uM | Dose=10uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| PB-13-ZD03_0.1uM | Dose=0.1uM, 1-N,3-N-bis(1-methylquinolin-1-ium-6-yl)benzene-1,3-dicarboxamide, DNA G-quadruplex (G4) Ligands;Telomerase Inhibitors targeting TERT |
| SA-37-YW78_0.1uM | Dose=0.1uM, 1,4-Bis(4-(pyrrolidinyl)piperidinyl)benzamide, Selective antagonist of L3MBTL3 targeting L3MBTL1, L3MBTL3, L3MBTL4 |
| NB-75-RF23_0.01uM | Dose=0.01uM |
| EE-18-HW72_1uM | Dose=1uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2 |
| OE-50-VB46_1uM | Dose=1uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2 |
| SF-52-LP14_10uM | Dose=10uM, (2R,3S,7R,8R,8aS)-6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3H-1-benzofuran]-7'-carboxylic acid, Complement Inhibitors targeting C3 |
| QC-90-PV99_0.01uM | Dose=0.01uM, 2-(Morpholinomethyl)-5-((5-((7-(trifluoromethyl)quinolin-4-yl)thio)pentyl)oxy)-4H-pyran-4-one, Rac1 GTPase Inhibitors;Angiogenesis Inhibitors targeting RAC1 |
| GA-30-HJ41_0.1uM | Dose=0.1uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| BE-77-XF69_10uM | Dose=10uM |
| LF-92-IK63_0.1uM | Dose=0.1uM, 2-{[4-Amino-3-(3-Fluoro-4-Hydroxyphenyl)-1h-Pyrazolo[3,4-D]pyrimidin-1-Yl]methyl}-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD, PIK3CG |
| LC-43-SE41_10uM | Dose=10uM, PRX-08066 free base, 5-HT2B Antagonists targeting HTR2B |
| SC-71-IB68_0.1uM | Dose=0.1uM, Sah 41-178, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| PA-40-HC94_1uM | Dose=1uM |
| BD-39-KG21_0.1uM | Dose=0.1uM, Selegiline, MAO-B Inhibitors targeting MAOB |
| ED-26-RU42_0.1uM | Dose=0.1uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| AA-94-TU18_1uM | Dose=1uM |
| AW-13-3788_1uM | Dose=1uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A |
| WD-75-LK69_10uM | Dose=10uM, 4-[6-[(2R)-2-(3-fluorophenyl)piperidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]benzonitrile |
| DD-85-AN28_10uM | Dose=10uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B |
| FC-13-VS25_1uM | Dose=1uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| AC-93-QD45_1uM | Dose=1uM, targeting CGAS |
| RB-42-MC53_0.1uM | Dose=0.1uM, 4-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-indol-1-yl}-piperidine-1-carboxylic acid tert-butyl ester, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| S0-EE-WNJC_1uM | Dose=1uM |
| TA-25-ZO44_1uM | Dose=1uM, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, Protein Kinase B (PKB/Akt) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting PDPK1 |
| DF-45-GA42_0.1uM | Dose=0.1uM, SB 224289, HTR1B antagonist targeting HTR1B |
| FD-37-GE41_10uM | Dose=10uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| IE-46-OA29_10uM | Dose=10uM, 6-Fluoro-3-((1E)-2-(3-pyridinyl)ethenyl)-1H-indole, Tryptophan 2,3 dioxygenase inhibitor targeting TDO2 |
| EF-33-IW50_10uM | Dose=10uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2 |
| AD-11-VE17_0.01uM | Dose=0.01uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5 |
| CC-18-YW57_0.01uM | Dose=0.01uM |
| AE-03-MJ64_0.01uM | Dose=0.01uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD |
| BC-11-LL59_0.1uM | Dose=0.1uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3 |
| FA-80-DR66_0.01uM | Dose=0.01uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| ZD-27-QL96_0.1uM | Dose=0.1uM, CDK Inhibitors |
| DD-15-VH74_0.1uM | Dose=0.1uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1 |
| CD-59-MG26_0.01uM | Dose=0.01uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| AF-10-BU38_0.01uM | Dose=0.01uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2 |
| EA-00-RN06_0.01uM | Dose=0.01uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AD-32-RF17_1uM | Dose=1uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| DA-77-II31_1uM | Dose=1uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7 |
| IB-96-PK68_1uM | Dose=1uM |
| LA-66-RT74_0.1uM | Dose=0.1uM, (4-Propan-2-ylphenyl)-[4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-yl]methanone, Parathyroid Hormone Secretion Stimulants targeting CASR |
| ZE-79-HJ46_10uM | Dose=10uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide |
| RB-48-AN54_10uM | Dose=10uM, Gsk984 |
| BD-32-GI59_10uM | Dose=10uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D |
| CF-83-PM81_10uM | Dose=10uM |
| GA-81-DL34_0.01uM | Dose=0.01uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7 |
| DD-47-GB64_0.01uM | Dose=0.01uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| AA-07-BW60_0.01uM | Dose=0.01uM, Moclobemide, MAO-A Inhibitors targeting MAOA |
| KB-88-OR49_10uM | Dose=10uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| DD-26-RY82_10uM | Dose=10uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR |
| LB-04-KP05_10uM | Dose=10uM, 1-Ethyl-2-benzimidazolinone, SK2 Potassium Channel Activators targeting KCNN2 |
| FC-67-SZ42_1uM | Dose=1uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| JA-02-IU07_10uM | Dose=10uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5 |
| OB-44-HO47_10uM | Dose=10uM |
| BE-07-NI91_10uM | Dose=10uM, Isradipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNB2, CACNA1H, CACNA2D2 |
| CD-30-JO39_10uM | Dose=10uM, [2-chloro-3-(trifluoromethyl)phenyl]-[1-(5-fluoropyrimidin-2-yl)-6,7-dihydro-4H-triazolo[4,5-c]pyridin-5-yl]methanone, P2RX7 antagonist targeting P2RX7 |
| GA-87-BR97_1uM | Dose=1uM |
| BB-37-LS05_0.1uM | Dose=0.1uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| EE-08-SZ54_0.01uM | Dose=0.01uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| EE-23-MF14_1uM | Dose=1uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| GB-31-HY20_0.01uM | Dose=0.01uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2 |
| ZE-79-HJ46_0.1uM | Dose=0.1uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide |
| KC-35-MF93_0.01uM | Dose=0.01uM |
| JA-42-NH96_0.01uM | Dose=0.01uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS |
| JB-89-SI60_0.01uM | Dose=0.01uM, (3s,5r)-N-{[9-(4-Methoxybutyl)-9h-Xanthen-9-Yl]methyl}-5-{[(4-Methylphenyl)sulfonyl]amino}piperidine-3-Carboxamide, Renin Inhibitors targeting REN |
| HB-09-OC16_1uM | Dose=1uM |
| DC-23-UM36_0.01uM | Dose=0.01uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| BA-60-DK24_1uM | Dose=1uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D |
| JB-23-ZE86_0.1uM | Dose=0.1uM, N-benzyl-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine, Lck Kinase Inhibitors targeting LCK |
| AA-98-PM63_0.01uM | Dose=0.01uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| EC-09-DC91_10uM | Dose=10uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| GA-32-TO88_1uM | Dose=1uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9 |
| DB-34-KT45_0.1uM | Dose=0.1uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| ME-62-IQ37_0.01uM | Dose=0.01uM, WY 47288, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| CC-90-FE70_10uM | Dose=10uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| HA-64-OZ89_1uM | Dose=1uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| FE-39-LJ73_0.1uM | Dose=0.1uM |
| XE-45-YU38_0.1uM | Dose=0.1uM |
| LF-30-FP85_0.01uM | Dose=0.01uM, 2-Chloro-5-[3-(5-chloro-2-methoxy-pyridin-4-yl)-1h-indole-6-carbonyl]-benzenesulfonamide |
| CC-67-LI41_1uM | Dose=1uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| GB-90-VQ08_10uM | Dose=10uM, PH 797804, P38a inhibitor targeting MAPK14 |
| JF-39-BZ76_0.1uM | Dose=0.1uM, Vs-4718, FAK inhibitor targeting PTK2 |
| BE-46-FY47_0.01uM | Dose=0.01uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A |
| UE-99-BK94_0.01uM | Dose=0.01uM, 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, KCNK3 gene inhibitor targeting KCNK3 |
| VD-76-SO91_0.1uM | Dose=0.1uM, N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide, NF-kappaB (NFKB) Activation Inhibitors;Antiinflammatory Drugs targeting NFKB1 |
| BC-75-CK91_0.1uM | Dose=0.1uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| DE-85-DO61_0.01uM | Dose=0.01uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2 |
| GA-18-KF56_1uM | Dose=1uM |
| AA-76-CL76_10uM | Dose=10uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| RA-53-JG50_0.01uM | Dose=0.01uM, (S)-N-(2,6-Dioxopiperidin-3-yl)undec-10-enamide, Broad Spectrum Chemokine Inhibitors (BSCI) targeting CCR2, CRBN |
| AC-00-BR21_0.1uM | Dose=0.1uM |
| SA-31-VB03_1uM | Dose=1uM, Ascochlorin, Electron Transport Chain Inhibitors;AP-1 Inhibitors targeting JUN, UQCRC1 |
| MF-65-HS14_0.01uM | Dose=0.01uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one |
| DC-84-CJ21_10uM | Dose=10uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3 |
| HB-79-CZ36_0.01uM | Dose=0.01uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2 |
| CC-04-YT10_0.1uM | Dose=0.1uM |
| HC-63-SV27_1uM | Dose=1uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| NE-42-YQ17_0.01uM | Dose=0.01uM |
| CE-15-DU45_0.01uM | Dose=0.01uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3 |
| YB-79-DM48_0.01uM | Dose=0.01uM, 3-Octadecyloxy-2-methoxypropylphosphonocholine, Angiogenesis Inhibitors;Lipid Homeostasis Modulator;Membrane Metabolism Inhibitor;CoA-Independent Transacyclase (CoA-IT) Inhibitors targeting PNPLA4, PLCB1, PNPLA2, PNPLA3 |
| ME-64-LE18_10uM | Dose=10uM, Brl 41992, ADRA2B antagonist targeting ADRA2B |
| GD-85-ST07_1uM | Dose=1uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))- |
| GB-39-OF03_0.1uM | Dose=0.1uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| PC-86-EW46_0.1uM | Dose=0.1uM, FG-2216, EGLN1 gene inhibitor targeting EGLN1, P4HA1, P4HB, P4HA2, P4HA3 |
| HC-83-TS50_0.01uM | Dose=0.01uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC |
| FF-22-NB12_0.01uM | Dose=0.01uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| WF-24-LG17_0.01uM | Dose=0.01uM, N-[1-(1h-Indol-3-Ylmethyl)piperidin-4-Yl]-L-Tryptophanamide |
| JD-12-CE09_0.01uM | Dose=0.01uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| OE-04-VO07_10uM | Dose=10uM, 2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylsulfinyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists targeting CASR |
| JD-79-ZS29_0.01uM | Dose=0.01uM, 1,1'-Methylenebis(2-naphthol), Antiamyloidogenic Agents targeting APP |
| TA-25-KO99_10uM | Dose=10uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4 |
| AA-62-OC45_1uM | Dose=1uM |
| AF-01-FE42_10uM | Dose=10uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| AF-65-CU85_0.01uM | Dose=0.01uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6 |
| GC-82-RV65_1uM | Dose=1uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B |
| JC-64-QI43_1uM | Dose=1uM, 4-Bromo-2,6-diisopropylphenol, Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.4 (SkM1) Sodium Channel Blockers targeting SCN2A, SCN4A |
| BE-46-FY47_10uM | Dose=10uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A |
| BB-62-MS83_10uM | Dose=10uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| HD-91-YX62_10uM | Dose=10uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile |
| IC-61-PQ10_10uM | Dose=10uM, Coumate, Steryl Sulfatase Inhibitors targeting STS |
| EC-17-MF19_1uM | Dose=1uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| DA-07-LL18_0.1uM | Dose=0.1uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| AE-72-UP91_1uM | Dose=1uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| JF-91-IG96_0.1uM | Dose=0.1uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one |
| NB-92-BG38_10uM | Dose=10uM, 5-HT7 agonist 2, HTR7 agonist targeting HTR7 |
| TE-32-AC63_0.1uM | Dose=0.1uM, Bay-299, Bromodomain inhibitor targeting TAF1, BRD1, TAF1L |
| AA-66-PC55_10uM | Dose=10uM, 9-Azapaullone, CDK9/Cyclin T1 Inhibitors;Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting CCNT1, CDK9, GSK3A |
| CA-23-BW20_10uM | Dose=10uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2 |
| KE-89-TF43_0.1uM | Dose=0.1uM, 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one, PDE9A gene inhibitor targeting PDE9A |
| AA-75-JH89_10uM | Dose=10uM, BAY-598 R-isomer |
| AC-31-AY35_0.1uM | Dose=0.1uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CE-04-OJ56_1uM | Dose=1uM, 2-(2-Aminoethyl)pyridine |
| VA-48-RJ44_0.01uM | Dose=0.01uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5 |
| CC-42-ZV45_10uM | Dose=10uM, (S)-2-amino-5-phosphonopentanoic acid |
| HA-81-VN33_0.1uM | Dose=0.1uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4 |
| S0-EE-Y6LH_0.01uM | Dose=0.01uM, PF 6767832, M1 postive allosteric modulator targeting CHRM1 |
| AC-56-ZV05_0.01uM | Dose=0.01uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK |
| OA-16-KC73_1uM | Dose=1uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1 |
| IE-44-GZ79_1uM | Dose=1uM, 2,3,4,5-Tetra(4-pyridyl)thiophene, Hedgehog Signaling Inhibitors targeting GLI1 |
| MC-40-KF76_10uM | Dose=10uM |
| HB-01-ZU75_0.01uM | Dose=0.01uM |
| BB-27-MC77_0.01uM | Dose=0.01uM |
| CC-55-CD84_1uM | Dose=1uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| LC-21-LG46_10uM | Dose=10uM |
| SA-37-YW78_10uM | Dose=10uM, 1,4-Bis(4-(pyrrolidinyl)piperidinyl)benzamide, Selective antagonist of L3MBTL3 targeting L3MBTL1, L3MBTL3, L3MBTL4 |
| HD-91-YX62_0.1uM | Dose=0.1uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile |
| UB-30-TL20_0.1uM | Dose=0.1uM, 1-Amino-4-[4-(2,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid targeting P2RY4 |
| AB-12-PP61_1uM | Dose=1uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2 |
| BA-84-TD72_0.01uM | Dose=0.01uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| JA-85-SW39_0.01uM | Dose=0.01uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2 |
| NA-29-UI75_0.01uM | Dose=0.01uM, Casp8-IN-1, covalent modifier of catalytic cysteine of pro-CASP8 targeting CASP8 |
| AB-64-ZX70_0.01uM | Dose=0.01uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| AC-19-TH24_0.1uM | Dose=0.1uM, Vigabatrin, GABA Aminotransferase Inhibitors targeting ABAT |
| GF-02-ER50_0.01uM | Dose=0.01uM, Ethane-1,2-diyl dicarbamimidothioate |
| SC-71-IB68_1uM | Dose=1uM, Sah 41-178, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| EE-61-NU30_0.1uM | Dose=0.1uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7 |
| WF-24-LG17_10uM | Dose=10uM, N-[1-(1h-Indol-3-Ylmethyl)piperidin-4-Yl]-L-Tryptophanamide |
| AA-01-JO26_0.1uM | Dose=0.1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| CA-64-LT35_10uM | Dose=10uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| TD-09-SX65_1uM | Dose=1uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2 |
| FA-43-TP28_10uM | Dose=10uM, Doxapram targeting KCNK3, KCNK9 |
| HA-57-XH23_0.1uM | Dose=0.1uM |
| ZD-15-SG14_0.01uM | Dose=0.01uM, 5,5'-Diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde |
| AE-97-TS20_0.01uM | Dose=0.01uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| AF-73-ON54_1uM | Dose=1uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| ZC-88-KS25_1uM | Dose=1uM |
| AB-47-BS00_10uM | Dose=10uM, Hydroxyurea, Ribonucleoside-Diphosphate Reductase Inhibitors;Antimetabolites;Nitric oxide donor targeting RRM1 |
| BD-34-PN26_0.1uM | Dose=0.1uM |
| AB-71-UV73_0.01uM | Dose=0.01uM, (3S)-3-amino-4-[5-[4-(4-chlorophenoxy)phenyl]tetrazol-2-yl]butanoic acid, inhibitor of leukotriene A4 hydrolase targeting LTA4H |
| GC-46-CA74_0.01uM | Dose=0.01uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R |
| AC-96-OO08_1uM | Dose=1uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| HF-68-PM58_0.01uM | Dose=0.01uM |
| AA-83-TW85_0.1uM | Dose=0.1uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2 |
| CF-82-AS63_0.01uM | Dose=0.01uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| AF-12-IW93_0.01uM | Dose=0.01uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| QB-29-GK19_1uM | Dose=1uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL |
| WD-65-PA90_10uM | Dose=10uM, Lafutidine, Histamine H2 Receptor Antagonists targeting HRH2 |
| UD-50-IU51_0.01uM | Dose=0.01uM, Geranyl biphosphonate |
| EC-60-CX20_0.1uM | Dose=0.1uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A |
| HA-38-ML65_0.1uM | Dose=0.1uM |
| JA-74-VZ14_1uM | Dose=1uM, CID 25108278, PAR2 Agonists;F2RL1 agonist targeting F2RL1 |
| TF-23-DD23_1uM | Dose=1uM, PF-4708671, Antagonist of S6K targeting RPS6KB1 |
| BB-39-DQ95_0.01uM | Dose=0.01uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7 |
| CF-83-HM41_1uM | Dose=1uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA |
| AB-70-GR31_0.01uM | Dose=0.01uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| SF-48-KT63_0.01uM | Dose=0.01uM, 4-((Aminosulfonyl)amino)benzenesulfonamide |
| DD-28-MZ39_0.01uM | Dose=0.01uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO |
| BA-46-AB67_0.01uM | Dose=0.01uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2 |
| HC-26-PX74_0.1uM | Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid |
| AF-16-GB72_10uM | Dose=10uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3 |
| ND-86-GT24_10uM | Dose=10uM, 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-, Histamine H4 Receptor Antagonists;HRH4 antagonist targeting HRH4 |
| QC-32-ZC28_1uM | Dose=1uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid |
| CA-17-QL18_0.01uM | Dose=0.01uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2 |
| FE-23-WP33_10uM | Dose=10uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1 |
| AE-66-YB82_0.1uM | Dose=0.1uM, 1-N,4-N-bis[4-[[amino-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]methylidene]amino]butyl]benzene-1,4-dicarboxamide, Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A |
| AA-12-VW53_0.01uM | Dose=0.01uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1 |
| BB-75-YK01_0.1uM | Dose=0.1uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one |
| NE-37-BQ24_10uM | Dose=10uM, (S) FTY720 Phosphate, S1PR3 agonist targeting S1PR3 |
| MB-72-YK93_1uM | Dose=1uM |
| CE-23-HP88_1uM | Dose=1uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| RE-22-MW21_0.01uM | Dose=0.01uM, HTR1A agonist |
| FE-92-ZL16_0.1uM | Dose=0.1uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2 |
| WE-48-PP43_0.1uM | Dose=0.1uM, (1S,2R)-2-[[9-ethyl-6-(4-piperidin-1-ylsulfonylanilino)purin-2-yl]amino]cyclohexane-1-carboxamide, Protein Kinase Inhibitors targeting SRC |
| KF-38-DH25_0.01uM | Dose=0.01uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2 |
| YA-61-RR36_0.1uM | Dose=0.1uM |
| CC-37-QW80_0.1uM | Dose=0.1uM |
| BA-65-YU25_10uM | Dose=10uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| LD-96-DG13_0.1uM | Dose=0.1uM, Tcs OX2 29, HCRTR2 antagonist;Orexin OX-2 Antagonists targeting HCRTR2 |
| CC-88-JZ09_0.01uM | Dose=0.01uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| AF-89-AD94_0.1uM | Dose=0.1uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7 |
| ZE-79-HJ46_1uM | Dose=1uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide |
| AD-30-SU93_0.01uM | Dose=0.01uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| MB-13-WR12_10uM | Dose=10uM, N-(1,3-benzodioxol-5-ylmethyl)-2-[5-[2-(3-methoxyanilino)-2-oxoethyl]sulfanyl-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]acetamide |
| HE-34-ZC14_0.1uM | Dose=0.1uM |
| DD-77-OI11_0.01uM | Dose=0.01uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2 |
| LF-85-QP07_1uM | Dose=1uM, (5,6-Dimethyl-thieno[2,3-d]pyrimidin-4-ylsulfanyl)-acetic acid, Palmitoleoyl-Protein Carboxylesterase NOTUM Inhibitors targeting NOTUM |
| OE-04-VO07_0.1uM | Dose=0.1uM, 2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylsulfinyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists targeting CASR |
| EA-67-FY34_1uM | Dose=1uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA |
| QA-34-BH60_0.1uM | Dose=0.1uM, rac-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide |
| DE-59-OT87_1uM | Dose=1uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3 |
| FA-52-OO58_0.1uM | Dose=0.1uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9 |
| DD-36-YH76_1uM | Dose=1uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| FB-56-SR65_1uM | Dose=1uM, Arginine |
| AW-16-2259_0.01uM | Dose=0.01uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB |
| AB-92-LS83_10uM | Dose=10uM, Flurbiprofen targeting SC5D |
| IE-34-IW27_0.1uM | Dose=0.1uM, 3-((4-(Trifluoromethyl)Phenyl)Amino)Benzoic Acid, AKR1C3 inhibitor targeting AKR1C3 |
| JB-58-VY51_1uM | Dose=1uM, Thymidine, Thymidine kinase 1 ligand;Thymidine kinase 2 ligand targeting TK1, TYMP, TK2 |
| FF-61-BU95_1uM | Dose=1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB |
| RE-72-IT14_0.01uM | Dose=0.01uM, 3-{4-[(E)-3-(4-tert-Butyl-piperazin-1-yl)-propenyl]-benzyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine |
| CD-90-SN76_0.01uM | Dose=0.01uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1 |
| IA-37-FR87_10uM | Dose=10uM, Pexacerfont, CRF1 Antagonists targeting CRHR1 |
| DF-46-QE34_0.01uM | Dose=0.01uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1 |
| AA-98-HX85_10uM | Dose=10uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| ED-11-BL19_10uM | Dose=10uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A |
| UA-20-YK17_10uM | Dose=10uM, (2R)-1-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropan-1-one, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| BD-48-JW52_0.01uM | Dose=0.01uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR |
| BB-57-AZ77_0.01uM | Dose=0.01uM |
| YE-57-WY37_0.01uM | Dose=0.01uM, 2-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]benzamide |
| ME-90-FS02_10uM | Dose=10uM, L 156373, Vasopressin (AVP) V1a Antagonists;Vasopressin (AVP) V2 Antagonists targeting AVPR1A, AVPR2 |
| EA-67-CO00_0.01uM | Dose=0.01uM, Flupirtine, Voltage-Gated K(V) 7 (KCNQ) Channel Activators targeting KCNQ2, KCNQ3, KCNQ4 |
| QE-93-PG25_0.01uM | Dose=0.01uM, 3-(8-(Hydroxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| HC-16-SU62_10uM | Dose=10uM, Belnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| AC-73-GJ74_0.01uM | Dose=0.01uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM |
| FE-12-TO68_10uM | Dose=10uM |
| WC-81-BR91_0.1uM | Dose=0.1uM, Bisanilinopyrimidine, 3d |
| KA-51-CQ55_0.1uM | Dose=0.1uM, N-Cyclohexyl-4-(4-phenyl-1-(piperazin-1-yl)-2,6-naphthyridin-3-yl)pyridin-2-amine, PKD inhibitor targeting PRKD1 |
| AB-01-NB05_0.01uM | Dose=0.01uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG |
| ME-49-AE45_0.01uM | Dose=0.01uM, (2S)-1-[2-(tert-butylamino)acetyl]pyrrolidine-2-carbonitrile |
| KF-00-NW62_0.1uM | Dose=0.1uM, 6-[(2-Aminopyridin-3-yl)methylamino]-1,3-bis[(4-methoxyphenyl)methyl]-1,3,5-triazine-2,4-dione, Prokineticin 1 Receptor (PKR1) Antagonist targeting PROKR1 |
| AB-01-UY50_0.01uM | Dose=0.01uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| ID-31-PA82_0.1uM | Dose=0.1uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1 |
| IC-28-HS37_1uM | Dose=1uM, Nvs-cecr2-1, CECR2 inhibitor;CECR2 inhbitor targeting CECR2 |
| DA-48-NC44_0.01uM | Dose=0.01uM |
| AC-17-PC87_1uM | Dose=1uM, Chk2 Inhibitor II targeting CHEK2 |
| DE-10-AU63_0.1uM | Dose=0.1uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR |
| DD-26-VR55_1uM | Dose=1uM, 6-[[2-(3-Methoxyanilino)pyrimidin-4-yl]amino]-2,3-dihydro-1,4-benzodioxine-5-sulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ALK, ZAP70 |
| WA-36-EE47_1uM | Dose=1uM, 1-{2-[1-(Aminomethyl)cyclohexyl]ethyl}-3-Isoquinolin-6-Ylurea, Allosteric PRMT3 inhibitor targeting PRMT3 |
| CA-42-YI34_10uM | Dose=10uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| LA-21-GQ75_10uM | Dose=10uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR |
| VF-49-KA00_0.01uM | Dose=0.01uM, 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde, ERN1 gene inhibitor targeting ERN1 |
| CC-05-MK46_10uM | Dose=10uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| CF-44-NQ13_0.1uM | Dose=0.1uM |
| BC-19-GQ25_0.1uM | Dose=0.1uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC |
| CB-93-YZ07_1uM | Dose=1uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| CE-57-KI16_0.1uM | Dose=0.1uM, CID 134691740, SPPL2A Inhibitor targeting SPPL2A |
| AD-91-LE02_10uM | Dose=10uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| MD-84-YS12_1uM | Dose=1uM, 2,4-dichloro-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamoyl]benzamide, PCTP (StARD2) Inhibitor targeting PCTP |
| MF-37-KQ09_1uM | Dose=1uM, 7alpha-Hydroxydehydroepiandrosterone, Estrogen Receptor (ER) beta Ligands targeting ESR2 |
| BE-72-EW73_10uM | Dose=10uM, Roscovitine, CDK inhibitors targeting CDK2, CDK5R1, CCNA1, CCNB2, CCNE2, CCNB3 |
| DA-27-BW20_0.1uM | Dose=0.1uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| BF-63-DQ96_0.01uM | Dose=0.01uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| LC-11-KD29_10uM | Dose=10uM, 1,4-Dimethylpyridinium |
| FE-37-OL13_0.01uM | Dose=0.01uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| NF-10-JP55_1uM | Dose=1uM |
| GB-16-SU72_0.01uM | Dose=0.01uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| WC-59-RG09_0.01uM | Dose=0.01uM, Osi-930, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors targeting ABL1, KDR, KIT, PDGFRB |
| IA-41-GR68_10uM | Dose=10uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP |
| AA-19-SX47_0.01uM | Dose=0.01uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1 |
| RE-04-MV24_0.01uM | Dose=0.01uM, Catpb, GPR43 antagonist targeting FFAR2 |
| ID-70-SM63_0.01uM | Dose=0.01uM, Masoprocol, IGF-1R Phosphorylation Inhibitors;ER stress inducer;Lipoxygenase Inhibitors targeting ALOX5, ALOX15 |
| NE-24-ZO47_1uM | Dose=1uM, N-[5-bromo-3-[[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]methoxy]pyrazin-2-yl]-4-methylbenzenesulfonamide, Chemokine CCR4 Antagonists targeting CCR4 |
| DA-60-KU38_0.1uM | Dose=0.1uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| VF-12-MF80_10uM | Dose=10uM, 2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide, Adenosine A2B Agonists targeting ADORA2B |
| QE-76-ST29_0.01uM | Dose=0.01uM, 5-Amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one |
| ZE-11-HK24_10uM | Dose=10uM, methyl (1R,2R,3S,3aR,8bS)-6-[[(2R,3R,6R)-6-[(1S)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate, EIF4A gene modulator targeting EIF4A1, EIF4A2, EIF4A3 |
| LA-86-XT29_0.01uM | Dose=0.01uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2 |
| EA-96-QK68_0.01uM | Dose=0.01uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AA-03-QM41_0.01uM | Dose=0.01uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R |
| AD-34-TG29_1uM | Dose=1uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP |
| UF-44-NQ36_10uM | Dose=10uM, Argipressin tannate, AVPR1A agonist targeting AVPR1A |
| DE-58-OW37_0.1uM | Dose=0.1uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L |
| BA-55-OU30_10uM | Dose=10uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B |
| UD-03-SW43_0.1uM | Dose=0.1uM |
| NB-75-RF23_1uM | Dose=1uM |
| OE-34-NH10_0.1uM | Dose=0.1uM, 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one, TIC10 inactivates Akt and ERK and induces TRAIL expression targeting TNFSF10 |
| LB-55-UZ51_10uM | Dose=10uM, Benzaldehyde semicarbazone |
| AC-50-TU13_10uM | Dose=10uM, 1,4-Dihydroxy-2-naphthoic acid, Tau Aggregation Inhibitors targeting MAPT |
| CC-00-ZO24_10uM | Dose=10uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R |
| GD-66-LN30_1uM | Dose=1uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A |
| SB-26-NB80_10uM | Dose=10uM, 1-(4-Chlorophenyl)-5-phenyl-4,5-dihydro-1h-pyrazol-3-amine, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO |
| GF-57-MY04_0.1uM | Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB |
| LD-37-JE11_10uM | Dose=10uM, SR7826, Limk1 inhibitor targeting LIMK1 |
| UE-50-KK32_10uM | Dose=10uM, 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile |
| LD-14-PB06_0.01uM | Dose=0.01uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET |
| GB-01-UN23_1uM | Dose=1uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| BD-98-TG79_0.01uM | Dose=0.01uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| DD-26-RY82_0.1uM | Dose=0.1uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR |
| ND-86-GT24_0.01uM | Dose=0.01uM, 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-, Histamine H4 Receptor Antagonists;HRH4 antagonist targeting HRH4 |
| AC-40-DU58_10uM | Dose=10uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP |
| LC-21-LG46_0.1uM | Dose=0.1uM |
| FB-84-TJ61_10uM | Dose=10uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D |
| ZE-53-LS38_0.1uM | Dose=0.1uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine |
| RD-64-KA33_1uM | Dose=1uM, Gsk983, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| FE-82-MY37_1uM | Dose=1uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| MA-42-UX14_0.1uM | Dose=0.1uM |
| BA-90-AA10_10uM | Dose=10uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| DF-00-NA25_1uM | Dose=1uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES |
| EB-08-WP80_10uM | Dose=10uM |
| AA-47-MP58_0.01uM | Dose=0.01uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| JB-82-SK68_1uM | Dose=1uM, Oxyfenthiin |
| KC-17-YN77_0.01uM | Dose=0.01uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5 |
| PE-82-OK78_1uM | Dose=1uM, 1-Cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine targeting SIGMAR1, TMEM97 |
| AC-10-JK64_10uM | Dose=10uM |
| DA-09-XJ53_0.1uM | Dose=0.1uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7 |
| HD-62-KE69_0.1uM | Dose=0.1uM, Roflumilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4, PDE2A |
| JC-02-ZR15_1uM | Dose=1uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2 |
| GE-01-QX17_0.1uM | Dose=0.1uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2 |
| ED-79-EW79_0.1uM | Dose=0.1uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5 |
| HD-26-KX74_10uM | Dose=10uM |
| KD-31-TU05_0.1uM | Dose=0.1uM, Lesinurad targeting SLC22A11, SLC22A12 |
| EF-52-ML96_0.01uM | Dose=0.01uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2 |
| NC-39-KP22_0.01uM | Dose=0.01uM, A-1210477, Mcl-1 inhibitor targeting MCL1 |
| EA-43-FS10_10uM | Dose=10uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| BE-66-GV20_0.1uM | Dose=0.1uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F |
| SE-81-RI20_0.1uM | Dose=0.1uM |
| OE-91-GF88_1uM | Dose=1uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG |
| AB-66-IL06_0.01uM | Dose=0.01uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| GA-59-RW04_0.01uM | Dose=0.01uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| CD-70-GD72_10uM | Dose=10uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| HF-82-PE14_1uM | Dose=1uM |
| CA-72-UL91_1uM | Dose=1uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| FC-82-WB67_0.01uM | Dose=0.01uM, Lycopene |
| PC-68-HN64_1uM | Dose=1uM, 3-(6-fluoro-1H-1,3-benzodiazol-2-yl)-5-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrazin-2-amine, c-Met) Inhibitors;AXL Kinase Inhibitors;HGFR (MET targeting AXL, MET |
| AC-41-IB85_0.01uM | Dose=0.01uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| BE-70-YH17_0.01uM | Dose=0.01uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| YB-80-KQ31_10uM | Dose=10uM, CD80 (B7-1) Inhibitors targeting CD80, CD28 |
| GB-19-AP57_0.1uM | Dose=0.1uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| EF-85-DA07_1uM | Dose=1uM |
| BC-75-CK91_0.01uM | Dose=0.01uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| UE-09-SD17_0.1uM | Dose=0.1uM |
| JA-82-EV20_0.01uM | Dose=0.01uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1 |
| AC-36-SY22_10uM | Dose=10uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| EF-61-NY75_0.1uM | Dose=0.1uM, US9580437, Example 229, PRC2/EED targeting EED |
| QE-11-DP47_1uM | Dose=1uM, 9-Hydroxycalabaxanthone |
| AD-32-RF17_10uM | Dose=10uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| DD-82-HB82_0.1uM | Dose=0.1uM, Prodipine targeting CYP2D6 |
| HB-92-PE54_0.01uM | Dose=0.01uM |
| IF-78-GO12_1uM | Dose=1uM, Acetaminophen, Cyclooxygenase-3 Inhibitors targeting PTGS1 |
| TD-35-IE25_10uM | Dose=10uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP |
| AC-14-FX35_1uM | Dose=1uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2 |
| ZB-28-SS80_1uM | Dose=1uM, (3-Cyano-4-{3-[(5-methyl-furan-2-ylmethyl)-sulfamoyl]-5-trifluoromethyl-phenyl}-pyrrol-1-yl)-acetic acid, GPR44 antagonist targeting PTGDR2 |
| AC-67-PZ77_1uM | Dose=1uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1 |
| SC-17-WW78_0.01uM | Dose=0.01uM, 2-[[4-(4-cyano-1-methylpiperidin-4-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile, MAP3K12 (DLK) Inhibitors targeting MAP3K12 |
| AA-97-XP63_0.1uM | Dose=0.1uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4 |
| DE-30-EA70_1uM | Dose=1uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1 |
| GB-81-GK41_0.01uM | Dose=0.01uM, QX-314, BLMH gene inhibitor targeting BLM |
| AD-29-IG16_0.01uM | Dose=0.01uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1 |
| GF-58-OL90_10uM | Dose=10uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| YC-80-XX73_0.1uM | Dose=0.1uM, 3-(Ethoxycarbonyl)-1,3-thiazolidine-4-carboxylic acid, Elastase Inhibitors targeting PI3 |
| AA-88-PJ86_0.1uM | Dose=0.1uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5 |
| IF-75-AJ33_10uM | Dose=10uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1 |
| PD-94-WO47_1uM | Dose=1uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1 |
| FD-74-LD52_10uM | Dose=10uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB |
| IC-27-TE11_1uM | Dose=1uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4 |
| BD-48-ZT65_1uM | Dose=1uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| AB-25-MR13_0.01uM | Dose=0.01uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2 |
| BF-54-GX35_1uM | Dose=1uM |
| VE-59-SD17_10uM | Dose=10uM, (3-(((6-Phenyl-5-(p-tolyl)pyridin-2-yl)methyl)amino)propyl)phosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists targeting S1PR1, S1PR3 |
| CA-11-KY95_0.1uM | Dose=0.1uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7 |
| GB-96-WX99_1uM | Dose=1uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1 |
| JA-85-CW09_0.01uM | Dose=0.01uM, 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK Inhibitors targeting CCND2, CCND3 |
| CE-88-RJ81_1uM | Dose=1uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| CB-99-OG76_0.1uM | Dose=0.1uM |
| DA-33-NF79_1uM | Dose=1uM, Brofaromine, MAO-A Inhibitors targeting MAOA |
| UC-19-KX65_10uM | Dose=10uM |
| EA-40-GQ08_0.01uM | Dose=0.01uM, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine, Endothelin ETB Receptor Antagonists targeting EDNRB |
| FE-64-KC49_1uM | Dose=1uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| ZE-11-HK24_0.01uM | Dose=0.01uM, methyl (1R,2R,3S,3aR,8bS)-6-[[(2R,3R,6R)-6-[(1S)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate, EIF4A gene modulator targeting EIF4A1, EIF4A2, EIF4A3 |
| JF-25-NM40_1uM | Dose=1uM |
| AE-71-VB70_10uM | Dose=10uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6 |
| IB-90-MD82_10uM | Dose=10uM, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine |
| NE-93-AH13_0.1uM | Dose=0.1uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one |
| CA-17-XB39_1uM | Dose=1uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3 |
| AD-83-MW95_0.1uM | Dose=0.1uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| DF-57-FI46_1uM | Dose=1uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1 |
| HF-36-FK93_0.1uM | Dose=0.1uM, (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide, SPHK1 inhibitor targeting SPHK1 |
| AC-54-FR31_10uM | Dose=10uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG |
| AD-45-YB25_1uM | Dose=1uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A |
| GF-19-NZ91_0.01uM | Dose=0.01uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| CA-84-IJ41_0.1uM | Dose=0.1uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EE-01-DO31_0.1uM | Dose=0.1uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8 |
| HD-96-GX64_0.1uM | Dose=0.1uM, Methyl 4-[(3,6-dichloro-2-methoxybenzoyl)amino]benzoate targeting TAS1R1 |
| AD-79-UU60_0.01uM | Dose=0.01uM, Het0016, 20-HETE receptor antagonist targeting CYP4A11 |
| GA-27-MH98_0.1uM | Dose=0.1uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3 |
| AB-51-WV08_1uM | Dose=1uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1 |
| JB-35-RC26_0.01uM | Dose=0.01uM, Valopicitabine |
| AA-83-TW85_0.01uM | Dose=0.01uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2 |
| UC-52-SS41_0.1uM | Dose=0.1uM, 1-(3-(Naphth-2-ylmethoxy)phenyl)-1-(thiazol-2-yl)propyl methyl ether, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| AE-41-GB05_1uM | Dose=1uM, Ave5638, Known Tryptase inhibitor targeting TPSB2 |
| DE-79-FD94_1uM | Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| XD-54-WU31_0.01uM | Dose=0.01uM, Hydroxycitric acid, ATP citrate lyase inhibitor targeting ACLY |
| OD-30-UF61_0.01uM | Dose=0.01uM |
| UE-90-KK72_1uM | Dose=1uM |
| AA-85-KR83_0.01uM | Dose=0.01uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35 |
| KA-92-WY22_0.01uM | Dose=0.01uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1 |
| NC-76-YX69_0.1uM | Dose=0.1uM, 2-Amino-4-methylbenzothiazole |
| XD-03-FM54_1uM | Dose=1uM |
| S0-EE-Y7IR_0.01uM | Dose=0.01uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1 |
| FE-73-PS05_1uM | Dose=1uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1 |
| PD-74-GP60_0.1uM | Dose=0.1uM, 2-[3-[2-Chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecan-9-yl]acetic acid, GPR120 agonist targeting FFAR4 |
| ED-14-GQ53_10uM | Dose=10uM, 2-(4-Methylphenoxy)benzoic acid |
| AA-74-OG49_0.1uM | Dose=0.1uM, Aminoglutethimide, Antiglucocorticoids;Aromatase Inhibitors targeting CYP11A1, CYP19A1, NR3C1 |
| AF-83-BX08_0.01uM | Dose=0.01uM |
| DE-82-SC55_1uM | Dose=1uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP |
| PA-15-CP52_1uM | Dose=1uM, (3aS,9bS)-2-(1-benzofuran-5-sulfonyl)-5-methyl-1H,2H,3H,3aH,4H,5H,9bH-pyrrolo[3,4-c]1,6-naphthyridin-4-one targeting GLRA1, GLRA2, GLRA3, GLRA4 |
| SC-76-YF40_0.1uM | Dose=0.1uM |
| SA-28-ZT78_0.1uM | Dose=0.1uM, Gavestinel, NMDA Glycine-Site Antagonists targeting GRIN1 |
| BD-94-KU93_1uM | Dose=1uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| IB-80-NT65_1uM | Dose=1uM |
| BE-67-QZ92_10uM | Dose=10uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B |
| FA-67-MV22_0.01uM | Dose=0.01uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1 |
| DD-54-MA35_10uM | Dose=10uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB |
| CB-47-SB29_1uM | Dose=1uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| DA-59-ZD74_0.01uM | Dose=0.01uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| XD-01-OY13_0.1uM | Dose=0.1uM, Cvt-12012, SCD1) Inhibitors;Stearoyl-CoA Desaturase (delta-9 Desaturase;SCD targeting SCD |
| KD-44-PB06_0.1uM | Dose=0.1uM, CID 10461016 |
| HD-89-HC56_0.1uM | Dose=0.1uM, eIF4A3-IN-2 targeting EIF4A3 |
| EC-00-KR26_0.01uM | Dose=0.01uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| UE-20-KA68_1uM | Dose=1uM, Z-FA-Fmk, Cathepsin B Inhibitors targeting CTSB |
| KD-42-UK08_10uM | Dose=10uM, AZ11657312 (salt free), P2X7 Receptor Antagonists targeting P2RX7 |
| BD-58-PT20_10uM | Dose=10uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2 |
| AA-45-SU80_10uM | Dose=10uM, Phenylpiperazine |
| BC-36-PL31_0.1uM | Dose=0.1uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| HE-15-UQ55_1uM | Dose=1uM |
| AA-01-PS31_10uM | Dose=10uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11 |
| FA-52-OO58_1uM | Dose=1uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9 |
| AE-13-WW30_1uM | Dose=1uM, CID 14403147, 5-HT3 Antagonists targeting HTR3A |
| JE-27-XK20_0.1uM | Dose=0.1uM, Rifapentine, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| IB-14-XS97_1uM | Dose=1uM, Pomalidomide-6-OH, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| WE-41-YO44_1uM | Dose=1uM, N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea, Angiogenesis Inhibitors;Urokinase (u-PA) Inhibitors targeting PLAU |
| OD-03-CA36_0.01uM | Dose=0.01uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide |
| BC-15-BY15_0.01uM | Dose=0.01uM |
| DA-75-KD59_0.1uM | Dose=0.1uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17 |
| GF-98-RS57_10uM | Dose=10uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1 |
| XD-53-KC50_10uM | Dose=10uM |
| IE-75-ZC91_10uM | Dose=10uM, 7-Hydroxyflavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1 |
| NB-73-PA21_1uM | Dose=1uM, {4-[4-(4-Isopropoxy-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazol-2-ylmethoxy]-2-methyl-phenoxy}-acetic acid targeting PPARD |
| OD-13-IE31_1uM | Dose=1uM |
| OF-37-IT01_10uM | Dose=10uM |
| IA-77-NA41_0.01uM | Dose=0.01uM, 6-(4-((diethylamino)methyl)benzyl)-7-neopentyl-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK |
| AB-33-VM36_10uM | Dose=10uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS |
| GB-05-QT17_10uM | Dose=10uM, 4-Nitro-N-(4-sulfamoylphenyl)benzene-1-sulfonamide, Carbonic anhydrase inhibitor targeting CA1 |
| AB-73-SW45_0.01uM | Dose=0.01uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| GA-77-MH38_0.1uM | Dose=0.1uM |
| JD-74-IP25_1uM | Dose=1uM, Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors |
| AE-26-JY57_0.01uM | Dose=0.01uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| GE-29-ZM45_0.01uM | Dose=0.01uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| KC-67-HN97_0.01uM | Dose=0.01uM, 2,2-Dimethyl-6-[(4,6-diphenyl-2-pyridyl)oxy]hexanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| JF-62-LU77_0.01uM | Dose=0.01uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN |
| AD-59-IN33_0.01uM | Dose=0.01uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| NE-34-OZ69_0.01uM | Dose=0.01uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1 |
| AC-12-PZ00_0.1uM | Dose=0.1uM |
| OD-09-LH57_0.01uM | Dose=0.01uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester |
| YA-21-RR66_0.01uM | Dose=0.01uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4 |
| PC-34-YF76_10uM | Dose=10uM, 1-[2-(2-Tert-butylanilino)pyridin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea, P2Y Antagonist targeting P2RY1 |
| SA-32-CC58_0.1uM | Dose=0.1uM, Piperidin-4-yl-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-amine, CDK inhibitors targeting CCNB2, CCNB3 |
| AC-74-BQ48_10uM | Dose=10uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R |
| HC-19-UZ81_0.01uM | Dose=0.01uM, Galgravin |
| JD-47-WR37_1uM | Dose=1uM |
| CB-52-IL46_0.1uM | Dose=0.1uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| QA-34-BH60_1uM | Dose=1uM, rac-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide |
| JD-00-TT75_0.01uM | Dose=0.01uM, 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid, Lactate dehydrogenase inhibitor targeting LDHA, LDHB |
| EA-12-SS08_0.01uM | Dose=0.01uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8 |
| YC-83-VF72_1uM | Dose=1uM |
| KA-62-FE69_0.01uM | Dose=0.01uM, 2-Methoxy-N-(3-Methyl-2-Oxo-1,2,3,4-Tetrahydroquinazolin-6-Yl)benzenesulfonamide, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| BB-80-NH42_10uM | Dose=10uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2 |
| BC-75-CK91_1uM | Dose=1uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| EA-81-CR68_1uM | Dose=1uM |
| CE-37-MS25_0.01uM | Dose=0.01uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2 |
| JE-52-BH86_0.1uM | Dose=0.1uM |
| OD-09-LH57_10uM | Dose=10uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester |
| ND-27-UQ99_0.01uM | Dose=0.01uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2 |
| AD-85-ME82_1uM | Dose=1uM, 15-O-Desmethylascomycin |
| AB-23-UX23_0.1uM | Dose=0.1uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1 |
| ND-66-KW81_10uM | Dose=10uM, A-161906, TNF-alpha Production Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| VA-48-RJ44_0.1uM | Dose=0.1uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5 |
| VF-49-KA00_0.1uM | Dose=0.1uM, 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde, ERN1 gene inhibitor targeting ERN1 |
| LB-60-OF61_10uM | Dose=10uM, CID 134692422 |
| LF-33-KO15_0.1uM | Dose=0.1uM, 9-Isopropyl-N-[3-(trifluoromethyl)benzyl]-9H-purin-6-amine, Casein kinase-I alpha inhibitor;Casein kinase-I delta inhibitor targeting CSNK1A1, CSNK1D |
| CD-10-LX95_1uM | Dose=1uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2 |
| FA-89-PW29_0.01uM | Dose=0.01uM, P505-15 targeting SYK |
| AB-14-QA30_0.01uM | Dose=0.01uM |
| IF-31-RN78_1uM | Dose=1uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1 |
| ZC-88-KS25_10uM | Dose=10uM |
| RC-47-LT41_0.1uM | Dose=0.1uM |
| CB-32-EI69_0.01uM | Dose=0.01uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| JD-79-ZS29_10uM | Dose=10uM, 1,1'-Methylenebis(2-naphthol), Antiamyloidogenic Agents targeting APP |
| BC-07-FZ32_0.01uM | Dose=0.01uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2 |
| BD-60-XA25_0.1uM | Dose=0.1uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine |
| EF-33-IW50_1uM | Dose=1uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2 |
| EE-01-DO31_10uM | Dose=10uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8 |
| KA-51-CQ55_10uM | Dose=10uM, N-Cyclohexyl-4-(4-phenyl-1-(piperazin-1-yl)-2,6-naphthyridin-3-yl)pyridin-2-amine, PKD inhibitor targeting PRKD1 |
| JE-31-PK61_1uM | Dose=1uM, 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, PDE9a inhibitor targeting PDE9A |
| AD-30-SU93_1uM | Dose=1uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| BA-92-CZ75_1uM | Dose=1uM |
| QA-25-HL62_0.01uM | Dose=0.01uM, 4-({3-chloro-4-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinoline-3-carbonitrile, Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors targeting MAP2K1 |
| FB-20-YQ23_0.01uM | Dose=0.01uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R |
| AD-20-CH42_1uM | Dose=1uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42 |
| CD-91-MI27_1uM | Dose=1uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7 |
| DE-48-FF01_1uM | Dose=1uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK |
| ED-98-UI13_0.01uM | Dose=0.01uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E |
| IA-95-KW09_0.01uM | Dose=0.01uM, (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester, Leukotriene Antagonists targeting CYSLTR1 |
| QA-67-IM54_0.01uM | Dose=0.01uM, CID 118626505 |
| DA-20-OX15_0.1uM | Dose=0.1uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9 |
| BF-02-QT56_0.01uM | Dose=0.01uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS |
| PB-59-HH22_10uM | Dose=10uM, 4-[[(4-Fluorophenyl)sulfonylamino]methyl]-~{n}-(Pyridin-3-Ylmethyl)benzamide, NR2A Antagonists targeting GRIN2A |
| CD-12-NI84_0.01uM | Dose=0.01uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| SE-15-AV21_0.1uM | Dose=0.1uM, 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea, Eukaryotic Translation Initiation Factor 2-alpha Kinase 1 (HRI) Activators targeting EIF2AK1 |
| ND-06-AJ85_10uM | Dose=10uM, N-[7-[1-[[2-(4-chlorophenyl)-6-fluorophenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2 |
| GD-96-AK08_0.01uM | Dose=0.01uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| AB-23-UX23_10uM | Dose=10uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1 |
| BC-56-WO88_0.01uM | Dose=0.01uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5 |
| UB-30-TL20_10uM | Dose=10uM, 1-Amino-4-[4-(2,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid targeting P2RY4 |
| FA-95-HA77_0.01uM | Dose=0.01uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2 |
| QA-87-NQ04_0.1uM | Dose=0.1uM, 5-(Methylamino)-2-(naphthalen-1-yl)-1,3-oxazole-4-carbonitrile, ALOX15 gene inhibitor targeting ALOX15 |
| EA-86-YK48_0.01uM | Dose=0.01uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1 |
| QF-45-KI95_0.1uM | Dose=0.1uM, 4-Bromanyl-~{n}-(6-Methoxy-1,3-Dimethyl-2-Oxidanylidene-Benzimidazol-5-Yl)-2-Methyl-Benzenesulfonamide, BRPF1B and BRPF2 inhibitor targeting BRPF1, BRD1 |
| DA-85-SU90_0.1uM | Dose=0.1uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1 |
| CC-07-LB64_10uM | Dose=10uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one |
| BD-40-EK64_1uM | Dose=1uM, Terbuficin, LDL Antioxidants targeting ABCA1 |
| NB-75-RF23_0.1uM | Dose=0.1uM |
| AF-48-FX20_0.01uM | Dose=0.01uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| AB-82-EP26_10uM | Dose=10uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| OE-78-TD20_0.1uM | Dose=0.1uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1 |
| AB-87-II61_1uM | Dose=1uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| BE-74-SX40_10uM | Dose=10uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3 |
| ZC-12-OO11_1uM | Dose=1uM, 5-(Pyridin-4-YL)-1H-imidazole-2-thiol, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| YE-55-YX75_0.01uM | Dose=0.01uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4 |
| EC-42-DO33_10uM | Dose=10uM, 1-Propyl-2,3,4,4a,10,10a-hexahydro-1H-9-oxa-1-aza-phenanthren-6-ol, Dopamine Autoreceptor Agonists;Prolactin Secretion Inhibitors targeting PRL |
| KD-14-RS67_0.1uM | Dose=0.1uM, 1-[4-(2,3-Dimethoxybenzoyl)piperazin-1-yl]-2-(3-methylphenoxy)ethanone, antagonist of CBX7ChD/methyl-lysine binding by blocking H3K27me3 binding;CBX7ChD antagonist targeting CBX7 |
| IC-79-JZ26_10uM | Dose=10uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide |
| EA-43-XP68_0.01uM | Dose=0.01uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| BD-02-US28_10uM | Dose=10uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2 |
| BC-38-UW37_0.01uM | Dose=0.01uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH |
| EA-90-PK44_10uM | Dose=10uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| LB-04-KP05_1uM | Dose=1uM, 1-Ethyl-2-benzimidazolinone, SK2 Potassium Channel Activators targeting KCNN2 |
| AB-01-UY50_10uM | Dose=10uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| LB-49-UZ91_0.1uM | Dose=0.1uM, 1-Methyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole |
| FF-35-JG06_1uM | Dose=1uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| BA-66-BL56_10uM | Dose=10uM, 1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-(naphthalen-2-yl)urea, frizzled-4 anatagonist targeting FZD4 |
| ME-16-XW76_0.01uM | Dose=0.01uM, 1-(3-Benzoylpropyl)-4-benzamidopiperidine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| BB-55-JH29_10uM | Dose=10uM |
| ID-37-UU19_1uM | Dose=1uM, 5-[[4-[3-(trifluoromethyl)anilino]phthalazin-1-yl]methyl]-1H-pyridin-2-one |
| AB-73-ZX03_1uM | Dose=1uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5 |
| FD-20-OG99_0.01uM | Dose=0.01uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| CF-01-IO46_10uM | Dose=10uM, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, Potassium Channel Blockers;Soluble Guanylyl Cyclase (sGC) Inhibitors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| CB-15-RU50_0.1uM | Dose=0.1uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| CD-08-MF16_0.01uM | Dose=0.01uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1 |
| GA-77-FY14_10uM | Dose=10uM |
| BF-22-EP86_0.01uM | Dose=0.01uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| BC-53-HT63_1uM | Dose=1uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| BA-44-SG89_0.1uM | Dose=0.1uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD |
| DA-78-WW87_0.1uM | Dose=0.1uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| DE-17-IZ77_1uM | Dose=1uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B |
| AC-98-UW57_10uM | Dose=10uM, Suplatast |
| MB-50-ZI28_10uM | Dose=10uM, (4S)-4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one |
| BF-18-MJ41_10uM | Dose=10uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1 |
| AE-00-WU78_1uM | Dose=1uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E |
| DD-15-VH74_0.01uM | Dose=0.01uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1 |
| TC-45-JH72_0.01uM | Dose=0.01uM, Vesamicol targeting SLC18A3 |
| HF-82-PE14_0.1uM | Dose=0.1uM |
| ED-81-ZH14_0.1uM | Dose=0.1uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK |
| KB-72-ID36_0.01uM | Dose=0.01uM, Tolimidone, Lyn kinase activator;Lyn Kinase Activators targeting LYN |
| HC-06-EN50_0.01uM | Dose=0.01uM |
| GB-45-CJ58_10uM | Dose=10uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C |
| JA-38-XE73_1uM | Dose=1uM |
| BF-13-HM71_10uM | Dose=10uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| BA-26-GI09_0.1uM | Dose=0.1uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR |
| CB-12-BV05_10uM | Dose=10uM |
| HB-96-QD61_10uM | Dose=10uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4 |
| DA-05-NN93_10uM | Dose=10uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| DB-05-UK61_1uM | Dose=1uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1 |
| RC-18-AD40_1uM | Dose=1uM, N-(3,5-dimethylphenyl)-4-(thiazol-2-yl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors;Syk Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting SYK, AURKB, GSK3A |
| UB-90-TA33_0.1uM | Dose=0.1uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile |
| AF-76-AY17_10uM | Dose=10uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| PE-39-HL72_10uM | Dose=10uM, 8-(1-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-3-acetic acid Methyl Ester, OPRL1 (Nociceptin Receptor) agonist targeting OPRL1 |
| RE-99-TA30_1uM | Dose=1uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R |
| CC-61-KS26_10uM | Dose=10uM, PK 11195, Pregnane X Receptor (PXR) Agonists;Peripheral Benzodiazepine Receptor (PBR) Antagonists;Constitutive Androstane Receptor (CAR) Antagonists targeting TSPO, NR1I2, NR1I3 |
| AA-86-YV75_0.1uM | Dose=0.1uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| AD-70-TH82_0.01uM | Dose=0.01uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| AE-90-RS19_1uM | Dose=1uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5 |
| EC-87-ZB49_1uM | Dose=1uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1 |
| S0-EE-Y9JI_1uM | Dose=1uM, Spt-IN-1, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| BC-53-HT63_0.01uM | Dose=0.01uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| CB-10-YX20_0.1uM | Dose=0.1uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1 |
| XB-22-LI07_10uM | Dose=10uM |
| NF-27-AQ24_1uM | Dose=1uM, GR 46611, HTR1D agonist targeting HTR1D |
| BB-58-LW82_0.1uM | Dose=0.1uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester |
| GA-06-UU42_0.1uM | Dose=0.1uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| CA-96-UO48_0.01uM | Dose=0.01uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| GE-77-FY84_0.01uM | Dose=0.01uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| BA-51-DL54_0.1uM | Dose=0.1uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1 |
| LD-23-UR32_1uM | Dose=1uM, (2R)-[[4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]methyl]-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol |
| DD-42-DB72_1uM | Dose=1uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1 |
| CC-20-ZO24_0.01uM | Dose=0.01uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| KA-54-MB31_1uM | Dose=1uM, 3-Amino-3,4-dihydro-1-hydroxy-2(1H)-quinolinone, Kynurenine Aminotransferase II (KAT II) Inhibitors targeting AADAT |
| GB-94-XG34_0.1uM | Dose=0.1uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN |
| IB-87-ZR37_0.1uM | Dose=0.1uM, 6-Chloro-2-[(4-chlorophenyl)methylsulfanyl]-1-(4-ethoxyphenyl)benzimidazole, Free Fatty Acid Receptor 1 (FFAR1;GPR40) Antagonists targeting FFAR1 |
| BC-22-DS93_0.01uM | Dose=0.01uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| GA-61-GX82_0.01uM | Dose=0.01uM, Abeorphine |
| DA-15-PU65_0.01uM | Dose=0.01uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| GC-09-XF08_10uM | Dose=10uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| KB-25-KP22_1uM | Dose=1uM, 4-(5,6-Dimethoxy-2-benzofuranyl)-piperidine, Serotonin Antagonists targeting HTR1A, MAOA, MAOB |
| DD-99-WQ55_1uM | Dose=1uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)- |
| LF-56-QX74_0.01uM | Dose=0.01uM, 4-Heptyloxyphenol, steroidogenic factor inhibitor targeting NR5A1 |
| HC-19-UZ81_1uM | Dose=1uM, Galgravin |
| JD-48-EV39_0.1uM | Dose=0.1uM, Xanthenone-4-acetic acid |
| TD-48-XJ84_1uM | Dose=1uM, 4-[2-Methoxy-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]benzonitrile |
| CA-11-KY95_1uM | Dose=1uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7 |
| LD-39-FL02_0.1uM | Dose=0.1uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside |
| BD-39-KG21_0.01uM | Dose=0.01uM, Selegiline, MAO-B Inhibitors targeting MAOB |
| RB-55-WB28_0.1uM | Dose=0.1uM, Verproside, TNFa - NFkB pathway inhibitor;TRADD-TRAF2 PPI inhibitor targeting TRAF2, TRADD |
| QD-39-YV36_10uM | Dose=10uM, (1S,3S)-3-amino-4-(2,2,2-trifluoro-1-trifluoromethylethylidene)cyclopentane, OAT inhibitor targeting OAT |
| BD-38-QC39_1uM | Dose=1uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| JB-74-LF71_1uM | Dose=1uM, 6-(6-(Diethylamino)pyridin-3-yl)-N-(4-morpholinophenyl)-9H-purin-2-amine, Jak3 Inhibitors targeting JAK3 |
| AB-63-OW35_0.1uM | Dose=0.1uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A |
| UB-40-KU41_0.1uM | Dose=0.1uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide |
| QA-81-IM40_0.01uM | Dose=0.01uM, 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine targeting KMT5A |
| JC-03-OI01_0.1uM | Dose=0.1uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA |
| NE-45-SF73_0.01uM | Dose=0.01uM |
| ZC-74-FT18_10uM | Dose=10uM, CID 25225521, Orexin 2 receptor antagonist targeting HCRTR2 |
| GA-18-PV59_0.1uM | Dose=0.1uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17 |
| DD-95-TY80_0.01uM | Dose=0.01uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| CE-21-UO81_0.1uM | Dose=0.1uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| HA-38-ML65_0.01uM | Dose=0.01uM |
| GB-93-CC27_0.1uM | Dose=0.1uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6 |
| EB-98-OI08_0.01uM | Dose=0.01uM |
| EA-07-RB34_1uM | Dose=1uM |
| YE-02-BO16_1uM | Dose=1uM, 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester, Anxiolytics targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| AC-74-UR36_0.01uM | Dose=0.01uM, Apixaban, Known FactorXa inhibitor targeting F10 |
| DB-89-DT62_1uM | Dose=1uM |
| QD-13-FQ44_0.01uM | Dose=0.01uM, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, PDCD1, PDE1A, PDE1C, PDE4C, PDE6A, PDE6C, PDE6D, PDE6G, PDE6H, PDE8A, PDE9A, PDE6B, PDE8B |
| CE-52-XV55_10uM | Dose=10uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A |
| RA-60-MZ29_10uM | Dose=10uM, KDM5A pan Inhibitor targeting KDM5A |
| BF-13-HM71_1uM | Dose=1uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| UA-25-LA05_0.01uM | Dose=0.01uM, N-(4-aminobutyl)-5-chloronaphthalene-1-sulfonamide |
| GE-32-JR10_10uM | Dose=10uM, 3-Phenylpropylamine |
| GB-51-MD79_0.01uM | Dose=0.01uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG |
| ED-00-OH22_0.01uM | Dose=0.01uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT |
| AB-50-OH27_0.1uM | Dose=0.1uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB |
| BD-65-VV48_0.01uM | Dose=0.01uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG |
| CC-07-DV77_1uM | Dose=1uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A |
| WE-69-LT10_10uM | Dose=10uM |
| BE-69-RD44_0.01uM | Dose=0.01uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1 |
| LC-54-XS57_0.1uM | Dose=0.1uM |
| CA-67-IB54_10uM | Dose=10uM, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| WC-22-DS16_10uM | Dose=10uM, N-(1-phenylethyl)-3-tosylthieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine |
| GF-73-HI61_1uM | Dose=1uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| KE-89-TF43_10uM | Dose=10uM, 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one, PDE9A gene inhibitor targeting PDE9A |
| SF-32-RC78_10uM | Dose=10uM, MAP3K5 gene inhibitor targeting MAP3K5 |
| GD-90-RA90_1uM | Dose=1uM, SIS3 free base targeting SMAD3 |
| NA-42-JG03_1uM | Dose=1uM, (3S,6S,8aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-(2-phenylethyl)-2,3,6,7,8,8a-hexahydro-1H-indolizine-3-carboxamide |
| AE-54-BN96_0.1uM | Dose=0.1uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3 |
| GA-23-VF89_0.1uM | Dose=0.1uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| IB-90-MD82_0.1uM | Dose=0.1uM, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine |
| FA-31-XR78_10uM | Dose=10uM |
| MA-64-FB16_1uM | Dose=1uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-2-[4-(2-methyltetrazol-5-yl)phenyl]-N-[5-(trifluoromethyl)pyrazin-2-yl]acetamide |
| ND-07-WN37_0.1uM | Dose=0.1uM, Padnarsertib, Allosteric inhibitor that degrades PAK4 targeting PAK4 |
| ID-30-ST90_10uM | Dose=10uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide |
| HE-95-KK46_10uM | Dose=10uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A |
| WB-43-IC00_10uM | Dose=10uM, Opaganib, Sphingosine Kinase 2 (SphK2) Inhibitors;Angiogenesis Inhibitors targeting SPHK2 |
| HD-36-DK23_1uM | Dose=1uM, N-[1-[[5-[(4-acetylpiperazin-1-yl)methyl]-4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-4-fluorobenzamide |
| FC-31-HE22_1uM | Dose=1uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1 |
| ZA-84-ZC97_0.01uM | Dose=0.01uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA |
| AB-25-NK66_0.01uM | Dose=0.01uM, Adh-1, N-cadherin Inhibitor targeting CDH2 |
| S0-EE-WW6E_0.1uM | Dose=0.1uM, N-(3-((Cyclopentylthio)methyl)-4-methoxyphenyl)benzimidamide targeting QRFPR |
| AD-02-XI19_0.1uM | Dose=0.1uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT |
| CC-06-WH01_0.01uM | Dose=0.01uM |
| BE-46-FY47_0.1uM | Dose=0.1uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A |
| HF-57-QB74_0.01uM | Dose=0.01uM, Ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate, steroidogenic factor 1 inhibitor;NR5A1 inhibitor targeting NR5A1 |
| EE-01-DO31_0.01uM | Dose=0.01uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8 |
| GA-48-QI68_10uM | Dose=10uM |
| AB-11-MO96_1uM | Dose=1uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| BA-02-RG00_10uM | Dose=10uM |
| CB-55-GX92_10uM | Dose=10uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2 |
| SC-25-HE80_0.1uM | Dose=0.1uM, 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-methylphenyl]-3-(trifluoromethyl)benzamide, DDR tyrosine kinase receptor inhibitor targeting DDR1, DDR2 |
| FB-88-FZ09_10uM | Dose=10uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1 |
| JC-53-YE56_0.1uM | Dose=0.1uM, Quiflapon |
| GE-25-YQ75_0.1uM | Dose=0.1uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2 |
| DA-10-VU83_0.01uM | Dose=0.01uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2 |
| TF-04-RX73_0.01uM | Dose=0.01uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile |
| BA-31-AB30_10uM | Dose=10uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA |
| BB-48-VW67_0.1uM | Dose=0.1uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| GB-62-IH36_1uM | Dose=1uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B |
| DD-28-MZ39_0.1uM | Dose=0.1uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO |
| AD-45-YB25_0.01uM | Dose=0.01uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A |
| AA-75-JH89_0.01uM | Dose=0.01uM, BAY-598 R-isomer |
| KB-46-EJ60_0.1uM | Dose=0.1uM |
| MD-60-WI93_1uM | Dose=1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR-1 (Flt-1) Inhibitors targeting FLT1 |
| EA-30-ZX90_10uM | Dose=10uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| S0-EE-X3ZZ_1uM | Dose=1uM, Pesampator targeting GRIA1 |
| EC-12-AY12_10uM | Dose=10uM, Lisofylline |
| ED-22-QV85_0.01uM | Dose=0.01uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3 |
| LB-70-YM83_1uM | Dose=1uM |
| DE-01-HO61_1uM | Dose=1uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR |
| FB-31-TA57_0.01uM | Dose=0.01uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7 |
| BB-50-CR51_1uM | Dose=1uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT |
| IE-28-SY71_1uM | Dose=1uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one |
| EA-06-CH36_10uM | Dose=10uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| DB-33-HZ87_10uM | Dose=10uM, Vgx-1027, Cytokine Modulators targeting TLR4 |
| CA-67-XI76_1uM | Dose=1uM, Racepinefrine, (S)- |
| LE-08-BO67_10uM | Dose=10uM, 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide, Muscarinic M5 receptor antagonist targeting CHRM5 |
| AE-63-ST43_0.01uM | Dose=0.01uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A |
| GC-67-AH43_1uM | Dose=1uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| AF-99-HA02_0.01uM | Dose=0.01uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| AB-41-IO16_1uM | Dose=1uM |
| AE-28-IQ88_1uM | Dose=1uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| AC-82-PZ00_0.01uM | Dose=0.01uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C |
| HA-36-VD41_10uM | Dose=10uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| YA-71-LR91_0.1uM | Dose=0.1uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-2-[4-(2-methyltetrazol-5-yl)phenyl]acetamide |
| QE-87-XW53_0.1uM | Dose=0.1uM, Dopexamine, Dopamine D1 Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, DRD1 |
| AE-65-LV28_0.01uM | Dose=0.01uM, Ketotifen |
| AB-05-FB25_10uM | Dose=10uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1 |
| IE-02-TR35_0.1uM | Dose=0.1uM, (S)-N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, NPSR1 antagonist targeting NPSR1 |
| DE-46-NH51_10uM | Dose=10uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one |
| BB-37-LS05_1uM | Dose=1uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| VC-94-CG67_0.1uM | Dose=0.1uM |
| KA-60-LC14_1uM | Dose=1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-3,3-dimethyl-2-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]amino]butanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| YD-71-BE10_10uM | Dose=10uM, Sgk1-IN-1, Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitors targeting SGK1, SGK2 |
| AW-13-3788_0.1uM | Dose=0.1uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A |
| AC-90-GY03_10uM | Dose=10uM |
| IB-14-YP50_1uM | Dose=1uM, Sar405, VPS34 inhibitor targeting PIK3C3 |
| EB-70-JQ38_1uM | Dose=1uM, Z-Phe-DL-Ala-fluoromethylketone |
| FE-59-BC81_0.1uM | Dose=0.1uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| DF-13-OP48_0.01uM | Dose=0.01uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol |
| IC-18-TY61_0.1uM | Dose=0.1uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD |
| KA-92-WY22_10uM | Dose=10uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1 |
| ZF-10-JD55_10uM | Dose=10uM |
| JF-74-GS02_0.1uM | Dose=0.1uM, alpha-Trifluoromethyl-alpha-hydroxybenzeneacetamide, T-Type Calcium Channel Blockers targeting KCNK3, KCNK9 |
| UB-28-WW60_0.1uM | Dose=0.1uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol |
| DA-49-ZD74_1uM | Dose=1uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| CE-17-FI51_1uM | Dose=1uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP |
| DD-68-ZP95_1uM | Dose=1uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A |
| ZF-00-MX33_0.01uM | Dose=0.01uM |
| HF-01-QN73_0.01uM | Dose=0.01uM, 1-Isopropyl-1h-1,2,3-benzotriazole-5-carboxylic acid, GPR109B agonist;HM74) Receptor Agonists;GPR109B;Nicotinic Acid (Niacin targeting HCAR3 |
| HB-01-ZU75_1uM | Dose=1uM |
| EA-43-XP68_10uM | Dose=10uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| HB-92-XE24_0.01uM | Dose=0.01uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| JC-96-ID26_0.01uM | Dose=0.01uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A |
| ZC-47-HL31_0.01uM | Dose=0.01uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1 |
| YA-61-RR36_0.01uM | Dose=0.01uM |
| BE-51-JY70_1uM | Dose=1uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK |
| ED-31-AA47_0.01uM | Dose=0.01uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2 |
| DD-93-NF74_10uM | Dose=10uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide |
| GD-66-XE49_1uM | Dose=1uM |
| SB-29-AN01_0.01uM | Dose=0.01uM, benzyl (2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carboxylate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| LC-57-RH78_1uM | Dose=1uM, K(ATP) Channel Blockers targeting ABCC8, ABCC9, KCNJ8, KCNJ11 |
| XA-39-SG64_0.01uM | Dose=0.01uM, MK-0354, GPR109a partial agonist targeting HCAR2 |
| AA-66-PC55_0.1uM | Dose=0.1uM, 9-Azapaullone, CDK9/Cyclin T1 Inhibitors;Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting CCNT1, CDK9, GSK3A |
| GF-90-DG49_0.01uM | Dose=0.01uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| AD-15-VR38_0.01uM | Dose=0.01uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| NE-92-EU87_10uM | Dose=10uM, Abl127, Protein Phosphatase Methylesterase 1 Inhibitor targeting PPME1 |
| AA-09-HG96_1uM | Dose=1uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA |
| AD-10-TH32_10uM | Dose=10uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1 |
| DC-17-EL33_10uM | Dose=10uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| AD-43-WX13_10uM | Dose=10uM, (2e,3ar,14as)-9-Bromo-2-Imino-1,2,3,5,6,14a-Hexahydro-4h,8h-Imidazo[4',5':5,6]pyrrolo[1',2':4,5]pyrazino[1,2-A]indol-8-One, Proteasome beta-5 subunit inhibitor targeting PSMB5 |
| KB-49-NF63_0.1uM | Dose=0.1uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-phenylpropanamide, VPAC1 (VIP1) Antagonists targeting VIPR1 |
| AF-87-II41_1uM | Dose=1uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10 |
| QB-87-TC65_0.01uM | Dose=0.01uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1 |
| CE-09-ZT22_1uM | Dose=1uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2 |
| DD-33-XP23_10uM | Dose=10uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| MC-30-BS07_10uM | Dose=10uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG |
| BC-56-WO88_1uM | Dose=1uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5 |
| OE-31-YC41_0.1uM | Dose=0.1uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2 |
| AD-86-ES28_0.01uM | Dose=0.01uM, LY2033298, M4 positive allosteric modulator targeting CHRM4 |
| BE-86-FY67_0.01uM | Dose=0.01uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3 |
| KF-18-RY71_0.01uM | Dose=0.01uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4 |
| IE-80-DC24_10uM | Dose=10uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide |
| OE-34-NH10_1uM | Dose=1uM, 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one, TIC10 inactivates Akt and ERK and induces TRAIL expression targeting TNFSF10 |
| CA-68-SW47_0.01uM | Dose=0.01uM, Sib-1893, mgluR5 Antagonists targeting GRM5 |
| BD-19-MD69_10uM | Dose=10uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| NE-95-RP07_0.01uM | Dose=0.01uM, N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea, ACAT Inhibitors;Lipid Lowering Agents targeting ACAT1, ACAT2, SOAT1 |
| AB-71-NB55_0.01uM | Dose=0.01uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14 |
| EF-92-OO68_0.1uM | Dose=0.1uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| FC-97-EO10_0.01uM | Dose=0.01uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide |
| EE-49-CD29_10uM | Dose=10uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| GB-73-QS80_1uM | Dose=1uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| IB-89-RS34_1uM | Dose=1uM, Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2 |
| AF-42-MP86_0.01uM | Dose=0.01uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide |
| JD-48-EV39_10uM | Dose=10uM, Xanthenone-4-acetic acid |
| CF-82-LL11_1uM | Dose=1uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5 |
| BD-47-DS20_0.01uM | Dose=0.01uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| CE-00-EK89_1uM | Dose=1uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| EC-08-KS82_1uM | Dose=1uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C |
| PA-75-VL17_0.1uM | Dose=0.1uM |
| BD-78-MJ16_0.01uM | Dose=0.01uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| EE-83-WF69_1uM | Dose=1uM, Nvp-dpp728, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| PE-82-OK78_0.1uM | Dose=0.1uM, 1-Cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine targeting SIGMAR1, TMEM97 |
| S0-EE-WHDK_10uM | Dose=10uM, 2-(6-aminopurin-9-yl)-N-[(4-sulfamoylphenyl)methyl]acetamide targeting CA2, CA9 |
| AF-12-IW93_1uM | Dose=1uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| GF-93-DV47_10uM | Dose=10uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1 |
| AE-74-SQ33_10uM | Dose=10uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| CF-22-IS33_0.01uM | Dose=0.01uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL |
| RA-02-OJ95_0.1uM | Dose=0.1uM, (3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol, Methylthioadenosine Phosphorylase (MTAP) Inhibitors targeting MTAP |
| DB-07-WB29_0.1uM | Dose=0.1uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| HF-01-QN73_10uM | Dose=10uM, 1-Isopropyl-1h-1,2,3-benzotriazole-5-carboxylic acid, GPR109B agonist;HM74) Receptor Agonists;GPR109B;Nicotinic Acid (Niacin targeting HCAR3 |
| AC-20-SO29_1uM | Dose=1uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| WA-03-KC95_0.01uM | Dose=0.01uM, (2,6-Dimethylpyridin-4-yl)methyl tert-butylcarbamate, Leptin Receptor (OBR) Agonists targeting LEPR |
| UB-21-MV06_0.1uM | Dose=0.1uM, 7-amino-6-(1H-benzo[d]imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-5(4H)-one, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| NC-35-BF58_0.1uM | Dose=0.1uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
| RD-90-OY66_0.1uM | Dose=0.1uM, Benzeneacetamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-(((2-hydroxy-1-(hydroxymethyl)ethyl)amino)methyl)-, CDK4 Inhibitors;CDK1 Inhibitors;CDK2/Cyclin E Inhibitors targeting CCNE1, CDK1, CDK2, CDK4, CCNE2 |
| FA-10-SN61_1uM | Dose=1uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN |
| NC-76-YX69_0.01uM | Dose=0.01uM, 2-Amino-4-methylbenzothiazole |
| HC-40-TX80_10uM | Dose=10uM, N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| ID-07-YY69_0.01uM | Dose=0.01uM, 2-{[2-amino-5-cyano-6-(methylsulfanyl)pyrimidin-4-yl]sulfanyl}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| FE-68-DZ79_0.01uM | Dose=0.01uM, N-benzylaminosulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| DD-48-MZ39_0.01uM | Dose=0.01uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid |
| FA-91-OA82_1uM | Dose=1uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7 |
| AC-37-OZ52_0.01uM | Dose=0.01uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| JD-90-SN16_10uM | Dose=10uM, 3-(2-Chloro-7-methoxyacridin-9-yl)sulfanylpropan-1-amine |
| BB-14-KA05_0.01uM | Dose=0.01uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
| LA-99-FV41_0.1uM | Dose=0.1uM, Dabigatran, Known Thrombin inhibitor targeting F2 |
| GD-33-XB49_10uM | Dose=10uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| LA-96-VT14_0.01uM | Dose=0.01uM |
| DE-30-EA70_0.1uM | Dose=0.1uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1 |
| HF-33-KS15_0.1uM | Dose=0.1uM, l-Menthol, TRPM8 (TRP-p8;CMR1) Agonists targeting TRPM8 |
| EA-40-KQ08_0.01uM | Dose=0.01uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| VA-15-ZR21_0.1uM | Dose=0.1uM |
| IF-08-GY16_10uM | Dose=10uM, (1E)-1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-1-hepten-3-one, IL-1 Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Tyrosinase Inhibitors;TNF-alpha Production Inhibitors;Antioxidants targeting NOS2, TYR |
| GA-51-DD14_0.1uM | Dose=0.1uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| EF-75-CQ05_0.1uM | Dose=0.1uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5 |
| FD-05-QX72_1uM | Dose=1uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11 |
| FC-71-PK06_1uM | Dose=1uM, 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1A, CACNA1B, CACNA1C, CACNA1S |
| AB-09-PR28_10uM | Dose=10uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE |
| AA-07-FZ97_10uM | Dose=10uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1 |
| BE-28-QT65_0.01uM | Dose=0.01uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| FC-64-QJ96_1uM | Dose=1uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AD-11-HV98_0.01uM | Dose=0.01uM, Balicatib, Cathepsin K Inhibitors targeting CTSK |
| PA-70-ZC89_1uM | Dose=1uM |
| AA-10-BH32_0.1uM | Dose=0.1uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP |
| RD-79-FH72_1uM | Dose=1uM, 4-(4-Chlorophenyl)-2-[(5-nitrofuran-2-carbonyl)amino]thiophene-3-carboxylic acid |
| IE-34-IW27_0.01uM | Dose=0.01uM, 3-((4-(Trifluoromethyl)Phenyl)Amino)Benzoic Acid, AKR1C3 inhibitor targeting AKR1C3 |
| SE-76-JI27_0.01uM | Dose=0.01uM, Pyridine-2-carboxylic acid {(S)-3-[(3,5-bis-trifluoromethyl-benzoyl)-methyl-amino]-4-phenyl-butyl}-amide, Orexin OX-2 Antagonists targeting HCRTR2 |
| AA-40-IA00_10uM | Dose=10uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1 |
| CD-13-QZ32_0.01uM | Dose=0.01uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| UF-44-NQ36_0.01uM | Dose=0.01uM, Argipressin tannate, AVPR1A agonist targeting AVPR1A |
| GA-51-DD14_0.01uM | Dose=0.01uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| YF-47-HO48_10uM | Dose=10uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC |
| LC-96-WR85_10uM | Dose=10uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17 |
| BA-15-VE07_10uM | Dose=10uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| JC-24-MC69_1uM | Dose=1uM, [4-(4-Phenylphenyl)-1-triazolyl]-(1-pyrrolidinyl)methanone, Acylaminoacyl peptidase inhibitor targeting APEH |
| AB-10-RE65_0.1uM | Dose=0.1uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AE-62-QI94_0.01uM | Dose=0.01uM, Zankiren, Renin Inhibitors targeting REN |
| EC-42-WE14_0.1uM | Dose=0.1uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2 |
| BD-27-CC87_0.01uM | Dose=0.01uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13 |
| RA-23-IX31_1uM | Dose=1uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1 |
| GD-41-HR28_0.01uM | Dose=0.01uM |
| BD-41-DB55_1uM | Dose=1uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3 |
| XB-75-YN01_0.01uM | Dose=0.01uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV |
| GC-08-VP20_1uM | Dose=1uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| AC-17-PC87_0.1uM | Dose=0.1uM, Chk2 Inhibitor II targeting CHEK2 |
| IA-65-QX27_0.1uM | Dose=0.1uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A |
| CA-48-JF51_0.01uM | Dose=0.01uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| TD-35-IE25_0.1uM | Dose=0.1uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP |
| CB-83-ZW70_1uM | Dose=1uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| BE-51-JY70_10uM | Dose=10uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK |
| HC-49-RF93_0.01uM | Dose=0.01uM |
| EE-98-PF86_1uM | Dose=1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| AB-86-XY72_1uM | Dose=1uM |
| AA-07-FZ97_1uM | Dose=1uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1 |
| AD-65-WK61_1uM | Dose=1uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P |
| ZB-28-SS80_10uM | Dose=10uM, (3-Cyano-4-{3-[(5-methyl-furan-2-ylmethyl)-sulfamoyl]-5-trifluoromethyl-phenyl}-pyrrol-1-yl)-acetic acid, GPR44 antagonist targeting PTGDR2 |
| EC-18-TF61_0.1uM | Dose=0.1uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1 |
| DE-57-XI06_0.1uM | Dose=0.1uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2 |
| ZB-09-RC84_0.1uM | Dose=0.1uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| IE-80-DC24_0.1uM | Dose=0.1uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide |
| KC-35-MF93_0.1uM | Dose=0.1uM |
| GF-73-HI61_0.1uM | Dose=0.1uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| HC-97-OH18_10uM | Dose=10uM, 1,3,5-Triazine, 2-isopropylamino-4,6-di(phenylamino)-, KCNH voltage-gated potassium channel-3 inhibitor targeting KCNH3 |
| CC-58-DF11_10uM | Dose=10uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5 |
| BF-96-PY22_0.1uM | Dose=0.1uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| LC-05-JF28_1uM | Dose=1uM, Obelin, Somatostatin SRIF2A (sst1) Antagonists targeting SSTR1 |
| JE-59-EI25_10uM | Dose=10uM, 2-Hydroxycarbazole-3-carboxylic acid 4-chloroanilide, Carboxylesterase Inhibitors targeting CES2 |
| AD-42-OW73_0.1uM | Dose=0.1uM, SB 415286 targeting GSK3A, GSK3B |
| LC-96-WR85_0.01uM | Dose=0.01uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17 |
| CB-84-FA85_0.1uM | Dose=0.1uM |
| AC-10-PK69_1uM | Dose=1uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AA-62-HP31_0.01uM | Dose=0.01uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| NE-55-KI60_10uM | Dose=10uM, Matrix Metalloproteinase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AE-95-ZK81_0.1uM | Dose=0.1uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3 |
| IF-45-JC86_10uM | Dose=10uM, 1-Piperazinylpyrazine |
| FE-95-PU35_0.01uM | Dose=0.01uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| BB-52-UP66_1uM | Dose=1uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| EA-98-NW07_0.1uM | Dose=0.1uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3 |
| OD-28-MX63_10uM | Dose=10uM, N-methyl-2-(1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine, HTR2C antagonist targeting HTR2C |
| KD-04-TL80_1uM | Dose=1uM |
| CD-59-PT17_10uM | Dose=10uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1 |
| AC-67-ZF49_1uM | Dose=1uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A |
| QB-72-LM87_0.01uM | Dose=0.01uM, NMDA Glycine B Receptor Antagonists targeting GRIN1 |
| KB-77-BA46_0.1uM | Dose=0.1uM, 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide, p38 MAPK Inhibitors targeting MAPK14 |
| DB-87-WL13_10uM | Dose=10uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| CA-90-TK74_1uM | Dose=1uM, Binds to hemoglobin, increases oxygen affinity thereby reducing sickling of cells |
| CE-72-SF92_1uM | Dose=1uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| AF-23-HJ84_0.1uM | Dose=0.1uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5 |
| IF-31-BQ95_0.01uM | Dose=0.01uM, Calcium-Sensing Receptor Antagonists I, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| BC-10-SB73_1uM | Dose=1uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14 |
| HB-90-QG69_10uM | Dose=10uM, Rucaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors;DNA Repair Inhibitors targeting PARP1, PARP2 |
| GB-16-SU72_1uM | Dose=1uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| NE-37-JX51_10uM | Dose=10uM |
| ZA-28-BF44_1uM | Dose=1uM, Amg-458, HGFR (MET;c-Met) Inhibitors targeting MET |
| IA-97-VE31_0.1uM | Dose=0.1uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-7-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| BD-85-GY20_0.1uM | Dose=0.1uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| AD-45-YB25_0.1uM | Dose=0.1uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A |
| UD-85-WR81_0.01uM | Dose=0.01uM, Gardiquimod |
| DD-01-VE87_0.01uM | Dose=0.01uM |
| CD-16-KY17_10uM | Dose=10uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| ZC-47-HL31_0.1uM | Dose=0.1uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1 |
| EB-82-QI99_0.1uM | Dose=0.1uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| BB-43-YQ76_10uM | Dose=10uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| WD-65-PA90_1uM | Dose=1uM, Lafutidine, Histamine H2 Receptor Antagonists targeting HRH2 |
| JA-52-PL41_0.01uM | Dose=0.01uM, [4-Chloro-3-(5-chloro-benzothiazol-2-yl)-phenyl]-carbamic acid prop-2-ynyl ester, Lysophosphatidic Acid-Acyltransferase beta (LPAAT-beta) Inhibitors targeting AGPAT2 |
| GE-97-UL88_1uM | Dose=1uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide |
| UF-43-HT41_0.01uM | Dose=0.01uM, (S)-3,4-Dcpg, mgluR8 Agonists targeting GRM8 |
| BE-59-WG31_0.01uM | Dose=0.01uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| ND-27-UQ99_1uM | Dose=1uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2 |
| BF-04-NQ13_10uM | Dose=10uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester |
| RA-60-MZ29_1uM | Dose=1uM, KDM5A pan Inhibitor targeting KDM5A |
| BE-70-YH17_0.1uM | Dose=0.1uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| AD-20-KA75_10uM | Dose=10uM, 1H-1,4-Diazepine, hexahydro-1-((5-iodo-1-naphthalenyl)sulfonyl)-, Myosin Light Chain Kinase (MLCK) Inhibitors targeting MYLK, MYLK2, MYLK3, MYLK4 |
| AB-10-RE65_0.01uM | Dose=0.01uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| FE-73-PS05_10uM | Dose=10uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1 |
| JC-05-CC41_0.01uM | Dose=0.01uM, 3-{(R)-3-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic acid |
| BC-84-BQ58_10uM | Dose=10uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1 |
| FB-49-NW04_0.01uM | Dose=0.01uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3 |
| MB-32-LQ97_1uM | Dose=1uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1 |
| VC-30-QH05_0.01uM | Dose=0.01uM, Zucapsaicin, TRPV1 (Vanilloid VR1 Receptor) Agonists targeting TRPV1 |
| CA-31-EL19_0.01uM | Dose=0.01uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM |
| IA-00-RJ06_1uM | Dose=1uM, N-(3-methylphenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CF-53-GP28_10uM | Dose=10uM, Retinol, 1 Epidermal transglutaminase inhibitor targeting TGM1 |
| AF-71-GL94_1uM | Dose=1uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide |
| EE-77-XO60_0.1uM | Dose=0.1uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol |
| GF-46-LK68_0.01uM | Dose=0.01uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2 |
| OD-39-RY38_10uM | Dose=10uM, (1z)-1-(3-Ethyl-5-Hydroxy-1,3-Benzothiazol-2(3h)-Ylidene)propan-2-One |
| CB-83-SC82_1uM | Dose=1uM |
| IE-47-KU59_0.01uM | Dose=0.01uM, Icerguastat, sustains UPR targeting PPP1R15A |
| QD-57-GT11_0.01uM | Dose=0.01uM |
| AC-99-ZN13_1uM | Dose=1uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| BD-78-MJ16_10uM | Dose=10uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| CB-69-DJ58_10uM | Dose=10uM, Midafotel, NMDA Antagonists targeting GRIN1 |
| SE-21-NB93_1uM | Dose=1uM, Stiripentol, GABA Reuptake Inhibitors;GABA Aminotransferase Inhibitors targeting ABAT |
| AC-93-QD45_10uM | Dose=10uM, targeting CGAS |
| HE-34-ZC14_0.01uM | Dose=0.01uM |
| QB-87-TC65_0.1uM | Dose=0.1uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1 |
| AF-06-ME04_0.01uM | Dose=0.01uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR |
| BD-32-GI59_1uM | Dose=1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D |
| WC-23-DZ10_10uM | Dose=10uM, 7-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine, Histamine H1 Receptor Ligands;Histamine H4 Receptor Agonists targeting HRH1, HRH4 |
| EF-33-QP63_10uM | Dose=10uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| FE-95-PU35_1uM | Dose=1uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| YE-01-JU83_10uM | Dose=10uM, N-p-Tolyl-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| DF-46-QE34_10uM | Dose=10uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1 |
| PA-39-SH87_0.1uM | Dose=0.1uM, 2-[6-[(Quinolin-2-yl)methoxy]naphthalen-2-yl]propanoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs;Leukotriene Antagonists targeting ALOX5 |
| LC-62-AU42_0.1uM | Dose=0.1uM |
| BD-07-IW65_10uM | Dose=10uM |
| BF-59-OR93_0.01uM | Dose=0.01uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| GD-90-RA90_0.01uM | Dose=0.01uM, SIS3 free base targeting SMAD3 |
| AB-16-HE44_0.1uM | Dose=0.1uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| CA-26-UY62_0.1uM | Dose=0.1uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BA-72-YP01_1uM | Dose=1uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1 |
| AF-16-GB72_0.01uM | Dose=0.01uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3 |
| SB-16-SI72_0.1uM | Dose=0.1uM, 8-pCPT-2'-O-Me-cAMP, PDE2A Inhibitor;RAPGEF3 activator;Activator of Epac targeting RAPGEF3, PDE2A |
| AB-86-GB42_10uM | Dose=10uM, 3-(3-(2-(4-Fluorophenyl)pyridin-4-yl)imidazo[1,2-a]pyridin-7-yl)-N-methylbenzamide, ALK5 inhibitor targeting TGFBR1 |
| FE-16-UK58_10uM | Dose=10uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| CB-29-KG96_1uM | Dose=1uM |
| HC-26-PX74_0.01uM | Dose=0.01uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid |
| IB-30-KN41_1uM | Dose=1uM, ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, Known Thrombin inhibitor targeting F2 |
| KC-10-GC29_0.01uM | Dose=0.01uM, Apoptosis Inducers;Antioxidants;Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| FA-45-PN48_10uM | Dose=10uM |
| CB-24-FA25_0.1uM | Dose=0.1uM, Spiperone |
| PD-14-WO27_10uM | Dose=10uM |
| DF-32-MM89_1uM | Dose=1uM, Dihydropyrimidine Dehydrogenase Inhibitors targeting DPYD |
| AB-63-HD20_0.1uM | Dose=0.1uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| GE-77-IH08_0.01uM | Dose=0.01uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| CA-07-KS70_1uM | Dose=1uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1 |
| AB-17-ZZ77_10uM | Dose=10uM, Estradiol Valerate |
| JB-81-XD04_1uM | Dose=1uM, N-Benzylphenethylamine targeting FARS2 |
| AE-94-ZD47_1uM | Dose=1uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| JC-64-QI43_0.1uM | Dose=0.1uM, 4-Bromo-2,6-diisopropylphenol, Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.4 (SkM1) Sodium Channel Blockers targeting SCN2A, SCN4A |
| IB-92-XA34_10uM | Dose=10uM, 3-Methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine, Anxiolytics targeting GABRA1 |
| CE-69-HJ13_10uM | Dose=10uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| AA-56-QO38_1uM | Dose=1uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| DB-47-EV77_0.1uM | Dose=0.1uM, Rofecoxib targeting SC5D |
| QE-98-XD90_0.1uM | Dose=0.1uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine |
| PC-63-CH43_0.1uM | Dose=0.1uM, 1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide, PARG inhibitor targeting PARG |
| IA-27-CK10_1uM | Dose=1uM, Sch 28080, Reversible H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| TD-35-IE25_0.01uM | Dose=0.01uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP |
| GD-63-XB79_1uM | Dose=1uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| HD-36-DK23_0.01uM | Dose=0.01uM, N-[1-[[5-[(4-acetylpiperazin-1-yl)methyl]-4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-4-fluorobenzamide |
| EE-99-ZM45_10uM | Dose=10uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H |
| JC-02-ZR15_0.01uM | Dose=0.01uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2 |
| BA-92-YC70_1uM | Dose=1uM, Temozolomide |
| IE-47-KU59_1uM | Dose=1uM, Icerguastat, sustains UPR targeting PPP1R15A |
| DE-65-KO26_0.1uM | Dose=0.1uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG |
| JC-86-PD41_0.01uM | Dose=0.01uM, CID 58580621, angiotensin I converting enzyme 2 inhibitor targeting ACE2 |
| FA-90-DR66_0.01uM | Dose=0.01uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| BB-47-YI31_1uM | Dose=1uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| FC-55-IG96_10uM | Dose=10uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6 |
| JF-39-BZ76_0.01uM | Dose=0.01uM, Vs-4718, FAK inhibitor targeting PTK2 |
| HE-84-RW47_10uM | Dose=10uM, Cytosporone B, NR4A1 gene stimulator targeting NR4A1 |
| ZC-09-IW47_1uM | Dose=1uM, 7-(2,2-Dimethylpropyl)-6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile |
| GB-01-UN23_0.01uM | Dose=0.01uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| BA-65-YU25_0.1uM | Dose=0.1uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| SC-59-TX35_10uM | Dose=10uM |
| PD-74-GP60_0.01uM | Dose=0.01uM, 2-[3-[2-Chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecan-9-yl]acetic acid, GPR120 agonist targeting FFAR4 |
| CB-69-DJ58_0.01uM | Dose=0.01uM, Midafotel, NMDA Antagonists targeting GRIN1 |
| ME-14-LE68_10uM | Dose=10uM, 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Tyrosine Kinase Inhibitors targeting FYN |
| AD-24-KU93_0.01uM | Dose=0.01uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone |
| ZF-00-MX33_1uM | Dose=1uM |
| GC-86-TD91_0.01uM | Dose=0.01uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| CC-51-KS26_0.01uM | Dose=0.01uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B |
| FD-20-DQ38_10uM | Dose=10uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| GD-71-OU80_0.1uM | Dose=0.1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| IB-26-FG03_0.01uM | Dose=0.01uM, 3-(2-amino-2-methylpropyl)-1H-indol-5-ol |
| VF-49-KA00_1uM | Dose=1uM, 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde, ERN1 gene inhibitor targeting ERN1 |
| JA-52-PL41_0.1uM | Dose=0.1uM, [4-Chloro-3-(5-chloro-benzothiazol-2-yl)-phenyl]-carbamic acid prop-2-ynyl ester, Lysophosphatidic Acid-Acyltransferase beta (LPAAT-beta) Inhibitors targeting AGPAT2 |
| ZB-92-PL24_0.1uM | Dose=0.1uM, Palonosetron, 5-HT3 Antagonists targeting HTR3A |
| KD-86-AJ75_0.1uM | Dose=0.1uM, 2-((10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)methyl)-N,5-dimethylbenzenesulfonamide, Glucocorticoid Receptor (GR) Antagonists;Mineralocorticoid Receptor (MR) Antagonists targeting NR3C1, NR3C2 |
| IF-92-OK68_1uM | Dose=1uM, Ethyl 4-(methylamino)-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3 |
| FE-23-WP33_1uM | Dose=1uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1 |
| AA-98-MW52_10uM | Dose=10uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2 |
| AC-82-PZ00_0.1uM | Dose=0.1uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C |
| FB-91-BU05_0.1uM | Dose=0.1uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| CF-56-LO98_0.1uM | Dose=0.1uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| GC-07-KH68_10uM | Dose=10uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| FC-88-AJ86_10uM | Dose=10uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one |
| YB-30-EK42_0.1uM | Dose=0.1uM |
| CC-46-CE74_1uM | Dose=1uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4 |
| IA-67-CK10_0.1uM | Dose=0.1uM, 1-Amino-4-m-anisidino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid |
| EA-25-VD74_1uM | Dose=1uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| AE-97-TS20_1uM | Dose=1uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| ND-20-AS37_0.01uM | Dose=0.01uM, 4-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| LA-44-KW22_0.01uM | Dose=0.01uM, targeting GSK3B |
| DA-10-GX45_0.01uM | Dose=0.01uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AC-14-FX35_0.01uM | Dose=0.01uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2 |
| AD-10-TH32_0.1uM | Dose=0.1uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1 |
| CD-08-MF16_0.1uM | Dose=0.1uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1 |
| JF-91-IG96_1uM | Dose=1uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one |
| IB-67-WH43_0.01uM | Dose=0.01uM, 4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid, mgluR1 Antagonists targeting GRM1 |
| BE-82-TS38_1uM | Dose=1uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| JB-09-SI50_0.1uM | Dose=0.1uM, 3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCG |
| BE-29-HA72_1uM | Dose=1uM, Ifosfamide |
| AC-53-YM36_0.1uM | Dose=0.1uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK |
| JB-72-IH66_0.01uM | Dose=0.01uM, CID 49843509, Proteinase activated receptor 2 (PAR2) partial agonist targeting F2RL1 |
| KD-86-AJ75_10uM | Dose=10uM, 2-((10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)methyl)-N,5-dimethylbenzenesulfonamide, Glucocorticoid Receptor (GR) Antagonists;Mineralocorticoid Receptor (MR) Antagonists targeting NR3C1, NR3C2 |
| RD-37-PW33_0.1uM | Dose=0.1uM, BAX activator targeting BAX |
| CC-56-MO03_10uM | Dose=10uM, 4-(1H-indol-3-yl)pyrimidin-2-amine |
| HA-99-PM50_0.01uM | Dose=0.01uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| DA-91-NR73_10uM | Dose=10uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester |
| SB-80-CR34_0.1uM | Dose=0.1uM |
| XD-71-WI50_1uM | Dose=1uM |
| AC-91-AV48_0.1uM | Dose=0.1uM |
| WA-90-HU51_10uM | Dose=10uM, 4-oxo-2-pentyl-1H-quinoline-3-carboxylic acid, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| AC-05-MR83_0.1uM | Dose=0.1uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| AE-15-HA32_10uM | Dose=10uM, (3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile |
| AC-31-SL44_1uM | Dose=1uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B |
| IE-75-ZC91_1uM | Dose=1uM, 7-Hydroxyflavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1 |
| IA-80-OW42_0.01uM | Dose=0.01uM, N-(3-Ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline, Cathepsin B Inhibitors targeting CTSB |
| CE-17-FI51_0.01uM | Dose=0.01uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP |
| CF-55-OA12_1uM | Dose=1uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| YA-85-VH07_0.01uM | Dose=0.01uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1 |
| FB-32-PY27_0.1uM | Dose=0.1uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4 |
| BA-29-OX17_1uM | Dose=1uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| GB-16-NN30_10uM | Dose=10uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2 |
| BC-53-HT63_0.1uM | Dose=0.1uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| S0-EE-Y97N_0.1uM | Dose=0.1uM, 4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, ALK2 inhibitor targeting TGFBR2 |
| AA-27-LG62_0.1uM | Dose=0.1uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG |
| JA-82-EV20_1uM | Dose=1uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1 |
| GF-05-GQ05_0.1uM | Dose=0.1uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1 |
| DA-76-NE84_10uM | Dose=10uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| KC-71-KK26_0.01uM | Dose=0.01uM, Gabazine free base, GABA(A) Receptor Antagonists targeting GABRA1, GABRB3, GABRG2 |
| NB-37-LA11_0.1uM | Dose=0.1uM, PLAUR gene inhibitor targeting PLAUR |
| CB-68-SP90_0.01uM | Dose=0.01uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| KB-17-DU74_0.1uM | Dose=0.1uM, SR8278, REV-ERB anatagonist targeting NR1D1 |
| AA-70-DH87_0.01uM | Dose=0.01uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B |
| MB-78-HH35_10uM | Dose=10uM, (2E)-2-[[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]-3-(2-nitrophenyl)propanoic acid, eiF4F complex assembly inhibitor;EIF4E-EIF6G interaction inhibitor targeting EIF4E, EIF4G1 |
| DE-15-GD59_10uM | Dose=10uM |
| GF-37-MB64_0.01uM | Dose=0.01uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| JE-22-JR20_0.01uM | Dose=0.01uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1 |
| PD-14-WO27_1uM | Dose=1uM |
| CA-26-UY62_10uM | Dose=10uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| XB-35-TO54_0.01uM | Dose=0.01uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4 |
| GD-17-GR17_1uM | Dose=1uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| S0-EE-XFDA_10uM | Dose=10uM, Unii-4P8laf78C2, ClC-7 Channel Blockers;Bone Resorption Inhibitors targeting CLCN7 |
| LD-50-SF36_0.1uM | Dose=0.1uM, Ro64-5229, GRM2 antagonist targeting GRM2 |
| CA-17-XB39_0.1uM | Dose=0.1uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3 |
| HE-43-BS90_0.1uM | Dose=0.1uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| HF-35-HT37_1uM | Dose=1uM |
| CB-05-AU50_1uM | Dose=1uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1 |
| DA-33-CX68_1uM | Dose=1uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B |
| KC-07-HN67_0.1uM | Dose=0.1uM, Ormetoprim, P2X2/3 Receptor Antagonists;P2X3 Receptor Antagonists targeting P2RX3 |
| UF-27-HS98_0.01uM | Dose=0.01uM, Toyocamycin targeting ADK |
| YF-46-CA32_0.1uM | Dose=0.1uM |
| UC-80-UO92_0.01uM | Dose=0.01uM, Momipp, Methuosis inducer targeting PIKFYVE, PIP5K1C |
| GD-90-RA90_0.1uM | Dose=0.1uM, SIS3 free base targeting SMAD3 |
| EE-16-RH01_1uM | Dose=1uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3 |
| AB-16-HE44_1uM | Dose=1uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| CE-40-VU73_0.1uM | Dose=0.1uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| AF-11-IL39_0.01uM | Dose=0.01uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2 |
| AC-91-AV48_1uM | Dose=1uM |
| AD-11-VE17_0.1uM | Dose=0.1uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5 |
| BD-06-VI74_0.1uM | Dose=0.1uM, Bezafibrate, PPARgamma Agonists;PPARalpha Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;PPARdelta Agonists;HSD11B1 Expression Inhibitors targeting HSD11B1, PPARA, PPARD, PPARG |
| FD-86-NE74_0.01uM | Dose=0.01uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300 |
| GE-40-GQ38_0.1uM | Dose=0.1uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| QB-99-OU03_0.1uM | Dose=0.1uM, 2-(s)Cyano-1-isoleucylpyrrolidine, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| ID-07-YY69_1uM | Dose=1uM, 2-{[2-amino-5-cyano-6-(methylsulfanyl)pyrimidin-4-yl]sulfanyl}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| CF-56-LO98_1uM | Dose=1uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| CF-81-DS26_0.01uM | Dose=0.01uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C |
| CB-31-UO16_0.1uM | Dose=0.1uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1 |
| NC-52-AG88_0.01uM | Dose=0.01uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1 |
| HE-34-ZC14_1uM | Dose=1uM |
| CF-15-FD69_0.01uM | Dose=0.01uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12 |
| WC-89-JT40_10uM | Dose=10uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10 |
| S0-EE-XYMJ_10uM | Dose=10uM, Gsk1331268, mgluR2 Positive Allosteric Modulator;postive allosteric modulator targeting GRM2 |
| EE-23-MF14_0.1uM | Dose=0.1uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| BA-50-HH67_0.01uM | Dose=0.01uM, Tomatidine |
| AA-94-OG89_10uM | Dose=10uM, Detrothyronine targeting THRA |
| AA-35-LB45_0.01uM | Dose=0.01uM, Amoxapine, 5-HT Reuptake Inhibitors;5-HT2A Antagonists;Norepinephrine Reuptake Inhibitors targeting HTR2A, SLC6A2, SLC6A4 |
| DB-42-FS68_1uM | Dose=1uM, Valspodar |
| FF-76-LK08_1uM | Dose=1uM |
| GD-63-XB79_0.1uM | Dose=0.1uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| QA-27-XW03_1uM | Dose=1uM, 1-[2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl]ethanone |
| PC-49-XP02_0.1uM | Dose=0.1uM |
| CB-12-BV05_1uM | Dose=1uM |
| CF-03-QN99_10uM | Dose=10uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8 |
| CF-92-QS83_0.01uM | Dose=0.01uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3 |
| BD-66-QO48_0.1uM | Dose=0.1uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12 |
| AD-72-RI24_0.1uM | Dose=0.1uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| AA-99-HG56_0.1uM | Dose=0.1uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3 |
| BB-75-UH54_1uM | Dose=1uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2 |
| AD-55-EA62_10uM | Dose=10uM, D-AP4 |
| CD-63-FZ67_1uM | Dose=1uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| ED-39-VX22_10uM | Dose=10uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| AA-50-HR61_10uM | Dose=10uM, Rifampin, RNA Polymerase (Bacterial) Inhibitors;Enzyme Inducers;DNA-Directed RNA Polymerase Inhibitors targeting NR1I2, SLCO1B1, POLRMT |
| RA-23-IX31_10uM | Dose=10uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1 |
| GB-62-IH36_10uM | Dose=10uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B |
| AA-10-BH32_0.01uM | Dose=0.01uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP |
| HC-15-LT47_10uM | Dose=10uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| AF-13-LM61_0.1uM | Dose=0.1uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B |
| EA-00-QR36_0.1uM | Dose=0.1uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A |
| TA-21-GI75_10uM | Dose=10uM, 2-[[5-(2,6-Dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid, NTSR1 antagonist;NTSR2 antagonist;Neurotensin Antagonists targeting NTSR1, NTSR2 |
| MF-11-EW49_1uM | Dose=1uM, Biochanin A, PPARgamma Agonists;Androgen Receptor Antagonists;Steroid 5alpha-Reductase Inhibitors;PPARalpha Agonists targeting AR, PPARA, PPARG, SRD5A1, SRD5A2 |
| OB-41-EW79_0.01uM | Dose=0.01uM, Liranaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE |
| PE-69-DO79_0.01uM | Dose=0.01uM, N-phenylaminosulfonamide, carbonic anhydrase inhibitor targeting CA1 |
| BB-75-UH54_10uM | Dose=10uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2 |
| CC-07-DV77_10uM | Dose=10uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A |
| CA-26-BI29_0.1uM | Dose=0.1uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR |
| TA-36-PC58_0.01uM | Dose=0.01uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5 |
| FE-23-WP33_0.1uM | Dose=0.1uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1 |
| CA-68-KG29_0.01uM | Dose=0.01uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| FD-69-CC31_0.1uM | Dose=0.1uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| EE-45-YQ15_0.01uM | Dose=0.01uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7 |
| HC-86-IA49_1uM | Dose=1uM |
| DA-67-HS65_0.01uM | Dose=0.01uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2 |
| AD-18-VX25_0.1uM | Dose=0.1uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18 |
| RC-21-IF98_0.1uM | Dose=0.1uM |
| YB-80-KQ31_0.1uM | Dose=0.1uM, CD80 (B7-1) Inhibitors targeting CD80, CD28 |
| GF-67-HH28_0.1uM | Dose=0.1uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| FC-13-VS25_10uM | Dose=10uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| SB-28-EJ14_0.01uM | Dose=0.01uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2 |
| FA-70-ZG69_0.01uM | Dose=0.01uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| KC-96-UA29_0.1uM | Dose=0.1uM, 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol, ADRB3 agonist targeting ADRB3 |
| YB-80-KQ31_1uM | Dose=1uM, CD80 (B7-1) Inhibitors targeting CD80, CD28 |
| KE-30-PJ81_0.01uM | Dose=0.01uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| JF-16-BD66_0.01uM | Dose=0.01uM, Gsk-690693, PKB gamma/Akt3 Inhibitors;Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors targeting AKT1, AKT2, DAPK3, PRKG1, PRKX, AKT3, PAK6 |
| AC-53-HJ29_0.01uM | Dose=0.01uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6 |
| EB-07-JB09_10uM | Dose=10uM |
| AD-26-SL71_10uM | Dose=10uM, 6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide, Adenosine A2A Agonists targeting ADORA2A |
| BE-33-IM71_1uM | Dose=1uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| QA-76-ZM47_1uM | Dose=1uM, N-(Carboxymethyl)-N-(3-Phenylpropyl)glycyl-N-Methyl-L-Histidinamide, IDE gene inhibitor targeting IDE |
| BC-06-CP81_10uM | Dose=10uM, Amitriptyline, 5-HT Reuptake Inhibitors;Nav1.4 (SkM1) Sodium Channel Blockers;Norepinephrine Reuptake Inhibitors targeting SCN4A |
| S0-EE-WNJ9_0.1uM | Dose=0.1uM, 2-N-methyl-6-[(1S)-1-phenylethyl]-4-N-(1H-pyrazol-4-yl)pyridine-2,4-dicarboxamide targeting BRD4 |
| HA-64-OZ89_0.01uM | Dose=0.01uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| EE-62-XB72_0.1uM | Dose=0.1uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1 |
| DE-09-HJ53_10uM | Dose=10uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| BB-39-YQ35_1uM | Dose=1uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| JE-63-IE01_1uM | Dose=1uM, Vercirnon, CCR9 chemokine antagonist targeting CCR9 |
| KD-50-WP70_1uM | Dose=1uM, N-(3,4-dichlorophenyl)guanidine, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| BE-45-UU35_10uM | Dose=10uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA |
| AC-76-BB02_0.01uM | Dose=0.01uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14 |
| CE-36-UR55_0.1uM | Dose=0.1uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| AB-46-GB72_0.1uM | Dose=0.1uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| AA-92-NW83_1uM | Dose=1uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| YB-31-TH67_10uM | Dose=10uM, Estradiol Acetate |
| DE-81-UE07_10uM | Dose=10uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| BE-07-XF09_1uM | Dose=1uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2 |
| FE-27-XB49_0.1uM | Dose=0.1uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP |
| DF-53-QT23_10uM | Dose=10uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9 |
| WB-92-TT14_0.1uM | Dose=0.1uM |
| DC-96-HY67_10uM | Dose=10uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1 |
| DC-43-KF54_0.01uM | Dose=0.01uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| AA-56-DV95_0.01uM | Dose=0.01uM |
| BA-97-CI76_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate |
| JC-05-CC41_1uM | Dose=1uM, 3-{(R)-3-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic acid |
| UC-00-QA88_0.1uM | Dose=0.1uM, 2-[4-(4-Amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]ethanol |
| LF-86-EA69_1uM | Dose=1uM, N-(3,5-dichlorophenyl)benzenesulfonamide, Dedicator of cytokenesis protein 5 inhibitor targeting DOCK5 |
| DA-88-JF21_0.01uM | Dose=0.01uM, FG-9041 targeting GRIA4 |
| DC-17-ZB19_0.01uM | Dose=0.01uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13 |
| AA-86-YY62_0.01uM | Dose=0.01uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12 |
| IC-05-WD74_0.01uM | Dose=0.01uM, N-[(2,6-dimethylphenyl)methyl]-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine, HRI Kinase inhibitor targeting EIF2AK1 |
| CF-01-BY15_10uM | Dose=10uM |
| EC-87-ZE76_1uM | Dose=1uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10 |
| DF-56-GR45_1uM | Dose=1uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| ME-47-KQ59_10uM | Dose=10uM, 4-(3-benzyl-4-{[5-(2-fluorophenyl)furan-2-yl]methylidene}-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid targeting BTRC |
| FA-65-UA27_0.01uM | Dose=0.01uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| BC-80-FK74_1uM | Dose=1uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| S0-EE-WIZB_0.1uM | Dose=0.1uM, Glpg-2451 targeting CFTR |
| HE-43-BS90_1uM | Dose=1uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| AC-98-QW77_1uM | Dose=1uM, CGC-11047 free base |
| CA-38-JF31_0.01uM | Dose=0.01uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8 |
| DD-64-ET45_10uM | Dose=10uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2 |
| IA-19-ET52_10uM | Dose=10uM, 2'-Deoxyadenosine |
| RE-99-TA30_10uM | Dose=10uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R |
| S0-EE-YAXR_0.01uM | Dose=0.01uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84 |
| AC-00-BR21_10uM | Dose=10uM |
| FA-16-KA99_1uM | Dose=1uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea |
| LC-57-RH78_0.1uM | Dose=0.1uM, K(ATP) Channel Blockers targeting ABCC8, ABCC9, KCNJ8, KCNJ11 |
| BA-28-JD87_0.01uM | Dose=0.01uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| BD-31-AE17_1uM | Dose=1uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1 |
| BE-15-IE57_1uM | Dose=1uM, 2-(Butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno(2,3-b)pyridin-3-amine, Prostaglandin-degrading enzyme 15-PGDH inhibitor;inhibitor of the prostaglandin-degrading enzyme 15-PGDH targeting HPGD |
| AF-28-FX20_1uM | Dose=1uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2 |
| KA-14-VZ39_1uM | Dose=1uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3 |
| PA-53-BA36_10uM | Dose=10uM, Wx-uk1 free base, Urokinase (u-PA) Inhibitors targeting PLAU, PLG |
| AB-11-MO96_0.01uM | Dose=0.01uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| QA-50-YO37_0.1uM | Dose=0.1uM, Semapimod, inhibits TNF-alpha - proposed NO inhibitor and/or p38 MAPK pathway; proposed to act via vagus nerve targeting DHPS |
| BA-40-KU28_10uM | Dose=10uM |
| KD-42-UK08_1uM | Dose=1uM, AZ11657312 (salt free), P2X7 Receptor Antagonists targeting P2RX7 |
| HD-29-PZ41_10uM | Dose=10uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one |
| WC-54-BJ14_1uM | Dose=1uM, Integrin-antagonist-1, ITGB6 antagonist targeting ITGA6, ITGB6 |
| CD-84-FJ21_0.1uM | Dose=0.1uM, Dpn 205-734 |
| AE-61-UO01_0.01uM | Dose=0.01uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| OB-44-HO47_0.01uM | Dose=0.01uM |
| DD-66-VY52_0.1uM | Dose=0.1uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3 |
| KF-73-PY04_0.01uM | Dose=0.01uM, Gsk 932121, P. falciparum Cytochrome b-c1 Complex (Complex III subunit 3) Inhibitors;Electron Transport Chain Inhibitors targeting UQCRC1 |
| FA-90-DR66_0.1uM | Dose=0.1uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AB-85-YK41_0.1uM | Dose=0.1uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME |
| TC-16-ZS56_10uM | Dose=10uM, Recilisib |
| EE-77-XO60_0.01uM | Dose=0.01uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol |
| EF-43-OP88_10uM | Dose=10uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD |
| JD-02-GA59_0.1uM | Dose=0.1uM |
| LD-69-TV81_0.01uM | Dose=0.01uM, 7-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| IC-99-JZ46_1uM | Dose=1uM, Lobeline, alpha4beta2 nicotinic acid receptor partial agonist;Dopamine Receptor Modulators targeting CHRNA4, CHRNB2, SLC18A2 |
| BC-88-KT45_10uM | Dose=10uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| HC-20-JJ81_0.01uM | Dose=0.01uM, 1-[[6-(2-Hydroxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| AB-82-ES53_10uM | Dose=10uM, Quercetin targeting SULT1A1 |
| CC-01-ER18_1uM | Dose=1uM, Pirodomast |
| SC-17-WW78_1uM | Dose=1uM, 2-[[4-(4-cyano-1-methylpiperidin-4-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile, MAP3K12 (DLK) Inhibitors targeting MAP3K12 |
| ZA-18-VC47_10uM | Dose=10uM, 2-[[4-(Cyclopropanecarbonyl)piperazin-1-yl]methyl]-1,2-benzothiazol-3-one targeting PDIA3, P4HB |
| GD-69-KC91_0.1uM | Dose=0.1uM, Bleomycin |
| UD-85-WR81_0.1uM | Dose=0.1uM, Gardiquimod |
| JB-37-OU59_1uM | Dose=1uM, GW766994, Chemokine CCR3 Antagonists targeting CXCR3 |
| MA-64-FB16_10uM | Dose=10uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-2-[4-(2-methyltetrazol-5-yl)phenyl]-N-[5-(trifluoromethyl)pyrazin-2-yl]acetamide |
| EA-02-ZO63_0.01uM | Dose=0.01uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3 |
| RA-18-CU16_1uM | Dose=1uM |
| BB-86-BE39_0.01uM | Dose=0.01uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| DB-67-IP73_0.1uM | Dose=0.1uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5 |
| AE-37-KS50_0.01uM | Dose=0.01uM, Cgp 52432 |
| DD-95-TY80_0.1uM | Dose=0.1uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| DC-39-CT52_0.01uM | Dose=0.01uM |
| ZE-37-PE19_0.01uM | Dose=0.01uM, 6,8-Dichloro-7-methoxy-9H-beta-carboline targeting CHUK |
| BD-46-RY02_0.1uM | Dose=0.1uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1 |
| CD-91-MI27_0.1uM | Dose=0.1uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7 |
| PC-18-VX23_0.01uM | Dose=0.01uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1 |
| AE-51-ZO26_0.1uM | Dose=0.1uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9 |
| EB-52-HZ20_0.01uM | Dose=0.01uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1 |
| XA-35-DA85_0.01uM | Dose=0.01uM |
| EE-49-CD29_1uM | Dose=1uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| EC-60-CX20_0.01uM | Dose=0.01uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A |
| BA-74-BQ33_0.01uM | Dose=0.01uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG |
| AD-28-GJ71_0.01uM | Dose=0.01uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A |
| FE-19-OW54_1uM | Dose=1uM, Fenofibric Acid |
| AA-35-VH74_1uM | Dose=1uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3 |
| EA-09-HM95_0.1uM | Dose=0.1uM |
| ED-11-KK36_1uM | Dose=1uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1 |
| VA-03-RM19_0.1uM | Dose=0.1uM, N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide, 5-hydroxytryptamine receptor 1F receptor agonist targeting HTR1F |
| CB-68-GZ09_1uM | Dose=1uM, SB-204741, HTR2B antagonist targeting HTR2B |
| AD-34-WD27_0.01uM | Dose=0.01uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT |
| BF-95-KA82_1uM | Dose=1uM, SOAT-1 inhibitor |
| AB-46-GB72_10uM | Dose=10uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| RD-57-WQ44_1uM | Dose=1uM, VU0650786, selective mGlu3 NAM targeting GRM3 |
| AE-69-CH29_10uM | Dose=10uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12 |
| UE-90-AA63_10uM | Dose=10uM |
| GD-07-XY44_1uM | Dose=1uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide |
| UC-21-PY73_1uM | Dose=1uM, Ro 46-2005, Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| KB-25-KP22_0.01uM | Dose=0.01uM, 4-(5,6-Dimethoxy-2-benzofuranyl)-piperidine, Serotonin Antagonists targeting HTR1A, MAOA, MAOB |
| HD-18-YL30_1uM | Dose=1uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1 |
| HF-25-LA47_0.1uM | Dose=0.1uM, Cathepsin inhibitor 1, Cathepsin L Inhibitors targeting CTSL, CTSV, CTSL3P |
| PB-66-RW16_0.1uM | Dose=0.1uM, PRMT6 gene inhibitor;PRMT6 inhibitor targeting PRMT6 |
| UE-99-BK94_10uM | Dose=10uM, 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, KCNK3 gene inhibitor targeting KCNK3 |
| FD-43-EF54_10uM | Dose=10uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1 |
| OC-56-RM62_10uM | Dose=10uM, ethyl 1-benzyl-4-(3,4-dimethoxyphenyl)-4H-quinoline-3-carboxylate targeting ABCB1 |
| TE-76-FI57_10uM | Dose=10uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2 |
| AA-31-NO26_0.01uM | Dose=0.01uM, Carbamazepine, Sodium Channel Blockers targeting SCN5A, SCN10A |
| EC-71-PH39_0.1uM | Dose=0.1uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1 |
| MD-92-LN15_0.01uM | Dose=0.01uM, 1-[(1s)-1-(4-Chloro-3-Fluorophenyl)-2-Hydroxyethyl]-4-[2-(Tetrahydro-2h-Pyran-4-Ylamino)pyrimidin-4-Yl]pyridin-2(1h)-One, ERK1/2 inhibitor targeting MAPK1, MAPK3 |
| FF-46-CU92_0.1uM | Dose=0.1uM |
| S0-EE-YNU4_0.1uM | Dose=0.1uM, (E)-4-(4-methyl-1H-indol-5-ylamino)-5-(2-(6-(morpholinomethyl)pyridin-2-yl)vinyl)nicotinonitrile, PKC theta inhibitor targeting PRKCQ |
| BC-26-LE04_10uM | Dose=10uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| FD-80-EG54_1uM | Dose=1uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| GE-01-QX17_0.01uM | Dose=0.01uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2 |
| NE-27-MD08_0.1uM | Dose=0.1uM, N-[1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide, Motilin Receptor Antagonist targeting MLNR |
| AB-21-CI37_0.1uM | Dose=0.1uM, Deferoxamine |
| WA-98-CM36_1uM | Dose=1uM, 5-chloro-N-(5-chloro-2-hydroxy-phenyl)-2-methoxy-benzamide, KCNMA1 gene stimulator;BKca channel opener targeting KCNMA1 |
| CB-45-VH79_0.1uM | Dose=0.1uM |
| OA-16-KC73_0.1uM | Dose=0.1uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1 |
| AD-66-NV75_10uM | Dose=10uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| BD-41-DI77_10uM | Dose=10uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A |
| OB-83-EA66_10uM | Dose=10uM, (S)-2-[((S)-3-Acetyl-thiazolidine-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGB1 |
| PD-31-RP17_0.01uM | Dose=0.01uM |
| BB-40-KK84_0.1uM | Dose=0.1uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2 |
| CD-44-XT40_0.1uM | Dose=0.1uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2 |
| NF-27-AQ24_0.1uM | Dose=0.1uM, GR 46611, HTR1D agonist targeting HTR1D |
| LE-65-RW44_0.01uM | Dose=0.01uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3 |
| CB-83-LF14_0.01uM | Dose=0.01uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| ND-54-FY31_1uM | Dose=1uM, 2-Nitrobenzenesulfonamide |
| GF-32-FY02_10uM | Dose=10uM |
| KA-52-MX24_1uM | Dose=1uM |
| SE-81-RI20_10uM | Dose=10uM |
| AE-64-KN26_1uM | Dose=1uM |
| AC-63-OM41_0.01uM | Dose=0.01uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| BE-82-TS38_0.01uM | Dose=0.01uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| DB-06-HE04_0.1uM | Dose=0.1uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF |
| UE-09-SD17_0.01uM | Dose=0.01uM |
| AE-71-CB15_1uM | Dose=1uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3 |
| FB-56-SR65_0.1uM | Dose=0.1uM, Arginine |
| EF-64-HJ41_1uM | Dose=1uM, LY 255283, LTB4R2 antagonist targeting LTB4R2 |
| HA-32-YH61_0.1uM | Dose=0.1uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP |
| BC-28-NG89_0.01uM | Dose=0.01uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists |
| AB-14-GQ48_0.01uM | Dose=0.01uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| WC-22-DS16_1uM | Dose=1uM, N-(1-phenylethyl)-3-tosylthieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine |
| HB-92-XE24_0.1uM | Dose=0.1uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| LB-24-KP05_0.1uM | Dose=0.1uM, Oxalylglycine, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| TC-69-EY43_0.01uM | Dose=0.01uM, PF-06761281 targeting SLC13A5 |
| BC-38-UW37_0.1uM | Dose=0.1uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH |
| MD-09-FE75_0.01uM | Dose=0.01uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2 |
| DE-14-EG14_1uM | Dose=1uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| AE-42-HT01_0.1uM | Dose=0.1uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| CE-36-HY42_0.01uM | Dose=0.01uM |
| BE-48-IT75_0.1uM | Dose=0.1uM |
| BC-09-XN48_0.1uM | Dose=0.1uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A |
| CE-04-PX35_10uM | Dose=10uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1 |
| EB-89-KM10_0.1uM | Dose=0.1uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| HA-36-VD41_0.01uM | Dose=0.01uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| LF-30-FP85_1uM | Dose=1uM, 2-Chloro-5-[3-(5-chloro-2-methoxy-pyridin-4-yl)-1h-indole-6-carbonyl]-benzenesulfonamide |
| JB-58-VY51_0.01uM | Dose=0.01uM, Thymidine, Thymidine kinase 1 ligand;Thymidine kinase 2 ligand targeting TK1, TYMP, TK2 |
| EA-69-VJ68_0.1uM | Dose=0.1uM |
| GD-69-GP37_0.1uM | Dose=0.1uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| S0-EE-XGII_10uM | Dose=10uM, 2-[2-[(4-carbamimidoylanilino)-(5-ethoxy-2-fluoro-3-propan-2-yloxyphenyl)methyl]-1H-imidazol-5-yl]benzamide, F7 gene inhibitor targeting F7 |
| LF-35-CP32_0.1uM | Dose=0.1uM, Adinazolam, Peripheral-type benzodiazepine receptors potentiator targeting TSPO |
| AB-41-IO16_10uM | Dose=10uM |
| CD-63-FZ67_0.01uM | Dose=0.01uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| ND-33-UV62_0.1uM | Dose=0.1uM, Tasquinimod, Histone Deacetylase 4 (HDAC4) Inhibitors;S100A9 Inhibitors targeting S100A9, HDAC4 |
| PC-74-OR34_0.01uM | Dose=0.01uM, CaV1.3 antagonist-1, CACNA1D calcium channel subunit inhibitor targeting CACNA1D |
| IC-98-UO17_0.01uM | Dose=0.01uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5 |
| BE-36-FY37_1uM | Dose=1uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| HA-27-FV67_1uM | Dose=1uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4 |
| IA-13-FI66_10uM | Dose=10uM, Way-213613, Excitatory amino acid transporter 2 inhibitor targeting SLC1A2 |
| IA-67-CK10_10uM | Dose=10uM, 1-Amino-4-m-anisidino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid |
| AC-71-VV28_1uM | Dose=1uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119 |
| LD-48-CY61_1uM | Dose=1uM, 4,6-Dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide, Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI2, ORAI1, ORAI3 |
| NC-01-ET52_0.01uM | Dose=0.01uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD |
| MC-82-RG58_1uM | Dose=1uM, (2E, 6E)-farnesylbisphosphonate, Squalene Synthase Inhibitors targeting FDFT1, GGPS1 |
| OE-78-XD40_0.01uM | Dose=0.01uM, (+)-Dibenzoyl-D-tartaric acid, Dopamine D3 Antagonists targeting DRD3 |
| AA-99-HG56_1uM | Dose=1uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3 |
| LD-36-DG33_10uM | Dose=10uM |
| AC-63-DM46_10uM | Dose=10uM |
| AD-20-AA40_10uM | Dose=10uM, Cdc2-like kinase inhibitor, CDC-like kinase-1 inhibitors targeting CLK1, CLK2, CLK4 |
| FD-37-GE41_0.01uM | Dose=0.01uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| AC-95-MU00_0.01uM | Dose=0.01uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A |
| DD-43-WW40_0.01uM | Dose=0.01uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| JB-81-XD04_10uM | Dose=10uM, N-Benzylphenethylamine targeting FARS2 |
| CC-01-PR23_0.1uM | Dose=0.1uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2 |
| CE-42-GB12_1uM | Dose=1uM |
| AA-58-BW57_0.01uM | Dose=0.01uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G |
| HD-22-KR30_1uM | Dose=1uM, K(V)1.5 Channel Blockers;K(V)1.3 Channel Blockers targeting KCNA3, KCNA5 |
| QE-76-ST29_10uM | Dose=10uM, 5-Amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one |
| BC-34-IH52_1uM | Dose=1uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| AA-57-CF49_0.1uM | Dose=0.1uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1 |
| FE-56-PV35_0.1uM | Dose=0.1uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B |
| FA-14-WC79_10uM | Dose=10uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| BB-58-LW82_1uM | Dose=1uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester |
| CB-72-CP81_1uM | Dose=1uM |
| BC-63-DM76_0.1uM | Dose=0.1uM, Cgs 22745 |
| CA-23-CC52_0.1uM | Dose=0.1uM, Gsk417651A, TRPC6 Antagonists;TRPC3 Antagonists targeting TRPC3, TRPC6 |
| GB-35-DG61_10uM | Dose=10uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| EE-16-RH01_10uM | Dose=10uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3 |
| AE-71-VB70_1uM | Dose=1uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6 |
| BB-75-YK01_1uM | Dose=1uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one |
| CB-83-SC82_10uM | Dose=10uM |
| FD-09-BQ45_10uM | Dose=10uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2 |
| CE-69-VJ68_0.1uM | Dose=0.1uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG |
| AA-85-KR83_0.1uM | Dose=0.1uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35 |
| UC-20-ZV24_10uM | Dose=10uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4 |
| AD-83-MW95_1uM | Dose=1uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| JF-14-JC89_0.01uM | Dose=0.01uM, Halicin, SAPK1c (JNK1) Inhibitors targeting MAPK8 |
| DD-55-AU25_0.01uM | Dose=0.01uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| GC-09-EG26_1uM | Dose=1uM, Carcinine, HRH3 antagonist targeting HRH3 |
| AC-11-BO01_0.1uM | Dose=0.1uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1 |
| UD-50-IU51_1uM | Dose=1uM, Geranyl biphosphonate |
| LF-50-IZ49_0.01uM | Dose=0.01uM, Alendronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors;Protein Tyrosine Phosphatase (PTP) Inhibitors targeting FDPS, FDFT1 |
| CA-73-TP18_0.01uM | Dose=0.01uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15 |
| BF-10-IO69_0.01uM | Dose=0.01uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| AF-18-FX20_10uM | Dose=10uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| FD-48-ZP65_10uM | Dose=10uM, 5-Fluoro-2-phenyl-1,2-benzothiazol-3-one, PMI Inhibitor targeting MPI |
| XD-53-KC50_0.1uM | Dose=0.1uM |
| CA-56-VE74_1uM | Dose=1uM, Ciprofloxacin |
| AA-71-XO01_1uM | Dose=1uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38 |
| BE-54-BG59_10uM | Dose=10uM, Sgc0946, Dot1L inhibitor targeting DOT1L |
| AF-76-FL46_0.01uM | Dose=0.01uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN |
| RC-92-EM42_1uM | Dose=1uM, CDK4 Inhibitors;CDK2 Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2, CDK4 |
| DF-41-HL79_0.01uM | Dose=0.01uM, D-Methionine |
| CC-90-NK44_0.01uM | Dose=0.01uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| DE-85-LX22_10uM | Dose=10uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| CE-40-VU73_10uM | Dose=10uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| LA-99-FV41_1uM | Dose=1uM, Dabigatran, Known Thrombin inhibitor targeting F2 |
| AD-19-GH34_0.01uM | Dose=0.01uM, Gsk-lsd1, KDM1A/B targeting KDM1A |
| OB-06-WW76_0.1uM | Dose=0.1uM, Roxatidine acetate, HRH2 antagonist targeting HRH2 |
| JA-17-JV87_0.1uM | Dose=0.1uM, Tegafur, Cytochrome P450 CYP2A6 inhibitor targeting CYP2A6 |
| DC-97-ZB69_0.01uM | Dose=0.01uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| HC-01-FD24_1uM | Dose=1uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol |
| OF-63-KD88_1uM | Dose=1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethyl ethyl carbonate |
| GA-56-IU17_10uM | Dose=10uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4 |
| QC-12-DW06_0.1uM | Dose=0.1uM, 4-Phenyl-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]piperidine-4-carboxamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| PA-84-RB96_0.1uM | Dose=0.1uM, 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one |
| AC-95-MU00_10uM | Dose=10uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A |
| KE-06-DQ22_10uM | Dose=10uM, 3-(2-carboxyethyl)-4-iodo-1H-indole-2-carboxylic acid |
| ED-84-WW97_1uM | Dose=1uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5 |
| BC-08-RC39_0.1uM | Dose=0.1uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3 |
| CA-25-LR28_0.01uM | Dose=0.01uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| EA-95-OQ30_0.01uM | Dose=0.01uM, Azinphos-methyl |
| IA-23-DB04_10uM | Dose=10uM, Avatrombopag, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| RD-66-DP49_1uM | Dose=1uM, 2-[(1-Methyl-2-Oxidanyl-4-Oxidanylidene-Quinolin-3-Yl)carbonylamino]ethanoic Acid, Prolyl 4-Hydroxylase Inhibitors;Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| FA-10-DN36_1uM | Dose=1uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B |
| TA-25-ZO44_0.1uM | Dose=0.1uM, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, Protein Kinase B (PKB/Akt) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting PDPK1 |
| IE-70-HC14_0.01uM | Dose=0.01uM, 5-[3-(5-aminopentyl)-5-[(7-methyl-1H-indol-3-yl)methyl]-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(3-chloro-4-hydroxyphenoxy)-N,N-dimethylbenzamide, SSTR2 agonist targeting SSTR2 |
| IF-92-OK68_0.01uM | Dose=0.01uM, Ethyl 4-(methylamino)-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3 |
| CA-75-HA22_0.01uM | Dose=0.01uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2 |
| IA-10-ET40_10uM | Dose=10uM, Anpirtoline, 5-HT1B Agonists targeting HTR1B |
| JC-47-KK95_10uM | Dose=10uM, 4-(2-Cyano-5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid |
| PB-34-EE63_10uM | Dose=10uM, Cinacalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR |
| UA-20-YK17_1uM | Dose=1uM, (2R)-1-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropan-1-one, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| FE-82-JV20_10uM | Dose=10uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2 |
| AA-50-FY68_0.01uM | Dose=0.01uM |
| FB-43-LF24_10uM | Dose=10uM |
| QE-98-XD90_10uM | Dose=10uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine |
| AD-98-UM13_0.01uM | Dose=0.01uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E |
| BC-56-WO88_0.1uM | Dose=0.1uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5 |
| OE-03-IU44_0.01uM | Dose=0.01uM, 6-(3-chlorophenyl)-3-[5-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-fluorophenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| GA-04-SF76_1uM | Dose=1uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| DD-82-GV50_10uM | Dose=10uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| JB-37-OU59_10uM | Dose=10uM, GW766994, Chemokine CCR3 Antagonists targeting CXCR3 |
| IC-37-QU39_0.01uM | Dose=0.01uM, Emixustat, Retinoid Isomerohydrolase (RPE65) Inhibitors targeting RPE65 |
| BE-47-IP08_1uM | Dose=1uM, Acifran, GPR109A agonist targeting HCAR2 |
| VE-33-MT21_10uM | Dose=10uM, Gdc-0834, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK |
| CF-44-NQ13_10uM | Dose=10uM |
| AC-31-AY35_1uM | Dose=1uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| BA-16-AB67_10uM | Dose=10uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| WA-80-EA43_0.1uM | Dose=0.1uM, N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-3-methoxypyridin-2-yl]-3-fluoro-4-(5-methylfuran-2-yl)benzenesulfonamide, GHS Receptor Agonists targeting GHSR |
| AE-18-ZM98_10uM | Dose=10uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| KB-39-DB68_1uM | Dose=1uM, 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| JE-43-OY99_10uM | Dose=10uM |
| BF-61-IO76_0.1uM | Dose=0.1uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| AA-27-TF89_0.1uM | Dose=0.1uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| BC-22-OI74_10uM | Dose=10uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH |
| GA-89-ZT62_0.1uM | Dose=0.1uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS |
| DE-05-NX87_10uM | Dose=10uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT |
| WA-36-EE47_0.1uM | Dose=0.1uM, 1-{2-[1-(Aminomethyl)cyclohexyl]ethyl}-3-Isoquinolin-6-Ylurea, Allosteric PRMT3 inhibitor targeting PRMT3 |
| HB-36-FN80_0.01uM | Dose=0.01uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| RD-92-QT24_0.01uM | Dose=0.01uM, Autophinib targeting PIK3C3 |
| ME-42-RD46_10uM | Dose=10uM, 2-[2-[[3-amino-5-[3-[(1S)-1-amino-2-hydroxyethyl]phenyl]phenyl]methoxy]phenyl]acetic acid, Complement factor D inhibitor targeting CFD |
| EC-96-KI84_1uM | Dose=1uM |
| BD-27-CC87_0.1uM | Dose=0.1uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13 |
| CA-72-UL91_10uM | Dose=10uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| ZE-13-SI09_0.01uM | Dose=0.01uM, (1-Amino-2-cyclohexylethyl)phosphonic acid, Leucine Aminopeptidase inhibitor targeting LAP3 |
| S0-EE-Y6LH_10uM | Dose=10uM, PF 6767832, M1 postive allosteric modulator targeting CHRM1 |
| YE-01-JU83_1uM | Dose=1uM, N-p-Tolyl-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| GD-56-YA39_0.1uM | Dose=0.1uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1 |
| BF-26-MB27_0.1uM | Dose=0.1uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG |
| AE-32-NZ70_0.01uM | Dose=0.01uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2 |
| AF-73-ON54_0.01uM | Dose=0.01uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| DD-23-ZC57_0.1uM | Dose=0.1uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12 |
| NA-00-YS67_0.1uM | Dose=0.1uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS |
| AC-65-TK51_0.01uM | Dose=0.01uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D |
| UC-52-SS41_1uM | Dose=1uM, 1-(3-(Naphth-2-ylmethoxy)phenyl)-1-(thiazol-2-yl)propyl methyl ether, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| DF-95-CY55_10uM | Dose=10uM |
| BF-19-KU00_1uM | Dose=1uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS |
| HD-22-KR30_0.1uM | Dose=0.1uM, K(V)1.5 Channel Blockers;K(V)1.3 Channel Blockers targeting KCNA3, KCNA5 |
| CD-12-NI84_1uM | Dose=1uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| PD-58-VA68_1uM | Dose=1uM |
| FE-99-RJ28_1uM | Dose=1uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1 |
| GB-35-DG61_0.1uM | Dose=0.1uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| GB-16-NN30_0.1uM | Dose=0.1uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2 |
| AA-92-NW83_10uM | Dose=10uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| BC-21-EB65_1uM | Dose=1uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| DA-01-GV68_0.01uM | Dose=0.01uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15 |
| GD-41-HR28_0.1uM | Dose=0.1uM |
| AB-00-HA50_1uM | Dose=1uM |
| AC-53-RC32_0.01uM | Dose=0.01uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide |
| OC-59-JO99_0.01uM | Dose=0.01uM, N-[(2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-methoxybut-2-ynoxy)benzamide |
| EB-82-QI99_0.01uM | Dose=0.01uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| AE-36-TF52_0.01uM | Dose=0.01uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN |
| AC-40-KV26_1uM | Dose=1uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1 |
| NB-79-SE70_0.01uM | Dose=0.01uM, N-(4-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| HB-49-VZ71_10uM | Dose=10uM, Krn-633, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK4, MAPK6, MAPK7, MAPK12, MAPK15 |
| CE-69-HJ13_0.01uM | Dose=0.01uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| OB-77-XJ02_1uM | Dose=1uM, Erythrodiol, IL-1beta Production Inhibitors;IL-6 Production Inhibitors targeting IL1B, IL6 |
| OC-25-TL77_0.1uM | Dose=0.1uM, Methyl 3-(2-phenylacetamido)thiophene-2-carboxylate |
| DE-81-PO11_0.1uM | Dose=0.1uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300 |
| FD-00-QG34_0.1uM | Dose=0.1uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E |
| AD-59-IN33_1uM | Dose=1uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| BD-63-KJ69_1uM | Dose=1uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| MD-06-ZJ05_10uM | Dose=10uM, Deoxycytidine |
| JC-57-DO70_1uM | Dose=1uM, Cabergoline, Dopamine D2 Agonists;Prolactin Secretion Inhibitors targeting DRD2, HTR2B, PRL |
| BD-60-ZK54_1uM | Dose=1uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| CF-15-GU15_0.1uM | Dose=0.1uM |
| BE-42-WI29_0.01uM | Dose=0.01uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| IB-14-XS97_10uM | Dose=10uM, Pomalidomide-6-OH, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| AA-98-PM63_1uM | Dose=1uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| BE-27-RQ61_10uM | Dose=10uM |
| LE-65-RW44_10uM | Dose=10uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3 |
| AF-89-AD94_0.01uM | Dose=0.01uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7 |
| RC-14-PH60_10uM | Dose=10uM, Lin28-let-7a antagonist 1 targeting LIN28A |
| BB-78-LT85_1uM | Dose=1uM |
| GF-81-MU70_1uM | Dose=1uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3 |
| AF-07-LS35_10uM | Dose=10uM, Somatostatin srif2B (sst4) Agonists |
| NB-21-MW29_10uM | Dose=10uM |
| DD-16-RV85_1uM | Dose=1uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1 |
| FE-82-WB22_0.1uM | Dose=0.1uM, MRT67307 HCl targeting ULK1 |
| AF-41-BY55_0.01uM | Dose=0.01uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2 |
| GF-98-RS57_0.1uM | Dose=0.1uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1 |
| GF-67-HH28_10uM | Dose=10uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| CD-49-HJ53_0.01uM | Dose=0.01uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13 |
| DE-81-OY65_1uM | Dose=1uM, Erlotinib, EGFR (HER1 or erbB1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting EGFR |
| AA-90-AU53_1uM | Dose=1uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| GC-82-RV65_0.01uM | Dose=0.01uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B |
| BA-72-YP01_10uM | Dose=10uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1 |
| KF-38-DH25_0.1uM | Dose=0.1uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2 |
| AA-07-BW60_1uM | Dose=1uM, Moclobemide, MAO-A Inhibitors targeting MAOA |
| AC-72-HZ80_10uM | Dose=10uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AE-64-IK64_0.01uM | Dose=0.01uM |
| RC-92-EM42_0.01uM | Dose=0.01uM, CDK4 Inhibitors;CDK2 Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2, CDK4 |
| GC-54-IZ89_0.01uM | Dose=0.01uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| AA-44-BX20_0.01uM | Dose=0.01uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| GE-58-RW27_10uM | Dose=10uM, Fomepizole |
| HA-29-ZM35_1uM | Dose=1uM |
| FA-16-KA99_0.01uM | Dose=0.01uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea |
| OD-96-TZ83_0.01uM | Dose=0.01uM, BAY 598-Bio-X, SMYD2 inhibitor targeting SMYD2 |
| AB-82-ES53_0.1uM | Dose=0.1uM, Quercetin targeting SULT1A1 |
| JF-93-EL43_1uM | Dose=1uM, Shp2 IN-1, SHP2 inhibitor targeting PTPN11 |
| DF-26-EY87_1uM | Dose=1uM |
| FA-39-ZT32_10uM | Dose=10uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6 |
| GA-94-KZ19_0.01uM | Dose=0.01uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2 |
| EE-35-XA42_0.1uM | Dose=0.1uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide |
| GE-01-QX17_1uM | Dose=1uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2 |
| CD-25-PY50_10uM | Dose=10uM, Lumacaftor, Specific stabilization of CFTR MSD1, specifically TMD1. targeting CFTR |
| ZB-62-QB90_0.1uM | Dose=0.1uM, Vidofludimus, Anti-IL-17;Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| GC-02-TV70_0.01uM | Dose=0.01uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| HF-73-FS05_10uM | Dose=10uM, 13-(Methylamino)-23,24,25-Trioxa-17,18,19,21-Tetrazatetracyclo-Tricosa-1(3),2(10),4(11),12(14),13(18),16(19)-Hexan-15-One, NUDT1 inhibitor;NUDT1 Inhibitor targeting NUDT1 |
| GD-82-CS38_0.01uM | Dose=0.01uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| BA-15-LA22_10uM | Dose=10uM |
| AA-83-TW85_1uM | Dose=1uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2 |
| JF-62-LU77_1uM | Dose=1uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN |
| TF-43-DT71_0.01uM | Dose=0.01uM |
| BB-08-WM33_1uM | Dose=1uM, AM 281, CNR1 antagonist targeting CNR1 |
| HE-55-QD94_1uM | Dose=1uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-phenoxyacetamide |
| CE-04-PX35_0.01uM | Dose=0.01uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1 |
| PE-63-ER67_10uM | Dose=10uM |
| LD-67-CX31_1uM | Dose=1uM, 4-(3-(Benzotriazol-1-yl)propyl)-1-(2-methoxyphenyl)piperazine, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A |
| AA-81-CY65_0.01uM | Dose=0.01uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3 |
| GE-17-FE71_0.1uM | Dose=0.1uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR |
| CE-73-XC72_10uM | Dose=10uM, Type 1 deiodinase inhibitor;Thyroid peroxidase inhibitor targeting TPO, DIO1 |
| BB-75-XU05_0.01uM | Dose=0.01uM, Scopoletin, LDL Antioxidants;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nicotinic Receptor Agonists;Acetylcholinesterase Inhibitors targeting ACHE, NOS2 |
| AA-98-MW52_1uM | Dose=1uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2 |
| CD-75-QY45_1uM | Dose=1uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| FF-76-LK08_0.1uM | Dose=0.1uM |
| IF-06-KQ42_0.01uM | Dose=0.01uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4 |
| SF-48-KT63_1uM | Dose=1uM, 4-((Aminosulfonyl)amino)benzenesulfonamide |
| FC-61-BK21_10uM | Dose=10uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1 |
| DE-85-LX22_0.1uM | Dose=0.1uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| S0-EE-WNJC_0.01uM | Dose=0.01uM |
| EB-28-HP05_10uM | Dose=10uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| DD-71-LY65_0.01uM | Dose=0.01uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| KD-30-SM33_1uM | Dose=1uM, Pyridoxamine |
| BE-25-UR78_1uM | Dose=1uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB |
| GC-02-TV70_0.1uM | Dose=0.1uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| LE-60-VC29_0.1uM | Dose=0.1uM, N-(2,4-dichlorobenzyl)-1-benzyl-5-oxopyrrolidine-3-carboxamide, P2X7 Receptor Antagonists targeting P2RX7 |
| AA-45-AA67_0.1uM | Dose=0.1uM, Fluorouracil, thymidylate synthase targeting TYMS |
| FD-43-EF54_1uM | Dose=1uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1 |
| HC-15-LT47_0.01uM | Dose=0.01uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| JE-63-IE01_0.01uM | Dose=0.01uM, Vercirnon, CCR9 chemokine antagonist targeting CCR9 |
| SC-09-QD27_0.1uM | Dose=0.1uM |
| AD-82-OW73_0.1uM | Dose=0.1uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2 |
| GC-09-EG26_10uM | Dose=10uM, Carcinine, HRH3 antagonist targeting HRH3 |
| AE-52-FP96_1uM | Dose=1uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| BC-09-JG96_0.01uM | Dose=0.01uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| MA-16-HJ95_10uM | Dose=10uM |
| AC-45-YY00_0.1uM | Dose=0.1uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol |
| CE-19-PD79_1uM | Dose=1uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| LB-24-DV44_10uM | Dose=10uM |
| AA-27-TF89_0.01uM | Dose=0.01uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| DA-08-XJ96_0.01uM | Dose=0.01uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| JE-13-EV67_0.01uM | Dose=0.01uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| SB-80-CR34_1uM | Dose=1uM |
| AD-89-ID99_0.01uM | Dose=0.01uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B |
| GD-69-KC91_0.01uM | Dose=0.01uM, Bleomycin |
| TD-17-NF32_0.1uM | Dose=0.1uM |
| S0-EE-WW96_0.01uM | Dose=0.01uM, eCF506 targeting FYN, SRC, YES1 |
| AB-11-MO96_10uM | Dose=10uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| YD-71-BE10_0.01uM | Dose=0.01uM, Sgk1-IN-1, Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitors targeting SGK1, SGK2 |
| ED-12-PB22_10uM | Dose=10uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT |
| YA-92-YO01_0.01uM | Dose=0.01uM, LL-Z 1271alpha |
| PE-68-QD35_0.01uM | Dose=0.01uM, Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate, TGFBR2 degrador targeting TGFBR2 |
| FA-57-OP23_0.01uM | Dose=0.01uM |
| AD-70-TH82_10uM | Dose=10uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| EC-96-OH91_10uM | Dose=10uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4 |
| PC-04-TO77_10uM | Dose=10uM |
| AE-63-ST43_0.1uM | Dose=0.1uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A |
| CC-14-WK34_0.01uM | Dose=0.01uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| BC-50-TK39_10uM | Dose=10uM, Vpc23019, Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg8 (S1P5) Receptor Partial Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Antagonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| HD-22-KR30_0.01uM | Dose=0.01uM, K(V)1.5 Channel Blockers;K(V)1.3 Channel Blockers targeting KCNA3, KCNA5 |
| AC-72-HZ80_0.1uM | Dose=0.1uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| GB-21-FN58_1uM | Dose=1uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK |
| EC-70-XX20_10uM | Dose=10uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5 |
| AC-86-XI84_0.01uM | Dose=0.01uM |
| BF-69-DX62_0.01uM | Dose=0.01uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| DE-82-SC55_10uM | Dose=10uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP |
| AD-43-EQ11_10uM | Dose=10uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one |
| DF-57-BL63_0.1uM | Dose=0.1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| PD-71-MW24_0.01uM | Dose=0.01uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA |
| AA-14-VK39_0.1uM | Dose=0.1uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide |
| LD-50-SF36_1uM | Dose=1uM, Ro64-5229, GRM2 antagonist targeting GRM2 |
| GA-06-UU42_10uM | Dose=10uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| HB-98-OB36_0.01uM | Dose=0.01uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| AD-11-VE17_10uM | Dose=10uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5 |
| BD-48-JW52_1uM | Dose=1uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR |
| KB-56-XG08_1uM | Dose=1uM |
| GA-48-JB51_0.01uM | Dose=0.01uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B |
| BC-91-YI62_1uM | Dose=1uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3 |
| S0-EE-Y9S3_10uM | Dose=10uM, PF-06471553, MOGAT 3 inhibitor targeting MOGAT3 |
| AE-73-KX58_0.1uM | Dose=0.1uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2 |
| AE-65-LV28_0.1uM | Dose=0.1uM, Ketotifen |
| DB-36-TR95_0.01uM | Dose=0.01uM, Ramatroban, PTGDR antagonist;Prostanoid TP Antagonists;CCL2 Expression Inhibitors;CRTH2 Receptor Antagonists;GPR44 antagonist targeting PTGDR, CCL2, TBXA2R, PTGDR2 |
| DE-23-IF54_1uM | Dose=1uM, (3R)-1,1-bis(ethoxymethyl)-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| OE-91-GF88_10uM | Dose=10uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG |
| FF-32-LL81_10uM | Dose=10uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1 |
| JB-34-VI53_0.1uM | Dose=0.1uM, 4-fluoro-N-(2-(4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)benzamide, PLD1 inhibitor targeting PLD1, PLD2 |
| AC-42-LW33_10uM | Dose=10uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one |
| AB-51-WV08_0.01uM | Dose=0.01uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1 |
| BA-29-OX17_0.1uM | Dose=0.1uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| KD-36-KT24_1uM | Dose=1uM, (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide |
| AB-32-QZ50_10uM | Dose=10uM |
| CB-82-BV25_10uM | Dose=10uM, [4-(2-Acetylamino-2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-benzyl]-phosphonic acid, Grb2 SH2 Domain Inhibitors targeting GRB2, PTK2B, PTK2, PTK6, PTK7 |
| EF-30-GD67_0.1uM | Dose=0.1uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2 |
| CF-26-ME34_1uM | Dose=1uM, N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide, 15-Lipoxygenase Inhibitors targeting ALOX15, ALOX15B |
| BA-65-YU25_1uM | Dose=1uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| DA-09-XJ53_1uM | Dose=1uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7 |
| CE-66-GR30_0.01uM | Dose=0.01uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2 |
| EA-60-LN91_0.01uM | Dose=0.01uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1 |
| JF-79-OI50_0.01uM | Dose=0.01uM, FK 409, Soluble Guanylyl Cyclase (sGC) Activators;Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| NC-94-LE33_10uM | Dose=10uM, Lomeguatrib, MGMT gene inhibitor targeting MGMT |
| TE-76-FI57_0.01uM | Dose=0.01uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2 |
| YF-00-IN39_0.01uM | Dose=0.01uM |
| IA-38-XE73_1uM | Dose=1uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3 |
| KF-37-OX16_1uM | Dose=1uM, N-[4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazol-2-yl]acetamide, TNF-alpha Production Inhibitors;Inhibitors of Signal Transduction Pathways;Adenosine A3 Antagonists;p38 MAPK Inhibitors targeting ADORA3, MAPK13 |
| BB-94-HN41_0.01uM | Dose=0.01uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1 |
| EB-66-IH06_0.01uM | Dose=0.01uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2 |
| SB-92-FF15_1uM | Dose=1uM, 1-[2-(1-Hydroxymethyl-cyclopentylamino)-acetyl]-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| OA-86-XP09_0.01uM | Dose=0.01uM, 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| PF-39-DY68_0.01uM | Dose=0.01uM, 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione |
| KB-39-DB68_0.01uM | Dose=0.01uM, 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AB-17-WP43_10uM | Dose=10uM, Loperamide, mu-Opioid Agonists targeting OPRM1 |
| PA-64-LE28_0.1uM | Dose=0.1uM, BN-82451, Lipid Peroxidation Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants;Sodium Channel Blockers targeting PTGS1, PTGS2, SCN1A, SCN2A, SCN3A |
| HC-38-KI38_0.1uM | Dose=0.1uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| AE-95-KU30_10uM | Dose=10uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C |
| GB-90-VQ08_0.1uM | Dose=0.1uM, PH 797804, P38a inhibitor targeting MAPK14 |
| YC-80-XX73_10uM | Dose=10uM, 3-(Ethoxycarbonyl)-1,3-thiazolidine-4-carboxylic acid, Elastase Inhibitors targeting PI3 |
| DA-59-ZD74_1uM | Dose=1uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| CC-47-VS90_0.01uM | Dose=0.01uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| TD-17-NF32_1uM | Dose=1uM |
| CE-09-ZT22_0.01uM | Dose=0.01uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2 |
| EA-67-FY34_0.1uM | Dose=0.1uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA |
| KA-14-VZ39_0.1uM | Dose=0.1uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3 |
| GD-73-ZF64_0.1uM | Dose=0.1uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9 |
| LE-83-PR92_1uM | Dose=1uM |
| HE-84-SC79_10uM | Dose=10uM |
| BA-13-CC32_1uM | Dose=1uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| DA-09-XJ53_0.01uM | Dose=0.01uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7 |
| FB-75-YG01_0.01uM | Dose=0.01uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| JC-51-JD64_10uM | Dose=10uM, Spirapril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| PB-05-XP37_0.01uM | Dose=0.01uM, (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid, allosteric PDK1 activator targeting PDK1 |
| HA-82-XO48_1uM | Dose=1uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK |
| DF-85-QA87_1uM | Dose=1uM, Htfmt, HRH1 agonist targeting HRH1 |
| AA-51-RY00_10uM | Dose=10uM, Chlorambucil |
| AC-11-BO01_0.01uM | Dose=0.01uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1 |
| BD-84-ZR31_0.1uM | Dose=0.1uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3 |
| LD-36-DG33_1uM | Dose=1uM |
| DE-03-BW70_10uM | Dose=10uM, 1-(6-Fluoro-2-methyl-3,4-dihydroquinolin-1(2h)-yl)-2-(isoquinolin-5-yloxy)ethanone, Bile Acid Responsive TGR5 Receptors (GPBAR1, AXOR 109, GPCR19) Agonists targeting GPBAR1 |
| IA-67-NA51_10uM | Dose=10uM, 3-[2-(Pyridin-2-ylamino)-5-pyrimidin-4-yl-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists targeting ADORA2B |
| HC-04-ZM18_1uM | Dose=1uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| OC-14-JE78_1uM | Dose=1uM, (2R,3S)-1-(Phenanthrene-2-carbonyl)-piperazine-2,3-dicarboxylic acid, NR2D Antagonists;NR2C Antagonists targeting GRIN2C, GRIN2D |
| AA-75-JH89_1uM | Dose=1uM, BAY-598 R-isomer |
| AD-24-KU93_0.1uM | Dose=0.1uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone |
| GF-84-NF76_0.01uM | Dose=0.01uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1 |
| AB-21-MV93_10uM | Dose=10uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4 |
| YE-45-AD07_1uM | Dose=1uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS |
| BD-22-KS33_1uM | Dose=1uM, Aptazapine, ADRA2A antagonist targeting ADRA2A |
| AB-55-HO71_0.01uM | Dose=0.01uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF |
| QF-05-OL72_1uM | Dose=1uM |
| KA-53-KV02_10uM | Dose=10uM, 3-(phenylsulfonyl)-N-((tetrahydrofuran-2-yl)methyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine, HTR6 antagonist;5-HT6 Antagonists targeting HTR6 |
| UE-78-EW35_0.1uM | Dose=0.1uM, 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole, HTR2A antagonist targeting HTR2A |
| ID-31-AD14_0.1uM | Dose=0.1uM, 3-(3,4-dimethoxyphenyl)-N-(3-morpholin-4-ylpropyl)pyrazolo[1,5-a]pyrimidin-5-amine |
| GA-87-BR97_0.1uM | Dose=0.1uM |
| BA-44-SG89_0.01uM | Dose=0.01uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD |
| NF-53-AH73_1uM | Dose=1uM, Riociguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| IF-86-JG83_10uM | Dose=10uM, (S)-2-benzylamino-3-phenyl-1-propanol |
| OE-50-VB46_0.1uM | Dose=0.1uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2 |
| YA-71-LR91_1uM | Dose=1uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-2-[4-(2-methyltetrazol-5-yl)phenyl]acetamide |
| YE-45-AD07_0.01uM | Dose=0.01uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS |
| ZD-74-FC07_0.1uM | Dose=0.1uM |
| CD-75-QY45_0.1uM | Dose=0.1uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| DB-33-TM61_10uM | Dose=10uM, Profenamine, NMDA Antagonists;Butyrylcholinesterase Inhibitors targeting BCHE |
| EB-98-LS52_10uM | Dose=10uM, (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium, Muscarinic receptor agonist targeting CHRM1, CHRM4, CHRM5, CHRM2, CHRM3 |
| S0-EE-YNU4_1uM | Dose=1uM, (E)-4-(4-methyl-1H-indol-5-ylamino)-5-(2-(6-(morpholinomethyl)pyridin-2-yl)vinyl)nicotinonitrile, PKC theta inhibitor targeting PRKCQ |
| JD-90-SN16_0.01uM | Dose=0.01uM, 3-(2-Chloro-7-methoxyacridin-9-yl)sulfanylpropan-1-amine |
| DB-93-SW55_1uM | Dose=1uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| GF-37-MB64_1uM | Dose=1uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| TC-16-ZS56_1uM | Dose=1uM, Recilisib |
| AB-34-RQ73_0.1uM | Dose=0.1uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| AF-23-RM26_1uM | Dose=1uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR |
| AF-41-BY55_1uM | Dose=1uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2 |
| ZD-84-PM36_10uM | Dose=10uM, Cyclopropanecarboxylic acid [4-(3-methoxy-phenoxy)-phenyl]-amide, Melatonin MT2 Receptor Ligands targeting MTNR1B |
| JB-28-VO37_0.01uM | Dose=0.01uM, 7-[(1R)-2-[[(1R,2R)-2-(3-ethoxyphenyl)cyclopentyl]amino]-1-hydroxyethyl]-4-hydroxy-3H-1,3-benzothiazol-2-one |
| GC-67-AH43_0.1uM | Dose=0.1uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| HE-59-VP02_0.1uM | Dose=0.1uM, (5R)-7-(3,5-dichlorophenyl)-5-methyl-3-piperazin-1-ylsulfonyl-5-[(4-pyrimidin-5-ylphenyl)methyl]imidazo[1,2-a]imidazol-6-one, Integrin alphaLbeta2 (LFA-1) Antagonists targeting ITGAL, ITGB2 |
| IA-28-VB61_0.1uM | Dose=0.1uM |
| AE-28-LX10_0.1uM | Dose=0.1uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| BC-25-VR48_1uM | Dose=1uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB |
| CB-68-HM58_10uM | Dose=10uM |
| CB-48-WM43_1uM | Dose=1uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E |
| BE-04-AN21_0.01uM | Dose=0.01uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| AE-06-JY57_1uM | Dose=1uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| JD-51-GD99_0.01uM | Dose=0.01uM, 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one, MAP3K11 gene inhibitor targeting MAP3K9, MAP3K11 |
| AC-80-DI95_0.01uM | Dose=0.01uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| HF-00-QG19_0.01uM | Dose=0.01uM, R-Psop, Neuromedin U Receptor 2 (NMU2) Ligands targeting NMUR2 |
| BF-69-DN58_0.1uM | Dose=0.1uM |
| QC-15-WY38_0.1uM | Dose=0.1uM, TRKA Inhibitors targeting NTRK1 |
| IA-97-VE31_0.01uM | Dose=0.01uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-7-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| GA-06-UU42_1uM | Dose=1uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| JA-77-UH38_0.01uM | Dose=0.01uM |
| UD-99-XG44_1uM | Dose=1uM, (1,2-Diphenyl-ethyl)-phosphonic acid |
| HE-27-FR27_0.01uM | Dose=0.01uM, 5-(3-Bromophenyl)-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one, Rho C GTPase Inhibitors targeting RHOC |
| AB-46-GB72_1uM | Dose=1uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| NC-39-KP22_0.1uM | Dose=0.1uM, A-1210477, Mcl-1 inhibitor targeting MCL1 |
| YE-55-YX75_0.1uM | Dose=0.1uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4 |
| WD-65-PA90_0.1uM | Dose=0.1uM, Lafutidine, Histamine H2 Receptor Antagonists targeting HRH2 |
| AC-63-OM41_1uM | Dose=1uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| AD-02-XI19_1uM | Dose=1uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT |
| OE-04-VO07_1uM | Dose=1uM, 2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylsulfinyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists targeting CASR |
| EA-95-YQ95_0.1uM | Dose=0.1uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6 |
| MD-03-GH73_0.1uM | Dose=0.1uM, Diacerein, IL-1 Inhibitors targeting IL1B |
| FE-21-KA32_1uM | Dose=1uM, Brl 55834 |
| BF-96-PY22_10uM | Dose=10uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| HB-96-QD61_0.1uM | Dose=0.1uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4 |
| QE-18-WG07_0.1uM | Dose=0.1uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2 |
| ZF-00-MX33_10uM | Dose=10uM |
| JB-55-CM55_10uM | Dose=10uM, 8-Chloro-6-phenylspiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7A gene inhibitor targeting PDE7A |
| EA-39-WW34_10uM | Dose=10uM, 5-Phosphono-D-norvaline, NMDA Antagonists targeting GRIN1 |
| BF-04-NQ13_0.1uM | Dose=0.1uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester |
| QA-27-XW03_0.01uM | Dose=0.01uM, 1-[2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl]ethanone |
| CF-24-PH37_0.01uM | Dose=0.01uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10 |
| AF-41-QY60_0.1uM | Dose=0.1uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| PA-75-VS64_10uM | Dose=10uM, 1G244, Known DPP8, DPP9 inhibitor targeting DPP8, DPP9 |
| BA-77-IP18_0.1uM | Dose=0.1uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| FA-16-HR75_1uM | Dose=1uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2 |
| BA-60-RH02_0.1uM | Dose=0.1uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1 |
| CB-13-WC72_1uM | Dose=1uM |
| AB-38-CX25_10uM | Dose=10uM, Methiothepin targeting HTR1E, HTR1F |
| BB-69-YQ35_10uM | Dose=10uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| YA-78-MS95_0.01uM | Dose=0.01uM, 2164U90, Ileal Bile Acid Transporter (IBAT) Inhibitors targeting SLC10A2 |
| AB-32-QZ50_1uM | Dose=1uM |
| IC-79-JZ26_1uM | Dose=1uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide |
| FB-49-NW04_1uM | Dose=1uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3 |
| AB-35-RU30_10uM | Dose=10uM |
| BE-48-TM93_10uM | Dose=10uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R |
| AF-80-QK39_10uM | Dose=10uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4 |
| CD-49-HJ53_0.1uM | Dose=0.1uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13 |
| AA-33-TW45_1uM | Dose=1uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL |
| GA-48-QI68_1uM | Dose=1uM |
| EC-07-AO30_0.01uM | Dose=0.01uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| DE-01-HO61_0.01uM | Dose=0.01uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR |
| BA-51-DL54_0.01uM | Dose=0.01uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1 |
| DD-33-XP23_1uM | Dose=1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| YC-83-VF72_0.01uM | Dose=0.01uM |
| RC-21-IF98_1uM | Dose=1uM |
| TF-43-DT71_1uM | Dose=1uM |
| AC-92-ZW28_10uM | Dose=10uM |
| FA-56-WH26_0.01uM | Dose=0.01uM, Venglustat targeting UGCG |
| HA-48-LV39_0.01uM | Dose=0.01uM, Allocryptopine |
| BB-21-KE77_1uM | Dose=1uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1 |
| AC-05-MR83_0.01uM | Dose=0.01uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| FC-15-XG61_1uM | Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| JE-55-OJ53_1uM | Dose=1uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile |
| JC-05-CC41_0.1uM | Dose=0.1uM, 3-{(R)-3-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic acid |
| BE-05-KR03_0.1uM | Dose=0.1uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK |
| XC-12-SL04_1uM | Dose=1uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1 |
| NA-22-BX39_10uM | Dose=10uM, 5,8-Dihydroxy-3-methyl-4-(9H)-naphtho(2,3-c)furanone, ELAVL1 gene inhibitor targeting ELAVL1, MYLK |
| AA-12-VW53_10uM | Dose=10uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1 |
| DB-28-SP20_0.1uM | Dose=0.1uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4 |
| SA-43-QT61_0.01uM | Dose=0.01uM, 2-Benzyl-5-(2,5-dichloro-phenyl)-2H-[1,2,4]triazole-3-thiol, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| KC-99-BS89_0.1uM | Dose=0.1uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine |
| AC-29-ZR23_0.01uM | Dose=0.01uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| LA-66-RT74_1uM | Dose=1uM, (4-Propan-2-ylphenyl)-[4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-yl]methanone, Parathyroid Hormone Secretion Stimulants targeting CASR |
| CC-58-RP30_10uM | Dose=10uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP |
| OB-75-VS99_10uM | Dose=10uM, 3-(Tetrahydrofuran-3-yl oxy)-4-(thieno[3,2-d]pyrimidin-4-yl amino)-benzamide, MAPK-Interacting Kinase (MNK) Inhibitors targeting MKNK2, SGK1, MKNK1 |
| DF-45-GA42_10uM | Dose=10uM, SB 224289, HTR1B antagonist targeting HTR1B |
| TA-19-YA45_0.01uM | Dose=0.01uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1 |
| ZB-42-PL54_10uM | Dose=10uM |
| CE-40-VU73_1uM | Dose=1uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| GF-93-DV47_0.1uM | Dose=0.1uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1 |
| HD-00-AG74_1uM | Dose=1uM |
| MF-65-HS14_10uM | Dose=10uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one |
| CB-86-ME74_0.01uM | Dose=0.01uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3 |
| AB-34-DD27_10uM | Dose=10uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| DC-87-HI21_1uM | Dose=1uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9 |
| SA-49-SD47_0.01uM | Dose=0.01uM, (3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, ADORA2A agonist;ADORA2B agonist targeting ADORA2A, ADORA2B |
| CB-62-TB77_1uM | Dose=1uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2 |
| AE-69-CH29_0.1uM | Dose=0.1uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12 |
| OE-78-TD20_0.01uM | Dose=0.01uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1 |
| RD-57-WQ44_10uM | Dose=10uM, VU0650786, selective mGlu3 NAM targeting GRM3 |
| JB-23-ZE86_1uM | Dose=1uM, N-benzyl-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine, Lck Kinase Inhibitors targeting LCK |
| TA-36-PC58_1uM | Dose=1uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5 |
| UD-50-IU51_0.1uM | Dose=0.1uM, Geranyl biphosphonate |
| NC-39-KP22_1uM | Dose=1uM, A-1210477, Mcl-1 inhibitor targeting MCL1 |
| FD-86-NE74_1uM | Dose=1uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300 |
| AA-98-FJ71_10uM | Dose=10uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| ZC-74-FT18_1uM | Dose=1uM, CID 25225521, Orexin 2 receptor antagonist targeting HCRTR2 |
| AD-89-LX67_1uM | Dose=1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| ZE-14-BN99_0.01uM | Dose=0.01uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19 |
| ZE-58-ZZ82_0.1uM | Dose=0.1uM |
| EF-64-HJ41_0.1uM | Dose=0.1uM, LY 255283, LTB4R2 antagonist targeting LTB4R2 |
| BC-36-PL31_0.01uM | Dose=0.01uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| ED-22-QV85_1uM | Dose=1uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3 |
| LB-04-KP05_0.01uM | Dose=0.01uM, 1-Ethyl-2-benzimidazolinone, SK2 Potassium Channel Activators targeting KCNN2 |
| GD-09-QJ83_1uM | Dose=1uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D |
| AE-56-SL06_0.1uM | Dose=0.1uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1 |
| GD-69-GP37_10uM | Dose=10uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| JA-02-IU07_0.01uM | Dose=0.01uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5 |
| BF-69-DX62_1uM | Dose=1uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| AB-72-EP76_0.1uM | Dose=0.1uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2 |
| DE-24-AX80_1uM | Dose=1uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| QE-79-XO29_0.01uM | Dose=0.01uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3 |
| AE-97-TS20_10uM | Dose=10uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| JA-46-LK88_10uM | Dose=10uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3 |
| IC-80-CT90_0.1uM | Dose=0.1uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea |
| FB-85-ND09_0.1uM | Dose=0.1uM |
| HC-76-SY22_10uM | Dose=10uM, Sulprostone |
| AB-64-NN66_1uM | Dose=1uM, [1-(2-Chloro-4-ethanesulfonyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid, CRTh2 antagonist targeting PTGDR2 |
| BE-66-GV20_1uM | Dose=1uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F |
| RB-74-JO32_10uM | Dose=10uM, 4',4''-Methylenebis(acetanilide) |
| YC-83-VF72_10uM | Dose=10uM |
| GF-16-AN80_0.1uM | Dose=0.1uM, 8-(3,5-Dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine, inhibitor of Grp94 targeting HSP90B1 |
| DC-87-HI21_0.1uM | Dose=0.1uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9 |
| ND-85-OJ63_1uM | Dose=1uM, Ezutromid, UTRN (Utrophin gene) Expression Enhancers targeting AHR |
| YD-21-ZR41_10uM | Dose=10uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2 |
| QA-30-EV79_0.01uM | Dose=0.01uM, Lusutrombopag, Thrombopoietin Receptor (c-MPL) agonist;Signal Transduction Modulators targeting MPL |
| BA-77-IP18_1uM | Dose=1uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| ND-33-UV62_1uM | Dose=1uM, Tasquinimod, Histone Deacetylase 4 (HDAC4) Inhibitors;S100A9 Inhibitors targeting S100A9, HDAC4 |
| XD-01-OY13_1uM | Dose=1uM, Cvt-12012, SCD1) Inhibitors;Stearoyl-CoA Desaturase (delta-9 Desaturase;SCD targeting SCD |
| JD-04-UT85_10uM | Dose=10uM, Lenalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting CRBN |
| EA-95-YQ95_10uM | Dose=10uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6 |
| CD-30-AD57_1uM | Dose=1uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| CA-73-BW50_0.1uM | Dose=0.1uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2 |
| FA-30-KQ38_1uM | Dose=1uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB |
| CF-53-HM41_1uM | Dose=1uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8 |
| AA-85-KR83_10uM | Dose=10uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35 |
| GB-86-PE04_10uM | Dose=10uM, N-(tert-Butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine, GLP-1 Receptor Agonists;positive allosteric modulator of GLP1R targeting GLP1R |
| GD-17-GR17_0.01uM | Dose=0.01uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| HD-22-GO73_10uM | Dose=10uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2 |
| KC-07-HN67_0.01uM | Dose=0.01uM, Ormetoprim, P2X2/3 Receptor Antagonists;P2X3 Receptor Antagonists targeting P2RX3 |
| QB-99-OU03_1uM | Dose=1uM, 2-(s)Cyano-1-isoleucylpyrrolidine, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| AB-87-KC82_0.1uM | Dose=0.1uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4 |
| ID-17-PL23_10uM | Dose=10uM, (S)-5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one targeting USP7 |
| CE-73-JW90_10uM | Dose=10uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2 |
| BB-55-JH29_1uM | Dose=1uM |
| DD-16-RV85_0.01uM | Dose=0.01uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1 |
| IA-38-XE73_0.1uM | Dose=0.1uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3 |
| OB-78-PA58_0.01uM | Dose=0.01uM, Teglarinad, Glycerol-3-Phosphate Dehydrogenase (NAD+) Inhibitors;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Signal Transduction Modulators;Inhibitory kappaB Kinase (IKK) Inhibitors targeting GPD1, NAMPT, CHUK |
| HF-66-BD96_1uM | Dose=1uM |
| AE-38-LX10_0.1uM | Dose=0.1uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| AB-05-JR93_0.1uM | Dose=0.1uM, Ketoprofen, Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| ND-35-VF18_1uM | Dose=1uM, (4-{[(5-{[(3-Chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, PTGER4 agonist;Prostanoid EP4 Agonists targeting PTGER4 |
| AC-63-DM46_1uM | Dose=1uM |
| AB-57-IZ37_1uM | Dose=1uM |
| BD-94-KU93_0.01uM | Dose=0.01uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| BC-09-JG96_1uM | Dose=1uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| DC-63-KC77_1uM | Dose=1uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13 |
| ED-98-UI13_10uM | Dose=10uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E |
| OF-32-PT74_0.1uM | Dose=0.1uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene |
| AF-33-GW65_10uM | Dose=10uM, Diazoxide, potassium channel activator;K(ATP) Channel Activators targeting CA1, KCNJ11 |
| AB-74-VK99_0.1uM | Dose=0.1uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| BA-10-WH12_0.01uM | Dose=0.01uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| GC-49-HD44_1uM | Dose=1uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1 |
| CB-68-SP90_1uM | Dose=1uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| BB-85-NU70_1uM | Dose=1uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ |
| JB-48-AO57_0.01uM | Dose=0.01uM, [(1S,3R,7S,8S,8aR)-8-[2-[(4R,6R)-3-[[4-(2-hydroxypropan-2-yl)phenyl]methyl]-4-(2-methoxy-2-oxoethyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate |
| YD-38-CI01_10uM | Dose=10uM, 4-Amino-5-chloro-2-methoxy-benzoic acid 2-pyrrolidin-1-yl-ethyl ester, HTR4 agonist targeting HTR4 |
| FC-61-BK21_1uM | Dose=1uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1 |
| NE-27-MD08_1uM | Dose=1uM, N-[1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide, Motilin Receptor Antagonist targeting MLNR |
| AB-85-JR73_0.01uM | Dose=0.01uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| QB-69-AR11_1uM | Dose=1uM, N-[(1S,2R,3S,4R)-4-(2-Chloro-6-cyclopentylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide, Adenosine A1 Agonists targeting ADORA1 |
| NF-77-LG65_1uM | Dose=1uM, 3-Biphenyl-4-yl-2-{[1-(2-mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| ID-90-NM43_0.1uM | Dose=0.1uM, Rx-5902, phosphorylated-p68 RNA helicase inhibitor targeting DDX5 |
| OA-10-PB21_0.1uM | Dose=0.1uM, Tiospirone, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| AF-33-AM86_0.1uM | Dose=0.1uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| ED-99-XG61_0.01uM | Dose=0.01uM, Kartogenin, Chondrogenesis activator targeting FLNA |
| PC-04-TO77_1uM | Dose=1uM |
| CA-16-ZL71_10uM | Dose=10uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b |
| BC-21-EB65_0.1uM | Dose=0.1uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| GC-11-YA32_0.01uM | Dose=0.01uM |
| MF-31-FM25_0.1uM | Dose=0.1uM, 1-methyl-3-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]thiourea |
| UF-85-NE30_0.1uM | Dose=0.1uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile |
| MF-62-JR25_1uM | Dose=1uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| DC-49-EJ23_0.1uM | Dose=0.1uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6 |
| BA-89-SR63_1uM | Dose=1uM, Pexidartinib, CSF1R inhibitor targeting CSF1R |
| GA-23-VF89_0.01uM | Dose=0.01uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| BC-43-JW95_10uM | Dose=10uM, Phenylalanine |
| FA-30-KQ38_10uM | Dose=10uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB |
| UD-49-HQ53_0.01uM | Dose=0.01uM, 6-[(1S)-1-hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methoxypyridine-3-carbonitrile, KCNJ1 inhibitor;KCNJ1 gene inhibitor targeting KCNJ1 |
| KE-41-JG66_0.01uM | Dose=0.01uM, 6-[(2-{[4-(4-Bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile |
| KE-53-DB74_10uM | Dose=10uM, N-[4-Methyl-2-(morpholin-4-YL)quinolin-6-YL]furan-2-carboxamide |
| AC-65-TK51_0.1uM | Dose=0.1uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D |
| CB-13-OP88_1uM | Dose=1uM, Benzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CE-04-OJ56_0.1uM | Dose=0.1uM, 2-(2-Aminoethyl)pyridine |
| MC-60-AC74_0.01uM | Dose=0.01uM, 1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid, IGFBP1-6 Inhibitor targeting IGFBP4 |
| AC-91-TS36_0.01uM | Dose=0.01uM |
| IB-23-AO00_0.01uM | Dose=0.01uM, 6-Amino-4-[(3-methylphenyl)amino]quinazoline, Inhibitors of Signal Transduction Pathways;Tyrosine Kinase Inhibitors targeting EGFR, TIE1 |
| MA-06-DJ95_0.01uM | Dose=0.01uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7 |
| BD-23-MT28_0.1uM | Dose=0.1uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR |
| FE-19-OW54_0.1uM | Dose=0.1uM, Fenofibric Acid |
| EB-07-JB09_0.01uM | Dose=0.01uM |
| JD-79-ZS29_0.1uM | Dose=0.1uM, 1,1'-Methylenebis(2-naphthol), Antiamyloidogenic Agents targeting APP |
| AA-90-AU53_0.01uM | Dose=0.01uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| AD-91-FB70_0.1uM | Dose=0.1uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2 |
| DD-96-VY72_0.1uM | Dose=0.1uM |
| AA-67-TP08_1uM | Dose=1uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| AF-40-QU33_0.01uM | Dose=0.01uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| HE-01-ND39_0.1uM | Dose=0.1uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| BB-99-UN48_0.1uM | Dose=0.1uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| FA-03-CZ62_1uM | Dose=1uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| FC-62-AI14_0.1uM | Dose=0.1uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ |
| DD-10-NA60_1uM | Dose=1uM |
| LA-31-YT57_0.01uM | Dose=0.01uM, 9-Chloro-2-(2-fluorophenyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-ol, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG1, GABRG2, GABRG3 |
| BB-29-VD14_0.1uM | Dose=0.1uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3 |
| GD-46-BU97_0.01uM | Dose=0.01uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| EC-56-YK73_0.1uM | Dose=0.1uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2 |
| AB-07-AZ97_0.1uM | Dose=0.1uM, CB1R antagonist 1, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM |
| ND-07-WN37_10uM | Dose=10uM, Padnarsertib, Allosteric inhibitor that degrades PAK4 targeting PAK4 |
| GD-09-QJ83_10uM | Dose=10uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D |
| AA-91-SB25_0.1uM | Dose=0.1uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK |
| NE-93-AH13_10uM | Dose=10uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one |
| LC-40-KC29_1uM | Dose=1uM |
| TE-32-AC63_1uM | Dose=1uM, Bay-299, Bromodomain inhibitor targeting TAF1, BRD1, TAF1L |
| KD-38-KY71_0.1uM | Dose=0.1uM, CID 44542178, NPFFR2 agonist, GIRK 1/4 blocker targeting NPFFR2 |
| KC-45-DZ26_0.01uM | Dose=0.01uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| MB-95-VI30_1uM | Dose=1uM |
| JD-01-RA07_10uM | Dose=10uM, N-(4,6-Dimethylpyrimidin-2-yl)-4-((2-methylbenzyl)amino)benzenesulfonamide, alpha2B-Adrenoceptor Antagonists targeting ADRA2B |
| HC-63-SV27_10uM | Dose=10uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| AD-12-YF12_0.01uM | Dose=0.01uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2 |
| CC-17-HI11_1uM | Dose=1uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| MA-64-FB16_0.01uM | Dose=0.01uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-2-[4-(2-methyltetrazol-5-yl)phenyl]-N-[5-(trifluoromethyl)pyrazin-2-yl]acetamide |
| CE-68-CC69_0.1uM | Dose=0.1uM |
| GB-16-NN30_0.01uM | Dose=0.01uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2 |
| DE-65-KO26_1uM | Dose=1uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG |
| ED-26-RU42_10uM | Dose=10uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| BD-69-YD09_0.1uM | Dose=0.1uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4 |
| BA-41-QF30_1uM | Dose=1uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide |
| QF-45-KI95_10uM | Dose=10uM, 4-Bromanyl-~{n}-(6-Methoxy-1,3-Dimethyl-2-Oxidanylidene-Benzimidazol-5-Yl)-2-Methyl-Benzenesulfonamide, BRPF1B and BRPF2 inhibitor targeting BRPF1, BRD1 |
| AA-67-TP08_10uM | Dose=10uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| HA-08-IL05_1uM | Dose=1uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| HA-88-JB21_0.1uM | Dose=0.1uM, 1,5-Dihydroxyisoquinoline, PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| ND-86-GT24_1uM | Dose=1uM, 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-, Histamine H4 Receptor Antagonists;HRH4 antagonist targeting HRH4 |
| YB-01-IL62_0.01uM | Dose=0.01uM, 4-Methyl-3-[(3-nitrophenyl)methyl]-7-pyrimidin-2-yloxychromen-2-one |
| HC-43-CV47_0.1uM | Dose=0.1uM, Bergapten |
| AD-82-AM64_1uM | Dose=1uM |
| CD-91-BY60_1uM | Dose=1uM, N'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide, Branched amino acid aminotransferase 1 inhibitor targeting BCAT1 |
| BF-08-RW47_10uM | Dose=10uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D |
| NB-37-AN17_0.01uM | Dose=0.01uM |
| FC-52-RL51_0.1uM | Dose=0.1uM, [1-[(2-Chlorophenyl)methyl]-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)indol-2-yl]methanol, PAR4 antagonist targeting F2RL3 |
| KC-45-DZ26_10uM | Dose=10uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN |
| LE-94-HL75_10uM | Dose=10uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2 |
| AC-91-TS36_0.1uM | Dose=0.1uM |
| RF-47-PC15_0.1uM | Dose=0.1uM, 4,6-Dinitro-2,1,3-benzothiadiazole |
| IF-22-EA89_1uM | Dose=1uM, Gusperimus |
| FA-45-PN48_0.01uM | Dose=0.01uM |
| QB-69-AR11_10uM | Dose=10uM, N-[(1S,2R,3S,4R)-4-(2-Chloro-6-cyclopentylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide, Adenosine A1 Agonists targeting ADORA1 |
| FA-10-SN61_0.1uM | Dose=0.1uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN |
| FA-17-JZ87_0.01uM | Dose=0.01uM, Valdecoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| WB-47-FS93_0.01uM | Dose=0.01uM, SecinH3, Cytohesin Inhibitors targeting CYTH2, CYTH1 |
| CA-66-FY97_0.01uM | Dose=0.01uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| AB-21-CI37_1uM | Dose=1uM, Deferoxamine |
| CA-61-VV83_1uM | Dose=1uM |
| LD-36-DG33_0.1uM | Dose=0.1uM |
| ZB-45-AK89_10uM | Dose=10uM, Nvp-dky709 |
| ME-77-TQ29_0.01uM | Dose=0.01uM, N,N'-bis-(2-hydroxybenzyl)-2,5-diamino-2,5-dimethyl-hexane, TRPA1 Antagonists targeting TRPA1 |
| AE-74-SQ33_0.1uM | Dose=0.1uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| BA-92-CZ75_0.01uM | Dose=0.01uM |
| ME-93-CO85_0.1uM | Dose=0.1uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine |
| JA-01-GQ75_1uM | Dose=1uM, NS 1652, Chloride Channel Blockers targeting GRIK1 |
| BA-46-RB17_1uM | Dose=1uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| RD-64-KA33_10uM | Dose=10uM, Gsk983, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| CE-69-VJ68_0.01uM | Dose=0.01uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG |
| AC-21-IE62_0.01uM | Dose=0.01uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| MD-40-FM63_0.01uM | Dose=0.01uM, nor-NOHA targeting ARG1 |
| AC-42-SI74_10uM | Dose=10uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| RF-95-QO64_0.1uM | Dose=0.1uM |
| KD-31-TU05_10uM | Dose=10uM, Lesinurad targeting SLC22A11, SLC22A12 |
| BC-52-NW28_0.01uM | Dose=0.01uM, Icmt-IN-1, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT |
| AA-66-YY32_1uM | Dose=1uM, Serazapine, 5-HT2A Antagonists targeting HTR2A |
| CD-84-BU23_10uM | Dose=10uM, Oseltamivir |
| EE-45-YQ15_0.1uM | Dose=0.1uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7 |
| DD-82-GV50_0.01uM | Dose=0.01uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| QA-27-XW03_10uM | Dose=10uM, 1-[2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl]ethanone |
| AA-07-FZ97_0.01uM | Dose=0.01uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1 |
| AA-01-XV28_10uM | Dose=10uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| FA-16-HR75_0.01uM | Dose=0.01uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2 |
| AC-58-RM63_1uM | Dose=1uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2 |
| WF-31-RY78_10uM | Dose=10uM, (3H)granisetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| FD-44-AD67_0.1uM | Dose=0.1uM, 3-(2,3-Difluoro-4-methoxyphenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine targeting GRM7, GRM8 |
| DA-20-OX15_1uM | Dose=1uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9 |
| BA-53-FM66_10uM | Dose=10uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN |
| EF-16-GV25_0.1uM | Dose=0.1uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1 |
| AE-70-QB23_0.1uM | Dose=0.1uM, Trifluperidol targeting CYP2D6 |
| BC-80-FK74_0.01uM | Dose=0.01uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| AC-40-PV46_0.1uM | Dose=0.1uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1 |
| VE-33-MT21_1uM | Dose=1uM, Gdc-0834, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK |
| HB-79-CT92_0.01uM | Dose=0.01uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2 |
| JD-50-EC04_0.1uM | Dose=0.1uM, 6-(4-Fluorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-amine, EphB4 Inhibitors;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, EPHB4, SRC, ABL2 |
| AE-11-VB80_0.1uM | Dose=0.1uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide |
| CA-88-FC74_0.01uM | Dose=0.01uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4 |
| BC-61-BE07_0.01uM | Dose=0.01uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1 |
| AC-42-LW33_1uM | Dose=1uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one |
| GE-72-PR35_0.01uM | Dose=0.01uM |
| XC-86-SR58_1uM | Dose=1uM |
| BC-11-LL59_10uM | Dose=10uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3 |
| BA-39-OX47_10uM | Dose=10uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| GA-09-TM90_0.1uM | Dose=0.1uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK |
| EA-86-QK08_0.1uM | Dose=0.1uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10 |
| GE-22-ME44_1uM | Dose=1uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2 |
| VC-79-JG59_0.1uM | Dose=0.1uM, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-(dimethylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, PYK2 inhibitor targeting PTK2B |
| HC-09-KP12_10uM | Dose=10uM, Cl-316243 Free diacid, ADRB3 agonist;beta3-Adrenoceptor Agonists targeting ADRB3 |
| AC-63-OM41_10uM | Dose=10uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| GF-73-HI61_10uM | Dose=10uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| IA-27-CK10_0.01uM | Dose=0.01uM, Sch 28080, Reversible H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| EB-52-HZ20_10uM | Dose=10uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1 |
| BD-59-MG06_0.01uM | Dose=0.01uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| CE-39-DG56_0.01uM | Dose=0.01uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| AE-85-LR48_0.01uM | Dose=0.01uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7 |
| XB-70-NK42_1uM | Dose=1uM, SR1001, Retinoid RORalpha Inverse Agonists;Retinoid RORgamma Inverse Agonists targeting RORA |
| TF-77-DW08_0.1uM | Dose=0.1uM, 3-[5-(4-chlorophenyl)-6-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide, Neuropeptide S Receptor 1 (NPSR1) Antagonists;NPSR1 antagonist targeting NPSR1 |
| CF-50-QK79_10uM | Dose=10uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2 |
| AD-09-MD49_0.01uM | Dose=0.01uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR |
| CB-13-WC72_10uM | Dose=10uM |
| KC-71-KK26_1uM | Dose=1uM, Gabazine free base, GABA(A) Receptor Antagonists targeting GABRA1, GABRB3, GABRG2 |
| CB-05-UD24_10uM | Dose=10uM, (3R)-3-amino-1-hydroxypyrrolidin-2-one, NMDA Glycine B Receptor Partial Agonists targeting GRIN1 |
| ME-14-LE68_0.1uM | Dose=0.1uM, 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Tyrosine Kinase Inhibitors targeting FYN |
| AA-51-RY00_0.1uM | Dose=0.1uM, Chlorambucil |
| KE-24-RZ94_0.1uM | Dose=0.1uM, Yoda-1, Piezo1 channel activator;GlyT-2 Inhibitors targeting SLC6A5, PIEZO1 |
| IA-28-VB61_1uM | Dose=1uM |
| DB-11-SS01_0.01uM | Dose=0.01uM, Thal-sns-032 targeting CDK9 |
| MF-20-QI53_0.01uM | Dose=0.01uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2 |
| LC-19-SF48_0.1uM | Dose=0.1uM, N-[5-(Adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin, Glucosylceramidase inhibitor targeting GBA2 |
| EB-82-QI99_10uM | Dose=10uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| DA-11-GV88_1uM | Dose=1uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| RD-39-ZE95_0.1uM | Dose=0.1uM, 3,4-Dichloro-1-benzothiophene-2-carbohydrazide, inhibitor of OGG1 targeting OGG1 |
| FB-86-IO73_0.01uM | Dose=0.01uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| ND-57-WU44_0.1uM | Dose=0.1uM, (2S,3R,4R)-3-hydroxy-4-[(4-phenylphenyl)methoxy]pyrrolidine-2-carboxylic acid, Anti-ASCT2 (Neutral Amino Acid Transporter) targeting SLC1A4, SLC1A5 |
| BC-74-QN56_0.01uM | Dose=0.01uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| EF-62-IO23_0.1uM | Dose=0.1uM |
| IB-94-WM88_10uM | Dose=10uM, Ethyl 4-[2-(4,6-dimethyl-3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)acetyl]piperazine-1-carboxylate, DTYMK inhibitor targeting DTYMK |
| GF-19-OF53_10uM | Dose=10uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5 |
| BB-55-JH29_0.1uM | Dose=0.1uM |
| UE-20-KA68_0.01uM | Dose=0.01uM, Z-FA-Fmk, Cathepsin B Inhibitors targeting CTSB |
| TD-36-JP74_10uM | Dose=10uM, N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide, Glucosylceramidase inhibitor targeting GBA |
| HF-57-QB74_0.1uM | Dose=0.1uM, Ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate, steroidogenic factor 1 inhibitor;NR5A1 inhibitor targeting NR5A1 |
| AA-46-HS88_1uM | Dose=1uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| DB-98-LQ88_1uM | Dose=1uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| FA-65-UA27_10uM | Dose=10uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| RD-57-WQ44_0.01uM | Dose=0.01uM, VU0650786, selective mGlu3 NAM targeting GRM3 |
| VE-28-FM71_0.01uM | Dose=0.01uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3 |
| FE-29-XM40_0.1uM | Dose=0.1uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2 |
| YE-57-WY37_10uM | Dose=10uM, 2-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]benzamide |
| JC-14-YI23_10uM | Dose=10uM, Sdccgsbi-0050877.P002 |
| IA-28-VB61_0.01uM | Dose=0.01uM |
| AC-76-BB72_0.01uM | Dose=0.01uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1 |
| KB-45-CF78_1uM | Dose=1uM, 2-Benzyl-4H-3,1-benzoxazin-4-one |
| KC-54-AS32_0.01uM | Dose=0.01uM, Miridesap, Antiamyloidogenic Agents;Anti-Human Serum Amyloid P (Anti-SAP) targeting APCS |
| MD-40-FM63_0.1uM | Dose=0.1uM, nor-NOHA targeting ARG1 |
| BA-69-DU95_0.01uM | Dose=0.01uM, Doconexent, PPARalpha Agonists targeting PPARA |
| EC-08-AP40_0.01uM | Dose=0.01uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP |
| AE-70-QB23_0.01uM | Dose=0.01uM, Trifluperidol targeting CYP2D6 |
| HE-09-WC21_1uM | Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| DB-63-TM61_0.1uM | Dose=0.1uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| HC-83-TS50_1uM | Dose=1uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC |
| CC-51-KS26_1uM | Dose=1uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B |
| DA-11-GV88_0.01uM | Dose=0.01uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| AA-57-FZ47_0.01uM | Dose=0.01uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| AD-30-OK99_0.1uM | Dose=0.1uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| HC-01-FD24_0.01uM | Dose=0.01uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol |
| ZD-09-WT25_10uM | Dose=10uM, 4-(Cyclopropylmethyl)-5-[2-(piperidin-4-ylamino)pyrimidin-4-yl]pyrimidin-2-amine |
| GE-34-TW62_10uM | Dose=10uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF |
| GB-73-QS80_0.01uM | Dose=0.01uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| CC-42-ZV45_1uM | Dose=1uM, (S)-2-amino-5-phosphonopentanoic acid |
| FA-72-JL16_0.01uM | Dose=0.01uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2 |
| BD-10-ZH17_0.1uM | Dose=0.1uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR |
| BE-59-WG31_1uM | Dose=1uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| IE-02-TR35_0.01uM | Dose=0.01uM, (S)-N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, NPSR1 antagonist targeting NPSR1 |
| XF-42-ES96_0.1uM | Dose=0.1uM, (1-(4-Nitrophenyl)piperidin-3-yl)methanol, CDK Inhibitors targeting CCND2, CCND3, CDK6 |
| AF-92-EP16_0.1uM | Dose=0.1uM, (2S,4R)-N-[(2S)-1-(1,3-benzoxazol-2-yl)-1-oxobutan-2-yl]-4-[(4-bromo-2-fluorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide |
| AC-53-HJ29_1uM | Dose=1uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6 |
| BA-29-OX17_0.01uM | Dose=0.01uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| BD-83-UC82_1uM | Dose=1uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2 |
| FC-97-EO10_10uM | Dose=10uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide |
| CE-18-CG29_10uM | Dose=10uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1 |
| KC-67-HN97_0.1uM | Dose=0.1uM, 2,2-Dimethyl-6-[(4,6-diphenyl-2-pyridyl)oxy]hexanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| UB-62-DF90_1uM | Dose=1uM |
| PE-58-WU11_10uM | Dose=10uM |
| OB-71-IZ36_0.01uM | Dose=0.01uM, 5-m-Tolyloxyuracil, Lyn Kinase Activators targeting LYN |
| LF-18-HE58_10uM | Dose=10uM |
| FB-39-VW14_0.1uM | Dose=0.1uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1 |
| GC-08-VP20_0.01uM | Dose=0.01uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| HA-82-OO58_0.01uM | Dose=0.01uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB |
| NE-42-YQ17_0.1uM | Dose=0.1uM |
| LF-56-QX74_10uM | Dose=10uM, 4-Heptyloxyphenol, steroidogenic factor inhibitor targeting NR5A1 |
| FA-90-DR66_1uM | Dose=1uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| IC-86-MA49_10uM | Dose=10uM, 2-Adamantanecarbonyl-arg-phe-NH2 trifluoroacetate, Neuropeptide FF Receptor Antagonists targeting NPFFR1 |
| EC-96-OH91_0.01uM | Dose=0.01uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4 |
| AE-32-NZ70_10uM | Dose=10uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2 |
| AE-64-KN26_10uM | Dose=10uM |
| ND-68-CU31_0.1uM | Dose=0.1uM, MR 16728, Acetylcholine Release Enhancers targeting KCNN4 |
| GA-23-VF89_10uM | Dose=10uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| OD-13-IE31_0.1uM | Dose=0.1uM |
| AB-04-NN16_10uM | Dose=10uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G |
| DC-28-NF06_0.01uM | Dose=0.01uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A |
| ED-83-GF49_0.01uM | Dose=0.01uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide |
| AD-06-OB47_0.01uM | Dose=0.01uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| AE-28-LX10_10uM | Dose=10uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| MB-86-VG83_1uM | Dose=1uM, N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, BRD7/9 inhbitor;BRD9 inhibitor;BRD7/9 Bromodomain Inhibitor targeting BRD7, BRD9 |
| DE-15-GD59_0.1uM | Dose=0.1uM |
| WC-22-DS16_0.01uM | Dose=0.01uM, N-(1-phenylethyl)-3-tosylthieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine |
| GB-46-CK08_0.01uM | Dose=0.01uM |
| UB-79-KN96_0.01uM | Dose=0.01uM |
| EC-85-CG61_0.1uM | Dose=0.1uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| AF-80-QK39_0.01uM | Dose=0.01uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4 |
| HB-69-CT62_0.1uM | Dose=0.1uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| BE-29-DG26_0.01uM | Dose=0.01uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C |
| KD-86-AJ75_0.01uM | Dose=0.01uM, 2-((10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)methyl)-N,5-dimethylbenzenesulfonamide, Glucocorticoid Receptor (GR) Antagonists;Mineralocorticoid Receptor (MR) Antagonists targeting NR3C1, NR3C2 |
| IF-87-AU84_0.1uM | Dose=0.1uM |
| BB-33-HC27_10uM | Dose=10uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| BD-85-IA32_0.1uM | Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| DC-01-WE57_0.01uM | Dose=0.01uM |
| AD-00-ZK94_0.1uM | Dose=0.1uM, 3-[(2,4-Dichlorophenyl)methylsulfanyl]-1,6-dimethylpyridazino[4,5-e][1,3,4]thiadiazin-5-one targeting GPR65 |
| JA-77-UH38_0.1uM | Dose=0.1uM |
| BE-70-CU78_1uM | Dose=1uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A |
| OB-06-WW76_1uM | Dose=1uM, Roxatidine acetate, HRH2 antagonist targeting HRH2 |
| IA-67-CK10_0.01uM | Dose=0.01uM, 1-Amino-4-m-anisidino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid |
| QC-32-ZC28_0.1uM | Dose=0.1uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid |
| HD-36-DK23_0.1uM | Dose=0.1uM, N-[1-[[5-[(4-acetylpiperazin-1-yl)methyl]-4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-4-fluorobenzamide |
| JA-57-AV27_10uM | Dose=10uM, SGC-iMLLT targeting MLLT1, MLLT3 |
| BF-94-GX05_1uM | Dose=1uM |
| MD-49-BL92_0.1uM | Dose=0.1uM, N-[5-(7-chloroquinolin-4-yl)sulfanyl-1,3,4-thiadiazol-2-yl]acetamide |
| CB-10-YX20_1uM | Dose=1uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1 |
| EA-09-HM95_0.01uM | Dose=0.01uM |
| VD-76-SO91_10uM | Dose=10uM, N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide, NF-kappaB (NFKB) Activation Inhibitors;Antiinflammatory Drugs targeting NFKB1 |
| FE-36-JU27_1uM | Dose=1uM, 4-ethyl-3-(3-methoxypropoxy)-N-[[(3S,4S)-4-[[methyl-(2-phenylacetyl)amino]methyl]pyrrolidin-3-yl]methyl]-N-propan-2-ylbenzamide, Renin Inhibitors targeting REN |
| DD-74-PJ26_10uM | Dose=10uM, Amn082, mgluR7 Agonists targeting GRM7 |
| TA-36-GV23_0.01uM | Dose=0.01uM, Kynurenic Acid, a7 nicotinic acetylcholine receptor Inhibitor;NMDA Antagonists;AMPA Receptor Modulators targeting CHRNA7 |
| FB-60-JQ38_1uM | Dose=1uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1 |
| UD-99-XG44_0.1uM | Dose=0.1uM, (1,2-Diphenyl-ethyl)-phosphonic acid |
| CE-69-FD64_0.1uM | Dose=0.1uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1 |
| CA-72-JV60_1uM | Dose=1uM, Benzamidine targeting PLG |
| DB-67-IP73_0.01uM | Dose=0.01uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5 |
| QA-81-IM40_0.1uM | Dose=0.1uM, 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine targeting KMT5A |
| FD-55-XG26_1uM | Dose=1uM |
| CC-09-YG11_0.1uM | Dose=0.1uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2 |
| DD-48-MZ39_10uM | Dose=10uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid |
| CC-30-TN36_10uM | Dose=10uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B |
| TF-23-DD23_10uM | Dose=10uM, PF-4708671, Antagonist of S6K targeting RPS6KB1 |
| BC-56-CP81_1uM | Dose=1uM, Adefovir Dipivoxil |
| HC-14-FM48_10uM | Dose=10uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| DE-24-AX80_0.1uM | Dose=0.1uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| AA-45-BL29_0.1uM | Dose=0.1uM, DL-Tyrosine |
| FD-85-SX37_0.1uM | Dose=0.1uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2 |
| DA-85-SU90_1uM | Dose=1uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1 |
| EF-52-ML96_0.1uM | Dose=0.1uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2 |
| HF-01-QN73_0.1uM | Dose=0.1uM, 1-Isopropyl-1h-1,2,3-benzotriazole-5-carboxylic acid, GPR109B agonist;HM74) Receptor Agonists;GPR109B;Nicotinic Acid (Niacin targeting HCAR3 |
| YA-44-LW45_0.1uM | Dose=0.1uM, 4-(4-Chlorophenyl)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propyl]piperidin-4-ol, Chemokine CC Antagonists;Antiinflammatory Drugs targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| MB-15-ZF03_0.01uM | Dose=0.01uM |
| EC-00-KR26_0.1uM | Dose=0.1uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| LA-99-FV41_0.01uM | Dose=0.01uM, Dabigatran, Known Thrombin inhibitor targeting F2 |
| BE-36-FY37_10uM | Dose=10uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| FE-58-ES32_1uM | Dose=1uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine |
| WA-43-MP01_10uM | Dose=10uM, 2-phenyl-1,2-benzisothiazol-3-(2H)-one |
| DA-33-IZ67_0.1uM | Dose=0.1uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1 |
| DE-59-HQ30_10uM | Dose=10uM, (2S,4R)-1-N-(1-carbamoylindol-3-yl)-4-fluoro-2-N-[2-fluoro-3-(trifluoromethoxy)phenyl]pyrrolidine-1,2-dicarboxamide, Complement Factor D (CFD) Inhibitor targeting CFD |
| IB-87-IU44_1uM | Dose=1uM, Thymol |
| BE-57-VZ17_1uM | Dose=1uM |
| S0-EE-YC7H_1uM | Dose=1uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6 |
| AA-45-AA67_0.01uM | Dose=0.01uM, Fluorouracil, thymidylate synthase targeting TYMS |
| AE-52-XF72_1uM | Dose=1uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10 |
| CE-02-FZ80_0.1uM | Dose=0.1uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1 |
| ZD-85-ID22_0.01uM | Dose=0.01uM, 2,6-Difluoro-4-[4-(4-fluorophenyl)pyridin-3-yl]phenol |
| KD-14-RS67_10uM | Dose=10uM, 1-[4-(2,3-Dimethoxybenzoyl)piperazin-1-yl]-2-(3-methylphenoxy)ethanone, antagonist of CBX7ChD/methyl-lysine binding by blocking H3K27me3 binding;CBX7ChD antagonist targeting CBX7 |
| FF-59-KC06_0.01uM | Dose=0.01uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B |
| DD-89-MJ03_1uM | Dose=1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| NB-37-LA11_1uM | Dose=1uM, PLAUR gene inhibitor targeting PLAUR |
| RB-80-II48_0.1uM | Dose=0.1uM, 8-(2,5-Dimethoxyphenyl)-1-(2-fluorophenyl)imidazo[4,5-c]quinoline, RET inhibitor targeting RET |
| SE-76-JI27_1uM | Dose=1uM, Pyridine-2-carboxylic acid {(S)-3-[(3,5-bis-trifluoromethyl-benzoyl)-methyl-amino]-4-phenyl-butyl}-amide, Orexin OX-2 Antagonists targeting HCRTR2 |
| EE-98-PF86_0.1uM | Dose=0.1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| OC-36-DG23_1uM | Dose=1uM, 1-[3-[(2R)-2,3-dihydroxypropyl]-5-[3-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]cyclopropane-1-carbonitrile, PKC epsilon inhibitor targeting PRKCE |
| FC-08-PZ84_10uM | Dose=10uM, 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid, SIRT6 inhibitor targeting SIRT6 |
| KA-63-FH23_0.1uM | Dose=0.1uM, Cgp 77675, Src Kinase Inhibitors targeting SRC |
| AE-09-SG21_1uM | Dose=1uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP |
| DF-57-BL63_1uM | Dose=1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| AD-32-RF17_0.1uM | Dose=0.1uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| AB-25-NK66_1uM | Dose=1uM, Adh-1, N-cadherin Inhibitor targeting CDH2 |
| FA-28-MT45_0.1uM | Dose=0.1uM, Cloprostenol, PTGFR agonist targeting PTGFR |
| DB-68-AC34_1uM | Dose=1uM, (3R)-N-[2-(4-cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-3-carboxamide, GPBAR1 agonist targeting GPBAR1 |
| GA-18-PV59_10uM | Dose=10uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17 |
| AE-52-XF72_0.01uM | Dose=0.01uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10 |
| OE-75-WF43_1uM | Dose=1uM, 8-(2-(3,5-Dimethylpiperazin-1-yl)-4- targeting EED |
| HA-36-VD41_1uM | Dose=1uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| EE-26-UK38_0.1uM | Dose=0.1uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A |
| FA-77-LS25_1uM | Dose=1uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| JB-48-TL55_10uM | Dose=10uM, Levamisole, Nicotinic Receptor Agonists targeting CHRNA3 |
| CE-68-CC69_10uM | Dose=10uM |
| AA-99-PN83_0.01uM | Dose=0.01uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide |
| DD-95-TY80_1uM | Dose=1uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| SD-51-LL22_0.1uM | Dose=0.1uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1 |
| AA-42-JP76_10uM | Dose=10uM, Imiquimod, Interferon Inducers;TLR7 Receptor Agonists targeting NQO2, TLR7 |
| GF-05-GQ05_0.01uM | Dose=0.01uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1 |
| DC-02-OP01_0.1uM | Dose=0.1uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5 |
| AA-35-VH74_10uM | Dose=10uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3 |
| GA-43-FL03_1uM | Dose=1uM, Aliskiren, Renin Inhibitors targeting REN |
| BC-37-HI51_10uM | Dose=10uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| BA-60-DK24_0.01uM | Dose=0.01uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D |
| AB-00-HA50_0.01uM | Dose=0.01uM |
| DB-58-ZC04_0.1uM | Dose=0.1uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2 |
| BF-96-PY22_1uM | Dose=1uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| GC-09-EG26_0.01uM | Dose=0.01uM, Carcinine, HRH3 antagonist targeting HRH3 |
| AE-17-IZ62_0.1uM | Dose=0.1uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide |
| CC-50-FK24_0.1uM | Dose=0.1uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| NF-27-AQ24_0.01uM | Dose=0.01uM, GR 46611, HTR1D agonist targeting HTR1D |
| HE-55-QD94_0.01uM | Dose=0.01uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-phenoxyacetamide |
| IC-18-TY61_1uM | Dose=1uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD |
| DB-33-HZ87_0.01uM | Dose=0.01uM, Vgx-1027, Cytokine Modulators targeting TLR4 |
| RB-56-FZ63_10uM | Dose=10uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1 |
| YF-46-CA32_1uM | Dose=1uM |
| GA-79-ZF28_1uM | Dose=1uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4 |
| EE-35-XA42_1uM | Dose=1uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide |
| BC-78-NC89_0.1uM | Dose=0.1uM, [(1R,3R)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| AA-24-SQ13_1uM | Dose=1uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1 |
| FF-34-KW62_1uM | Dose=1uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| AB-11-QV43_10uM | Dose=10uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| AD-21-WS76_1uM | Dose=1uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| AE-38-QT35_0.01uM | Dose=0.01uM, ML324, KDM4E targeting KDM4E |
| CE-39-DG56_1uM | Dose=1uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| AB-16-HE44_0.01uM | Dose=0.01uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| BB-62-MS83_1uM | Dose=1uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| CB-38-AW77_0.01uM | Dose=0.01uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1 |
| YB-30-EK42_0.01uM | Dose=0.01uM |
| JE-72-KV75_0.1uM | Dose=0.1uM, 6-Chloro-2-(2-Fluoro-4,5-Dimethoxyphenyl)-N-(Piperidin-4-Ylmethyl)-3h-Imidazo[4,5-B]pyridin-7-Amine, JAK1 selective inhibitors targeting CDK2, JAK1, AURKB |
| CE-36-UR55_1uM | Dose=1uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| WE-25-AN91_1uM | Dose=1uM, CP 96345, Tachykinin NK1 Antagonists;Non-Steroidal Antiinflammatory Drugs targeting CACNA1C, CACNA1F, CACNA1S |
| JA-42-NH96_1uM | Dose=1uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS |
| JE-27-XK20_10uM | Dose=10uM, Rifapentine, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| JD-01-RA07_0.01uM | Dose=0.01uM, N-(4,6-Dimethylpyrimidin-2-yl)-4-((2-methylbenzyl)amino)benzenesulfonamide, alpha2B-Adrenoceptor Antagonists targeting ADRA2B |
| DE-27-WV67_10uM | Dose=10uM |
| GE-29-BW04_0.1uM | Dose=0.1uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A |
| HA-17-MS45_0.01uM | Dose=0.01uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| DE-73-JX23_0.1uM | Dose=0.1uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1 |
| MD-70-GS72_10uM | Dose=10uM, 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid |
| AE-37-MC27_0.1uM | Dose=0.1uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| GB-62-IH36_0.01uM | Dose=0.01uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B |
| ED-25-BD54_1uM | Dose=1uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| AE-41-GB05_10uM | Dose=10uM, Ave5638, Known Tryptase inhibitor targeting TPSB2 |
| HE-95-KK46_0.01uM | Dose=0.01uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A |
| AA-58-JC44_0.01uM | Dose=0.01uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2 |
| JC-19-ST72_10uM | Dose=10uM, US10669234, Example 126 targeting USP30 |
| DA-67-HS65_1uM | Dose=1uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2 |
| CD-84-FJ21_10uM | Dose=10uM, Dpn 205-734 |
| AE-72-UP91_0.01uM | Dose=0.01uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| DC-98-HC94_1uM | Dose=1uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| AA-31-YE07_0.01uM | Dose=0.01uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| DE-59-OT87_0.1uM | Dose=0.1uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3 |
| DA-19-JA87_0.01uM | Dose=0.01uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1 |
| HB-72-BR75_1uM | Dose=1uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3 |
| VA-48-TW80_1uM | Dose=1uM, GABA receptor ligand targeting GABRA2 |
| YB-31-TH67_0.1uM | Dose=0.1uM, Estradiol Acetate |
| MD-09-FE75_1uM | Dose=1uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2 |
| WE-97-CV00_0.1uM | Dose=0.1uM |
| DF-93-BT88_0.01uM | Dose=0.01uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C |
| CA-48-SW47_10uM | Dose=10uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| AD-10-TH32_1uM | Dose=1uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1 |
| AF-16-IB77_10uM | Dose=10uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| AB-33-EM56_0.01uM | Dose=0.01uM |
| DE-28-ZP75_1uM | Dose=1uM, Deserpidine |
| YF-35-FN16_0.01uM | Dose=0.01uM, N-[2-[2-(cyclohexylamino)pyridin-4-yl]-6-piperazin-1-ylpyridin-4-yl]methanesulfonamide |
| S0-EE-Y7SS_1uM | Dose=1uM |
| YC-06-WA22_0.01uM | Dose=0.01uM, 2-(4-(Pyrrolidin-1-yl)but-2-ynyl)isoxazolidin-3-one, Muscarinic M2 Agonists;Muscarinic M1 Agonists;Muscarinic M3 Agonists targeting CHRM5 |
| BC-21-EB65_0.01uM | Dose=0.01uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| IF-28-AV94_10uM | Dose=10uM |
| FB-60-JQ38_0.1uM | Dose=0.1uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1 |
| BE-42-IC00_0.01uM | Dose=0.01uM, Zygosporin A, actin polymerization targeting ACTA1 |
| JC-26-DD86_0.01uM | Dose=0.01uM, 1-[6-(4-Methylphenyl)-[1,3]oxazolo[4,5-b]pyridin-2-yl]-6-phenylhexan-1-one, dual diacyglycerol lipase alpha and beta reversible inhibitor targeting DAGLA, DAGLB |
| CE-38-KX20_0.1uM | Dose=0.1uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| DC-84-GJ21_0.01uM | Dose=0.01uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK |
| OA-16-KC73_10uM | Dose=10uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1 |
| FF-14-JG89_10uM | Dose=10uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2 |
| FC-03-PM86_10uM | Dose=10uM, Oxytocin, OXTR agonist targeting OXTR |
| NB-89-OV56_10uM | Dose=10uM, PF 04802367, GSK3a/b inhibitor targeting GSK3B, GSK3A |
| EC-87-ZE76_0.1uM | Dose=0.1uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10 |
| TB-55-WY28_0.01uM | Dose=0.01uM, SB 204990, ATP citrate lyase inhibitor targeting ACLY |
| AC-91-AV48_10uM | Dose=10uM |
| SE-21-NB93_0.01uM | Dose=0.01uM, Stiripentol, GABA Reuptake Inhibitors;GABA Aminotransferase Inhibitors targeting ABAT |
| AB-10-RE65_1uM | Dose=1uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AE-38-QT35_0.1uM | Dose=0.1uM, ML324, KDM4E targeting KDM4E |
| MF-11-EW49_10uM | Dose=10uM, Biochanin A, PPARgamma Agonists;Androgen Receptor Antagonists;Steroid 5alpha-Reductase Inhibitors;PPARalpha Agonists targeting AR, PPARA, PPARG, SRD5A1, SRD5A2 |
| DA-45-PU65_0.1uM | Dose=0.1uM, Torsemide, Drugs Acting on Potassium Channels targeting SLC12A1, SLC12A2 |
| BD-83-UC82_0.1uM | Dose=0.1uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2 |
| FE-19-SC91_0.1uM | Dose=0.1uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6 |
| GB-81-UN03_0.01uM | Dose=0.01uM, 4-Quinolinamine, 2-(2-thienyl)- |
| CE-85-KN13_10uM | Dose=10uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| TE-12-BW46_10uM | Dose=10uM, F16357, PAR1) Antagonist;Proteinase-Activated Receptor 1 (F2R targeting F2R |
| HD-16-HN20_10uM | Dose=10uM |
| FF-76-LK08_0.01uM | Dose=0.01uM |
| AE-36-TF52_0.1uM | Dose=0.1uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN |
| GD-59-QF63_0.01uM | Dose=0.01uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| KD-31-TU05_0.01uM | Dose=0.01uM, Lesinurad targeting SLC22A11, SLC22A12 |
| HE-14-AT80_10uM | Dose=10uM, Filgotinib targeting JAK1, JAK2, JAK3, TYK2 |
| KF-09-GB83_1uM | Dose=1uM, (+)-Nomifensine |
| KB-84-OL45_0.1uM | Dose=0.1uM, Cgs 26393, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME, ECE1, ECE2 |
| AD-98-UM13_1uM | Dose=1uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E |
| DA-69-UN88_0.01uM | Dose=0.01uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1 |
| ND-27-UQ99_0.1uM | Dose=0.1uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2 |
| HC-15-LT47_1uM | Dose=1uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| BB-69-WN73_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BC-00-YH62_0.01uM | Dose=0.01uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AB-37-JM16_0.01uM | Dose=0.01uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB |
| AA-20-DK54_0.01uM | Dose=0.01uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| DD-74-PJ26_1uM | Dose=1uM, Amn082, mgluR7 Agonists targeting GRM7 |
| AB-00-VH52_0.01uM | Dose=0.01uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| BA-44-WG29_10uM | Dose=10uM, Oxprenolol, beta-Adrenoceptor Antagonists targeting ADRB1, ADRB2 |
| BC-86-PL11_10uM | Dose=10uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF |
| DB-28-ZJ81_0.01uM | Dose=0.01uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9 |
| FA-77-LS25_10uM | Dose=10uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| EA-12-SS08_1uM | Dose=1uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8 |
| IE-46-VU57_1uM | Dose=1uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1 |
| AE-02-OC25_0.1uM | Dose=0.1uM, Caffeic Acid Phenethyl Ester |
| EB-85-JN83_1uM | Dose=1uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| CA-56-VE74_0.1uM | Dose=0.1uM, Ciprofloxacin |
| BD-74-LH52_10uM | Dose=10uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL |
| AC-44-UR36_0.1uM | Dose=0.1uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT |
| BA-19-VU85_0.01uM | Dose=0.01uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| AD-32-RF17_0.01uM | Dose=0.01uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| CB-72-CP81_0.01uM | Dose=0.01uM |
| BE-61-CB85_0.01uM | Dose=0.01uM |
| EB-61-FU05_1uM | Dose=1uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A |
| AC-85-MR73_0.1uM | Dose=0.1uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C |
| EC-31-MR88_0.1uM | Dose=0.1uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14 |
| MB-67-UU04_0.1uM | Dose=0.1uM, 6-[4-[2-(3-Fluoropyridin-4-yl)imidazo[4,5-b]pyridin-3-yl]piperidin-1-yl]sulfonyl-2-methyl-1,3-benzoxazole, CFTR Modulator targeting CFTR |
| AA-98-FJ71_1uM | Dose=1uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| BE-13-XC52_10uM | Dose=10uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| IA-50-ET40_1uM | Dose=1uM, N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide, dual CHRM2/CHRM4 antagonist targeting CHRM2, CHRM4 |
| FF-08-DP35_0.1uM | Dose=0.1uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2 |
| BB-89-HE42_10uM | Dose=10uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1 |
| XD-60-SU16_10uM | Dose=10uM, Prt-4165, Ubiquitin Protein Ligase E3 Inhibitors targeting RNF2, BMI1, RING1 |
| BF-69-DX62_0.1uM | Dose=0.1uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| DA-23-TZ42_1uM | Dose=1uM |
| UC-83-VC55_1uM | Dose=1uM, N-[4-(trifluoromethyl)phenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| MF-62-JR25_10uM | Dose=10uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| S0-EE-WH3B_10uM | Dose=10uM, 1-(4-cyanophenyl)-N-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxamide targeting ALDH1A2 |
| OE-91-GF88_0.01uM | Dose=0.01uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG |
| VF-03-AC40_10uM | Dose=10uM, 3-chloro-N-[(E)-[1-[4-(trifluoromethoxy)phenyl]pyrrol-2-yl]methylideneamino]-5-(trifluoromethyl)pyridin-2-amine |
| RE-72-IT14_1uM | Dose=1uM, 3-{4-[(E)-3-(4-tert-Butyl-piperazin-1-yl)-propenyl]-benzyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine |
| PF-84-RH50_0.1uM | Dose=0.1uM |
| FC-05-ID99_0.01uM | Dose=0.01uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET |
| LC-43-SE41_0.01uM | Dose=0.01uM, PRX-08066 free base, 5-HT2B Antagonists targeting HTR2B |
| FD-00-QG34_0.01uM | Dose=0.01uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E |
| IF-22-EA89_0.01uM | Dose=0.01uM, Gusperimus |
| AD-91-FZ23_10uM | Dose=10uM, Piracetam, AMPA Receptor Postiive Allosteric Modulators;Nootropic targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DB-32-FS68_0.1uM | Dose=0.1uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| FC-58-QS77_10uM | Dose=10uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4 |
| SD-51-LL22_0.01uM | Dose=0.01uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1 |
| BE-74-SX40_0.1uM | Dose=0.1uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3 |
| GF-05-GQ05_1uM | Dose=1uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1 |
| JD-74-IP25_0.01uM | Dose=0.01uM, Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors |
| HB-72-BR75_0.1uM | Dose=0.1uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3 |
| GF-92-IR00_0.1uM | Dose=0.1uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| EB-85-JN83_0.1uM | Dose=0.1uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| DB-74-HJ91_0.1uM | Dose=0.1uM, Dazoxiben, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| JF-45-JM50_0.01uM | Dose=0.01uM, Rauwolscine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| BB-40-KK84_1uM | Dose=1uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2 |
| QE-00-EB96_0.01uM | Dose=0.01uM, MERTK gene inhibitor targeting MERTK |
| AC-40-KV26_0.01uM | Dose=0.01uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1 |
| KD-36-KT24_0.01uM | Dose=0.01uM, (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide |
| JD-12-YK78_0.1uM | Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| CC-07-LB64_1uM | Dose=1uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one |
| MB-01-IW99_10uM | Dose=10uM, (1-Amino-3-methylbutyl)phosphonic acid targeting LAP3 |
| WF-96-ME07_0.01uM | Dose=0.01uM, Cur 61414, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| AB-99-PR28_10uM | Dose=10uM, Ribavirin, Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Hepatitis C virus inhibitor targeting IMPDH1 |
| JE-61-XN48_0.01uM | Dose=0.01uM, HC-030031, TRPA1 Antagonists targeting TRPA1 |
| BF-97-LS55_0.01uM | Dose=0.01uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| KE-74-EB71_0.1uM | Dose=0.1uM, 2,3-Dihydroxypropyl dodecanoate |
| UD-85-WR81_10uM | Dose=10uM, Gardiquimod |
| VA-57-TF22_0.01uM | Dose=0.01uM |
| RA-55-DY98_1uM | Dose=1uM |
| AE-61-UO01_1uM | Dose=1uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| CE-74-KU68_1uM | Dose=1uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| AD-20-CH42_0.1uM | Dose=0.1uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42 |
| LB-24-DV44_0.1uM | Dose=0.1uM |
| AD-94-TN76_0.01uM | Dose=0.01uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN |
| WC-81-BR91_10uM | Dose=10uM, Bisanilinopyrimidine, 3d |
| AD-99-SN88_0.1uM | Dose=0.1uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| CE-68-CC69_1uM | Dose=1uM |
| CF-32-LB77_1uM | Dose=1uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2 |
| CD-75-QY45_0.01uM | Dose=0.01uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| CC-04-YT10_1uM | Dose=1uM |
| BA-79-ZR48_0.01uM | Dose=0.01uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5 |
| DF-57-BL63_10uM | Dose=10uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| AA-99-OX27_0.01uM | Dose=0.01uM, Tolnaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE |
| BA-38-XM43_10uM | Dose=10uM, Paxilline targeting KCNMA1, KCNMB1 |
| VC-94-CG67_1uM | Dose=1uM |
| TD-17-NF32_0.01uM | Dose=0.01uM |
| BB-72-TP61_1uM | Dose=1uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide |
| DA-28-TM43_0.1uM | Dose=0.1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2 |
| AA-64-WG29_10uM | Dose=10uM, Cgs-27023, Matrix metalloproteinase inhibitor;MMP-9 (Gelatinase B) Inhibitors;Angiogenesis Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP8, MMP9, MMP14, MMP16, MMP11, MMP15, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| LC-62-AU42_10uM | Dose=10uM |
| DD-96-VY72_1uM | Dose=1uM |
| AE-59-ZQ55_0.01uM | Dose=0.01uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1 |
| HD-00-AG74_0.01uM | Dose=0.01uM |
| FB-19-ZG81_1uM | Dose=1uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY |
| UF-86-ME07_0.1uM | Dose=0.1uM, 2-Mercaptoethylguanidine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Cyclooxygenase (COX) Inhibitors;Antiinflammatory Drugs;Free Radical Scavengers targeting NOS2 |
| UD-03-SW43_0.01uM | Dose=0.01uM |
| MF-65-HS14_0.1uM | Dose=0.1uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one |
| DB-01-BR68_1uM | Dose=1uM, Guaifenesin |
| SC-71-IB68_0.01uM | Dose=0.01uM, Sah 41-178, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| OF-63-KD88_0.01uM | Dose=0.01uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethyl ethyl carbonate |
| BB-73-ZW70_0.1uM | Dose=0.1uM |
| AD-51-BB90_1uM | Dose=1uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA |
| BC-37-HI51_1uM | Dose=1uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| UD-27-FS48_10uM | Dose=10uM, Neuropeptide Y1 (NPY Y1) Antagonists;NPY1R antagonist targeting NPY1R |
| OC-14-JE78_0.1uM | Dose=0.1uM, (2R,3S)-1-(Phenanthrene-2-carbonyl)-piperazine-2,3-dicarboxylic acid, NR2D Antagonists;NR2C Antagonists targeting GRIN2C, GRIN2D |
| UF-61-QB73_0.1uM | Dose=0.1uM, (S)-1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropan-1-ol, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors targeting CYP17A1 |
| DE-98-FC24_0.1uM | Dose=0.1uM |
| FD-80-EG54_0.01uM | Dose=0.01uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| S0-EE-XNAL_0.1uM | Dose=0.1uM, Venuloside A, SLC43A1 gene inhibitor targeting SLC43A1 |
| BA-77-NI61_0.1uM | Dose=0.1uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine |
| HC-83-TS50_0.1uM | Dose=0.1uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC |
| BB-47-YI31_10uM | Dose=10uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DA-77-II31_0.1uM | Dose=0.1uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7 |
| S0-EE-XNAL_10uM | Dose=10uM, Venuloside A, SLC43A1 gene inhibitor targeting SLC43A1 |
| BE-86-FY67_10uM | Dose=10uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3 |
| BA-07-GC72_10uM | Dose=10uM, Flutamide, Androgen Receptor Antagonists targeting AR, CYP1B1 |
| AB-07-AZ97_1uM | Dose=1uM, CB1R antagonist 1, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM |
| CB-88-OC19_0.01uM | Dose=0.01uM, Prenalterol, beta-Adrenoceptor Agonists targeting ADRB1 |
| FB-32-TL51_1uM | Dose=1uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| AC-05-MR83_1uM | Dose=1uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| ZE-13-SI09_1uM | Dose=1uM, (1-Amino-2-cyclohexylethyl)phosphonic acid, Leucine Aminopeptidase inhibitor targeting LAP3 |
| UF-98-OM26_0.01uM | Dose=0.01uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| LD-96-DG13_1uM | Dose=1uM, Tcs OX2 29, HCRTR2 antagonist;Orexin OX-2 Antagonists targeting HCRTR2 |
| YB-54-ET23_1uM | Dose=1uM, 5-Chloro-2-{2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl}pyridine, JMJD2 Histone Demethylase Inhibitor targeting KDM4C, KDM4E, KDM4B |
| DB-54-GQ68_0.01uM | Dose=0.01uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| HC-43-CV47_10uM | Dose=10uM, Bergapten |
| EB-33-ZP53_1uM | Dose=1uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA |
| AE-38-ZM08_1uM | Dose=1uM |
| DA-77-II31_10uM | Dose=10uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7 |
| ID-43-YL08_0.01uM | Dose=0.01uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3 |
| AF-25-BS76_0.1uM | Dose=0.1uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4 |
| FD-80-EG54_0.1uM | Dose=0.1uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| BA-41-QF30_0.1uM | Dose=0.1uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide |
| BE-29-HA72_0.1uM | Dose=0.1uM, Ifosfamide |
| NA-30-EF36_0.1uM | Dose=0.1uM, Oicr-9429, WDR5 Inhibitor;WDR5 inhibitor targeting WDR5 |
| IB-67-WH43_1uM | Dose=1uM, 4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid, mgluR1 Antagonists targeting GRM1 |
| WC-95-BX35_10uM | Dose=10uM, [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-(4z)-ylidene]-acetic acid |
| CB-16-JO93_0.1uM | Dose=0.1uM |
| CE-37-XI06_0.01uM | Dose=0.01uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| FF-07-FL63_0.01uM | Dose=0.01uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| AA-68-MW92_10uM | Dose=10uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AC-71-YF45_0.01uM | Dose=0.01uM |
| BE-42-WI29_10uM | Dose=10uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| BF-18-MJ41_0.1uM | Dose=0.1uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1 |
| CC-15-HU70_0.01uM | Dose=0.01uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12 |
| AB-31-VZ28_1uM | Dose=1uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A |
| EB-28-ZJ41_0.01uM | Dose=0.01uM, Cidofovir |
| WC-54-BJ14_10uM | Dose=10uM, Integrin-antagonist-1, ITGB6 antagonist targeting ITGA6, ITGB6 |
| YD-85-OD87_0.01uM |
